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Abstract 
Ischaemic heart disease (IHD) is a major cause of morbidity and mortality in the world. 
Coronary  artery  bypass  graft  (CABG)  surgery  is  the  revascularisation  strategy  of 
choice in a significant number of patients, particularly those with diabetes mellitus and 
complex coronary disease. During cardiac surgery, the myocardium is subjected to 
peri-operative myocardial injury (PMI), which has been associated with worse short 
and long-term clinical outcomes. Higher-risks patients are currently being operated on 
with subsequent higher risk of PMI and worse prognosis: therefore new strategies are 
required  to  potentiate  the  innate  mechanisms  of  cardioprotection.  In  this  regard, 
remote ischaemic preconditioning (RIPC) is a promising non-invasive intervention able 
to reduce PMI in these patients: however, not all the studies have shown significant 
cardioprotection with RIPC for a number of factors, amongst which the intensity of the 
preconditioning stimulus may play a significant role. 
We therefore investigated whether an enhanced RIPC stimulus, given with transient 
simultaneous multi-limb ischaemia/reperfusion, was able to reduce PMI and improve 
short-term  clinical  outcomes  in  patients  undergoing  elective  cardiac  surgery:  we 
demonstrated that our preconditioning stimulus can significantly reduce PMI, length of 
intensive care unit (ICU) stay and incidence of atrial fibrillation (AF) in these patients. 
In addition, further retrospective analyses showed improved myocardial protection in 
preconditioned  diabetic  patients  undergoing  CABG  surgery  and  in  control  CABG 
subjects  receiving  combined  antegrade  and  retrograde  cardioplegia  compared  to 
control  CABG  patients  having  antegrade  cardioplegia  or  intermittent  cross-clamp-
fibrillation. 
We also conducted a multi-centre, double-blinded randomised control clinical trial, in 
which we investigated the effects of RIPC on clinical outcomes at 1 year in high-risk   5 
patients undergoing elective CABG surgery with or without valve surgery (the ERICCA 
trial). The results of this study are due to be presented in March 2015 and have the 
potential to significantly impact on clinical practice in cardiac surgery. 
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CHAPTER 1 
 
 
 
1. Introduction 
 
1.1. Epidemiology of Coronary Heart Disease.  
IHD  remains  a  major  cause  of  morbidity  and  mortality  in  the  world  despite 
significant advances in diagnostic and therapeutic measures over the last decades: in 
2012 an estimated 56 million people died worldwide (http://www.who.int/mediacentre) 
and cardiovascular diseases (CVD), cancer, diabetes mellitus (DM) and chronic lung 
diseases represented the main causes (Table 1.1). CVD accounted for the death of 
17.5 million people in 2012 (3 in every 10 deaths) (2, 3), of whom 7.4 million people 
died  of  IHD  and  6.7  million  from  stroke,  which  correspond  to  13.2%  and  11.9% 
respectively of the total number of deaths in the world (3). IHD is the leading cause of 
death  in  high-income  countries  and  lower-middle  countries  (4),  and  its  incidence 
continues  to  rise  in  upper-middle  and  low-middle  countries  (3),  which  follows  the 
dramatic  increase  in  cardiovascular  risk  factors  in  these  regions  (5-7).  Crucially, 
following an ST-Segment Elevation MI (STEMI) mortality rate remains as high as 2.5-
10%, with slightly better outcomes (approximately 2-4%) in Non-ST Segment Elevation 
MI  (NSTEMI)(8,  9),  and  with  an  overall  estimated  rate  of  10%  of  in-hospital  heart 
failure or shock, 6-7% of re-infarction at 1 year, 1.8% of in-hospital major bleeding, and 
1.8-2% stroke at 1 year (10). Crucially, IHD also represents a significant economic 
burden for health care systems: in 1999, IHD accounted for an estimated total NHS 
cost of £7055 billion (11), due to direct and informal healthcare costs and productivity 
loss (11).   29 
Table 1.1. The ten leading causes of death in the world in 2012 compared to 2000  
Disease 
 
N (million)  
in 2012 (2010) 
% 
Ischaemic heart disease 
 
7.4 (6)  13.2 
Stroke 
 
6.7 (5.7)  11.9 
COPD 
 
3.1 (3.1)  5.6 
Lower respiratory tract infections 
 
3.1 (3.5)  5.5 
Trachea, bronchus, lung cancer 
 
1.6 (1.2)  2.9 
HIV/AIDS 
 
1.5 (1.7)  2.7 
Diarrhoeal disease 
 
1.5 (2.2)  2.7 
Diabetes mellitus 
 
1.5 (1)  2.7 
Road injury 
 
1.3 (1)  2.2 
Hypertensive heart disease 
 
1.1 (0.8)  2 
COPD=chronic obstructive pulmonary disease; HIV=human immune-deficiency virus; AIDS=acquired 
immunodeficiency syndrome 
 
 
 
Appropriate treatment strategies are therefore required in order to reduce morbidity 
and  mortality  secondary  to  IHD  and  revascularization  with  either  percutaneous 
coronary intervention  (PCI) or coronary artery bypass graft (CABG) surgery provide 
the best therapeutic approaches. The choice of treatment strategy varies according to 
clinical  presentation,  coronary  anatomy,  presence  of  co-morbidities,  concomitant 
therapy, prognostic advantages, and patient’s preference (12). In patients with stable 
angina, CABG is the revascularisation treatment of choice when (13-15): 
a) their symptoms are not satisfactorily controlled with optimal medical therapy (OMT) 
and revascularisation is considered appropriate albeit not achievable with PCI; 
b) both procedures would be suitable, however patients present multi-vessel disease, 
their symptoms are not satisfactorily controlled with OMT, have DM or are over 65 
years or have anatomically complex three-vessel disease, with or without involvement 
of  the  LMS:  in  theses  case,  CABG  has  been  demonstrated  to  offer  a  survival 
advantage over PCI (13-15).   30 
1.2.  Historical  background  and  techniques  of  myocardial 
preservation during cardiac surgery 
Since  the  first  application  of  cardiac  surgery  in  1953,  when  John  Gibbon 
performed the first surgical closure of atrial septal defect, an impressive advancement 
of  surgical  techniques  has  occurred  over  the  last  few  decades,  with  crucially  the 
introduction of methods aiming at preserving myocardial function in the peri-operative 
period (16). The concept of myocardial preservation during cardiac surgery became 
soon  of  critical  importance  in  the  success  of  the  operation  and  patient’s  survival. 
Against the significant risks of air embolism and blood loss of the operation with “a 
beating heart”, the technique of cross-clamp of the aorta was introduced in order to 
ensure a dry operative field. This was also able to induce transient global ischaemia, 
during  which  time  a  cardiopulmonary  bypass  (CPB)  machine  would  provide  organ 
oxygenation  and  perfusion.  However  global  ischaemia  itself,  albeit  transient,  was 
associated with significant PMI, which then led to poor patient outcomes. Therefore 
the concepts of PMI and myocardial preservation or cardioprotection became closely 
interrelated  and  have  been  a  major  area  of  interest  in  research  over  the  last  few 
decades. 
Hypothermia  with  or without  cardio-circulatory  arrest  was  the first  method of 
myocardial preservation to be introduced (17, 18), but was soon replaced by the use of 
“cardioplegic”  solutions,  able  to  induce  cardiac  arrest  due  to  a  high  potassium 
concentration. However due to the significant myocardial damage observed with this 
technique,  it  soon  became  “obsolete”  in  the  1960s.  During  this  time,  hypothermic 
arrest with continuous coronary perfusion was further improved with the introduction of 
ventricular fibrillation, which uses an alternating current in order to induce ventricular 
standstill. Importantly, the latter was soon found to cause subendocardial ischaemia   31 
through an increase in left ventricular (LV) end-diastolic pressure during perfusion and 
was then used in combination with intermittent cross-clamp of the aorta, which instead 
causes transient global ischaemia of the myocardium (19): the resulting technique was 
therefore termed  intermittent cross-clamp fibrillation (ICCF) and partially obviated the 
relative myocardial damage induced by both techniques (20).  
Interestingly,  in  the  1970s  there  was  a  renewed  interest  in  the  cardioplegic 
strategy,  in  view  of  the  significant  myocardial  ischaemia  induced  with  the  first 
technique of ICCF and new forms of cardioplegia were therefore developed, such as 
hypothermic,  normothermic,  crystalloid,  substrate-enhanced  and  blood  cardioplegia 
(21-24). In particular the St. Thomas cardioplegia solution-1, which introduced the era 
of crystalloid cardioplegia, whilst allowing good visualisation of the operating field, it 
also  caused  a  slow  recovery  of  myocardial  function  and  aerobic  myocardial 
metabolism, hence facilitating lactate production and myocardial injury (25). Crystalloid 
solutions  have  high  potassium  concentration,  buffers  such  as  amino  acids  and 
bicarbonate, and various substances increasing oncotic activities, including mannitol, 
lidocaine,  procaine,  plus  low  (Bretschneider’s  solution)  or  high  (St.  Thomas 
cardioplegia  solution  2)  calcium  content  (with  low  sodium  in  the  former  and  high 
magnesium  in  the  latter)  (26).    Conversely,  blood  cardioplegic  solutions  consist  of 
native blood and a crystalloid solution in a ratio of 4:1, and have potassium in high 
concentrations and calcium in low concentrations (respectively to allow cardioplegic 
arrest and prevent cardiomyocyte apoptosis and necrosis), buffers, amino acids  (to 
facilitate  aerobic  metabolism  and  high  oncotic  pressure),  and  glucose  content  (to 
prevent myocardial oedema) (27). This leads to important advantages of blood over 
crystalloid  cardioplegia  on  cardiomyocyte  protection,  such  as  the  versatility  in 
maintaining an oncotic balance, the buffering and anti-oxidant properties and oxygen   32 
delivery (27, 28), thereby accelerating the recovery of myocardial aerobic metabolism 
and reducing reperfusion damage (29). A survey conducted in the UK and Ireland in 
2004 estimated that approximately 16% of surgeons use ICCF and 84% cardioplegia, 
of whom 83.5% use blood and 16.5% crystalloid cardioplegia (30). However, due to its 
shorter  ischaemic  times  (31),  ICCF  remains  the  preferred  technique  of  myocardial 
preservation in patients with pre-operative conduction abnormalities (it presents low 
incidence of conduction complications), or with a permanent pacemaker (which needs 
to be disconnected in the context of cardioplegia) or with cold agglutinins, as in this 
case a normothermic field and therefore shorter ischaemic times are required (32).  
In  summary,  despite  very  significant  improvements  of  the  above-mentioned 
techniques  of  myocardial  preservation,  the  level  of  PMI  sustained  during  cardiac 
surgery  is  still  considerable,  partly  because  of  the  relative  inadequacy  of  these 
methods and partly because of the change in risk profile of patients being operated on, 
with a subsequent relevant impact on short and long-term clinical outcomes in these 
subjects.   
 
1.2.1.  Short  and  long-term  clinical  outcomes  in  patients  undergoing  cardiac 
surgery 
Over  the  last  few  decades  the  profile  of  patients  undergoing  cardiac  surgery  has 
significantly  changed  due  multiple  factors  including  the  ageing  population,  the 
presence of co-morbidities such as diabetes and hypertension, more complex CAD 
being operated on, and concomitant valve surgery, all of which increase peri-operative 
risk by exposing the patient to peri-operative complications (33, 34). These include: 
1.  Myocardial dysfunction, which can be a consequence of: 
a.  Acute  spasm  or  occlusion  of  a  coronary  graft,  prosthetic  or   33 
paraprosthetic  valve  regurgitation,  cardiac  tamponade,  pneumothorax, 
haemothorax. 
b.  Inadequate  preload,  excessive  afterload,  impaired  ventricular  function 
due to ischaemic event and myocardial reperfusion injury in the intra-
operative period (this will be discussed later). 
c.  Tachy-bradyarrhythmias,  including  AF,  ventricular  arrhythmias,  high 
degree atrio-ventricular block. 
d.  Peri-operative myocardial infarction (discussed later) 
2.  Vasodilatory shock, due to systemic inflammatory response to ischaemia and 
reperfusion  and  to  the  exogenous  substances  included  in  the  cardioplegic 
solution. 
3.  Haematological  dysfunction,  causing  thrombosis  or  bleeding,  due  to  platelet 
and  coagulation  cascade  abnormalities,  residual  heparin  effect,  incomplete 
surgical haemostasis. 
4.  Pulmonary  dysfunction,  including  pleural  effusion,  pneumonia,  atelectasis, 
acute  lung  injury  (ALI),  diaphragmatic  incompetence,  endotracheal intubation 
complications. 
5.  Neurological  dysfunction,  such  as  cerebro-vascular  accidents  (CVA),  coma, 
memory deficit, intellectual decline and seizures. 
6.  Renal dysfunction (this will be discussed later). 
7.  Mortality: currently peri-operative mortality  rate in patients undergoing CABG 
surgery is approximately 1% for low-risk patients and 2-5% for the remaining 
patients (35-38), although there is considerable variation in the different centers 
(39).  A  series  of  factors  have  been  implicated  as  potential  contributory  to 
mortality following cardiac surgery and include:   34 
a)  Previous  cardiac  centers  experience:  studies  have  proved  that  mortality 
rates  are  lower  in  those  centers  with  high  volume  operations  per  year, 
particularly for patients at moderate and high risk (37, 38, 40-43). 
b)  The surgeon’s experience, which is a mortality predictor independent of the 
hospital load but strictly correlated to the latter, with the lowest incidence of 
mortality with high-volume surgeons at high-volume centers, particularly for 
moderate to high-risk patients (38, 42). 
c)  LV function, which is a major risk factors for peri-operative mortality (44, 45) 
as  poor  LV  function  has  been  associated  with  a  6%  increased  risk  of 
mortality (45).  
d)  Age: as previously described, an increasing number of elderly patients are 
being operated on (34), with a higher associated risk of in-hospital mortality 
and stroke (46) 
e)  Acute  kidney  injury  (AKI):  this  will  be  discussed  in  more  details  in  the 
discussion section of chapter 2.  
f)  Chronic kidney disease (CKD), which has been associated with both short 
and long-term post-operative mortality (1, 47-49) even in the presence of 
mild  renal  dysfunction  (50),  with  an  increasing  risk  as  the  renal  function 
becomes more impaired (51). 
g)  The presence of new Q waves (52). 
h)  Arterial graft and coronary artery diameter: the use of arterial grafts such the 
IMA has been associated with a significantly reduced rate of in-hospital and 
long-term mortality (53, 54), with no significant difference if single or multiple 
arterial grafts are performed (55-57). In addition, patients with a relatively 
small  diameter  of  the  coronary  arteries,  particularly  the  left  anterior   35 
descending (LAD), have an increased peri-operative risk, likely secondary to 
technical difficulties, thrombosis and reduced graft patency (58-60) 
i)  Other rarer complications, which have an impact on peri-operative mortality 
in patients undergoing CABG surgery, are gastrointestinal (61), metabolic 
(62) and haematological (63-66). 
Furthermore, risk factors of long-term mortality of patients undergoing cardiac surgery 
include: 
1.  Factors related to grafts used. The use of an IMA to LAD has been associated with 
better long-term clinical outcomes compared to the use of saphenous vein grafts 
(SVG) only (53, 54, 67-70). 
2.  PMI: this will be discussed later. 
3.  AKI and chronic kidney disease. 
4.  AF: this will be discussed later. 
5.  Pre-operative haemoglobin level (64). 
6.  Cardiovascular (CVS) risk factors including advanced age, hypercholesterolemia, 
diabetes, hypertension and smoking history, which have also been associated with 
increased mortality in patients undergoing CABG surgery (71-74). 
Crucially, the identification of these risk factors has also provided the opportunity to 
develop algorithms able to predict mortality risk in patients undergoing cardiac surgery, 
which  have  proved  to  be  a  very  useful  guide  to  clinicians  and  patients  on  the 
advisability  of  the  operation  by  weighing  both  risk  and  benefits  (75):  of  these,  the 
EuroSCORE  (European  System for Cardiac  Operative  Risk  Evaluation)  (1,  48,  76) 
(Table 1.2), is widely used in Europe and has recently also been adopted worldwide, 
due to its accurate predictive power of 1 and 12 months mortality. 
   36 
Table 1.2. EuroSCORE mortality risk prediction algorithm in patients undergoing cardiac surgery 
(modified from Nashef et al (1)) 
Predictor  Definition   Points 
Age  Per 5 years or part thereof over 60 years  1 
Sex  Female  1 
Chronic pulmonary disease  Long-term use of bronchodilators or steroids for lung disease  1 
Extracardiac arteriopathy  Any one or more of the following: claudication, carotid occlusion or >50 percent 
stenosis, previous or planned intervention on the abdominal aorta, limb arteries 
or carotids 
2 
Neurological dysfunction  Disease severely affecting ambulation or day-to-day functioning  2 
Previous cardiac surgery  Requiring opening of the pericardium  3 
Serum creatinine  >200 mmol/L (2.3 mg/dL) preoperatively  2 
Active endocarditis  Patient still under antibiotic treatment for endocarditis at the time of surgery  3 
Critical preoperative state  Any one or more of the following: ventricular tachycardia or fibrillation or 
aborted  sudden  death,  preoperative  cardiac  massage,  preoperative 
ventilation  before  arrival  in  the  anesthetic  room,  preoperative  inotropic 
support,  intra-aortic  balloon  counterpulsation,  preoperative  acute  renal 
failure (anuria or oliguria <10 mL/hour) 
3 
Unstable angina  Rest angina requiring intravenous nitrates until arrival in the anesthetic room  2 
LV dysfunction  Moderate or LVEF 30-50% 
Poor or LVEF<30% 
1 
3 
Recent myocardial infarct  <90 days  2 
Pulmonary hypertension  SPAP >60 mmHg  2 
Emergency operation  Carried out on referral before the beginning of the next working day  2 
Other than isolated CABG  Major cardiac procedure other than or in addition to CABG  2 
Surgery on thoracic aorta  For disorder of ascending, arch or descending aorta  3 
Post-infarct septal rupture    4 
LV=left ventricular; LVEF=left ventricular ejection fraction; SPAP=systolic pulmonary artery pressure; 
CABG=coronary artery bypass graft. 
 
 
It and can be used as both an additive or a logistic risk model: the former is a very 
useful “bedside” system, which enables the operator to classify patients undergoing 
cardiac  surgery  into,  low,  intermediate  and  high-risk  (Tables  1.3).  The  latter  uses 
logistic regression to calculate the risk of death. In our studies, we widely utilised the 
additive EuroSCORE due to its simplicity of use.   37 
Table 1.3. Peri-operative Mortality risk in patients undergoing cardiac surgery based on additive 
EuroSCORE (modified from Nashef et al(1)) 
EuroSCORE    Risk stratification                    Peri-operative Mortality 
0-2 
  Low risk  0.8% (0.56-1.1) 
3-5 
  Intermediate risk  3% (2.62-3.51) 
≥6 
  High risk  11.2% (10.25-12.16) 
 
 
 
 
 
 
1.3. Peri-operative Myocardial Injury 
Peri-operative  myocardial  injury  (PMI)  describes  the  damage  sustained  by  the 
myocardium  during  an  invasive  procedure  or  operation.  In  the  context  of  cardiac 
surgery it has been associated with worse short and long-term clinical outcomes (77-
82) and a significant number of factors have been implicated as potential underlying 
mechanisms (83). They include: 
1)  Direct myocardial damage, due retraction and handling of the heart (83). 
2)  Poor surgical technique, which might results in the following complications (84): 
a.  failure  of  the  aorto-coronary  bypass  grafts  due  to  inadequate  distal 
anastomoses or poor harvesting technique of saphenous veins (85); 
b.  prosthetic valve incompetence secondary to poor placement; 
c.  incomplete revascularisation, due to failure to recognise significant CAD 
or to achieve full revascularisation in severely diseased coronary arteries 
(84); 
d.  erroneous decision on repairing rather replacing a mitral valve (MV). 
3)  Systemic  inflammatory  response  to  extraneous  substances  in  the  CPB  circuit 
coming  into  contact  with  patient’s  blood,  direct  surgical  trauma,  blood  loss  and 
hypothermia,  which  can  induce  the  activation  of  complement  cascade,   38 
inflammatory  mediators  release  including  cytokines,  chemokines,  hormones, 
vasoactive  substances,  reactive  oxygen  species  (ROS),  enzymes,  ultimately 
leading  to  severe  inflammation,  coagulation  factors  consumption,  micro-
embolisation and multi-organ failure (86, 87). 
4)  LV over-distension, which can particularly occur when CPB has been established 
and  in  the  presence  of  significant  aortic  valve  (AV)  regurgitation,  leading  to 
retrograde  blood  flow  through  the  incompetent  AV  and  subsequently  to  LV 
distension and dysfunction (84). 
5)  Coronary athero-embolization, consisting in embolization of intracoronary thrombus 
or atherosclerotic particulate debris during coronary manipulation (88). 
6)  Increased cardiac workload in the intra-operative period (84).  
7)  Ischaemic injury, which can occur in the setting of both ICCF and cardioplegia as a 
consequence  of  intermittent  cross-clamp  of  the  aorta  carried  out  during  the 
attachment of the distal end of the graft anastomosis whereas the proximal end is 
constructed after declamping and therefore during the reperfusion phase. 
  In ICCF, despite the shorter cross-clamp times, the ischaemic insult is 
significant due to a combination of global ischaemia induced by cross-
clamp and subendocardial ischaemia caused by ventricular fibrillation in 
the reperfusion phase. 
  In  Cardioplegia,  the  more  significant  global  ischaemia  due  to  longer 
cross-clamp times is mitigated by the administration of cellular protective 
solutions initially and during each episode of aortic cross-clamp. 
In  summary,  the  magnitude  of  PMI  in  the  context  of  ICCF  and  cardioplegia  is 
essentially equivalent (31, 89-93) and the implications of this will be discussed in 
chapter 3.   39 
8)  Genetic predisposition (84): the presence of specific gene polymorphism has been 
associated  with  a  pro-inflammatory  state  generating  an  “excessive”  systemic 
inflammatory response to the above-mentioned factors, thereby leading to more 
significant PMI (94). 
9)  Myocardial stunning, a reversible contractile dysfunction secondary to reperfusion 
that follows global ischaemia induced by aortic cross-clamp (95). 
10)   Myocardial  ischaemia-reperfusion  injury  (IRI):  this  describes  the  myocardial 
damage induced by the restoration of blood flow following a period of prolonged 
ischaemia (96).  In the context of cardiac surgery, it is the results of intermittent 
aortic  cross-clamping,  intermittent  or  continuous  administration  of  cardioplegic 
solutions,  cross-clamp  fibrillation  or  a  combinations  of  these  procedures  (83). 
Myocardial IRI has been recognised as the most relevant potential cause of PMI in 
patients undergoing cardiac surgery (83) and has therefore been the subject of 
extensive  experimental  and  clinical  investigations  conducted  throughout  the  last 
few decades. These will be discussed in details in the next section. 
It is often difficult to distinguish PMI from MI associated with CABG surgery, termed 
type  5  MI,  and  this  is  due  to  the  fact  the  two  processes  have  some  pathogenetic 
factors in common and can be identified with similar diagnostic tools (97). Type 5 MI is 
defined by  cardiac  biomarkers rise  more  than  five  times the  99th  percentile  of the 
normal reference range during the first 72 hours following CABG, associated with the 
appearance of new pathological Q-waves or new left bundle branch block (LBBB), or 
angiographically documented new graft or native coronary artery occlusion, or imaging 
evidence  of  new  loss  of  viable  myocardium  (97).  Similarly  to  PMI,  Type  5 
pathogenesis is related to multiple potential factors leading to peri-procedural necrosis, 
including direct myocardial trauma from sewing needles or manipulation of the heart,   40 
coronary  dissection,  global  or  regional  ischaemia  secondary  to  inadequate  cardiac 
protection, microvascular events due to reperfusion, myocardial damage induced by 
ROS  generation,  or  failure  to  reperfuse  areas  of  the  myocardium  that  are  not 
subtended by graftable vessels (98-100).  
 
 
1.3.1. Identification of PMI following cardiac surgery 
As with type 5 MI, a variety of diagnostic approaches have been developed to identify 
PMI during cardiac surgery and correlate this with prognostic significance: clearly one 
of the most important strategy is a close monitor of any potential ECG changes, which 
might be suggestive of myocardial ischaemia.  During the last few decades, also highly 
sensitive imaging tests have been developed and include: 
  contrast  enhanced  cardiac  magnetic  resonance  imaging  (CMR),  which  has 
demonstrated  a  diminished  degree  of  LV  ejection  fraction  (LVEF)  reduction  in 
patients  undergoing  off-pump  cardioplegia  compared  to  those  undergoing 
cardioplegia (101); 
  tissue Doppler echocardiography, which has showed an association between PMI 
measured by  troponin  I  (TnI)  rise  and  reduced  right  ventricular    (RV)  velocities 
following paediatric surgery (102); 
  in  addition,  several  radionuclide  tracers,  including  thallium-201,  technetium-99m 
MIBI, tetrofosmin and 18F2-fluorodeoxyglucose (FDG) allow viable myocytes to be 
imaged directly (103-105),  although the relatively low resolution of the images can 
limit  the  detection  of  small  areas  of  infarction  (106).  In  particular,  ECG-gated 
imaging  provides  a  reliable  assessment  of  myocardial  motion,  thickening,  and 
global function (107, 108).   41 
Crucially, these imaging modalities often fail to identify subtle degrees of myocardial 
injury which may have instead prognostic relevance (109) and furthermore, their use in 
research and clinical practice is limited by their significant financial burden and the 
more  accessible  availability  and  sensitivity  of  serum  cardiac  biomarkers.  The 
emergence of cardiac biomarkers has made considerable advance in understanding 
the  occurrence  of  myocardial  injury  during  cardiac  surgery,  and  its  prognostic 
significance (Table 1.4).  
In particular, the GUARDIAN and ARTS studies first and Brener and colleagues 
showed  that  post-operative  CK-MB  levels  greater  than  10  times  the  upper  limit  of 
normal (ULN), were a positive predictor of mortality at 6-months and one-year (110, 
111). However, it was with the introduction of cardiac troponin that the diagnosis of 
PMI in cardiac surgery and in general of MI has been truly revolutionised. Cardiac 
troponin isoforms, such as troponin T, I or C (TnT, TnI, TnC) are integral part of the 
thin  filaments  of  myocite  cytoskeleton:  TnT  and  TnI  are  not  expressed  in  skeletal 
muscle,  whereas  TnC  is  also  present  in  smooth  muscle,  which  makes  the  former 
specific markers of myocardial injury (112).  Following myocardial injury, there is first a 
troponin release within 3-5 hours from membrane destruction, and a second release 
on the 5th subsequent day due to contractile apparatus damage (113). Eigel et al were 
the first to look at the prognostic implications of cardiac troponin rise following cardiac 
surgery: in a study of 540 patients undergoing CABG surgery, they showed that post-
surgical  increases  of  cTnI  concentrations  were  associated  with  worse  clinical 
outcomes  and  that  a  cut-off  at  cTnI>0.495ng/L  was  a  strong  predictor  of  adverse 
prognosis. TnI has also been demonstrated to be superior to CK-MB in identifying PMI 
in  patients  undergoing  CABG  surgery  as  it  offers  greater  accuracy  and  a  higher 
sensitivity, although more recently this finding has been quite controversial (82): in a   42 
retrospective analysis of 545 patients undergoing CABG surgery, Muehlschlegel and 
co-workers (82) demonstrated that cTnI was the strongest predictor of 5-year mortality 
compared to ECG and CK-MB. These findings were subsequently validated by other 
studies confirming that both TnT (114-117) and TnI (80, 118) rise following cardiac 
surgery is associated with worse short and long-term clinical outcomes (77, 82). More 
recently, a high-sensitivity TnT assay (hsTnT) has been introduced to increase TnT 
detection and is between 1000 and 10000 times more sensitive than the original first 
generation  assays  (Singulex  high  sensitivity  TnI):  it  therefore  has  a  high  negative 
predictive value in the diagnosis of ACS and myocardial injury in general, allowing an 
improvement of diagnosis certainty and timing at time points earlier than 10-12hrs. 
HsTnT 99th percentile of ULN is 0.014 ng/L with a 10% coefficient of variation of 0.03 
ng/L  and  a  limit  of  detection  of  0.0053  ng/L.  However,  the  disadvantage  of  its 
sensitivity is the frequent occurrence of hsTnT rise also in the context of conditions 
other  than  myocardial  injury,  particularly  inflammatory-infective  illnesses  and  renal 
impairment (112). It is relevant to note that hsTnT assay was used at the single centre 
where  we  conducted  our  study  on  remote  ischaemic  preconditioning  (RIPC)  using 
multi-limb IR, as well as at the 28 participating centres of the ERICCA trial. 
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Table 1.4. Major studies investigating the prognostic value of cardiac biomarkers in the setting 
of cardiac surgery 
Study   Patient number and clinical 
setting 
 
Cardiac 
biomarker  
Outcome  
Brener(119) 
2002  
3812  
CABG 
CK-MB   > 10 x ULN = independent predictor of 
mortality 
Eigel (120) 
2001 
540  
CABG 
 
Troponin-I    > 0.495ng/L = cut-off adverse outcomes 
prediction 
Lasocki (121) 
2002  
502  
CABG or valve surgery 
 
Troponin-I    >13ng/ml independent predictor of in-
hospital mortality.  
Fellahi (80) 
2003 
202  
CABG 
 
Troponin-I    >13ng/ml = increased 2-year mortality risk 
Katherisan (77) 
2004 
136  
CABG 
 
Troponin-T   > 1.58ng/ml = 1-year mortality rate 
predictor 
Lehrke (78) 
2004 
204  
CABG 
Troponin-T  >/=0.46ug/L = 4.9-fold increase risk of 
mortality 
Paparella (122) 
2005 
230  
CABG 
Troponin-I    > 13ng/l = predictor of in-hospital mortality, 
not of 2 years outcome 
Bottio (123) 
2006  
520  
Correction of congenital heart 
disease 
 
Troponin-I    >35μg/L = no prognostic significance at 12 
months 
Mildh (124) 
2006 
1001  
Paediatric cardiac surgery 
 
Troponin-I    > 5.9μg/L = predictor of death 
Fellahi (115) 
2008 
184  
CABG or AVR 
Troponin-I    serial troponin-I release and single 24-hr 
measurement were equally good as 
predictors of in-hospital outcome 
Buse (125) 
2009 
741  
CABG 
 
Troponin-T  > 0.1μg/L = predictor of 12-month mortality  
Nesher (118) 
2008 
1918  
CABG and/or valve surgery 
  
Troponin-T   >0.8μg/L = increased MACCE 
Muehlschlegel (82) 
2009  
545  
CABG 
Troponin-I    Compared with ECG and CK-MB, 
troponin-I was strongest predictor of 5 year 
mortality 
Mohammed (79) 
2009 
847  
CABG 
Troponin-T  Levels associated linearly with length of 
stay and ventilator hours and with death, 
death or heart failure, death or need for 
vasopressor and the composite of all 3 
 
Van Geene (117) 
2010 
938  
CABG or valve surgery 
Troponin-I    > 4.25nl/L = cut-off as in-hospital mortality 
predictor 
CABG=coronary  artery  bypass  graft;  AVR=aortic  valve  replacement;  ULN=upper  limit  of  normal; 
CK=creatine kinase; MACCE=major adverse cardiac and cerebrovascular events 
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1.4. Myocardial Ischaemia-Reperfusion Injury 
As  previously  described,  myocardial  IRI  defines  the  phenomenon  by  which  the 
restoration  of  blood  flow  to  an  organ  or  tissue  following  a  prolonged  period  of 
ischaemia can paradoxically lead to this organ or tissue injury (96, 126). This process 
has  been  extensively  investigated  in  the  heart  and  more  recently  has  also  been 
observed in other organs or tissues, such as kidneys, lungs, liver, brain, intestine, skin, 
skeletal  muscle  and  ovaries,  as  we  will  discuss  later.  In  the  context  of  acute  MI, 
successful restoration of reperfusion through thrombolytic therapy or primary PCI can 
itself induce cardiomyocyte death and increase infarct size. In animal models, it has 
been observed that IRI could account for up to 50% of the final infarct size (96, 127, 
128). Manifestations of myocardial IRI may manifest include (129): 
1.  Reperfusion arrhythmias. 
2.  Myocardial stunning. 
3.  No-reflow phenomenon. 
4.  Lethal ischaemia-reperfusion injury (IRI). 
 
 
1.4.1. Ischaemic Injury 
With  the  ischaemic  insult  and  the  depletion  of  oxygen  and  nutrients,  oxidative 
phosphorylation is significantly reduced with progressive ATP depletion and activation 
of the anaerobic glycolytic pathway, therefore leading to intracellular accumulation of 
lactic acid and loss of sodium and potassium (130). This subsequently causes gradual 
cellular swelling and increases cellular acidosis thus activating the sodium-hydrogen 
exchanger, with further sodium accumulation and initiation of reversed activity of the 
sodium-calcium exchanger. In physiological conditions the latter favours sodium import   45 
and calcium export in order to constantly regulate intracellular calcium concentration. 
However,  in  the  context  of  an  ischaemic  insult  causing  sodium  accumulation,  the 
sodium-calcium exchanger removes sodium from the cell and imports calcium into it 
(131). At the same time, in an attempt at ensuring ATP production, the cell uses fatty 
acids  from  cellular  and  mitochondrial  membranes,  therefore  leading  to  loss  of 
membrane integrity with further accumulation of sodium and calcium inside cytoplasm 
and  mitochondrial  matrix.  This  then  worsens  the  loss  of  cellular  components  and 
contributes to a transition from a potentially reversible phenomenon into an irreversible 
process leading to initiation of cell necrosis (132). The loss of mitochondrial membrane 
integrity also induces intracellular release of enzymes including cytochromes, caspase 
and protheolytic enzymes, ultimately responsible for cellular apoptosis and autophagy 
(130, 132).  
 
1.4.2. Reperfusion arrhythmias  
In the clinical setting, these occur particularly following thrombolysis, PPCI or cardiac 
surgery  and  may  manifest  as  an  accelerated  idioventricular  rhythm  (133).  The 
pathogenesis  of  reperfusion  arrhythmias  is  linked  to  the  loss  of  permeability  of 
mitochondrial membrane, which leads to destabilisation of the action potential across 
the cell membrane thereby increasing the susceptibility for the initiation of arrhythmias 
(133). 
 
1.4.3. Myocardial stunning 
This describes the myocardial dysfunction occurring further to an ischaemic injury and 
blood flow restoration. It is a transient, reversible phenomenon caused by persistent 
anaerobic metabolism following reperfusion and oxidative stress (134).   46 
1.4.4. No-reflow phenomenon or microvascular obstruction 
This may represent the consequence of platelet and complement cascade activation 
initiated by the ischaemic insult and consists of severe dysfunction of the resting blood 
flow in the microvasculature within the ischaemic area (135). Terminal complement 
cascade components cause direct injury to endothelial cells with platelet activation and 
reduced  endothelial  production  of  nitric  oxide  (NO),  subsequent  vasoconstriction, 
diminished microvascular perfusion and tissue necrosis (136).  
 
1.4.5. Lethal ischaemia-reperfusion injury 
Lethal IRI refers to the cell injury and death resulting from the restoration of blood flow 
to a tissue or organ subjected to a prolonged period of ischaemia and only reversibly 
injured by the ischaemic event (96).  
A  significant  number  of  potential  mechanisms  have  been  implicated  in  the 
pathogenesis of lethal IRI and these have been the subject of extensive experimental 
studies, however the translation of these findings from animal models to the clinical 
setting has been often disappointing (96) thereby raising the question of potentially 
significant disparities between the two settings (96). Therefore further laboratory and 
clinical  studies  are  needed  in  order  to  more  extensively  explore  these  fascinating 
mechanisms and identify agents able to reduce myocardial IRI and improve clinical 
outcomes  in  patients  with  known  IHD  and  undergoing  revascularisation  (137). 
Mechanisms implicated in the pathogenesis of lethal IRI include: 
1.  Oxygen  paradox. Restoration of oxygenation to an ischaemic area leads to 
activation  of  xanthine  oxydase,  neutrophils,  cyclooxygenase,  lipoxygenase,  and  to 
catecholamine oxidation, with subsequent ROS production, cell injury and death (138, 
139).   47 
2.  pH Paradox. Reperfusion enables cell washout of the previously accumulated 
lactic  acid,  with  rapid  restoration  of  intracellular  pH,  and  in  concomitance  with  the 
sodium-hydrogen  exchanger  and  the  sodium-bicarbonate  exchanger  activation:  this 
paradoxically  contributes  to  lethal IRI  by  inducing  the  mPTP  opening  and myocyte 
hypercontracture (140). 
3.  Calcium  paradox.  Following  restoration  of  normal  pH,  an  increased 
intracellular calcium accumulation occurs as a consequence of the reversed activity of 
the calcium-sodium exchanger due to sodium-hydrogen exchanger activation, and to 
cell,  sarcolemmal  and  mitochondrial  membrane  permeability  loss  (141),  with 
disproportionate  myofibrils  contracture  and  subsequent  myocyte  hypercontracture 
(142),  damage  to  myofibrils  and  other  cytoskeletal  components,  and  loss  of 
intercellular junctions (140).  
4.  Inflammation. Cytokines and activated complement components released by 
the  damaged  myocardium  induce  neutrophil  activation  (143),  with  subsequent 
production of proteases and elastases, which then contribute to cell destruction and 
death (144).  
 
In summary, it is clear that the understanding of the mechanisms underlying IRI 
can have an enormous impact on treatment of IHD and in general of conditions where 
IRI can occur. One of the potential crucial aspects of managing patients presenting 
with acute MI is, besides the prompt restoration of blood flow to the ischaemic areas, 
the prevention or at least the limitation of IRI and, in this regard, the seminal paper by 
Murry et al (145) provided a new potential strategy to limit infarct size and heralded the 
era of ischaemic preconditioning. 
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1.5. Ischaemic Preconditioning 
The  myocardium  possesses  innate  physiological  adaptive  processes  enabling  it  to 
become  more  resistant  to  subsequent  lethal  ischaemic  injury.  These  include  the 
development of coronary collaterals vessels, myocardium stunning and hibernation, 
and crucially ischaemic preconditioning (IPC) and postconditioning (IPost) (146). The 
concept of IPC was first introduced with the pioneering work by Murry et al in 1986 
(145), who reported a 75% infarct size reduction in dogs subjected to four-five minutes 
episodes of regional myocardial ischaemia, each followed by a five-minute period of 
reperfusion, and prior to a prolonged period of ischaemia: the protection given by brief 
episodes of sub-lethal ischaemia prior to a lethal index ischaemic insult   was then 
confirmed in a significant number of studies (147-151), and was also demonstrated in 
other organs, including  kidney (152), brain (153), lung (154), liver (155) and skeletal 
muscle  (156).  Crucially,  following  an  ischaemic  event,  studies  have  showed  a  first 
period  of  protection,  called  “first  window  of  preconditioning”  or  “early”  or  “classic” 
preconditioning which occurs immediately after the index insult and usually wanes off 
after  1-2  hours  (157,  158),  and  a  delayed  and  less  protective  “second  window  of 
preconditioning” after 12-24 hours, lasting up to 72 hours (159-162). 
 
 
1.5.1. Mechanisms of IPC 
The mechanisms underlying IPC involve the production of mediators, which following 
the binding with specific receptors, activate intracellular transduction pathways able to 
induce end-effectors ultimately responsible for cell protection.  
Potential mediators of IPC have been identified in adenosine (163-165), opioids (166-
170), acetylcholine (171, 172), catecholamines (173), angiotensin II (174), bradykinin   49 
(175), endothelin (176), and ROS (177-181). Cell membrane receptors include: Gi 
protein-coupled receptor (GPCR), for adenosine (165), bradykinin (175), opioids (168), 
angiotensin II (174), catecholamines (173), endothelin (176), urocortin, adrenomedullin 
and glucagon-like peptide (182); growth-factor receptors, for insulin, insulin-like-growth 
factor,  transforming  growth  factor,  fibroblast  growth  factor,  granulocyte  colony 
stimulating  factor,  erythropoietin  and  adipocytokines  (182);  and  ligand  specific 
receptors for atrial natriuretic peptide (ANP). In addition other non-receptor mediated 
pathways involved in IPC triggers have been described, such as mechanical stimuli 
such  heat  and  stretch,  and  substances  such  as  metformin,  statins  and  volatile 
anaesthetics (182). 
Following  receptors  activation,  an  intriguing  cascade  of  signal  intracellular 
transduction  pathways  occurs  and  involves  the  activation  of  pro-survival  protein 
kinases, such as the Reperfusion Injury Salvage Kinase (RISK)(182, 183), Survivor 
Activator Factor Enhancement (SAFE)(184), which ultimately lead to the inhibition of 
the opening of mitochondrial permeability transition pore (mPTP) (185, 186), the most-
important end-effector of IPC, thereby producing anti-necrotic, anti-apoptotic and anti-
autophagic  effects  and  reducing  cardiomyocyte  death  (182,  187).  MPTP  is  a  non-
specific  high  conductance  channel  situated  in  the  inner  mitochondrial  membrane, 
which  remains  closed  during  ischemia  and  opens  in  the  first  few  minutes  of 
reperfusion (188). It plays a major role in IRI as its opening induces: 1) increased 
water  and  solutes  influx  into  the  mitochondria,  with  subsequent  rupture  of  outer 
mitochondrial membrane and release of intermembrane cytochrome C and initiation of 
cell apoptosis and necrosis (189, 190); 2)  uncoupling of oxidative phosphorylation, 
leading to ATP hydrolysis, progressive ATP depletion, collapse of the mitochondrial 
membrane  potential  and  cardiomyocyte  death  (189,  190).  MPTP  comprises  the   50 
complex FOF1 ATP synthase (or complex V), the rotary enzyme able to synthetise the 
vast  majority  of  ATP  on  the  inner  mitochondrial  membrane  (191),  and  to  bind 
magnesium  and  ADP/ATP  in  the  presence  of  low  calcium  concentrations  (191): 
however,  the high calcium levels subsequent to an ischaemic event lead cyclophylin-
D  in  the  mitochondrial  matrix  to  bind  with  the  lateral  stalk  of  complex  V,  thereby 
causing a conformational change ultimately responsible for mPTP formation. Crucially, 
cyclosporine-A inhibits mPTP opening by preventing cyclophylin-D from binding FOF1 
dimers (191, 192) and has been demonstrated to induce LV function recovery, ATP 
preservation,  and  MI  reduction  when    given  at  reperfusion  (193):  it  is  therefore 
understandable  that  mPTP  has  soon  become  an  important  target  of  a  significant 
number  of  both  experimental  and  clinical  studies  in  the  search  for  the  specific 
mechanism able to prevent mPTP formation and subsequent myocardial cell death 
(194).Two  other  major  end-effectors  are  the  sodium-hydrogen  exchanger,  which 
reduces oncotic swelling of the cells and inhibits sodium-calcium exchanger thereby 
reducing  intracellular  calcium  accumulation,  and  the  gap  junctions  which  favour 
electrical coupling of cardiomyocytes and transport of active substances (195). 
 
 
 
1.6. Ischaemic Postconditioning 
A  crucial  aspect  of  the  cardioprotective  effects  of  IPC  is  the  need  to  apply  the 
preconditioning  stimulus  prior  to  the  index  ischaemic  insult.  However  in  clinical 
practice this is not applicable, as the onset of ischaemia in acute settings such as an 
MI  cannot  be  anticipated.  In  this  regard,  the  finding  that  the  application  of  the 
conditioning stimulus after the onset of the index ischaemic insult (IPost) is able to   51 
protect the heart from lethal IRI (196), provided a new potential strategy to reduce 
lethal  IRI.  Intriguingly,  further  studies  demonstrated  that  IPC  and  IPost  may  share 
similar  mechanisms  (197-200).  However,  both  IPC  and  IPost  require  an  invasive 
stimulus  to  be  applied  to  the  heart  in  order  to  confer  cardioprotection,  which  has 
significantly  limited  their  clinical  application:  the  discovery  that  the  heart  can  be 
protected by brief episodes of ischaemia and reperfusion applied to a distant organ or 
tissue prior to a period of sustained ischaemia, offered the potential of an innovative 
strategy for enhancing cardioprotection (201). 
 
 
 
1.7. Remote Ischaemic Preconditioning 
Remote ischaemic preconditioning (RIPC) describes the phenomenon by which brief 
episodes of sub-lethal ischaemia and reperfusion to one organ or tissue distant from 
another  organ  or  tissue,  are  able  to  reduce  IRI  in  this  organ/tissue  (201).  This 
intriguing  concept  was  first  introduced  by  Przyklenk  et  al  (201)  with  an  ingenious 
experiment sought to determine whether in anaesthetised dogs brief occlusions in one 
myocardial  vascular  bed  could  also  limit  infarct  size  and/or  attenuate  contractile 
dysfunction  in  remote  “virgin”  myocardium  subjected  to  subsequent  sustained 
coronary occlusion. Dogs were subjected to four episodes of 5-minute circumflex (Cx) 
occlusion and 5-minute reperfusion, followed by 1 hour of sustained LAD occlusion 
and  4.5  hours  of  reflow.  Infarct  size  was  significantly  reduced  (63%)  in  Cx 
preconditioned dogs compared to controls, proving that virgin myocardium could be 
protected  from  subsequent  sustained  coronary  occlusion  by  brief  episodes  of 
ischaemia  in  a  distant  or  “remote”  vascular  bed.  They  also  suggested  that  this   52 
protective effect could be mediated by “factor(s) activated, produced, or transported 
throughout the heart during brief ischemia/reperfusion” (201). This was therefore the 
first demonstration at the same time of the existence of both RIPC and its potential 
underlying mechanism: however similar results could not be reproduced in a study by 
Nakano  and  colleagues  (202),  who    subjected  rabbit  hearts  to  IPC  followed  by 
explantation  of  the  hearts  and  30  minutes  of  global  ischaemia  with  two  hours  of 
reperfusion: only the areas previously receiving IPC could be protected whereas those 
distant  or  “remote”  had  no  benefit:  this  led  to  the  conclusion  that  RIPC  could  be 
species or protocol-specific but also subsequently to the concept that intact humoral or 
neural mechanisms are required for RIPC to occur (203). 
From  these  models  of  intra-myocardium  or  intra-organ  RIPC,  subsequent 
experimental studies have brought to the discovery that cardioprotection can also be 
elicited when the RIPC stimulus is applied to organs or tissues different from the heart, 
including kidneys (204-209), intestine (205, 210-216), skeletal muscle (217-230) but 
not brain (231-233), therefore leading to the concept of inter-organ RIPC. 
Importantly,  the  recent  discovery  that  cardioprotection  can  be  induced  by  remotely 
preconditioning skeletal muscle/hind limbs led to the vast application of this type of 
RIPC stimulus to human studies: Birnbaum et al (217) were the first group to apply 
RIPC  to  an  animal  model  hind  limb.  In  a  seminal  study,  they  randomised 
anaesthetised  rabbits  to  30  minutes  of  waiting  period  (controls),  or  55%  to  65% 
reduction  of  femoral  artery  stenosis,  or  electrical  stimulation  of  the  gastrocnemius 
muscle,  or  stenosis  plus  stimulation:  this  was  followed  by  30  minutes  of  coronary 
artery occlusion and 4 hours of reperfusion. They found that the ratio of infarct size/risk 
zone  was  significantly  smaller  in  the  stenosis  plus  stimulation  group  compared  to 
control, stenosis, and stimulation groups, thereby concluding that the combination of   53 
muscle  stimulation  and  reduction  of  femoral  arterial  blood  flow  but  not  muscle 
stimulation  alone  or  flow  restriction  alone  could  reduce  MI  size.  An  important 
implication of this study was that by reducing arterial blood to 55-65% and inducing at 
the same time a demand-supply imbalance with the rapid pacing of the gastrocnemius 
muscle, the “transport” of a mediator of RIPC would be facilitated thereby obviating the 
need  for  a  reperfusion  phase.  From  Birnbaum’s  innovative  idea,  Oxman  and 
colleagues  (218)  were  the  first  to  apply  a  non-invasive  method  of  preconditioning 
stimulus. In rat models, they used a tourniquet to induce 10 minutes ischaemia and 
reperfusion  of  hind  limb  and  found  a  significant  reduction  of  the  incidence  of 
reperfusion tachyarrhythmias in the preconditioned group. Whilst a significant value of 
this study was to suggest a potential mediator for RIPC, its most important contribution 
to the further progress in understanding the mechanisms of preconditioning was the 
application of a non-invasive method of cardioprotection, which would understandably 
find wide application to humans in a number of different clinical settings. 
 
1.7.1. Mechanisms of RIPC  
A  significant  number  of  experimental  and  clinical  studies  has  been  conducted 
throughout the decades in order to identify the mechanistic pathway through which 
RIPC can protect an organ or tissue “at a distance”. These have been focused on 
three crucial targets (234): 
1)  the  mechanisms  triggered  by  the  preconditioning  stimulus  in  the  remote 
organ/tissue subjected to IR; 
2)  the transmission pathway of the protective stimulus from the organ or tissue 
where it is applied to the organ or tissue that is ultimately protected; 
3)  the cellular mechanisms through which this stimulus is able to confer organ or   54 
tissue protection against a sustained lethal ischaemia. 
 
1.7.1.1.  Generation  of  the  cardioprotective  stimulus  in  the  preconditioned 
remote organ/tissue 
Despite  the  significant  amount  of  research  in  this  filed,  we  are  still  far  from  the 
identification of the specific mechanisms triggered by the preconditioning stimulus at 
the distant organ or tissue. However, it is well known that transient periods of IR trigger 
the production  and  subsequent  release of  various  substances from  the  temporarily 
ischaemic  tissue  (234):  these  present  an  inter-species  variability  but  also,  and 
intriguingly,  an  intra-species  variability  (235),  which  could  also  be  related  to  the 
different  types  of  mediators  and  mechanisms  involved  at  the  different  sites  of  the 
stimulus (236). 
In the context of cardioprotection induced by skeletal muscle IR, opioids have been 
found to play a crucial role: Patel et al (211) demonstrated for the first time that the 
protective myocardial effect given by RIPC in rats could be abolished by the opioids 
antagonist naloxone: this finding was also by subsequent studies later (220, 237-239), 
which also led to the identification of δ1-(220, 238) and k-(239) opioid receptors ad key 
components of the intracellular transmission of the preconditioning stimulus. 
Importantly, Chen et al (224) demonstrated that NO could represent another important 
mediator  of  limb  RIPC  in  rats  where  the  protective  effects  of  hind  limb  IR  was 
abolished  by  NO-synthase  antagonist  L-nitro-arginine  methyl  ester  (L-NAME)  and 
similarly  Shashid  and  colleagues  (221)  proved  that  femoral  artery  ischaemia-RIPC 
was mediated by a combination of NO production, mito-KATP channel activation and 
ROS release. Subsequently, Chen and co-workers (240) confirmed the involvement of 
ROS in skeletal muscle IR by showing that the protective myocardial effects in rats   55 
were  associated  with  increased  activity  of  superoxidase  dismutase  and  glutathione 
peroxidase  and  could  be  abolished  by  mercaptopropionyl-glycine,  a  free  radical 
scavenger. 
In the context of mesenteric ischaemia, opioids (211, 241) and cannabinoids 
(242,  243)  have  been  found  to  be  implicated  in  cardioprotection,  with  particular 
evidence in favour of endocannabinoid CB2 receptors but not endocannabinoid CB1 
receptors. The neurotransmitter CGRP has also been found be involved in both early 
and late preconditioning (213, 244) following the intriguing experiments by Tang and 
colleagues  (213)  who  observed  reduced  CGRP  levels  and  abrogation  of  RIPC  in 
rabbits  following  the  administration  of  capsaicin,  which  cause  nerve  depletion  of 
CGRP.  As  with  studies  involving  adenosine,  it  has  also  been  proved  that  the 
administration of hexametonium could abolish preconditioning induced by CGRP and 
this was correlated with diminished PKC-ε activation (245). Similarly, the activation of 
intracellular PKC-ε (215) and the abrogation of cardioprotection with the administration 
of  bradykinin  B2  receptor  antagonist  HOE140  and  hexametonium  followed  by 
reactivation of RIPC further to bradykinin infusion (212) proved that bradykinin may 
also be implicated in RIPC. 
Interestingly, adenosine has been found to be involved in cardioprotection by renal 
ischaemia, both with “neural transmission” at remote level and translation of neural 
signals in the preconditioned organ (210), as demonstrated by: 
  the  abrogation  of  the  protective  effects  in  the  presence  of  adenosine  receptor 
antagonists (206, 207);  
  the increased blood level of adenosine in preconditioned rabbits (207) and mice 
(233); 
  the resistance to cerebral RIPC in adenosine receptor (A1R) knockout mice (233);   56 
  the  attenuation  of  renal  efferent  nerves  discharge  following  preconditioning  by 
adenosine receptor antagonist 8-sulphophenyltheophylline (8-SPT) (246); 
  the  reoccurrence  of  cardioprotection  following  intra-mesenteric  infusion  of 
adenosine  further to the addition of hexametonium and 8-SPT (247) and infra-
femoral infusion of adenosine further to femoral never section and the addition of 8-
SPT (248). 
These mediators, once released following the transient IR stimulus from the remote 
organ or tissue, are then able to “transfer” the signal to the myocardium as well as 
other distant organs or tissues including kidney, liver, lungs, brain, skin, ovaries and 
gastro-intestinal system. The specific mechanisms responsible for the “transmission” 
of  the  preconditioning  stimulus  to  the  targets  organ/tissue  have  not  yet  been  fully 
determined,  however  three  main  pathways  have  been  identified  with  evidence  in 
favour of each of them (234): 
1.  neural pathway; 
2.  humoral pathway; 
3.  systemic inflammatory response. 
 
1.7.1.2. Signal transmission to target organ/tissue 
In  1996,  Gho  and  co-workers  (205)  made  the  crucial  discovery  that 
cardioprotection could be induced by applying the preconditioning stimulus with brief 
episodes of anterior mesenteric artery or left renal artery occlusion and identified two 
fundamental aspects of the potential underlying RIPC mechanisms:  
1)  transient but not continuous mesenteric occlusion enhanced cardioprotection,   57 
suggesting  that  a  period  of  washout  was  necessary  for  a  putative  humoral 
factor  to  be  produced  in  the  ischaemic  tissue  or  organ  and  to  be  then 
transferred to distant organs or tissues; 
2)  the  administration  of  the  ganglion  blocker  hexametonium  abolished  the 
cardioprotective effects of transient mesenteric ischaemia, therefore indicating 
the possibility of an involvement of also a neuronal mechanism. 
Over the years, the scientific community has produced studies in favour of both the 
humoral and the neuronal theory but we are still quite far from the identification of the 
exact mechanism and more importantly, of the agent ultimately responsible for remote 
protection.  The  neural  theory  postulates  that  mediators  produced  in  the  “distant” 
ischaemic territory activate local afferent pathways first and efferent pathways then, 
which are then responsible for the transmission of the remote preconditioning stimulus 
to the target organ/tissue (234). Conversely, the humoral theory hypothesises that 
that  the  transient  ischaemic  insult  in  the  remote  organ/tissue  leads  to  the  local 
production of substances and their subsequent release into the systemic circulation, 
through which they are then able to reach and “protect” the target organ/tissue (234): 
this was consolidated by the finding that a period of reperfusion of the remote organ 
was necessary following brief ischaemia, suggesting that the reperfusion phase was 
required  to  ‘washout’  a  substance  or  humoral  factor  generated  by  the  transiently 
ischaemic territory, to be then transported through the vascular system to the heart 
(234). Birnbaum et al (217) hypothesised that cardioprotection could be induced via a 
humoral pathway  by  rapid pacing of  the  gastrocnemius muscle  in  the  rabbit  which 
caused partial femoral artery occlusion and therefore in the absence of the reperfusion 
phase. Subsequently, the humoral theory was further confirmed by Kristiansen (226) 
and  Kostantinov  (225),  who  found  that  previously  preconditioned  explanted  and   58 
therefore denervated hearts could be protected against prolonged ischaemia in rats 
(249)  and  pigs  (225,  249).  Similarly,  Wang  et  al  (214)  demonstrated  that 
hexametonium did not abolish cardioprotection induced by mesenteric ischaemia in 
contrast with the finding from Gho and co-workers (205), and Dickson’s groups (237, 
241, 250, 251) went further on to the “search” for the humoral factor, suggesting that 
this could involve norepinephrine as a potential mediator of RIPC (251). To date we 
have  not  yet  identified  such  a  mediator:  crucially,  it  has  been  identified  as  a 
thermolabile, hydrophobic substance with a molecular weight between 3.5 KDa (252) 
and  15  kDa  (230,  253).  Other  potential  “humoral”  mediators  of  RIPC  have  been 
identified in erythropoietin (208), hypoxia-inducible factor (HIF) (209), stromal derived 
factor-1 (254) and angiotensin-I (255) although their exact role has yet to be clarified.  
Importantly, at the same time, other relevant studies strengthened the neuronal 
theory  confirming  Gho’s  observation  that  cardioprotection  could  be  blocked  by 
ganglion antagonist hexametonium (210, 212, 215) and by proving that an intact renal 
nerve was essential in cardioprotection by renal preconditioning (246), although the 
role of an intact femoral nerve was more controversial (228, 248). In addition, nicotinic 
receptors antagonists and reserpine, a neurotransmitter uptake inhibitor at the level of 
the synaptic vesicle, have been demonstrated to interfere with RIPC (218, 256) and 
activation of the dorsal motor nucleus of the vagus nerve has been showed to induce 
cardioprotection even in the absence of the remote preconditioning stimulus in the 
skeletal muscle (257). Furthermore, substances such as adenosine (258), bradykinin 
(212) and CGRP have been associated with the neuronal mechanisms of RIPC, as 
findings suggest that their production is increased in the preconditioned organ and that 
they  activate  afferent  neural  pathways,  which  are  ultimately  responsible  for  the 
cardioprotective  effect.  Crucially  some  of  these  substances  activate  intra-cellular   59 
preconditioning pathways through the binding and stimulation of membrane receptors, 
such as A1, BK2, δ1-opioid, k-opioid and angiotensin 1-receptors, which all belong to 
the GPCR family and have already been described in the previous sections (234). An 
important  implication  of  this  is  that  IPC,  RIPC  and  IPostC  may  share  intracellular 
pathways in order to ultimately induce cardioprotection (234). Furthermore, Jensen et 
al (259) suggested that MI size in isolated naïve rabbit hearts could be reduced by the 
plasma dialysate obtained by RIPC-treated patients with or without DM and without 
sensory neuropathy but not by RIPC-treated diabetics with sensory neuropathy: this 
suggested firstly a crucial interaction between neural (vagal) and humoral pathways 
and secondly a sequential activation of mechanisms given by adenosine production in 
the preconditioned limb, sensory neural pathway activation though NO and brainstem 
dorsal  nuclei  stimulation,  although  the  process  through  which  the  signalling  is 
transmitted from the brainstem to the heart remains unclear (257, 260).  
In addition, the third potential mechanism potentially able to explain RIPC-signal 
transmission  is  the  systemic  anti-inflammatory  response:  this  was  first 
hypothesised by Peralta and colleagues  (261), who found that hepatic RIPC could 
produce  an  anti-inflammatory  effect  through  modulation  of  myocardial  gene 
transcription  profile  with  P-selectin  up-regulation  inhibition,  ultimately  resulting  in 
reduced  neutrophil  migration  and  oxidative  stress  and  therefore  in  an  anti-
inflammatory and anti-apoptotic effect. This concept was subsequently confirmed by 
further animal studies involving different organs including lungs (262, 263), stomach 
(244), and myocardium (264) but also in human trials (265).  
In  conclusion,  it  is  important  to  appreciate  that  despite  significant  efforts  to 
elucidate these mechanistic pathways, none of these has been fully and exclusively 
accepted and it is more likely that no single mechanism is uniquely responsible but   60 
rather that several complementary pathways coexist, interact with each other and are 
therefore not mutually exclusive (234). 
 
1.7.1.3. Intracellular signal transduction pathways and end-effectors of RIPC 
Experimental studies have showed that  PKC activation may mediate the protective 
effects of RIPC and that cardioprotection could be abolished by the administration of 
PKC blockers (214, 215, 228, 245): the isoform PKC-ε may be particularly implicated 
in the signal transduction following bradykinin BK2 (215) and CGRP (245) receptors 
stimulation.  Similarly,  mito-KATP  channel  has  a  role  in  the  signalling  pathways,  as 
demonstrated  by  the  abrogation  of  RIPC  with  specific  blockers  such  as  5-
hydroxytryptamine  (5HD)  blocker  (206)  and  glibenclamide  (225,  226).  Crucially, 
Loukogeorgakis et al (266) demonstrated that the protective effects of both remote 
post-conditioning  (RIPostC)  and  RIPC  on  endothelial  function  in  humans  was 
mediated  by  mito-KATP channel  and  that,  similarly  to  animal  models,  this  could  be 
blocked by the administration of glibenclamide.  Additionally, as with IPC, ROS might 
also have a significant role in transduction of the remote preconditioning stimulus (220) 
and its function might be closely correlated to that of NO and mito-KATP channel (221). 
NO  has  itself  been  showed  to  be  involved  in  RIPC  as  demonstrated  by  both  the 
induction of preconditioning following the administration of NO donors in rats (267) and 
the observation that such cardioprotection could be abolished by NO inhibitor L-NAME 
(224,  267),  whereas  further  experimental  studies  particularly  in  mice  have 
demonstrated the predominant role of NO in the delayed rather than the acute phase 
of preconditioning (214, 216, 225, 232). Crucially, the RISK pathway is the family of 
pro-survival  protein  kinases  the  main  components  of  which  are  PI3-K/Akt  and  Erk   61 
(1/2), may play an essential role in the intracellular mechanisms of IPC (183, 268-273), 
IPostC (274), but also in RIPC as recent studies have demonstrated that: 
  inhibition  of  p38,  Erk  1/2  and  JNK  1/2  abrogates  cardioprotection  following 
mesenteric preconditioning (275),  
  activation  of  p38  can  mediate  rat  adipocutaneous  flaps  induced  by  limb  IR 
(276), 
  p42/44  stimulation  is  essential  for  the  cardioprotective  effects  of  limb 
preconditioning both in rabbits and humans (229). 
Another  important  similarity  amongst  these  cardioprotective  mechanisms  is 
represented  by  the  end-effector  mPTP:  in  the  context  of  RIPC,  mPTP  has  been 
showed to represent the likely downstream target of both mito-KATP activation (277) 
and RISK pathway (272, 273). Cao et al (278) demonstrated that in anesthetised male 
Sprague-Dawley rats, cardioprotection could be induced by three cycles of 5 minutes 
of right femoral artery occlusion followed by 5 minutes of reperfusion and that these 
effects were attenuated by the mPTP activator atractyloside, whereas administration of 
the mPTP inhibitor cyclosporin A decreased the effect of IR, thereby demonstrating 
that the inhibition of mPTP opening is a crucial aspect of cardioprotection by RIPC. 
 
 
1.7.2. Clinical applications of RIPC 
Following  the  pioneering  discovery  that  the  myocardium  could  be  protected 
against IRI by transient hind limb IR in animal models (217, 218), the clinical potential 
of RIPC soon became very clear. Two major clinical properties of RIPC allowed its 
rapid translation into clinical research:   62 
1.  Its feasibility: the seminal finding that a non-invasive preconditioning stimulus 
could be applied to human volunteers with inflation/deflation of a simple blood 
pressure cuff inducing transient limb IR (222), heralded the application of RIPC 
into different clinical settings, which rapidly increased throughout the years and 
is yet intriguingly due to further expand to new contexts not so far being fully 
investigated. 
2.  Its flexibility: the main limitations of both IPC and IPost are the requirement for 
the stimulus to be applied at a specific time, respectively prior to the ischaemic 
phase  and  at  the  onset  of  the  reperfusion  phase,  and  directly  to  the  heart; 
conversely, the remote  conditioning stimulus can be applied prior to (RIPC), 
after  the  onset  of  (RiPerC)  or at  the  end  of  (RiPostC)  ischaemia  and  to  an 
organ/tissue distant or “remote” from the heart (274).  
Crucially,  the  first  clinical  trial  to  investigate  the  effects  of  RIPC  on  myocardial 
protection  was  by  Gunaydin  et  al  (279)  in  patients  undergoing  CABG  surgery:  the 
RIPC  stimulus  was  applied  by  simply  using  a  tourniquet  around  the  patients’  right 
upper arm for 3 minute, followed by 2 minutes of tourniquet release (a cycle which was 
repeated twice). Markers of PMI including CK-MB and lactate dehydrogenase (LDH) 
were  measured  before  CPB,  prior  to  declamping  of  the  aorta  and  5  minute  after 
declamping of the aorta. Only LDH levels at the second time point were significantly 
higher in the preconditioned patients with no other statistically significant difference 
between the groups: however this study was clearly underpowered as it only included 
8  patients.  Subsequently,  MacAllister’s  group  (222)  characterised  a  simple  non-
invasive RIPC protocol in healthy human volunteers, which was then extensively used 
in the subsequent clinical trials on RIPC: in this pioneering study, three cycles of 5-
minute ischemia and reperfusion of the upper limb with a simple blood pressure cuff   63 
inflation to 200 mmHg and deflation were applied prior to prolonged ischaemia in the 
contralateral  arm  subjected  to  blood  pressure  cuff  inflation  to  200  mm  Hg  for  20 
minutes, followed by deflation. This resulted in an increased response to acetylcholine 
in  the  forearm  subjected  to  prolonged  ischaemia  as  demonstrated  by  venous 
plethysmography. The application of this simple, non-invasive and virtually risk-free 
intervention heralded a new era of research of the potential benefits of RIPC delivered 
by transient limb IR in the setting of cardiac surgery in the first instance, and more 
recently also in different contexts, including non-cardiac surgery, elective or primary 
PCI (280). Importantly, the remote conditioning stimulus applied in the setting of PPCI, 
is  more  correctly  defined  as  remote  ischaemic  perconditioning  (RIPerC)  as  the 
transient limb IR induced by inflation and deflation of the blood pressure cuff takes 
place after the onset of the ischaemic insult (274). Conversely, the stimulus is termed 
remote  ischaemic  postconditioning  (RIPostC)  when  applied  at  the  time  of 
myocardial reperfusion (144). 
 
 
1.7.2.1. RIPC and Cardiac Surgery 
Following the original study by MacAllister’s group (222), Cheung et al (281) 
were  the  first  apply  the  concept  of  RIPC  with  limb  IR  to  the  clinical  setting:  in  a 
pioneering  trial  involving  17  children  undergoing  repair  of  congenital  heart  defects, 
they demonstrated that RIPC, induced by 4 cycles of 5 minute inflation of a blood 
pressure cuff applied to the lower limb, followed by 5 minutes of deflation, reduced 
postoperative  levels  of  cTnI,  inotropic  requirements  at  3  and  6  hours,  and  airway 
resistance.   64 
Our group (282) showed for the first time that adult patients undergoing elective 
CABG  surgery  and  receiving  three-5  minutes  cycles  of  upper  arm  IR  sustained  a 
significantly  lower  magnitude  of  PMI  than  control  patients.  Since  these  ingenious 
applications,  RIPC  with  limb  IR  has  been  extensively  investigated  in  a  significant 
number of clinical studies in the setting of CABG surgery alone, valve surgery alone or 
a  combination  of  the  two  and  in  the  context  of  corrective  paediatric  surgery  for 
congenital  heart  disease  (Table  1.5):  importantly,  the  majority  of  these  trials  have 
confirmed the cardioprotective effects of RIPC, however more recently a number of 
RCTs  have  failed  to  demonstrate  any  significant  beneficial  effects.  The  potential 
reasons for this will be extensively elucidated in chapter 3, however here we intend to 
briefly explain the limitations of these studies and the possible causes for the negative 
results in order to then clarify the rationale of our two studies.  
 
1.7.2.1.1. “Drawbacks” of clinical trials on RIPC in cardiac surgery 
A  first  crucial  consideration  emerging  from  the  analysis  of  the  RCTs  so  far 
conducted  to  determine  the  effects  of  RIPC  in  the  context  of  cardiac  surgery  is 
represented  by  the  highly  difficult  translation  “from  benchmark  to  bedside”  and 
therefore from the setting of experimental studies to that of human trials. The clinical 
context that most closely matches the experimental model is the patient undergoing 
PPCI  for  STEMI,  which  is  secondary  to  acute  coronary  artery  occlusion:  similarly, 
animal models are subjected to myocardial IRI by direct ligature of the coronary artery. 
Conversely, the majority of the clinical studies on RIPC have been conducted in the 
context of elective cardiac surgery, where also the magnitude of myocardial injury is 
relatively low and it is therefore possible that the further beneficial effect provided to 
these  patients by  RIPC might be  too  small  to  be  have  significant  relevance  in the   65 
studies  evaluated  (280).  Moreover,  animal  models  present  either  no  pre-existing 
disease or experimentally reproduced conditions, whereas the vast majority of patients 
with CAD have multiple co-morbidities, such as hypercholesterolemia, hypertension 
and  above  all  diabetes,  which  may  have  a  crucial  impact  on  RIPC-induced 
cardioprotection  (this  will  be  discussed  in  details  in  chapter  6).  In  addition,  animal 
models  are  not  on  concomitant  pharmacological  therapy  and,  conversely,  patients 
enrolled  into  RCTs  are  often  on  various  medications,  including  insulin,  atorvastatin 
nicorandil, clopidogrel, cangrelor, and may additionally receive further agents during 
surgery,  such  as  inhalant  anaesthetics,  glyceryl trinitrate  (GTN),  opioid  (comprising 
morphine,  fentanyl  or  remifentanyl).  It  is  extremely  relevant  to  note  that  these 
pharmacological  agents  have  been  demonstrated  to  mimic  IPC  (283)  and  that 
therefore  it  is  again  possible  that  RIPC  may  add  no  further  benefit.  Ultimately,  in 
experimental studies no CPB is used, which instead is extensively utilised on patients 
recruited in the vast majority of RCTs, with the exception of the two studies from Hong 
et  al  (284,  285)  where  only  patients  undergoing  off-pump  CABG  surgery  were 
enrolled:  in the next chapters, this will be extensively explained. 
 
We have so far explained the crucial differences between preclinical and clinical 
studies and the reasons for the difficult translation of the encouraging outcomes in the 
former  to  positive  findings  in  the  latter.  In  addition,  other  critical  differences  exist 
amongst the various published RCTs in this field and this might also in part explain the 
discrepancies of the results obtained. In the first instance, we have already mentioned 
that  elective  cardiac  surgery  is  the  clinical  setting  observed  in  the  vast  majority  of 
these trials: intriguingly, one of the so far largest proof-of-concept trials enrolled both 
stable and unstable patients (286). Importantly, unstable angina (UA) is secondary to   66 
transient ischaemia and could therefore act as a preconditioning stimulus before an 
MI: there is currently clear evidence that patients who have experienced episodes of 
UA prior to MI have better outcomes than those with no pre-existing symptoms (287, 
288),  who  conversely  represent  the  closest  translation  of  animal  models.  A 
consequence of this is that the additional benefit provided by RIPC in subjects already 
“preconditioned”  by  recent  angina  episodes  might  only  lead  to  non-significant 
differences in PMI and clinical outcomes. Furthermore, from table 1.10 it is clear that 
diabetes has played a major role in the selection of patients recruited into the different 
clinical  studies  and  this  is  due  to  the  interference  of  this  condition  with  the 
cardioprotective mechanisms of RIPC: in the literature, we have therefore observed 
trials excluding patients with DM or involving both diabetic and non-diabetic subjects or 
crucially enrolling diabetic patients only. This important aspect will represent the focus 
of our attention in chapter 6 where we will describe a retrospective analysis of our 
principal  study  involving  subgroups  with  or  without  DM.  Other  crucial  elements  of 
differentiation exist amongst the clinical studies and consist of:  
  the  type  of  operation,  including  CABG  surgery  alone,  valve  surgery  alone  or  a 
combination of the two, with subsequent different magnitude of PMI sustained; 
  the technique of myocardial preservation utilised, comprising ICCF or cardioplegia, 
and  amongst  those  studies  involving  cardioplegia  only,  the  delivery  and 
composition of cardioplegia; 
  the  anaesthetic  regime  used,  with  clinical  studies  utilising  a  strict  anaesthetic 
regime or protocols related to the anaesthetists’ individual experience. 
Ultimately, a further critical aspect needs careful consideration and is given by the 
diversity of the protective  stimulus applied: indeed the preconditioning stimulus in 
different clinical studies varies considerably with respect to number of cycles, timing of   67 
delivery (prior to versus after surgical incision), upper or lower limb utilised for the 
application, blinding and delivery of the stimulus (in the study by Rahman et al (286), 
the cuff was kept hidden under a surgical gown in order to ensure blindness in the 
study protocol). Whilst it is therefore clear that further studies are required in order to 
characterise the preconditioning stimulus in this regard, it is also crucial to emphasise 
the potentially critical role of the intensity of the preconditioning stimulus, which may 
not be sufficient to elicit cardioprotection under specific conditions: the majority of the 
clinical studies have used a standard single-limb RIPC protocol comprising three or 
four-5 minute cycles of inflation/deflation of a cuff placed on either the upper arm or 
thigh  to  induce  transient  IR.  However,  several  recent  studies  have  failed  to 
demonstrate  a  significant  reduction  in  PMI  using  this  standard  single  limb  RIPC 
stimulus, suggesting that this RIPC stimulus may be ineffective  in specific settings. 
Importantly,  in  our  single  centre  RCT,  we  have  used  a  simultaneous  multi-limb 
preconditioning  stimulus  in  order  to  “overcome”  potential  resistance  to  the 
cardioprotective effect. 
It is also extremely relevant to highlight fundamental aspects of both positive 
and negative RCTs: as clearly evidenced in table 1.10, the vast majority of the RCTs 
investigating the effects of RIPC in the context of cardiac surgery are represented by 
small proof-of-concept trials, recruiting a limited number of patients in single centers: it 
is therefore possible that larger multi-centre studies will be able to more accurately 
evaluate the potential beneficial effects of RIPC. Moreover, most of these trials were 
single-blinded which may have introduced an element of bias into the final outcomes: 
intriguingly,  it  has  been  suggested  that  the  majority  of  single-blinded  studies  were 
positive, whereas the majority of the double-blinded studies were negative (289). In 
addition,  in  most  cases,  the  study  primary  end-point  consisted  in  the  total  PMI,   68 
measured  by  troponin  or  CK-MB  release  at  specific  time-points,  either  as  peak  or 
mean concentration or as a total post-operative AUC: this outcome has been clearly 
associated  with  short  and  long-term  morbidity  and  mortality  in  these  patients  (see 
table 1.9), however it represents a “surrogate” endpoint and therefore stronger clinical 
outcomes are required in order to accurately evaluate the potential effects of RIPC in 
cardiac  surgery.  A  further  significant  drawback  of  the  above-mentioned  RCTs  is 
patient selection, with exclusion of high-risk patients, particularly those with DM, CKD, 
recent ACS or undergoing complex cardiac surgery. Crucially in these regards and 
compared to the so far published proof-of-concept studies, the ERICCA trial has the 
significant  advantages  of  being  a  large  multi-centre  doubled  blinded  randomised 
clinical trial with a total of 1612 high-risk patients undergoing CABG surgery with or 
without valve surgery recruited and with an additive EuroSCORE of at least 5: the 
study primary study-endpoint is the rate of major cardiac and cerebro-vascular events 
(MACCE) at 1 year following surgery (290): the results of this trial, available in March 
2015,  have  therefore  the  potential  to  change  current  clinical  practice  with  the 
application of a simple non-invasive and non-pharmacological intervention.  
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Table 1.5. Major clinical studies investigating the effects of RIPC in cardiac surgery 
 
Group 
 
 
Patient group and 
surgery setting 
 
 
RIPC Stimulus 
 
Myocardial Injury 
Outcome 
 
Note 
 
 
CABG with or without valve surgery 
 
 
Hausenloy  (282) 
(2007) 
 
 
 
57  
Elective CABG 
Cold-blood 
cardioplegia 
and ICCF  
 
 
Upper-limb 
ischaemia 
(3 cycles of 5 min) 
 
 
↓ AUC of cTnT 
(43%) 
 
 
Patients with CKD excluded 
 
 
Venugopal (291) 
(2009) 
 
 
 
45  
Elective CABG±Valve 
Surgery  
Cold-blood cardioplegia 
 
Upper-limb 
ischaemia  
(3 cycles of 5 min) 
↓ AUC of cTnT 
(42.4%) 
 
Patients with DM and/or CKD 
excluded 
 
 
Ali (292) 
2010 
 
 
100  
Elective CABG  
 
Upper-limb 
ischaemia  
(3 cycles of 5 min) 
↓ AUC of CK-MB  Enrolled patients with two or 
three vessel disease 
 
Thielmann (293) 
(2010) 
 
 
 
53  
Elective CABG 
Cold crystalloid 
cardioplegia 
 
Upper-limb 
ischaemia  
(3 cycles of 5 min) 
↓ AUC of cTnI 
(44.5%) 
 
Diabetic patients excluded 
 
 
Rahman  (286) 
(2010) 
 
 
 
162  
Elective CABG  
Cold-blood cardioplegia 
 
Upper-limb 
ischaemia  
(3 cycles of 5 min) 
No difference in cTnT, 
ECG changes, 
inotrope score, renal 
and lung injury 
Diabetic patients excluded 
 
 
Karuppasamy (294) 
2011 
54 
Elective CABG  
Cold-blood cardioplegia 
and cross-clamp 
fibrillation  
 
Upper-limb 
ischaemia  
(3 cycles of 5 min) 
No difference in cTnI, 
BNP, CK-MB, 
cytokines or growth 
factors 
All patients received isoflurane 
before CPB and propofol post-
CPB. 
 
 
Hong (284) 
2010 
 
 
130  
Elective off-pump CABG 
Upper-limb 
ischaemia 
(4 cycles of 5 min) 
No significant 
difference in AUC of 
cTnI  
 
No RIPC alone or RIPost 
alone groups. 
 
Wagner (295) 
2010 
101 
Elective CABG 
Cold crystalloid 
cardioplegia 
 
Upper limb 
ischaemia 
(3 cycles of 5 min) 
 
↓TnI at 8 hours only 
Tramadol group had 
↑ TnI at 8, 16 and 24 
hours. 
RIPC protocol delivered 18 
hours before operation 
Third group included patients 
receiving tramadol day before 
and on the day of the 
operation 
 
 
Young (296) 
2012 
 
96 
High risk cardiac 
surgery 
Cold blood cardioplegia 
Upper-limb 
ischemia  
(3 cycles of 5 min) 
↑ hsTnT release in 
RIPC group. 
High risk = CABG + valve 
surgery, CABG with 
LVEF<50%, any “redo” 
operation, MV surgery, double 
or triple valve surgery 
 
 
 
Lomirotov  (297) 
2012 
 
 
80  
Elective CABG 
Cold crystalloid 
cardioplegia 
 
 
Upper-limb 
ischemia  
(3 cycles of 5 min) 
 
 
No difference in TnI or 
CK-MB release 
 
 
Patients with DM and/or CKD 
excluded 
TnI and CK-MB measured 
pre-operatively and at 6, 24 
and 48 hours post-CPB but 
not at 12 and 72 hours post-
CPB.  
 
 
Kottenberg (298) 
2012 
72 
Elective CABG 
Cold crystalloid 
cardioplegia 
Upper-limb 
ischemia  
(3 cycles of 5 min) 
 
Reduction of cTnI 
AUC only when 
RIPC given with 
isoflurane and not 
propofol 
 
 
 
Diabetic patients excluded 
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Hong (285) 
2012 
 
 
70 
Elective off-pump 
CABG 
 
Lower-limb 
ischaemia 
(4 cycles of 5 min) 
 
↓ AUC of cTnI 
 
 
RIPC was given with RIPost 
 
 
Lucchinetti (299) 
2012 
 
 
55 
Elective CABG 
Cold blood 
cardioplegia 
 
Lower limb 
ischaemia 
(4 cycles of 5 min) 
 
No difference in 
TnT, BNP, CRP, 
S100 protein or long 
term-clinical 
outcomes 
 
 
BP inflated to 300mmHg 
Anaesthesia induction: 
opioids, propofol 
Anaesthesia maintenance: 
isoflurane 
 
 
Thielmann (300) 
2013 
 
329  
Elective CABG  
Cold crystalloid 
cardioplegia 
 
Upper-limb 
ischaemia  
(3 cycles of 5 min) 
↓ AUC of cTnI 
↓ All-cause mortality 
Diabetic patients excluded 
 
 
 
Valve surgery  
 
 
Li (301) 
2001 
 
 
 
 
40 
MVR, AVR, DVR 
Crystalloid cardioplegia 
 
Aortic cross-clamping 
(two cycles of 3 
minutes of ischaemia 
and 2 minutes of 
reperfusion) 
 
Improved 
pulmonary 
function and 
decreased 
inflammatory 
response 
 
 
Li (302) 
2010 
 
81 
Elective valve replacement 
Cold crystalloid-blood 
cardioplegia 
 
RIPC group: lower 
limb ischemia (3 x 4 
min) before aortic 
cross-clamping 
RIPerC group: lower 
limb ischemia (3 x 4 
min) after aortic cross-
clamping 
RIPC group: no 
difference in TnI 
AUC 
RIPerC group: 
40% reduction of 
peak TnI but no 
difference in TnI 
AUC 
 
Preconditioning stimulus: blood 
pressure inflation around the upper 
thigh to 600 mmHg 
 
Excluded patients with DM, CAD, 
IE, HTN, PAD affecting lower 
limbs, and previous cardiac 
surgery. 
 
Choi (303) 
2011 
 
76 
Complex valve surgery 
Blood cardioplegia 
 
Lower limb ischemia 
(3 x 10 min) 
Significant CK-MB 
reduction at 24 
hours only 
 
No difference in 
renal injury 
biomarkers 
CK-MB measured pre-operatively 
and at 12 and 24 hours post-
operatively 
 
Complex valve surgery = double-
valve surgery, combined valve and 
CABG procedures, Bentall 
operation, combined MV and TV 
annuloplasty or reoperation 
 
 
Xie (304) 
2011 
 
 
 
73  
Elective valve replacement 
Cold blood cardioplegia 
 
 
 
Upper-limb ischemia  
(3 x 5 min) 
 
 
44% reduction in 
TnI AUC 
 
Young (296) 
2012 
 
96 
High risk cardiac surgery 
Blood cardioplegia 
 
 
Upper-limb ischemia  
(3 x 5 min) 
Increased hsTnT 
release in RIPC 
group. 
High risk = CABG + valve surgery, 
CABG with LVEF<50%, any “redo” 
operation, MV surgery, double or 
triple valve surgery 
 
Kim (305) 
2012 
 
 
 
 
 
54 
Complex valve surgery 
Blood cardioplegia 
 
RIPCpre plus RIPost 
stimulus: 3 x 10 
minutes cycles of 
lower limb ischaemia 
10 minutes after 
anaesthetic induction 
and prior to CPB 
discontinuation 
 
 
No myocardial 
injury outcome 
 
No difference of 
pulmonary 
function between 
intervention 
groups. 
 
 
 
Cuff inflated to 250 mmHg 
Wu (306) 
2011 
75 
MVR 
Blood cardioplegia 
 
 
 
 
LIPC-I (3x5 cycles of 
upper arm ischaemia) 
LIPC-II (3x5 cycles of 
upper arm ischaemia) 
plus 2x10 min cycles 
of upper leg 
ischaemia) 
 
Reduced TnI 
release in LIPC-II 
group only 
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Corrective paediatric surgery 
 
 
Cheung (281) 
(2006) 
 
 
 
 
37 
Elective paediatric 
cardiac surgery 
 
Lower-limb 
ischaemia 
(4 cycles of 5 min) 
 
↓ cTnI 
↓ inotrope score 
↓ airway resistance 
 
   
Zhou (307) 
2010 
 
60 
Elective surgical 
repair of simple 
congenital heart 
defect 
 
Upper-limb 
ischaemia  
(3 cycles of 5 min) 
 
 
↓ cTnI/CK, CK-MB 
↓ systemic inflammatory 
response 
↓ airway resistance 
 
RIPC applied 24 hrs and  
1 hr prior to surgery 
Pavione (308) 
2012 
 
22 
Elective paediatric 
cardiac surgery 
 
Lower-limb 
ischemia 
(4 cycles of 5 min) 
No significant TnI 
reduction 
Significant reduction of 
NT-proBNP AUC 
No difference in post-
operative inflammatory 
response 
 
RIPC stimulus given 24 hrs prior 
to the operation 
 
Jones (309) 
2013 
 
39  
Elective paediatric 
surgery 
 
Lower-limb 
ischemia 
(4 cycles of 5 min) 
No significant difference in 
PMI, inotropic 
requirement, renal or 
cerebral injury 
 
Neonates with transposition of 
the great arteries or  
hypoplastic left heart syndrome 
McCrindle (310) 
2014 
299 
Elective paediatric 
cardiac surgey 
 
Lower-limb 
ischemia 
(4 cycles of 5 min) 
No difference in hospital 
stay duration 
   
RIPC=remote ischemic  preconditioning; cTnI=cardiac troponin-I; CK=creatine  kinase; NT-proBNP=N-
terminal pro-brain natriuretic peptide; AUC=area-under-the-curve; CABG=coronary artery bypass graft; 
cTnT=cardiac  troponin-T  RIPost=remote  ischaemic  postconditioning;  CKD=chronic  kidney  disease; 
DM=diabetes  mellitus;  LVEF=left  ventricular  ejection  fraction;  CPB=cardiopulmonary  bypass; 
BNP=brain natriuretic peptide; CRP=C-reactive protein; MV=mitral valve. DVR=aortic and mitral valve 
replacement; MVR=mitral valve replacement; LIPC=limb ischaemic preconditioning 
 
 
 
1.7.2.2. RIPC and Non-Cardiac Surgery 
The setting of major vascular surgery and particularly elective abdominal aortic 
aneurysm  (AAA)  repair  has  been  another  important  field  to  which  the  concept  of 
cardioprotection  induced  by  RIPC  has  been  applied  (Table  1.6):  MI  was  the  most 
common cause of both early and late mortality after elective AAA repair and affected 
3.1% of patients in a survey involving 557 subjects  (311). Haggart and colleagues 
(312) demonstrated that cTnI can rise in up 58% of emergency AAA repair operations 
and 29% of elective cases. Moreover, Barbagallo et al (313) showed that even small 
early  increases  of  cardiac  enzymes  can  affect  morbidity  and  mortality  in  patients 
undergoing major vascular surgery. Crucially, preoperative coronary revascularisation   72 
has not been demonstrated to provide additional benefits on clinical outcome post-
AAA repair (314), and this could be as a result of non-haemodynamically significant 
stenosis (315). 
Another  important  aspect  of  post-operative  complication  of  major  vascular 
surgery is AKI, which can occur in up to 10% of these patients as a consequence of 
hypoperfusion secondary to aortic cross-clamp and IRI (316). It also affects morbidity 
and mortality after elective AAA repair (317) and is an independent predictor of death 
in these patients  (318). It is therefore clear that  strategies are required in order to 
protect the myocardium and the kidney during the perioperative period in these high-
risk patients and RIPC offers the potential to provide multi-system protection from PMI, 
AKI and other major organ injury. 
Ali et al (292) were the first group to apply the concept of RIPC to patients 
undergoing AAA repair: in a study involving 82 subjects, RIPC was given with two 
cycles of intermittent cross-clamping of the common iliac artery with 10 minutes of 
ischaemia followed by 10 minutes of reperfusion, and was associated with a reduced 
incidence of PMI, post-operative MI and AKI.  Subsequently, Walsh and colleagues 
(319) evaluated cardiac and renal injury in 40 patients undergoing endovascular AAA 
repair (EVAR) using sequential lower limb ischaemia and concluded that there was no 
difference  between  preconditioned  and  control  patients  with  respect  to  cardiac 
outcomes,  however  RIPC  subjects  had  a  lower  increase  in  postoperative  urinary 
retinol  binding  protein  (RBP)  levels  and  a  lower  median  urinary  albumin/creatinine 
ratio. In two additional studies (320, 321), the same authors failed to provide beneficial 
effects of RIPC on cardiac or renal outcomes in the setting of elective open infra-renal 
aortic aneurysm repair (320), or of elective carotid endarterectomy (CEA) (321), where 
the  preconditioning  stimulus  applied  with  10-minute  inflation-deflation  of  a  blood   73 
pressure cuff around both upper thighs sequentially. Finally, Li et al (322) showed that 
standard upper limb IR reduced pulmonary and intestinal injury in patients undergoing 
elective  open  AAA  repair,  however  no  benefit  was  found  with  RIPC  in  cardiac  or 
neurological outcomes or hospital/ICU stay. 
It  is  also  relevant  to  note  that  the  on-going  Preconditioning  Shields  Against 
Vascular Events in Surgery (SAVES) RCT is being conducted in order to determine 
whether RIPC with 4 cycles of upper arm IR improves MACCE rate at 30 days in 
patients  undergoing  aortic  aneurysm  repair,  carotid  endarterectomy,  lower  limb 
surgical  revascularisation  and  major  lower  limb  amputation  for  end-stage  vascular 
disease (ClinicalTrials.gov identifier: NCT01691911) 
 
 
 
 
Table 1.6. Major clinical studies investigating the effects of RIPC in vascular surgery 
 
Group 
 
 
Patient group and 
surgery setting 
 
 
RIPC Stimulus 
 
Myocardial Injury Outcome 
 
 
 
Ali (292) 
2007 
 
 
 
41 
Elective AAA repair 
 
2 cycles of sequential cross 
clamping of right and left iliac vessel 
for 10 min 
 
↓ PMI and AKI 
Walsh (319) 
2009 
 
18 
Elective EVAR 
 
2 cycles of lower limb ischemia an 
reperfusion (each 10 min) 
No difference in cardiac or renal outcomes  
Walsh (320) 
2009 
 
22 
Elective open AAA 
repair 
 
2 cycles of sequential cross 
clamping of right and left iliac vessel 
for 10 min 
 
No difference in cardiac, renal or clinical 
outcomes  
 
Walsh (321) 
2010 
 
34 
Elective CEA 
2 cycles of lower limb ischemia an 
reperfusion (each 10 min) 
No difference in cardiac or renal outcomes 
or saccadic latency 
Li (322) 
2013 
 
31 
Elective open 
infrarenal AAA repair 
 
Upper-limb ischaemia 
(3 cycles of 5 min) 
 
↓ Pulmonary and intestinal injury and 
systemic inflammatory response. No 
difference in renal, neurological or cardiac 
outcomes 
 
RIPC=remote ischemic preconditioning; AAA=abdominal aortic aneurysm; EVAR=endovascular aortic 
aneurysm  repair;  CEA=carotid  endo-arterectomy;  PMI=peri-operative  myocardial  injury;  AKI=acute 
kidney injury. 
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1.7.2.3. RIPC and elective PCI 
Patients undergoing elective PCI are subject to PMI in up to one third of cases (323) 
and,  similarly  to  the  context  of  cardiac  and  non-cardiac  surgery,  post-procedure 
elevation of cardiac biomarkers including CK-MB, TnI, TnT has been associated with 
worse short and long-term clinical outcomes (324-329). A number of factors have been 
identified for their significant impact on PMI magnitude in elective PCI and are related 
to (330):  
1.  patient, such as advanced age (331), systemic atherosclerosis (332), diffuse CAD 
(332), multi-vessel CAD (332), CKD (333), anaemia (334), CRP elevation (335) 
and white blood cell count>9.5 x106 prior to PCI (336); 
2.  angiographic  lesion,  including  calcification,  anatomical  complexity  of  the  lesion, 
plaque burden, bifurcation lesions and tortuosity (13, 337); 
3.  procedure, comprising stent length, suboptimal stent insertion, directional coronary 
atherectomy versus angioplasty. 
In the context of PCI, PMI can be caused by two different mechanisms:  
a.  side branch occlusion (19% of cases) during balloon inflation or stent insertion: it  
occurs adjacent to the treated coronary segment due to plaque shift, dissection, 
spasm, embolization and thrombus formation (proximal type or type 1) (338);  
b.  structural  and  functional  micro-vascular  obstruction  in  the  territory  distal  to  the 
treated  segment  (50-75%  of  cases),  due  to  distal  embolisation,  microvascular 
plugging  secondary  to  platelet  and  neutrophils  activation,  oxidative  stress, 
inflammation, vascular neuro-hormonal modulation (distal type or type 2) (338). 
The concept of PMI in the context of elective PCI and the subsequent prognostic value 
of  cardiac  biomarkers have  therefore  led  to  the  application  of  RIPC to  this clinical   75 
setting  with  the  aim  to  reduce  post-procedure  myocardial  damage  and  therefore 
improve patients’ clinical outcomes (Table 1.7). 
In a first study conducted by Iliodromitis et al (339) on patients with single-vessel 
CAD undergoing elective uncomplicated PCI, RIPC, given with three-5 minutes cycles 
of  both  upper  limbs  IR,  did  not  attenuate  the  inflammatory  response  and  was 
associated with a significant CK-MB and troponin rise. However, it is possible that the 
latter could be due to the induction of bilateral upper limb ischaemia causing a more 
severe enzyme leakage in preconditioned patients: moreover, crucially in the clinical 
setting of elective PCI, minimal PMI is sustained and therefore beneficial effects of 
RIPC are less evident.  
Hoole and colleagues extensively investigated the effects of RIPC in the context 
of elective PCI (340-343): they first found that RIPC with standard upper limb IR was 
associated with significantly lower median cTnI at 24 hours after PCI, and reduced 
incidence of chest discomfort, ST-segment deviation and MACCE rate at 6 months 
(340) and 6 years (343). However, the same stimulus did not result in reduction of 
micro-vascular  resistance  or  improvement of  coronary  flow  velocity  in  patients  with 
single vessel disease or when it was applied through target vessel balloon occlusion 
(cardiac RIPC) to those with MVD (341). Similarly, RIPC did not improve ischaemic LV 
dysfunction in patients with single vessel disease (342). 
Interestingly, subsequent studies demonstrated that three- (344) or even one-5 
minutes  (345)  cycles  of  arm  RIPC  reduced  PMI  in  patients  with  stable  angina 
undergoing elective PCI however diabetic subjects were not showed to be protected 
by standard RIPC stimulus (346). Liu and colleagues (347) found that a late RIPC 
stimulus, applied 18-24 hours prior to elective PCI, reduced incidence of chest pain 
and ST elevation, and decreased median TnI, CK and CK-MB, although the same   76 
stimulus,  applied  immediately  before  elective  PCI,  was  not  effective  (348,  349). 
Importantly, a recent meta-analysis confirmed the cardioprotective effects of RIPC in 
this  clinical  setting  (350)  and  currently  studies  are  being  undertaken  in  order  to 
evaluate the effects of RIPC on contrast-induced nephropathy (CIN), PMI and clinical 
outcomes  in  subjects  undergoing  elective  PCI  (351)  and  on  CIN  in  the  context  of 
elective coronary angiography (352). 
 
 
 
1.7.2.4. RIPC and Primary PCI 
In patients presenting with STEMI, early restoration of blood flow with PPCI is 
currently the best strategy to reduce infarct size and improve  patient morbidity and 
mortality.  Experimental studies have demonstrated that following an AMI, IRI can be 
responsible  for  up  to  50%  of  the  final  infarct  size  (96):  similarly,  in  humans  PMI 
secondary to IRI might in part explain the high incidence of  death and heart failure 
following AMI (96), which remain as  high as 10% (353) and 25% (354) respectively at 
1  year.  Therefore  adjuvant  treatments  have  been  investigated  to  potentiate  innate 
cytoprotective mechanisms and therefore to potentially limit infarct size, preserve LV 
function and improve clinical outcomes. Crucially the more recent application of RIPC 
to  patients  presenting  with  STEMI  and  undergoing  PPCI  represents  the  closest 
translation  of  experimental  studies  into  the  clinical  scenario  (96):  the  complete 
occlusion (TIMI-0 flow) of coronary arteries in STEMI patients resembles the direct 
ligature of the coronary artery of animal models of MI and often these subjects have no 
pre-existing  condition  and  are  on  no  concomitant  medication  as  it  occurs  in 
experimental studies (234).    77 
Table 1.7. Major clinical studies investigating the effects of RIPC in elective or primary PCI 
Group 
 
Patient group 
and clinical 
setting 
RIPC Stimulus  Myocardial Injury Outcome 
 
Iliodromitis (339)  
2006 
 
41 
Elective PCI 
Bilateral ischaemia 
(3 cycles of 5 min) 
 
↑inflammatory response and PMI 
 
Hoole (340) 
2009 
 
202 
Elective PCI 
Upper-limb ischaemia 
(3 cycles of 5 min) 
 
↓PMI, MACCE and CP/ST changes 
Hoole (341) 
2010 
 
54 
Elective PCI 
Upper-limb ischaemia 
(3 cycles of 5 min) 
 
No difference in coronary flow velocity or 
microvascular resistance 
Hoole (342) 
2010 
 
42 
Elective PCI 
Upper-limb ischaemia 
(3 cycles of 5 min) 
 
No difference in myocardial stunning or 
ventricular dysfunction  
 
Rentoukas (355) 
2010 
 
31 
Primary PCI 
 
Upper-limb ischaemia 
(4 cycles of 4 min, 
20mmHg>SBP)+tramadol 
 
↓PMI and improved ST-segment 
elevation resolution 
 
Bøtker (356, 357) 
2010 
333 
Primary PCI 
Upper-limb ischaemia 
(4 cycles of 5 min) 
 
↑ Myocardial salvage at 1 month.  
No difference in troponin release or 
MACCE 
Ghaemian (358) 
2012 
80 
Elective PCI 
 
Lower-limb ischaemia 
(2 cycles of 5 min) 
 
↓troponin at 24 hours 
↓CP/ST-deviation during procedure 
Davies (343) 
2013 
 
192 
Elective PCI 
Upper-limb ischaemia 
(3 cycles of 5 min) 
 
↓rate of all-cause mortality, non-fatal MI, 
CVA, hospital admission fro heart failure 
at 6 years 
Er (357) 
2013 
 
50 
Elective coronary 
angiography 
 
Upper-limb ischaemia 
(4 cycles of 5 min, 
50mmHg>SBP) 
 
↓contrast-induced nephropathy 
Luo (344) 
2013 
 
101 
Elective PCI 
Upper-limb ischaemia 
(3 cycles of 5 min) 
 
↓PMI and MI 4a.  
No difference in renal outcomes 
Prasad (349) 
2013 
 
95 
Elective/urgent 
PCI 
Upper-limb ischaemia 
(3 cycles of 5 min) 
No difference in PMI reduction, 
inflammatory response or circulating 
endothelial progenitor cell counts 
Ahmed (348) 
2013 
 
149 
Elective PCI 
Upper-limb ischaemia 
(3 cycles of 5 min) 
↓troponin at 16 hours 
No difference in post procedural MI, 
CKMB, or CRP levels 
 
Xu (346) 
2013 
 
 
200 
Elective PCI in 
diabetic patients 
only 
 
Upper-limb ischaemia 
(3 cycles of 5 min) 
 
No difference on PMI or MI 4a 
Crimi (359) 
2013 
 
96 
Primary PCI 
Upper-limb ischaemia 
(3 cycles of 5 min) 
 
↓CK-MB release  
Improved myocardial oedema and ST-
segment elevation resolution 
 
Zografos (345) 
2014 
 
94 
Elective PCI 
Upper-limb ischaemia 
(1 cycle of 5 min) 
 
↓troponin at 24 hours/MI 4a 
 
Liu (347) 
2014 
 
200 
Elective PCI 
Upper-limb ischaemia 
(3 cycles of 5 min) 18 hrs  
prior to PCI 
 
↓troponin/CK-MB at 24 hours 
↓ chest pain/ST-changes 
Sloth (360) 
2014 
333 
Primary PCI 
Upper-limb ischaemia 
(4 cycles of 5 min) 
 
↓MACCE rate at 3.7 years median 
follow-up 
White (361) 
2014 
197 
Primary PCI 
Upper-limb ischaemia 
(4 cycles of 5 min) 
↓hsTnT release, infarct size and 
myocardial oedema 
↑Myocardial salvage 
 
Prunier (362) 
2014 
 
151 
Primary PCI 
Upper-limb ischaemia 
(3 cycles of 5 min)+/-IPostC 
(4x 1 min cycles balloon) 
↓CK-MB but no difference between 
RIPerC and RIPerC+IPotstC groups 
 
Manchurov (363) 
2014 
 
48 
Primary PCI 
 
Upper-limb ischaemia 
(4 cycles of 5 min) 
 
 
Improved endothelial function up to a 
week 
Hausenloy 
2014, (ERIC-LYSIS, 
NCT02197117) 
519 
Primary PCI 
Upper-limb ischaemia 
(4 cycles of 5 min) 
 
↓troponin/CK-MB  
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RIPC=remote ischemic preconditioning; PCI=percutaneous intervention; PMI=peri-operative myocardial 
injury;  AKI=acute  kidney  injury;  MACCE=major  cardiac  and  cerebrovascular  events;  CP=chest  pain 
SBP=systolic  blood  pressure;  MI=myocardial  infarction;  CK=creatine  kinase;  hsTnT=high-sensitivity 
troponin-T; RIPerC=remote ischaemic perconditioning; IPostC=ischaemic postconditioning. 
 
 
 
Rentoukas  et  al.  (355)  were  the  first  group  to  apply the  concept  of  remote 
conditioning to the setting of STEMI (Table 1.7): the conditioning stimulus was induced 
by inflating a blood pressure cuff on the upper limb to 20 mm Hg above systolic blood 
pressure  for  4  minutes,  followed  by  deflation  for  4  minutes,  a  cycle  which  was 
repeated  three  times  beginning  10  minutes  before  the  estimated  time  of  the  first 
balloon inflation. A total of 96 patients were randomised to control, remote conditioning 
alone,  or  remote  conditioning  plus  morphine.  Patients  receiving  the  conditioning 
stimulus plus morphine presented the highest rate of full ST-segment resolution and 
reduction  of  ST-segment  deviation  score  during  hospitalization,  the  lowest  peak  of 
cTnI and the highest occurrence of ST-segment deviation resolution. However, the 
study had no group receiving morphine only and therefore no evaluation of the effects 
of morphine alone on cardioprotection was carried out. 
Bøtker and colleagues (356) demonstrated for the first time the beneficial effects 
of remote conditioning in a large seminal study including 142 patients with evolving 
STEMI: the stimulus was applied by intermittent upper limb ischaemia through four-5 
minute cycles of arm IR during transport to hospital and prior to PPCI. Myocardial 
salvage index measured with myocardial nuclear scanning at 30 days after PPCI was 
significantly improved in conditioned patients, although the incidence of major adverse 
coronary events (death, reinfarction and heart failure) was similar in the two groups. 
Subsequently,  the  same  authors  (360)  demonstrated  that  a  similar  conditioning 
stimulus was also able to reduce MACCE rate for a median follow-up of 3.8 years in   79 
patients with STEMI. In addition, Manchurov et al (363) showed improved endothelial 
function up to a week post-procedure in a similar clinical setting and more recently, 
Crimi and colleagues (359) found that a standard conditioning stimulus reduced total 
CK-MB  release  and  improved  T2-weighted  oedema  volumes  and  ST-segment 
elevation  resolution  in  patients  undergoing  PPCI  for  occluded  LAD.  Ultimately  our 
group was able to demonstrate that an increased conditioning stimulus (four-5 minutes 
cycles of upper arm IR) reduced total hsTnT release and CMR-measured infarct size 
and  myocardial  oedema,  and  improved  myocardial  salvage  in  STEMI  patients 
receiving PPCI (361).  It is important to note that, particularly based on the beneficial 
outcomes of Botker’s group study and on the high risk profile of patients recruited into 
our ERICCA,  we  decided  to adopt  the  same  preconditioning  stimulus  consisting of 
four-5 minutes cycles of upper arm IR in our multi-centre ERICCA RCT (Chapter 5). 
1.7.2.5. Protection of organs other than the heart by RIPC 
The discovery that the myocardium could be protected by a preconditioning stimulus 
given “at a distance” soon led to the evaluation of a potential similar protective effect 
on organs other than the heart, which typically are subjected to IRI in clinical practice, 
such as the kidneys in the context of cardiac and vascular surgery (364, 365), the 
lungs  following  cardiac,  pulmonary  and  orthopaedic  surgery  (366-370),  the  brain 
subsequently to ischaemic insults associated with CVAs or from IRI secondary to CEA 
(371, 372), and the liver (373-377), skin (378-380), pancreas (381), intestine (382), 
and  ovaries  (383-387)  in  the  setting  of  organ  resection  and/or  transplantation.  An 
overview of experimental and clinical studies is given in Tables 1.8-1.9, although it is 
essential  to  highlight  that  the  vast  majority  of  human  studies  were  small  proof-of-
concepts trials and therefore not adequately powered. In this regard, large RCT are 
currently being conducted to determine whether RIPC confers protection to kidneys   80 
(ERICCA  and  REPAIR  trials,  see  chapter  3),  lungs  (ClinicalTrials.gov  identifiers: 
NCT01144585 and NCT01344239), liver (ClinicalTrials.gov identifiers: NCT00796588 
and  NCT00975702),  brain  (ClinicalTrials.gov  identifiers:  NCT01739088, 
NCT01158508,  NCT01515072,  NCT01175876,  NCT01570231,  NCT01321749)  and 
gastro-intestinal system (ClinicalTrials.gov identifier: NCT00975702).  
Crucially,  the  outcomes  of  these  studies  will  give  us  the  essential  answer  as  to 
whether RIPC is capable to provide systemic multi-organ protection against acute IRI 
(388). 
 
 
 
 
 
 
 
Table 1.8. Major experimental studies evaluating the effects of RIPC on organs other than the 
heart 
 
Experimental 
study 
 
Experimental 
setting: model 
 
RIPC protocol 
 
Outcomes 
 
Kidney 
 
Ates (389) 
2002 
 
Rat 
 
One-10 min cycle of 
hepatic IR 
 
↓BUN and improved histology. 
 
 
Song (390) 
2007 
Rat  
 
 
Three-8 min cycles of 
small intestine IR 
 
↓Cr, BUN and renal morphologic change. 
 
Lazaris (391) 
2009 
Rat   One-15 min cycle of aortic 
clamping/declamping  
 
↓lactate/MDA and renal tissue MDA. 
 
Kadkhodaee (392) 
2011 
Rat  
 
Four-5 min cycles of IR to 
hindlimb during renal IR 
(RIPerC+RIPost).  
    
↓Cr/BUN  
 
 
Wever (393) 
2011 
Rat 
  
One-12 min or three-4 min 
cycles of IR to one or both 
hind limbs. (repeatedx4)   
  
↓AKI except 12 min IR protocol 
 
Wever (394) 
2012 
Rat 
 
Three-5 min cycles of IR 
to both hind limbs-RIPost 
↓AKI. RIPC effect synergistic with local IPost 
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Lungs 
 
Peralta (261) 
2001 
 
Rat 
 
 
One-10 min cycle of 
hepatic IR  
 
 
↓inflammatory response 
 
Harkin (263) 
2002 
Pig 
 
Three-5 min cycles of 
bilateral hind-limb IR  
↓inflammatory response/pulmonary 
oedema/respiratory failure 
 
Xia (395) 
2003 
 
Sheep (myocardial IR)  
 
Three-5 min cycles of iliac 
artery IR  
 
↓pulmonary vascular resistance/artery 
pressure  
Waldow  
2005 (396) 
Pig   
 
Three-5 min cycles of CFA 
IR 
  
↓ALI/pulmonary hypertension 
Olguner (262) 
2006 
Rat (hind-limb IRI) 
 
Three-10 min cycles of 
hind limb IR  
 
↓inflammatory response 
 
Kharbanda (227) 
2006 
Pig (myocardial IR)  Four-5 min cycles of hind-
limb IR 
 
↑lung compliance, ↓pulmonary resistance  
 
Leung (397) 
2014 
Mouse  (haemorragic 
stroke/resuscitation) 
 
1 cycle of left femoral 
artery IR 
↓ALT/TNF-ʱ/IL-1 and improved lung 
histology  
 
Wang (398) 
2014 
Rat (intestinal IR)  Three-5 min cycles of 
SMA IR 
↓MPO/MDA/TNF-ʱ/IL-1  
 
 
Liver 
 
Lai (399) 
2006 
 
 
 
 
Rat  
 
Four-10 min cycles of 
hind-limb  IR 
 
↓ALT. 
↑HO-1 
  
 
Kanoria (400) 
2006 
Rabbit  
 
Three-10 min cycles of 
hind-limb IR 
↓ALT/AST. Preserved PLBF  
↑hepatic nitrite/nitrate levels.  
 
Gustaffson (401) 
2006 
Rat  
 
One-10 min episode of 
hind-limb IR  
↓ALT, no difference in PLBF  
 
 
Tapuria (402) 
2009 
Rat  
 
Four-4 min cycles of hind-
limb IR 
↑hepatic perfusion  
↓inflammatory response 
 
 
Wang (403) 
2010 
 
Mouse  One-10 min episode of 
hind-limb ischemia.   
↓ALT/TNF-ʱ 
↑HMG-B1. 
 
Abu-Amara (404) 
2011 
Mouse  Six-4 min cycles of hind-
limb IR 
↓ALT/AST 
RIPC blocked by NO inhibitor 
 
Abu-Amara (405) 
2011 
Mouse  Six-4 min cycles of hind-
limb IR 
↓ALT/AST 
 
 
Kanoria (406)  
2012 
Rabbit   Three-10 min of hind-limb 
IR 
↓ALT/AST  
↑mitochondrial oxygenation/hepatic nitrite-
nitrate  
 
Abu-Amara (407) 
2012 
 
Mouse 
 
Six-4 min cycles of hind-
limb IR 
 
↓ALT/AST  
 
 
Wang (408) 
2012 
Rat  
(liver transplantation) 
Four-4 min cycles of hind-
limb IR 
↓ALT/AST/TNF-ʱ. 
 
 
Uysal (409) 
2014 
 
Rat  
 
Three-5 min cycles of 
hind-limb IR 
↓ALT/AST  
Wang (410) 
2014 
 
Mouse   Six-4 min cycles of hind-
limb IR 
↓HO1-mediated liver autophagy 
Shin (411) 
2014 
 
Mouse (hepatic injury in 
LPS-sepsis) 
 
Three-10 min cycles of 
hind-limb IR 
↓TNF-ʱ/NF-Κb/neutrophil accumulation 
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Kageyama (412) 
2014 
 
Rat  
 
Two-4 minutes cycles 
SMA clamping/11-minute 
declamping 
 
 
↓ALT/AST/TNF-ʱ  
Leung (397) 
2014 
Mouse (haemorragic 
stroke/resuscitation) 
 
1-cycle of CFA IR  ↓ALT/TNF-ʱ/IL-1; improved liver/lung 
histology  
 
 
Brain 
 
Dave (413)  
2006 
 
Rat  
 
 
One-15 or 30 min episode 
of hind-limbs IR 
 
 
Preserved CA1-hippocampal neurones 
Gurcun (414) 
2006 
Rabbit (spinal cord IRI) 
 
Two-5 min cycles of 5 min 
renal IR. 
 
Improved neurological recovery. 
 
Zhao (415) 
2007 
Rat   Three-10 min cycles of 
hind-limb IR 
↓neurological dysfunction/infarct size  
 
 
Rehni (416) 
2007 
Mouse  One-15 min episode of 
intestinal IR 
 
↓cerebral infarct size/functional deterioration 
 
Ren (417) 
2008 
Mouse 
 
Three-15 min cycles of 
hind-limb IR  
 
↓cerebral infarct size  
Ren (417) 
2009 
Mouse  Three-15 min cycles of 
hind-limb IR (RIPost).  
 
↓cerebral infarct size  
Saxena (418) 
2009   
Rat  Five-5 min cycles of hind-
limb IR   
 
No effect on CA1-hippocampal neurones. 
 
Yannopoulos (419) 
2010 
Pig (CPB)  Four-5 min cycles of hind-
limb IR  
 
↓cerebral lactate/glucose/glycerol 
 
Xu (420) 
2011 
Rat  Three-10 min cycles of 
hind-limb IR 
 
↑neurocognitive function/Bcl2 expression 
 
Malhotra (421) 
2011 
Rat 
 
 
  
Three-10 min cycles of 
infra-renal aortic IR 
 
↓cerebral infarct size  
 
 
 
Jensen (422) 
2011 
 
Pig (CPB) 
 
Four-5 min cycles to hind-
limb IR   
 
 
↓cerebral lactate/histological injury  
Zhou (423) 
2011 
Rat  Four-10 min cycles of 
hind-limbs IR (RIPost) 
 
↓cerebral infarct size 
 
 
 
 
Hahn (424) 
2011 
Rat   Four-5 min cycles to hind-
limb IR   
 
↓cerebral infarct  
Sun (425) 
2012 
Rat   Three-5 min cycles of 
hind-limbs IR (RIPost)    
 
↓cerebral infarct size  
Geng (426) 
2012 
 
Rat   Repeated episodes of 
hind-limbs IR 
No beneficial effects  
Wei (427) 
2012 
Rat   Three-15 min cycles of 
hind-limb IR.  
 
↓cerebral infarct size/oedema/brain-barrier 
permeability. 
 
Hu (428) 
2012 
Rat   Three-5 min cycles of 
hind-limb IR  
 
↓cerebral infarct size  
Yannopoulos (429) 
2012 
Pig  Four-5 min cycles of hind-
limb IR 
↑cerebral oxygen tension 
       
Hu (430) 
2013 
 
Rat   Four-5 min cycles of hind- 
limb IR 
↑neurofunction  
Yannopoulos (431) 
2013 
 
Pig 
 
Four-5 min cycles of hind-
limb IR 
↑mitochondrial respiratory function and 
↓inflammatory response   83 
 
Sichuan 
2014 
 
 
Rat  
 
Lower hind limb IR  
 
↓neurological deficit/infarct size 
 
Hu (432) 
2014 
Rat (haemorrragic 
stroke) 
Four-5 min cycles of hind-
limb IR  
 
↑myocardial indices  
↓neurological deficit  
IRI=ischaemia-reperfusion  injury;  RIPC=remote  ischaemic  preconditioning;  RIPost=remote  ischaemic 
postconditioning;  RIPerC=remote  ischaemic  perconditioning;  BUN=blood  urea  nitrogen;  MDA= 
malonedialadehyde;  IR=ischaemia  reperfusion;  ALT=aspartate  transaminase;  ALT=alanine 
transaminase;  LPD=lipopolysaccharide;  TNF-ʱ=  tumor  necrosis  factor-ʱ;  MPO=  myeloperoxidase; 
SMA-superior  mesenteric  artery;  TNF=tumor  necrosis  factor;  IL=interleukin;  CFA=common  femoral 
artery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table  1.10.  Major  clinical  studies  investigating  the  effects  of  RIPC  on  renal  and  pulmonary 
protection in patients undergoing cardiac or vascular surgery or elective PCI 
 
Clinical study 
 
 
Clinical setting 
 
RIC protocol 
 
Result of RIC 
Renal Protection  
 
 
Ali  (292) 
2007 
 
 
 
82 
Elective AAA repair  
 
10 min right-CIA clamping+ left-CIA 
clamping  
 
↓renal impairment incidence 
Walsh (319) 
2009 
40 
Elective EVAR 
10min right thigh inflation+10 min left 
thigh inflation 
 
↓urinary retinol binding 
protein 
 
Walsh(433) 
2010 
40 
Elective open infrarenal-AAA 
repair 
 
10 min right-CIA clamping+ left-CIA 
clamping  
No effect on urinary retinol 
binding/albumin:Cr ratio 
Venugopal  (434) 
2009 
 
78 
Adult CABG surgery 
Three-5 min arm IR   ↓incidence of AKI  
 
Choi (303) 
2011 
 
76 
Adult complex valve surgery 
Three-10 min thigh IR 
 
No effect on AKI  
Zimmerman(435) 
2011 
120 
Adult CABG surgery 
Three-5 min thigh IR  ↓incidence of AKI  
 
 
Pedersen(436) 
2011 
 
 
103 
Paediatric cardiac surgery  
 
Four-5 min thigh IR 
 
 
No effect on AKI  
Whittaker (437) 
2012 
43 
Adult patients with mild CKD 
undergoing PPCI  
 
>4 inflations/deflations of angioplasty 
balloon 
Preserved renal function 
Er (357) 
2012 
100 
Adult patients with moderate 
CKD undergoing elective 
PCI  
 
Four-5 min upper arm IR  ↓ contrast-AKI incidence    84 
Pulmonary Protection 
 
 
Cheung (281) 
2006 
 
37 
Paediatric cardiac surgery  
 
Four-5 min cycles of thigh IR 
 
↓airway resistance  
 
Li (301) 
2010 
 
40 
Adult CABG surgery 
 
 
Two-3 min cycles aortic cross 
clamping  
 
↓ventilation 
requirements/pulmonary 
oedema/inflammatory 
response 
 
Zhou (307) 
2013 
60 
Paediatric cardiac surgery  
 
Three-5 min cycles of arm IR  
  
↑lung static+dynamic 
compliance. 
Li  (302) 
2010 
 
81 
Adult valve surgery 
Three-4 min cycles of thigh IR 
 
No effect on ventilation time. 
 
Lin (438) 
2012 
 
 
 
30 
Lower limb orthopaedic 
surgery  
Three-5 min cycles of leg IR 
 
↓pulmonary injury. 
Young (296) 
2011 
 
96 
Adult high-risk CABG surgery 
Three-5 min cycles of arm IR 
 
↑ventilation time 
Kim  (439) 
 
54 
Adults complex valve surgery 
Three-10 min cycles of thigh 
IR 
 
No effect on PaO2/FiO2/ALI 
incidence 
 
Lomivorotov (297) 
2012 
80 
Adult CABG surgery 
 
Three-5 min cycles of arm IR 
 
No effect on ventilation time 
 
Renal and Pulmonary protection 
 
 
Thielmann (293) 
2010 
 
53 
Adult CABG surgery  
 
Three-5 min upper arm IR 
 
No difference in Cr/eGFR  
 
Rahman (286) 
2010 
 
163 
Adult CABG surgery 
 
Three-5 min upper arm IR 
 
 
No difference in 
AKI/ventilation time  
 
Hong (285) 
2010 
 
 
70 
Adult off-pump CABG 
surgery 
  Four-5 min cycles of thigh IR  No difference in 
Cr/PaO2/FiO2 ratio 
Thielmann (300) 
2013 
329  
Elective CABG  
 
  Three-5 min upper arm IR             No difference in 
AKI/ventilation time 
AAA=abdominal  aortic  aneurysm;  Cr=creatinine;  CABG=coronary  artery  bypass  graft; 
PCI=percutaneous  intervention;  AKI=acute  kidney  injury;  RIPC=remote  ischaemic  preconditioning; 
PaO2 =oxygen tension; FiO2=Fraction of inspired Oxygen ratio; CIA= common iliac artery 
 
 
 
 
 
 
 
 
 
 
 
   85 
1.8. Conclusions 
RIPC, in which the application of one or more brief cycles of non-lethal IR to an organ 
or tissue protects the heart against a lethal episode of acute IRI, has emerged as a 
non-invasive,  low-cost  therapeutic  intervention for potentially  reducing  the  extent of 
PMI in patients undergoing CABG and/or valve surgery and elective or primary PCI. It 
has  also  been  demonstrated  to  reduce  IRI  in  organs  and  tissue  other  than  the 
myocardium, such as the kidneys, lung, liver, brain, skin, gastro-intestinal system and 
ovaries. With particular regards to the effects of RIPC on PMI in the context of cardiac 
surgery, the majority of the clinical studies investigating the effects of a preconditioning 
stimulus  on  myocardial  damage  have  reported  beneficial  effects  using  a  standard 
single-limb  RIPC protocol  comprising  three  or four-5  minute  cycles  of  inflation  and 
deflation of a cuff placed on either the upper arm or thigh to induce transient limb 
ischaemia. However, several recent studies have failed to demonstrate a statistically 
significant PMI reduction using this standard single limb RIPC stimulus, suggesting 
that  under  certain  conditions  this  RIPC  stimulus  may  be  ineffective.  This  can  be 
attributed to different potential mechanisms including the clinical setting, the patient 
selection and the intensity and modality of delivery of the preconditioning stimulus. 
Whether increasing the intensity of the RIPC stimulus by simultaneously applying the 
RIPC  protocol  to  the  upper  arm  and  thigh  may  be  more  effective  in  inducing  PMI 
reduction and  improving  short-term  clinical outcomes  in  patients undergoing  CABG 
and/or valve surgery is unknown and its implications will be extensively described in 
the next chapters. 
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CHAPTER 2 
 
 
2. Effect of multi-limb remote ischemic preconditioning on 
clinical  outcomes  in  patients  undergoing  cardiac  bypass 
surgery 
 
Aims and Objectives 
 
During cardiac surgery, the myocardium is subjected to PMI, as demonstrated by post-
operative rise of cardiac enzymes concentrations, including CK-MB (119), TnT (77-
79), TnI (80, 81):  this has been associated with worse short and long-term clinical 
outcomes  (77-82),  with  therefore  a  significant  impact  on  patients’  morbidity  and 
mortality.  
Acute  IRI  secondary  to  intermittent  aortic  cross-clamp,  ICCF  or  intermittent  or 
continuous  administration  of  cardioplegia  (83)  has  been  recognised  as  one  of  the 
crucial mechanisms underlying PMI in this context. RIPC, describing the phenomenon 
by which brief episodes of transient limb ischaemia to one organ or tissue prior to a 
prolonged period  of  ischaemia  in  a distant or “remote” organ or tissue  protect  this 
organ/tissue from IRI, offers a promising non invasive and risk-free strategy to reduce 
PMI in these subjects and therefore to potentially improve their short and long-term 
prognosis (96).     87 
A significant number of RCTs have been carried out in order to determine the 
cardioprotective  effects  of  RIPC  in  the  context  cardiac  surgery,  albeit  with  often 
discordant  outcomes  (Tables  1.6):  we  discussed  the  potential  reasons  for  these 
findings in chapter 1 and identified in the intensity of the preconditioning stimulus one 
of the possible causes of the failure to significantly reduce PMI in some of the RCTs.  
 
 
2.1. Hypothesis 
We  hypothesised  that  an  enhanced  RIPC  stimulus  with  two-5  minutes  cycles  of 
simultaneous IR to the upper arm and upper thigh reduces PMI and improves short-
term clinical outcomes in patients undergoing CABG and/or valve surgery.  
 
 
2.2. Overall Aim 
To  investigate  the  effects  of  an  enhanced  RIPC  stimulus  on  PMI  and  short-term 
clinical  outcomes  in  patients  undergoing  cardiac  surgery,  including  CABG  surgery 
alone, valve surgery alone or a combination of the two. 
 
 
2.3. Objectives 
2.1.3.1. To investigate the effects of multi-limb RIPC on PMI and short-term clinical 
outcomes in an unselected population including patients undergoing CABG surgery, 
valve surgery alone or CABG plus valve surgery. 
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Short-term clinical outcomes investigated in our study include:  
1.  AKI score in the first 72 post-operative hours. 
2.  Inotrope requirement during the first 3 post-operative days. 
3.  Length of ICU stay. 
4.  Length of hospital stay. 
5.  New onset AF in the first 72 hours after surgery. 
6.  Adverse events during hospital stay including:  
  Skeletal muscle injury. 
  Death. 
  Non-fatal MI. 
  Coronary artery revascularization.  
  Stroke. 
7.  Clinical outcomes at 6 weeks: 
  Death. 
  Non-fatal MI. 
  Coronary artery revascularization.  
  Stroke. 
 
 
2.1.3.2. To investigate the effects of multi-limb RIPC on PMI and short-term clinical 
outcomes in patients undergoing:   
a.  CABG surgery,  with or without valve surgery, using cardioplegia as the only 
technique of myocardial preservation; 
b.  CABG surgery, with or without valve surgery, using ICCF as the only technique 
of myocardial preservation;   89 
c.  CABG surgery with or without valve surgery; 
d.  CABG surgery alone; 
e.  CABG surgery alone using cardioplegia as the only technique of myocardial 
preservation; 
f.  valve  surgery  alone,  including  AVR  alone  or  mitral  valve  (MV)  surgery 
(replacement or repair); 
g.  cardiac  surgery,  with  or  without  intra-operative  administration  of  intra-
intravenous (iv) nitrates. 
 
2.1.3.3. To investigate the effects of multi-limb RIPC on PMI and short-term clinical 
outcomes in diabetic and non-diabetic patients undergoing:   
a.  cardiac surgery, including CABG surgery, valve surgery alone or CABG plus 
valve surgery; 
b.  CABG surgery,  with or without valve  surgery, using cardioplegia as the only 
technique of myocardial preservation; 
c.  CABG surgery alone; 
d.  CABG  surgery  alone  using  cardioplegia  only  as  the  only  technique  of 
myocardial preservation. 
 
2.1.3.4. To investigate the effects of combined antegrade and retrograde cardioplegia 
compared to antegrade cardioplegia alone and  ICCF alone on PMI and short-term 
clinical outcomes in control patients undergoing CABG surgery. 
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CHAPTER 3 
 
3. Effect of multi-limb remote ischemic preconditioning on 
clinical  outcomes  in  patients  undergoing  cardiac  bypass 
surgery 
 
Methods and Results 
 
3.1. Overview 
We  conducted  a  single-centre  single-blinded  randomised  controlled  clinical  trial 
between  December  2010  and  July  2012  in  order  to  investigate  the  effects  of  an 
enhanced RIPC stimulus induced by transient simultaneous multi-limb IR on PMI and 
short-term clinical outcomes in an unselected population of adult patients undergoing 
CABG surgery or valve surgery or a combination of the two. A schematic overview of 
the study design is given in Fig. 3.1. 
 
 
3.2. Ethical approval and informed consent 
This  parallel  single-blinded  randomised  controlled  clinical  trial  received  local  Ethics 
Committee  approval,  and  was  conducted  at  the  Heart  Hospital,  University  College 
London  Hospital  (London,  UK),  in  accordance  with  the  International  Conference  of 
Harmonisation-Good  Clinical  Practice  (ICH-GCP)  guidance.  Study  protocol,  patient 
information sheet and consent forms were approved by the joint University College   91 
London and University College London Hospital NHS Trust Committees for the ethics 
of  human  research.  I  provided  major  and  minor  amendments  to  previous  study 
protocols, which received approval from the local ethical committee. Eligible patients 
were approached the day before or on the day of their admission and prior to their 
surgery,  so  that  they  had  sufficient  time  to  provide  their  informed  consent  when 
agreed. Written consent was obtained from all patients recruited into the study. I then 
obtained two photocopies of the signed consent form: the original copy was added to 
the patient’s medical notes, one copy was given to the patient and one copy was kept 
in a separate file at the Hatter Cardiovascular Institute. 
 
 
3.3. Study Design 
3.3.1. Original Hypothesis and Experimental Design 
The study was originally designed in 2001 in order to establish whether the effects of 
IPC  in  diabetic  patients  undergoing  cardiac  surgery  might  be  abrogated  by 
glibenclamide  (substudy  1)  and  was  stopped  as  this  anti-diabetic  medication  was 
used very rarely. It was then amended in 2006 (substudy  2) to establish whether 
RIPC protects non-diabetic or diabetic patients undergoing cardiac surgery. 
As already mentioned in chapter 1, recent RCTs investigating the effects of RIPC on 
PMI  and  clinical  outcomes  in  patients  undergoing  cardiac  surgery  have  provided 
discrepant  results.  More  recently,  an  increased  intensity  of  the  RIPC  stimulus  has 
been found to be beneficial in patients presenting with STEMI and undergoing PPCI 
and,  crucially,  preclinical  studies  have  demonstrated  that  the  diabetic  myocardium 
requires a higher threshold for cardioprotection to be achieved prior to a prolonged 
period of ischaemia (440).   92 
 I therefore provided the amendments to previous study protocol and obtained ethical 
approval, in order to investigate whether: 
  an  enhanced  preconditioning  stimulus  protects  patients  undergoing  cardiac 
surgery (substudy 3); 
  an  enhanced  preconditioning  stimulus  protects  both  diabetic  (substudy  3a) 
and non-diabetic (substudy 3b) patients undergoing cardiac surgery. 
The enhanced preconditioning stimulus for which I obtained ethical approval consisted 
of 2 cycles of simultaneous blood pressure (BP) cuff inflations, one placed around the 
upper arm and one placed around the upper leg for 5 minutes followed by deflation for 
5 minutes.  
 
 
3.4. Patient recruitment  
Adult patients were screened against inclusion and exclusion criteria and recruited if 
considered eligible to the study and following informed consent between December 
2010 and July 2012. 
 
3.4.1. Inclusion criteria 
a.  Age more than 18 years. 
b.  Patients  undergoing  CABG  surgery  and/or  valve  surgery  at  the  Heart  Hospital 
(UCLH). 
c.  Patient given informed consent. 
 
3.4.2. Exclusion criteria 
a.  Cardiogenic shock or cardiac arrest preceding surgery.    93 
Cardiogenic shock was defined as: 
  Systolic  BP  (SBP)<90  mmHg for 30 minutes  before  inotrope/vasopressor 
administration  
or  
  Vasopressors  or  intra-aortic  balloon  pump  (IABP)  required  to  maintain 
SBP>90 mm Hg. 
b.  Positive baseline serum hsTnT and/or CK-MB. We excluded these patients, as it 
was  possible  that  they  might  have  been  already  preconditioned  by  the  recent 
event, with a subsequent potential impact on RIPC prior to cardiac surgery. 
c.  Pregnancy. 
d.  Significant peripheral arterial disease (PAD) affecting upper and/or lower limbs. 
e.  Significant hepatic dysfunction, with an International Normalized Ratio (INR)>2.0. 
f.  Significant  pulmonary  disease,  with  a  Forced  Expiratory  Volume  (FEV)-1<40% 
predicted. 
g.  Renal failure  with  an estimated  glomerular filtration  rate  (eGFR)<30mL/min/1.73 
m2.  These  patients  were  excluded  as  the  excretion  of  troponin  occurs  via  the 
kidneys  and  is  therefore  impaired  in  the  presence  of  acute  or  chronic  kidney 
disease thereby making hsTnT evaluation unreliable. 
h.  Concomitant therapy with glibenclamide or nicorandil, as these medications may 
interfere with RIPC (171, 441). 
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Fig. 3.1. Study profile 
 
RIPC=remote  ischaemic  preconditioning;  eGFR=estimated  glomerular  filtration  rate;  PAD=peripheral 
arterial disease; FEV=forced expiratory volume 
 
 
!
 
Assessed for eligibility (n=340) 
 
 
Randomized 1:1 (n=180) 
 
 
Allocated to RIPC (n=90) 
Received RIPC (n=90) 
 
 
Data analysed (n=89) 
 
 
Allocated to control (n=90) 
Received control (n=90) 
 
 
Data analysed (n=89) 
 
 
Excluded (n=160) 
!   Refused to participate (n=2) 
!   Recruited into another study (n=131) 
!   Not meeting inclusion criteria (n=27) 
!   Positive baseline cardiac enzymes (n=7) 
!   eGFR <30ml/min/1.73m
2 (n=8) 
!   Cardiac arrest preceding surgery (n=3) 
!   Concomitant nicorandil (n=2) 
!   Significant PAD (n=4) 
!   FEV-1<40% predicted (n=3) 
 
Excluded from analysis (n=1): 
patient died intra-operatively 
 
 
Excluded from analysis (n=1): 
patient died intra-operatively 
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3.5. Randomisation 
Randomisation  was  carried  out  using  a  computer-generated  list  of  randomised 
numbers, and allocation concealment obtained using Sequentially Numbered Opaque 
Sealed  Envelopes  (SNOSE).  In  all  patients  it  occurred  prior  to  transfer  to  the 
anaesthetic room on the day of surgery. 
 
 
3.6. Blinding 
This  was  a  single-centre,  single  blinded  randomised  control  clinical  trial.  The 
investigator  collecting  and  analysing  the  data,  patients,  cardiac  surgeons  and 
anaesthetists, operating theatre staff, and staff on ICU and cardiac wards  were all 
blinded to treatment allocation.  
 
 
3.7. Intervention: RIPC and sham treatment protocols  
RIPC  and  control  protocols  were  applied  after  anaesthesia  induction  and  prior  to 
sternotomy. RIPC was delivered with one standard BP cuff placed on the upper arm 
and  another  standard  BP  cuff  placed  on  the  upper  thigh.  The  cuffs  were 
simultaneously inflated to 200 mmHg and left inflated for 5 minutes, to be then deflated 
to 0 mmHg and left deflated for 5 minutes. This cycle was repeated twice, so that the 
total duration of the intervention was 15 minutes. If the patient’s SBP was greater than 
185 mmHg, the cuffs were inflated to 15 mmHg above that level.  
For the control protocol, the two cuffs were simultaneously placed on the upper arm 
and the upper thigh and left un-inflated for 15 minutes.   96 
The arm BP cuff was placed contralaterally to the arm used for arterial line insertion 
and invasive BP monitoring. When possible, the leg BP cuff was placed ipsilaterally to 
the arm cuff in order to facilitate the operator’s delivery of the intervention. Both RIPC 
and  sham  protocols  were  delivered  following  induction  of  anaesthesia  to  avoid 
patient’s discomfort.  
 
 
3.8. Anaesthetic procedure 
Patients  received  pre-medication  with  oral  temazepam 10-20 mg  one  hour prior to 
surgery. The patient was then taken to the anaesthetic room where  iv access was 
gained through a peripheral venous cannula and continuous invasive BP monitoring 
was achieved with the insertion of an arterial line.  
    Anaesthesia  induction  was  obtained  with  a  combination  of  midazolam, 
etomidate,  propofol,  fentanyl  and  anti-nicotinic  agents  including  rocuronium, 
vecuronium  or  pancuronium.  Following  anaesthesia  induction,  the  trachea  was 
intubated  and  mechanical  ventilation  commenced  with  oxygen  with  or  without  air. 
Anaesthesia  maintenance  was  achieved  with  volatile  anaesthetic  agents,  including 
isoflurane or sevoflurane, and propofol infusion, with or without fentanyl. Arterial BP, 
central venous pressure, leads I and III of the electrocardiogram and nasopharyngeal 
temperature were continuously recorded. Intravenous glyceryl trinitrate (GTN) infusion 
was administered at the discretion of the anaesthetist in order to optimise BP control 
and improve intraoperative coronary vasodilatation. 
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3.9. Surgical procedure   
    Following  anaesthesia,  the  patient  was  transferred  to  theatre  were  mid-line 
sternotomy was performed: at that point the left  IMA (LIMA) was isolated from the 
thoracic wall if needed and great saphenous vein was harvested as necessary.   
    Standard non-pulsatile CPB was employed using a membrane oxygenator and 
cardiotomy  suction  and  further to  cannulation  of  the  aortic  root and  the  right  atrial 
appendage: the proximal end of each anastomosis was created during CPB with the 
distal end to the coronary arteries being constructed during cardiac standstill achieved 
with aortic root cross-clamp and either induction of ventricular fibrillation or injection of 
a cardioplegic solution. 
    With  the  technique  of  ICCF,  ventricular  fibrillation  was  induced  through  the 
application  of  an  alternating  current  to  the  epicardium  and  following  aortic  root 
clamping. The distal end of each anastomosis was then constructed, following which 
the aortic root was declamped and ventricular fibrillation was reverted through a direct 
current shock. 
With  regards  to  the  cardioplegic  technique  of  myocardial preservation,  this was 
achieved through two different methods: 
1)  antegrade cardioplegia: 1 litre of cold blood cardioplegic solution (1 part of St. 
John’s Cardioplegia solution mixed with 4 parts of cold blood) was delivered to 
myocardial cells through the aortic root further to aortic cross-clamp, followed 
by a maintenance cold blood cardioplegia, which was given down the grafts in 
occluded arteries and also into the aortic root every 20-30 minutes. Systemic 
temperature in these patients was 28-32 0C; 
2)  antegrade  and  retrograde  cardioplegia:  an  initial  800ml  dose  of  antegrade 
cardioplegia  was  administered  into  the  aortic  root  followed  by  400ml  of   98 
retrograde  cardioplegia  solution  given  through  the  coronary  sinus.  Following 
this,  maintenance  was  achieved  with  100ml  of  retrograde  cardioplegia  after 
each anastomosis. A hot shot of warm blood without potassium was given after 
the  LIMA  anastomosis  and  prior  to  removal  of  the  cross-clamp.  All 
anastomoses  were  constructed  with  the  single-clamp  technique.  Systemic 
temperature in these patients was 35 0C. 
With  the  completion  of  the  anastomosis  of  the  grafts,  CPB  was  discontinued, 
rewarming was initiated and protamine was used in order to achieve heparin reversal. 
 
 
 
3.10. Study Endpoints: rationale and assessment  
3.10.1. Study primary end-point: PMI 
The study primary end-point was PMI, measured by the area under the curve (AUC) of 
the total release of hsTnT over the 72 post-operative hours. As previously described, 
post-operative release of hsTnT may have a significant impact on short and long-term 
clinical outcomes (77-82) and the potentially insufficient intensity of the preconditioning 
stimulus may in part explain the negative outcome of recent proof-of-concept studies 
investigating the effects of RIPC on PMI in patients undergoing cardiac surgery. We 
therefore intended to establish whether an enhanced RIPC stimulus may reduce PMI 
in our patient cohort. 
Samples  were  collected  pre-operatively  and  at  6,  12,  24,  48,  72  hours  following 
discontinuation of CPB; hsTnT  was measured quantitatively by a one-step enzyme 
immunoassay based on electrochemiluminescence technology (Elecsys 2010, Roche, 
Switzerland). This assay allows detection of concentrations <1.0 ng/L and measures   99 
the upper range limit (URL) with a coefficient of variation (CV)<10%. The threshold 
level of ≥14 ng/L indicates significant myocardial necrosis. The unit for reporting was 
ng/L and the reference range was ≤14 ng/L (14 ng/L is the 99th centile of reference 
population with CV risk of <10%).  
Absolute hsTnT release over the 72 post-operative period was calculated with AUC 
using the following Excel Office 2010 formulas: 
1) AUC between two specific time-points (for example time-points 1 and 2): 
AUC t1-t2 = [(hsTnT at t1 hours + hsTnT at t2 hours)/2] x (t2-t1)  
2) Total AUC over the three-post-operative days:  
AUC-72 hours= AUC0-6+AUC6-12+AUC12-24+AUC24-48+AUC48-72. 
 
 
 
3.10.2. Study Secondary Endpoints 
3.10.2.1. AKI  
In the context of cardiac surgery AKI can occur in up to 30% of patients requiring 
dialysis in 1-2% of patients and leading to an 8-fold increase in the death (364, 365): 
RIPC  has  become  a  promising  non-invasive  strategy  potentially  able  to  reduce 
incidence and severity of AKI post-cardiac surgery. 
Peri-operative AKI was calculated with the AKI Score over the first 3 post-operative 
days through a combination of laboratory and clinical data (Table 2.1.) (442):  
1.  Serum  Creatinine  was  measured  pre-operatively  and  at  24,  48,  72  hours 
following discontinuation of CPB. 
2. Urine volumes were monitored daily and calculated as urine output at 24, 48, 
72 hours and the total of these individual values.   100 
AKI was therefore classified into three grades derived from Riffle’s criteria (Table 2.1) 
(442). 
 
Table 3.1. AKI score as modified from Riffle’s criteria (442) 
AKI Grade 
 
Creatinine criteria 
 
Urine output criteria 
1  Creatinine rise>26.4 μmol/L or 150-200% of baseline 
 
<0.5ml/kg/hr for >6 hours 
 
2  Creatinine rise 200-300% of baseline 
 
<0.5ml/kg/hr for >12 hours 
 
3  Creatinine rise>300% or >354 μmol/L with an acute 
rise of at least 44μmol/L 
 
<0.3ml/kg/hr for >24 hours 
or anuria for 12 hours 
 
AKI=acute kidney injury 
 
 
 
3.10.2.2. Inotrope requirement 
Post-operative inotrope requirement is a crucial reflection of the outcome of cardiac 
surgery and has in turn the potential of significantly impact on total ICU and hospital 
stay and ultimately on NHS resources. The inotrope score adapted from a study by Ko 
and  co-workers  (443),  provides  an  objective  measurement  of  the  requirement  of 
inotropes in the immediate postoperative period: data were collected daily from the 
medical drug chart on ICU and calculated at 0 (time when CPB was terminated), 24, 
48 and 72 hours after CPB discontinuation using the formula provided below.  
Inotrope score = Dosages (in μg/kg/min) of: 
[Dopamine  +  Dobutamine  +  Dopeximine]+  [(Adrenaline  +  Noradrenaline  + 
Isoproterenol) x 100] + [(Enoximone + Milrinone) x 15] 
The  inotrope  score  for  each  time  point  was  calculated  as  follows:  at  time  0,  the 
inotrope score was calculated from the dose of the individual inotropes used at the   101 
time of coming off bypass. For 24, 48 and 72 hour time-points, the inotrope score was 
calculated from the maximum dose of the individual inotropes used in the previous 24 
hour period.  
 
 
 
 
 
3.10.2.3. ICU and hospital stay 
The  length  of  ICU  and  hospital  stay  is  an  important  post-operative  parameter  and 
represents a significant component of NHS costs and resources in patients undergoing 
cardiac surgery. ICU stay was calculated using ICU chart and medical notes based on 
numbers  of  days  on  ICU  and  in  hospital  respectively.  When  the  patient  was 
considered fit for transfer from ICU to the ward although the transfer could not occur 
for reason not directly related to the patient’s condition (i.e. bed not available), ICU 
stay was counted up to the day when it was clearly documented in the medical notes 
that it was appropriate for the patient to be transferred from ICU. Similarly, when the 
patient was considered fit for discharge from hospital but this could not take place due 
to various reason (social reasons, family reasons), the number of days of hospital stay 
was  again  counted  up  to  the  day  that  medical  notes  clearly  documented  patient’s 
fitness for hospital discharge.  
 
 
3.10.2.4. New onset of post-operative AF  
New onset of post-operative AF occurs in 30-50% of patients following cardiac surgery 
(30% post-CABG surgery, 40% following valve surgery and 50% further to CABG plus 
valve surgery) (444), and is associated with worse morbidity and mortality (444). Post-
operative  AF  is  secondary  to  hypovoloemia,  electrolyte  imbalance,  central  venous   102 
catheters  insertion,  prolonged  aortic  cross-clamp  times,  increased  automaticity, 
increased sympathetic tone and importantly acute myocardial IRI (444). Therefore we 
intended  to  establish  whether  an  enhanced  preconditioning  stimulus  may  protect 
patients from new  post-operative AF in these  subjects. This was calculated as  the 
incidence of new onset AF in the first 72 hours after surgery detected by continuous 
telemetry  and  ECG  (performed  by  a  blinded  staff  nurse  on  a  daily  basis  and 
immediately after the detection of AF on the telemetry, and then analysed by a blinded 
investigator) and requiring intervention with pharmacological treatment and/or direct 
current  cardioversion.  Patients  with  known  permanent  AF  or  paroxysmal  AF  were 
excluded from the evaluation of this secondary end-point. 
 
 
3.10.2.5. Skeletal muscle injury  
Skeletal muscle injury was measured to evaluate the magnitude of IRI of upper arm 
and  thigh  muscles  subsequent  to  potential  damage  caused  by  the  increased 
preconditioning stimulus. It was analysed with CK levels measured pre-operatively and 
at  6,  12,  24,  48  and  72  hours  post-discontinuation  of  CPB.  Total  release  was 
calculated as AUC of total CK release over the first 72 post-operative hours, using a 
similar formula to the one utilised for the evaluation of hsTnT AUC. 
 
 
3.10.2.6. Short-term clinical outcomes  
We  calculated  the  incidence  of  MACCE  in  order  to  assess  whether  an  enhanced 
preconditioning stimulus may have an impact on short-term clinical outcomes. This   103 
was  based  on  the  rate  of  cardiovascular  death,  non-fatal  MI,  coronary  artery 
revascularization, and stroke up to discharge and at six weeks outpatient follow-up. 
1.  Cardiovascular death was defined as death due to a known cardiovascular cause 
or where the cause of death was unknown i.e. where no other cause of death was 
identified from the medical history or an autopsy. 
2.  Myocardial  infarction  included  both  peri-operative  MI  and  MI  following  cardiac 
surgery.  
  Peri-operative MI (type 5 MI) (97) was indicated by hsTnT rise more than 
five times the 99th percentile of the upper reference limit (URL) during the 
first 72 hours following surgery,  when associated with the appearance of 
new pathological Q-waves or new LBBB, or angiographically documented 
new graft or native coronary artery occlusion, or imaging evidence of new 
loss of viable myocardium.  
  Post-surgical MI was defined as a rise and/or fall of hsTnT with at least one 
value  above  the  99th  percentile  of  the  URL  together  with  evidence  of 
myocardial ischaemia with at least one of the following: 
o  Symptoms of ischaemia 
o  ECG  changes  indicative  of  new  ischaemia  (new  ST-T  changes  of 
new LBBB) 
o  Development of Q waves in the ECG 
o  Imaging evidence of new loss of viable myocardium or new regional 
wall motion abnormality. 
o  Sudden unexpected cardiac death involving cardiac arrest often with 
symptoms suggestive of myocardial ischaemia and accompanied by 
presumably new ST elevation or new LBBB and/or fresh thrombus on   104 
coronary angiography and/or at autopsy, but death occurring before 
blood samples could be obtained or at time before the appearance of 
hsTnT in the blood. 
1.  Repeat revascularisation was defined as any repeat PCI or CABG with or without 
valve surgery within the first year post-surgery.  
2.  Stroke was defined as a focal, central neurological deficit lasting more than 72 
hours and resulting in irreversible brain damage or body impairment.  
 
 
 
3.11. Statistical analysis and sample size estimation 
Data are presented as mean (standard deviation (SD)) or median (inter-quartile range 
(IQR)). Comparison between treatment groups was made using unpaired Student T-
Test for approximately normally distributed variables or Wilcoxon-Mann-Whitney test 
for  non-normal  data.  For  outcomes  collected  at  different  time  points  a  repeated 
measures linear regression model was used to estimate the difference at each time 
point and 95% confidence intervals.  Categorical data were analysed using Fisher’s 
exact  test.  The  post-hoc  analysis  of  associations  between  RIPC  and  GTN  was 
performed using an interaction test in a linear regression model. A value of P<0.05 
was considered significant. We hypothesised that RIPC would reduce hsTnT AUC by 
a standardised difference of 0.6. At 90% power and significance at the two-sided 5% 
level,  this  required  a  sample  size  of  60  subjects,  which  we  increased  by  33%  to 
accommodate withdrawal or missing data points. A sample size of at least 80 patients 
per intervention group was determined based on the following assumptions: (a) the 
largest study on RIPC in PMI published at the time of this trial initiation (286); (b) a   105 
power of least 90%; (c) a SD of 0.2µg/L; and (d) type I error rate of 5%. Analysis was 
by  intention-to-treat.  No  adjustment  for  multiplicity  was  applied  for  secondary 
outcomes or post-hoc analyses.  Data were analysed using Stata version 12.1. 
 
 
 
3.12. Results:  Total  unselected  cohort  of  patients  undergoing 
cardiac bypass surgery 
 
A total of 340 patients were assessed for eligibility (Figure 3.1). Of these 160 patients 
were excluded from the study as 2 patients refused to take part, 131 were included in 
the ERICCA trial, 27 did not meet inclusion criteria and the remaining subjects had 
exclusion  criteria,  with  7  patients  having  positive  cardiac  enzymes  at  the  time  of 
potential enrolment, 8 an eGFR<30 ml/min/1.73m2, 3 presenting with cardiac arrest 
prior to surgery, 2 being on concomitant nicorandil, 4 having significant PAD and 3 an 
FEV-1<40%  predicted.  Therefore  180  patients  were  recruited  and  randomised  to 
receive either RIPC (n=90) or control (n=90): 2 patients, 1 in each intervention group, 
died intra-operatively or in the immediate post-operative period thereby leaving 178 
subjects for the final analysis. RIPC protocol was completed within 45 minutes of the 
first aortic cross-clamp in all patients. No significant difference was found between the 
two treatment groups with respect to baseline patient characteristics (Table 3.2).  
The following characteristics had missing values: body mass index (Control 2, RIPC 
2), systolic BP (Control 2, RIPC 2), diastolic BP (Control 2, RIPC 2), heart rate (Control 
2,  RIPC  2),  New  York  Health  Association  (Control  3,  RIPC  4),  Canadian 
Cardiovascular Society (Control 3, RIPC 4), other co-morbidities (Control 1, RIPC 1),   106 
aspirin (Control 2, RIPC 3), clopidogrel/prasugrel (Control 2, RIPC 3), warfarin (Control 
2,  RIPC  3),  beta-blocker  (Control  2,  RIPC  3),  calcium-channel  blocker  (Control  2, 
RIPC  3),  statin  (Control  2,  RIPC  3),  Angiotensin-Converting-Enzyme-
Inhibitor/Angiotensin receptor blocker (Control 2, RIPC 3), long-acting nitrates (Control 
2, RIPC 3), insulin (Control 2, RIPC 3), biguanide (Control 2, RIPC 3), sulphonylurea 
(Control 2, RIPC 3), diuretics (Control 2, RIPC 3).  
Similarly operative parameters were similar in the two groups with the only exception 
of the use of intra-operative GTN, which was significantly higher in the sham group (65 
patients vs 53, p=0.035; Table 3.3.). In particular, no statistically significant difference 
was found between the two groups in terms of additive EuroSCORE, CPB and aortic 
cross-clamp times and use of anaesthetic agents. The following procedure variables 
had missing values: CPB time (Control 2, RIPC 1), cross-clamp time (Control 4, RIPC 
1), anti-nicotinic agents (Control 5, RIPC 4), midazolam (Control 5, RIPC 4), etomidate 
(Control 3, RIPC 4), fentanyl (Control 3, RIPC 4), propofol on induction (Control 3, 
RIPC  4),  propofol  during  maintenance  (Control  3,  RIPC  4),  volatile  anaesthetics 
(Control 3, RIPC 4), intra-operative GTN (Control 3, RIPC 1). There were no untoward 
consequences or side effects with the RIPC protocol. 
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Table 3.2. Patient baseline characteristics  
Patients  Control  (n=89) 
(mean±SD) 
RIPC  (n=89) 
(mean±SD) 
P value 
Age (years) 
Gender 
Male 
Female 
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
Chinese 
BMI  
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
 
Smoking History 
Smoker 
Ex-smoker 
Non-smoker 
Family History of IHD 
 
NYHA Class 
                  0 
                  I 
                  II 
                  III 
                  IV 
CCS Class  
                  0 
                  I 
                  II 
                  III 
                  IV 
LVEF 
>50% 
30%-50% 
<30% 
 
Co-morbidities 
Diabetes mellitus 
Hypertension 
Hypercholesterolemia 
Atrial Fibrillation 
Previous MI 
Previous PCI 
Previous CVA/TIA 
Previous Cardiac Surgery 
Other co-morbidities 
Peripheral Arterial Disease 
 
Drug History 
Aspirin   
Clopidogrel/Prasugrel 
Warfarin  
Beta-blocker 
Calcium Channel Blocker 
Statin 
ACE-I/ARB  
Long acting nitrates 
Antidiabetics 
Insulin 
Biguanide 
Sulphonylurea 
Diuretics 
66±10 
 
67 (75%) 
22 (25%) 
 
74 (83%) 
10 (11%) 
4 (5%) 
1 (1%) 
 
28.4±5.5 
130.0±18.0 
70.7±9.0 
69.2±11.7 
 
12 (14%) 
52 (58%) 
25 (28%) 
57 (64%) 
 
 
8 (9%) 
22 (26%) 
38 (44%) 
17 (20%) 
1 (1%) 
 
30 (35%) 
17 (20%) 
30 (35%) 
7 (8%) 
2 (2%) 
 
70 (79%) 
17 (19%) 
2 (2%) 
 
 
24 (27%) 
70 (79%) 
64 (72%) 
16 (18%) 
23 (26%) 
11 (12%) 
9 (10%) 
2 (2%) 
35 (40%) 
6 (7%) 
 
66 (76%) 
27 (31%) 
9 (10%) 
55 (63%) 
32 (37%) 
72 (83%) 
61 (70%) 
14 (16%) 
 
7 (8%) 
16 (18%) 
11 (13%) 
27 (31%) 
65±10 
 
72 (81%) 
17 (19%) 
 
71 (80%) 
12 (13%) 
6 (7%) 
0 (0%) 
 
28.8±7.1 
129.0±15.7 
70.8±9.4 
66.3±9.8 
 
11 (12%) 
48 (54%) 
30 (34%) 
64 (72%) 
 
 
8 (9%) 
31 (36%) 
39 (46%) 
7 (8%) 
0 (0%) 
 
25 (29%) 
19 (22%) 
30 (35%) 
9 (11%) 
2 (2%) 
 
67 (75%) 
16 (18%) 
6 (7%) 
 
 
28 (32%) 
65 (73%) 
68 (76%) 
10 (11%) 
28 (32%) 
11 (12%) 
5 (6%) 
4 (5%) 
32 (36%) 
1 (1%) 
 
72 (84%) 
24 (28%) 
6 (7%) 
57 (66%) 
22 (26%) 
72 (84%) 
57 (66%) 
12 (14%) 
 
8 (9%) 
19 (22%) 
7 (8%) 
31 (36%) 
0.268 
0.469 
 
 
0.649 
 
 
 
 
 
0.700 
0.710 
0.948 
0.079 
0.720 
 
 
 
0.335 
 
0.056 
 
 
 
 
 
0.437 
 
 
 
 
 
0.351 
 
 
 
 
 
0.621 
0.484 
0.608 
0.390 
0.507 
1.000 
0.149 
0.600 
0.427 
0.118 
 
0.390 
0.239 
0.710 
0.543 
0.098 
0.400 
0.494 
0.368 
 
0.521 
0.724 
0.611 
0.600 
SD=standard deviation; RIPC= Remote Ischaemic Preconditioning; NYHA= New York Health Association; 
CCS=  Canadian  Cardiovascular  Society;  MI=  Myocardial  infarction;  PCI=  Percutaneous  coronary 
intervention;  CVA=  Cerebrovascular  accident;  TIA=  Transient  ischaemic  attack;  ACE-I=  Angiotensin-
converting enzyme inhibitor; ARB= Angiotensin receptor blocker; LVEF= left ventricular ejection fraction. 
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Table 3.3. Details of surgical procedure 
Patients  Control  (n=89) 
(mean±SD) 
RIPC  (n=89) 
(mean±SD) 
P value 
Indication for Surgery 
Angina 
Myocardial Infarction 
Valve Disease 
Angina and Valve Disease 
Myocardial Infarction and Valve Disease 
Infective Endocarditis 
 
EuroSCORE 
 
Additive perioperative risk 
Low (EuroSCORE 0-2) 
Medium (EuroSCORE 3-5) 
High (EuroSCORE >5) 
 
Bypass-time (min)  
 
Cross-clamp time (min)  
 
Cardioprotection 
Blood cardioplegia 
Cross-clamp fibrillation 
 
Operation 
            CABG alone 
AVR alone 
CABG+AVR  
MVR or MV Repair         
AVR+MVR 
 
Number of grafts 
One  
Two  
Three  
Four 
 
Anesthetic agents 
Induction 
Anti-nicotinic agents 
Rocuronium 
Pancuronium 
Vecuronium 
Midazolam 
Etomidate 
Fentanyl 
Propofol 
 
Maintenance  
Propofol 
Volatile Anesthetics 
Isoflurane 
Sevoflurane 
 
Intra-operative GTN 
 
44 (49%) 
12 (14%) 
23 (26%) 
7 (8%) 
1 (1%) 
2 (2%) 
 
3.72±2.03 
 
 
26 (29%) 
47 (53%) 
16 (18%) 
 
96.7±32.6 
 
64.8±26.4 
 
 
73 (82%) 
16 (18%) 
 
 
54 (61%) 
15 (17%) 
10 (11%) 
9 (10%) 
1 (1%) 
 
 
4 (6%) 
19 (30%) 
29 (45%) 
12 (19%) 
 
 
 
 
68 (81.0%) 
14 (17%) 
2 (2%) 
45 (54%) 
8 (9%) 
86 (100%) 
76 (88%) 
 
 
86 (100%) 
 
80 (93%) 
6 (7%) 
 
65 (76%) 
 
40 (45%) 
19 (21%) 
23 (26%) 
4 (5%) 
2 (2%) 
1 (1%) 
 
3.70±2.59 
 
 
29 (33%) 
38 (43%) 
22 (25%) 
 
89.6±31.0 
 
61.5±26.9 
 
 
75 (84%) 
14 (16%) 
 
 
57 (64%) 
14 (16%) 
9 (10%) 
8 (9%) 
1 (1%) 
 
 
5 (8%) 
15 (23%) 
35 (53%) 
11 (17%) 
 
 
 
 
76 (89%) 
6 (7%) 
3 (4%) 
33 (39%) 
7 (8%) 
85 (100%) 
77 (91%) 
 
 
85 (100%) 
 
81 (95%) 
4 (5%) 
 
53 (60%) 
0.661 
 
 
 
 
 
 
 
0.949 
 
0.356 
 
 
 
 
0.145 
 
0.419 
 
 
0.297 
0.842 
 
0.994 
 
 
 
 
 
 
0.713 
 
 
 
 
 
 
0.274 
 
 
 
 
0.265 
0.805 
1.000 
0.637 
 
 
1.000 
0.527 
 
 
 
0.035 
 
SD=standard deviation; RIPC= Remote Ischaemic Preconditioning; CABG= Coronary artery bypass graft; 
AVR=Aortic valve replacement; MVR= Mitral valve replacement; MV= Mitral valve; GTN=glyceryl trinitrate 
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3.12.1. RIPC reduced the magnitude of PMI 
Baseline  pre-operative  hsTnT  levels  were<0.02  μg/L  and  not  significantly  different 
between  RIPC  and  control  patients  (Figure  3.2,  Table  3.4).  Post-operative  hsTnT 
concentration rose in both groups with a peak at 6 hours: in patients randomised to 
RIPC, mean hsTnT was significantly reduced at 6, 12, 24, 48 and 72 hours following 
surgery (Figure 3.2, Table 3.4). The total hsTnT release over the 72 post-operative 
hours, calculated as total AUC of hsTnT, was significantly lower in the preconditioned 
group compared to control patients and resulted in a statistically significant reduction 
of 25.6%, from 36.307±24.542 μg/L  to 27.004±16.523 μg/L  [-9.303; CI: -15.626, -
2.979; p=0.004] (Figures 3.3, Table 3.4).  
 
 
 
 
 
 
 
 
Table 3.4. High-sensitivity Troponin-T release at the specified time point post-surgery 
Endpoint  Control (n=89) 
(mean [SD]) 
RIPC (n=89) 
(mean [SD]) 
Difference 
(95% CI) 
P value 
 
hsTnT (μg/L) 
Pre-operatively 
 
0.018 (0.019)  0.015 (0.020)  -0.003 (-0.099, 0.093)  0.310 
6 hours post-operatively 
 
0.802 (0.498)  0.614 (0.381)  -0.188 (-0.285, -0.092)  0.005 
12 hours post-operatively 
 
0.709 (0.438)  0.556 (0.376)  -0.153 (-0.250, -0.057)  0.013 
24 hours post-operatively 
 
0.529 (0.341)  0.408 (0.268)  -0.124 (-0.221 -0.027)  0.009 
48 hours post-operatively 
 
0.440 (0.408)  0.307 (0.202)  -0.137 (-0.234, -0.041)  0.007 
72 hours post-operatively 
 
0.407 (0.349)  0.277 (0.219)  -0.136 (-0.233, -0.038)  0.004 
Total 72 hours AUC 
 
36.307(24.542)  27.004 (16.523)  -9.303 (-15.626, -2.979)  0.004 
RIPC=Remote ischaemic preconditioning; SD=standard deviation; CI=confidence interval; hsTnT=high 
sensitivity Troponin-T   110 
Fig. 3.2. HsTnT concentrations at 0, 6, 12, 24, 48 and 72 hours post-surgery (mean±SEM) 
 
hsTnT=high sensitivity Troponin T; RIPC=Remote ischaemic preconditioning 
 p<0.05 (unpaired Student T-Test); SEM=standard error of the mean 
 
 
 
Fig. 3.3. Total Area under the Curve of high-sensitivity Troponin T over the 72 post-operative 
hours (mean±SEM)   
 
AUC=area  under  the  curve;  RIPC=Remote  ischaemic  preconditioning;  SEM=standard  error  of  the 
mean. * Unpaired Student T-Test 
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3.12.1.2. RIPC protected kidney function   
There was a significant improvement in urine output at 72 hours post-operatively and 
in  total  post-operative  urine  output  in  RIPC-treated  patients  (p=0.007  and  0.011 
respectively). Creatinine levels rose in both groups with a peak at 48 hours: however, 
we found no significant difference in serum creatinine levels pre-operatively and at 24, 
48 and 72 hours post-surgery. Importantly, both the incidence and the severity of AKI 
were decreased in RIPC patients and particularly we observed 19 new cases of AKI 
amongst  control  patients  and  9  cases  amongst  preconditioned  subjects:  this 
corresponded to a 53% reduction of the total number of AKI, which was very close to 
statistical significance (Table 3.5). 
 
Table 3.5. Summary of renal outcomes  
Endpoint  Control: n=89 
(mean [SD]) 
RIPC: n=89 
(mean [SD]) 
Difference 
(95% CI) 
P value 
AKI score (N) 
0  70 (79%)  80 (90%)     
1  11 (12%)   6 (7%)     
2  5 (6%)  2 (2%)     
3  3 (3%)  1 (1%)     
 
Total number of AKI cases 
 
19 (21%) 
 
9 (10%) 
   
0.063 
 
Creatinine (mg/ml) 
Pre-operatively  87.1 (19.6)  86.1 (27.2)  -1.0 (-8.0, 6.0)  0.780 
24 hours post-operatively  92.4 (30.0)  87.6 (27.0)  -4.7 (-13.2, 3.8)  0.278 
48 hours post-operatively  103.3 (49.3)  92.1 (38.5)  -11.2 (-24.3, 1.9)  0.094 
72 hours post-operatively  98.8 (52.6)  91.3 (43.0)  -7.5 (-21.7, 6.7)  0.306 
 
Urine Output (ml) 
24 hours post-operatively  1989.3 (764.5)  2171.4 (626.7)  182.1 (-33.8, 398.0)  0.098 
48 hours post-operatively  2144.0 (921.1)  2349.7 (848.9)  205.7 (-84.9, 496.2)  0.160 
72 hours post-operatively  2026.1 (859.1)  2486.1 (832.7)  460.0 (129.3, 790.7)  0.007 
Total  5858.1 (1748.7)  6706.8 (1580.2)  848.7 (197.9, 1499.5)  0.011 
RIPC=remote ischemic preconditioning; sd=standard deviation; AKI= acute kidney injury   112 
3.12.1.3. RIPC reduced the incidence of post-operative AF  
In the RIPC group the incidence of new AF was significantly reduced with 22 new 
cases of AF in the control group and 10 new cases in preconditioned patients (Table 
3.6),  which  corresponded  to  a  statistically  significant  reduction  of  56%  of  post-
operative AF (p=0.03). 
 
 
3.12.1.4. RIPC reduced the length of ICU stay  
RIPC reduced the length of ICU stay (2.0 vs 3.0 days; p=0.04) and the total hospital 
stay  (8.5  vs  8  days)  although  the  latter  did  not  reached  statistical  significance 
(p=0.094) (Table 3.6). 
 
 
 
3.12.1.5. Safety of RIPC: skeletal muscle injury and clinical outcomes 
Total  CK  release  was  not  statistically  different  between  control  and  RIPC  patients 
(32,543±27,087 µg/L vs 36,312ﾱ19,496 μg/L [3769.6; CI -4647.0, 12186.2; p=0.38], 
demonstrating that the enhanced multi-limb RIPC stimulus was not associated with a 
significant increase in muscle injury (Table 3.6). Furthermore, there was no difference 
in  major  adverse  clinical  events  at  6  weeks  in  patients  randomised  to  RIPC when 
compared to control (Table 3.6): interestingly, we observed 5 deaths at six weeks in 
the preconditioned group and no death in control patients, although this did not reach 
statistically significant significance (p=0.057). 
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Table 3.6. Summary of study endpoints  
 
Endpoint 
 
Control (n=89) 
(mean [SD]) 
 
RIPC (n=89) 
(mean [SD]) 
 
Difference* 
(95% CI) 
 
P value* 
 
CK (μg/L) 
Total AUC  32542.8 (19495.5)  36312.3 (27087.2)        3769.6 (-4647.0, 12186.2)  0.377 
 
Inotrope Score (mg/kg/hr) 
Post bypass  6.8 (13.5)  6.8 (15.3)  0.0 (-4.8, 4.8)   
24 hours post-operatively  11.6 (20.9)  9.4 (16.6)  -2.2 (-7.0, 2.6)   
48 hours post-operatively  8.4 (19.1)  5.5 (14.1)  -2.9 (-7.7, 2.0)   
72 hours post-operatively  5.6 (16.8)  1.7 (8.3)  -3.9 (-8.7, 1.0)   
Total  32.7 (58.8)  22.7 (42.3)  -10.0 (-25.6, 5.6)  0.206 
 
New onset AF (N) 
       
   
22 (25%) 
 
10 (11%) 
   
0.031 
 
Length of ICU stay (days) 
       
   
3.0 (2.0 - 4.5)** 
 
2 .0 (1.0 – 4.0)** 
   
0.043*** 
 
Length of hospital stay (days) 
       
   
8.5 (7.0 – 12.0)** 
 
8.0 (6.0 – 10.0)** 
   
0.094*** 
 
Clinical outcomes at six weeks (N) 
Death  5 (7%)  0 (0%)    0.057 
Myocardial infarction  1 (1%)  0 (0%)    0.401 
Stroke  0 (0%)  1 (1%)    0.451 
Revascularisation  0 (0%)  0 (0%)    1.000 
RIPC=remote ischemic preconditioning; SD=standard deviation; AUC=area-under-the-curve; AF=atrial fibrillation; 
CK=creatine kinase; ICU=intensive care unit 
*Differences, 95% CIs of the differences and p value are calculated from repeated measures regression 
model. 
**Results shown as median (IQR).  
***P Value for Mann–Whitney–Wilcoxon test. 
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3.13. Discussion 
3.13.1. Effects of simultaneous multi-limb RIPC on PMI  
This  single-centre  single-blinded  randomised  control  clinical  trial  has  demonstrated 
that  RIPC  induced  by  simultaneous  multi-limb  IR  reduces  PMI  as  evidenced  by  a 
statistically significant 25.6% reduction of hsTnT release. 
    Following cardiac surgery, the release of cardiac enzymes, including  CK-MB 
(119), TnT (77-79), TnI (80, 81), has been associated with worse short and long-term 
clinical outcomes (77-82) with therefore a significant impact on patients’ morbidity and 
mortality. As previously discussed, one of the potential mechanisms underlying PMI 
during  cardiac  surgery  is  represented  by  acute  IRI  secondary  to  intermittent  aortic 
cross-clamp, ICCF or intermittent or continuous administration of cardioplegia (83). In 
this regard, RIPC, describing the protection provided to an organ/tissue by a stimulus 
generated  in  a  remote  or  distant  organ/tissue  subjected  to  transient  IR  prior  to 
prolonged ischaemia, offers a non-invasive strategy capable to reduce PMI in patients 
undergoing cardiac surgery and therefore to potentially improve their morbidity and 
mortality. 
    The concept of RIPC was first introduced by Przyklenk and colleagues (201), 
who found a significant reduction of MI size in dogs subjected to four-5-minutes cycles 
of  Cx  occlusion  prior  to  1  hour  of  sustained  LAD  ischaemia.  From  this 
“intramyocardial” application of IPC, Birnbaum et al (217) went on to demonstrate that 
“remote” transient ischaemia in the hind-limb, applied with a partial occlusion of the 
femoral artery in conjunction with rapid pacing of the gastrocnemius muscle, could 
reduce MI size in rabbits. Subsequently, Kharbanda and co-workers (222) were the 
first to apply the concept of RIPC to healthy human volunteers by inducing transient   115 
non-invasive  limb  ischemia  with  a  simple  BP  cuff  applied  to  one  arm  and 
demonstrating improved endothelial function in the contralateral arm.  
A significant number of RCTs have followed this pioneering discovery with often 
discordant outcomes (Tables 1.10): Cheung et al (281) were the first to apply RIPC in 
a  clinical  setting  and  randomised  37  children  in  the  context  of  elective  corrective 
paediatric surgery for congenital heart defect to either control or RIPC given with 4 
cycles  of  lower  limb  IR  with  a  simple  BP  cuff  and  demonstrated  decreased  PMI, 
inotropic requirements and airway resistance in the preconditioned group. Similarly, 
within  the  context  of  paediatric  surgery,  Zhou  and  colleagues  (307)  showed  that 
children undergoing surgical repair of simple ventricular septal defect receiving RIPC 
with three-5 minutes cycles of left upper arm IR 24 hours and 1 hour prior to surgery, 
reduced serum concentrations of IL-6, IL-8, IL-10, TNF-alpha, LDH, CK, CK-MB, and 
cTnI, thereby attenuating systemic inflammatory response as well as myocardial and 
pulmonary  injury.  Again,  in  a  third  interesting  clinical  trial  in  corrective  paediatric 
surgery,  Pavione  and  co-workers  (308)  applied the  preconditioning  stimulus  (four-5 
minutes  cycles  of  lower  limb  IR)  24  hours  prior  to  the  operation  and  failed  to 
demonstrate  enhanced  cardioprotection  or  reduced  post-operative  inflammatory 
response:  nevertheless,  it  is  possible  that  in  this  case,  as  previously  known,  the 
negative findings obtained could be attributed to the inferior intensity of myocardial 
protection  provided  by  the  second  window  of  preconditioning  compared  to  classic 
preconditioning. 
However it was in the setting of adult CABG surgery that understandably RIPC 
found an extensive application. Here we will concentrate on the discussion of RCTs in 
the setting of CABG surgery with or without valve surgery whereas studies on valve 
surgery alone will be described in the next section.    116 
Our research group was the first to demonstrate that RIPC reduced PMI in adult 
patients  undergoing  elective  CABG  surgery  (282):  in  a  pioneering  single-blinded 
controlled  RCT  (282) involving  57  patients undergoing  elective  CABG  surgery  with 
either cardioplegia or ICCF and randomised to RIPC (three-5 minute cycles of inflation 
and deflation of BP cuff placed on the upper arm) or control (an un-inflated BP cuff 
placed on the upper arm for 30 minutes), we found that preconditioned subjects had a 
43%  reduction  of  cardiac  cTnT  release  over  the  72-hour  peri-operative  period 
compared to controls. These findings were confirmed with a further study involving 45 
non-diabetic  patients  undergoing  elective  CABG  with  or  without  valve  surgery  and 
receiving cold-blood cardioplegia alone (291), thereby reflecting the more common use 
of this method of myocardial protection  in the UK and  worldwide: RIPC given with 
three-5 minute cycles of upper arm IR significantly reduced the 72-hour AUC of cTnT 
by  42.4%,  demonstrating  that  PMI  can  be  reduced  by  RIPC  irrespective  of  the 
technique of myocardial preservation. The same preconditioning stimulus was applied 
by  Ali  and  colleagues  (445)  in  a  study  including  100  patients  undergoing  elective 
CABG for two or three-vessel CAD and similarly led to a significant reduction of post-
operative CK-MB levels.  
The concept of RIPC in the context of elective CABG was then extended to 
patients receiving antegrade cold crystalloid cardioplegia in two seminal studies by 
Thielmann and colleagues (293, 300). In the former (293), non-diabetic patients with 
triple-vessel CAD subjected to a preconditioning stimulus with three 5-minute transient 
upper  arm  IR  sustained  a  significantly  lessened  PMI  compared  to  control,  with  a 
44.5%  reduction  of  total  72  hr  AUC  of  cTnI,  demonstrating  that  RIPC  can  induce 
myocardial protection also in the context of crystalloid cardioplegia. In the latter (300), 
which recruited 329 patients undergoing first-time CABG surgery and is therefore the   117 
so  far  largest  proof-of-concept  RCT  on  RIPC  in  cardiac  surgery,  the  same 
preconditioning stimulus improved myocardial protection (ratio of RIPC/control for cTnI 
AUC was 0.83) and more importantly significantly reduced the combined endpoint of 
all-cause  mortality,  major  adverse  cardiac  and  cerebrovascular  events,  and  repeat 
revascularisation: this will be further discussed in details in chapter 7.  
However, recently a number of studies have failed to demonstrate significant 
cardioprotection provided by RIPC: within again the context of crystalloid cardioplegia 
the same group (295), for example, only showed a small beneficial effect of RIPC, 
applied 18 hours prior to elective CABG surgery with or without AVR, with TnT release 
only significantly reduced at 8 hours post-operatively but not at 16 or 24 hours, thereby 
reflecting that the late window of preconditioning is a less potent strategy than classic 
preconditioning.  Moreover,  in  a  third  additional  treatment  group  including  subjects 
receiving tramadol 200 mg retard at 19:00 hours the day before surgery and at 06:00 
hours on the day of the operation, PMI was significantly higher than the control group 
at all the time points. Similarly, Lomivorotov and co-workers (297) did not find any 
statistically significant benefit on PMI in patients undergoing CABG surgery with cold 
crystalloid cardioplegia, although importantly in this study they only measured cTnI 
and CK-MB pre-operatively and at 6, 24 and 48 hours post-surgery only, thereby not 
reflecting the true absolute post-operative release of cardiac biomarkers provided by 
total AUC. 
Similarly, in a large trial involving 162 patients undergoing CABG surgery (286), 
Rahman and colleagues found no statistically significant difference between patients 
receiving sham or RIPC protocols (three-5 minute cycles of upper limb IR) in cTnT 
release, ECG changes, cardiac index, inotrope and vasoconstrictor requirement, renal 
impairment  and  lung  injury.  However,  importantly  the  study  included  patients   118 
undergoing elective or urgent (post-ACS) CABG surgery and it is therefore possible 
that the beneficial effects of RIPC might have been attenuated by the previous acute 
event,  which  could  have  already  “preconditioned”  the  patients.    Moreover,  in  this 
double-blinded  study,  patients  were  prepared  and  draped  so  that  to  obscure  the 
visibility of both the BP cuff placed around the upper arm and the one placed around a 
“dummy arm” and although the correct inflation was verified though the disappearance 
of a pulsatile signal on a pulse oximeter, it is still possible that during the inflation and 
deflation phases, the cuff might have moved and that the RIPC stimulus might have 
not been delivered correctly. Third and importantly, a significant proportion of these 
patients  received  GTN  intra-operatively  which  might  have  interfered  with 
cardioprotection provided by RIPC: this will be also discussed in a separate section. 
Subsequently,  Young  and  colleagues  (296),  failed  to  demonstrate  that  a  standard 
preconditioning stimulus could improve PMI, AKI incidence or inotrope requirement in 
a study enrolling 96 patients undergoing high-risk cardiac surgery, including combined 
CABG  and  valve  surgery,  CABG  surgery  with  LVEF<50%,  “redo-operation”,  MV 
surgery, double or triple valve surgery.  
Using the hypothesis that RIPC is cardioprotective under a strict anaesthetic 
regime, Karuppasamy and co-workers (294) recruited 54 patients undergoing elective 
CABG  surgery  and  receiving  the  volatile  anesthetic  isoflurane before  CPB and the 
intravenous anaesthetic propofol thereafter until the completion of surgery: patients 
subjected  to  a  standard  RIPC  stimulus  had  no  significant  benefit  in  terms  of  total 
release of cTnI, BNP, CK-MB, cytokines and growth factors. Two other major clinical 
studies used a strict anaesthetic regime with similarly no significant impact on PMI 
(298, 299): in a first RCT involving 72 non-diabetic patients referred for elective CABG 
surgery (298) with crystalloid cardioplegia, anaesthesia induction was achieved in all   119 
subjects with a combination of sufentanil, etomidate and rocuronium, and anaesthesia 
maintenance  was  ensured  with  either  inhaled  isoflurane  or  propofol  infusion  with 
additional sufentanil administered in both cases at the discretion of the anaesthetist: 
intriguingly  the  authors  found  that  only  with  isoflurane  anaesthesia  RIPC  could 
significantly  reduce  PMI  compared  to  isoflurane  alone,  whereas  no  significant 
difference  was  found  in  patients  receiving  RIPC  with  propofol  compared  to  those 
receiving propofol alone. In a further study on 55 patients undergoing CABG surgery 
with cold blood cardioplegia (299), anaesthesia was induced with propofol, an opioid  
(either  fentanyl,  sufentanil  or  romifentanil)  and  rocuronium  and  maintained  with 
isoflurane: RIPC consisted of four-5 minutes cycles of 300mmHg cuff inflation/deflation 
of a BP cuff around the upper leg prior to aortic cross-clamping and did not reduce the 
total  release  of  cTnT,  pro-BNP,  CRP,  S100  protein  (a  marker  of  cerebral  injury); 
importantly,  the  incidence  of  the  composite  endpoint  of  post-operative  new 
arrhythmias and MI was significantly higher in the preconditioned group. 
Furthermore, in a proof-of-concept study involving 130 patients undergoing off-
pump CABG surgery (284), RIPC was induced by four cycles of five-minute upper limb 
IR and reduced total cTnI AUC by 26%, which did not reach statistical significance. 
However, the same group found that the combination of RIPC with RIPostC (285) in 
an analogous surgical setting (the same stimulus was applied twice, immediately after 
anaesthesia induction -RIPC- and just after completion of anastomoses -RIPostC-), 
could lead to a significant cTnI AUC reduction in the preconditioned group. 
Additionally, a number of systematic reviews investigating the effects of RIPC 
on PMI with or without clinical outcomes in patients undergoing cardiac or vascular 
surgery or elective PCI have been conducted (289, 446-455), concluding that RIPC   120 
reduces post-procedure myocardial damage in these subjects but does not impact on 
their clinical outcomes (456). 
    In  summary,  it  is  evident  that  the  overall  results  of  the  numerous  RCTs 
investigating the effects of RIPC on PMI in patients undergoing cardiac surgery have 
not been overwhelmingly positive. Multiple potential factors can be identified in order 
to  provide  a  satisfactory  explanation  in  this  regard  and  these  can  be  classified  in 
patients’  characteristics,  clinical  settings,  anaesthetic  regimes  and  other  agents 
administered in the peri-operative period.  
 
    Patients’ characteristics particularly involve baseline factors such as age and 
the presence of co-morbidities: more recently the risk profile of patients undergoing 
cardiac surgery has significantly changed and this is also due to the ageing population 
and therefore to patients with more advanced age being operated on (34). Ageing is 
characterised  by  up-regulation  of  Angiotensin-II  receptors,  activation  of  NADPH 
oxidase,  increased  oxidase-A  activity  and  mitochondrial  oxidative  defense  which 
ultimately increase oxidative stress and render ageing myocardium more susceptible 
to  IRI  (457):  intriguingly  the  response  of  ageing  myocardium  to  cardioprotection 
provided by IPC, RIPC and RIPostC as well as by pharmacological agents including 
opioids  remains  controversial  (457).  Moreover  it  has  been  established  that  the 
presence  of  comorbidities  such  as  diabetes,  hypertension,  and  dyslipidaemia  may 
interfere with cardioprotection. In the next chapter we will discuss about the crucial role 
of diabetes in cardiovascular disease and its implications in the outcomes of studies 
evaluating the effects of RIPC on PMI in diabetic patients undergoing cardiac surgery. 
Intriguingly, cardioprotection provided by IPC my be lost in aging hypertensive hearts 
(458)  and  discordant  results  have  been  obtained  from  experimental  and  human   121 
studies evaluating the effects of dyslipidaemia on myocardial IRI and more importantly 
on its impact on IPC, RIPC and RIPostC: there is also evidence that statins might 
interfere with cardioprotection though mechanisms that might be independent on their 
lipid-lowering actions, such plaque stabilisation, endothelial function preservation, free 
radical  scavenging,  anti-proliferative,  anti-ischaemic,  anti-inflammatory  and  anti-
apoptotic  effects  (457).  In  this  regard,  we  hypothesised  that  an  enhanced 
preconditioning  stimulus  would  be  able  to  overcome  the  impaired  or  attenuated 
response to cardioprotection in patients with any of the above individual or combined 
conditions. Moreover and importantly, in our study we found no statistically significant 
difference between preconditioned and control patients in terms of age, comorbidities 
and concomitant medications. 
    In addition, pharmacological agents administered concomitantly with cardiac 
surgery have also been demonstrated to have a significant impact on cardioprotection 
achieved with RIPC, with particular regards to anaesthetic drugs and iv nitrates given 
prior to, during and post-surgery. We will discuss the role of iv GTN elsewhere. Here 
we will concentrate on the role of anaesthetics in preconditioning. Inhaled anaesthetics 
have been showed to provide myocardial protection in patients undergoing cardiac 
surgery (299, 459-461), either used alone or in combination with propofol (284, 298). 
However the use of propofol alone does not lead to cardioprotection (298), and this is 
probably due to the lack of action on KATP channels and its interference with ROS, 
which have both been implicated in mechanisms underlying RIPC (298). It is therefore 
possible that inhaled anaesthetics, either alone or in combination with propofol, are 
capable  to  reach  the  necessary  threshold  to  induce  cardioprotection  and  that  the 
addition of RIPC may not provide any further benefit. In our study, propofol was given 
to 88% of controls and 91% of preconditioned patients during anaesthesia induction   122 
and  to  100%  of  patients  in  both  groups  during  anaesthesia  maintenance  with  no 
significant  difference  between  the  two  groups;  similarly,  volatile  anaesthetics  were 
given  to  all  control  and  RIPC  patients  during  maintenance,  in  the  form  of  either 
isoflurane (93% and 95% respectively) or sevoflurane (7% and 5% respectively), with 
again no difference between the two groups. 
 
    The clinical setting is another crucial aspect potentially able to interfere with 
cardioprotection and therefore with outcomes of some of the above-mentioned RCTs. 
Crucially, when patients undergoing urgent CABG were also included in the analysis 
(286), the recent occurrence of ACS might have inadvertently preconditioned  these 
subjects and therefore attenuated cardioprotection provided by a subsequent RIPC 
stimulus: in this regard, our study only included patients undergoing elective cardiac 
surgery  and  with  negative  hsTnT  at  baseline.  In  addition,  the  vast  majority  of  the 
clinical  trials  on  RIPC  in  cardiac  surgery  are  small  proof-of-concept  studies  and 
therefore  it  is  possible  that  small  differences  in  PMI  magnitude  between 
preconditioned  and  control  patients  might  have  not  reached  statistical  significance: 
hence we intended to maximise patient recruitment in order to increase our sample 
size. At the time of our recruitment completion, our study was the largest proof-of-
concept clinical trial (n=180) investigating the effects of RIPC on PMI in an unselected 
population undergoing cardiac surgery. More importantly, patients undergoing elective 
CABG surgery sustain an overall small magnitude of PMI compared to that observed 
in patients presenting with STEMI (280): the detection of myocardial damage in these 
subjects can occur by measuring the increase of cardiac biomarkers and/or performing 
imaging tests as described in chapter 1. In addition, given recent developments of on-
going treatment approaches of patients with CAD and more importantly the advance of   123 
operative  methods  of  myocardial  preservation,  surgical  techniques  and  anaesthetic 
agents, it is possible that the additional benefit provided by RIPC  to these patients 
might not be significant or identifiable with the current strategies. Again, we sought to 
overcome  this  potential  disadvantage  by  delivering  a  higher  intensity  protective 
stimulus in order to render evident the effects of RIPC in these patients. 
    Therefore, from these observations, it is possible to identify in the intensity of 
the preconditioning stimulus one of the most important factors potentially able to 
impact on myocardial preservation in cardiac surgery: indeed an “insufficiently potent” 
stimulus might be associated only with a non-significant benefit compared to the one 
already provided by the optimisation of surgical and anaesthetic techniques as well as 
by pharmacological treatment or might not be able to overcome the interference due to 
a recent cardiac event or concomitant comorbidities and/or medications. Therefore, 
with our simultaneous multi-limb preconditioning stimulus we intended to “cross” the 
potential threshold in order to enhance cardioprotection. Moreover, in some studies 
the preconditioning stimulus has been delivered in different ways, by using a different 
number  and  duration  of  IR  cycles,  upper  limbs  versus  lower  limbs,  dummy  arms 
besides patients’ arms and covered by surgical gown in order to ensure blindness but 
at the same time leading to the possibility of misplacement of the cuff between one 
cycle  and  the  other.  We  therefore  hypothesised  that  PMI  could  be  reduced  by 
increasing  the  intensity  of  the  preconditioning  stimulus  by  applying  transient 
simultaneous multi-limb IR: 2 cycles of 5 minutes inflation-deflation of two BP cuffs 
around the upper arm and the upper thigh respectively are potentially equivalent to 4 
cycles of arm conditioning only, which have been successfully used in a recent trial 
investigating the effects of remote preconditioning in patients presenting with STEMI 
and  undergoing  PPCI  (356).  Only  one  study  (306),  unpublished at  the time of  our   124 
patients’  recruitment,  had  used  a  comparable  preconditioning  stimulus  in  patients 
undergoing  MVR  with  or  without  concomitant  TV  valvuloplasty.  RIPC  consisted  of 
three-5 minutes cycles of upper arm IR or three-5 minutes cycles of upper arm IR plus 
two 10 minutes cycles of upper leg IR. Intriguingly, whilst no difference of total cTnI 
was  found  between  control  and  patients  receiving  the  standard  preconditioning 
stimulus,  simultaneous  multi-limb  preconditioning  significantly  reduced  mean  cTnI, 
although no total TnI AUC was evaluated and no significant difference was observed 
in other outcomes.  
    The second considerable advantage of our simultaneous limbs preconditioning 
resides in the shortened time required for the delivery of the stimulus (15 minutes vs 
the 25 minutes used in the vast majority of clinical trials and the 35 minutes needed in 
Botker’s work (462)) and therefore in its practicality, which represent important aspects 
of  the  patients’  preparation  and  optimisation  in  the  period  immediately  preceding 
cardiac surgery (by increasing the intensity of the stimulus using one limb only we 
would inevitably prolong the time necessary for the stimulus to be applied).  
    In  conclusion  our  study  demonstrated  that  by  increasing  the  intensity  of  the 
preconditioning  stimulus  by  simultaneous multi-limb IR,  it  is possible  to  reduce  the 
magnitude of PMI in an unselected population undergoing cardiac surgery. We will 
show  in  the  next  section  the  impact  of  these  enhanced  stimulus  on  other  study 
endpoints: the large multi-centre randomised control double-blinded clinical trials that 
are currently being undertaken will be able to potentially confirm these findings and 
more  importantly  to  establish  whether  RIPC  provides  beneficial  effects  on  clinical 
outcomes  in  patients  undergoing  cardiac  surgery  (ERICCA  trial,  ClinicalTrial.gov 
identifier: NCT01247545, and RIPHeart, ClinicalTrials.gov identifier: NCT01067703). 
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3.13.2. Effects of simultaneous multi-limb RIPC on AKI 
AKI  is  a  potential  major  complication  following  cardiac  surgery  and  can 
significantly impact on patients’ morbidity and mortality: studies have showed that it 
can affect up to 30% of patients and require dialysis in 1-2% of cases (364), potentially 
leading to an 8-fold increased death rate (365). In major vascular surgery involving the 
abdominal aorta, AKI has been observed in almost 10% of patients  (316) and in a 
prospective  cohort  study  of  4118  patients  undergoing  cardiac  and  thoracic  aortic 
surgery (463), even changes in serum creatinine concentration higher than or equal to 
0.5 ml/dL were associated with a 35% mortality rate at 30 days post-surgery. Different 
mechanisms have been hypothesised in order to explain renal injury following cardiac 
surgery and include haemodynamic effects related to CBP, metabolic factors, neuro-
hormonal  stimulation,  systemic  inflammatory  response  to  CBP,  exogenous  and 
endogenous toxins, production of micro-emboli and oxidative stress (364). Importantly, 
different strategies have so far been investigated in order to preserve renal function 
following  cardiac  surgery,  however  with  often  unsatisfactory  results  (364),  and 
therefore novel protective strategies are required to reduce AKI incidence and improve 
clinical outcomes in these patients: in this regard, RIPC has increasingly become an 
encouraging promise in a significant number of preclinical and clinical studies (Table 
1.16). In a retrospective analysis of two randomised trials primarily investigating the 
effects of RIPC on PMI in cardiac surgery, Venugopal et al (434) found a significant 
decrease of the occurrence of AKI in 38 non-diabetic patients subjected to standard 
RIPC stimulus: importantly this secondary analysis was small and excluded patients 
with  diabetes  and/or  CKD,  who  are  at  significantly  higher  risk  of  developing  AKI 
following cardiac surgery.   126 
Subsequently,  a  prospective  double-blinded  RCT  on  76  patients  undergoing 
complex valve surgery (303) failed to prove statistically significant benefit of RIPC on 
AKI,  although  it  demonstrated  a  significant  reduction  in  CK-MB  release  during  the 
post-operative  24  hours.  Similarly,  still  within  the  context  of  valve  surgery,  no 
significant difference was found in AKI or ALI incidence between preconditioned and 
control patients in another study applying combined RIPC and RIPostC (305). These 
discrepant  results  between  myocardial,  lung  and  renal  protection  could  potentially 
reflect different mechanisms underlying RIPC in these organs, being the heart directly 
and  the  kidneys  and  lungs  indirectly  subjected  to  IRI  during  cardiac  surgery.  In  a 
further study investigating renal outcomes in 118 patients undergoing CABG  (435), 
Zimmermann  and  colleagues  found  a  reduction  in  the  occurrence  of  AKI  in  the 
preconditioned  group,  with  an  absolute  AKI  risk  reduction  of  0.27  and  a  relative 
reduction  of  0.43,  although  no  difference  was  identified  in  Neutrophil  Gelatinase 
Associated Lipocalin (NGAL) levels measured before and 3 hours after CBP. In a post-
hoc analysis, the same authors also demonstrated a reduction of AKI 1-2 and of the 
incidence of AKI for at least 48 hours in the preconditioned patients. Interestingly, in 
another  study  by  Pedersen  (436)  involving  105  children  undergoing  complex 
congenital heart disease, RIPC, consisting of four-5 minutes cycles of inflation to 40 
mmHg  above  SBP  of  a  cuff  placed  around  the  thigh,  followed  by  5  minutes  of 
deflation,  no  difference  was  found  in  primary  endpoints  including  AKI,  initiation  of 
dialysis, serum creatinine, eGFR, plasma cystatin C, NGAL and urinary output.  
Similarly, no difference in renal outcomes was found in subsequent studies in 
patients undergoing CABG when off-pump surgery was performed (284), or high risk 
patients  were  included  (296),  or  crystalloid  cardioplegia  (297)  or  strict  anaesthetic 
regimes  (298)  were  delivered.  Thielmann  et  al.  (293)  demonstrated  significantly   127 
reduced  post-operative  cTnI  and  serum  creatinine  concentrations  in  non-diabetic 
subjects  undergoing  CABG  surgery  with  crystalloid  cardioplegia,  although  renal 
protection could not be confirmed in a more recent study by the same group  (300) 
using a similar preconditioning stimulus in a comparable surgical setting. In the study 
by  Rahman  and  colleagues  (286),  RIPC  did  not  achieve  statistically  significant 
myocardial or renal protection in subjects undergoing elective or urgent CABG surgery 
with blood cardioplegia. 
A recently published large systematic review of RCTs investigating the effects of RIPC 
on  myocardial  and  renal  protection  (450)  included  17  studies  on  a  total  of  689 
preconditioned patients and 682 control subjects undergoing CABG with or without 
valve surgery (279, 282, 284, 286, 291, 293, 445), valve surgery alone (302), open 
AAA repair (292, 319, 321) and elective (339, 340) or primary PCI (355, 356). The 
meta-analysis  concluded  that  RIPC  patients  had  lower  reduced  PMI  (standardised 
mean difference (SMD), 0.54; 95% CI -1.01 -0.08; p=0.01) and a lower incidence of 
perioperative  MI  (7.9%  RIPC  vs  13.9%  placebo;  RR,  0.56;  95%  CI,  0.37-0.84; 
p=0.005); in patients undergoing AAA repair, RIPC also decreased renal injury when 
compared to control (SMD, 0.28; 95% CI -0.49, -0.08; p=0.007).  
  In our study we demonstrated a reduction of post-operative AKI incidence in 
preconditioned patients compared to control, with 9 new cases of AKI in the former 
versus 19 in the latter, which corresponded to an overall 53% reduction of the total AKI 
cases  in  our  cohort  population  (Table  3.5).  However,  this  approached  but  did  not 
reach statistical significance (p=0.063), although it is possible that it might be related to 
the relatively small number of patients recruited into the study. Importantly also the 
severity of AKI was reduced in the preconditioned group although with no statistical 
significance (Table 3.5). Encouragingly, we found a significant improvement in urine   128 
output  at  72  hours  post-operatively  and  total  post-operative  urine  output  in  RIPC-
treated patients although with no significant difference in serum creatinine levels pre-
operatively and at 24, 48 and 72 hours post-surgery. It is therefore possible that an 
enhanced RIPC stimulus may lead to an improved renal function in the post-operative 
period and that a large and adequately powered RCT would be able to confirm these 
findings. In this regard, our large multi-centre randomised double-blinded controlled 
ERICCA trial investigated the effect of RIPC on a number of parameters including AKI 
in high risk patients undergoing elective CABG±valve surgery (290) and will provide 
essential conclusions as to whether this simple intervention may positively impact on 
these subjects’ clinical outcomes. Noticeably, another important RCT  undertaken in 
the  UK  involving  patients  undergoing  live-donor-related  renal  transplantation,  found 
that  limb  RIPC  of  both  donors  and  recipients  preserved  the  transplanted  kidney 
function  at  6  months  in  recipients  of  live-donor  related  renal  transplantation  and 
therefore showed the protective function of RIPC on transplanted renal grafts (REPAIR 
trial:  ‘Renal  Protection  Against  Ischaemia-Reperfusion  in  Transplantation’, 
ISRCTN30083294). 
In  conclusion,  similarly  to  the  field  of  myocardial  protection,  clinical  trials  on 
renal outcomes with RIPC following cardiac surgery, major vascular procedures and 
elective  PCI  have  often  led  to  discrepant  results  and  therefore  larger  multicentre 
studies are required in order to determine whether the application of RIPC to these 
clinical  settings  will  translate  into  improvement  of  kidney  protection  –  as  well  as 
cardioprotection- and therefore of morbidity and mortality in these patients.  
 
 
   129 
3.13.3.  Effects  of  simultaneous  multi-limb  RIPC  on  new  onset  of 
post-operative AF 
In  our  study,  RIPC  reduced  the  incidence  of  post-operative  AF  by  55% 
compared to control. New onset AF occurs in 30-50% of patients following cardiac 
surgery  (444),  with  an  incidence  of  30%  post-CABG  surgery,  40%  following  valve 
surgery and 50% further to CABG plus valve surgery (444). Importantly AF is also 
associated  with  increased  rates  of  death,  thrombo-embolic  events,  LV  failure, 
prolonged hospitalization, reduced quality of life and poor exercise capacity (444). The 
aetiology  of  post-operative  AF  is  multi-factorial  and  can  be  related  to  common 
pathogenetic factors to the general populations, such as age, CAD, rheumatic heart 
disease,  thyrotoxicosis,  cardiomyopathy,  MV  disease,  haemochromatosis,  infection, 
but also and more importantly to parameters directly or indirectly related to the surgery 
in  itself,  including  hypovoloemia,  electrolyte  imbalance,  central  venous  catheters, 
prolonged  aortic  cross-clamp  times,  increased  automaticity,  increased  sympathetic 
tone (also due to the use of inotropes) and importantly acute myocardial IRI (444).  
Rahman et al (286) failed to demonstrate any beneficial effect of RIPC on AF 
incidence following cardiac surgery, the potential reasons for which have already been 
discussed.  Similarly  no  difference  was  found  in  patients  undergoing  valve  surgery 
alone (305), or CABG surgery when RIPC was applied during isoflurane inhalation 
(299) or in children receiving corrective repair for congenital heart disease when RIPC 
was delivered with four-5 cycles of lower limb IR 24 hours before the operation (in this 
case the authors showed no statistical difference in the total rate of post-operative 
arrhythmias) (308). 
In our cohort, RIPC reduced the incidence of new post-operative AF by 55%, 
with 10 new cases in the RIPC group and 22 in the control group, which corresponded   130 
to 25% and 11% of patients respectively, a reduction which we found to be statistically 
significant (p=0.031) (Table 3.6). It is possible that, given that IRI is one of the most 
relevant pathogenetic factors implicated in the mechanisms of AF following cardiac 
surgery, RIPC may have decreased the incidence of post-operative AF by protecting 
the  myocardium  against  acute  IRI.  This  may  imply  that  compared  to  the  above-
mentioned  studies,  by  increasing  our  preconditioning  stimulus  and  therefore  by 
achieving a significant PMI reduction, we have reached the potential threshold capable 
to  enhance  cardioprotection  and  its  consequences,  including  amongst  others  the 
decreased incidence of new onset post-operative AF. 
Additionally, a 55% reduction in post-operative AF is extremely encouraging as 
it would also be expected to have beneficial effects on short and long-term clinical 
outcomes resulting in improved patient morbidity and mortality and reduced healthcare 
costs. This again leads to the significant relevance of large RCTs to investigate the 
effects of RIPC on new onset of post-operative AF in the context of cardiac surgery in 
order  to  better  understand  the  mechanisms  underlying  its  occurrence  and  more 
importantly the impact of PMI reduction on its incidence and on subsequent clinical 
outcomes.  In  this  regard,  the  on-going  large  multi-centre  RICO  trial  is  also 
investigating the effects of RIPC on AF incidence in CABG patients (464). 
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3.13.4. Effects of simultaneous multi-limb RIPC on ICU/hospital stay 
    In our cohort, we were able to find a statistically significant difference between 
the two treatment groups in term of length of ICU stay, with 2 versus 3 days of total 
ICU  stay  in  RIPC  and  control  groups  respectively  (p=0.043)  (Table  3.6).  Previous 
studies including children undergoing corrective cardiac surgery (306-308, 436), adults 
receiving  valve  surgery  alone  (301,  302,  305,  306)  or  elective  CABG  surgery  with 
crystalloid  cardioplegia  (293,  300),  elective  or  urgent  CABG  (286)  failed  to 
demonstrate this beneficial effect. However, similarly to these studies, we found no 
significant difference in total hospital stay (p=0.094). 
    We  hypothesise  that  in  our  RCT,  ICU  stay  reduction  could  be  directly  or 
indirectly related to the enhanced preconditioning stimulus delivered and particularly 
to: 
1)  the  reduction  in  PMI,  which  can potentially  improve  cardiac function  thereby 
limiting the period of time for the patient to require intensive care management; 
2)  the decrease in new onset of post-operative AF, therefore reducing the potential 
haemodynamic instability that could arise subsequently to poorly controlled AF; 
3)  the reduction of AKI incidence and severity, although this only approached but 
did not reach statistical significance. 
The  importance  of  this  finding  in  our  single-centre  study  has  the  potential  to  be 
clinically relevant as clearly a reduction of ICU total stay may have a significant impact 
on patients short and long term clinical outcomes and subsequently on NHS resources 
and costs. However, it is also relevant to specify again that the reduction of ICU stay 
did not result in a significant decrease of total hospital stay: our ERICCA trial will once 
again give us clarification on such an intriguing result. 
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3.13.5. Effects of simultaneous multi-limb RIPC on other secondary 
end-points 
    In  addition  to  the  above  findings,  our  study  did  not  show  any  significant 
difference  between  preconditioned  and  control  patients  in  terms  of  inotrope 
requirement (Table 3.6). This also confirms similar outcomes from previous studies 
(286,  297,  300,  302,  305,  306,  436).  Importantly,  RIPC  has  been  associated  with 
increased inotropic requirement in high-risk patients undergoing double or triple valve 
surgery,  MV  surgery,  CABG  plus  valve  surgery  or  CABG  with  pre-operative 
LVEF<50%  (296)  and  only  two  studies  (281,  301)  have  so  far  reported  beneficial 
effects of RIPC on this outcome: the former was the first fundamental application of 
RIPC in the clinical setting and showed that lower limb IR also induced myocardial and 
lung protection in corrective paediatric surgery (281); the latter included valve surgery 
alone and concluded that both the total of number of patients requiring inotropes and 
the  total  inotrope  dose  needed  were  significantly  lower  in  preconditioned  subjects 
(301). 
    Crucially, we also find that our enhanced preconditioning stimulus did not result 
in significant muscle damage: one could argue that transient simultaneous multi-limb 
IRI by inflating two BP cuffs, one around the upper arm and one around the upper 
thigh,  could  lead  to  an  increased  limb  skeletal  muscle  injury.  For  this  reason,  we 
excluded patients with known significant PAD of upper and/or lower limbs. We found 
no statistically significant difference in total CK AUC (32542.8±19495.5 μg/L in controls 
versus  36312.3±27087.2  μg/L  in  preconditioned  patients  [3769.6;  CI  -4647.0, 
12186.2;p=0.377]  (Table  3.6)  (465),  therefore  proving  that  our  increased  RIPC 
stimulus does not results  in relevant muscle damage and can safely be delivered in 
the absence of significant PAD.   133 
    Finally,  despite  the  non-statistically  significant  incidence  of  5  deaths  in  the 
preconditioned group at six weeks post-surgery versus no death in the control group, 
we found no relevant difference in short term clinical outcomes between control and 
RIPC subjects (Table 3.6): this will be further discussed in chapter 5, where we will 
also explain the potential impact of an increased RIPC on clinical outcomes at one 
year, the primary study endpoint of our ERICCA trial (290).  
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3.13. Post-hoc subgroup analyses 
Our relatively large cohort size allowed us to perform a series of retrospective sub-
group  analyses  to  determine  whether  the  protective  effects  of  our  enhanced 
preconditioning stimulus we have found in the principal study would also apply in more 
specific settings, based on the technique of myocardial preservation utilised, the type 
of operation and crucially the presence or absence of diabetes. However, it is also 
crucial  to  highlight  that,  whilst  our  principal  study  was  adequately  powered  for  the 
primary  end-point  of  PMI,  findings  deriving  from  these  retrospective  sub-group 
analyses are only suggestive of potential outcomes and certainly require larger RCTs 
to be confirmed.  
 
 
3.13.1 Multi-limb RIPC and techniques of myocardial preservation: effects 
on cardioprotection in patients undergoing cardiac bypass surgery using 
either cardioplegia or ICCF  
We  have  so  far  described  the  effects  of  an  enhanced  RIPC  stimulus  in  an 
unselected  cohort  of  patients  undergoing  cardiac  surgery  and  demonstrated  that 
simultaneous transient multi-limb IR significantly reduces PMI, new post-operative AF 
incidence and total ICU stay length with no significant impact on inotrope requirement, 
hospital  stay  duration  and  clinical  outcomes  at  six  weeks  and  a  trend  towards 
statistical  significance  of  AKI  incidence  reduction.  As  previously  discussed, 
cardioplegia is the prevalent technique of myocardial preservation in cardiac surgery 
(30, 466, 467), although studies have proved that the magnitude of cardioprotection 
provided  by  cardioplegia  or  ICCF  is  essentially  equivalent,  as  the  more  significant 
cellular protective effects of cardioplegia are balanced by the more prolonged cross-  135 
clamp times (89-93) compared to ICCF. Also, interestingly so far only one small RCT 
has demonstrated the cardioprotective effects of  IPC in patients undergoing CABG 
using ICCF (468) and no published study has been conducted to evaluate the potential 
impact of RIPC in these subjects.  We therefore conducted a retrospective analysis in 
order to establish whether the same enhanced preconditioning stimulus may enhance 
cardioprotection irrespective of the technique of myocardial preservation used. 
 
3.13.1.1. Results 
From  a  total of  178  patients  recruited  into  our  study,  148  subjects  received 
cardioplegia and the remaining 30 ICCF: in the first subgroup, 73 were randomised to 
the sham protocol and 75 to RIPC (82% and 84% respectively in the sham and RIPC 
groups), whereas in the ICCF subgroup we had 16 control and 14 RIPC patients (18% 
and 16% respectively,  Table  3.7). We therefore wish to emphasise again that this 
retrospective analyses are clearly underpowered and, for this reason, findings should 
be  considered  as  suggestive  of  potential  effects  of  RIPC  in  these  setting  and  will 
require further confirmation with larger RCTs studies. We found no difference in terms 
of patients’ baseline characteristics between control and preconditioned patients within 
both  cardioplegia  and  ICCF  subgroups  (Tables  3.7).  With  regards  to  parameters 
related to surgery, again no statistically significant difference was observed within the 
ICCF groups, whereas in patients receiving cardioplegia the only significant difference 
between the two intervention groups was interestingly the use of intra-operative GTN, 
which was higher in the control group (51 versus 41 patients; p=0.037, Tables 3.8): we 
will  discuss  later  in  more  details  about  the  significance  of  intravenous  GTN  peri-
operatively.  
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Table 3.7. Patient baseline characteristics in patients receiving cardioplegia or ICCF 
Patients  Cardioplegia  Cross-clamp fibrillation 
Control   
(n=73) 
RIPC   
(n=75) 
P value  Control   
(n=16) 
RIPC   
(n=14) 
P value 
Age (years) 
 
Gender 
Male 
Female 
 
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
Chinese 
 
BMI  
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
 
Smoking History 
Smoker 
Ex-smoker 
Non-smoker 
 
Family History of IHD 
 
NYHA Class 
CCS Class  
 
LVEF 
>50% 
30%-50% 
<30% 
 
Co-morbidities 
Diabetes mellitus 
Hypertension 
Hypercholesterolemia 
Atrial Fibrillation 
Previous MI 
Previous PCI 
Previous CVA/TIA 
Previous Cardiac Surgery 
Other comorbidities 
Peripheral Arterial Disease 
 
Drug History 
Aspirin   
Clopidogrel/Prasugrel 
Warfarin  
Beta-blocker 
Calcium Channel Blocker 
Statin 
ACE-I/ARB  
Long acting nitrates 
Antidiabetics 
Insulin 
Biguanide 
Sulphonylurea 
Diuretics 
67±10 
 
 
55 (75.3%) 
18 (24.7%) 
 
 
61 (83.6%) 
8 (11.0%) 
3 (4.1%) 
1 (1.4%) 
 
28.0±5.5 
130.3±18.4 
70.2±8.7 
69.3±11.9 
 
 
8 (11.0%) 
44 (60.3%) 
21 (28.8%) 
 
44 (60.3%) 
 
2.88±0.9 
2.17±1.2 
 
 
58 (79.5%) 
14 (19.2%) 
1 (1.4%) 
 
 
18 (24.7%) 
57 (78.1%) 
49 (67.1%) 
16 (21.9%) 
20 (27.4%) 
10 (13.7%) 
9 (12.3%) 
2 (2.8%) 
6 (8.2%) 
5 (6.8%) 
 
54 (74.0%) 
24 (32.8%) 
9 (12.3%) 
43 (58.9%) 
26 (35.6%) 
14 (80.8%) 
51 (69.9%) 
10 (13.7%) 
 
 
5 (6.9%) 
13 (17.8%) 
9 (12.3%) 
23 (31.5%) 
66±10 
 
 
58 (77.3%) 
17 (22.7%) 
 
 
58 (77.3%) 
11 (14.7%) 
6 (8.0%) 
0 (0%) 
 
28.7±7.5 
129.5±16.6 
71.1±9.7 
66.4±9.7 
 
 
9 (12.0%) 
42 (56.0%) 
24 (32.0%) 
 
54 (72.0%) 
 
2.58±0.8 
2.25±1.1 
 
 
57 (76.0%) 
13 (17.3%) 
5 (6.7%) 
 
 
23 (30.7%) 
56 (74.7%) 
56 (74.7%) 
9 (12.0%) 
23 (30.7%) 
8 (10.7%) 
5 (6.6%) 
4 (5.3%) 
3 (4.1%) 
1 (1.3%) 
 
59 (80.8%) 
18 (24.7%) 
5 (6.9%) 
45 (61.6%) 
20 (27.4%) 
13 (82.2%) 
58 (65.8%) 
10 (13.7%) 
 
 
5 (6.8%) 
17 (23.0%) 
8 (8.6%) 
26 (35.6%) 
0.334 
 
0.848 
 
 
 
0.471 
 
 
 
 
 
0.563 
0.799 
0.579 
0.110 
 
0.870 
 
 
 
 
0.165 
 
0.036 
0.661 
 
0.261 
 
 
 
 
 
0.414 
0.625 
0.367 
0.247 
0.719 
0.622 
0.138 
0.615 
0.550 
0.114 
 
0.609 
0.207 
0.529 
0.588 
0.099 
0.332 
0.383 
0.362 
 
 
0.574 
0.480 
0.802 
0.861 
62±10 
 
 
12 (75.0%) 
4 (25.0%) 
 
 
13 (81.3%) 
2 (12.5%) 
1 (6.3%) 
0 (0%) 
 
30.4±4.9 
128.3±16.9 
73.6±10.6 
65.9±10.4 
 
 
4 (25.0%) 
8 (50.0%) 
4 (25.0%) 
 
13 (81.3%) 
 
2.29±0.9 
2.43±0.85 
 
 
12 (75.0%) 
3 (18.8%) 
1 (6.3%) 
 
 
6 (37.5%) 
13 (81.3%) 
15 (93.8%) 
0 (0%) 
3 (18.8%) 
1 (6.3%) 
0 (0%) 
0 (0%) 
1 (6.7%) 
1 (6.3%) 
 
12 (85.8%) 
3 (21.4%) 
0 (0%) 
11 (78.6%) 
3 (21.4%) 
13 (92.8%) 
8 (50.0%) 
2 (14.3%) 
 
 
2 (14.3%) 
1 (7.1%) 
2 (14.3%) 
4 (28.6%) 
60±10 
 
 
14 (100.0%) 
0 (0.0%) 
 
 
13 (92.9%) 
1 (7.1%) 
0 (0%) 
0 (0%) 
 
29.4±4.3 
126.2±10.0 
69.5±7.6 
65.9±10.4 
 
 
2 (14.3%) 
6 (42.9%) 
6 (42.9%) 
 
10 (71.4%) 
 
2.23±0.8 
2.85±0.89 
 
 
10 (71.4%) 
3 (21.4%) 
1 (7.1%) 
 
 
5 (45.5%) 
9 (64.3%) 
12 (85.7%) 
1 (7.1%) 
5 (35.7%) 
3(21.4%) 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
 
13 (81.3%) 
4 (30.8%) 
1 (7.1%) 
12 (92.3%) 
2 (15.4%) 
12 (82.3%) 
8 (69.2%) 
2 (15.4%) 
 
 
3 (23.1%) 
0 (0.0%) 
0 (0.0%) 
5 (38.5%) 
0.434 
 
0.103 
 
 
 
0.547 
 
 
 
 
 
0.573 
0.697 
0.279 
0.486 
 
0.542 
 
 
 
 
0.526 
 
0.872 
0.227 
 
0.976 
 
 
 
 
 
0.919 
0.295 
0.464 
0.277 
0.417 
0.222 
1.000 
1.000 
0.452 
0.341 
 
0.289 
0.580 
0.290 
0.315 
0.686 
0.985 
0.714 
0.936 
 
 
0.557 
0.617 
0.157 
0.156 
ICCF=intermittent cross-clamp fibrillation; RIPC=Remote Ischemic Preconditioning; NYHA=New York 
Health  Association;  CCS=Canadian  Cardiovascular  Society;  MI=Myocardial  infarction; 
PCI=Percutaneous  coronary  intervention;  CVA=  Cerebrovascular  accident;  TIA=Transient  ischemic 
attack; ACE-I=Angiotensin-converting enzyme-inhibitor; ARB= Angiotensin receptor blocker; LVEF= left 
ventricular ejection fraction. 
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Table 3.8. Details of surgical procedure in patients receiving cardioplegia or ICCF 
Patients  Cardioplegia  Cross-clamp fibrillation 
Control 
(n=73) 
RIPC   
(n=75) 
P value  Control   
(n=16) 
RIPC   
(n=14) 
P value 
Indication for Surgery 
Angina 
Myocardial Infarction 
Valve Disease 
Angina and Valve Disease 
MI and Valve Disease 
Infective Endocarditis 
 
EuroSCORE 
 
Additive perioperative risk 
Low (EuroSCORE 0-2) 
Medium (EuroSCORE 3-5) 
High (EuroSCORE >5) 
 
Bypass-time (min)  
 
Cross-clamp time (min)  
 
 
Operation 
CABG alone 
AVR alone 
CABG+AVR  
MVR or MV Repair         
AVR+MVR 
 
Number of grafts 
One  
Two  
Three  
Four 
 
Anesthetic agents 
Induction 
Anti-nicotinic agents 
Rocuronium 
Pancuronium 
Vecuronium 
Midazolam 
Etomidate 
Fentanyl 
Propofol 
 
Maintenance  
Propofol 
Volatile Anesthetics 
Isoflurane 
Sevoflurane 
 
Intra-operative GTN  
 
31 (42.5%) 
9 (12.3%) 
23 (31.5%) 
7 (9.6%) 
1 (1.4%) 
2 (2.7%) 
 
3.95±2.03 
 
 
18 (24.7%) 
40 (54.8%) 
15 (20.5%) 
 
104.4±33.12 
 
70.56±24.44 
 
 
 
38 (52.1%) 
15 (20.5%) 
10 (13.7%) 
9 (12.3%) 
1 (1.4%) 
 
 
4 (5.5%) 
16 (21.9%) 
19 (26.0%) 
9 (12.3%) 
 
 
 
 
56 (78.9%) 
13 (18.3%) 
2 (2.8%) 
38 (53.5%) 
6 (8.3%) 
73 (100%) 
64 (88.9%) 
 
 
73 (100%) 
 
68 (93.1%) 
6 (7.1%) 
 
51 (72.9%) 
 
28 (37.3%) 
17 (22.7%) 
23 (30.7%) 
4 (5.3%) 
2 (2.7%) 
1 (1.3%) 
 
4.03±2.54 
 
 
20 (26.7%) 
34 (45.3%) 
21 (28.0%) 
 
91.99±32.73 
 
66.49±26.41 
 
 
 
43 (57.3%) 
14 (18.7%) 
9 (12.0%) 
8 (10.7%) 
1 (1.3%) 
 
 
5 (6.7%) 
14 (18.7%) 
26 (34.7%) 
7 (9.3%) 
 
 
 
 
65 (90.3%) 
5 (6.9%) 
2 (2.8%) 
28 (38.9%) 
7 (9.7%) 
75 (100%) 
64 (88.9%) 
 
 
75 (100%) 
 
73 (97.2%) 
4 (4.8%) 
 
41 (55.4%) 
0.539 
 
 
 
 
 
 
 
0.830 
 
0.464 
 
 
 
 
0.122 
 
0.336 
 
 
0.980 
 
 
 
 
 
 
0.802 
 
 
 
 
 
 
 
0.149 
 
 
 
0.094 
0.771 
1.000 
1.000 
 
 
1.000 
 
1.000 
0.441 
 
0.037 
 
13 (81.3%) 
3 (18.8%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
 
2.69±1.70 
 
 
8 (50.0%) 
7 (43.8%) 
1 (6.3%) 
 
77.2±21.9 
 
33.0±7.5 
 
 
 
16 (100%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
 
 
0 (0.0%) 
3 (18.8%) 
10 (62.5%) 
3 (18.8%) 
 
 
 
 
12 (92.3%) 
1 (7.7%) 
0 (0.0%) 
7 (53.8%) 
2 (14.3%) 
16 (100%) 
12 (85.7%) 
 
 
16 (100%) 
 
15 (92.9%) 
1 (7.1%) 
 
14 (87.5%) 
 
12 (85.7%) 
2 (14.3%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
 
1.93±2.2 
 
 
9 (64.3%) 
4 (28.6%) 
1 (7.1%) 
 
77.3±15.1 
 
35.3±7.1 
 
 
 
14 (100%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
 
 
0 (0.0%) 
1 (7.1%) 
9 (64.3%) 
4 (28.6%) 
 
 
 
 
11 (84.6%) 
1 (7.7%) 
1 (7.7%) 
5 (38.5%) 
0 (0.0%) 
14 (100%) 
14 (100%) 
 
 
14 (100%) 
 
12 (84.6%) 
2 (4.8%) 
 
12 (85.7%) 
0.743 
 
 
 
 
 
 
 
0.296 
 
0.388 
 
 
 
 
0.992 
 
0.424 
 
 
1.00 
 
 
 
 
 
 
0.587 
 
 
 
 
 
 
 
0.385 
 
 
 
0.431 
0.157 
1.00 
0.157 
 
 
1.000 
 
0.265 
0.805 
 
0.886 
ICCF=intermittent  cross-clamp  fibrillation;  RIPC=Remote  Ischemic  Preconditioning;  MI=myocardial 
infarction;  CABG=Coronary  artery  bypass  graft;  AVR=Aortic  valve  replacement;  MVR=Mitral  valve 
replacement; MV=Mitral valve; GTN=glyceryl trinitrate. 
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Importantly, whilst the cardioplegia group comprised patients undergoing CABG 
and/or valve surgery, in the ICCF group we only had patients receiving CABG: this 
was also associated with significantly higher EuroSCORE, bypass times and cross-
clamp times in the cardioplegia group compared to cross-clamp group (p<0.001, Table 
3.9).  
 
 
Table  3.9.  Comparison  of  EuroSCORE,  cardio-pulmonary  and  cross-clamp  times  between 
cardioplegia and ICCF groups 
Parameters  Cardioplegia 
(n=148) 
ICCF 
(n=30) 
Difference 
(95% CI) 
P 
value 
 
EuroSCORE   
 
3.99 (2.30) 
 
2.33 (1.95) 
 
1.65 (0.77, 2.54) 
 
<0.001 
Cardio-pulmonary bypass time  96.18 (33.09)  77.25 (18.52)  18.93 (6.21, 31.66)  <0.001 
Cross-clamp time  68.49 (25.45)  34.19 (7.25)  34.31 (24.55, 44.07)  <0.001 
ICCF=intermittent cross-clamp fibrillation; CI=confidence interval 
 
 
For this reason it is clear that the cardioplegia group had the potential of being 
subjected to a more significant PMI than the patients receiving ICCF: therefore in this 
sub-group analysis we were intrigued to know whether our multi-limb preconditioning 
stimulus  may  protect  patients  receiving  either  the  techniques  of  myocardial 
preservation and particularly those higher risk patients receiving cardioplegia. 
In  the  cardioplegia  group,  we  found  no  difference  in  baseline  hsTnT  level, 
however  crucially  hsTnT  concentrations  were  significantly  lower  in  preconditioned 
patients at 6, 12, 24, 48, and 72 hours post-surgery (Table 3.11, Fig. 3.4) and more 
importantly,  the  total  72  hours  AUC  of  hsTnT  was  37.089±25.730μg/L  versus 
27.942±17.386μg/L  in  control  and  preconditioned  patients  respectively,  with  a   139 
significant AUC reduction of approximately 25% [9.146; 1.861-16.433; p=0.014] (Table 
2.11,  Fig.  2.5).  Crucially,  in  the  ICCF  group  mean  hsTnT  levels  were  similar  pre-
operatively between RIPC and control groups and significantly lower in preconditioned 
patients  at  6,  12  and  72  hours  post-surgery,  with  a  trend  towards  statistical 
significance  at  24  and  48  hours  (Table  2.11,  Fig.  2.6)  and total  hsTnT  AUC  was 
32.885±18.771  μg/L  in  preconditioned  patients  and  20.692±6.039  μg/L  in  sham 
subjects, which corresponded to a statically significant reduction of 37% [12.192; CI 
0.066, 24.319; p=0.044] (Table 2.11, Fig. 2.7) 
 
 
 
 
 
Table  3.10.  High-sensitivity  Troponin-T  release  at  the  specified  time  point  post-surgery  in 
patients receiving cardioplegia or ICCF 
RIPC=Remote ischaemic preconditioning; SD=standard deviation; CI=confidence interval; hsTnT=high 
sensitivity Troponin-T; ICCF=intermittent cross-clamp fibrillation; AUC=area-under-the-curve 
Endpoint  Control  
Cardioplegia:n=73 
ICCF: n=16 
(mean (sd)) 
RIPC  
Cardioplegia:n=75 
ICCF: n=14 
 (mean (sd)) 
Difference 
(95% CI) 
P value 
 
hsTnT (μg/L) 
Pre-operatively  Cardioplegia 
ICCF 
0.017 (0.018) 
0.022 (0.022) 
0.016 (0.021) 
0.011 (0.013) 
0.001 (-0.005,0.008) 
0.011 (-0.003, 0.024) 
0.656 
0.126 
6 hours post-
operatively 
Cardioplegia 
ICCF 
0.826 (0.537) 
0.696 (0.235) 
0.633 (0.404) 
0.511 (0.199) 
0.192 (0.038, 0.035) 
0.185 (0.021, 0.349) 
0.015 
0.029 
12 hours post-
operatively 
Cardioplegia 
ICCF 
0.727 (0.474) 
0.631 (0.195) 
0.574 (0.399) 
0.457 (0.187) 
0.152 (0.009, 0.294) 
0.173 (0.029, 0.317) 
0.036 
0.020 
24 hours post-
operatively 
Cardioplegia 
ICCF 
0.542 (0.349) 
0.476 (0.305) 
0.427 (0.286) 
0.309 (0.102) 
0.115 (0.01, 0.219) 
0.166 (-0.003, 0.336) 
0.030 
0.054 
48 hours post-
operatively 
Cardioplegia 
ICCF 
0.447 (0.423) 
0.409 (0.339) 
0.321 (0.214) 
0.228 (0.080) 
0.126 (0.017, 0.235) 
0.182 (-0.016, 0.379) 
0.026 
0.071 
72 hours post-
operatively 
Cardioplegia 
ICCF 
0.413 (0.366) 
0.381 (0.271) 
0.290 (0232) 
0.189 (0.066) 
0.123 (0.022, 0.222) 
0.192 (0.043, 0.341) 
0.019 
0.014 
Total 72 hours 
AUC 
Cardioplegia 
ICCF 
37.089 (25.730) 
32.885 (18.771) 
27.942 (17.386) 
20.692 (6.039) 
9.146 (1.861, 16.433) 
12.192 (0.066, 24.319) 
0.014 
0.049   140 
Fig. 3.4. High-sensitivity Troponin T at 0, 6, 12, 24, 48 and 72 hours post-surgery in patients 
receiving cardioplegia (mean±SEM)   
 
hsTnT=high sensitivity troponin T; RIPC=Remote ischaemic preconditioning; SEM=standard error of the 
mean; *p<0.05 (unpaired Student T-Test) 
 
 
Fig. 3.5. High-sensitivity Troponin T at 0, 6, 12, 24, 48 and 72 hours post-surgery in patients 
receiving ICCF (mean±SEM)   
 
ICCF= intermittent cross-clamp fibrillation; hsTnT=high sensitivity troponin T; RIPC=Remote ischaemic 
preconditioning; SEM=standard error of the mean. *p<0.05 (unpaired Student T-Test) 
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Interestingly, in contrast with the findings arising from the main analysis in the 
previous  section,  we  found  no  statistically  significant  difference  of  any  of  the 
secondary endpoints in ether the cardioplegia or ICCF groups (Tables 3.12 and 3.13). 
In  particular  in  the  cardioplegia  group,  we  observed  a  higher  incidence  of  post-
operative AKI in the RIPC group, however this did not reach statistical significance. 
Conversely, we found an important reduction of new-onset AF occurrence and total 
inotrope requirement, although once again statistical analysis showed no significance 
difference. Similarly,  in  the  ICCF  group, despite  an  important  reduction  of  inotrope 
score, this did not reach statistical significance: interestingly, no death, stroke, repeat 
revascularisation or myocardial infarction was observed in ICCF patients at six weeks 
follow-up. 
 
Fig. 3.6. Total Area under the Curve of high-sensitivity Troponin T over the 72 post-operative 
hours in patients receiving cardioplegia or ICCF (mean±SEM)
 
RIPC=Remote ischaemic preconditioning; AUC=area under the curve; SEM=standard error of the 
mean. * Unpaired Student T-Test 
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Table 3.11. Summary of major secondary endpoints in patients receiving cardioplegia* 
Endpoint  Control (n=73) 
(mean (sd)) 
RIPC (n=75) 
(mean (sd)) 
Difference 
(95% CI) 
P value 
CK (μg/L) 
Total AUC  30389.7 (13465.8)  35747 (24932.9)  -5357 (-12998.2, 2283.4)  0.158 
Creatinine (mg/ml) 
Pre-operatively  86.8 (19.5)  84.5 (25.9)  2.3 (-5.2, 9.8)  0.542 
24 hours post-operatively  89.0 (25.9)  87.3 (27.3)  1.8 (-6.9, 10.4)  0.678 
48 hours post-operatively  97.3 (38.3)  90.7 (38.6)  -6.6 (-5.9, 19.0)  0.300 
72 hours post-operatively  94.3 (48.1)  90.44 (41.9)  3.9 (-10.8, 18.6)  0.601 
Urine Output (ml) 
24 hours post-operatively  1998.5 (762.1)  2150.6 (554.2)  -152.1 (-376.6, 72.3)  0.182 
48 hours post-operatively  2162.5 (922.9)  2309.7 (816.9)  -147.2 (-456.6, 162.2)  0.350 
72 hours post-operatively  1944.2 (786.0)  2476.7 (877.7)  -532.5.0 (-892.2, -172.8)  0.004 
Total  5829.9 (1706.2)  6687.1 (1636.2)  -857.2.7 (-1578.2.9, -136.6)  0.020 
AKI score 
0  61  68    0.099 
1  7  4     
2  2  1     
3  2  0     
Acute Kidney Injury  3 (5%)  6 (8%)    0.207 
Inotrope score 
Post bypass  7.4 (13.9)  7.7 (16.3)  -0.3 (-5.3, 4.7)  0.905 
24 hours post-operatively  11.9 (20.7)  9.8 (17.0)  2.1 (-4.2, 8.4)  0.510 
48 hours post-operatively  7.1 (14.6)  5.9 (14.8)  1.1 (-3.8, 6.0)  0.652 
72 hours post-operatively  3.9 (10.6)  1.5 (8.3)  -3.9 (-8.0, 0.1)  0.128 
Total  30.7 (49.2)  24.1 (43.8)  6.6 (-8.9, 22.1)  0.405 
New onset AF  17 (23%)  9 (12%)    0.071 
Length of ICU stay (days)  3.0 (2.0 - 4.0)**  2.0 (1.0 – 3.5)**    0.846*** 
Length of hospital stay (days)  9.0 (7.0 – 12.0)**  8.0 (6.0 – 10.5)**    0.256*** 
Clinical outcomes at six weeks 
Death  1  0    0.353 
Myocardial infarction  1  0    0.309 
Stroke  0  2    0.225 
Revascularization  1  0    0.309 
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Table 3.12. Summary of study endpoints in patients receiving ICCF* 
Endpoint  Control (n=16) 
(mean [SD]) 
RIPC (n=14) 
(mean [SD]) 
Difference 
(95% CI) 
P value 
 
CK (μg/L) 
Total AUC  48844.29 (42601.95) 
 
40995.43 (43496.62)  7848.86 (-42290.09, 57987.81)  0.739 
 
Creatinine (mg/ml) 
Pre-operatively  88.2 (20.9)  94.4 (33.0)  -6.2 (-26.7, 14.2)  0.536 
24 hours post-operatively  107.5 (42.1)  89.6 (26.6)  17.9 (-8.9, 44.7)  0.182 
48 hours post-operatively  130.6 (79.2)  99.5 (38.7)  31.1 (-15.2, 77.4)  0.177 
72 hours post-operatively  119.4 (67.7)  96.0 (49.7)  23.4 (-21.6, 68.4)  0.296 
 
Urine Output (ml) 
24 hours post-operatively  1941.9 (806.7)  2283.5 (949.9)  -341.6 (-1054.9, 371.7)   0.333 
48 hours post-operatively  2033.1 (951.3)  2582.2 (1029.1)  -549.1 (-1453.7, 355.5)  0.219 
72 hours post-operatively  2456.0 (1138.4)  2526.5 (640.1)  -70.5 (-968.5, 827.5)  0.870 
Total  6006.3 (2080.1)  6791.6 (1387.3)  -785.4 (-2656.2, 1085.5)  0.378 
 
AKI score 
0  10 (71.4%)  12 (85.7%)    0.789 
1  1 (7.1%)   1 (7.1%)     
2  2(4.5%)  1 (7.1%)     
3  1 (7.1%)  0 (0.0%)     
 
Acute Kidney Injury 
 
2 (16.8%) 
 
0 (0.0%) 
   
0.171 
 
Inotrope score 
Post bypass  4.029 (11.923)  2.031 (4.958)  1.998 (-5.347, 9.342)  0.560 
24 hours post-operatively  10.107 (22.884)  7.192 (13.879)  2.915 (-12.236, 18.066)  0.695 
48 hours post-operatively  14.928 (33.571)  2.923 (9.673)  12.005 (-7.921, 31.932)  0.219 
72 hours post-operatively  13.543 (33.128)  2.590 (8.478)  10.953 (-8.594, 30.499)  0.251 
Total  42.536 (94.659)  14.736 (32.703)  27.799 (-29.252, 84.852)  0.325 
 
New onset AF 
 
5 (31.3%) 
 
1 (7.1%) 
   
0.101 
 
Length of ICU stay (days) 
 
3.0 (1.0-7.5)** 
 
2.0 (1.0 – 4.0)** 
   
0.245*** 
 
Length of hospital stay (days) 
 
8.0 (6.0 – 10.5)** 
 
8.0 (6.0 – 9.0)** 
   
0.237*** 
 
Clinical outcomes at six weeks 
Death  0 (0.0%)  0 (0.0%)    1.000 
Myocardial infarction  0 (0.0%)  0 (0.0%)    1.000 
Stroke  0 (0.0%)  0 (0.0%)    1.000 
Revascularization  0 (0.0%)  0 (0.0%)    1.000 
*List of abbreviations 
ICCF=intermittent  cross-clamp  fibrillation;  RIPC=Remote  ischemic  preconditioning;  CK=Creatinine  Kinase; 
AKI=Acute Kidney Injury; AF=atrial fibrillation; ICU=Intensive Care Unit; AUC=Area-under-the-curve 
**Results shown as median (inter-quartile range); *** P-value for Mann-Whitney-Wilcoxon test 
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3.13.1.2. Discussion 
In the previous section we demonstrated that an enhanced preconditioning stimulus 
reduces PMI, incidence of new onset AF and total ICU stay in an unselected cohort of 
patients undergoing CABG surgery and/or valve surgery using either cardioplegia or 
ICCF  as  the  technique  of  myocardial  preservation.  Importantly  in  our  cohort 
comprising a total of 178 patients, 83% of subjects received cardioplegia and 17% 
ICCF.  Crucially,  in  this  retrospective  analysis  we  have  found  that,  by  applying 
simultaneous multi-limb IR, the total hsTnT AUC was reduced from  37.089±25.730 
μg/L to 27.942±17.386 μg/L [9.146; 1.861-16.433;p=0.014] in the cardioplegia group 
and from 32.885±18.771 μg/L to 20.692±6.039 μg/L  [12.192; 0.066-24.319; p=0.049] 
in the ICCF group, thereby resulting in a significant reduction of total hsTnT AUC of 
25%  and  37%  respectively.  This  therefore  demonstrates  that  an  enhanced 
preconditioning stimulus is able to reduce PMI in patients undergoing cardiac surgery 
irrespective of the technique of myocardial preservation used. 
The vast majority of proof-of-concept studies investigating the effects of RIPC 
on  PMI  in  cardiac  surgery  included  patients  receiving  cardioplegia,  reflecting  the 
current clinical practice with cardioplegia being the preferred technique of myocardial 
preservation  worldwide:  our  group  (282)  was  able  to  demonstrate  that  RIPC  could 
reduce PMI with a 43% decrease of total cTnT AUC in patients undergoing CABG 
surgery  in  a  seminal  study  including  a  total  of  57  subjects:  however,  22  patients 
received cardioplegia and 35 ICCF, which was not an “accurate reflection” of the real 
world. The same authors (291) then went on to confirm these beneficial effects in 45 
patients  undergoing  CABG  with  or  without  valve  surgery  and  receiving  cold-blood 
cardioplegia, with a 42.4% reduction of cTnT AUC. Similar findings resulted in two 
further studies by Thielmann and colleagues (293, 300, 469) but not by Lomivorotov et   145 
al  (297)  on  patients  undergoing  CABG  surgery  and  receiving  cold  crystalloid 
cardioplegia.  Again  in  the  context  of  cold  crystalloid  cardioplegia, Wagner  and  co-
workers  (295)  found  that  late  RIPC  only  reduced  mean  cTnI  levels  8  hours  post-
operatively and Kottenberg et al (298) demonstrated that RIPC could reduce PMI in 
combination with isoflurane but not propofol. Similarly, a strict anaesthetic regime was 
also used by Karuppasamy and co-workers (294), who found no difference in cTnI, 
BNP  or  CK-MB  release  between  intervention  groups  in  a  study  involving  patients 
undergoing CABG surgery and receiving either cold cardioplegia or ICCF. 
  Within the context of cold blood cardioplegia, no significant PMI reduction was 
found (296) in high-risk patients undergoing complex cardiac surgery with a higher 
mean EuroSCORE than those documented in other clinical studies (7.1 vs 6.6 in RIPC 
and control groups respectively), in elective or urgent CABG (286) or elective CABG 
patients receiving opioids and propofol for anaesthesia induction, and isoflurane for 
anaesthesia maintenance (299). 
In  summary,  both  in  the  context  of  blood  cardioplegia  and  crystalloid 
cardioplegia, RCTs have demonstrated positive or negative outcomes in PMI reduction 
provided  by  RIPC:  a recent  survey  in  the UK  and  Ireland  (30) showed  that of  the 
84.3% of surgeons using cardioplegia (with the remaining 15.7% using ICCF), 83.5% 
used blood cardioplegia and 16.5% crystalloid cardioplegia: the reasons for this reside 
in the potential advantage of cold blood cardioplegia of more closely approximating 
normal  physiology,  because  of  the  significant  amount  of  oxygen  carried  by  the 
haemoglobin, the metabolic substrates present in the blood, the physiological buffers 
and  osmotic  pressure  (470).  However,  hypothermia  induced  during  surgery  might 
cause  a  left  shift  in  the  oxyhaemoglobin  dissociation  curve,  which  can  partially 
counteract  these  effects,  and  oxygen  supply  to  the  ischaemic  myocardium  during   146 
intermittent reperfusion might favour the formation of ROS, which could ultimately lead 
to lethal myocardial IRI (470): clearly these potential complications of the use of blood 
cardioplegia have not been observed with crystalloid cardioplegia. 
Whilst  the  cardioprotective  effects  of  cardioplegia  and  ICCF  have  been 
demonstrated to be equivalent, a number of studies and systematic reviews (reviewed 
in  (470))  have  compared  blood  cardioplegia  (antegrade  intermittent  or  continuous, 
antegrade/retrograde intermittent or continuous) with crystalloid cardioplegia: a recent 
meta-analysis  (470)  concluded  that  the  former  is  associated  with  reduced  peri-
operative MI (17 cases out of 1434 patients versus 32 cases out of 1310 patients 
(RR=2.30  [1.33,  3.98],  p=0.003),  although  no  difference  was  found  in  the  overall 
incidence of spontaneous sinus rhythm, mortality within 30 days, new onset of AF and 
stroke (27). However, no study has so far directly compared the beneficial effects of 
RIPC  on  PMI  between  patients  receiving  blood  or  crystalloid  cardioplegia.  At  the 
tertiary centre where we conducted our study, only blood cardioplegia was used and in 
chapter 4 we will evaluate further the different types of blood cardioplegia and delivery 
techniques utlised and their impact on PMI.  
Importantly, with regards to the findings in the ICCF group, we could only find 
one study (468) in the literature in which recruited patients undergoing CABG surgery 
received ICCF as the only technique of myocardial preservation: however in this RCT, 
the preconditioning stimulus (IPC) was given invasively by two three minute periods of 
ischaemia  by  aortic  cross-clamping,  each  separated  by  two  minutes  of  reperfusion 
before the first anastomosis.  
In conclusion, we have showed that our enhanced preconditioning stimulus is 
able to provide significant cardioprotection in patients undergoing cardiac surgery and 
receiving either blood cardioplegia or ICCF and therefore irrespective of the technique   147 
of myocardial preservation utilised. As previously described, mechanisms underlying 
RIPC are yet not entirely understood and therefore it is difficult to explain the potential 
reason for these findings: certainly, whilst ICCF has not been extensively investigated 
as  the  sole  technique  of  myocardial preservation,  the  role  of  cardioplegia  in  RIPC 
induced  cardioprotection  in  the  setting  of  cardiac  surgery  remains  controversial. 
However, importantly, whilst the above-mentioned proof-of-concept clinical trials have 
used  a  standard  RIPC  stimulus,  in  our  study  we  used  simultaneous  multi-limb  IR, 
which  represents  a  more  potent  preconditioning  stimulus,  thereby  once  again 
corroborating  our  hypothesis  that  the  intensity  of  the  RIPC  stimulus  may  play  an 
essential role in the cardioprotective effects induced by this non-invasive strategy.  
Another important aspect of our  retrospective analysis is that, in accordance 
with  previous  studies  (31,  89-93),  the  total  AUC  of  control  patients  receiving 
cardioplegia  was  not  statistically  significantly  different  from  that  of  sham  subjects 
undergoing ICCF (respectively 37.089±25.730 μg/L and 32.885±18.771 μg/L [4.204; 
CI  -9.369-17.778;  p=0.540]  (Fig.  3.7),  despite  significantly  shorter  CPB  times 
(100.44±33.12  min  versus  77.21±21.98  min    [23.22;  CI  8.75-37.69;  p=0.003])  and 
cross-clamp times (70.56±24.44 min versus 33.00±7.49 min [37.56; CI 30.46-44.65; 
p<0.001])  in  the  ICCF  group  compared  to  the  cardioplegia  group.  However,  it  is 
important  also  to  confirm  that  whilst  the  ICCF  group  only  comprised  patients 
undergoing  CABG  surgery,  the  cardioplegia  group  also  consisted  of  subjects 
undergoing  CABG  plus  AVR,  AVR  only,  MV  surgery  and  AVR  plus  MVR  with 
understandably  prolonged  CPB  and  cross-clamp  times  as  previously  described. 
Therefore in the next sections we will explain the significance of the impact of CPB 
and cross-clamp time on PMI in cardiac surgery and we will also describe in more 
details the most significant differences amongst more homogenous groups of control   148 
patients undergoing CABG surgery alone in both the cardioplegia and ICCF groups in 
terms of PMI, CPB and cross-clamp times. 
 
 
 
 
 
 
 
Fig. 3.7. Comparison of hsTnT AUC between control patients in the cardioplegia and ICCF group 
(mean±SEM)   
 
AUC= area under the curve; SEM=standard error of the mean. * Unpaired Student T-Test 
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3.13.2.  Multi-limb  RIPC  and  types  of  cardiac  surgery:  effects  on 
cardioprotection  in  patients  undergoing  CABG  surgery  and/or  valve 
surgery  
 
Further to the intriguing findings from the previous sections, where we established that 
an enhanced preconditioning stimulus is able to reduce PMI in unselected patients 
undergoing cardiac surgery and irrespective of the type of myocardial preservation, we 
also wished to establish whether this protective strategy is effective in the context of 
any  type  of  cardiac  surgery,  including  CABG  with  or  without  valve  surgery,  CABG 
surgery alone, CABG plus AVR, and valve surgery alone. Therefore we conducted a 
further series of retrospective analyses using the significant amount of data deriving 
from our principal study. Within the group comprising CABG surgery alone, we then 
analysed data deriving from patients receiving cardioplegia as the only technique of 
myocardial preservation in relation to those undergoing ICCF in order to obtain a direct 
comparison between more homogenous groups (Table 3.14). 
 
 
Table. 3.13. Distribution of different types of surgery in control and RIPC groups  
 
Type of Surgery 
 
 
Control (n=89) 
 
RIPC (n=89) 
 
CABG alone 
AVR alone 
CABG+AVR  
MV Replacement/Repair         
AVR+MV Replacement/Repair         
 
54 (61%) 
15 (17%) 
10 (11%) 
9 (10%) 
1 (1%) 
 
57 (64%) 
14 (16%) 
9 (10%) 
8 (9%) 
1 (1%) 
CABG=coronary  artery  bypass  graft;  RIPC=Remote  ischemic  preconditioning;  AVR=aortic  valve 
replacement; MV=mitral valve   150 
3.13.2.1. Effects of multi-limb RIPC on cardioprotection in patients undergoing 
CABG surgery with or without valve surgery 
 
    A total of 130 patients underwent CABG surgery with or without valve surgery, 
of whom 64 received the sham protocol, 66 the preconditioning protocol (Table 3.15). 
Baseline patients’  characteristics  were  comparable between the two  groups  (Table 
3.15)  and  similarly  no  statistically  significant  difference  was  found  in  any  of  the 
parameters  described  in  Table  3.16.  In  particular  no  difference  was  identified  with 
regards to peri-operative risks as indicated by mean EuroSCORE as well as in terms 
of CPB and cross-clamp times. The different types of operation were again equally 
distributed in the two groups. Importantly the use of peri-operative GTN was again 
similar between control and preconditioned subjects, and this will be further discussed 
in the last section of the current chapter. 
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Table 3.14. Patient baseline characteristics in patients undergoing CABG surgery with or without 
valve surgery 
Patients  Control   
(n=64) 
RIPC  
(n=66) 
P value 
Age 
Gender 
Male 
Female 
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
Chinese 
BMI  
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
 
Smoking History 
Smoker 
Ex-smoker 
Non-smoker 
Family History of IHD 
 
NYHA Class 
CCS Class 
LVEF 
>50% 
30%-50% 
<30% 
 
Co-morbidities 
Diabetes Mellitus 
Hypertension 
Hypercholesterolemia 
Atrial Fibrillation 
Previous MI 
Previous PCI 
Previous CVA/TIA 
Previous Cardiac Surgery 
Other comorbidities 
Peripheral Arterial Disease 
 
Drug History 
Aspirin   
Clopidogrel/Prasugrel 
Warfarin  
Beta-blocker 
Calcium Channel Blocker 
Statin 
ACE-I/ARB  
Long acting nitrates 
Antidiabetics 
Insulin 
Biguanide 
Sulphonylurea 
Diuretics 
66±9 
 
53 (82.8%) 
11 (17.2%) 
 
51 (79.7%) 
9 (14.1%) 
3 (4.7%) 
1 (1.6%) 
28.9±5.0 
129.9±18.6 
70.5±8.7 
68.0±11.7 
 
 
10 (15.6%) 
36 (56.3%) 
18 (28.1%) 
45 (70.3%) 
 
2.61±0.9 
2.59±1.0 
 
48 (75.0%) 
14 (21.9%) 
2 (3.1%) 
 
 
21 (32.8%) 
54 (84.4%) 
56 (87.5%) 
7 (11.0%) 
22 (34.4%) 
10 (15.6%) 
6 (9.4%) 
0 (0.0%) 
4 (6.3%) 
6 (9.4%) 
 
 
52 (83.9%) 
23 (37.1%) 
3 (4.8%) 
45 (72.6%) 
24 (38.7%) 
58 (93.5%) 
43 (69.4%) 
13  (21.0%) 
 
6 (9.7%) 
3 (4.7%) 
9 (14.5%) 
16 (25.8%) 
64±10 
 
57 (86.4%) 
9 (13.6%) 
 
53 (80.3%) 
12 (18.2%) 
1 (1.5%) 
0 (0%) 
28.0±7.6 
128.6±16.6 
70.0±8.6 
65.4±9.8 
 
 
9 (13.6%) 
38 (57.6%) 
19 (28.8%) 
51 (77.3%) 
 
2.43±0.8 
2.65±0.9 
 
46 (69.7%) 
15 (22.7%) 
5 (7.6%) 
 
 
24 (36.4%) 
50 (75.8%) 
54 (81.8%) 
4 (6.0%) 
27 (40.9%) 
10 (15.2%) 
4 (6.0%) 
1 (1.5%) 
2 (3.1%) 
1 (1.5%) 
 
 
61 (95.4%) 
22 (34.4%) 
2 (3.1%) 
45 (70.3%) 
15 (23.4%) 
58 (90.6%) 
42 (65.6%) 
12 (18.8%) 
 
7 (10.9%) 
3 (4.8%) 
6 (9.4%) 
20 (31.3%) 
0.114 
0.632 
 
 
0.487 
 
 
 
 
0.943 
0.678 
0.760 
0.167 
 
0.950 
 
 
 
0.427 
 
0.229 
0.731 
0.514 
 
 
 
 
 
0.715 
0.275 
0.468 
0.285 
0.473 
1.000 
0.349 
1.000 
0.612 
0.060 
 
 
0.090 
0.261 
0.594 
0.845 
0.096 
0.494 
0.875 
0.589 
 
1.000 
0.995 
0.388 
0.672 
RIPC=Remote  Ischemic  Preconditioning;  NYHA=New  York  Health  Association;  CCS=Canadian 
Cardiovascular  Society;  MI=Myocardial  infarction;  PCI=Percutaneous  coronary  intervention; 
CVA=Cerebrovascular  accident;  TIA=Transient  ischemic  attack;  ACE-I=Angiotensin-converting 
enzyme-inhibitor; ARB=Angiotensin receptor blocker; LVEF=left ventricular ejection fraction. 
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Table 3.15. Details of surgical procedure in patients undergoing CABG surgery with or without 
valve surgery 
 
RIPC=Remote Ischemic Preconditioning;  CABG=Coronary  artery bypass graft; AVR=Aortic valve 
replacement; MVR=Mitral valve replacement; MV=Mitral valve; GTN=glyceryl trinitrate. 
 
 
 
 
 
 
 
 
 
 
Patients  Control   
(n=64) 
RIPC  
(n=66) 
P value 
Indication for Surgery 
Angina 
Myocardial Infarction 
Angina and Valve Disease 
Valve disease 
Myocardial infarction and valve disease 
 
EuroSCORE 
 
Additive perioperative risk 
Low (EuroSCORE 0-2) 
Medium (EuroSCORE 3-5) 
High (EuroSCORE >5) 
 
Bypass-time (min)  
 
Cross-clamp time (min)  
 
Cardioprotection 
Blood cardioplegia 
Cross-clamp fibrillation 
 
 
Number of grafts 
One  
Two  
Three  
Four 
 
Anesthetic agents 
Induction 
Anti-nicotinic agents 
Rocuronium 
Pancuronium 
Vecuronium 
Midazolam 
Etomidate 
Fentanyl 
Propofol 
 
Maintenance  
Propofol 
Volatile Anesthetics 
Isoflurane 
Sevoflurane 
 
Intra-operative GTN  
 
44 (68.8%) 
11 (20.4%) 
6 (9.4%) 
2 (3.1%) 
1 (1.6%) 
 
3.38±1.86 
 
 
23 (35.9%) 
33 (51.6%) 
8 (12.5%) 
 
93.85±33.47 
 
61.25±27.15 
 
 
48 (75.0%) 
16 (25.0%) 
 
 
 
4 (6.3%) 
19 (29.7%) 
29 (45.3%) 
12 (18.8%) 
 
 
 
 
46 (76.7%) 
12 (20.0%) 
2 (3.3%) 
31 (51.7%) 
7 (11.5%) 
64 (100%) 
52 (85.2%) 
 
 
64 (100%) 
 
56 (91.8%) 
5 (8.2%) 
 
51 (83.6%) 
 
40 (60.6%) 
18 (28.1%) 
4 (6.1%) 
2 (3.0%) 
2 (3.0%) 
 
3.24±2.61 
 
 
25 (37.9%) 
30 (45.5%) 
11 (16.7%) 
 
90.09±30.93 
 
60.14±27.16 
 
 
52 (78.8%) 
14 (21.2%) 
 
 
 
5 (7.6%) 
15 (22.7%) 
35 (53.0%) 
11 (16.7%) 
 
 
 
 
56 (88.9%) 
5 (7.9%) 
1 (1.6%) 
27 (42.9%) 
6 (9.5%) 
63 (100%) 
56 (88.9%) 
 
 
63 (100%) 
 
60 (95.2%) 
3 (4.8%) 
 
47 (72.3%) 
 
 
0.630 
 
 
 
 
 
0.740 
 
0.788 
 
 
 
 
0.716 
 
0.510 
 
0.818 
 
 
 
 
0.405 
 
 
 
 
 
 
 
0.763 
 
 
 
0.282 
0.369 
0.776 
1.000 
 
 
0.600 
 
1.000 
0.488 
 
0.140 
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Baseline  mean  hsTnT  was  not  statistically  different  between  the  two  intervention 
groups and, crucially RIPC significantly reduced mean hsTnT at all the studied post-
operative  time-points  (Table  3.17,  Fig.  3.8).  More  importantly,  total  hsTnT  release 
expressed as 72 hours hsTnT AUC was reduced from 33.526±20.164 μg/L in control 
patients to 24.772±12.640 μg/L in preconditioned subjects [8.753; CI 2.808, 14.688; 
p=0.004], with a significant reduction of 26% (Fig. 3.9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table  3.16.  High-sensitivity  Troponin-T  levels  and  total  AUC  post-  operatively  in  patients 
undergoing CABG surgery with or without valve surgery 
Endpoint  Control (n=64) 
(mean (sd)) 
RIPC (n=66) 
(mean (sd)) 
Difference 
(95% CI) 
P value 
 
hsTnT (μg/L) 
Pre-operatively  0.020 (0.018)  0.016 (0.022)  0.004 (-0.003, 0.011)  0.210 
6 hours post-operatively  0.780 (0.491)  0.614 (0.306)  0.166 (0.024, 0.307)  0.023 
12 hours post-operatively  0.694 (0.428)  0.543 (0.344)  0.152 (0.017, 0.286)  0.027 
24 hours post-operatively  0.494 (0.304)  0.370 (0.213)  0.124 (0.033, 0.215)  0.008 
48 hours post-operatively  0.379 (0.278)  0.272 (0.144)  0.107 (0.030, 0.184)  0.007 
72 hours post-operatively  0.378 (0.325)  0.232 (0.161)  0.147 (0.055, 0.237)  0.002 
Total 72 hours AUC  33.526 (20.164)  24.772 (12.640)  8.753 (2.808, 14.688)  0.004 
RIPC=Remote ischemic preconditioning; SD=standard deviation; CI=confidence interval; hsTnT=high 
sensitivity Troponin-T; AUC=area-under-the-curve 
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Fig. 3.8. High-sensitivity Troponin T at 0, 6, 12, 24, 48 and 72 hours post-operatively in patients 
undergoing CABG surgery with or without valve surgery (mean±SEM)   
 
RIPC=remote ischaemic preconditioning; hsTnT=high-sensitivity Troponin-T; SEM=standard error of the 
mean; *p<0.05 (unpaired Student T-Test) 
 
Fig. 3.9. Total hsTnT AUC in patients undergoing CABG surgery with or without valve surgery 
(mean±SEM)   
 
RIPC=Remote  ischaemic  preconditioning;  AUC=area  under  the  curve;  SEM=standard  error  of  the 
mean. * Unpaired Student T-Test 
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With regards to our study secondary end-points (Table 3.18), similarly to our 
previous  findings,  we  found  no  difference  in  skeletal  muscle  injury,  inotrope 
requirement or clinical outcomes at 6 weeks and AKI incidence was reduced by 54% 
in preconditioned patients, although this did not reach statistical significance. Crucially 
we observed a significant decrease in new onset AF incidence of 63% (p=0.008) and 
length of ICU stay of 1 day (p=0.020) albeit not of hospital stay. 
Crucially, when we then excluded patients receiving ICCF from our retrospective 
analysis, we found similar outcomes in the RIPC group compared to control patients 
(Table 3.19):  
1)  24% of total AUC reduction, from 33.74ﾱ20.81 μg/L to 25.64ﾱ13.52 μg/L [8.11; CI 
1.01,  15.21;  p=0.026],  as  well  as  mean  hsTnT  release  24  and  72  hours  post-
operatively; 
2)  improved urine output over the three days post-surgery from 5830.3±1838.4 mls to 
6737.6±1564.8 mls [-907.4; CI -1803.4, -11.3; p=0.047]; 
3)  60% reduction of new onset AF incidence from 20 to 8 new cases (p=0.004); 
4)  two days reduction of total ICU stay from a median of 3.0 (IQR: 2.0 - 4.0) days vs 
1.0 (IQR: 2.0 – 3.0) days (p=0.033); 
5)  importantly and uniquely in the present study, a 1.5 day of reduction of total length 
of hospital stay, from 8.5 (7.0 – 12.0) days vs 7.0 (6.0 – 9.5) days (p=0.050). 
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Table 3.17. Study secondary end-points in patients undergoing CABG with or without valve surgery* 
Endpoint  Control (n=54) 
(mean (sd)) 
RIPC (n=57) 
(mean (sd)) 
Difference 
(95% CI) 
P 
value 
CK (μg/L) 
Total AUC  34307.86 (21857.37)  36752.39 (26453.21)  -2444.53 (-12580.60, 7691.54)  0.633 
Creatinine (mg/ml) 
Pre-operatively  76.72 (14.16)  91.09 (20.10)  4.39 (-3.89, 12.68)  0.296 
24 hours post-operatively  94.52 (30.91)  87.47 (26.51)  5.05 (-2.94, 17.03)  0.165 
48 hours post-operatively  108.63 (51.25)  91.29 (35.28)  17.34 (2.11, 32.57)  0.026 
72 hours post-operatively  104.38 (51.25)  91.29 (26.51)  14.59 (-1.96, 31.13)  0.434 
Urine Output (ml) 
24 hours post-operatively  1958.8 (608.7)  2195.02 (659.2)  -236.24 (-470.4, -2.05)  0.048 
48 hours post-operatively  2207.3 (964.9)  2354.4 (833.8)  -147.02 (-496.88, 202.84)  0.407 
72 hours post-operatively  2003.2 (921.2)  2486.3 (851.2)  -483.05 (-888.15, -77.96)  0.020 
Total  5869.4 (1864.9)  6571.1 (1505.2)  -881.76 (-1663.09, 100.44)  0.026 
AKI score 
0  51  60    0.295 
1  8  4     
2  2  2     
3  3  0     
Acute Kidney Injury  13 (20%)  6 (9%)    0.085 
Inotrope score 
Post bypass  5.66 (11.25)  6.38 (15.58)  -0.72 (-5.62, 4.17)  0.770 
24 hours post-operatively  10.40 (19.46)  9.21 (16.92)  1.19 (-5.36, 7.74)  0.719 
48 hours post-operatively     8.01 (19.79)  5.23 (14.45)  2.78 (-3.44, 9.00)  0.379 
72 hours post-operatively  5.58 (18.49)  0.87  (4.16)  4.71 (-0.29, 9.72)  0.065 
Total  29.96 (57.97)  21.69 (43.03)  8.27 (-10.37, 26.91)  0.381 
New onset AF  19 30%)  7 (11%)    0.008 
Length of ICU stay (days)  3.0 (2.0-4.5)**  2.0 (1.0-4.0)**    0.020*** 
Length of hospital stay (days)  8.0 (6.5-11.5)**  7.5 (6.0-9.0)**    0.075*** 
Clinical outcomes at six weeks 
Death  3  0    0.118 
Myocardial infarction  1  0    0.593 
Stroke  0  0    1.000 
Revascularization  0  0    1.000 
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Table 3.18. Study end-points in patients undergoing CABG with or without valve surgery with 
cardioplegia * 
 
Endpoint  Control (n=48) 
(mean (sd)) 
RIPC (n=52) 
(mean (sd)) 
Difference 
(95% CI) 
P value 
hsTnT (μg/L) 
Pre-operatively  0.020 (0.017)  0.017 (0.023)  0.003 (-0.006, 0.011)  0.513 
6 hours post-operatively  0.808 (0.549)  0.642 (0.325)  0.166 (-0.016, 0.348)  0.073 
12 hours post-operatively  0.716 (0.481)  0.566 (0.374)  0.150 (-0.022, 0.322)  0.087 
24 hours post-operatively  0.501 (0.307)  0.387 (0.233)  0.114 (0.005, 0.223)  0.041 
48 hours post-operatively  0.368 (0.257)  0.283 (0.155)  0.085 (-0.001, 0.171)  0.052 
72 hours post-operatively  0.377 (0.345)  0.241 (0.174)  0.135 (0.024, 0.247)  0.018 
Total 72 hours AUC  33.74 (20.81)  25.64 (13.52)  8.11 (1.01, 15.21)  0.026 
CK (μg/L) 
Total AUC  31481.3 (14549.4)  36045.2 (23211.8)  -4563.8 (-13476.1, 4348.4)  0.311 
Creatinine (mg/ml) 
Pre-operatively  92.1 (19.9)  84.6 (25.2)  7.45 (-1.6, 16.5)  0.106 
24 hours post-operatively  90.2 (17.5)  86.9 (26.7)  3.3 (-7.1, 13.6)  0.530 
48 hours post-operatively  101.3 (36.0)  89.1 (34.4)  12.2 (-1.8, 26.2)  0.086 
72 hours post-operatively  99.4 (52.1)  88.1 (33.3)  11.3 (-5.9, 28.5)  0.198 
Urine Output (ml) 
24 hours post-operatively  1964.0 (545.3)  2171.1 (567.3)  -207.1 (-440.9, 26.9)  0.082 
48 hours post-operatively  2252.0 (975.6)  2297.4 (781.1)  -45.4 (-429.5, 338.7)  0.815 
72 hours post-operatively  1873.9 (828.2)  2472.9 (919.9)  -599.0 (-1060.6, -137.4)  0.012 
Total  5830.3 (1838.4)  6737.6 (1564.8)  -907.4 (-1803.4, -11.3)  0.047 
AKI score 
0  40  47    0.114 
1  6  3     
2  0  2     
3  2  0     
Acute Kidney Injury  8  5    0.377 
Inotrope score 
Post bypass  6.2 (11.1)  7.5 (17.2)  -1.3 (-7.3, 4.6)  0.655 
24 hours post-operatively  10.5 (18.5)  9.7 (17.7)  0.8 (-6.7, 8.2)  0.839 
48 hours post-operatively  5.8 (12.3)  5.8 (15.5)  -0.1 (-5.9, 5.8)  0.980 
72 hours post-operatively  2.9 (9.4)  0.4 (1.8)  2.6 (-0.4, 5.5)  0.084 
Total  25.9 (40.5)  23.5 (45.4)  2.4 (-15.5, 20.2)  0.793 
New onset AF  20  8    0.004 
Length of ICU stay (days)  3.0 (2.0-4.0)**  1.0 (2.0–3.0)**    0.033*** 
Length of hospital stay (days)  8.5 (7.0–12.0)**  7.0 (6.0–9.5)**    0.050***   158 
Clinical outcomes at six weeks 
Death  3  0    0.240 
Myocardial infarction  1  0    0.561 
Stroke  0  0    1.000 
Revascularization  0  0    1.000 
*List of abbreviations 
RIPC=Remote  ischemic  preconditioning;  CK=Creatinine  Kinase;  AKI=Acute  Kidney  Injury;  AF=atrial 
fibrillation; ICU=Intensive Care Unit; AUC=Area-under-the-curve 
*P-value for test of interaction between RIC and GTN given; **Results shown as median (inter-quartile 
range); *** P-value for Mann-Whitney-Wilcoxon test 
 
 
 
 
 
 
 
3.13.2.2. Effects of multi-limb RIPC on cardioprotection in patients undergoing 
CABG surgery alone 
 
From  the  cohort  of  patients  recruited  into  the  main  study,  111  subjects 
underwent CABG surgery alone, of which 54 were randomised to control and 57 to 
RIPC. Again patients’ baseline characteristics were essentially similar both in control 
and preconditioned patients, with the only exception of PAD, which was significantly 
more frequent in the sham group compared to the RIPC group with 6 vs 1 patients 
respectively  with  known  PAD  (p=0.043)  (Table  3.19).  With  regards  to  parameters 
related to surgery, as observed in the main analysis, we found that the only statistically 
significant difference was the administration of intra-operative GTN, with 46 control 
patients versus 41 RIPC patients receiving iv nitrates during the operation (p=0.045) 
(Table 3.20).   159 
Table 3.19. Baseline characteristics in patients undergoing CABG surgery alone 
Patients  Control  (n=54) 
(mean (SD)) 
RIPC (n=57) 
(mean (SD)) 
P value 
Age 
Gender 
Male 
Female 
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
Chinese 
BMI  
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
 
Smoking History 
Smoker 
Ex-smoker 
Non-smoker 
Family History of IHD 
 
NYHA Class 
CCS Class 
 
LVEF 
>50% 
30%-50% 
<30% 
 
Co-morbidities 
Diabetes Mellitus 
Hypertension 
Hypercholesterolemia 
Atrial Fibrillation 
Previous MI 
Previous PCI 
Previous CVA/TIA 
Previous Cardiac Surgery 
Other comorbidities 
Peripheral Arterial Disease 
 
Drug History 
Aspirin   
Clopidogrel/Prasugrel 
Warfarin  
Beta-blocker 
Calcium Channel Blocker 
Statin 
ACE-I/ARB  
Long acting nitrates 
Antidiabetics 
Insulin 
Biguanide 
Sulphonylurea 
Diuretics 
66±9 
 
43 (79.6%) 
11 (20.4%) 
 
43 (79.6%) 
7 (13.0%) 
3 (5.6%) 
1 (1.9%) 
28.4±4.9 
130.2±20 
70.8±9.2 
 
67.1±11.3 
 
9 (16.7%) 
31 (57.4%) 
14 (25.9%) 
39 (72.2%) 
 
2.45±0.8 
2.59±1.0 
 
 
38 (70.4%) 
14 (25.9%) 
2 (3.7%) 
 
 
17 (31.5%) 
45 (83.3%) 
48 (88.9%) 
5 (9.3%) 
22 (40.7%) 
9 (20.8%) 
6 (16.7%) 
0 (0.0%) 
4 (7.5%) 
6 (11.1%) 
 
 
46 (88.4%) 
21 (40.3%) 
3 (5.7%) 
41 (78.8%) 
21 (40.3%) 
50 (94.2%) 
36 (69.2%) 
13  (25.0%) 
 
6 (11.5%) 
12 (23.1%) 
7 (13.5%) 
13 (25.0%) 
64±10 
 
49 (86.0%) 
8 (14.0%) 
 
48 (84.2%) 
8 (14.0%) 
1 (1.8%) 
0 (0%) 
28.4±7.9 
127.4±16.2 
69.4±8.9 
 
64.4±9.6 
 
8 (14.0%) 
31 (54.4%) 
18 (31.6%) 
42 (73.7%) 
 
2.41±0.8 
2.70±0.9 
 
 
41 (71.9%) 
12 (21.1%) 
4 (7.0%) 
 
 
19 (33.3%) 
42 (73.7%) 
46 (80.7%) 
4 (7.0%) 
22 (38.6%) 
9 (15.8%) 
3 (5.3%) 
1 (1.8%) 
2 (3.6%) 
1 (1.8%) 
 
 
53 (96.4%) 
19 (34.5%) 
2 (3.6%) 
40 (72.7%) 
12 (21.8%) 
50 (90.9%) 
38 (69.1%) 
11 (20.0%) 
 
7 (12.7%) 
13 (23.7%) 
4 (7.3%) 
15 (27.3%) 
0.198 
0.453 
 
 
0.520 
 
 
 
 
0.453 
0.454 
0.388 
 
0.188 
0.787 
 
 
 
0.862 
 
0.784 
0.549 
 
0.652 
 
 
 
 
 
0.835 
0.217 
0.231 
0.584 
0.817 
0.900 
0.355 
0.328 
0.249 
0.043 
 
 
0.254 
0.255 
0.585 
0.461 
0.066 
0.455 
0.964 
0.532 
 
0.851 
0.991 
0.324 
0.761 
RIPC=Remote  Ischemic  Preconditioning;  NYHA=New  York  Health  Association;  CCS=Canadian 
Cardiovascular  Society;  MI=Myocardial  infarction;  PCI=Percutaneous  coronary  intervention; 
CVA=Cerebrovascular accident; TIA=Transient ischemic attack; ACE-I=Angiotensin-converting enzyme-
inhibitor; ARB=Angiotensin receptor blocker; LVEF=left ventricular ejection fraction. 
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Table 3.20. Details of surgical procedure in patients undergoing CABG surgery alone 
 
RIPC= Remote Ischemic Preconditioning; GTN=glyceryl trinitrate 
 
 
 
 
 
As found in group and subgroup analyses so far performed, baseline hsTnT levels 
were  similar  in  the  two  groups  and  importantly  mean  hsTnT  concentrations  were 
significantly  lower  in  RIPC  patients  at  all  the  specified  time-points  (Table  3.21, 
Fig.2.11).  
 
Patients  Control  (n=54) 
(mean (SD)) 
RIPC (n=57) 
(mean (SD)) 
P value 
Indication for Surgery 
Angina 
Myocardial Infarction 
Angina and Valve Disease 
 
EuroSCORE 
 
Additive perioperative risk 
Low (EuroSCORE 0-2) 
Medium (EuroSCORE 3-5) 
High (EuroSCORE >5) 
 
Bypass-time (min)  
 
Cross-clamp time (min)  
 
Cardioprotection 
Blood cardioplegia 
Cross-clamp fibrillation 
 
Number of grafts 
One  
Two  
Three  
Four 
 
Anesthetic agents 
Induction 
Anti-nicotinic agents 
Rocuronium 
Pancuronium 
Vecuronium 
Midazolam 
Etomidate 
Fentanyl 
Propofol 
 
Maintenance  
Propofol 
Volatile Anesthetics 
Isoflurane 
Sevoflurane 
 
Intra-operative GTN  
 
43 (79.6%) 
11 (20.4%) 
0 (0.0%) 
 
3.17±1.83 
 
 
22 (40.7%) 
26 (48.1%) 
6 (11.1%) 
 
86.77±29.07 
 
55.06±23.3 
 
 
18 (75.0%) 
6 (25.0%) 
 
 
1 (1.9%) 
13 (24.1%) 
28 (51.9%) 
12 (22.2%) 
 
 
 
 
42 (84.0%) 
6 (12.0%) 
2 (4.0%) 
25 (47.9%) 
5 (9.8%) 
54 (100%) 
49 (90.2%) 
 
 
54 (100%) 
 
47 (92.2%) 
4 (7.8%) 
 
46 (88.5%) 
 
40 (70.2%) 
16 (28.1%) 
1 (1.8%) 
 
2.84±2.39 
 
 
25 (43.9%) 
24 (42.1%) 
8 (14.0%) 
 
85.84±21.81 
 
54.84±19.29 
 
 
23 (82.1%) 
5 (17.9%) 
 
 
1 (1.8%) 
14 (24.6%) 
31 (54.4%) 
11 (19.3%) 
 
 
 
 
49 (90.7 
3 (5.6%) 
2 (3.7%) 
22 (40.7%) 
5 (9.3%) 
57 (100%) 
52 (88.9%) 
 
 
57 (100%) 
 
51 (94.4%) 
3 (5.6%) 
 
41 (73.2%) 
0.376 
 
 
 
 
0.425 
 
0.788 
 
 
 
 
0.695 
 
0.956 
 
 
 
 
 
0.985 
 
 
 
 
 
 
 
0.335 
 
 
 
0.343 
0.924 
1.000 
0.827 
 
 
1.000 
0.639 
 
 
 
0.045 
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Table  3.21.  High-sensitivity  Troponin-T  release  at  the  specified  time  points  in  patients 
undergoing CABG surgery alone 
Endpoint  Control (n=54) 
(mean (sd)) 
RIPC (n=57) 
(mean (sd)) 
Difference 
(95% CI) 
P value 
 
hsTnT (μg/L) 
Pre-operatively  0.019 (0.019)  0.013 (0.020)  0.003 (-0.001, 0.014)  0.091 
6 hours post-operatively  0.778 (0.509)  0.618 (0.314)  0.160 (-0.001, 0.321)  0.051 
12 hours post-operatively  0.636 (0.404)  0.529 (0.353)  0.106 (-0.362, 0.249)  0.142 
24 hours post-operatively  0.453 (0.294)  0.344 (0.182)  0.109 (0.168, 0.202)  0.021 
48 hours post-operatively  0.349 (0.182)  0.254 (0.135)  0.095 (0.016, 0.173)  0.018 
72 hours post-operatively  0.327 (0.235)  0.219 (0.157)  0.107 (0.030, 0.184)  0.007 
Total 72 hours AUC  30.753 (18.948)  23.609 (12.004)  7.14 (1.076, 13.21)  0.022 
RIPC=Remote ischemic preconditioning; SD=standard deviation; CI=confidence interval; hsTnT=high-
sensitivity Troponin-T 
 
 
 
 
More  interestingly  total  hsTnT  in  preconditioned  patients  was  reduced  from 
30.753±18.949 μg/L to 23.609±12.004 μg/L [7.14; CI (1.076, -13.21; p=0.022], which 
corresponded to a statistically significant reduction of 23%, thereby demonstrating that 
transient  simultaneous  multi-limb  IR  can  reduce  PMI  in  patients undergoing  CABG 
surgery alone (Table 3.21, Fig.2.12). 
With regards to the study secondary end-points (Table 3.22), we were able to 
confirm a statistically significant 60% reduction of the onset of new post-operative AF, 
with  15  new  cases  in  the  control group  and  6  new  cases  amongst  preconditioned 
patients (p=0.028) as well as a 55% reduction of AKI incidence, although again this did 
not reach statistical significance (p=0.107). We also observed 3 deaths and 1 MI in the 
sham group with no events in the preconditioned group at the six weeks follow-up 
(p=0.108 and 0.575 respectively).  
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Fig. 3.10. High-sensitivity Troponin T at 0, 6, 12, 24, 48 and 72 hours post-surgery in patients 
undergoing CABG surgery alone (mean±SEM)   
 
RIPC=remote ischaemic preconditioning; hsTnT= high-sensitivity Troponin-T; SEM=standard error of 
the mean; *p<0.05 (unpaired Student T-Test) 
 
 
Fig. 3.11. Total hsTnT AUC in patients undergoing CABG surgery alone (mean±SEM) 
 
RIPC=remote ischaemic preconditioning; AUC=area-under-the-curve; SEM=standard error of the  
mean. * Unpaired Student T-Test 
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Table 3.22. Summary of major secondary endpoints in patients undergoing CABG surgery alone 
Endpoint  Control (n=54) 
(mean (sd)) 
RIPC (n=57) 
(mean (sd)) 
Difference 
(95% CI) 
P value 
CK (μg/L) 
Total AUC  34387.11 (23849.96)  35267.12 (27496.90)  -880.01 (-12749.70, 10989.69)  0.883 
Creatinine (mg/ml) 
Pre-operatively  88.98 (19.43)  86.14 (25.21)  2.84 (-5.7, 11.3)  0.509 
24 hours post-operatively  93.50 (32.82)  85.68 (23.24)  7.82 (-2.89, 18.54)  0.151 
48 hours post-operatively  107.09 (54.21)  89.93 (30.38)  17.16 (0.45, 33.88)  0.044 
72 hours post-operatively  99.87 (49.88)  89.16 (33.32)  10.71 (-5.17, 26.59)  0.184 
Urine Output (ml) 
24 hours post-operatively  1966.0 (649.7)  2195.06 (680.0)  -229.1 (-498.3, 40.2)  0.095 
48 hours post-operatively  2206.0 (939.6)  2291.9 (803.5)  -85.70 (-475.1, 163.6)  0.662 
72 hours post-operatively  2122.9 (939.6)  2399.2 (792.3)  -276.3 (-716.1, -35.44)  0.214 
Total  6002.6 (2012.3)  6550.6 (1375.8)  -547.9 (-1411.7, 315.8)  0.209 
AKI score 
0  43  52    0.295 
1  7  4     
2  2  1     
3  2  0     
Acute Kidney Injury  11  5    0.107 
Inotrope score 
Post bypass  5.61 (12.57)  4.45 (9.63)  1.16 (-5.279, 7.592)  0.719 
24 hours post-operatively  9.04 (18.90)  8.38 (13.69)  0.661 (-8.808, 10.131)  0.893 
48 hours post-operatively  10.52 (22.53)  4.80 (12.87)  5.722 (-4.661, 16.105)  0.273 
72 hours post-operatively     8.55 (20.99)  0.57  (2.45)  7.981 (-0.196, 16.157)  0.098 
Total  30.55 (62.65)  19.34 (41.19)  11.21 (-9.48, 31.89)  0.285 
New onset AF  15  6    0.028 
Length of ICU stay (days)  2.0 (2.0–4.0)**  2.0 (1.0-3.0)**    0.567*** 
Length of hospital stay (days)  8.0 (6.0-11.0)**  7.0 (6.0-9.0)**    0.784*** 
Clinical outcomes at six weeks 
Death  3  0    0.108 
Myocardial infarction  1  0    0.575 
Stroke  0  0    1.000 
Revascularization  0  0    1.000 
RIPC=Remote  ischemic  preconditioning;  CK=Creatinine  Kinase;  AKI=Acute  Kidney  Injury;  AF=atrial 
fibrillation; ICU=Intensive Care Unit; AUC=Area-under-the-curve 
**Results shown as median (inter-quartile range); *** P-value for Mann-Whitney-Wilcoxon test 
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3.13.2.3. Effects of multi-limb RIPC on cardioprotection in patients undergoing 
CABG surgery only with cardioplegia  
 
We then proceeded to analyse data from the  81 patients  undergoing CABG 
surgery  alone  and  receiving  blood  cardioplegia  as  the  only  technique  of 
cardioprotection. Of these, 38 patients received the sham protocol and 43 the RIPC 
protocol. We found no significant difference in baseline characteristics between the 
two intervention groups (Table 3.23). Similarly, surgical parameters were not different 
and in particular, EuroSCORE, CPB and cross-clamp times were comparable between 
sham and preconditioned patients (Table 3.24). Interestingly, the use of intra-operative 
GTN was not statistically different between groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   165 
Table 3.23. Patient baseline characteristics in patients undergoing CABG surgery with 
cardioplegia  
Patients  Control  (n=38) 
(mean (SD)) 
RIPC (n=43) 
(mean (SD)) 
P value 
Age 
Gender 
Male 
Female 
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
Chinese 
BMI  
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
 
Smoking History 
Smoker 
Ex-smoker 
Non-smoker 
 
Family History of IHD 
 
NYHA Class 
CCS Class 
 
LVEF 
>50% 
30%-50% 
<30% 
 
Co-morbidities 
Hypertension 
Hypercholesterolemia 
Diabetes Mellitus 
Atrial Fibrillation 
Previous MI 
Previous PCI 
Previous CVA/TIA 
Previous Cardiac Surgery 
Other comorbidities 
Peripheral Arterial Disease 
 
Drug History 
 
Aspirin   
Clopidogrel/Prasugrel 
Warfarin  
Beta-blocker 
Calcium Channel Blocker 
Statin 
ACE-I/ARB  
Long acting nitrates 
Anti-diabetics 
Insulin 
Sulphonylurea 
Biguanide 
Diuretics 
68±8 
 
31 (81.6%) 
7 (18.4%) 
 
30 (78.9%) 
5 (13.2%) 
2 (5.3%) 
1 (2.6%) 
 
27.7±4.7 
130.6±20.6 
69.9±8.6 
66.5±11.7 
 
5 (13.2%) 
23 (60.5%) 
10 (26.3%) 
 
26 (68.4%) 
 
2.51±0.77 
2.65±1.1 
 
 
26 (68.4%) 
11 (28.9%) 
1 (2.6%) 
 
 
32 (84.2%) 
33 (86.8%) 
11 (28.9%) 
4 (10.5%) 
19 (50.0%) 
8 (21.1%) 
6 (15.8%) 
0 (0.0%) 
2 (7.4%) 
5 (13.2%) 
 
 
34 (89.5%) 
18 (48.4%) 
3 (7.9%) 
30 (78.9%) 
16 (42.1%) 
36 (98.0%) 
26 (68.4%) 
10 (26.3%) 
 
4 (10.5%) 
5 (13.2%) 
2 (5.3%) 
9 (23.7%) 
65±9 
 
35 (81.4%) 
8 (18.6%) 
 
35 (81.4%) 
7 (16.3%) 
1 (2.3%) 
0 (0%) 
 
29.4±8.9 
127.8±17.9 
69.3±9.4 
63.9±9.4 
 
6 (14.0%) 
25 (58.1%) 
12 (27.9%) 
 
32 (74.4%) 
 
2.46±0.81 
2.66±0.97 
 
 
31 (72.1%) 
9 (20.9%) 
3 (7.0%) 
 
 
33 (76.7%) 
34 (79.1%) 
14 (32.6%) 
1 (2.3%) 
17 (39.5%) 
6 (14.0%) 
3 (6.9%) 
1 (2.3%) 
1 (3.4%) 
1 (2.3%) 
 
 
40 (95.2%) 
15 (35.7%) 
1 (2.4%) 
28 (66.7%) 
10 (23.8%) 
38 (96.0%) 
29 (69.0%) 
9 (21.4%) 
 
4 (9.5%) 
4 (9.5%) 
3 (7.1%) 
10 (23.8%) 
0.208 
0.983 
 
 
0.626 
 
 
 
 
 
0.286 
0.514 
0.752 
0.978 
0.976 
 
 
 
 
0.625 
 
0.781 
0.966 
 
0.513 
 
 
 
 
 
0.577 
0.394 
0.812 
0.286 
0.377 
0.557 
0.166 
0.344 
0.213 
0.094 
 
 
0.607 
0.221 
0.447 
0.316 
0.051 
0.281 
0.474 
0.640 
 
0.881 
0.489 
0.935 
0.662 
RIPC=Remote  Ischemic  Preconditioning;  NYHA=New  York  Health  Association;  CCS=Canadian 
Cardiovascular  Society;  MI=Myocardial  infarction;  PCI=Percutaneous  coronary  intervention; 
CVA=Cerebrovascular accident; TIA=Transient ischemic attack; ACE-I=Angiotensin-converting enzyme-
inhibitor; ARB=Angiotensin receptor blocker; LVEF=left ventricular ejection fraction. 
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Table 3.24. Details of surgical procedure in patients undergoing CABG surgery with cardioplegia  
Patients  Control (n=38) 
(mean (SD)) 
RIPC  (n=43) 
(mean (SD)) 
P value 
 
Indication for Surgery 
Angina 
Myocardial Infarction 
 
EuroSCORE 
 
Additive perioperative risk 
Low (EuroSCORE 0-2) 
Medium (EuroSCORE 3-5) 
High (EuroSCORE >5) 
 
Bypass-time (min)  
 
Cross-clamp time (min)  
 
Graft 
One 
Two 
Three 
Four 
 
Anesthetic agents 
Induction 
Anti-nicotinic agents 
Rocuronium 
Pancuronium 
Vecuronium 
Midazolam 
Etomidate 
Fentanyl 
Propofol 
 
Maintenance  
Propofol 
Volatile Anesthetics 
Isoflurane 
Sevoflurane 
 
Intra-operative GTN  
 
 
30 (78.9%) 
8 (21.1%) 
 
3.37±1.87 
 
 
14 (36.8%) 
19 (50.0%) 
5 (13.2%) 
 
90.29±30.79 
 
62.61±21.86 
 
 
 
1 (3.8%) 
6 (22.2%) 
14 (51.9%) 
6 (22.2%) 
 
 
 
30 (81.1%) 
5 (13.5%) 
2 (5.4%) 
18 (48.6%) 
3 (8.1%) 
38 (100%) 
34 (91.9%) 
 
 
38 (100%) 
 
34 (91.9%) 
3 (8.1%) 
 
32 (88.9%) 
 
 
28 (65.1%) 
9 (32.6%) 
 
3.14±2.34 
 
 
16 (37.2%) 
20 (46.5%) 
7 (16.3%) 
 
87.30±23.20 
 
61.21±17.66 
 
 
 
1 (3.6%) 
9 (31.0%) 
15 (51.7%) 
4 (13.8%) 
 
 
 
38 (92.7%) 
1 (4.9%) 
1 (2.4%) 
17 (41.5%) 
5 (12.2%) 
43 (100%) 
35 (85.4%) 
 
 
43 (100%) 
 
40 (97.6%) 
1 (2.4%) 
 
29 (69.0%) 
 
0.300 
 
 
 
0.636 
 
0.912 
 
 
 
 
0.621 
 
0.752 
 
0.810 
 
 
 
 
 
 
 
0.307 
 
 
 
0.649 
0.715 
1.000 
0.487 
 
 
1.000 
0.341 
 
 
 
0.053 
 
 
RIPC= Remote Ischemic Preconditioning; GTN=glyceryl trinitrate 
 
 
 
Crucially and in contrast with what we have found so far, although mean hsTnT was 
lower in the RIPC at each of six the measured time-points, this did not reach statistical 
significance  (Table  3.25).  More  importantly,  we  found  a  non-statistically  significant 
reduction of total hsTnT AUC of 18% only, from 29.832±19.206 μg/L in the control 
group to 24.355±13.052 μg/L in the RIPC group [5.477 CI -1.985-12.938; p=0.147] 
(Table 3.25, Fig. 3.13).   167 
Table  3.25.  High-sensitivity  Troponin-T  release  in  patients  undergoing  CABG  surgery  with 
cardioplegia  
Endpoint  Control (n=38) 
 (mean [SD]) 
RIPC (n=43) 
 (mean [SD]) 
Difference 
(95% CI) 
P value 
 
hsTnT (μg/L) 
 
Pre-operatively 
 
0.019 (0.019)  0.014 (0.023)  0.005 (-0.004, 0.015)  0.285 
6 hours post-operatively 
 
0.813 (0.588)  0.653 (0.339)  0.159 (-0.572, 0.377)  0.146 
12 hours post-operatively 
 
0.638 (0.468)  0.553 (0.391)  0.085 (-0.107, 0.278)  0.381 
24 hours post-operatively 
 
0.444 (0.292)  0.355 (0.201)  0.056 (-0.024, 0.202)  0.089 
48 hours post-operatively 
 
0.323 (0.208)  0.262 (0.147)  0.061 (-0.021, 0.142)  0.132 
72 hours post-operatively 
 
0.303 (0.218)  0.228 (0.173)  0.076 (-0.011, 0.163)  0.087 
Total 72 hours AUC 
 
29.832 (19.206)  24.355 (13.052)  5.477 (-1.985, 12.938)  0.147 
RIPC=Remote ischemic preconditioning; SD= standard deviation; CI= confidence interval; hsTnT=high 
sensitivity Troponin-T 
 
 
 
 
 
 
Fig. 3.12. High-sensitivity Troponin-T at 0, 6, 12, 24, 48 and 72 hours post-operatively in patients 
undergoing CABG surgery with cardioplegia (mean±SEM)   
 
RIPC=remote ischaemic preconditioning; hsTnT= high-sensitivity Troponin-T; SEM=standard error of 
the mean. *Unpaired Student T-Test 
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Fig. 3.13. Total Area under the Curve of high-sensitivity Troponin-T in patients undergoing CABG 
surgery with cardioplegia (mean±SEM)   
 
RIPC=remote ischaemic preconditioning; AUC=area under the curve; SEM=standard error of the mean. 
* Unpaired Student T-Test 
 
 
 
 
Similarly, secondary outcomes were comparable in the two groups (Table  3.26): in 
particular, even though we observed a 50% reduction of the onset of new AF post-
operatively from 10 to 5 new cases, this was not statistically significant (p=0.150) 
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Table 3.26. Summary of study endpoints in patients undergoing CABG surgery with cardioplegia  
Endpoint  Control (n=38) 
(mean [SD]) 
RIPC (n=43) 
(mean [SD]) 
Difference 
(95% CI) 
P value 
 
CK (μg/L) 
Total AUC  30772.82 (15660.18) 
 
34087.77 (23750.26)  -3314.94 (-13783.98, 7154.09)  0.529 
 
Creatinine (mg/ml) 
Pre-operatively  89.3 (19.0)  83.4 (21.9)  5.9 (-3.6, 15.0)  0.204 
24 hours post-operatively  87.6 (26.5)  84.4 (21.9)  3.3 (-7.5, 13.9)  0.547 
48 hours post-operatively  97.2 (36.4)  86.8 (26.9)  10.4 (-3.7, 24.4)  0.146 
72 hours post-operatively  91.7 (38.4)  86.9 (26.4)  4.7 (-10.1, 19.5)  0.516 
 
Urine Output (ml) 
24 hours post-operatively  1975.8 (589.0)  2165.6 (576.3)  -189.8 (-466.7, 87.2)   0.176 
48 hours post-operatively  2265.7 (1041.7)  2203.7 (715.0)  62.6 (-373.9, 499.0)  0.776 
72 hours post-operatively  1989.6 (843.5)  2346.1 (854.5)  -356.5 (-875.4, 162.5)  0.173 
Total  6001.2 (2039.6)  6450.2 (1388.1)  -449.0 (-1542.0, 644.0)  0.392 
 
AKI score 
0  32 (84.2%)  39 (90.7%)    0.408 
1  5 (13.2%)   3 (7.0%)     
2  0 (0.0%)   1 (2.3%)     
3  1 (2.6%)   0 (0.0%)     
 
Acute Kidney Injury 
 
6 (15.8%) 
 
4 (9.3%) 
   
0.503 
 
Inotrope score 
Post bypass  6.35 (12.11)  6.97 (17.26)  -0.63 (-7.56, 6.30)  0.857 
24 hours post-operatively  9.72 (18.68)  8.59 (16.85)  1.13 (-7.05, 9.32)  0.783 
48 hours post-operatively  7.11 (13.72)  4.72 (14.61)  2.38 (-4.25, 9.02)  0.476 
72 hours post-operatively  1.91 (4.79)  0.52 (1.99)  1.39 (-0.25, 3.04)  0.125 
Total  25.46 (43.73)  20.79 (43.79)  4.66 (-15.75, 25.08)  0.650 
 
New onset AF 
 
10 (26.3%) 
 
5 (11.6%) 
   
0.150 
 
Length of ICU stay (days) 
 
2.0 (2.0-4.0)** 
 
2.0 (1.0 – 3.0)** 
   
0.188*** 
 
Length of hospital stay (days) 
 
8.0 (7.0-11.0)** 
 
7.0 (6.0 – 9.0)** 
   
0.102*** 
 
Clinical outcomes at six weeks 
Death  3 (10.3%)  0 (0.0%)    0.107 
Myocardial infarction  1 (2.6%)  0 (0.0%)    0.528 
Stroke  0 (0.0%)  0 (0.0%)    1.000 
Revascularization  0 (0.0%)  0 (0.0%)    1.000 
RIPC=Remote ischemic preconditioning; CK =Creatinine Kinase; AKI =Acute Kidney Injury; AF=atrial 
fibrillation; ICU=Intensive Care Unit; AUC=Area-under-the-curve 
**Results shown as median (inter-quartile range); *** P-value for Mann-Whitney-Wilcoxon test 
 
 
   170 
3.13.2.4. Discussion 
In  these  retrospective  analyses  we  have  been  able  to  demonstrate  that  our 
enhanced preconditioning stimulus can reduce PMI, new AF incidence and total ICU 
stay in patients undergoing CABG surgery with or without valve surgery. The same 
results  were  obtained  when  in  the  analysis  we  only  included  subjects  undergoing 
CABG with or without valve surgery and receiving cardioplegia, although we found no 
statistically significant difference of any of the study end-points in the context of CABG 
surgery alone with cardioplegia or CABG plus AVR surgery. Crucially and uniquely in 
this study and from the current literature, we found a reduction of 1.5 days of total 
hospital stay duration although with a weaker statistical significance (p=0.050) in RIPC 
patients undergoing CABG with or without valve surgery with cardioplegia only. 
In the first instance, our findings confirm the positive effects of RIPC on PMI in 
CABG  patients  receiving  cardioplegia  or  ICCF  (274)  and  those  on  CABG  with  or 
without valve surgery receiving cardioplegia only (291), when our Institute observed a 
significant PMI reduction of 43% and 42.4% respectively in preconditioned subjects. 
However,  it  is  relevant  to  notice  that  in  this  second  study,  patients  with  DM  were 
excluded in contrast with the first study and our current subgroup analysis, in which we 
included  both  diabetic  and  non-diabetic  subjects  corresponding  to  31%  and  69% 
respectively of the total cohort: whether the exclusion of patients with known DM would 
lead to different outcomes will be discussed later.  
Importantly, in the context of CABG surgery alone, our preconditioning stimulus 
led  to  a  significant  PMI  reduction  when  both  cardioplegia  and  ICCF  patients  were 
included but not when ICCF subjects were excluded: in this regard, it also relevant to 
mention that, with such exclusion our cohort size was reduced from 111 to 81 cases   171 
and therefore it is possible that the smaller cohort could have had a relevant impact on 
the final outcome.  
Similarly, in another study including patients undergoing CABG only with cold 
blood cardioplegia (286), Rahman and colleagues failed to show any beneficial effect 
of RIPC on PMI: however, differently from our study, importantly they also included 
patients undergoing urgent CABG surgery and excluded diabetic patients. Crucially, 
while a total of 162 patients were recruited into this study, our retrospective analysis 
only included 81 patients, of whom 25 were diabetic: our study was not powered for 
this type of analysis and therefore the ERICCA trial will ultimately give us the answer 
as  to  whether  an  enhanced  preconditioning  stimulus  can  protect  high  risk  patients 
undergoing CABG with or without valve surgery with blood cardioplegia and improve 
their clinical outcomes. In the other study involving CABG patients only with cold blood 
cardioplegia and ICCF, (294), a strict anaesthetic regime had been used, however with 
a failure to show beneficial effects of RIPC on PMI. Interestingly, volatile agents had 
been  used  in  the  study  by  Rahman  et  al  (286),  which  similarly  showed  no  RIPC 
mediated  cardioprotection  but  not  in  the  studies  from  our  group  (282,  291)  and 
Thielmann (293, 298, 300). Previous RCTs demonstrated that inhalant anaesthetics 
reduce  PMI  and  mortality  in  patients  undergoing  cardiac  surgery  (460,  471,  472): 
therefore Karuppasamy and colleagues concluded that the reason for their negative 
findings could be attributed to the use of inhalant agents which may have optimised 
cardioprotection  and  therefore  the  addition  of  the  benefits  provided  by  RIPC  was 
essentially not significant (294). Similarly, Lucchinetti et al (299) failed to show RIPC-
induced cardioprotection in CABG patients receiving cardioplegia and isoflurane for 
anaesthesia maintenance and Kottenberg and colleagues (298) observed improved 
myocardial  preservation  only  when  RIPC  was  applied  with  the  administration  of   172 
isoflurane and not propofol, although these patients received crystalloid and not blood 
cardioplegia. 
Importantly, in contrast with the hypotheses generated from these studies, we 
have  demonstrated  that  in  the  context  of  a  combined  use  of  volatile  agents  and 
propofol,  RIPC improves  myocardial preservation  and  decreases  post-operative  AF 
incidence: in the tertiary centre where we conducted our study, it is common practice 
to induce anaesthesia with a combination midazolam, fentanyl, anti-nicotinic agents 
and  propofol/etomidate,  whereas  maintenance  is  guaranteed  by  the  use  of  volatile 
anaesthetics and propofol. Indeed, in the subgroup analysis including CABG patients 
only, propofol was used in 90.2% of patients in the induction phase and 100% of cases 
in the maintenance phase, whereas either isoflurane or sevoflurane were administered 
exclusively  during  maintenance  alongside  propofol  in  all  patients.    Similarly  in  the 
subgroup including CABG and cardioplegia patients only, propofol was given to 91.9% 
of patients during induction and 100% during maintenance, whereas volatile agents 
were given only during maintenance and to all the patients included.  It is therefore 
unlikely that the use of inhalant agents might have had a significant impact on the 
outcomes  of  the  studies  considered,  which  crucially  used  a  standard  upper  limb 
preconditioning  stimulus  in  contrast  with  our  study  using  multi-limb  IR,  therefore 
confirming our hypothesis that an enhanced RIPC stimulus reduces PMI in patients 
undergoing CABG surgery with or without valve surgery.  
Additionally,  of  the  published  studies  using  cold  crystalloid  and  not  blood 
cardioplegia (293, 295, 297, 298, 300), Wagner and colleagues only showed reduced 
mean TnI at 8 hours post-CPB with a preconditioning stimulus applied the day prior to 
surgery (295) and Lomivorotov et al (297) showed no cardioprotection provided by 
RIPC in a small population of low risk patients whose mean EuroSCORE was 2.2±0.6   173 
and 2.5±0.8 respectively in control and preconditioned groups, and for whom therefore 
the additional benefit provided by RIPC potentially might have not been significant. 
Conversely,  Thielmann  and  colleagues,  on  two  separate  RCTs  (293,  300), 
demonstrated first in a small group of 53 non-diabetic patients (293) and then in a 
large cohort of 329 diabetic and non-diabetic patients that RIPC could reduce PMI 
(respectively of 45% and 17.3%). Interestingly, whilst our hsTnT reduction of 23% in 
CABG  was  statistically  significant,  the  one  of  18%  in  CABG  patients  receiving 
cardioplegia only did not reach statistical significance despite being superior to that 
observed in the most recent study from Thielmann and colleagues (300). Moreover, in 
the  latter  work,  the  authors  could  also  importantly  demonstrate  an  improvement  in 
clinical  outcomes  at  1  year,  with  a  significant  reduction  of  all-cause  mortality  and 
MACCE rate, mainly driven by reduced MI events and with no significant difference in 
the  incidence  of  stroke,  repeat  revascularisation,  and  cardiac  death.  Of  note,  our 
smaller RCT showed no difference in MACCE at 6 weeks follow-up. Another important 
difference  between  our  study  and  the  most  recent  RCT  from  Thielmann  and  co-
workers is again the type of myocardial preservation used: in our proof-of-concept trial, 
we used either blood cardioplegia or ICCF, differently from the study from Thielmann 
et al, which used cold crystalloid cardioplegia only: the implications of blood versus 
crystalloid  cardioplegia  on  PMI  in  cardiac  surgery  have  already  been  extensively 
described in the previous section.  
In summary, as previously discussed the inconsistent findings deriving from the 
outcomes  of  the  different  proof-of-concept  RCTs  are  very  likely  to  be  related  to  a 
number  of  potential  factors,  including  intervention  protocols,  confounding 
comorbidities,  concomitant  pharmacological  therapy,  anaesthetic  regimens,  surgical 
techniques and intra-operative methods of myocardial protection, and each of these   174 
factors  can  individually  have  an  impact  on  the  final  magnitude  of  RIPC-induced 
cardioprotection.  
Importantly, we have found that in control patients total 72 hours hsTnT AUC 
was not significantly different between those receiving cardioplegia and those having 
ICCF  (respectively  37.089±25.730  μg/L  and  32.885±18.771 μg/L [4.204;  CI  -9.369-
17.778; p=0.540], although CPB and cross-clamp times were significantly lower in the 
ICCF  group  (100.44±33.12  min  versus  77.21±21.98  min    [23.22;  CI  8.75-37.69; 
p=0.003]  and  70.56±24.44  min  versus  33.00±7.49  min  [37.56;  CI  30.46-44.65; 
p<0.001]  respectively.  However,  whilst  the  cardioplegia  group  included  patients 
receiving different types of cardiac surgery including CABG with or without AVR, AVR 
only, MV surgery and AVR plus MVR with understandably prolonged CPB and cross-
clamp times, ICCF was only used in patients undergoing CABG surgery alone. We 
therefore  intended to perform a  retrospective  analysis  to  assess PMI magnitude  in 
control patients undergoing CABG only and receiving either cardioplegia or ICCF to 
then evaluate the potential benefit provided by the application of our preconditioning 
stimulus  (Table  3.28).  In  the  first  instance  we  found  that  in  control  ICCF  patients, 
hsTnT AUC was only marginally increased to 10% compared to control cardioplegia 
subjects  29.832±19.206  μg/L  to  32.885±18.771  μg/L  [-3.053;  CI  -14.618,  8.408; 
p=0.593],  therefore  confirming  similar  findings  from  previous  studies  (31,  89-93) 
showing that the overall PMI magnitude is not different between subjects receiving the 
two  techniques  of  myocardial  preservation  (Table  3.28,  Fig.  3.14).  As  previously 
discussed, this is due to the fact that the potential more severe ischaemic damage 
induced by ICCF might be compensated by its significantly shorter ischaemic times 
compared  to  cardioplegia,  which  conversely  provides  significant  myocardial  cell 
protection at the expense of more prolonged ischaemic times.    175 
Table 3.27. AUC, EuroSCORE, CPB and cross-clamp times in patients undergoing CABG surgery 
only and receiving cardioplegia or ICCF 
Parameters 
 
 
  Cardioplegia 
Control: n=37 
RIPC: n=43 
(mean (SD)) 
ICCF 
Control: n=16 
RIPC: n=14 
(mean (SD)) 
Difference 
(95% CI) 
 
 
P value 
 
 
 
 
 
AUC 
 
 
 
Control 
 
RIPC 
 
29.832 (19.206) 
 
24.355 (13.052) 
 
32.885 (18.771) 
 
20.692 (6.039) 
 
-3.053 (-14.618, 8.408) 
 
3.663 (-4.490, 11.816) 
 
 
0.593 
 
0.371 
 
 
 
EuroSCORE 
 
 
 
Control 
 
RIPC 
 
3.37 (1.87) 
 
3.14 (2.34) 
 
 
2.69 (1.70) 
 
1.93 (2.2) 
 
 
0.68 (-0.41, 1.77) 
 
1.21 (-0.24, 2.66) 
 
0.215 
 
0.100 
 
 
CPB time 
 
 
 
Control 
 
RIPC 
90.29 (30.79) 
 
87.30 (23.20) 
 
77.21 (21.98) 
 
77.30 (15.1) 
 
 
13.08 (-4.98, 31.13) 
 
10.02 (-3.28, 23.31) 
 
0.152 
 
0.137 
 
Cross-clamp 
time 
 
 
 
Control 
 
RIPC 
 
62.61 (21.86) 
 
61.21 (17.66) 
 
 
 
33.00 (7.49) 
 
35.30 (7.10) 
 
 
 
29.61 (17.11, 42.10) 
 
25.92 (16.18, 35.67) 
 
 
 
<0.001 
 
<0.001 
 
 
RIPC=remote  ischaemic  preconditioning;  SD=standard  deviation;  ICCF=intermittent  cross-clamp 
fibrillation, CI=confidence interval; AUC=area under the curve; CPB=cardio-pulmonary bypass 
 
 
 
 
 
Fig. 3.14. Comparison of AUC in control and RIPC patients receiving either ICCF or cardioplegia 
(mean±SEM)   
RIPC=remote ischaemic preconditioning; ICCF=intermittent cross-clamp fibrillation;  AUC=area-under-
the-curve; SEM=standard error of the mean. *Unpaired Student T-Test 
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*p=0.049 *p=0.147  176 
It  is  has  been  demonstrated  that  ischaemic  times  are  correlated  to  PMI  in 
cardiac  surgery  (473,  474):  these  refer  to  the  period  of  time  during  which  the 
myocardium is deprived of blood supply and in the context of on-pump cardiac surgery 
and  correspond  to  aortic  cross-clamp  times,  during  which  coronary  perfusion  is 
interrupted. Ischaemic times are independent predictor of PMI in cardiac surgery and 
aortic cross-clamp times longer than 100 min have been associated with significant 
PMI in CABG patients (474). In a more recent study, aortic cross-clamp time greater 
than  90  minutes  and  CPB  time  greater  than  180  minutes,  were  also  independent 
predictors  of  myocardial  damage  (473).  In  our  subgroup  analysis  we  have 
demonstrated that PMI magnitude was not significantly changed in control patients 
receiving ICCF and therefore subjected to significantly shorter ischaemic times than 
those having cardioplegia. Crucially the application of our enhanced preconditioning 
stimulus to CABG patients only led to significant PMI reduction in patients receiving 
ICCF: whilst this could be well related to the relatively small cohort size, it is also 
valuable to note that in preconditioned patients, the use of ICCF was not associated 
with  a  significantly  lower  PMI:  whether  the  beneficial  effects  provided  by  ICCF  in 
preconditioned patients may be less significant as cardioprotection may have already 
been “optimised” by our RIPC stimulus is difficult to know and certainly larger studies 
would be able to confirm this. 
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3.13.2.5.  Effects  of  multi-limb  RIPC  on  cardioprotection  in  patients 
undergoing valve surgery 
 
As with studies on CABG with or without valve surgery, previous RCTs on valve 
surgery  alone  have  showed  conflicting  results  and  therefore  it  is  still  not  unclear 
whether  RIPC  provides  a  beneficial  cardioprotective  effect  on  these  patients.  The 
combination of high mean EuroSCORE, CPB times and cross-clamp times categorises 
these  subjects  into  a  high  peri-operative  risk  category:  we  therefore  conducted  a 
further  retrospective  analysis  in  order  to  establish  whether  an  enhanced 
preconditioning  stimulus  reduces  PMI  and  improves  clinical  outcomes  in  these 
subjects. 
A total of 48 patients underwent valve surgery alone, including either AVR or 
MV repair or replacement, of which 25 randomised to control and 23 to RIPC (Table 
3.29). We found no significant difference in patients’ baseline characteristics or details 
of surgery, except for the use of intra-operative GTN, which was higher in the sham 
group, with 14 patients in the sham group versus 6 in the RIPC group receiving iv 
GTN, corresponding to respectively 56% and 26% of subjects.  (Tables  3.29-3.30). 
Importantly all these patients received cardioplegia for myocardial preservation.  
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Table 3.28. Patient baseline characteristics in patients undergoing valve surgery alone  
Patients  Control  (n=25) 
(mean (SD)) 
 
RIPC (n=23) 
(mean (SD)) 
 
P value 
Age 
Gender 
Male 
Female 
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
Chinese 
BMI  
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
 
Smoking History 
Smoker 
Ex-smoker 
Non-smoker 
 
Family History of IHD 
 
NYHA Class 
CCS Class 
 
LVEF 
>50% 
30%-50% 
<30% 
 
Co-morbidities 
Diabetes Mellitus 
Hypertension 
Hypercholesterolemia 
Atrial Fibrillation 
Previous MI 
Previous PCI 
Previous CVA/TIA 
Previous Cardiac Surgery 
Other comorbidities 
Peripheral Arterial Disease 
 
Drug History 
Aspirin   
Clopidogrel/Prasugrel 
Warfarin  
Beta-blocker 
Calcium Channel Blocker 
Statin 
ACE-I/ARB  
Long acting nitrates 
Antidiabetics 
Insulin 
Biguanide 
Sulphonylurea 
Diuretics 
65±13 
 
14 (56.0%) 
11 (44.0%) 
 
23 (92.0%) 
1 (4.0%) 
1 (4.0%) 
0 (0.0%) 
27.2±6.3 
130.2±17 
72.0±10.0 
67.1±11.5 
 
 
2 (8.0%) 
31 (57.4%) 
16 (64.0%) 
 
12 (48.0%) 
 
3.20±0.9 
1.28±0.74 
 
 
22 (88.0%) 
3 (12.0%) 
0 (0.0%) 
 
 
3 (12.0%) 
16 (64.0%) 
8 (32.0%) 
10 (40.0%) 
1 (4.0%) 
1 (4.0%) 
3 (12.0%) 
2 (8.0%) 
3 (12.0%) 
0 (0.0%) 
 
14 (56.0%) 
4 (16.0%) 
1 (4.0%) 
9 (36.0%) 
7 (28.0%) 
14 (56.0%) 
13 (52.0%) 
1 (4.0%) 
 
0 (0.0%) 
0 (0.0%) 
1 (4.0%) 
11 (44.0%) 
66±12 
 
15 (65.2%) 
8 (34.8%) 
 
18 (78.3%) 
0 (0.0%) 
5 (21.7%) 
0 (0%) 
28.2±5.6 
130.3±12.1 
73.1±11.2 
68.9±9.4 
 
 
2 (8.7%) 
31 (54.4%) 
10 (43.5%) 
 
13 (56.5%) 
 
2.82±0.73 
1.45±1.06 
 
 
21 (71.9%) 
1 (4.3%) 
1 (4.3%) 
 
 
4 (17.4%) 
15 (65.2%) 
14 (60.9%) 
8 (34.8%) 
1 (4.3%) 
1 (4.3%) 
1 (4.3%) 
3 (13.0%) 
1 (4.3%) 
0 (0.0%) 
 
11 (50.0%) 
0 (0.0%) 
1 (4.3%) 
12 (54.5%) 
7 (31.8%) 
15 (63.6%) 
12 (54.5%) 
0 (0.0%) 
 
1 (4.3%) 
2 (8.6%) 
1 (4.3%) 
11 (50.0%) 
0.836 
0.566 
 
 
0.122 
 
 
 
 
0.980 
0.555 
0.329 
0.124 
 
0.334 
 
 
 
 
0.578 
 
0.124 
0.511 
 
0.378 
 
 
 
 
 
0.696 
1.000 
0.081 
0.772 
1.000 
1.000 
0.383 
0.794 
0.502 
1.000 
 
0.773 
0.112 
0.845 
0.256 
0.626 
0.098 
0.168 
1.000 
 
0.851 
0.222 
1.000 
0.666 
RIPC=Remote  Ischemic  Preconditioning;  NYHA=New  York  Health  Association;  CCS=Canadian 
Cardiovascular  Society;  MI=Myocardial  infarction;  PCI=Percutaneous  coronary  intervention; 
CVA=Cerebrovascular  accident;  TIA=Transient  ischemic  attack;  ACE-I=Angiotensin-converting 
enzyme-inhibitor; ARB=Angiotensin receptor blocker; LVEF=left ventricular ejection fraction. 
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Table 3.29. Details of surgical procedure in patients undergoing valve surgery alone 
 
RIPC=Remote  Ischemic  Preconditioning;  CABG=Coronary  artery  bypass  graft;  AVR=Aortic  valve 
replacement. 
 
 
 
 
 
 
Despite  a  reduction  of  mean  hsTnT  levels  in  the  preconditioned  group  at  all  the 
specified time-points, this did not reach statistical relevance (Table 3.31, Fig.  2.15). 
Similarly, RIPC reduced total hsTnT AUC from 43.925±33.144 μg/L to  33.395±23.719 
μg/L, corresponding to a non-significant 24% decrease of hsTnT release in the 72 
post-operative hours [10.529; CI -6.868, 27.927; p=0.229](Table 3.31, Fig. 2.16). 
Patients  Control  (n=25) 
(mean (SD)) 
RIPC (n=23) 
(mean (SD)) 
P value 
Indication for Surgery 
Valve Disease  
SBE 
Angina and Valve Disease 
 
EuroSCORE 
 
Additive perioperative risk 
Low (EuroSCORE 0-2) 
Medium (EuroSCORE 3-5) 
High (EuroSCORE >5) 
 
Bypass-time (min)  
 
Cross-clamp time (min)  
 
Cardioprotection 
Blood cardioplegia 
 
Anesthetic agents 
Induction 
Anti-nicotinic agents 
Rocuronium 
Pancuronium 
Vecuronium 
Midazolam 
Etomidate 
Fentanyl 
Propofol 
 
Maintenance  
Propofol 
Volatile Anesthetics 
Isoflurane 
Sevoflurane 
 
Intra-operative GTN  
 
23 (92.0%) 
2 (8.0%) 
1 (4.0%) 
 
4.60±2.22 
 
 
3 (12.0%) 
14 (56.0%) 
8 (32.0%) 
 
103.76±29.95 
 
73.88±22.49 
 
 
25 (100%) 
 
 
 
 
22 (91.7%) 
2 (4.2%) 
0 (0.0%) 
14 (58.3%) 
1 (4.0%) 
25 (100%) 
24 (96.0%) 
 
 
25 (100%) 
 
24 (96.0%) 
1 (4.0%) 
 
14 (56.0%) 
 
22 (95.6%) 
1 (4.4%) 
0 (0.0%) 
 
5.00±2.07 
 
 
4 (17.4%) 
8 (34.8%) 
11 (47.8%) 
 
88.32±31.99 
 
65.68±26.34 
 
 
23 (100%) 
 
 
 
 
20 (90.9%) 
1 (4.5%) 
1 (4.5%) 
6 (27.3%) 
1 (4.5%) 
23 (100%) 
22 (95.5%) 
 
 
21 (95.5%) 
 
51 (94.4%) 
1 (4.5%) 
 
6 (26.1%) 
0.741 
 
 
 
 
0.522 
 
0.337 
 
 
 
 
0.094 
 
0.261 
 
 
1.000 
 
 
 
0.570 
 
 
 
0.420 
1.000 
1.000 
1.000 
 
 
1.000 
1.000 
 
 
 
0.045 
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Table 3.30. High-sensitivity Troponin-T release at the specified time point in patients undergoing 
valve surgery alone 
Endpoint  Control (n=25) 
(mean (sd)) 
RIPC (n=23) 
(mean (sd)) 
Difference 
(95% CI) 
P value 
 
hsTnT (μg/L) 
Pre-operatively  0.012 (0.019)  0.012 (0.014)  -0.000 (-0.010, 0.009)  0.927 
6 hours post-operatively  0.859 (0.523)  0.613 (0.552)  0.246 (0.066, 0.588)  0.120 
12 hours post-operatively  0.748 (0.469)  0.594 (0.462)  0.153 (0.117, 0.424)  0.260 
24 hours post-operatively  0.621 (0.607)  0.411 (0.298)  0.101 (-0.133, 0.334)  0.390 
48 hours post-operatively  0.486 (0.404)  0.406 (0.305)  0.183 (-0.103, 0.471)  0.205 
72 hours post-operatively  0.378 (0.325)  0.232 (0.161)  0.080 (-0.135, 0.296)  0.457 
Total 72 hours AUC  43.925 (33.144)  33.395 (23.719)  10.529 (-6.868, 27.927)  0.229 
RIPC=Remote ischemic preconditioning;  SD=standard deviation; CI=confidence interval; hsTnT=high 
sensitivity Troponin-T 
 
 
 
 
 
 
 
Fig. 3.15. High-sensitivity Troponin-T at 0, 6, 12, 24, 48 and 72 hours post-operatively in patients 
undergoing valve surgery alone (mean±SEM*)   
 
RIPC=remote ischaemic preconditioning; hsTnT=high-sensitivity Troponin-T; SEM=standard error of the 
mean. *Unpaired Student T-Test 
.00000
.20000
.40000
.60000
.80000
1.00000
1.20000
0 6 12 24 48 72
h
s
T
n
T
 
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
μ
g
/
L
)
Time (hours) 
Control
RIPC  181 
Fig. 3.16. Total Area under the Curve of high-sensitivity Troponin T in patients undergoing valve 
surgery alone  (mean±SEM)   
 
RIPC=remote ischaemic preconditioning; AUC=area under the curve 
* Unpaired Student T-Test 
 
 
 
 
 
 
 
 
With regards to secondary end-points, we observed a reduction of 50% of total AKI 
cases and 35% of total inotrope requirement although again no statistical significance 
was  reached  (Table  3.32).  The  remaining  study  outcomes  were  essentially 
comparable between the two intervention groups. 
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Table 3.31. Summary of major secondary endpoints in patients undergoing valve surgery alone 
Endpoint  Control (n=54) 
(mean (sd)) 
RIPC (n=57) 
(mean (sd)) 
Difference 
(95% CI) 
P value 
CK (μg/L) 
Total AUC  28078.06 (10857.95)  34964.63 (29810.70)  -6886.57 (-22625.51, 8852.37)  0.395 
Creatinine (mg/ml) 
Pre-operatively  76.72 (14.16)  84.22 (28.39)  -7.40 (-20.37, 5.38)  0.262 
24 hours post-operatively  86.84 (27.43)  87.96 (28.52)  -1.12 (-17.38, 15.14)  0.891 
48 hours post-operatively  89.56 (41.89)  94.39 (47.35)  -4.83 (-30.76, 21.10)  0.709 
72 hours post-operatively  84.64 (38.44)  95.70 (57.38)  -11.06 (-39.22, 17.11)  0.434 
Urine Output (ml) 
24 hours post-operatively  2056.3 (1040.9)  2105.86 (534.9)  -49.54 (-546.2, 447.1)  0.842 
48 hours post-operatively  1996.3 (812.2)  2336.9 (911.5)  -340.6 (-885.3, 204.2)  0.214 
72 hours post-operatively  2084.8 (701.4)  2485.5 (806.5)  -400.7 (-998.5, -197.2)  0.180 
Total  5829.1 (1470.0)  6570.3 (1852.4)  -741.2 (-2079.4, 597.1)  0.259 
AKI score 
0  19  20    0.246 
1  3  2     
2  3  0     
3  0  0     
Acute Kidney Injury  6  3    0.466 
Inotrope score 
Post bypass  9.62 (17.81)  8.13 (14.61)  1.48 (-8.17, 11.14)  0.758 
24 hours post-operatively  14.44 (24.21)  10.00 (15.84)  4.43 (-7.78, 16.63)  0.469 
48 hours post-operatively     9.44 (17.88)  6.34 (12.87)  3.09 (-6.29, 12.49)  0.510 
72 hours post-operatively  5.66 (12.48)  3.97  (14.79)  1.69 (-6.32, 9.70)  0.673 
Total  38.94 (61.39)  25.48 (40.96)  13.46 (-17.66, 44.58)  0.377 
New onset AF  3  3    1.000 
Length of ICU stay (days)  3.0 (2.0 – 5.0)**  3.0 (3.0– 4.0)**    0.706*** 
Length of hospital stay (days)  10.0 (8.0 – 13.0)**  11.0 (9.0– 17.0)**    0.534*** 
Clinical outcomes at six weeks 
Death  2  0    0.499 
Myocardial infarction  0  0    1.000 
Stroke  0  1    0.211 
Revascularization  0  0    1.000 
RIPC=Remote  ischemic  preconditioning;  CK=Creatinine  Kinase;  AKI=Acute  Kidney  Injury;  AF=atrial 
fibrillation; ICU=Intensive Care Unit; AUC=Area-under-the-curve 
**Results shown as median (inter-quartile range); *** P-value for Mann-Whitney-Wilcoxon test 
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We obtained similar results when, within this patient groups, we went on to analyse the 
29 subjects undergoing AVR only, of whom 15 were randomised to control and 14 to 
RIPC; furthermore, 17 patients, 9 control and 8 RIPC, received MV surgery, with 14 
undergoing  surgical  repair  and  3  undergoing  replacement:  we  did  not  proceed  to 
analyse data from MV surgery patients only as the sample size was too small for any 
relevant finding. No significant difference was found between control and RIPC groups 
within  AVR  surgery  subjects  with  regards  to  baseline  characteristics  and  surgical 
parameters (Tables 2.33-2.34). In particular, CPB and cross-clamp times were longer 
in  the  control  AVR  group,  however  this  did  not  reach  statistical  significance. 
Interestingly,  intra-operative  use  of  GTN  was  not  statistically  different  between  the 
intervention groups. 
Mean hsTnT levels were lower in the preconditioned patients compared to control, 
however with no statistical relevance. Our enhanced preconditioning stimulus reduced 
the total hsTnT AUC from 38.499ﾱ37.661 μg/L to 27.947ﾱ24.678 μg/L [10.55; CI  -
14.96, 36.06; p=0.402], which corresponded to a non-statistical significant reduction of 
27% (Table 2.35). Mean hsTnT was lower in the preconditioned group at all the post-
operative time-points, however this did not reach statistical significance. Interestingly, 
we found for the first and unique time in our study, that hsTnT at 48 hours was higher 
than the preceding mean at 24 hours: it is difficult to explain this finding, although it is 
highly likely to be related to the small number of patients in this subgroup analysis and 
therefore  to  chance.  Preconditioned  and  control  patients  had  comparable  AKI  and 
similarly all the remaining secondary end-points were similar amongst the intervention 
groups (Table 2.35). 
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Table 3.32. Baseline characteristics of patients undergoing AVR alone  
Patients   Control  (n=15)  
(mean (SD)) 
 
RIPC  (n=14) 
(mean (SD)) 
 
P value 
Age (years) 
Gender 
Male 
Female 
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
Chinese 
 
BMI  
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
Smoking History 
Smoker 
Ex-smoker 
Non-smoker 
Family History of IHD 
 
NYHA Class 
CCS Class  
LVEF 
>50% 
30%-50% 
<30% 
 
Co-morbidities 
Diabetes mellitus 
Hypertension 
Hypercholesterolemia 
Atrial Fibrillation 
Previous MI 
Previous PCI 
Previous CVA/TIA 
Previous Cardiac Surgery 
Other comorbidities 
Peripheral Arterial Disease 
 
Drug History 
Aspirin   
Clopidogrel/Prasugrel 
Warfarin  
Beta-blocker 
Calcium Channel Blocker 
Statin 
ACE-I/ARB  
Long acting nitrates 
Antidiabetics 
Insulin 
Biguanide 
Sulphonylurea 
Diuretics 
64±13 
 
9 (60.0%) 
6 (40.0%) 
 
15 (100.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
 
29.5±6.5 
131.8±16.4 
72.3±11.3 
68.6±11.9 
 
1 (6.7%) 
12 (80.0%) 
2 (13.3%) 
8 (53.3%) 
 
3.13±0.7 
1.33±0.7 
 
14 (93.3%) 
1 (6.7%) 
0 (0.0%) 
 
 
2 (13.3%) 
10 (66.7%) 
7 (46.7%) 
2 (13.3%) 
1 (6.7%) 
1 (6.7%) 
1 (6.7%) 
0 (0.0%) 
2 (13.3%) 
0 (0.0%) 
 
 
12 (80.0%) 
2 (13.3%) 
1 (6.7%) 
6 (40.0%) 
6 (40.0%) 
10 (66.6%) 
17 (74.9%) 
1 (6.7%) 
 
1 (6.7%) 
1 (6.7%) 
1 (6.7%) 
7 (46.7%) 
67±13 
 
10 (71.4%) 
4 (28.6%) 
 
12 (60.7%) 
2 (14.3%) 
0 (0.0%) 
0 (0.0%) 
 
29.1±5.4 
135.9±13.9 
77.5±10.8 
70.2±8.9 
 
1 (7.1%) 
7 (50.0%) 
6 (42.9%) 
9 (64.3%) 
 
2.85±0.8 
1.38±0.9 
 
13 (93.9%) 
0 (0.0%) 
1 (7.1%) 
 
 
2 (14.3%) 
11 (78.6%) 
9 (64.3%) 
6 (42.9%) 
1 (7.1%) 
1 (7.1%) 
1 (7.1%) 
1 (7.1%) 
0 (0.0%) 
0 (0.0%) 
 
 
6 (46.2%) 
0 (0.0%) 
2 (15.4%) 
10 (76.9%) 
4 (30.8%) 
10 (76.9%) 
21 (75%) 
0 (0.0%) 
 
1 (7.1%) 
1 (7.1%) 
1 (7.1%) 
5 (38.5%) 
0.551 
0.518 
 
 
0.129 
 
 
 
 
 
0.892 
0.604 
0.226 
0.702 
0.193 
 
 
 
0.550 
 
0.334 
0.866 
0.367 
 
 
 
 
 
0.941 
0.474 
0.340 
0.075 
0.960 
0.960 
0.960 
0.292 
0.139 
1.000 
 
 
0.062 
0.172 
0.542 
0.602 
0.615 
0.536 
0.797 
0.343 
 
0.364 
0.364 
0.916 
0.909 
RIPC=Remote  Ischemic  Preconditioning;  NYHA=New  York  Health  Association;  CCS=Canadian 
Cardiovascular  Society;  MI=Myocardial  infarction;  PCI=Percutaneous  coronary  intervention;  CVA= 
Cerebrovascular  accident;  TIA=Transient  ischemic  attack;  ACE-I=Angiotensin-converting  enzyme-
inhibitor; ARB=Angiotensin receptor blocker; LVEF= eft ventricular ejection fraction. 
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Table 3.33. Details of surgical procedure of patients undergoing AVR alone 
Patients   Control  (n=15)  
(mean (SD)) 
RIPC  (n=14) 
(mean (SD)) 
P value 
RIPC= Remote Ischemic Preconditioning; CABG=Coronary artery bypass graft 
 
 
 
 
Table 3.34. Summary of major endpoints in patients undergoing AVR 
Endpoint  Control (n=15) 
(mean (sd)) 
RIPC (n=14) 
(mean (sd)) 
Difference 
(95% CI) 
P 
value 
 
hsTnT (μg/L) 
 
Pre-operatively  0.0147 (0.024)  0.015 (0.017)  -0.0006 (0.08, -0.016)  0.937 
6 hours post-operatively 
 
0.680 (0.381)  0.529 (0.645)  0.151 (-0.252, 0.430)  0.447 
 
12 hours post-operatively 
 
0.590 (0.382)  0.501 (0.508)  0.089 (0.101, -0.053)  0.595 
 
24 hours post-operatively  0.530 (0.438)  0.415 (0.366) 
 
0.115 (-0.202, 0.431) 
 
0.462 
 
48 hours post-operatively 
 
0.582 (0.763) 
 
0.326 (0.285) 
 
0.255 (-0.206, 0.717) 
 
0.266 
 
72 hours post-operatively  0.436 (0.465)  0.386 (0.339) 
 
0.050 (-0.274, 0.375) 
 
0.753 
 
Total 72 hours AUC 
 
38.499 (37.661) 
 
27.947 (24.678) 
 
10.55 (-14.96, 36.06) 
 
0.402 
 
Indication for Surgery 
Dyspnoea 
Valve Disease 
Infective Endocarditis 
 
EuroSCORE 
Additive perioperative risk 
Low (EuroSCORE 0-2) 
Medium (EuroSCORE 3-5) 
High (EuroSCORE >5) 
 
Bypass-time (min)  
 
Cross-clamp time (min)  
 
Cardioprotection 
Blood cardioplegia 
Cross-clamp fibrillation 
 
Anesthetic agents 
Induction 
Anti-nicotinic agents 
Rocuronium 
Pancuronium 
Vecuronium 
Midazolam 
Etomidate 
Fentanyl 
Propofol 
 
Maintenance  
Propofol 
Volatile Anesthetics 
Isoflurane 
Sevoflurane 
 
Intra-operative GTN  
 
1 (6.7%) 
13 (86.7%) 
1 (6.7%) 
 
4.13±1.84 
 
2 (13.3%) 
9 (60.0%) 
4 (26.7%) 
 
99.13±23.63 
 
74.36±21.79 
 
 
15 (100%) 
0 (0.0%) 
 
 
 
 
14 (93.3%) 
1 (6.7%) 
0 (0.0%) 
10 (66.7%) 
1 (6.7%) 
15 (100%) 
14 (93.3%) 
 
 
15 (100%) 
 
15 (100%) 
0 (0.0%) 
 
7 (46.7%) 
 
1 (7.1%) 
13 (92.9%) 
0 (0.0%) 
5.14±1.99 
 
2 (14.3%) 
5 (35.7%) 
7 (50.0%) 
 
81.86±26.38 
 
65.0±25.5 
 
 
14 (100%) 
0 (0.0%) 
 
 
 
 
15 (100.0%) 
0 (0.0%) 
0 (0.0%) 
3 (23.1%) 
0 (0.0%) 
14 (100%) 
15 (100.0%) 
 
 
14 (100%) 
 
14 (100%) 
0 (0.0%) 
 
2 (14.3%) 
0.617 
 
 
 
 
0.168 
0.381 
 
 
 
 
0.074 
 
0.097 
 
 
1.000 
 
 
 
 
0.343 
 
 
 
0.021 
0.343 
1.000 
0.343 
 
 
1.000 
 
1.000 
 
 
0.060   186 
CK (μg/L) 
Total AUC  26435.73 (10165.51)  35844.33 (35412.65)  -9408.60 (-32821.92, 
14004.71) 
0.410 
Creatinine (mg/ml) 
Pre-operatively  77.80 (14.07)  84.50 (29.57)  --6.70 (-24.15, 10.75)  0.451 
24 hours post-operatively  86.87 (24.69)  92.50 (33.39)  -5.63 (-27.91, 16.64)  0.608 
48 hours post-operatively  91.00 (38.48)  103.86 (55.79)  -12.86 (-49.15, 23.44)  0.474 
72 hours post-operatively  83.87 (29.39)  106.29 (68.24)  -22.42 (-61.97, 17.13)  0.255 
Urine Output (ml) 
24 hours post-operatively  1998.1 (898.5)  2289.7.4 (553.9)  -291.56 (-882.87, 299.76)  0.320 
48 hours post-operatively  2151.9 (933.3)  2576.7 (894.5)  -424.91 (-1203.0, 353.3)  0.270 
72 hours post-operatively  2028.9 (906.2)  2566.2 (567.8)  -537.30 (-1481.5, 406.9)  0.236 
Total  5912.6 (1719.3)  6903.5 (1812.2)  -990.90 (-3148.75, 1166.89)  0.337 
AKI score 
0  12  12    0.341 
1  1  2     
2  2  0     
3  0  1     
Acute Kidney Injury  3  3    1.000 
Inotrope score 
Post bypass  9.86 (20.55)  4.65 (10.67)  5.21 (-7.83, 18.24)  0.419 
24 hours post-operatively  7.96 (12.98)  5.66 (12.23)  2.31 (-7.54, 12.15)  0.634 
48 hours post-operatively  4.17 (11.89)  4.73 (12.52)  -0.56 (-10.1, 8.9)  0.904 
72 hours post-operatively     2.07 (4.06)  1.07  (3.46)  0.99 (-1.96, 3.95)  0.494 
Total  23.45 (45.86)  15.85 (33.93)  7.60 (-24.17, 39.37)  0.627 
New onset AF  3  1    0.598 
Length of ICU stay (days)  2.0 (2.0–3.0)**  2.0 (2.0–3.0)**    0.747*** 
Length of hospital stay (days)  8.0 (7.0 –13.5)**  8.5 (8.0-10.0)**    0.780*** 
Clinical outcomes at six weeks 
Death  2  0    0.487 
Myocardial infarction  0  0    1.000 
Stroke  0  0    1.000 
Revascularization  0  0    1.000 
RIPC=Remote  ischemic  preconditioning;  CK=Creatinine  Kinase;  AKI=Acute  Kidney  Injury;  AF=atrial 
fibrillation;  ICU=Intensive  Care  Unit;  AUC=Area-under-the-curve;  **Results  shown  as  median  (inter-
quartile range). *** P-value for Mann-Whitney-Wilcoxon test 
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Fig. 3.17. Mean high-sensitivity Troponin-T levels at 0, 6, 12, 24, 48 and 72 hours post-AVR 
(mean±SEM*)    
 
RIPC=remote ischaemic preconditioning; SEM=standard error of the mean. * Unpaired Student T-Test 
 
 
Fig. 3.18. Total Area under the Curve of high-sensitivity Troponin-T post-AVR (mean±SEM)   
RIPC=remote ischaemic preconditioning; AUC=area under the curve; SEM=standard error of the mean. 
* Unpaired Student T-Test 
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3.13.2.5.1. Discussion 
Our retrospective analysis showed that an enhanced preconditioning stimulus failed to 
demonstrate  any  protective  effect  on  either  PMI  or  short-term  clinical  outcomes  in 
patients undergoing AVR. 
In the first RCT investigating cardioprotection in the context of valve surgery alone 
(301), cardiac preconditioning reduced polymorphonuclear leukocytes, thromboxane 
B2, malonedialadehyde and pulmonary artery pressure and resistance and increased 
SOD and CGRP levels, pO2 and cardiac index. However the stimulus consisted of 
two-3 minutes  cycles  of  aortic-cross  clamping  and 2  minutes  of reperfusion  before 
cardioplegic  arrest,  thereby  representing  an  invasive  strategy,  in  contrast  with  our 
protocol. Subsequently, three-minutes cycles of upper leg IR with a tourniquet after 
aortic cross-clamping were showed to reduce cTnI 5 minutes before declamping and 
30 minutes after declamping, compared to the RIPC group, where the same stimulus 
was  given  after  induction  of  anaesthesia,  and  the  control  group,  where  a  sham 
tourniquet was applied around the upper thigh (302). However, no significant reduction 
of total cTnI AUC or clinical outcomes, including ventilation times, inotrope score, ICU 
and hospital stay, was achieved and despite a decrease in post-operative defibrillation 
rate.  Based  on  these  findings  and  combining  the  application  of  both  RIPC  and 
RIPostC, Kim and colleagues (305) evaluated the effects of three-10 minutes cycles of 
right lower limb ischaemia (at 250mmHg) 10 minutes after anaesthetic induction and 
from discontinuation of CPB in patients undergoing complex valve surgery: combined 
RIPC and RIPostC did not provide any significant benefit in pulmonary function and 
post-operative  levels  of  IL-6,  IL-8,  IL-10  and  TNF-ʱ.  However,  in  their  study,  they 
included  a  total  of  27  patients  undergoing  MV  replacement  (MVR)  plus  TV 
annuloplasty,  13  patients  receiving  AVR  plus  ascending  aorta  replacement  and  1   189 
patient  having  CABG  plus  MVR,  which  we  excluded  from  the  current  analysis. 
Moreover,  no  RIPC  group  alone  or  RIPostC  group  alone  were  included  and  no 
parameter related to cardioprotection was assessed (305). In the study from Young 
and co-workers (296), where complex cardiac operations were performed including 
high-risk CABG and combined CABG-valve surgery with an overall EuroSCORE of 
7.1±6.1  and  6.6±6.1  in  preconditioned  and  control  patients  respectively,  subjects 
randomised to standard RIPC had higher hsTnT release and inotropic requirements.  
However,  it  is difficult  to  compare  this  study  with  our  retrospective  analysis as the 
former also included CABG patients and importantly only measured hsTnT levels at 6 
and  12  hours,  therefore  failing  to  evaluate  total  hsTnT  release  over  the  72  post-
operative hours with AUC, which gives a true measure of total PMI magnitude. 
In another study where RIPC was applied with three-10 minutes cycles of lower 
limb  IR  to  patients  undergoing  complex  valve  surgery  (303),  Choi  and  colleagues 
found no difference in serum biomarkers levels of renal injury, although CK-MB was 
significantly  decreased  at  24  hours  after  surgery  and  ICU  stay  was  reduced  from 
3.4±1.4 days to 2.7±0.7 days in the preconditioned group.  
The  most  comparable  RCT  to  our  subgroup  analysis  included  a  total  of  73 
patients undergoing MV, AV or TV surgery (304), where anaesthesia was induced and 
maintained  with  sufentanil,  etomidate  and  only  in  a  small  amount  of  patients  with 
sevoflurane (no patient received propofol): standard RIPC reduced mean cTnI at 6, 12, 
24, 48, and 72 hours and total AUC by 44% and improved NYHA and LVEF at 39 
months follow-up. In our study, we found no statistically significant difference even 
when  we  combined  the  data  from  all  valve  operations.  Importantly  our  study 
significantly differed from the work from Xie and colleagues (304) for the different type 
of  anaesthetic  regime  used  and  more  importantly  for  the  smaller  sample  size  (25   190 
versus  35  patients  in  the  control  groups  and  23  versus  38  patients  in  the  RIPC 
groups): it is therefore possible that once again, anaesthetic regime might have had a 
significant  impact  on  the  cardioprotective  effects  of  RIPC  and  that  studies  with 
standardised  protocols  will  need  to  be  carried  out.  Secondly,  our  study  was  not 
powered enough in order to evaluate the effects of RIPC in such a small population of 
patients undergoing valve surgery alone. 
Additionally,  patients  receiving  valve  surgery  only  were  not  included  in  our 
multi-centre study and this was in order to evaluate a homogenous population were 
surgical  parameters  could  be  comparable  between  intervention  groups  (290).  This 
implies  that  large  RCTs  are  required  in  order  to  further  evaluate  the  relationship 
between the intensity of the preconditioning stimulus and its effects on PMI in patients 
undergoing valve surgery alone.  
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CHAPTER 4 
 
 
4.  Effects  of  combined  antegrade  and  retrograde 
cardioplegia  on  cardioprotection  in  patients  undergoing 
cardiac surgery  
 
 
4.1. Introduction 
In chapter 1 we described the use of different techniques of myocardial preservation 
during  cardiac  surgery,  comprising  cardioplegia  and  ICCF,  and  throughout  our 
analyses  in  chapter  3  we  assessed  the  effects  of  our  enhanced  preconditioning 
stimulus  in  the  setting  of  different  types  of  operation  and  with  specific methods  of 
myocardial preservation: crucially, with the technique of cardioplegia, different types of 
solution, temperature and delivery have been developed throughout the decades, with 
specific centres and surgeons preferring one method versus the other.  
The  two  most  commonly  used  cardioplegic  solutions  are  crystalloid  and  blood 
cardioplegia; with regards to the route of administration and temperature (21-24) the 
different combinations include: cold blood antegrade cardioplegia with topical cooling, 
warm blood antegrade cardioplegia, warm blood antegrade and retrograde combined 
cardioplegia, cold blood antegrade and retrograde combined cardioplegia, alternating 
cold or warm blood antegrade, retrograde combined cardioplegia and simultaneous 
cold  or  warm  blood  antegrade  and  retrograde  combined  cardioplegia.  Despite 
significant distinctions, these methods are equally able to preserve myocardial function 
and therefore to limit PMI during cardiac surgery.    192 
  One  of  the  most  important  aspects  of  the  use  of  cardioplegia  to  achieve 
successful myocardial protection is the prompt delivery of the solution to all myocardial 
territories (475): in this regard, the most commonly used technique is the antegrade 
route, where cardioplegia is administered either into the aortic root or directly into the 
coronary ostia (476). Crucially, adequate delivery of the solution to  cardiomyocytes 
occurs in the context of unobstructed coronary arteries and therefore the presence of 
significant coronary stenoses might compromise the homogenous distribution of the 
solution (477).  This might render the post-stenotic myocardial territories particularly 
vulnerable  to  ischemia  during  aortic  cross-clamp  (478)  and  therefore  resulting  in 
substantial PMI and potential post-operative LV dysfunction (479).  
Moreover,  in  the  presence  of  significant  aortic  stenosis,  the  marked  LV 
hypertrophy typical of these patients might once again limit the consistent delivery of 
the  solution  due  the  increased  LV  wall  thickness  (478)  and  when  concomitant  AR 
occurs, pressure at the aortic root level might prove insufficient to allow even perfusion 
of  the  cardioplegic  solution  through  the  myocardium  thereby  further  increasing  the 
potential risk of PMI (480, 481). Importantly, even increasing the infusion pressure at 
the  aortic  root  has  been  demonstrated  to  be  insufficient  in  this  regard  (482). 
Conversely,  the  use  of  the  retrograde  technique  has  offered  the  opportunity  to 
overcome this drawback by the delivery of cardioplegic solution through the coronary 
sinus, the Thebesian veins and subsequently, and without hindrance, a trans-mural 
network of veins, which have no valves or, differently from the coronary arteries, any 
type  of  atherosclerotic  lesions  (483):  this  can  therefore  serve  as  a  conduit  for  the 
delivery of cardioplegic solution in a more homogenous manner than what observed 
with obstructed or sub-obstructed coronary arteries (484, 485). Additionally, retrograde 
cardioplegia also offer the advantage of a better visualisation particularly in the context   193 
of  AVR  as  the  catheter  is  placed  distant  from  the  AV  (486).  Nevertheless,  crucial 
limitations of retrograde cardioplegia are identified in:  
1.  technical difficulties, related to the cannulation of the coronary sinus in itself, the 
balloon inflation which can often cause venous rupture, and the perfusion pressure 
(487, 488); 
2.  the potential inadequate supply of the RV and posterior septum by the myocardial 
venous  system  as  the  anterior  cardiac  veins  supplying  the  RV  are  not  directly 
connected to the coronary sinus (489, 490). 
The combination of both methods of antegrade and retrograde cardioplegia is thought 
to  overcome  limitations  inherent  to  both  techniques  and  has  now  become  an 
increasingly  used  method  of  myocardial  preservation  during  cardiac  surgery  (491): 
interestingly,  although  both  retrograde  coronary  sinus  perfusion  and  antegrade 
perfusion have been studied  individually in experimental trials and used in patients 
undergoing CABG surgery, little information is available on the direct comparison of 
PMI magnitude between the two different methods of cardioprotection. 
At the tertiary centre where this study was carried out, cardioplegia was used as 
either  antegrade  cold  blood  cardioplegia  or  antegrade/retrograde  warm  blood 
cardioplegia (Table  4.1): we therefore conducted a retrospective analysis of control 
patients undergoing first time CABG surgery recruited in our principal study in order to 
determine whether the addition of retrograde cardioplegia to antegrade cardioplegia 
leads to  similar or  improved  myocardial  preservation  in  these patients. We did not 
attempt to carry out a similar analysis in other subgroups given the small population 
size and in order to compare equivalent cohort of subjects. 
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Table  4.1.  Distribution  of  different  types  of  operations  according  to  technique  of  myocardial 
preservation and intervention 
Operation    Antegrade  
Cardioplegia (%) 
Intermittent cross-
clamp fibrillation (%) 
Antegrade/retrograde 
Cardioplegia (%) 
CABG  Control 
RIPC 
28 (32%) 
27 (30%) 
16 (18%) 
14 (16%) 
10 (11%) 
16 (18%) 
AVR  Control 
RIPC 
13 (15%) 
13 (15%) 
0 (0%) 
0 (0%) 
2 (2%) 
1 (1%) 
CABG + AVR  Control 
RIPC 
10 (11%) 
6 (7%) 
0 (0%) 
0 (0%) 
0 (0%) 
3 (3%) 
MV Surgery  Control 
RIPC 
9 (10%) 
6 (7%) 
0 (0%) 
0 (0%) 
0 (0%) 
2 (2%) 
CABG=coronary  artery  bypass  graft;  AVR=aortic  valve  replacement;  MV=mitral  valve;  RIPC=remote 
ischaemic preconditioning 
 
 
 
 
 
 
 
 
4.2. Methods  
As  this  type  of  analysis  involved  direct  comparison  of  three  subgroups,  statistical 
analysis  was  in  part  different  from  the  one  presented  elsewhere  in  this  work. 
Comparison between exposure groups was made by including the exposure variable 
as  a  categorical  variable  in  a  linear  regression  model  for  approximately  normally 
distributed endpoint variables. For very skewed endpoint variables the median T-test 
was used. Where continuous endpoint variables were measured over time a repeated 
measures  linear  regression  model  was  fitted  to  measure  the  association  between 
exposure  variable  and  endpoint.  The  assumptions  of  the  linear  regression  models 
were  performed  by  analysis  of  residuals.  Categorical  data  were  analysed  using 
Fisher’s exact test. No adjustment for multiplicity has been made. Data were analysed 
using Stata version 12.1.    195 
4.3. Results     
A total of 44 control patients undergoing elective CABG surgery were included in this 
analysis: 28 received antegrade cold blood cardioplegia (group 1), 16 ICCF (group 2) 
and  10  antegrade/retrograde  warm  blood  cardioplegia  (group  3).  With  regards  to 
baseline characteristics, group 3 had a lower rate of positive family history of CAD and 
previous PCI, whereas group 2 had a higher incidence of CVA prior to CABG surgery 
(Table 4.2): we found no other significant difference between the three groups (Table 
4.2). However, when we then analysed the details of surgical procedures, expectedly, 
we found that cross-clamp times were significantly lower in group 2 than groups 1 and 
3, however all the remaining parameters of surgery were similar amongst the 3 groups 
(Table 4.3). 
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Table 4.2. Patient baseline characteristics in control patients undergoing elective CABG surgery 
with antegrade/retrograde cardioplegia, antegrade cardioplegia or ICCF  
Patients  Group 1 (n=28) 
(mean (SD)) 
Group 2 (n=16) 
(mean (SD)) 
Group 3 (n=10) 
(mean (SD)) 
Age 
Gender 
Male 
Female 
Ethnicity 
Caucasian 
Afro-Caribbean 
Asian 
Chinese 
BMI  
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
 
Smoking History 
Smoker 
Non-smoker 
Ex-smoker 
 
Family History of IHD 
NYHA Class 
0 
I 
II 
III 
IV 
CCS Class 
0 
I 
II 
III 
IV 
LVEF 
>50% 
30%-50% 
<30% 
 
Co-morbidities 
Diabetes mellitus 
Hypertension 
Hypercholesterolemia 
Atrial Fibrillation 
Previous MI 
Previous PCI 
Previous CVA/TIA 
Previous Cardiac Surgery 
Peripheral Arterial Disease 
 
Drug History 
Aspirin   
Clopidogrel/Prasugrel 
Warfarin  
Beta-blocker 
Calcium Channel Blocker 
Statin 
ACE-I/ARB  
Long acting nitrates 
Antidiabetics 
Insulin 
Biguanide 
Sulphonylurea 
Diuretics 
 
67±8 
 
23 (82%) 
5 (18%) 
 
21 (75%) 
1 (4%) 
5 (18%) 
1 (4%) 
27.6±4.9 
131.3±20.8 
70.3±7.4 
66.8±11.1 
 
 
4 (14%) 
6 (21%) 
18 (64%) 
 
22 (79%) 
 
2 (7%) 
8 (29%) 
17 (61%) 
1 (4%) 
0 (0%) 
 
5 (18%) 
4 (14%) 
16 (57%) 
2 (7%) 
1 (4%) 
 
19 (68%) 
8 (29%) 
1 (4%) 
 
 
11 (39%) 
25 (89%) 
25 (89%) 
3 (11%) 
13 (47%) 
8 (29%) 
3 (11%) 
0 (0%) 
3 (11%) 
 
 
3 (11%) 
2 (7%) 
1 (4%) 
22 (79%) 
12 (43%) 
26 (93%) 
20 (71%) 
7 (25%) 
 
4 (14%) 
2 (7%) 
5 (18%) 
7 (25%) 
 
62±10 
 
12 (75%) 
4 (25%) 
 
13 (81%) 
1 (6%) 
2 (13%) 
0 (0%) 
30.4±5.0 
128.3±16.9 
73.4±10.6 
68.6±10.5 
 
 
4 (25%) 
4 (25%) 
8 (50%) 
 
13 (81%) 
 
3 (21%) 
5 (34%) 
5 (34%) 
1 (7%) 
0 (0%) 
 
2 (14%) 
5 (36%) 
6 (43%) 
1 (7%) 
0 (0%) 
 
12 (75%) 
3 (19%) 
1 (6%) 
 
 
6 (38%) 
13 (81%) 
15 (94%) 
0 (0.0%) 
3 (19%) 
1 (6%) 
0 (0%) 
0 (0%) 
1 (6%) 
 
 
2 (14%) 
0 (0%) 
0 (0%) 
11 (79%) 
3 (21%) 
13 (93%) 
8 (57%) 
2 (14%) 
 
2 (14%) 
1 (7%) 
2 (14%) 
4 (29%) 
 
69±9 
 
8 (80%) 
2 (20%) 
 
9 (90%) 
1 (10%) 
0 (0%) 
0 (0%) 
27.8±4.5 
128.9±21.2 
69.1±11.6 
65.7±13.9 
 
 
1 (10%) 
4 (40%) 
5 (50%) 
 
4 (40%) 
 
2 (22%) 
4 (44%) 
2 (22%) 
1 (11%) 
0 (0%) 
 
3 (33%) 
0 (0%) 
4 (44%) 
1 (11%) 
1 (11%) 
 
7 (70%) 
3 (30%) 
0 (0%) 
 
 
0 (0%) 
7 (70%) 
8 (80%) 
2 (20%) 
6 (60%) 
0 (0%) 
3 (30%) 
0 (0%) 
2 (20%) 
 
 
0 (0%) 
0 (0%) 
0 (0%) 
8 (80%) 
4 (40% 
10 (100%) 
6 (60%) 
3 (30%) 
 
0 (0%) 
0 (0%) 
0 (0%) 
2 (20%) 
 
RIPC=Remote  Ischemic  Preconditioning;  NYHA=New  York  Health  Association;  CCS=Canadian 
Cardiovascular  Society;  MI=Myocardial  infarction;  PCI=Percutaneous  coronary  intervention; 
CVA=Cerebrovascular accident; TIA=Transient ischemic attack; ACE-I=Angiotensin-converting enzyme-
inhibitor; ARB=Angiotensin receptor blocker; LVEF=left ventricular ejection fraction.   197 
Table 4.3. Details of surgical procedure in control patients undergoing elective CABG surgery 
with antegrade/retrograde cardioplegia, antegrade cardioplegia or ICCF  
Patients  Group 1 (n=28) 
(mean (SD)) 
Group 2 (n=16) 
(mean (SD)) 
Group 3 (n=10) 
(mean (SD)) 
Indication for Surgery 
Angina 
Myocardial Infarction 
 
EuroSCORE 
 
Additive perioperative risk 
Low (EuroSCORE 0-2) 
Medium (EuroSCORE 3-5) 
High (EuroSCORE >5) 
 
Bypass-time (min) 
Cross-clamp time (min)  
 
Number of grafts 
One  
Two  
Three  
Four 
Anesthetic agents 
Induction 
Anti-nicotinic agents 
Rocuronium 
Pancuronium 
Vecuronium 
Midazolam 
Etomidate 
Fentanyl 
Propofol 
Maintenance  
Propofol 
Volatile Anesthetics 
Isoflurane 
Sevoflurane 
 
Intra-operative GTN 
 
23 (82%) 
5 (18%) 
 
3.2±1.9 
 
 
13 (46%) 
12 (43%) 
3 (11%) 
 
93.9±34.6 
62.2±24.4 
 
 
1 (4%) 
9 (32%) 
10 (36%) 
8 (29%) 
 
 
 
24 (86%) 
3 (11%) 
1 (4%) 
12 (43%) 
1 (4%) 
28 (100%) 
27 (96%) 
 
28 (100%) 
 
25 (89%) 
3 (11%) 
 
24 (89%) 
 
13 (81%) 
3 (19%) 
 
2.7±1.7 
 
 
8 (50%) 
7 (44%) 
1 (6%) 
 
77.2±22.0 
33.0±7.5 
 
 
0 (0.0%) 
3 (19%) 
10 (63%) 
3 (19%) 
 
 
 
12 (92%) 
1 (7%) 
0 (0.0%) 
7 (54%) 
2 (14%) 
14 (100%) 
12 (86%) 
 
14 (100%) 
 
13 (93%) 
1 (7%) 
 
14 (86%) 
 
7 (70%) 
3 (30%) 
 
3.8±1.8 
 
 
1 (10%) 
7 (70%) 
2 (20%) 
 
80.3±12.8 
63.7±13.4 
 
 
0 (0.0%) 
1 (10.0%) 
8 (80.0%) 
1 (10.0%) 
 
 
 
6 (60%) 
2 (22%) 
1 (11%) 
6 (67%) 
2 (22%) 
9 (100%) 
7 (78%) 
 
9 (100%) 
 
9 (100.%) 
0 (0.0%) 
 
8 (89%) 
GTN= glyceryl trinitrate. 
 
 
 
 
 
    Baseline  pre-operative  hsTnT  levels  were<0.02  μg/L  and  not  significantly 
different  between  the  3  groups  (Fig.  2,  Table  2).  There  was  evidence  that  mean 
hsTnT at 6 [-0.56; 95% CI: -0.78, -0.34; p<0.001] and 12 hours [-0.43, CI: -0.65, -0.21; 
p<0.001] was lower in group 3 than group 1 (Fig. 2, Table 2). Total 72 hr hsTnT AUC 
was lower in group 3 compared to group 1 [-16.55; CI -30.08, -3.01; p=0.018] with a 
slightly weaker evidence of lower hsTnT AUC in group 3 compared to group 2 [-15.13; 
CI -29.87, -0.39; p=0.044] and no significant difference between group 2 to group 1       198 
[-1.42; 95% CI: -12.95, 10.12, p=0.806] (Fig. 4.2, Table 4.4). No statistically significant 
difference was found amongst the three groups with regards to each of the secondary 
endpoints (Table 4.3). 
 
 
 
 
 
 
Table 4.4. Mean high-sensitivity troponin-T at the specified time-points and total AUC in control patients 
undergoing elective CABG surgery with antegrade/retrograde cardioplegia, antegrade cardioplegia or 
ICCF  
 
Patients 
 
Group 1 
 (n=28) 
(mean [SD]) 
 
Group 2 
 (n=16) 
(mean [SD]) 
 
Group 3 
 (n=10) 
(mean [SD]) 
 
 
 
Comparison 
Group 
 
Difference 
(95% CI) 
 
Sub-group  
P value 
Total 72 hours 
AUC 
34.30 (20.35)  32.89 (18.77)  17.76 (7.54)  P= 0.050 
 
1 vs 2 
1 vs 3 
2 vs 3 
 
-1.42 (-12.95, 10.12) 
-16.55 (-30.08, -3.01) 
-15.13 (-29.87, -0.39) 
 
0.806 
0.018 
0.044 
 
 
Pre-operatively 
 
 
0.021 (0.020)  0.022 (0.022)  0.014 (0.012)  P= 0.997 
1 vs 2 
1 vs 3 
2 vs 3 
 
0.000 (-0.188, 0.188) 
-0.008 (-0.229, 0.213) 
-0.008 (-0.250, 0.234) 
 
6 hours  
post-operatively 
0.961 (0.619)  0.696 (0.235)  0.399 (0.117)  P<0.001 
 
1 vs 2 
1 vs 3 
2 vs 3 
 
 
-0.265 (-0.453, -0.077) 
-0.562 (-0.783, -0.341) 
-0.297 (-0.539, -0.055) 
 
12 hours  
post-operatively 
0.752 (0.494)  0.631 (0.195)  0.319 (0.112)  P<0.001 
 
1 vs 2 
1 vs 3 
2 vs 3 
 
 
-0.121 (-0.309, 0.067) 
-0.433 (-0.654, -0.212) 
-0.312 (-0.557, -0.070) 
 
24 hours  
post-operatively 
0.508 (0.309)  0.476 (0.305)  0.266 (0.134)  P= 0.100 
 
1 vs 2 
1 vs 3 
2 vs 3 
 
 
-0.032 (-0.220, 0.156) 
-0.241 (-0.463, -0.020) 
-0.209 (-0.451, 0.033) 
 
48 hours  
post-operatively 
0.359 (0.224)  0.410 (0.339)  0.227 (0.114)  P= 0.335 
 
1 vs 2 
1 vs 3 
2 vs 3 
 
 
0.044 (-0.144, 0.233) 
-0.139 (-0.360, 0.083) 
-0.183 (-0.425, 0.059) 
 
72 hours  
post-operatively 
0.347 (0.231)  0.381 (0.271)  0.186 (0.119)  P= 0.257 
 
1 vs 2 
1 vs 3 
2 vs 3 
 
 
0.027 (-0.161, 0.216) 
-0.168 (-0.390, 0.054) 
-0.195 (-0.437, 0.047) 
 
hsTnT=high sensitivity troponin-T; AUC=area-under-the-curve   199 
Fig. 4.1: Mean high-sensitivity troponin-T pre-operatively and at 6, 12, 24, 48 and 72 hours post-
surgery  in  control  patients  undergoing  elective  CABG  surgery  with  antegrade/retrograde 
cardioplegia, antegrade cardioplegia or ICCF (mean±SEM) 
 
hsTnT=high sensitivity troponin-T; ICCF=intermittent cross-clamp fibrillation; SEM=standard error of the 
mean. * p<0.05 (unpaired Student T-Test) 
 
 
Fig.  4.2.  Total  hsTnT-AUC  in  control  patients  undergoing  elective  CABG  surgery  with 
antegrade/retrograde cardioplegia, antegrade cardioplegia or ICCF (mean±SEM) 
 
AUC=area-under-the-curve; ICCF=intermittent cross-clamp fibrillation; SEM=standard error of the mean 
*Unpaired Student T-Test 
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Table 4.5. Summary of secondary endpoints in control patients undergoing elective CABG 
surgery with antegrade/retrograde cardioplegia, antegrade cardioplegia or ICCF 
Patients  Group 1 (n=28) 
(mean [sd]) 
Group 2 (n=16) 
(mean [sd]) 
 
Group 3 (n=10) 
(mean [sd]) 
P value 
Creatinine (mg/ml) 
 
Pre-operatively  87.7±17.4  88.2±20.0  93.9±23.5  0.681 
24 hours post-operatively  86.7±27.5  107.5±42.1  90.1±24.8  0.121 
48 hours post-operatively  98.8±36.0  130.6±79.2  92.8±39.01  0.111 
72 hours post-operatively  93.0±40.0  119.4±67.8  87.8±34.99  0.170 
Urine Output (ml) 
24 hours post-operatively  1885.3±589.4  1941.9±806.7  2247.5±531.4  0.398 
48 hours post-operatively  2274.1±1111.4  2033.1±951.3  2236.9±859.8  0.826 
72 hours post-operatively  1912.0±852.7  2456.0±1138.1  2222.4±863.0  0.419 
Total  5768.6±2187.1  6006.2±2080.0  6699.0±1485.4  0.686 
Pre-operatively  87.7±17.4  88.2±20.0  93.9±23.5  0.681 
AKI (N) 
0  22 (79%)  11 (69%)  10 (100.0%) 
 
1  5 (18%)  2 (13%) 
(0.0%)   
2  0 (0.0%)  2 (13%) 
(0.0%)   
3  1 (4%)  1 (6%)  (0.0%)   
Total number of AKI cases  6 (21%)  5 (31%)  0 (0.0%)  0.281* 
Inotrope Score (mg/kg/hr) 
Post bypass  7.24 (13.79)  4.03 (11.92)  3.76 (4.35)  0.816** 
24 hours post-operatively  11.90 (21.32)  10.11 (22.88)  3.67 (4.36)  0.635** 
48 hours post-operatively  8.76 (15.39)  14.93 (33.57)  1.94 (2.98)  0.101** 
72 hours post-operatively  1.85 (5.30)  13.54 (33.13)  2.13 (2.95)  0.015** 
Total   29.88 (49.10)  42.54 (94.66)  11.66 (13.79)  0.545*** 
New onset AF (N)  6 (21%)  5 (31%)  4 (40.0%)  0.475* 
Length of ICU stay (days)  2.0 (2.0-4.0)****  3 (1.0-7.5)****  2.0 (1.0-3.0)****  0.802***** 
Length of Hospital stay (days)  8.5 (7.0-11.50)****  8.0 (6.0-10.50)****  7.5 (6.0-9.00)****  0.523***** 
Clinical Outcomes at 6 weeks (N) 
Death  3 (14%)  0 (0.0%)  0 (0.0%)  0.283* 
Myocardial infarction  1 (4%)  0 (0.0%)  0 (0.0%)  1.000* 
Stroke  0 (0.0%)  0 (0.0%)  0 (0.0%)  1.000 
Revascularization  0 (0.0%)  0 (0.0%)  0 (0.0%)  1.000* 
sd=standard deviation; AKI=Acute Kidney Injury; AF=atrial fibrillation; ICU=Intensive Care Unit. *P value 
for Fisher’s exact test; ** P-value from repeated measures linear regression model; *** P-value form 
linear regression model; **** Results shown as median (inter-quartile range); ***** P-value for Median T 
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4.4. Discussion 
    In  our  retrospective  analysis  we  have  found  that  the  addition  of  retrograde 
cardioplegia  to  the  antegrade  technique  reduces  PMI  compared  to  the  use  of 
antegrade cardioplegia alone or ICCF in control patients undergoing elective CABG 
surgery, although we found no significant impact on the study secondary outcomes.  
    Myocardial  preservation  during  cardiac  surgery  is  certainly  one  of  the  most 
debated topics in this field. A variety of myocardial protection strategies are currently 
used  in  the  UK  and  the  world  and  the  choice  of  the  type  of  technique,  route  and 
temperature of delivery is in the vast majority of cases at the surgeon’s discretion as 
no  consensus  has  yet  been  achieved  on using  a  specific  technique.  However,  the 
most commonly utilised technique by the majority of cardiac surgeons is the antegrade 
delivery of cardioplegia in which the solution is administered into the aortic root and 
spreads  via  the  coronary  arteries  throughout  the  myocardium.  Current  clinical 
evidence  favours  the  safety  of  this  method,  although  the  presence  of  severely 
stenosed coronaries in patients with advanced CAD can limit the uniform distribution of 
the  cardioplegic  solution,  thereby  exposing  the  myocardial  areas  not  adequately 
reached by the solution to more severe ischemic injury during cardiac surgery (492). A 
proposed solution to this potential disadvantage is the retrograde route of delivery, 
with which cardioplegia is administered through the coronary sinus thereby relying on 
the  extensive  venous  network  of  the  heart  and  on  the  absence  of  atherosclerotic 
lesions  compromising  homogeneous  cardioplegia  distribution.  In  1898  Pratts 
introduced  the  concept  of  the  potential  to  “revive”  an  ischemic  myocardium  by 
supplying oxygenated blood through its venous system (493) and Blanco et al (486) in 
1956,  were  the  first  group  to  successfully  carry  out  a  retrograde  perfusion  of  the 
cardioplegia in the context of cardiac surgery: however, over the decades the concept   202 
of  retrograde  technique  has  not  become  a  widespread  practice  for  myocardial 
protection in cardiac surgery for various reasons:  
  the risk of vein rupture, which increases when the perfusion pressure into the 
coronary  sinus  is  higher  than  the  pressure  in  the  venous  system,  which  is 
between 30 and 40mmHg (494, 495); 
  the catheter used for the solution delivery can cause mechanical injury of the 
coronary sinus or even its rupture and more worryingly the laceration of the 
atrioventricular  groove  due  to  balloon  over-inflation  or  over-pressurised 
perfusion flow (496). This can be avoided by careful catheters inflation (496) 
and  slow  flow  rates  and  pressures,  which  however  are  associated  with 
significant ischaemic injury for the delay in arresting the heart when retrograde 
cardioplegia is used alone (497, 498);  
  the  presence  of  a  large  Thebesian  valve,  an  embryological  remnant  of  the 
sinoatrial valves located at the orifice of the coronary sinus, of which it covers 
more than 75%  (499), can potentially interfere with the uniform administration 
of cardioplegia retrogradely (500); 
  although  still  controversial,  retrograde  administration  of  cardioplegic  solution 
may  lead  to  inadequate  delivery  to  RV  and  posterior  septum,  which  can 
potentially expose the latter to more severe ischaemic injury (501). 
 
The  combined  use  of  antegrade  and  retrograde  techniques  is  potentially  able  to 
overcome the limitations presented by the two technique individually and to improve 
myocardial preservation in patients undergoing cardiac surgery: the outcomes of our 
retrospective  study  are  strongly  suggestive  of  this  as  they  provide  an  objective 
evidence  of  a  significant  reduction  of  the  total  hsTnT  release  over  the  72  post-  203 
operative  hours.  This  is  therefore  in  contrast  with  the  majority  of  previous  studies 
which  however  have  used  the  two  techniques  separately  and  not  in  combination: 
Menasche et al (481) first showed that cardiac outputs and RV-LV stroke indices were 
similar in patients receiving antegrade or cardioplegia during AVR. They then went on 
to retrospectively analyse clinical outcomes in a large cohort of patients undergoing 
either AVR alone or CABG plus AVR surgery and receiving retrograde cardioplegia 
only,  thereby  with  no  antegrade  cardioplegia  group  for  direct  comparison  (502): 
documented complications rate was 0.6% in a total of 500 patients, with an overall 
mortality  incidence  of  1.6%,  which  they  found  were  similar  to  those  of  previously 
documented literature on antegrade cardioplegia only (502). 
    A further larger retrospective study was then conducted (503) on 1280 patients 
undergoing CABG surgery and/or valve repair/replacement and receiving antegrade 
cardioplegia followed by retrograde cardioplegia with shorter (less than 120 minutes) 
or longer aortic cross-clamping times (more than 120 minutes): crucially, despite a 
significantly higher number of combined CABG/AVR operations and reoperations in 
the  long  cross-clamp  group,  hospital  mortality  rates  were  similar  between  the  two 
groups, although inotropic requirement, CK and CK-MB levels and hospital stay were 
lower in the short cross-clamp group. This importantly demonstrated that operations 
involving longer cross-times with antegrade followed by retrograde cardioplegia were 
equally  safe  than  similar  operations  with  shorter  ischaemic  times,  in  contrast  with 
previous  literature,  which  associated  longer  ischaemic  times  with  worse  patients’ 
morbidity and mortality (504, 505). 
    Subsequently,  in  a  small  study  on  20  patients  undergoing  CABG  surgery 
randomised  to  either  antegrade  or  retrograde  cardioplegia  (506),  Kaukoranta  et  al 
showed  that  oxygen  extraction,  lactate  production,  adenosine  catabolites  analised   204 
from myocardial biopsies of both ventricles, were higher in the RV of subjects of the 
retrograde  group,  which  conversely,  had  higher  total  TnT  and  CK-MB  release.  
Therefore they concluded that retrograde mild hypothermic blood cardioplegia leads to 
metabolic  changes  compatible  with  RV  ischemia,  albeit  with  preserved  associated 
levels of high-energy phosphates, and uneventful postoperative course, and that this 
technique  would  need  careful  consideration  particularly  in  patients  with  RV 
hypertrophy or dysfunction if used alone.  
    Crucially, in a study similar to ours involving 120 patients undergoing elective 
fist-time CABG surgery and comparing  outcomes of subjects receiving antegrade cold 
blood  cardioplegia  with  those  having  the  combined  technique  (484),  despite 
significantly  longer  infusion  times  in  the  antegrade/retrograde  cohort,  postoperative 
cardiac output, ECG changes, cardiac biomarkers, temporary pacing requirement and 
30-day morbidity were similar in both groups. Similarly, in a RCT enrolling 87 patients 
undergoing CABG surgery  (490), subjects receiving the combined technique had a 
16.5%  decrease  of  inotropic  requirement,  compared  to  those  having  antegrade 
cardioplegia only, although no difference was found in terms of patients’ morbidity and 
mortality.  
    In our retrospective analysis we found no significant benefit of any of the study 
secondary  endpoints  amongst  the  three  groups  and  similarly  to  the  work  from 
Radhemhr and colleagues, we intended to directly compare biochemical and clinical 
outcomes between patients receiving antegrade cardioplegia alone and the combined 
technique of antegrade/retrograde cardioplegia. In addition to this and for the first time 
in the literature, we also intended to compare these findings with those from patients 
receiving  ICCF.  In addition,  we  measured hsTnT  concentrations  at  6  different time 
points for all patients and calculated the total release with the 72-hours hsTnT AUC.   205 
There is no study in our knowledge, that combines the following four factors including 
aortic  cross-clamping  times,  combined  versus  antegrade  cardioplegia  alone  versus 
ICCF,  hsTnT  levels  at  6  different  time-points  with  consequent  total  AUC  and 
exclusively CABG patients. Furthermore, although increased cross-clamp times have 
been associated with worse PMI in cardiac surgery (484, 505), our study suggests that 
despite longer cross-clamp times, patients receiving combined antegrade/retrograde 
cardioplegia sustained less PMI compared to antegrade alone or ICCF alone, thereby 
indicating that the relationship between these two factors might be different and that 
cross-clamp  time  might  be  potentially  less  relevant  than  the  type  of  myocardial 
protection used, as previously found by Bar-El et al (503). This is potentially crucial in 
complex  cases  where  long  cross  clamp  times  are  anticipated  and/or  patients  are 
known to have poor LV function, for whom the best myocardial protection available 
would be warranted. 
Another  important  aspect  of  our  analysis  was  the  different  temperature 
employed between our two cardioplegia groups, with the antegrade method using cold 
blood and the combined technique using warm blood (see also chapter 1): the optimal 
temperature  of  cardioplegia  during  cardiac  surgery  is  another  crucial  element  of 
myocardial  protection  and  it  could  be  argued  that  the  lower  troponin  rise  in  the 
combined  group  may  be  partially  explained  by  the  temperature  difference.  Cold 
cardioplegia is able to attenuate myocardial oxygen demand and the risk of ischaemic 
damage but conversely may lead to the inhibition of myocardial enzymes leading to a 
stunning of the metabolic and functional recovery following surgery. However warm 
blood cardioplegia is thought to counteract this potential deleterious effect. In a meta-
analysis (507) involving 8814 patients randomised to either warm or cold cardioplegia 
predominantly in the setting of CABG surgery, no significant difference was found in   206 
all-cause mortality or incidence of MI, IABP use, stroke, low-output syndromes and 
post-operative  AF  between  the  two  groups  and  postoperative  cardiac  index  was 
significantly improved in the warm blood cardioplegia group. Similarly, no difference 
was found in mortality, peri-operative MI, stroke or inotrope requirement between cold 
and tepid cardioplegia (508). 
Our retrospective study has several limitations. The cohort population was small 
and  additionally  patients  in  group  3  were  operated  on  by  one  consultant,  with  a 
subsequent  potential  bias.  Typically  in  a  study  of  this  type  strong  prognostic  and 
confounding  variables  would  be  adjusted  for,  however,  the  small  sample  size 
precluded  detailed  adjustment  and  we  therefore  acknowledge  that  some  residual 
confounding  bias  may  remain.  Finally,  we  have  not  adjusted  for  multiplicity  in  our 
analysis  and  there  is  a  possibility  that  the  results  may  have  arisen  by  chance. 
Moreover,  our  study  suggests  a  significant  PMI  reduction  with  the  addition  of 
retrograde to antegrade cardioplegia, although we found no significant difference in 
any other outcome and therefore, whether the combined technique has an impact on 
patient morbidity and mortality is still unknown and will need to be verified in larger and 
adequately powered studies 
    In addition to this, we were also intrigued to know whether the application of our 
preconditioning stimulus  had a different impact based on the different technique of 
myocardial preservation, and particularly based on the administration of cold blood 
antegrade  cardioplegia  versus  warm  antegrade/retrograde  cardioplegia:  amongst 
preconditioned CABG patients, 27 received antegrade cardioplegia, 14 ICCF and 16 
antegrade/retrograde cardioplegia (Table 4.1). We found that only the application of 
RIPC  in  the  context  of  ICCF  significantly  reduced  hsTnT  release,  whereas  PMI 
magnitude  in  control  and  preconditioned  patients  undergoing  antegrade/retrograde   207 
cardioplegia was essentially similar. This therefore suggests that the protective effect 
of RIPC might not be significant in patients receiving this technique and this could well 
be related to either the relatively small PMI magnitude achieved in these subjects or to 
the relatively small level of additional benefit provided by limb IR. Once again it is 
important to emphasise that the current study was not powered for this type of analysis 
and  therefore  findings  arising  from  here  should  be  taken  with  very  careful 
consideration:  only large randomised RCTs will be able to further clarify firstly the role 
of antegrade/retrograde cardioplegia in myocardial protection in patients undergoing 
cardiac surgery, and secondly whether the combination of RIPC with this technique 
might be able to provide further beneficial effects on PMI and clinical outcomes. In this 
regard, our ERICCA trial, although not originally powered for this evaluation as the 
above findings were only obtained following ERICCA initiation, will hopefully be able to 
further clarify these crucial aspects. 
   
   
 
Table 4.6. Total AUC in patients undergoing elective CABG surgery with antegrade/retrograde 
cardioplegia, antegrade cardioplegia or ICCF 
 
Technique of myocardial preservation 
Intervention (n) 
 
CABG 
 
Control 
(mean (SD)) 
RIPC 
(mean (SD)) 
Difference 
(95% CI) 
P value 
Antegrade Cardioplegia 
Control: n=28 
RIPC: n=27 
 
34.30 (20.35) 
 
28.19 (13.55) 
 
6.11 (-3.33, 15.55) 
 
0.200 
Antegrade/retrograde Cardioplegia 
Control: n=10 
RIPC: n=16 
 
17.76 (7.54) 
 
17.88 (9.34) 
 
-0.12 (-7.37, 7.12) 
 
0.973 
Intermittent cross-clamp fibrillation 
Control: n=16 
RIPC: n=11 
 
32.88 (18.77) 
 
20.69 (6.04) 
 
12.19 (0.66, 
24.32) 
 
0.049 
CABG=coronary artery bypass graft; CI=confidence interval; RIPC=remote ischaemic preconditioning 
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CHAPTER 5 
 
 
5. Effect of multi-limb RIPC on cardioprotection in patients 
undergoing cardiac bypass surgery using GTN 
 
 
 
5.1. Introduction 
We have so far demonstrated that an enhanced preconditioning stimulus reduces PMI 
in  an  unselected  cohort  of  patients  undergoing  elective  cardiac  surgery  and 
irrespective of the technique of myocardial preservation, and in patients having CABG 
with  or  without  valve  surgery.  During  these  analyses,  we  found  no  significant 
difference  in baseline  and  surgical  parameters  between preconditioned  and  control 
patients in the vast majority of cases.  However, we identified in the  peri-operative 
administration of iv GTN one of the most important variables with different frequency 
between the intervention groups (Table  5.1): GTN is a nitrate functioning as a NO 
donor  and  is  widely  used  in  the  context  of  cardiac  surgery  and  particularly  CABG 
surgery  in  order  to  achieve  effective  and  rapid  BP  control  and  ensure  coronary 
vasodilatation, thereby improving intra-operative coronary perfusion and maintaining 
graft patency post-operatively (509). NO has been demonstrated to interfere with IPC 
and RIPC in experimental studies, however its role in the clinical setting is yet to be 
clarified (510-521). We have therefore conducted a further retrospective analysis in 
order  to  determine  whether  the  intra-operative  use  of  GTN  has  an  impact  on  the 
protective effects of RIPC on PMI in patients undergoing cardiac surgery.    209 
Table 5.1. Total AUC reduction and GTN use in different subgroup analyses 
Operation  Control 
 
RIPC 
 
AUC 
P value 
GTN given  
P value 
   
AUC (μg/L) 
(mean (sd)) 
 
GTN given  
(N, %) 
 
AUC μg/L) 
(mean (sd)) 
 
GTN given  
(N, %) 
   
All cardiac surgery  36.307 (24.542)  65/89 (73%)  27.004 (16.523)  53/89 (60%)  0.004  0.035 
All cardiac surgery 
Cardioplegia 
 
37.089 (25.730) 
 
51/73 (70%) 
 
27.942 (17.386) 
 
41/75 (55%)  0.014  0.037 
All cardiac surgery 
Cross-clamp fibrillation 
32.885 (18.771)  14/16 (88%)  20.692 (6.039)  12/14 (86%)  0.049  0.886 
CABG+/-valve surgery  33.526 (20.164)  51/64 (80%)  24.772 (12.640)  47/66 (71%)  0.004  0.140 
CABG alone  30.753 (18.948)  46/54 (85%)  23.609 (12.004)  41/57 (72%)  0.022  0.045 
CABG alone 
Cardioplegia 
29.832 (19.206)  32/38 (84%)  24.355 (13.052)  29/43 (67%)  0.147  0.053 
CABG/AVR  48.22 (21.01)  5/10 (50%)  31.75 (14.82)  6/9 (67%)  0.068  0.629 
Valve surgery alone  43.925 (33.144)  14/25 (56%)  33.395 (23.719)  6/23 (26%)  0.229  0.450 
AVR  38.499 (37.661)  7/15 (47%) 
 
27.947 (24.678) 
 
2/14 (14%) 
 
0.402 
 
0.060 
MV surgery  53.246 (25.406)  6/9 (67%)  44.902 (19.314)  3/8 (38%) 
 
0.472 
 
0.229 
AUC=area-under-the-curve; RIPC=remote ischaemic preconditioning; GTN=glyceryl trinitrate; sd=standard 
deviation; CABG=coronary artery bypass graft; AVR=aortic valve replacement; MV=mitral valve. 
 
 
 
5.2. Results 
    Of the 178 patients included in our principal study, 3 were excluded from this 
sub-group analysis as there was no clear documentation in their medical notes on 
whether iv GTN had been used during surgery: of the remaining 175 subjects, 118 
received GTN intra-operatively and were randomised to control (n=65) or RIPC (n=53),   210 
56 only patients were not administered GTN, of which 21 received the sham protocol 
and 35 the RIPC protocol (Table 5.1). Amongst patients receiving GTN we found no 
statistically significant difference of baseline characteristics between control and RIPC 
subjects, whereas in the group not receiving GTN preconditioned patients presented a 
lower NYHA status and incidence of hypercholesterolemia (Table 5.2).  
    Additionally,  there  was  no  statistically  significant  difference  of  surgical 
procedure parameters between control and preconditioned patients in either the GTN 
or no-GTN groups (Table 5.3). Additive EuroSCORE and use of anaesthetic regimes 
were comparable between groups although subjects not receiving GTN had a lower 
proportion  of  patients  undergoing  CABG  alone  and  a  higher  proportion  of  patients 
undergoing AVR compared to subjects receiving GTN (Table 5.3). 
    In the GTN group, mean hsTnT concentrations were lower in preconditioned 
patients at all the post-operative time-points (Table  5.4,  Fig.  5.1), however, with a 
statistical  significance  only  at  72  hours:  RIPC  reduced  total  AUC  from 
30.81ﾱ17.56μg/L  to  26.69ﾱ13.93μg/L  [4.12;  CI  -1.92,  10.17;  p=0.179],  which 
corresponded  to  only  a  non-significant  reduction  of  13%  (Table  5.4,  Fig.  5.3). 
Conversely, in patients not administered GTN, the RIPC group had significantly lower 
mean hsTnT levels at all the post-operative time-points and a decreased total AUC 
from 50.52ﾱ34.20 μg/L to 27.86±20.01 μg/L, which corresponded to a very significant 
reduction of 45% [22.66; CI 8.03, 37.29; p=0.003] (Table 5.4, Figs. 5.2, 5.4).  
    With regards to secondary endpoints, the use of combined GTN and RIPC was 
associated  with  a  significantly  improved  urine  output  at  24  and  72  hours  post-
operatively  and  as  a  total  amount  over  the  three  days  post-surgery,  whereas  no 
significant difference was found in the remaining end-points (Table 5.5). 
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Table 5.2. Baseline characteristics of patients in GTN and No-GTN groups 
Patients  GTN  
(mean (SD)) 
No-GTN 
(mean (SD)) 
Control   
(n=65) 
RIPC  
(n=53) 
P value  Control   
(n=21) 
RIPC  
(n=35) 
P value 
Age 
Gender 
Male 
Female 
 
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
Chinese 
 
BMI  
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
 
Smoking History 
Smoker 
Ex-smoker 
Non-smoker 
 
Family History of IHD 
 
NYHA Class 
CCS Class 
 
LVEF 
>50% 
30%-50% 
<30% 
 
Co-morbidities 
Diabetes Mellitus 
Hypertension 
Hypercholesterolemia 
Atrial Fibrillation 
Previous MI 
Previous PCI 
Previous CVA/TIA 
Previous Cardiac Surgery 
Other comorbidities 
Peripheral Arterial Disease 
 
Drug History 
Aspirin   
Clopidogrel/Prasugrel 
Warfarin  
Beta-blocker 
Calcium Channel Blocker 
Statin 
ACE-I/ARB  
Long acting nitrates 
Antidiabetics 
Insulin 
Biguanide 
Sulphonylurea 
Diuretics 
66±9 
 
48 (73.8%) 
17 (26.2%) 
 
 
54 (83.1%) 
8 (12.3%) 
2 (3.1%) 
1 (1.5%) 
 
28.5±5.3 
128.32±18.2 
70.3±9.0 
69.8±11.9 
 
 
8 (12.3%) 
39 (60.0%) 
18 (27.7%) 
 
45 (69.2%) 
 
2.61±0.9 
2.19±1.14 
 
 
47 (72.3%) 
16 (24.6%) 
2 (3.0%) 
 
 
19 (29.2%) 
50 (76.9%) 
50 (76.9%) 
13 (20.0%) 
19 (29.2%) 
9 (13.8%) 
8 (12.3%) 
2 (3.0%) 
6 (9.4%) 
3 (4.6%) 
 
 
48 (76.2%) 
23 (60.0%) 
9 (14.2%) 
44 (69.9%) 
23 (60.0%) 
54 (84.7%) 
41 (65.1%) 
14 (19.0%) 
 
6 (9.5%) 
2 (3.2%) 
8 (12.7%) 
20 (31.7%) 
64±10 
 
46 (86.8%) 
7 (13.2%) 
 
 
41 (77.4%) 
9 (17.0%) 
3 (5.7%) 
0 (0.0%) 
 
29.5±8.3 
131.1±16.0 
71.56±8.96 
66.5±10.1 
 
 
9 (17.0%) 
27 (50.9%) 
17 (32.1%) 
 
38 (71.7%) 
 
2.56±0.76 
2.46±1.07 
 
 
39 (73.6%) 
9 (17.0%) 
5 (9.4%) 
 
 
18 (34.0%) 
36 (67.9%) 
37 (69.8%) 
7 (13.2%) 
20 (37.7%) 
7 (13.2%) 
3 (5.7%) 
1 (1.9%) 
1 (1.9%) 
0 (0.0%) 
 
 
46 (90.2%) 
18 (36.0%) 
2 (3.9%) 
35 (68.6%) 
7 (21.6%) 
43 (84.3%) 
31 (60.8%) 
9 (17.6%) 
 
5 (9.8%) 
2 (3.9%) 
4 (7.8%) 
19 (37.3%) 
0.473 
0.108 
 
 
 
0.607 
 
 
 
 
 
0.457 
0.392 
0.441 
0.108 
 
0.589 
 
 
 
 
0.841 
 
0.749 
0.210 
 
0.247 
 
 
 
 
 
0.690 
0.188 
0.407 
0.303 
0.432 
1.000 
0.657 
0.794 
0.245 
0.251 
 
 
0.148 
0.355 
0.052 
0.662 
0.179 
0.394 
0.914 
0.423 
 
0.631 
0.930 
0.635 
0.769 
68±12 
 
17 (81.0%) 
4 (19.0%) 
 
 
17 (81.0%) 
2 (9.5%) 
2 (9.5%) 
0 (0.0%) 
 
28.6±6.2 
135.1±18.2 
72.2±9.7 
68.5±11.0 
 
 
2 (9.5%) 
13 (61.9%) 
6 (28.6%) 
 
11 (52.4%) 
 
3.24±0.6 
2.10±1.09 
 
 
20 (95.2%) 
1 (4.8%) 
0 (0.0%) 
 
 
5 (23.8%) 
17 (81.0%) 
12 (57.1%) 
4 (19.0%) 
4 (19.0%) 
2 (9.5%) 
1 (4.8%) 
0 (0.0%) 
6 (28.6%) 
3 (14.3%) 
 
 
16 (76.2%) 
2 (9.2%) 
0 (0.0%) 
10 (47.6%) 
8 (38.1%) 
15 (71.4%) 
14 (66.7%) 
0 (0.0%) 
 
1 (4.8%) 
1 (3.2%) 
1 (4.8%) 
6 (28.6%) 
65±11 
 
26 (74.3%) 
9 (25.7%) 
 
 
29 (77.4%) 
3 (8.6%) 
3 (8.6%) 
0 (0.0%) 
 
27.8±4.7 
126.1±15.0 
69.9±10.14 
65.8±9.4 
 
 
2 (5.7%) 
13 (37.1%) 
20 (57.1%) 
 
6 (74.3%) 
 
2.56±0.76 
2.18±1.11 
 
 
27 (77.1%) 
7 (20.0%) 
1 (1.9%) 
 
 
10 (28.6%) 
29 (82.9%) 
31 (88.6%) 
5 (14.3%) 
8 (22.9%) 
8 (22.9%) 
2 (5.7%) 
1 (1.9%) 
3 (8.1%) 
1 (2.9%) 
 
 
25 (66.0%) 
6 (17.6%) 
1 (2.9%) 
22 (64.7%) 
11 (32.4%) 
28 (82.4%) 
23 (67.6%) 
3 (8.8%) 
 
3 (8.8%) 
3 (8.8%) 
2 (5.9%) 
11 (32.40%) 
0.255 
0.747 
 
 
 
0.984 
 
 
 
 
 
0.615 
0.052 
0.393 
0.336 
 
0.740 
 
 
 
 
0.145 
 
0.001 
0.792 
 
0.197 
 
 
 
 
 
0.764 
1.000 
0.010 
0.715 
0.432 
1.000 
1.000 
0.794 
0.386 
0.143 
 
 
0.578 
0.182 
0.264 
0.266 
0.186 
0.394 
0.239 
0.371 
 
1.000 
0.812 
1.000 
0.611 
RIPC=Remote  Ischemic  Preconditioning;  NYHA=New  York  Health  Association;  CCS=Canadian 
Cardiovascular  Society;  MI=Myocardial  infarction;  PCI=Percutaneous  coronary  intervention;  CVA= 
Cerebrovascular accident; TIA=Transient ischemic attack; ACE-I=Angiotensin-converting enzyme-inhibitor; 
ARB=Angiotensin receptor blocker; LVEF=left ventricular ejection fraction. 
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Table 5.3. Details of surgical procedure of patients in GTN and No-GTN groups 
 
RIPC=Remote  Ischemic  Preconditioning;  CABG=Coronary  artery  bypass  graft;  AVR=Aortic  valve 
replacement. 
 
 
Patients  GTN   No-GTN 
Control  
(n=65) 
RIPC  
(n=53) 
P value  Control   
(n=21) 
RIPC  
(n=35) 
P value 
Indication for Surgery 
Angina 
MI 
Valve Disease  
Angina and Valve Disease 
MI and Valve Disease  
SBE 
 
EuroSCORE 
 
Additive perioperative risk 
Low (EuroSCORE 0-2) 
Medium (EuroSCORE 3-5) 
High (EuroSCORE >5) 
 
Bypass-time (min)  
 
Cross-clamp time (min)  
 
Cardioprotection 
Blood cardioplegia 
Cross-clamp fibrillation 
 
 
Number of grafts 
Zero 
One  
Two  
Three  
Four 
 
Operation 
CABG 
CABG/AVR 
AVR 
MV surgery 
AVR/MVR 
 
Anesthetic agents 
Induction 
Anti-nicotinic agents 
Rocuronium 
Pancuronium 
Vecuronium 
Midazolam 
Etomidate 
Fentanyl 
Propofol 
 
Maintenance  
Propofol 
Volatile Anesthetics 
Isoflurane 
Sevoflurane 
 
35 (53.8%) 
11 (16.9%) 
13 (20.0%) 
6 (9.2%) 
0 (0.0%) 
 
 
3.54±1.79 
 
 
20 (30.8%) 
14 (55.4%) 
9 (13.8%) 
 
103.76±29.95 
 
63.52±27.38 
 
 
51 (78.5%) 
14 (21.5%) 
 
 
 
14 (21.5%) 
2 (3.1%) 
15 (23.1%) 
23 (35.4%) 
11 (16.9%) 
 
 
46 (70.8%) 
5 (7.7%) 
12 (18.5%) 
6 (9.2%) 
1 (1.5%) 
 
 
 
 
48 (80.0%) 
10 (16.7%) 
2 (3.3%) 
34 (56.7%) 
7 (11.3%) 
63 (100%) 
56 (90.3%) 
 
 
63 (100%) 
 
57 (91.9%) 
5 (8.1%) 
 
27 (50.9%) 
14 26.4%) 
5 (9.4%) 
2 (3.8%) 
1 (1.9%) 
 
 
3.49±2.67 
 
 
18 (34.0%) 
23 (43.4%) 
12 (22.6%) 
 
88.32±31.99 
 
59.46±19.28 
 
 
41 (77.4%) 
12 (22.6%) 
 
 
 
6 (11.3%) 
4 (7.5%) 
10 (18.9%) 
25 (47.2%) 
8 (15.1%) 
 
 
41 (77.4%) 
6 (11.3%) 
8 (15.1%) 
3 (5.7%) 
1 (1.9%) 
 
 
 
 
45 (90.0%) 
4 (8.0%) 
1 (2.0%) 
22 (44.0%) 
6 (12.0%) 
54 (100%) 
43 (86.0%) 
 
 
54 (100%) 
 
48 (96.0%) 
2 (4.0%) 
0.206 
 
 
 
 
 
 
 
0.908 
 
0.333 
 
 
 
 
0.176 
 
0.357 
 
0.645 
 
 
 
 
0.374 
 
 
 
 
 
 
0.304 
 
 
 
 
 
 
 
 
0.544 
 
 
 
0.250 
1.000 
1.000 
0.559 
 
 
1.000 
0.458 
 
 
 
 
6 (28.6.8%) 
1 (4.8%) 
10 (47.6%) 
0 (0.0%) 
1 (4.8%) 
 
 
4.52±2.54 
 
 
5 (23.8%) 
9 (42.9%) 
7 (33.3%) 
 
103.76±29.95 
 
65.85±23.04 
 
 
19 (90.5%) 
2 (9.5%) 
 
 
 
11 (52.4%) 
2 (9.5%) 
4 (19.0%) 
4 (19.0%) 
0 (0.0%) 
 
 
6 (28.6%) 
4 (19.0%) 
12 (57.1%) 
3 (9.2%) 
0 (0.0%) 
 
 
 
 
17 (81.0%) 
4 (19.0%) 
0 (0.0%) 
11 (52.4%) 
1 (4.8%) 
21 (100%) 
17 (81.0%) 
 
 
21 (100%) 
 
21 (100%) 
0 (0.0%) 
 
12 (34.3%) 
5 (14.3%) 
18 (51.4%) 
0 (0.0%) 
0 (0.0%) 
 
 
4.00±2.50 
 
 
10 (28.6%) 
15 (43.4%) 
10 (28.6%) 
 
88.32±31.99 
 
65.14±35.59 
 
 
33 (94.3%) 
2 (5.7%) 
 
 
 
17 (48.6%) 
1 (2.9%) 
4 (11.4%) 
10 (28.6%) 
3 (8.6%) 
 
 
15 (42.9%) 
3 (8.6%) 
15 (42.9%) 
5 (14.3%) 
0 (0.0%) 
 
 
 
 
30 (88.2%) 
2 (5.9%) 
2 (5.9%) 
11 (22.4%) 
1 (2.9%) 
34 (100%) 
33 (97.1%) 
 
 
34 (100%) 
 
32 (94.1%) 
2 (5.9%) 
0.159 
 
 
 
 
 
 
 
0.454 
 
0.901 
 
 
 
 
0.704 
 
0.937 
 
0.626 
 
 
 
 
0.415 
 
 
 
 
 
 
0.386 
 
 
 
 
 
 
 
 
0.185 
 
 
 
0.166 
1.000 
1.000 
0.064 
 
 
1.000 
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Table 5.4. Mean hsTnT and AUC in patients in GTN and no-GTN groups 
Endpoint  GTN  
intra-operatively 
Control 
GTN: n=65 
No-GTN: n=53 
(mean (sd)) 
RIPC (n=53) 
GTN: n=21 
No-GTN: n=35 
(mean (sd)) 
Difference 
(95% CI) 
P value 
 
hsTnT (μg/L) 
Pre- operatively  GTN   0.015 (0.015)  0.018 (0.023)  -0.002 (-0.009, 0.004)  0.510 
  No-GTN   0.027 (0.027)  0.011 (0.015)  0.016 (0.005, 0.027)  0.018 
6 hours post-
operatively 
GTN   0.750 (0.487)  0.635 (0.319)  0.114 (-0.039, 0.268)  0.129 
  No-GTN   0.905 (0.468)  0.591 (0.464)  0.312 (0.055, 0.570)  0.018 
12 hours post-
operatively 
GTN   0.627 (0.395)  0.578 (0.371)  0.050 (-0.091, 0.190)  0.485 
  No-GTN   0.905 (0.447)  0.533 (0.389)  0.372 (0.114, 0.144)  0.002 
24 hours post-
operatively 
GTN   0.454 (0.265)  0.401 (0.239)  0.054 (-0.039, 0.147)  0.254 
  No-GTN   0.745 (0.446)  0.320 (0.317)  0.320 (0.093, 0.546)  0.007 
48 hours post-
operatively 
GTN   0.358 (0.214)  0.296 (0.168)  0.061 (-0.011, 0.133)  0.096 
  No-GTN   0.701 (0.678)  0.327 (0.249)  0.374 (0.056, 0.693)  0.023 
72 hours post-
operatively 
GTN   0.350 (0.300)  0.250 (0.165)  0.100 (0.007, 0.194)  0.036 
  No-GTN   0.552 (0.436)  0.321 (0.281)  0.231 (0.037, 0.424)  0.020 
Total 72 hours AUC  GTN   30.81 (17.56)  26.69 (13.93)  4.12 (-1.92, 10.17)  0.179 
  No-GTN   50.52 (34.20)  27.86 (20.01)  22.66 (8.03, 37.29)  0.003 
RIPC=Remote ischemic preconditioning;  SD=standard deviation; CI=confidence interval; hsTnT=high 
sensitivity Troponin T; AUC= area-under-the-curve; GTN=glyceryl trinitrate 
 
 
 
 
 
 
In patients not receiving GTN, interestingly RIPC led to a significantly lower incidence 
of post-operative AKI with 4 new cases vs 14 new cases in the control group and 
therefore to a reduction of 71% of cases (p=0.042) (Table 5.6): remarkably, 5 deaths 
occurred  in  the  sham  group  and  none  in  the  RIPC  group  and  this  was  close  to 
statistical  significance  (p=0.061).  We  did  not  attempt  to  conduct  further  subgroup 
analyses within the GTN and no-GTN groups with regards to type of operation and/or 
technique of myocardial preservation, as this would have led to small sample size with 
therefore unreliable tests results.   214 
Fig. 5.1. Mean high-sensitivity Troponin T levels at 0, 6, 12, 24, 48 and 72 hours in the GTN group 
(mean±SEM*)   
 
RIPC=remote ischaemic preconditioning; hsTnT=high sensitivity troponin-T; SEM=standard error of the 
mean. * Unpaired Student T-Test 
 
 
 
Fig. 5.2. Mean high-sensitivity Troponin T levels at 0, 6, 12, 24, 48 and 72 hours in the No-GTN 
group (mean±SEM*)   
 
RIPC=remote ischaemic preconditioning; hsTnT=high sensitivity troponin-T; SEM=standard error of the 
mean. *p<0.05 (unpaired Student T-Test) 
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Fig. 5.3. Total Area under the Curve of high-sensitivity Troponin T in patients in GTN and No-
GTN groups (mean±SEM)    
 
RIPC=remote ischaemic preconditioning; AUC=area under the curve; SEM=standard error of the mean 
*Unpaired Student T-Test 
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Table 5.5. Summary of major secondary endpoints in the GTN group* 
Endpoint  Control (n=65) 
(mean (sd)) 
RIPC (n=53) 
(mean (sd)) 
Difference 
(95% CI) 
P value 
CK (μg/L) 
Total AUC  33021.79 (23496.79)  37912.06 (27494.08)  -4890.27 (-16877.14, 7096.60)  0.419 
Creatinine (mg/ml) 
Pre-operatively  86.97 (19.12)  88.04 (29.37)  -1.07 (-9.96, 7.82)  0.812 
24 hours post-operatively  91.71 (27.08)  88.74 (25.87)  2.97 (-6.76, 12.70)  0.546 
48 hours post-operatively  102.89 (46.11)  93.00 (38.29)  9.82 (-5.79, 25.57)  0.214 
72 hours post-operatively  99.25 (52.97)  92.04 (40.35)  7.21 (-10.29, 24.70)  0.416 
Urine Output (ml) 
24 hours post-operatively  1900.3 (633.6)  2207.7 (691.9)  -307.46 (-560.4, 554.5)  0.018 
48 hours post-operatively  2169.2 (908.2)  2333.9 (861.6)  -164.8 (-528.2, 198.6)  0.370 
72 hours post-operatively  1922.1 (801.5)  2490.3 (900.1)  -568.2 (-977.1, -159.3)  0.007 
Total  5790.2 (1834.5)  6706.4 (1618.3)  -916.2 (-1745.9, -86.4)  0.031 
AKI score 
0  16  30     
1  3  2     
2  2  2     
3  0  1     
Acute Kidney Injury  5  5    0.476 
Inotrope score 
Post bypass  7.09 (14.46)  6.99 (16.45)  0.094 (-5.67, 5.86)  0.974 
24 hours post-operatively  11.26 (22.13)  10.74 (18.14)  0.514 (-7.16, 8.19)  0.895 
48 hours post-operatively    7.40 (18.10)  6.74 (16.15)  6.53 (-5.85, 7.16)  0.843 
72 hours post-operatively  4.08 (14.92)  2.43  (10.56)  1.65 (-3.30, 6.59)  0.510 
Total  30.28 (61.45)  25.70 (46.63)  4.59 (-16.23, 25.40)  0.663 
New onset AF  3  3    0.661 
Length of ICU stay (days)  2.0 (2.0-4.0)**  2.0 (1.0-4.0)**    0.256*** 
Length of hospital stay (days)  9.0 (7.0-13.0)**  8.0 (6.0-9.0)**    0.068*** 
Clinical outcomes at six weeks 
Death  0  0    1.000 
Myocardial infarction  0  0    1.000 
Stroke  0  1    0.417 
Revascularization  0  0    1.000 
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Table 5.6. Summary of major secondary endpoints in the No-GTN group* 
Endpoint  Control (n=21) 
(mean (sd)) 
RIPC (n=35) 
(mean (sd)) 
Difference 
(95% CI) 
P value 
CK (μg/L) 
Total AUC  32194.11 (102249.05)  34616.80 (27434.32)  -2422.69 (-13605.14, 8759.90)  0.664 
Creatinine (mg/ml) 
Pre-operatively  87.38 (22.23)  83.49 (24.14)  3.90 (-9.08, 16.87)  0.550 
24 hours post-operatively  97.76 (38.74)  86.57 (28.73)  11.19 (-6.95, 29.34)  0.222 
48 hours post-operatively  110.33 (59.93)  91.17 (39.78)  19.16 (-7.53, 45.87)  0.156 
72 hours post-operatively  102.90 (54.60)  90.91 (47.63)  11.99 (-15.86, 39.84)  0.392 
Urine Output (ml) 
24 hours post-operatively  2226.9 (1039.7)  2116.3 (517.9)  110.60 (-316.3, 537.5)  0.605 
48 hours post-operatively  2075.6 (994.9)  2373.2 (843.6)  -297.6 (-823.8, 228.5)  0.261 
72 hours post-operatively  2318.5 (1022.2)  2479.7 (739.7)  -161.2 (-868.7, 546.3)  0.604 
Total  5988.5 (1578.8)  6706.4 (1559.9)  -718.9 (-1875.1, 437.4)  0.214 
AKI score 
0  51  49     
1  8  4     
2  3  0     
3  3  0     
Acute Kidney Injury  14  4    0.042 
Inotrope score 
Post bypass  5.72 (10.92)  6.60 (13.52)  -0.856 (-7.87, 6.16)  0.808 
24 hours post-operatively  12.55 (18.05)  7.42 (13.86)  5.12 (-3.54, 13.79)  0.241 
48 hours post-operatively    11.83 (22.28)  3.68 (10.28)  8.16 (-0.70, 17.02)  0.127 
72 hours post-operatively  10.25 (21.37)  0.54  (2.26)  9.71 (-0.04, 19.47)  0.051 
Total  39.80 (52.85)  18.12 (34.97)  21.68 (-4.83, 48.20)  0.105 
New onset AF  18  7    0.071 
Length of ICU stay (days)  3.0 (2.0-5.0)**  2.0 (1.0-3.0)**    0.767*** 
Length of hospital stay (days)  8.5 (7.0-11.5)**  8.0 (6.0-10.5)**    0.485*** 
Clinical outcomes at six weeks 
Death  5  0    0.061 
Myocardial infarction  1  0    0.643 
Stroke  0  0    1.000 
Revascularization  0  0    1.000 
*List of abbreviations 
RIPC=Remote  ischemic  preconditioning;  CK=Creatinine  Kinase;  AKI=Acute  Kidney  Injury;  AF=atrial 
fibrillation; ICU=Intensive Care Unit; AUC=Area-under-the-curve 
**Results shown as median (inter-quartile range); *** P-value for Mann-Whitney-Wilcoxon test 
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5.3. Discussion 
    With this subgroup analysis we have demonstrated that the application of our 
enhanced  preconditioning  stimulus,  in  the  absence  of  intra-operative  GTN 
administration, leads to a significant reduction of the mean hsTnT release at all the 
specified time-points and more importantly of the total hsTnT release over the 3 post-
operative days, with a 45% reduction of AUC, compared to control patients who did 
not  received  nitrates  during  cardiac  surgery.  Conversely,  in  patients  administered 
GTN,  we  found  no  statistically  significant  difference  of  the  72  hours  hsTnT  AUC 
between  the  two  intervention  groups.  This  extremely  intriguing  finding  suggests  a 
potential involvement of NO donors in the RIPC mechanisms and particularly that the 
beneficial  effects  induced  by  RIPC  could  be  inhibited  by  the  administration  of  NO 
donors.  
It is well established that NO improves LV function and oxygen demand/supply 
ratio  at  low  concentration  in  short-term  hibernating  myocardium  (510),  whereas  it 
triggers inflammation and reduces LV systolic function at high concentration (512). NO 
has been demonstrated to play a major role in the initiation of the late phase of IPC 
(511, 513, 514): in particular, in conscious rabbits subjected to 30-minute coronary 
occlusion and 3 days of reperfusion, iv administration of nitroglycerin reduced infarct 
size when it was delivered 1 hour prior to occlusion but also interestingly when the 
interval  between  nitroglycerin  infusion  and  occlusion  was  extended  to  24  and  72 
hours, thereby indicating a potent late preconditioning effect (515). Preclinical studies 
demonstrated  that  endothelial  NO-synthase  (eNOS)  is  a  potent  trigger  of  delayed 
preconditioning  whilst  inducible  NO-synthase  (iNOS)  functions  as  a  mediator  of 
delayed  preconditioning  (516):  iNOS  overexpression  has  been  associated  with 
inhibition of mPTP opening (517) and additionally NO has also been found to be a   219 
potent  mediator of  IPost  (518).  More  recently,  pre-treatment  with  the  NO-donor S-
nitroso-N-acetylpenicillamine or nerve transection have been demonstrated to abolish 
the cardioprotective effect of intra-arterial adenosine and RIPC in rabbits (519).  
Within  the  clinical  setting,  in  a  post-hoc  analysis  examining  the  late 
preconditioning mimetic effects of nitroglycerin on PMI in patients undergoing PCI for 
single obstructive CAD (520), no significant difference in PMI was found in patients 
receiving nitroglycerin prior to preconditioning and PCI. Interestingly, in the study by 
Wagner  and  colleagues  (295),  there  was  a  small,  significant  increase  in  iNOS 
expression after CPB in the control group, whereas no significant difference was found 
before or after CPB in eNOS concentration in the same group or iNOS or eNOS levels 
in  the  RIPC  or  tramadol  patients.  Crucially,  in  a  context  very  similar  to  our  study, 
Kleinbongard and colleagues (521) found that the administration of nitroglycerin after 
induction  of  anaesthesia  did  not  impact  on  final  PMI  magnitude  in  either 
preconditioned or control patients. In addition, in the largest proof-of-concept study on 
RIPC  in  cardiac  surgery  at  the  time  of  our  recruitment  (286),  patients  routinely 
received iv GTN administration in the peri-operative period, which however, has not 
always been clearly documented in similar works.  
Whether our potentially crucial finding might give an explanation to the failure to 
observe  RIPC  cardioprotection  in  these  RTCs  is  clearly  difficult  to  establish  but 
nevertheless it offers an important suggestion for future studies: this is therefore the 
first analysis to demonstrate a significant impact of iv nitrates in patients undergoing 
elective cardiac surgery.  
Furthermore,  our  control  GTN-subgroup  sustained  39%  less  PMI  than  the 
control no-GTN subgroup, with a total AUC of 30.81ﾱ17.56 μg/L versus 50.52ﾱ34.20 
μg/L [-19.70; CI -35.79, 3.61; p=0.019] (Table 5.7, Fig. 5.5). Amongst RIPC patients,   220 
we found no significant difference in total AUC between GTN and no-GTN subjects, 
with AUCs of 26.69ﾱ13.93 μg/L and 27.86ﾱ20.01 μg/L respectively [-1.17; CI -8.53, 
6.19;  p=0.753]  (Table  5.7,  Fig.  5.5).  There  are  two  potential  explanations  to  our 
findings: 
1.  the beneficial effects of RIPC on PMI are inhibited by GTN, and therefore  RIPC 
may not be able to elicit cardioprotection in the presence of concomitant iv GTN 
administration ; 
2.  GTN is able to enhance cardioprotection and the additional protection provided 
by RIPC may not be significant. 
 
 
Fig. 5.4. Total AUC in control and RIPC patients in GTN and No-GTN groups (mean±SEM)   
 
GTN=glycerine  trinitrate,  AUC=area-under-the-curve;  RIPC=remote  ischaemic  preconditioning; 
SEM=standard error of the mean. * Unpaired Student T-Test 
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Table 5.7. Major details of surgery and total AUC in patients undergoing elective cardiac surgery 
in GTN and No-GTN groups 
 
Parameters 
 
GTN  
Control: n=65 
RIPC: n=53 
(mean (sd)) 
 
No-GTN  
Control: n=21 
RIPC: n=35 
(mean (sd)) 
 
Difference 
(95% CI) 
 
P value 
 
EuroSCORE  Sham 
RIPC 
3.54 (1.79) 
3.49 (2.68) 
4.52 (2.54) 
4.00 (2.50) 
-0.99 (-2.21, 0.24) 
-0.51 (-1.64, 0.620) 
0.111 
0.372 
Cardio-pulmonary bypass time  Sham 
RIPC 
95.84 (33.08) 
88.98 (20.37) 
95.57 (30.20) 
91.51 (42.56) 
0.270 (-15.97, 16.51) 
-2.53 (-16.09, 11.02) 
0.974 
0.745 
Cross-clamp time  Sham 
RIPC 
63.52 (27.38) 
59.46 (19.25) 
65.85 (23.04) 
65.14 (35.59) 
-2.33 (-15.85, 11.18) 
-5.90 (-5.68, 6.06) 
0.732 
0.392 
AUC  Sham 
RIPC 
30.81 (17.56) 
26.69 (13.93) 
50.52 (34.20) 
27.86 (20.01) 
-19.70 (-35.79, 3.61) 
-1.17 (-8.53, 6.19) 
0.019 
0.753 
GTN=glycerine trinitrate, CI=confidence interval; sd=standard deviation; AUC=area-under-the-curve 
 
 
 
 
 
    In addition, we have found an extremely intriguing association between total 
hsTnT release and GTN use between preconditioned and control patients in the vast 
majority of cases. Crucially, we observed a significantly higher use of intra-operative 
GTN in control patients undergoing cardiac surgery, cardiac surgery with cardioplegia 
and CABG surgery alone (p=0.035, 0.037 and 0.045 respectively), which conversely 
corresponded to a significantly lower PMI in preconditioned patients (p=0.004, 0.014 
and  0.022  respectively)  (Table  5.7).    Interestingly,  in  patients  undergoing  CABG 
surgery alone with cardioplegia, CABG plus AVR, all valve surgery alone, AVR alone 
and MV surgery alone, where there was no statistically significant difference between 
control and RIPC subjects with regards to GTN administration (p=0.053, 0.629, 0.450, 
0.060 and 0.229 respectively), we also found no statistically significant difference in 
total  hsTnT  AUC  (p=0.147,  0.068,  0.229,  0.402  and  0.472  respectively).  Only  in   222 
patients receiving ICCF or undergoing CABG ±valve surgery, we found a discrepancy 
between a non-significant difference of GTN use (p=0.886 and 0.140 respectively) and 
a significant PMI reduction in RIPC subjects (p=0.049 and 0.004 respectively).  
    Moreover, whilst in GTN-administered patients the incidence of AKI and new AF 
onset was identical between preconditioned and control groups, in the no-GTN group 
RIPC reduced AKI incidence by 71% with 14 new cases in the control group and 4 
new cases in the RIPC group (p=0.041): this represents the first evidence that our 
enhanced  preconditioning  stimulus  achieved  significant  reno-protection  in  patients 
undergoing cardiac surgery. Whether GTN plays an important role in reducing renal 
IRI is difficult to establish at this stage but certainly we provide an intriguing suggestion 
for future studies in this field.  
    Nevertheless it is also important to note that whilst the number of patients was 
sufficiently  high  in  the  GTN  group  (65  control  and  53  preconditioned),  with  no 
significant hsTnT reduction found, the sample size was considerably lower in the no-
GTN group (21 control and 35 preconditioned) where both mean hsTnT and AUC were 
significantly reduced by RIPC, and therefore it is possible that once again the cohort 
size might have had an impact on the final outcomes. 
    In conclusion, it will be essential to confirm whether GTN and NO have a major 
impact on myocardial and renal injury in the context of cardiac surgery, and whether 
RIPC-cardio  and  reno-protection  are  attenuated  with  the  concomitant  GTN 
administration  in  a  suitably  powered  prospective  RCT  trial,  for  which  we  strongly 
believe that our subgroup analysis has given a crucial suggestion. 
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CHAPTER 6 
 
 
6. Effects of multi-limb RIPC on cardioprotection in diabetic 
and non-diabetic patients undergoing cardiac surgery  
 
 
6.1. Introduction: DM and IHD 
DM is the most potent cardiovascular risk factor with devastating multi-system 
effects (522): 381 million people in the world had DM which also caused 4.6 million 
deaths in 2011, with a projected prevalence of almost double by 2030 (523), due to a 
rapidly  increasing  incidence  in  the  developing  world,  particularly in  Asia  and  Africa 
(523, 524): 90% of subjects with DM have Type 2 DM with the remaining 10% being 
affected by Type 1 DM (523). Macrovascular disease, including CAD, stroke and PVD 
occurs in 20% of patients with Type 2 DM and is responsible for 59% of death in these 
subjects (525): in particular, patients with type 2 DM without previous MI have been 
observed to have the same risk of sustaining an MI than non-diabetic subjects with 
previous  MI  (526),  with  increased  rates  of  subsequent  LV  failure,  re-infarction  and 
death (527-529). Crucially, compared to non-diabetics, diabetic subjects have higher 
incidence of multi-vessel CAD (527) and worse clinical outcomes following coronary 
revascularization, with increased rates of in-stent restenosis in subjects undergoing 
PCI (530, 531) and higher short and long-term mortality in those undergoing CABG 
(532, 533).  
  It is therefore clear that DM represents one of the most important challenges of 
healthcare systems in the UK and the world and that, whilst a crucial component of   224 
these patients’ management is an aggressive glycaemic control and prevention of both 
acute  and  chronic  complications,  new  protective  strategies  are  required  in  diabetic 
patients undergoing revascularisation in order to improve their morbidity and mortality. 
 
 
6.2. DM, IRI and IPC: where we stand 
Animal  studies  have  showed  that  the  diabetic  myocardium  may  have  an 
increased resistance to IRI compared to the non-diabetic heart, although significant 
differences  in  results  have  been  obtained  from  different  animal  models  and  with 
different techniques of diabetes induction (534-543).  Whilst this was initially attributed 
to the acute pharmacological induction of type 1 diabetes in rats, mice, dogs or rabbits 
through the administration of pancreato-toxic substances including stretozotocin and 
alloxan (534-543), in contrast with the human model of chronic type 2 diabetes (544), 
further  experimental  studies  have  however  confirmed  reduced  IRI  also  in  animal 
models of type 2 DM, such as Goto-Kakizaki and Zucker fatty rats (545). The majority 
of these studies also suggested the possibility of reduced resistance to IRI in animals 
with  a  longer  history  of  DM  (534,  535).    Similarly,  IPC  has  been  demonstrated  to 
reduce IRI in animal models of acute type 1 diabetes, however interestingly this effect 
was lessened in rats which had been diabetic for a few weeks (540). Crucially, in the 
first animal model of type 2 DM (545), the authors confirmed that chronically diabetic 
rats sustained less IRI, however they failed to demonstrate reduced myocardial injury 
by IPC in these models. In a seminal study, our group (440) showed that one or two 
cycles of IPC were effective in control Wistar rats but not in diabetic Goto-Kakizaki 
rats, which could only be protected by increasing the stimulus to three cycles. This 
was therefore the first demonstration that diabetic myocardium requires an increased   225 
preconditioning  stimulus  and  that  the  threshold  required  for  this  stimulus  to  be 
protective was higher in diabetic hearts than in non-diabetic hearts. Importantly, the 
deficient  phosphorylation  (but  not  the  total  amount)  of  Akt  in  diabetic  rats  was 
identified  as  the  potential  reason  for  the  discrepancy  between  diabetic  and  non-
diabetic myocardium in response to different IPC stimuli intensity, although it could not 
be clarified whether this could be related to a specific alteration of Akt or whether the 
potential  defect  resided  upstream.  However,  subsequently,  reduced  Akt 
phosphorylation in diabetic hearts aws found to be secondary to increased levels of 
phosphatase  and  tensin  homologue  on  chromosome  10  (PTEN),  which  negatively 
regulates PI3-K/Akt pathway (546).  
Human  studies  of  the  cardioprotective  effects  of  IPC  in  diabetes  have 
particularly  focussed  on  the  analysis  of  recovery  of  atrial  trabecular  contractility  in 
response to an IPC stimulus. Following the concept of an increased preconditioning 
threshold in the diabetic heart, our group demonstrated that human atrial trabeculae 
isolated from diabetic patients undergoing CABG surgery recovered a more significant 
contractile  function  when  subjected  to  prolonged  hypoxic  preconditioning  (547).  In 
addition,  lower  levels  of  phosphorylated  Akt  were  found  in  diabetic  myocardium 
thereby confirming outcomes of experimental studies. Subsequently, Hassouna and 
colleagues (548) demonstrated that mitochondrial dysfunction could represent a key 
pathophysiological factor in  diabetic  myocardium  by  proving  that mito-KATP  channel 
opener diazoxide could not protect the diabetic trabeculae, likely due to the lack of 
mitochondrial  membrane  depolarisation  and  ROS  production,  and  that 
cardioprotection could be re-established with the addition of PKC and p38 activators 
and superoxide donors, thereby suggesting that these factors are downstream of mito-
KATP channel.    226 
Based on the intriguing results of animal and human studies, we conducted a 
further retrospective subgroup analysis to evaluate the effects of an enhanced RIPC 
stimulus on PMI and short-term clinical outcomes in diabetic and non-diabetic patients 
undergoing elective cardiac surgery: in the first instance we will evaluate results in the 
context  of  unselected  cardiac  surgery  to  then  continue  our  journey  through  the 
different techniques of myocardial preservation and ultimately focus our attention onto 
CABG surgery with cardioplegia. We did not conduct any further subgroup analysis 
due to the relatively small sample size.  Once again, it is crucial to highlight that our 
study  was  not  powered  for  this  type  of  analysis  and  therefore  it  will  be  more 
appropriate to consider these findings as suggestive of potential effects of RIPC on 
diabetics.  
 
 
 
 
 
6.3. Effects of multi-limb RIPC on cardioprotection in diabetic and 
non-diabetic patients undergoing unselected cardiac surgery 
 
We  found  52  subjects  with  a  pre-operative  diagnosis  of  DM,  of  whom  24 
randomised to control and 28 to RIPC (Table 6.1).  Of the remaining 126 non-diabetic 
patients, 65 received the sham protocol and 61 the preconditioning protocol. We found 
no  statistical  significant  differences  in  either  these  subgroups  in  terms  of  baseline 
characteristics or surgical parameters (Tables 6.1-6.2). 
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Table  6.1.  Patient  baseline  characteristics  in  diabetic  and  non-diabetic  patients  undergoing 
unselected cardiac surgery 
Patients  Diabetics  Non-diabetics 
Control   
(n=24) 
RIPC   
(n=28) 
P value  Control   
(n=65) 
RIPC   
(n=61) 
P value 
Age (years) 
Gender 
Male 
Female 
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
Chinese 
 
BMI  
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
Smoking History 
Smoker 
Ex-smoker 
Non-smoker 
Family History of IHD 
 
NYHA Class 
CCS Class  
LVEF 
>50% 
30%-50% 
<30% 
 
Co-morbidities 
Hypertension 
Hypercholesterolemia 
Atrial Fibrillation 
Previous MI 
Previous PCI 
Previous CVA/TIA 
Previous Cardiac Surgery 
Other comorbidities 
Peripheral  Arterial 
Disease 
 
Drug History 
Aspirin   
Clopidogrel/Prasugrel 
Warfarin  
Beta-blocker 
Calcium Channel Blocker 
Statin 
ACE-I/ARB  
Long acting nitrates 
Antidiabetics 
Insulin 
Biguanide 
Sulphonylurea 
 
Diuretics 
65±8 
 
18 (75.0%) 
6 (25.0%) 
 
19 (79.2%) 
3 (12.5%) 
1 (4.2%) 
1 (4.2%) 
 
29.6±6.6 
133.2±20 
72.9±10.3 
73.5±11.9 
 
4 (16.7%) 
14 (58.3%) 
6 (16.7%) 
16 (66.7%) 
 
2.86±0.8 
2.45±1.2 
 
17 (70.8%) 
5 (20.8%) 
2 (8.3%) 
 
 
19 (79.2%) 
19 (79.2%) 
3 (12.5%) 
4 (16.7%) 
5 (20.8%) 
2 (8.4%) 
1 (4.2%) 
8 (34.7%) 
2 (8.3%) 
 
 
17 (77.3%) 
6 (27.3%) 
2 (9.1%) 
15 (68.1%) 
10 (45.5%) 
19 (86.1% 
17 (74.9%) 
8  (36.3%) 
 
 
7 (31.8%) 
16 (72.7%) 
11 (50%) 
 
7 (31.8%) 
65±10 
 
25 (89.3%) 
3 (10.7%) 
 
17 (60.7%) 
9 (32.1%) 
2 (7.1%) 
0 (0%) 
 
29.6±5.4 
128.8±14.7 
69.7±7.5 
66.2±9.0 
 
1 (3.6%) 
17 (60.7%) 
10 (35.7%) 
23 (82.1%) 
 
2.63±0.7 
2.70±1.1 
 
19 (67.9%) 
6 (21.4%) 
3 (10.7%) 
 
 
25 (89.3%) 
25 (89.3%) 
2 (7.1%) 
1 (39.3%) 
6 (21.4%) 
1 (3.6%) 
2 (7.1%) 
11 (39.3%) 
1 (3.6%) 
 
 
24 (85.7%) 
10 (35.7%) 
2 (7.1%) 
21 (75%) 
7 (25.0%) 
25 (89.2%) 
21 (75%) 
5 (17.9%) 
 
 
8 (28.6%) 
16 (57.1%) 
6 (21.4%) 
 
13 (46.4%) 
0.981 
0.272 
 
 
0.245 
 
 
 
 
 
0.986 
0.371 
0.205 
0.0.17 
0.247 
 
 
 
0.220 
 
0.287 
0.458 
0.954 
 
 
 
 
 
0.447 
0.608 
0.652 
0.124 
1.000 
0.546 
1.000 
0.920 
0.590 
 
 
0.489 
0.559 
0.127 
0.426 
0.098 
0.096 
0.797 
0.241 
 
 
0.522 
0.522 
0.060 
 
0.512 
66±10 
 
49 (75.4%) 
16 (24.6%) 
 
55 (84.6%) 
7 (10.8%) 
3 (4.6%) 
0 (0%) 
 
28.0±4.9 
128.8±17.5 
69.9±8.5 
67.7±11.3 
 
8 (12.3%) 
38 (58.5%) 
25 (29.3%) 
41 (63.1%) 
 
2.75±0.9 
2.13±1.1 
 
53 (81.5%) 
12 (18.5%) 
0 (0.0%) 
 
 
51 (78.5%) 
45 (69.2%) 
13 (20.0%) 
19 (29.2%) 
6 (9.2%) 
7 (10.8%) 
1 (1.5%) 
6 (9.2%) 
4 (6.2%) 
 
 
49 (75.4%) 
21 (32.3%) 
7 (10.8%) 
40 (61.5%) 
22 (33.8%) 
53 (81.5%) 
44 (67.7%) 
6 (9.2%) 
 
 
 
 
 
 
20 (30.8%) 
64±10 
 
47 (77.0%) 
14 (23%) 
 
54 (88.5%) 
3 (4.9%) 
4 (6.6%) 
0 (0%) 
 
28.4±7.8 
129.1±16.3 
71.3± 
66.3±10.2 
 
10 (16.4%) 
31 (50.8%) 
30 (32.8%) 
41 (67.2%) 
 
2.48±0.8 
2.17±1.0 
 
48 (78.7%) 
10 (16.4%) 
3 (4.9%) 
 
 
40 (65.6%) 
43 (70.5%) 
8 (13.1%) 
17 (27.9%) 
5 (8.2%) 
4 (6.6%) 
2 (3.2%) 
2 (3.3%) 
0 (0.0%) 
 
 
48 (83.8%) 
14 (24.1%) 
4 (6.9%) 
36 (62.1%) 
15 (25.9%) 
47 (81.0%) 
35 (60.3%) 
7 (12.1%) 
 
 
 
 
 
 
18 (31.0%) 
0.208 
0.826 
 
 
0.443 
 
 
 
 
 
0.735 
0.937 
0.417 
0.477 
0.626 
 
 
 
 
0.335 
0.099 
0.807 
0.192 
 
 
 
 
 
0.116 
0.878 
0.497 
0.866 
0.837 
0.062 
0.584 
0.384 
0.120 
 
 
0.606 
0.158 
0.308 
0.952 
0.448 
0.211 
0.383 
0.467 
 
 
 
 
 
 
0.600 
RIPC=Remote  Ischemic  Preconditioning;  NYHA=New  York  Health  Association;  CCS=Canadian 
Cardiovascular  Society;  MI=Myocardial  infarction;  PCI=Percutaneous  coronary  intervention; 
CVA=Cerebrovascular accident; TIA=Transient ischemic attack; ACE-I=Angiotensin-converting enzyme-
inhibitor; ARB=Angiotensin receptor blocker; LVEF=left ventricular ejection fraction. 
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Table  6.2.  Details  of  surgical  procedure  in  diabetic  and  non-diabetic  patients  undergoing 
unselected cardiac surgery 
Patients  Diabetics  Non-diabetics 
         Control 
(n=24) 
RIPC 
      (n=28) 
P  
value 
Control   
(n=65) 
  RIPC   
(n=61) 
  P 
value 
Indication for Surgery 
Angina 
Myocardial Infarction 
Valve Disease 
Angina and Valve Disease 
MI and Valve Disease 
Infective Endocarditis 
 
EuroSCORE 
 
Additive perioperative risk 
Low (EuroSCORE 0-2) 
Medium (EuroSCORE 3-5) 
High (EuroSCORE >5) 
 
Bypass-time (min)  
 
Cross-clamp time (min)  
 
Cardioprotection 
Blood cardioplegia 
Cross-clamp fibrillation 
 
Operation 
CABG alone 
AVR alone 
CABG+AVR  
MVR or MV Repair         
AVR+MVR 
 
Number of grafts 
One  
Two  
Three  
Four 
 
Anesthetic agents 
Induction 
Anti-nicotinic agents 
Rocuronium 
Pancuronium 
Vecuronium 
Midazolam 
Etomidate 
Fentanyl 
Propofol 
 
Maintenance  
Propofol 
Volatile Anesthetics 
Isoflurane 
Sevoflurane 
 
Intra-operative GTN  
 
17 (70.8%) 
0 (0.0%) 
4 (16.7%) 
7 (7.9%) 
2 (8.3%) 
2 (2.2%) 
 
3.21±1.87 
 
 
26 (29.2%) 
47 (52.8%) 
16 (18%) 
 
101.50±27.75 
 
63.4±23.1 
 
 
18 (75.0%) 
6 (25.0%) 
 
 
17 (70.8%) 
2 (8.3%) 
4 (16.7%) 
1 (4.2%) 
0 (0.0%) 
 
 
1 (4.2%) 
8 (33.3%) 
7 (29.2%) 
5 (20.8%) 
 
 
 
 
18 (81.8%) 
3 (13.6%) 
2 (2.4%) 
9 (40.9%) 
0 (0.0%) 
24 (100%) 
20 (90.9%) 
 
 
24 (100%) 
 
20 (90.9%) 
2 (9.1%) 
 
19 (79.2%) 
 
         14 (50.0%) 
6 (21.4%) 
23 (25.8%) 
4 (14.3%) 
2 (7.1%) 
1 (1.1%) 
 
4.00±3.31 
 
 
29 (32.6%) 
38 (42.7%) 
22 (24.7%) 
 
91.85±29.12 
 
65.0±25.5 
 
 
23 (82.1%) 
5 (17.9%) 
 
 
19 (67.9%) 
2 (7.1%) 
5 (17.9%) 
1 (3.6%) 
1 (3.6%) 
 
 
3 (10.7%) 
5 (17.9%) 
13 (46.4%) 
3 (10.7%) 
 
 
 
 
23 (85.2%) 
3 (11.1%) 
3 (3.6%) 
12 (44.4%) 
3 (11.1%) 
28 (100%) 
24 (88.9%) 
 
 
28 (100%) 
 
25 (92.6%) 
2 (7.4%) 
 
18 (64.3%) 
0.174 
 
 
 
 
 
 
 
0.304 
 
0.356 
 
 
 
 
0.245 
 
0.826 
 
 
0.073 
 
 
0.922 
 
 
 
 
 
 
0.427 
 
 
 
 
 
 
0.992 
 
 
 
 
0.804 
0.805 
1.000 
0.816 
 
 
1.000 
0.830 
 
 
 
0.238 
 
 
27 (41.5%) 
12 (18.5%) 
19 (29.2%) 
5 (7.7%) 
0 (0.0%) 
2 (3.1%) 
 
3.91±2.07 
 
 
26 (29.2%) 
47 (52.8%) 
16 (18%) 
 
95.1±34.2 
 
65.2±25.6 
 
 
55 (84.6%) 
16 (18.0%) 
 
 
37 (56.9%) 
13 (20.0%) 
6 (9.2%) 
8 (12.3%) 
1 (1.5%) 
 
 
3 (4.6%) 
11 (16.9%) 
22 (33.8%) 
7 (10.8%) 
 
 
 
 
50 (80.6%) 
11 (17.7%) 
1 (1.6%) 
36 (58.1%) 
8 (12.5%) 
65 (100%) 
56 (87.5%) 
 
 
65 (100%) 
 
60 (93.8%) 
4 (6.3%) 
 
46 (74.2%) 
 
26 (42.6%) 
13 (21.3%) 
19 (31.1%) 
2 (3.3%) 
0 (0.0%) 
1 (1.6%) 
 
3.56±2.2 
 
 
29 (32.6%) 
38 (42.7%) 
22 (24.7%) 
 
88.7±32.0 
 
59.9±25.6 
 
 
52 (85.2%) 
14 (15.9%) 
 
 
38 (62.3%) 
12 (19.7%) 
4 (6.6%) 
7 (11.5%) 
0 (0.0%) 
 
 
2 (3.3%) 
10 (16.4%) 
22 (36.1%) 
8 (13.1%) 
 
 
 
 
53 (91.4%) 
3 (5.2%) 
2 (3.4%) 
21 (36.2%) 
4 (6.9%) 
61 (100%) 
53 (91.4%) 
 
 
61 (100%) 
 
56 (96.6%) 
2 (3.4%) 
 
35 (58.3%) 
0.817 
 
 
 
 
 
 
 
0.359 
 
0.356 
 
 
 
 
0.360 
 
0.286 
 
 
0.828 
0.842 
 
0.845 
 
 
 
 
 
 
0.982 
 
 
 
 
 
 
0.152 
 
 
 
 
0.019 
0.299 
1.000 
0.566 
 
 
1.000 
0.527 
 
 
 
0.840 
RIPC=  Remote  Ischemic  Preconditioning;  CABG=  Coronary  artery  bypass  graft;  AVR=Aortic  valve 
replacement; MVR= Mitral valve replacement; MV= Mitral valve; MI=myocardial infarction. 
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In the diabetic groups, preconditioned patients had lower mean hsTnT levels at all the 
specified time points, however this reached statistically significance only at 72 hours 
post-operatively  (Fig.  6.1,  Table  6.3).  Similarly  RIPC  reduced  total  AUC  from 
35.993ﾱ21.859  μg/L  to  25.927±20.031  μg/L,  which  failed  to  reach  statistical 
significance [10.07; CI -1.844; 21.00; p=0.096] (Fig. 6.2, Table 6.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.3. High-sensitivity Troponin-T release pre-operatively and at 6, 12, 24, 48 and 72 hours 
post-operatively in diabetic and non-diabetic patients undergoing unselected cardiac surgery 
Endpoint  Control 
DM: n=24 
Non-DM: n=65 
(mean (sd)) 
RIPC 
DM: n=28 
Non-DM: n=61 
(mean (sd)) 
Difference 
(95% CI) 
P value 
 
hsTnT (μg/L) 
Pre-operatively 
 
DM 
No-DM 
0.021 (0.023)  0.018 (0.025)  0.003 (0.007, -0.011)  0.682 
0.017 (0.017)  0.013 (0.018)  0.003 (-0.003, -0.009)  0.275 
6 hours post-operatively 
 
DM 
No-DM 
0.761 (0.383)  0.600 (0.502)  0.161 (-.0.091, 0.413)  0.206 
0.817 (0.536)  0.620 (0.316)  0.197 (0.043, 0.352)  0.013 
12 hours post-operatively 
 
DM 
No-DM 
0.701 (0.325)  0.551 (0.394)  0.149 (0.101, -0.053)  0.145 
0.712 (0.475)  0.558 (0.371)  0.154 (0.004, 0.304)  0.044 
24 hours post-operatively 
 
DM 
No-DM 
0.517 (0.321)  0.413 (0.322)  0.104 (-0.075, 0.283)  0.248 
0.535 (0.351)  0.406 (0.242)  0.129 (0.022, 0.135)  0.018 
48 hours post-operatively 
 
DM 
No-DM 
0.440 (0.342)  0.294 (0.225)  0.146 (-0.015, 0.307)  0.075 
0.440 (0.432)  0.313 (0.193)  0.127 (0.007- 0.248)  0.035 
72 hours post-operatively 
 
DM 
No-DM 
0.451 (0.432)  0.227 (0209)  0.224 (0.033, 0.414)  0.022 
0.389 (0.314)  0.299 (0.223)  0.091 (-0.007, 0.188)  0.068 
Total 72 hours AUC 
 
DM 
No-DM 
35.993 (21.859)  25.927 (20.031)  10.07 (-1.844, 21.00)  0.096 
36.428 (25.673)  27.479 (14.899)  8.949 (1.423, 16.477)  0.020 
RIPC=Remote ischemic preconditioning;  SD=standard deviation; CI=confidence interval; hsTnT=high 
sensitivity Troponin-T 
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Fig.  6.1.  Mean  high-sensitivity  Troponin-T  levels  at  0,  6,  12,  24,  48  and  72  hours  in  diabetic 
patients undergoing unselected cardiac surgery (mean±SEM) 
 
RIPC=remote ischaemic preconditioning; hsTnT=high sensitivity troponin-T; SEM=standard error of the 
mean. *p<0.05 (unpaired Student T-Test) 
 
 
 
Fig. 6.2. Mean high-sensitivity Troponin-T levels at 0, 6, 12, 24, 48 and 72 hours in non-diabetic 
patients undergoing unselected cardiac surgery (mean±SEM) 
 
RIPC=remote ischaemic preconditioning; hsTnT=high sensitivity troponin-T; SEM=standard error of the 
mean. *p<0.05 (unpaired Student T-Test) 
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Conversely  and  similarly  to  our  general  cohort,  RIPC  significantly  reduced  mean 
hsTnT in non-diabetic patients at all the different time points and lessened total AUC 
from 36.428ﾱ25.673 μg/L to 27.479ﾱ14.899μg/L, which corresponded to a significant 
25% reduction [8.949; CI 1.423, 16.477; p=0.020] (Fig. 6.3, Table 6.3). 
We found no difference in secondary endpoints between control and preconditioned 
patients in either diabetic or diabetic subgroups (Tables 6.4-6.5).  
 
  
 
 
Fig. 6.3. Total AUC in control and RIPC diabetic and non-diabetic patients undergoing 
unselected cardiac surgery (mean±SEM)
 
RIPC=remote ischaemic preconditioning; SEM=standard error of the mean; AUC=area-under-the-curve 
*Unpaired Student T-Test 
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Table 6.4. Summary of major secondary endpoints in diabetic patients undergoing unselected 
cardiac surgery* 
Endpoint  Control (n=24) 
(mean (sd)) 
RIPC (n=28) 
(mean (sd)) 
Difference 
(95% CI) 
P 
value 
 
CK (μg/L) 
Total AUC  30650.65 (17259.69)  35084.74 (25290.42)  -4434.09 (-18850, 9982.36)  0.537 
 
Creatinine (mg/ml) 
Pre-operatively  92.67 (21.51)  96.14 (36.75)  -3.476 (-20.627, 13.674)  0.686 
24 hours post-operatively  97.79 (37.08)  96.48 (33.82)  1.310 (-18.635, 21.255)  0.896 
48 hours post-operatively  112.54 (47.45)  108.36 (53.28)  4.185 (-24.132, 32.501)  0.768 
72 hours post-operatively  112.25 (62.25)  106.93 (62.55)  5.321 (-29.55, 40.193)  0.760 
 
Urine Output (ml) 
24 hours post-operatively  1874.6 (667.2)  2171.4 (626.7)  -113.04 (-521.84, 295.755)  0.580 
48 hours post-operatively  2036.1 (876.9)  2351.8 (903.1)  -315.65 (-872.70, 241.400)  0.257 
72 hours post-operatively  1935.9 (1071.9)  2715.8 (883.4)  -779.89 (-1524.3, -35.44)  0.041 
Total  5571.9 (1650.6)  6722.4 (1413.2)  -1150.5 (-2317.6, 16.517)  0.058 
 
AKI score 
0  71  80    0.12 
1  8  5     
2  4  1     
3  3  0     
 
Acute Kidney Injury (total)  
 
2 
 
6 
   
0.208 
 
Inotrope score 
Post bypass  5.61 (12.57)  4.45 (9.63)  1.16 (-5.279, 7.592)  0.719 
24 hours post-operatively  9.04 (18.90)  8.38 (13.69)  0.661 (-8.808, 10.131)  0.893 
48 hours post-operatively  10.52 (22.53)  4.80 (12.87)  5.722 (-4.661, 16.105)  0.273 
72 hours post-operatively     8.55 (20.99)  0.57  (2.45)  7.981 (-0.196, 16.157)  0.098 
Total  33.83 (12.56)  18.08 (5.99)  15.75 (-10.37, 41.87)  0.231 
 
New onset AF 
 
7 
 
3 
   
0.157 
 
Length of ICU stay (days) 
 
3.0 (2.0-5.5)** 
 
2.0 (1.0-3.5)** 
   
0.567*** 
 
Length of hospital stay (days) 
 
9.0 (7.5-11.5)** 
 
8.0 (6.0-10.5)** 
   
0.784*** 
 
Clinical outcomes at six weeks 
Death  1  0    0.462 
Myocardial infarction  0  0    1.000 
Stroke  0  0    1.000 
Revascularization  0  0    1.000 
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Table  6.5.  Summary  of  major  secondary  endpoints  in  non-diabetic  patients  undergoing 
unselected cardiac surgery* 
Endpoint  Control (n=65) 
(mean (sd)) 
RIPC (n=61) 
(mean (sd)) 
Difference 
(95% CI) 
P 
value 
 
CK (μg/L) 
Total AUC  33290.79 (20455.04)  36984.57 (28928.43)  -3693.78 (-14327.34, 6939.78)  0.492 
 
Creatinine (mg/ml) 
Pre-operatively  84.9 (18.7)  81.4 (20.3)  3.56 (3.31, 10.43)  0.307 
24 hours post-operatively  90.35 (27.1)  83.8 (22.7)  6.62 (-2.21, 15.44)  0.140 
48 hours post-operatively  99.9 (49.9)  84.6 (26.8)  15.23 (1.18, 29.26)  0.034 
72 hours post-operatively  93.9 (48.2)  84.2 (27.9)  9.73 (-4.28, 23.74)  0.172 
 
Urine Output (ml) 
24 hours post-operatively  2030.1 (797.7)  2255.2 (571.6)  -225.13 (-481.13, 30.88)  0.084 
48 hours post-operatively  2181.4 (941.3)  2348.7 (829.9)  -167.26 (-515.57, 181.06)  0.343 
72 hours post-operatively  2057.7 (785.9)  2386.7 (801.8)  -329.00 (-696.93, 38.93)  0.079 
Total  5958.7 (1792.8)  6700.0 (1665.7)  -741.35 (-1543.36, 60.66)  0.069 
 
AKI score 
0  71  80    0.12 
1  8  5     
2  4  1     
3  3  0     
 
Acute Kidney Injury (total)  
 
3 
 
0 
   
0.236 
 
Inotrope score 
Post bypass  7.2 (13.9)  7.9 (17.2)  -0.69 (-6.32, 4.92)  0.806 
24 hours post-operatively  12.5 (21.7)  9.9 (17.8)  2.59 (-4.60, 9.79)  0.477 
48 hours post-operatively  7.7 (17.9)  5.9 (14.8)  1.88 (-4.11, 7.86)  0.536 
72 hours post-operatively  4.6 (15.2)  2.2 (9.9)  2.41 (-2.27, 7.09)  0.311 
Total  32.30 (59.69)  24.80 (46.68)  7.50 (-12.02, 27.02)  0.448 
 
New onset AF 
 
15 
 
7 
   
0.086 
 
Length of ICU stay (days) 
 
3.0 (2.0-4.0)** 
 
2.0 (1.0–4.0)** 
   
0.313*** 
 
Length of hospital stay (days) 
 
8.0 (7.0–12.0)** 
 
8.0 (6.0–10.0)** 
   
0.078*** 
 
Clinical outcomes at six weeks 
Death  1  0    0.331 
Myocardial infarction  1  0    0.331 
Stroke  0  2    0.214 
Revascularization  0  0    1.000 
*List of abbreviations.  
RIPC=Remote  ischemic  preconditioning;  CK=Creatinine  Kinase;  AKI=Acute  Kidney  Injury;  AF=atrial 
fibrillation;  ICU=Intensive  Care  Unit;  AUC=Area-under-the-curve.  **Results  shown  as  median  (inter-
quartile range); *** P-value for Mann-Whitney-Wilcoxon test   234 
6.4.  Effect  of  multi-limb  RIPC  on  cardioprotection  in  diabetic  and 
non-diabetic  patients  undergoing  unselected  cardiac  surgery  with 
cardioplegia  
 
In  our  main  cohort  analysis  we  found  that  RIPC  reduced  total  hsTnT  AUC 
irrespective  of  the  technique  of  myocardial  preservation.  Hence  we  intended  to 
establish  whether  the  protective  effects  of  our  enhanced  preconditioning  stimulus 
would  be  beneficial  to  diabetic  and/or  non-diabetic  subjects  undergoing  unselected 
cardiac  surgery  with  cardioplegia.  We  did  not  perform  subgroup  analysis  of  ICCF 
patients with or without DM due their small sample size.  
Diabetic patients were 18 and 23 in control and RIPC groups respectively and 
non-diabetic subjects were 23 and 52 respectively (Table 6.6). Preconditioned patients 
had a lower mean heart rate within the diabetic subgroup (64.8±8.5 versus 71.9±12.1; 
p=0.033) and a less significant pre-operative history of CVA within the non-diabetic 
subgroup  (3  versus  6  cases;  p=0.038)  (Table  6.6).  We  found  no  other  significant 
difference between control and RIPC patients in any of the subgroups with regards to 
other baseline or surgical parameters (Tables 6.6-6.7). 
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Table  6.6.  Baseline  characteristics  in  diabetic  and  non-diabetic  patients  undergoing  cardiac 
surgery with cardioplegia 
Patients  Diabetics  Non-diabetics 
Control   
(n=18) 
RIPC   
(n=23) 
P value  Control   
(n=55) 
RIPC   
(n=52) 
P value 
Age (years) 
Gender 
Male 
Female 
 
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
Chinese 
 
BMI  
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
 
Smoking History 
Smoker 
Ex-smoker 
Non-smoker 
 
Family History of IHD 
 
NYHA Class 
CCS Class  
 
LVEF 
>50% 
30%-50% 
<30% 
 
Co-morbidities 
Hypertension 
Hypercholesterolemia 
Atrial Fibrillation 
Previous MI 
Previous PCI 
Previous CVA/TIA 
Previous Cardiac Surgery 
Other comorbidities 
Peripheral Arterial Disease 
 
Drug History 
Aspirin   
Clopidogrel/Prasugrel 
Warfarin  
Beta-blocker 
Calcium Channel Blocker 
Statin 
ACE-I/ARB  
Long acting nitrates 
Antidiabetics 
Insulin 
Biguanide 
Sulphonylurea 
Diuretics 
65±7 
 
14 (77.8%) 
4 (22.2%) 
 
 
14 (77.8%) 
2 (11.1%) 
1 (5.6%) 
1 (5.6%) 
 
29.9±6.6 
133.6±19.4 
71.7±8.8 
71.9±12.1 
 
 
3 (16.7%) 
10 (55.6%) 
5 (27.8%) 
 
13 (72.2%) 
 
3.00±0.69 
2.44±1.2 
 
 
13 (72.2%) 
4 (22.2%) 
1 (5.6%) 
 
 
14 (77.8%) 
14 (77.8%) 
3 (16.7%) 
4 (22.2%) 
4 (22.2%) 
2 (11.2%) 
1 (5.6%) 
1 (5.6%) 
2 (11.2%) 
 
 
14 (77.8%) 
6 (33.3%) 
2 (11.1%) 
12 (66.7%) 
7 (38.9%) 
16 (81.4%) 
15 (65.5%) 
7 (38.9%) 
 
4 (22.2%) 
7 (38.9%) 
9 (50.0%) 
7 (38.9%) 
 
67±10 
 
20 (87.0%) 
3 (13.0%) 
 
 
13 (56.5%) 
8 (34.8%) 
2 (8.7%) 
0 (0%) 
 
29.1±5.4 
129.5±14.8 
70.7±7.5 
64.8±8.5 
 
 
0 (0%) 
13 (56.5%) 
10 (43.5%) 
 
18 (78.3%) 
 
2.73±0.70 
2.68±1.1 
 
 
15 (65.2%) 
5 (21.7%) 
3 (13.0%) 
 
 
20 (87.0%) 
20 (87.0%) 
1 (4.3%) 
9 (39.1%) 
5 (21.7%) 
1 (4.3%) 
2 (8.7%) 
2 (3.9%) 
1 (4.3%) 
 
 
19 (82.6%) 
8 (34.8%) 
1 (4.3%) 
16 (69.6%) 
6 (26.1%) 
20 (69.5%) 
31 (62.0%) 
5 (21.7%) 
 
5 (21.7%) 
12 (52.1%) 
6 (26.1%) 
10 (43.5%) 
 
0.517 
0.438 
 
 
 
0.219 
 
 
 
 
 
0.687 
0.447 
0.675 
0.033 
 
0.105 
 
 
 
 
0.655 
 
0.225 
0.532 
 
0.721 
 
 
 
 
 
0.438 
0.438 
0.187 
0.248 
0.970 
0.507 
0.702 
0.837 
0.905 
 
 
0.923 
0.184 
0.493 
0.136 
0.580 
0.191 
0.332 
0.566 
 
0.515 
0.689 
0.136 
0.418 
68±11 
 
41 (74.5%) 
14 (25.5%) 
 
 
47 (85.5%) 
6 (10.9%) 
2 (3.6%) 
0 (0%) 
 
27.4±5.0 
129.2±18.1 
69.7±8.7 
68.4±11.9 
 
 
5(9.1%) 
34 (61.8%) 
16 (29.1%) 
 
31 (56.4%) 
 
2.83±0.95 
2.07±1.1 
 
 
45 (81.8%) 
10 (18.2%) 
0 (0%) 
 
 
43 (78.2%) 
35 (63.6%) 
13 (23.6%) 
16 (29.1%) 
6 (10.9%) 
7 (12.4%) 
1 (1.8%) 
5 (9.1%) 
3 (5.5%) 
 
 
40 (72.7%) 
18 (32.7%) 
7 (12.7%) 
32 (58.2%) 
20 (36.3%) 
43 (78.2%) 
36 (65.5%) 
5 (9.1%) 
 
 
 
 
16 (29.1%) 
 
65±10 
 
38 (73.1%) 
14 (26.9%) 
 
 
45 (86.5%) 
3 (5.8%) 
4 (7.7%) 
0 (0%) 
 
28.5±8.4 
130.0±17.5 
71.3±10.7 
67.1±10.2 
 
 
9 (17.3%) 
29 (55.8%) 
14 (26.9%) 
 
36 (69.2%) 
 
2.52±0.79 
2.06±1.0 
 
 
42 (80.8%) 
8 (15.4%) 
2 (3.8%) 
 
 
36 (69.2%) 
36 (69.2%) 
8 (15.4%) 
24 (26.9%) 
3 (5.8%) 
4 (7.7%) 
2 (3.8%) 
2 (3.9%) 
0 (0.0%) 
 
 
40 (80.0%) 
10 (20.0%) 
4 (8.0%) 
29 (58.0%) 
14 (28.0%) 
40 (80.0%) 
31 (62.0%) 
5 (10.0%) 
 
 
 
 
16 (32.0%) 
 
0.160 
0.863 
 
 
 
0.443 
 
 
 
 
 
0.433 
0.918 
0.420 
0.545 
 
0.452 
 
 
 
 
0.169 
 
0.071 
0.948 
 
0.326 
 
 
 
 
 
0.292 
0.540 
0.484 
0.803 
0.038 
0.061 
0.586 
0.562 
0.088 
 
 
0.683 
0.160 
0.300 
0.985 
0.464 
0.191 
0.382 
0.566 
 
 
 
 
0.805 
RIPC=Remote  Ischemic  Preconditioning;  NYHA=New  York  Health  Association;  CCS=Canadian 
Cardiovascular  Society;  MI=Myocardial  infarction;  PCI=Percutaneous  coronary  intervention; 
CVA=Cerebrovascular accident; TIA=Transient ischemic attack; ACE-I=Angiotensin-converting enzyme-
inhibitor; ARB=Angiotensin receptor blocker; LVEF=left ventricular ejection fraction. 
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Table 6.7. Details of surgical procedure in diabetic and non-diabetic patients undergoing cardiac 
surgery with cardioplegia 
Patients  Diabetics  Non-diabetics 
     Control 
      (n=18) 
RIPC 
(n=23) 
P  
value 
Control   
(n=55) 
RIPC   
(n=52) 
P  
value 
Indication for Surgery 
Angina 
Myocardial Infarction 
Valve Disease 
Angina and Valve Disease 
MI and Valve Disease 
Infective Endocarditis 
 
EuroSCORE 
 
Additive perioperative risk 
Low (EuroSCORE 0-2) 
Medium (EuroSCORE 3-5) 
High (EuroSCORE >5) 
 
Bypass-time (min)  
 
Cross-clamp time (min)  
 
Number of grafts 
One  
Two  
Three  
Four 
 
Operation 
CABG alone 
AVR alone 
CABG+AVR  
MVR or MV Repair         
AVR+MVR 
 
Anesthetic agents 
Induction 
Anti-nicotinic agents 
Rocuronium 
Pancuronium 
Vecuronium 
Midazolam 
Etomidate 
Fentanyl 
Propofol 
 
Maintenance  
Propofol 
Volatile Anesthetics 
Isoflurane 
Sevoflurane 
 
Intra-operative GTN  
 
 
11 (61.1%) 
0 (0.0%) 
4 (22.2%) 
2 (11.1%) 
1 (5.6%) 
 
3.33±1.9 
 
 
7 (38.9%) 
9 (50.0%) 
2 (11.1%) 
 
102.44±28.71 
 
67.67±21.97 
 
 
3 (16.7%) 
1 (5.6%) 
7 (38.9%) 
4 (22.2%) 
3 (16.7%) 
 
11 (61.1%) 
2 (11.1%) 
4 (22.2%) 
1(5.6%) 
0 (0.0%) 
 
 
 
 
14 (77.8%) 
3 (16.7%) 
1 (5.6%) 
9 (50.0%) 
0 (0.0%) 
18 (100%) 
16 (88.9%) 
 
 
18 (100%) 
 
16 (88.9%) 
3 (5.6%) 
 
14 (77.8%) 
 
 
9 (39.1%) 
6 (26.1%) 
4 (17.4%) 
2 (8.7%) 
2 (8.7%) 
 
4.70±3.2 
 
 
5 (21.7%) 
9 (39.1%) 
9 (39.1%) 
 
96.55±30.07 
 
72.23±22.55 
 
 
4 (17.4%) 
3 (13.0%) 
4 (17.4%) 
9 (39.1%) 
3 (13.0%) 
 
14 (60.9%) 
2 (8.7%) 
5 (21.7%) 
1 (4.3%) 
1 (4.3%) 
 
 
 
 
19 (86.4%) 
2 (9.1%) 
1 (4.5%) 
9 (40.9%) 
3 (13.6%) 
23 (100%) 
19 (86.4%) 
 
 
23 (100%) 
 
21 (95.5%) 
1 (2.0%) 
 
13 (56.5%) 
 
0.198 
 
 
 
 
 
 
0.121 
 
0.120 
 
 
 
 
0.533 
 
0.524 
 
0.505 
 
 
 
 
 
0.928 
 
 
 
 
 
 
 
 
0.712 
 
 
 
0.565 
0.103 
1.000 
0.810 
 
 
1.00 
 
0.433 
0.346 
 
0.154 
 
 
 
20 (36.4%) 
9 (16.4%) 
19 (34.5%) 
5 (9.1%) 
2 (3.6%) 
 
4.15±2.04 
 
 
11 (20.0%) 
31 (56.4%) 
13 (23.6%) 
 
99.78±34.66 
 
71.52±25.33 
 
 
22 (40.0%) 
3 (5.5%) 
9 (16.4%) 
15 (27.3% 
6 (10.9%) 
 
27 (49.1%) 
13 (23.6%) 
6 (10.9%) 
7 (77.8%) 
2 (22.2%) 
 
 
 
 
42 (79.2%) 
10 (18.9%) 
1 (1.9%) 
29 (54.7%) 
6 (11.1%) 
54 (100%) 
48 (88.9%) 
 
 
54 (100%) 
 
51 (94.4%) 
3 (5.6%) 
 
37 (71.2%) 
 
 
19 (36.5%) 
11 (21.2%) 
19 (36.5%) 
2 (3.8%) 
1 (1.9%) 
 
3.73±2.14 
 
 
15 (28.8%) 
25 (48.11%) 
12 (23.1%) 
 
90.06±33.89 
 
64.06±27.73 
 
 
19 (36.5%) 
2 (3.8%) 
10 (19.2%) 
17 (32.7%) 
4 (7.7%) 
 
29 (55.8%) 
12 (23.1%) 
4 (7.7%) 
7 (87.5%) 
1 (12.5%) 
 
 
 
 
46 (92.0%) 
3 (6.0%) 
1 (2.0%) 
19 (38.0%) 
4 (8.0%) 
50 (100%) 
45 (90.0%) 
 
 
50 (100%) 
 
49 (98.0%) 
1 (2.0%) 
 
28 (54.9%) 
 
0.779 
 
 
 
 
 
 
0.308 
 
0.545 
 
 
 
 
0.146 
 
0.151 
 
0.923 
 
 
 
 
 
0.827 
 
 
 
 
 
 
 
 
0.224 
 
 
0.089 
0.591 
1.000 
0.854 
 
 
 
1.00 
 
0.274 
0.346 
 
0.087 
 
RIPC=Remote  Ischemic  Preconditioning;  CABG=Coronary  artery  bypass  graft;  AVR=Aortic  valve 
replacement; MVR=Mitral valve replacement; MV=Mitral valve; MI=myocardial infarction. 
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Diabetic preconditioned patients had lower mean hsTnT concentrations at all the time 
points  without  however  reaching  statistical  significance  (Fig.  6.4,  Table  6.8),  in 
contrast with the significantly lower hsTnT at 6, 24 hours post-operatively in the non-
diabetic  group  (Fig.  6.5,  Table  6.8).  RIPC  reduced  total  AUC  in  diabetics  from 
34.88±20.576 μg/L to 26.59±21.23 μg/L [7.51; CI 0.066, 21.029; p=0.216] and in non-
diabetics from 37.85±27.43 μg/L to 28.55±15.55 μg/L [9.30; CI 0.58, 18.02; p=0.037], 
which  corresponded  to  a  non-significant  reduction  of  24%  in  the  former  and  a 
significant decrease of 25% in the latter (Fig. 6.6, Table 6.8). 
 
 
 
 
 
Table 6.8. Mean high-sensitivity Troponin-T pre-operatively and at 6, 12, 24, 48 and 72 hours 
post-operatively in diabetic and non-diabetic patients undergoing unselected cardiac surgery 
with cardioplegia 
Endpoint  Control  
DM: n=18 
Non-DM: n=55 
(mean (sd)) 
RIPC  
DM: n=23 
Non-DM: n=52 
(mean (sd)) 
Difference 
(95% CI) 
P value 
 
hsTnT (μg/L) 
Pre-operatively 
 
DM 
No-DM 
0.018 (0.019)  0.019 (0.026)  -0.002 -0.017, 0.013)  0.825 
0.017 (0.018)  0.014 (0.019)  0.035 (-0.004, 0.010)  0.417 
6 hours post-operatively 
 
DM 
No-DM 
0.786 (0.432)  0.608 (0.550)  0.1788 (-0.141, 0.498)  0.265 
0.838 (0.571)  0.644 (0.326)  0.194 (-0.017, 0.371)  0.032 
12 hours post-operatively 
 
DM 
No-DM 
0.700 (0.354)  0.563 (0.429)  0.137 (-0.116, 0.391)  0.280 
0.735 (0.509)  0.580 (0.390)  0.156 (-0.018, 0.329)  0.078 
24 hours post-operatively 
 
DM 
No-DM 
0.515 (0.283)  0.432 (0.353)  0.084 (-0.123, 0.290)  0.417 
0.550 (0.371)  0.424 (0.253)  0.126 (0.004, 0.248)  0.042 
48 hours post-operatively 
 
DM 
No-DM 
0.403 (0.276)  0.301 (0.241)  0.102 (-0.062, 0.265)  0.217 
0.462 (0.463)  0.330 (0.203)  0.132 (-0.006, 0.269)  0.061 
72 hours post-operatively 
 
DM 
No-DM 
0.431 (0.460)  0.237 (0.221)  0.187 (-0.017, 0.411)  0.083 
0.407 (0.332)  0.314 (0.234)  0.923 (-0.020, 0.205)  0.107 
Total 72 hours AUC 
 
DM 
No-DM 
34.88 (20.576)  26.59 (21.23)  7.51 (0.066, 21.029)  0.216 
37.85 (27.43)  28.55 (15.55)  9.30 (0.58, 18.02)  0.037 
RIPC=Remote ischemic preconditioning; SD= standard deviation; CI= confidence interval; hsTnT= high 
sensitivity Troponin-T 
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Fig.  6.4.  Mean  high-sensitivity  Troponin-T  levels  at  0,  6,  12,  24,  48  and  72  hours  in  diabetic 
patients undergoing unselected cardiac surgery with cardioplegia (mean±SEM*) 
 
RIPC=remote ischaemic preconditioning; hsTnT=high sensitivity troponin-T; SEM=standard error of the 
mean. *Unpaired Student T-Test 
 
Fig. 6.5. Mean high-sensitivity Troponin-T levels at 0, 6, 12, 24, 48 and 72 hours in non-diabetic 
patients undergoing unselected cardiac surgery with cardioplegia (mean±SEM) 
 
RIPC=remote ischaemic preconditioning; hsTnT=high sensitivity troponin-T; SEM=standard error of the 
mean. *p<0.05 (unpaired Student T-Test) 
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Fig. 6.6. Total AUC in control and RIPC diabetic and non-diabetic patients undergoing 
unselected cardiac surgery with cardioplegia (mean±SEM) 
 
RIPC=remote ischaemic preconditioning; SEM=standard error of the mean; AUC=area under the curve 
* Unpaired Student T-Test 
 
 
 
 
 
 
 
Similarly  we  found  no  statistically  significant  difference  in  any  of  the  secondary 
endpoints between control and preconditioned patients in either the diabetic or non-
diabetic subgroups (Tables 6.9-6.10). 
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Table 6.9. Summary of major secondary endpoints in diabetic patients undergoing unselected 
cardiac surgery with cardioplegia* 
Endpoint  Control (n=18) 
(mean [SD]) 
RIPC (n=23) 
(mean [SD]) 
Difference 
(95% CI) 
P value 
 
CK (μg/L) 
Total AUC  31546.88 (17412.40) 
 
35719.90 (26354.35)  -4712.13 (-19634.78, 11290.53)  0.587 
 
Creatinine (mg/ml) 
Pre-operatively  91.4 (20.4)  92.5 (33.2)  -1.0 (-19.1, 17.0)  0.908 
24 hours post-operatively  91.5 (25.9)  95.1 (34.6)  -3.6 (-23.6, 16.4)  0.718 
48 hours post-operatively  104.1 (29.5)  102.8 (53.6)  1.3 (-27.2, 29.7)  0.928 
72 hours post-operatively  105.6 (64.8)  100.9 (60.7)  4.6 (-35.2, 44.4)  0.816 
 
Urine Output (ml) 
24 hours post-operatively  1817.5 (546.5)  1986.6 (559.1)  -169.1 (-535.4, 197.2)   0.355 
48 hours post-operatively  2012.9 (868.9)  2217.3 (737.8)  -204.4 (-748.5, 339.8)  0.451 
72 hours post-operatively  1771.3 (932.1)  2722.3 (910.4)  -951.1 (-1731.1, -171.0)  0.019 
Total  5480.3 (1689.2)  6758.6 (1266.4)  -1278.3 (-2542.2, -14.3)  0.048 
 
AKI score 
0  15 (83.3%)  22 (95.7%)    0.252 
1  1 (5.6%)   1(4.3%)     
2  0 (0.0%)  0 (0.0%)     
3  2 (11.1%)  0 (0.0%)     
 
Acute Kidney Injury 
 
2 (11.1%) 
 
0 (0.0%) 
   
0.101 
 
Inotrope score 
Post bypass  6.81 (13.72)  5.46 (10.44)  1.35 (-6.49, 9.18)  0.729 
24 hours post-operatively  10.17 (20.90)  8.491 (13.42)  1.68 (-9.48, 12.84)  0.762 
48 hours post-operatively  7.88 (15.52)  5.76 (14.12)  2.13 (-7.52, 11.78)  0.658 
72 hours post-operatively  5.86 (14.49)  0.57 (2.67)  5.29 (-2.22, 12.81)  0.156 
Total  30.91 (53.45)  20.13 (33.57)  10.79 (-17.55, 39.12)  0.445 
 
New onset AF 
 
5 (27.8%) 
 
3 (13.0%) 
   
0.237 
 
Length of ICU stay (days) 
 
3.0 (2.0-5.0)** 
 
2.0 (1.0-3.5)** 
   
0.803*** 
 
Length of hospital stay (days) 
 
9.0 (7.0–12.0)** 
 
8.0 (6.0–10.5)** 
   
0.207*** 
 
Clinical outcomes at six weeks 
Death  1 (5.6%)  0 (0.0%)    0.252 
Myocardial infarction  0 (0.0%)  0 (0.0%)    1.000 
Stroke  0 (0.0%)  0 (0.0%)    1.000 
Revascularization  0 (0.0%)  0 (0.0%)    1.000 
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Table  6.10.  Summary  of  major  secondary  endpoints  in  non-diabetic  patients  undergoing 
unselected cardiac surgery with cardioplegia* 
Endpoint  Control (n=55) 
(mean [SD]) 
RIPC (n=52) 
(mean [SD]) 
Difference 
(95% CI) 
P value 
 
CK (μg/L) 
Total AUC  29889.32 (11607.54) 
 
35763.08 (24462.53)  -5873.766 (-14808.49, 3060.97)  0.193 
 
Creatinine (mg/ml) 
Pre-operatively  85.3 (19.1)  80.9 (21.5)  4.3 (-3.5, 12.1)  0.273 
24 hours post-operatively  88.2 (26.0)  83.9 (23.1)  4.3 (-5.2, 13.7)  0.374 
48 hours post-operatively  95.1 (40.7)  85.4 (28.7)  9.7 (-3.9, 23.3)  0.160 
72 hours post-operatively  90.7 (41.4)  85.8 (29.8)  4.9 (-9.02, 18.8)  0.489 
 
Urine Output (ml) 
24 hours post-operatively  2060.0 (818.3)  2220.9 (542.6)  -160.9 (-438.4, 116.7)   0.253 
48 hours post-operatively  2216.9 (945.5)  2351.7 (855.2)  -134.8 (-516.9, 247.3)  0.485 
72 hours post-operatively  2013.3 (725.7)  2381.6 (860.8)  -368.2 (-776.8, 40.3)  0.076 
Total  5969.7 (1721.2)  6659.4 (1776.8)  -689.7 (-1586.3, 207.0)  0.129 
 
AKI score 
0  47 (85.5%)  49 (94.2%)    0.228 
1  6 (10.9%)   3 (5.8%)     
2  2 (3.6%)  0 (0.0%)     
3  0 (0.0%)  0 (0.0%)     
 
Acute Kidney Injury 
 
8 (14.5%) 
 
3 (5.8%) 
   
0.135 
 
Inotrope score 
Post bypass  7.58 (14.02)  8.68 (18.34)  -1.10 (-7.46, 5.26)  0.732 
24 hours post-operatively  12.49 (20.79)  10.40 (18.51)  2.10 (-5.65, 9.84)  0.593 
48 hours post-operatively  6.85 (14.43)  6.09 (15.19)  0.76 (-5.09, 6.61)  0.796 
72 hours post-operatively  3.35 (9.073)  1.92 (9.87)  1.42 (-2.32, 5.16)  0.452 
Total  30.59 (48.22)  25.85 (47.87)  4.74 (-14.23, 23.71)  0.621 
 
New onset AF 
 
12 (21.8%) 
 
6 (11.5%) 
   
0.155 
 
Length of ICU stay (days) 
 
2.0 (2.0-4.0)** 
 
2.0 (1.5-3.5)** 
   
0.898*** 
 
Length of hospital stay (days) 
 
9.0 (7.0–12.5)** 
 
8.0 (6.0–10.5)** 
   
0.176*** 
 
Clinical outcomes at six weeks 
Death  1 (1.8%)  0 (0.0%)    0.329 
Myocardial infarction  1 (1.8%)  0 (0.0%)    0.329 
Stroke  1 (1.8%)  0 (0.0%)    0.215 
Revascularization  1 (1.8%)  0 (0.0%)    0.329 
*List of abbreviations.  
RIPC=Remote  ischemic  preconditioning;  CK=Creatinine  Kinase;  AKI=Acute  Kidney  Injury;  AF=atrial 
fibrillation;  ICU=Intensive  Care  Unit;  AUC=Area-under-the-curve.  **Results  shown  as  median  (inter-
quartile range); *** P-value for Mann-Whitney-Wilcoxon test   242 
6.5.  Effect  of  multi-limb  RIPC  on  cardioprotection  in  diabetic  and 
non-diabetic patients undergoing CABG surgery 
 
Similarly  to  the  subgroup  analysis  conducted  in  chapter  3,  we  intended  to 
determine whether our enhanced preconditioning stimulus can protect diabetic and/or 
non/diabetic patients undergoing CABG surgery alone. 
Within the diabetic sub-population, 17 subjects received the sham protocol and 
19  non-diabetics  the  RIPC  protocol,  whereas  in  the  non-diabetic  group  sham  and 
RIPC patients were 37 and 38 respectively. Interestingly, control patients in the DM 
group  had  a  lower  mean  diastolic  BP  (p=0.036),  a  lower  mean  HR  (p=0.030),  a 
reduced  use  of  statins  pre-operatively  (p=0.031).  In  the  non-DM  group,  the  only 
significant difference between control and RIPC subjects was the lower incidence of 
PAD in the latter (p=0.037). 
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Table  6.11.  Patient  baseline  characteristics  in  diabetic  and  non-diabetic  patients  undergoing 
CABG surgery  
Patients  Diabetics  Non-diabetics 
Control   
(n=17) 
(mean (SD)) 
RIPC   
(n=19) 
(mean (SD)) 
P value  Control   
(n=37) 
(mean (SD)) 
RIPC   
(n=38) 
(mean (SD)) 
P value 
Age (years) 
Gender 
Male 
Female 
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
Chinese 
 
BMI  
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
 
Smoking History 
Smoker 
Ex-smoker 
Non-smoker 
 
Family History of IHD 
 
NYHA Class 
CCS Class  
 
LVEF 
>50% 
30%-50% 
<30% 
 
Co-morbidities 
Hypertension 
Hypercholesterolemia 
Atrial Fibrillation 
Previous MI 
Previous PCI 
Previous CVA/TIA 
Previous Cardiac Surgery 
Other comorbidities 
Peripheral Arterial Disease 
 
Drug History 
Aspirin   
Clopidogrel/Prasugrel 
Warfarin  
Beta-blocker 
Calcium Channel Blocker 
Statin 
ACE-I/ARB  
Long acting nitrates 
Antidiabetics 
Insulin 
Biguanide 
Sulphonylurea 
 
Diuretics 
65±8 
 
13 (76.5%) 
4 (23.5%) 
 
12 (70.6%) 
3 (17.6%) 
1 (5.9%) 
1 (5.9%) 
 
28.9±5.5 
135.0±21 
73.7±11 
72.4±12.1 
 
 
4 (23.5%) 
11 (64.7%) 
2 (11.8%) 
 
11 (64.7%) 
 
2.60±0.63 
2.87±1.1 
 
 
10 (58.8%) 
5 (29.4%) 
2 (11.8%) 
 
 
15 (88.2%) 
16 (94.1%) 
1 (5.9%) 
4 (23.5%) 
5 (29.4%) 
2 (11.8%) 
0 (0.0%) 
1 (5.9%) 
2 (11.8%) 
 
 
13 (86.6%) 
5 (33.3%) 
1 (6.7%) 
12 (80.0%) 
6 (40.0%) 
16 (83.3%) 
12 (80.0%) 
7 (46.7%) 
 
6 (40.0%) 
6 (40.0%) 
7 (46.7%) 
 
6 (40.0%) 
 
63±10 
 
17 (89.5%) 
2 (10.5%) 
 
14 (73.7%) 
5 (26.3%) 
0 (0%) 
0 (0%) 
 
30.0±5.4 
128.0±17 
67.2±6.2 
64.4±8.7 
 
 
1 (5.3%) 
11 (57.9%) 
7 (36.8%) 
 
15 (78.9%) 
 
2.61±0.78 
2.83±0.9 
 
 
14 (73.7%) 
4 (21.1%) 
1 (5.3%) 
 
 
18 (94.7%) 
18 (94.7%) 
1 (5.3%) 
7 (36.8%) 
5 (26.3%) 
1 (5.3%) 
0 (0.0%) 
1 (3.9%) 
1 (5.3%) 
 
 
17 (89.5%) 
9 (47.7%) 
2 (10.5%) 
16 (82.2%) 
4 (21.1%) 
18 (84.7%) 
15 (79.3%) 
5 (26.3%) 
 
7 (36.8%) 
10 (62.6%) 
4 (21.1%) 
 
6 (31.6%) 
 
0.549 
0.296 
 
 
0.466 
 
 
 
 
 
0.575 
0.516 
0.036 
0.030 
 
0.106 
 
 
 
 
0.341 
 
0.965 
0.924 
 
0.606 
 
 
 
 
 
0.481 
0.935 
0.935 
0.387 
0.836 
0.558 
1.000 
0.837 
0.917 
 
 
0.670 
0.409 
0.239 
0.749 
0.212 
0.031 
0.968 
0.218 
 
0.851 
0.564 
0.116 
 
0.843 
67±10 
 
30 (81.1%) 
7 (18.9%) 
 
31 (83.8%) 
4 (10.8%) 
2 (5.4%) 
0 (0%) 
 
28.2±4.7 
127.8±18.9 
69.7±8.2 
64.5±10.4 
 
 
5 (13.5%) 
20 (54.1%) 
12 (32.4%) 
 
28 (75.7%) 
 
2.39±0.87 
2.47±1.0 
 
 
13 (72.2%) 
4 (22.2%) 
1 (5.6%) 
 
 
30 (81.1%) 
32 (86.5%) 
4 (10.8%) 
18 (48.6%) 
4 (10.8%) 
4 (10.8%) 
0 (0.0%) 
3 (8.1%) 
4 (10.8%) 
 
 
33 (89.2%) 
16 (43.3%) 
2 (5.4%) 
29 (78.4%) 
14 (37.8%) 
35 (94.6%) 
24 (63.9%) 
6 (14.2%) 
 
 
 
 
 
7 (18.9%) 
 
64±10 
 
32 (84.2%) 
6 (15.8%) 
 
34 (89.5%) 
3 (7.9%) 
1 (2.6%) 
0 (0%) 
 
29.1±9.1 
126.9±16.1 
70.5±9.9 
64.4±10.1 
 
 
7 (18.4%) 
20 (52.6%) 
11 (28.9%) 
 
27 (71.1%) 
 
2.31±0.82 
2.31±0.82 
 
 
15 (65.2%) 
5 (21.7%) 
3 (13.0%) 
 
 
24 (63.2%) 
28 (73.7%) 
3 (7.9%) 
15 (39.5%) 
4 (10.5%) 
2 (5.3%) 
1 (2.6%) 
1 (2.6%) 
0 (0.0%) 
 
 
36 (100.0%) 
10 (27.8%) 
0 (0.0%) 
24 (66.7%) 
8 (22.2%) 
34 (88.9%) 
23 (63.9%) 
6 (16.7%) 
 
 
 
 
 
9 (25.0%) 
 
0.263 
0.720 
 
 
0.740 
 
 
 
 
 
0.609 
0.788 
0.722 
0.848 
 
0.834 
 
 
 
 
0.651 
 
0.678 
0.473 
 
0.721 
 
 
 
 
 
0.084 
0.166 
0.502 
0.424 
0.968 
0.178 
0.321 
0.213 
0.037 
 
 
0.127 
0.183 
0.157 
0.262 
0.263 
0.446 
0.863 
0.579 
 
 
 
 
 
0.724 
RIPC=Remote  Ischemic  Preconditioning;  NYHA= New  York  Health  Association;  CCS= Canadian 
Cardiovascular  Society;  M I=Myocardial  infarction;  PCI= Percutaneous  coronary  intervention; 
CVA=Cerebrovascular accident; TIA=Transient ischemic attack; ACE-I=Angiotensin-converting enzyme-
inhibitor; ARB=Angiotensin receptor blocker; LVEF=left ventricular ejection fraction. 
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Table 6.12. Details of surgical procedure in diabetic and non-diabetic patients undergoing CABG 
surgery  
Patients  Diabetics  Non-diabetics 
        Control 
(n=17) 
(mean (SD)) 
RIPC 
(n=19) 
(mean (SD)) 
P 
value 
Control   
(n=37) 
(mean (SD)) 
RIPC   
(n=38) 
(mean (SD)) 
P value 
Indication for Surgery 
Angina 
Myocardial Infarction 
 
EuroSCORE 
 
Additive perioperative risk 
Low (EuroSCORE 0-2) 
Medium (EuroSCORE 3-5) 
High (EuroSCORE >5) 
 
Bypass-time (min)  
 
Cross-clamp time (min)  
 
Myocardial Preservation 
Cardioplegia 
Cross-clamp Fibrillation 
 
Number of grafts 
One  
Two  
Three  
Four 
 
Anesthetic agents 
Induction 
Anti-nicotinic agents 
Rocuronium 
Pancuronium 
Vecuronium 
Midazolam 
Etomidate 
Fentanyl 
Propofol 
 
Maintenance  
Propofol 
Volatile Anesthetics 
Isoflurane 
Sevoflurane 
 
Intra-operative GTN  
 
17 (100.0%) 
0 (0.0%) 
 
2.76±1.9 
 
 
9 (52.9%) 
7 (41.2%) 
1 (5.9%) 
 
91.47±25.72 
 
51.93±16.34 
 
 
11 (64.7%) 
6 (35.3%) 
 
 
0 (0.0%%) 
5 (29.4%) 
7 (41.2%) 
5 (29.4%) 
 
 
 
 
13 (86.7%) 
1 (5.9%) 
1 (5.9%) 
5 (33.3%) 
0 (0.0%) 
17 (100.0%) 
17 (100.0%) 
 
 
17 (100.0%) 
 
13 (13.3%) 
2 (13.3%) 
 
15 (88.2%) 
 
14 (73.7%) 
5 (26.3%) 
 
2.68±2.9 
 
 
9 (47.4%) 
7 (36.8%) 
3 (15.8%) 
 
83.05±20.21 
 
56.79±18.99 
 
 
14 (73.7%) 
5 (26.3%) 
 
 
0 (0.0%%) 
5 (26.3%) 
11 (57.9%) 
3 (15.8%) 
 
 
 
 
15 (83.3%) 
2 (11.2%) 
1 (5.6%) 
9 (50.0%) 
3 (16.7%) 
18 (100.0%) 
18 (100.0%) 
 
 
18 (100.0%) 
 
16 (88.9%) 
2 (11.1%) 
 
13 (68.4%) 
0.023 
 
 
 
0.923 
 
0.640 
 
 
 
 
0.293 
 
0.461 
 
 
0.090 
 
 
 
0.527 
 
 
 
 
 
 
0.831 
 
 
 
0.335 
0.097 
1.000 
1.000 
 
 
1.000 
 
0.846 
0.846 
 
0.153 
 
 
26 (70.3%) 
11 (29.7%) 
 
3.35±1.8 
 
 
13 (35.1%) 
19 (51.4%) 
5 (13.5%) 
 
84.86±30.45 
 
56.24±25.37 
 
 
26 (73.0%) 
10 (27.0%) 
 
 
1 (2.7%) 
8 (21.6%) 
21 (56.8%) 
7 (18.9%) 
 
 
 
 
29 (82.9%) 
5 (14.3%) 
1 (2.9%) 
9 (50.0%) 
20 (57.1%) 
5 (13.9%) 
37 (100%) 
 
 
36 (100%) 
 
34 (94.4%) 
2 (5.6%) 
 
31 (88.6%) 
 
26 (39.1%) 
27 (71.0%) 
 
2.92±2.1 
 
 
16 (42.1%) 
17 (44.7%) 
5 (13.2%) 
 
85.74±22.77 
 
53.87±19.18 
 
 
29 (76.3%) 
9 (23.7%) 
 
 
1 (2.6%) 
4 (17.4%) 
3 (13.0%) 
4 (17.4%) 
 
 
 
 
34 (94.4%) 
1 (2.8%) 
1 (2.8%) 
9 (40.9%) 
13 (36.1%) 
2 (5.6%) 
38 (100%) 
 
 
38 (100%) 
 
35 (97.2%) 
1 (2.8%) 
 
28 (75.7%) 
0.611 
 
 
 
0.346 
 
0.815 
 
 
 
 
0.888 
 
0.648 
 
0.739 
 
 
 
0.987 
 
 
 
 
 
 
 
0.218 
 
 
 
0.076 
0.233 
1.000 
0.453 
 
 
1.000 
0.555 
 
 
 
0.155 
 
RIPC=Remote  Ischemic  Preconditioning;  CABG=Coronary  artery  bypass  graft;  AVR=Aortic  valve 
replacement; MVR=Mitral valve replacement; MV=Mitral valve. 
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    Intriguingly, we found that in diabetic patients RIPC significantly reduced mean 
hsTnT at 12, 48 and 72 hours (Fig. 6.7, Table 6.13) and total AUC from 31.73±18.63 
μg/L to 19.63±9.19 μg/L, which corresponded to a statistically significant reduction of 
38%  [12.09;  CI  1.83,  22.35;  p=0.022]  (Fig.  6.9,  Table  6.13).  Conversely,  in  non-
diabetic subjects no significant reduction of hsTnT concentrations or total AUC was 
observed (Figs. 6.8-6.9, Table 6.13). 
 
 
 
 
 
Table 6.13. Mean high-sensitivity Troponin T release at the specified time points in diabetic and 
non-diabetic patients undergoing CABG surgery  
Endpoint  Control  
DM: n=17 
Non-DM: n=37 
(mean (sd)) 
RIPC  
DM: n=19 
Non-DM: n=38 
(mean (sd)) 
Difference 
(95% CI) 
P value 
 
hsTnT (μg/L) 
Pre-operatively 
 
DM 
No-DM 
0.024 (0.025)  0.016 (0.025)  0.008 (-0.009, 0.026)  0.330 
0.018 (0.017)  0.012 (0.018)  -0.006 (-0.002, 0.013)  0.150 
6 hours post-operatively 
 
DM 
No-DM 
0.709 (0.328)  0.544 (0.302)  0.164 (-0.049, 0.378)  0.126 
0.809 (0.576)  0.655 (0.318)  0.155 (-0.061, 0.371)  0.156 
12 hours post-operatively 
 
DM 
No-DM 
0.653 (0.276)  0.459 (0.211)  0.194 (0.029, 0.359)  0.023 
0.628 (0.455)  0.564 (0.404)  0.063 (-0.134, 0.261)  0.527 
24 hours post-operatively 
 
DM 
No-DM 
0.515 (0.283)  0.302 (0.145)  0.147 (-0.009, 0.305)  0.065 
0.455 (0.295)  0.365 (0.196)  0.090 (-0.026, 0.206)  0.125 
48 hours post-operatively 
 
DM 
No-DM 
0.389 (0.322)  0.217 (0.101)  0.173 (0.011, 0.335)  0.038 
0.331 (0.218)  0.272 (0.146)  0.058 (-0.029, 0.144)  0.187 
72 hours post-operatively 
 
DM 
No-DM 
0.368 (0.251)  0.158 (0.088)  0.210 (0.079, 0.342)  0.004 
0.307 (0.228)  0.307 (0.174)  0.06 (-0.036, 0.154)  0.218 
Total 72 hours AUC 
 
DM 
No-DM 
31.73 (18.63)  19.63 (9.19)  12.09 (1.83, 22.35)  0.022 
30.29 (19.34)  25.43 (12.79)  4.86 (-2.84, 12.56)  0.212 
RIPC=Remote ischemic preconditioning; SD=standard deviation; CI=confidence interval; hsTnT= high 
sensitivity Troponin T 
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Fig.  6.7.  Mean  high-sensitivity  Troponin-T  levels  at  0,  6,  12,  24,  48  and  72  hours  in  diabetic 
patients undergoing CABG surgery (mean±SEM) 
 
RIPC=remote ischaemic preconditioning; hsTnT=high sensitivity troponin-T; SEM=standard error of the 
mean 
 p<0.05 (unpaired Student T-Test) 
 
 
Fig. 6.8. Mean high-sensitivity Troponin-T levels at 0, 6, 12, 24, 48 and 72 hours in non-diabetic 
patients undergoing CABG surgery (mean±SEM*) 
 
RIPC=remote ischaemic preconditioning; hsTnT=high sensitivity troponin-T; SEM=standard error of the 
mean. * Unpaired Student T-Test 
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Fig. 6.9. Total AUC in control and RIPC diabetic and non-diabetic patients undergoing CABG 
surgery (mean±SEM) 
 
RIPC=remote ischaemic preconditioning; SEM=standard error of the mean; AUC=area-under-the-curve 
* Unpaired Student T-Test 
 
 
 
 
 
 
Additionally, we found that simultaneous multi-limb preconditioning significantly 
reduced the incidence of new post-operative AF of 83% in the diabetic cohort, with 
only  1  new  case  of  AF  in  the  RIPC  group  versus  6  new  cases  amongst  control 
(p=0.023)  (Table  6.14).  In  the  non-diabetic  group,  the  only  significant  difference 
between the two intervention cohorts was given by the improvement in urine output at 
24 hours in preconditioned patients (p=0.041) (Table 6.15). Interestingly, we found no 
death,  revascularisation,  stroke  or  MI  at  6  weeks  in  any  of  the  above-mentioned 
subgroups (Tables 6.14-6.15). 
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Table 6.14. Summary of study endpoints in diabetic patients undergoing CABG surgery* 
Endpoint  Control 
(n=18) 
(mean [SD]) 
RIPC 
(n=23) 
(mean [SD]) 
Difference 
(95% CI) 
P value 
 
CK (μg/L) 
Total AUC  30348.50 (19176.29) 
 
30933.80 (20762.26)  -585.30 (-16602.13, 15431.53)  0.941 
 
Creatinine (mg/ml) 
Pre-operatively  93.9 (20.14)  94.4 (32.5)  -0.5 (-19.1, 17.9)  0.953 
24 hours post-operatively  103.4 (41.1)  93.3 (28.3)  10.1 (-14.0, 34.3)  0.399 
48 hours post-operatively  118.1 (51.4)  102.2 (39.6)  15.9 (-14.9, 46.8)  0.303 
72 hours post-operatively  109.9 (39.5)  99.4 (19.8)  10.5 (-18.4, 39.4)  0.465 
 
Urine Output (ml) 
24 hours post-operatively  1931.6 (788.6)  2022.6 (864.7)  -91.0 (-704.8, 522.7)   0.764 
48 hours post-operatively  2164.7 (961.9)  2279.6 (884.3)  -114.9 (-835.5, 605.7)  0.746 
72 hours post-operatively  2136.6 (1077.9)  2632.5 (926.7)  -495.9 (-1466.0, 474.2)  0.296 
Total  5776.1 (1723.9)  6488.2 (1410.4)  -712.1 (-229.9, 805.7)  0.336 
 
AKI score 
0  13 (76.5%)  18 (94.7%)    0.386 
1  2 (11.8%)   1(5.3%)     
2  1 (5.9%)  0 (0.0%)     
3  1 (5.9%)  0 (0.0%)     
 
Acute Kidney Injury 
 
4 (23.5%) 
 
1 (5.3%) 
   
0.114 
 
Inotrope score 
Post bypass  6.28 (14.87)  2.87 (8.05)  3.41 (-4.97, 11.79)  0.412 
24 hours post-operatively  11.10 (22.77)  5.82 (9.93)  5.28 (-6.91, 17.47)  0.383 
48 hours post-operatively  15.64 (26.38)  0.98 (2.49)  14.66 (1.95, 27.37)  0.058 
72 hours post-operatively  8.44 (21.72)  0.17 (0.71)  8.28 (-2.14, 18.68)  0.178 
Total  41.62 (66.46)  9.83 (15.39)  31.79 (-7.07, 70.65)  0.101 
 
New onset AF 
 
6 (35.3%) 
 
1 (5.3%) 
   
0.023 
 
Length of ICU stay (days) 
 
2.5 (2.0-5.5)** 
 
1.0 (1.0-2.0)** 
   
0.085*** 
 
Length of hospital stay (days) 
 
9.0 (7.0-14.5)** 
 
8.0 (6.0-9.0)** 
   
0.128*** 
 
Clinical outcomes at six weeks 
Death  0 (0.0%)  0 (0.0%)    1.000 
Myocardial infarction  0 (0.0%)  0 (0.0%)    1.000 
Stroke  0 (0.0%)  0 (0.0%)    1.000 
Revascularization  0 (0.0%)  0 (0.0%)    1.000 
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Table 6.15. Summary of study endpoints in non-diabetic patients undergoing CABG surgery* 
Endpoint  Control 
(n=18) 
(mean [SD]) 
RIPC 
(n=23) 
(mean [SD]) 
Difference 
(95% CI) 
P value 
 
CK (μg/L) 
Total AUC  36494.22 (26109.06) 
 
37767.12 (30831.17)  -1272.90 (-17810.34, 15264.54)  0.876 
 
Creatinine (mg/ml) 
Pre-operatively  86.7 (18.9)  82.0 (19.9)  -4.7 (-4.2, 13.7)  0.296 
24 hours post-operatively  91.5 (25.9)  95.1 (34.6)  6.9 (-4.2, 17.9)  0.220 
48 hours post-operatively  104.1 (29.5)  102.8 (53.6)  18.2 (-1.5, 37.9)  0.070 
72 hours post-operatively  105.6 (64.8)  100.9 (60.7)  11.2 (-7.9, 30.4)  0.248 
 
Urine Output (ml) 
24 hours post-operatively  1981.6 (546.5)  1986.6 (590.6)  -297.3.1 (-581.7, -12.8)   0.041 
48 hours post-operatively  2224.5 (1050.9)  2298.2 (773.7)  -73.7 (-555.2, 407.7)  0.760 
72 hours post-operatively  2116.4 (898.6)  2301.9 (728.7)  -185.5 (-686.5, 315.4)  0.459 
Total  6109.9 (2171.5)  6576.6 (1391.0)  -466.7 (-1568.3, 634.9)  0.397 
 
AKI score 
0  32 (86.5%)  36 (94.7%)    0.528 
1  3 (8.1%)   1(2.6%)     
2  1 (2.7%)  1(2.6%)     
3  1 (2.7%)  0 (0.0%)     
 
Acute Kidney Injury 
 
5 (13.5%) 
 
2 5.2%) 
   
0.219 
 
Inotrope score 
Post bypass  5.44 (10.86)  7.24 (17.82)  -1.79 (-8.81, 5.22)  0.611 
24 hours post-operatively  9.31 (18.71)  9.47 (18.40)  -0.15 (-9.01, 8.70)  0.972 
48 hours post-operatively  6.80 (18.92)  5.94 (16.29)  0.86 (-7.60, 9.33)  0.839 
72 hours post-operatively  4.08 (17.69)  1.44 (5.44)  2.64 (-3.54, 8.82)  0.397 
Total  25.85 (61.41)  24.08 (48.82)  1.76 (-24.79, 28.31)  0.895 
 
New onset AF 
 
9 (24.3%) 
 
5 (13.2%) 
   
0.215 
 
Length of ICU stay (days) 
 
2.0 (1.0-4.0)** 
 
2.0 (1.0–4.0)** 
   
0.376*** 
 
Length of hospital stay (days) 
 
8.0 (6.0–11.0)** 
 
7.0 (6.0–9.0)** 
   
0.276*** 
 
Clinical outcomes at six weeks 
Death  0 (0.0%)  0 (0.0%)    1.000 
Myocardial infarction  0 (0.0%)  0 (0.0%)    1.000 
Stroke  0 (0.0%)  0 (0.0%)    1.000 
Revascularization  0 (0.0%)  0 (0.0%)    1.000 
*List of abbreviations.  
RIPC=Remote  ischemic  preconditioning;  CK=Creatinine  Kinase;  AKI=Acute  Kidney  Injury;  AF=atrial 
fibrillation;  ICU=Intensive  Care  Unit;  AUC=Area-under-the-curve.  **Results  shown  as  median  (inter-
quartile range); *** P-value for Mann-Whitney-Wilcoxon test   250 
6.6.  Effect  of  multi-limb  RIPC  on  cardioprotection  in  diabetic  and 
non-diabetic patients undergoing CABG surgery using cardioplegia  
 
 
In our previous analysis, we found that our enhanced preconditioning stimulus 
protected diabetic patients undergoing CABG surgery alone. However, we could not 
find similar beneficial effects in a similar cohort of non-diabetic patients. Moreover, in 
chapter 3 we found that the same stimulus improved cardioprotection in both CABG 
patients alone and in subjects undergoing cardiac surgery with cardioplegia but not in 
CABG  patients  receiving  cardioplegia.  We  therefore  wished  to  conduct  a  further 
subgroup analysis to determine whether multi-limb IR reduced PMI in diabetic and/or 
non-diabetic patients undergoing CABG surgery and receiving cardioplegia.  
The diabetic subgroup comprised 11 control patients and 14 RIPC subjects, 
whereas the non-diabetic subgroup had 27 controls and 29 preconditioned subjects 
(Table  6.16).  Diabetic  control  patients  had  a  more  significant  non-smoking  history 
(p=0.027): we found no other significant difference amongst the 4 subgroups (Table 
6.16-6.17). 
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Table  6.16.  Patient  baseline  characteristics  in  diabetic  and  non-diabetic  patients  undergoing 
CABG surgery with cardioplegia 
Patients  Diabetics  Non-diabetics 
Control   
(n=11) 
(mean (SD)) 
RIPC   
(n=14) 
(mean (SD)) 
P value  Control   
(n=27) 
(mean (SD)) 
RIPC   
(n=29) 
(mean (SD)) 
P value 
Age (years) 
Gender 
Male 
Female 
 
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
Chinese 
 
BMI  
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
 
Smoking History 
Smoker 
Ex-smoker 
Non-smoker 
 
Family History of IHD 
 
NYHA Class 
CCS Class  
 
LVEF 
>50% 
30%-50% 
<30% 
 
Co-morbidities 
Hypertension 
Hypercholesterolemia 
Atrial Fibrillation 
Previous MI 
Previous PCI 
Previous CVA/TIA 
Previous Cardiac Surgery 
Other comorbidities 
Peripheral Arterial Disease 
 
Drug History 
Aspirin   
Clopidogrel/Prasugrel 
Warfarin  
Beta-blocker 
Calcium Channel Blocker 
Statin 
ACE-I/ARB  
Long acting nitrates 
Antidiabetics 
Insulin 
Biguanide 
Sulphonylurea 
 
Diuretics 
66±6 
 
9 (81.8%) 
2 (18.2%) 
 
 
7 (63.6%) 
2 (18.2%) 
1 (9.1%) 
1 (9.1%) 
 
29.0±5.0 
136.4±20 
72.1±9 
69.6±12.1 
 
 
3 (27.3%) 
7 (63.6%) 
1 (9.1%) 
 
8 (72.7%) 
 
2.73±0.48 
3.00±1.0 
 
 
6 (54.5%) 
4 (36.4%) 
1 (9.1%) 
 
 
10 (90.9%) 
11 (100.0%) 
1 (9.1%) 
4 (36.4%) 
4 (36.4%) 
2 (18.2%) 
0 (0.0%) 
1 (9.1%) 
2 (18.2%) 
 
 
10 (89.9%) 
5 (45.5%) 
1 (9.1%) 
9 (81.8%) 
6 (54.6%) 
11 (100.0%) 
10 (81.9%) 
6 (54.6%) 
 
4 (36.4%) 
4 (36.4%) 
10 (91.0%) 
 
66 (54.6%) 
 
66±11 
 
12 (85.7%) 
2 (14.3%) 
 
 
10 (71.4%) 
4 (28.6%) 
0 (0%) 
0 (0%) 
 
29.4±4.9 
129.6±17 
67.9±6.1 
61.4±6.5 
 
 
0 (0%) 
7 (50.0%) 
7 (50.0%) 
 
10 (71.4%) 
 
2.77±0.73 
2.85±0.9 
 
 
10 (71.4%) 
3 (21.4%) 
1 (7.1%) 
 
 
13 (92.9%) 
13 (92.9%) 
0 (0.0%) 
5 (35.7%) 
4 (28.6%) 
1 (7.1%) 
0 (0.0%) 
1 (7.1%) 
1 (7.1%) 
 
 
12 (85.7%) 
7 (50.0%) 
1 (7.1%) 
11 (78.6%) 
3 (21.4%) 
14 (100.0%) 
10 (71.4%) 
5 (35.7%) 
 
4 (28.6%) 
10 (71.4%) 
14 (100.0%) 
 
3 (21.4%) 
 
0.952 
0.792 
 
 
 
0.411 
 
 
 
 
 
0.901 
0.381 
0.181 
0.064 
 
0.027 
 
 
 
0.943 
 
0.871 
0.695 
0.672 
 
 
 
 
 
 
0.859 
0.366 
0.250 
0.973 
0.678 
0.500 
1.000 
0.918 
0.399 
 
 
0.916 
0.821 
0.357 
0.840 
0.179 
0.694 
0.482 
0.346 
 
 
0.678 
0.773 
0.293 
 
0.196 
69±9 
 
22 (81.5%) 
5 (18.5%) 
 
 
23 (85.2%) 
3 (11.1%) 
1 (3.7%) 
0 (0%) 
 
27.1±4.7 
128.3±20.6 
69.1±8.4 
65.3±11.5 
 
 
2 (7.4%) 
16 (59.3%) 
9 (33.3%) 
 
18 (66.7%) 
 
2.50±1.11 
2.47±1.0 
 
 
20 (74.1%) 
7 (25.9%) 
0 (0.0%) 
 
 
22 (81.5%) 
22 (81.5%) 
3 (11.1%) 
15 (55.6%) 
4 (14.8%) 
4 (14.8%) 
0 (0.0%) 
2 (7.4%) 
3 (11.1%) 
 
 
24 (88.9%) 
13 (48.1%) 
2 (7.4%) 
21 (77.8%) 
12 (44.4%) 
24 (92.6%) 
16 (59.3%) 
5 (18.5%) 
 
 
 
 
 
3 (11.1%) 
 
65±9 
 
23 (79.3%) 
6 (20.7%) 
 
 
25 (86.2%) 
3 (10.3%) 
1 (3.4%) 
0 (0%) 
 
29.4±10.3 
126.9±18.3 
70.0±10.7 
65.2±10.4 
 
 
6 (20.7%) 
18 (62.1%) 
5 (17.2%) 
 
22 (75.9%) 
 
2.57±0.99 
2.31±0.82 
 
 
21 (72.4%) 
6 (20.7%) 
2 (6.9%) 
 
 
20 (69.0%) 
21 (72.4%) 
1 (3.4%) 
12 (41.4%) 
2 (6.9%) 
2 (6.9%) 
1 (3.4%) 
1 (3.4%) 
0 (0.0%) 
 
 
29 (100.0%) 
8 (28.6%) 
0 (0.0%) 
17 (60.7%) 
7 (25.0%) 
26 (89.3%) 
19 (67.9%) 
6 (14.3%) 
 
 
 
 
 
7 (25.0%) 
 
0.138 
0.838 
 
 
 
0.994 
 
 
 
 
 
0.298 
0.796 
0.724 
0.978 
 
0.203 
 
 
 
 
0.447 
 
0.658 
0.804 
 
0.362 
 
 
 
 
 
0.280 
0.422 
0.485 
0.289 
0.338 
0.166 
0.330 
0.213 
0.461 
 
 
0.190 
0.175 
0.142 
0.171 
0.238 
0.493 
0.474 
0.586 
 
 
 
 
 
0.321 
RIPC=Remote  Ischemic  Preconditioning;  NYHA=New  York  Health  Association;  CCS=Canadian 
Cardiovascular  Society;  MI=Myocardial  infarction;  PCI=Percutaneous  coronary  intervention; 
CVA=Cerebrovascular accident; TIA=Transient ischemic attack; ACE-I=Angiotensin-converting enzyme-
inhibitor; ARB=Angiotensin receptor blocker; LVEF=left ventricular ejection fraction. 
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Table 6.17. Details of surgical procedure in diabetic and non-diabetic patients undergoing CABG 
surgery with cardioplegia 
Patients  Diabetics  Non-diabetics 
        Control 
(n=11) 
 
RIPC 
(n=14) 
P value  Control   
(n=27) 
RIPC   
(n=29) 
P value 
Indication for Surgery 
Angina 
Myocardial Infarction 
 
EuroSCORE 
 
Additive perioperative risk 
Low (EuroSCORE 0-2) 
Medium (EuroSCORE 3-5) 
High (EuroSCORE >5) 
 
Bypass-time (min)  
 
Cross-clamp time (min)  
 
Number of grafts 
One  
Two  
Three  
Four 
 
Anesthetic agents 
Induction 
Anti-nicotinic agents 
Rocuronium 
Pancuronium 
Vecuronium 
Midazolam 
Etomidate 
Fentanyl 
Propofol 
 
Maintenance  
Propofol 
Volatile Anesthetics 
Isoflurane 
Sevoflurane 
 
Intra-operative GTN  
 
11 (100.0%) 
0 (0.0%) 
 
2.76±1.9 
 
 
7 (63.6%) 
3 (27.3%) 
1 (9.1%) 
 
91.47±25.72 
 
51.93±16.34 
 
 
0 (0.0%%) 
4 (36.4%) 
4 (36.4%) 
3 (27.3%) 
 
 
 
 
9 (81.8%) 
1 (9.1%) 
1 (9.1%) 
5 (45.5%) 
0 (0.0%) 
11 (100.0%) 
11 (100.0%) 
 
 
11 (100.0%) 
 
8 (81.8%) 
2 (18.2%) 
 
10 (90.9%) 
 
9(64.3%) 
5 (35.7%) 
 
2.68±2.9 
 
 
5 (35.7%) 
6 (42.9%) 
3 (21.4%) 
 
83.05±20.21 
 
56.79±18.99 
 
 
0 (0.0%%) 
4 (28.6%) 
7 (50.0%) 
3 (21.4%) 
 
 
 
 
11 (84.6%) 
1 (7.7%) 
1 (7.7%) 
6 (46.2%) 
3 (23.1%) 
14 (100.0%) 
11 (76.9%) 
 
 
14 (100.0%) 
 
12 (92.3%) 
1 (7.7%) 
 
8 (57.1%) 
0.207 
 
 
 
0.566 
 
0.367 
 
 
 
 
0.293 
 
0.461 
 
0.793 
 
 
 
 
 
 
 
0.983 
 
 
 
0.973 
0.089 
1.000 
0.089 
 
 
1.000 
 
0.439 
 
 
0.062 
 
 
19 (70.4%) 
8 (29.6%) 
 
3.63±1.76 
 
 
7 (25.9%) 
16 (59.3%) 
4 (14.8%) 
 
84.86±30.45 
 
56.24±25.37 
 
 
1 (3.8%) 
6 (22.2%) 
14 (51.9%) 
6 (22.2%) 
 
 
 
 
21 (80.8%) 
4 (15.4%) 
1 (3.8%) 
13 (50.0%) 
3 (11.5%) 
27 (100%) 
23 (88.5%) 
 
 
27 (100%) 
 
25 (96.2%) 
1 (3.8%) 
 
22 (88.0%) 
 
19 (65.5%) 
9 (31.0%) 
 
3.03±2.04 
 
 
11 (37.9%) 
14 (48.3%) 
4 (13.8%) 
 
85.74±22.77 
 
53.87±19.18 
 
 
1 (3.6%) 
9 (31.0%) 
15 (51.7%) 
4 (13.8%) 
 
 
 
 
27 (96.4%) 
1 (3.6%) 
0 (0.0%) 
11(39.3%) 
2 (7.1%) 
29 (100%) 
25 (89.3%) 
 
 
29 (100%) 
 
29 (100%) 
0 (0.0%) 
 
21(75.0%) 
0.610 
 
 
 
0.249 
 
0.621 
 
 
 
 
0.888 
 
0.648 
 
0.810 
 
 
 
 
 
 
 
0.218 
 
 
 
0.429 
0.233 
1.000 
0.923 
 
 
1.000 
0.295 
 
 
 
0.227 
 
RIPC=Remote  Ischemic  Preconditioning;  CABG=Coronary  artery  bypass  graft;  AVR=Aortic  valve 
replacement; MVR=Mitral valve replacement; MV=Mitral valve. 
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    Interestingly we found that mean hsTnT was reduced in preconditioned patients 
at 48 and 72 hours post-operatively in the DM group with no significant difference 
between sham and RIPC subjects in non-DM group (Figs.  6.10-6.11,  Table  6.18). 
Total  AUC  was  reduced  in  preconditioned  diabetics  and  non-diabetics  although 
without  reaching  statistical  relevance  (respectively  27.59ﾱ11.46  μg/L  versus 
19.37ﾱ10.03  μg/L  [8.22;  CI  -0.68,  17.11;  p=0.069]  and  30.78ﾱ21.81  μg/L  versus 
26.76ﾱ13.79 μg/L [4.02; CI -5.74, 13.78; p=0.413])  (Fig. 6.12, Table 6.18). 
 
 
 
 
 
Table  6.18.  Mean  high-sensitivity  Troponin-T  release  in  diabetic  and  non-diabetic  patients 
undergoing CABG surgery with cardioplegia 
Endpoint  Control  
DM: n=11 
Non-DM: n=14 
(mean (sd)) 
RIPC  
DM: n=27 
Non-DM: 
n=29 
(mean (sd)) 
Difference 
(95% CI) 
P value 
 
hsTnT (μg/L) 
Pre-operatively 
 
DM 
No-DM 
0.019 (0.022)  0.016 (0.028)  0.004 (-0.018, 0.025)  0.723 
0.019 (0.017)  0.013 (0.019)  0.006 (-0.004, 0.015)  0.263 
6 hours post-operatively 
 
DM 
No-DM 
0.722 (0.395)  0.537 (0.339)  0.185 (-0.119, 0.489)  0.220 
0.849 (0.654)  0.709 (0.329)  0.141 (-0.142, 0.424)  0.320 
12 hours post-operatively 
 
DM 
No-DM 
0.626 (0.299)  0.445 (0.229)  0.181 (0.037, 0.399)  0.100 
0.642 (0.526)  0.605 (0.444)  0.038 (-0.222, 0.298)  0.771 
24 hours post-operatively 
 
DM 
No-DM 
0.409 (0.197)  0.293 (0.169)  0.116 (-0.036, 0.268)  0.127 
0.458 (0.326)  0.386 (0.211)  0.073 (-0.076, 0.222)  0.329 
48 hours post-operatively 
 
DM 
No-DM 
0.301 (0.110)  0.206 (0.105)  0.095 (0.005, 0.184)  0.038 
0.332 (0.239)  0.289 (0.158)  0.043 (-0.069, 0.154)  0.444 
72 hours post-operatively 
 
DM 
No-DM 
0.289 (0.128)  0.158 (0.098)  0.131 (0.038, 0.224)  0.008 
0.309 (0.248)  0.261 (0.192)  0.049 (-0.071, 0.168)  0.422 
Total 72 hours AUC 
 
DM 
No-DM 
27.59 (11.46)  19.37 (10.03)  8.22 (-0.68, 17.11)  0.069 
30.78 (21.81)  26.76 (13.79)  4.02 (-5.74, 13.78)  0.413 
RIPC=Remote ischemic preconditioning; SD=standard deviation; CI=confidence interval; hsTnT=high 
sensitivity Troponin-T 
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Fig. 6.10. Mean high-sensitivity Troponin-T levels at 0, 6, 12, 24, 48 and 72 hours in diabetic 
patients undergoing CABG surgery with cardioplegia (mean±SEM) 
 
RIPC=remote ischaemic preconditioning; hsTnT=high sensitivity troponin-T; SEM=standard error of the 
mean. *p<0.05 (unpaired Student T-Test) 
 
Fig. 6.11. Mean high-sensitivity Troponin-T levels at 0, 6, 12, 24, 48 and 72 hours in non-diabetic 
patients undergoing CABG surgery with cardioplegia (mean±SEM*) 
 
RIPC=remote ischaemic preconditioning; hsTnT=high sensitivity troponin-T; SEM=standard error of the 
mean. *p<0.05 (unpaired Student T-Test) 
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Fig. 6.12. Total AUC in control and RIPC diabetic and non-diabetic patients undergoing CABG 
surgery (mean±SEM) 
 
RIPC=remote ischaemic preconditioning; SEM=standard error of the mean; AUC=area-under-the-curve 
* Unpaired Student T-Test 
 
 
 
 
 
 
 
 
Amongst secondary endpoints, we observed a reduction of post-operative AKI 
and AF incidence in RIPC diabetic patients from 2 to 0 and from 4 to 1 respectively, 
which however only approximated to but did not reach statistical significance (p=0.096 
and  0.070  respectively)  (Tables  6.19-6.20).  No  difference  in  any  other  secondary 
endpoint was found in this subgroup analysis (Tables 6.19-6.20). 
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Table 6.19. Summary of  study endpoints in diabetic patients undergoing CABG surgery with 
cardioplegia* 
Endpoint  Control 
(n=11) 
(mean [SD]) 
RIPC 
(n=14) 
(mean [SD]) 
Difference 
(95% CI) 
P value 
 
CK (μg/L) 
Total AUC  31624.64 (19570.55) 
 
31319.77 (22243.63)  304.88 (-17401.82, 18011.55)  0.972 
 
Creatinine (mg/ml) 
Pre-operatively  92.6 (17.3)  87.8 (21.6)  4.8 (11.8, 21.3)  0.557 
24 hours post-operatively  96.2 (28.5)  89.7 (26.9)  6.5 (-17.0, 29.9)  0.573 
48 hours post-operatively  107.3 (26.0)  90.9 (30.4)  16.4 (-7.4, 40.2)  0.167 
72 hours post-operatively  97.6 (24.0)  86.9(25.5)  10.8 (-9.9, 31.5)  0.293 
 
Urine Output (ml) 
24 hours post-operatively  1857.3 (671.5)  2035.3 (712.1)  -178.0 (-797.9, 441.9)   0.556 
48 hours post-operatively  2153.3 (972.0)  2002.3 (884.3)  151.0 (-515.9, 817.9)  0.641 
72 hours post-operatively  1914.6 (906.3)  2590.0 (1011.5)  -675.4 (-1795.1, 444.3)  0.213 
Total  5664.4 (1807.7)  6404.5 (1053.1)  -740.1 (-2550.9, 1070.7)  0.391 
 
AKI score 
0  9 (81.8%)  14 (100.0%)    0.251 
1  1 (9.1%)   0 (0.0%)     
2  0 (0.0%)  0 (0.0%)     
3  1 (9.1%)  0 (0.0%)     
 
Acute Kidney Injury 
 
2 (18.8%) 
 
0 (0.0%) 
   
0.096 
 
Inotrope score 
Post bypass  8.60 (17.27)  3.98 (9.33)  4.62 (-7.03, 16.28)  0.419 
24 hours post-operatively  13.84 (26.74)  5.02 (6.76)  8.82 (-7.12, 24.77)  0.263 
48 hours post-operatively  13.20 (18.75)  1.13 (2.84)  12.07 (1.17, 22.97)  0.032 
72 hours post-operatively  3.82 (8.04)  0.00 (0.00)  3.82 (-0.79, 8.42)  0.100 
Total  39.78 (64.53)  10.12 (15.72)  29.66 (-8.73, 68.05)  0.123 
 
New onset AF 
 
4 36.4%) 
 
1 (7.1%) 
   
0.070 
 
Length of ICU stay (days) 
 
3.0 (2.0-4.5)** 
 
1.0 (1.0-2.0)** 
   
0.096*** 
 
Length of hospital stay (days) 
 
9.0 (7.0-14.5)** 
 
6.5 (6.0-8.0)** 
   
0.118*** 
 
Clinical outcomes at six weeks 
Death  0 (0.0%)  0 (0.0%)    1.000 
Myocardial infarction  0 (0.0%)  0 (0.0%)    1.000 
Stroke  0 (0.0%)  0 (0.0%)    1.000 
Revascularization  0 (0.0%)  0 (0.0%)    1.000 
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Table 6.20. Summary of study endpoints in non-diabetic patients undergoing CABG surgery with 
cardioplegia 
Endpoint  Control 
(n=18) 
(mean [SD]) 
RIPC 
(n=23) 
(mean [SD]) 
Difference 
(95% CI) 
P value 
 
CK (μg/L) 
Total AUC  30221.65 (13177.39) 
 
35801.29 (25015.85)  -5579.64 (-19217.85, 8058.57)  0.412 
 
Creatinine (mg/ml) 
Pre-operatively  88.0 (19.8)  81.3 (22.1)  6.7 (-4.6, 17.9)  0.243 
24 hours post-operatively  84.1 (25.4)  82.0 (19.8)  2.1 (-10.0, 14.3)  0.729 
48 hours post-operatively  93.1 (39.5)  84.9 (25.5)  8.2 (-9.5, 25.9)  0.357 
72 hours post-operatively  89.2 (43.1)  86.9 (27.2)  2.3 (-16.9, 21.4)  0.814 
 
Urine Output (ml) 
24 hours post-operatively  2029.7 (556.0)  2223.5 (509.6)  -193.8 (-500.5, 112.9)   0.210 
48 hours post-operatively  2324.9 (1097.6)  2291.6 (807.6)  33.3 (-545.8, 612.5)  0.908 
72 hours post-operatively  2039.6 (836.3)  2264.8 (811.8)  -225.2 (-852.4, 401.9)  0.468 
Total  6225.8 (2229.0)  6465.4 (1509.9)  -239.7 (-1634.0, 1154.6)  0.727 
 
AKI score 
0  7 (70.0%)  8 (88.9%)    0.528 
1  1 (10.0%)   0 (0.0%)     
2  1 (10.0%)   1(11.1%)     
3  1 (10.0%)   0 (0.0%)     
 
Acute Kidney Injury 
 
10 (38.5%) 
 
9 (31.0%) 
   
0.511 
 
Inotrope score 
Post bypass  5.44 (9.64)  78.36 (19.90)  -2.92 (-11.71, 5.84)  0.508 
24 hours post-operatively  8.00 (14.50)  10.24 (19.78)  -2.24 (-12.04, 7.57)  0.648 
48 hours post-operatively  4.46 (10.29)  6.39 (17.42)  -1.93 (-10.22, 6.36)  0.642 
72 hours post-operatively  1.09 (2.15)  0.76 (2.39)  0.33 (-0.96, 1.62)  0.610 
Total  19.23 (30.74)  25.75 (51.49)  -6.51 (-31.07, 18.04)  0.596 
 
New onset AF 
 
6 (22.2%) 
 
4 (13.8%) 
   
0.411 
 
Length of ICU stay (days) 
 
2.0 (1.0-3.0)** 
 
2.0 (2.0-3.0)** 
   
0.321*** 
 
Length of hospital stay (days) 
 
8.0 (6.5-11.0)** 
 
7.0 (6.0–10.0)** 
   
0.903*** 
 
Clinical outcomes at six weeks 
Death  0 (0.0%)  0 (0.0%)    1.000 
Myocardial infarction  0 (0.0%)  0 (0.0%)    1.000 
Stroke  0 (0.0%)  0 (0.0%)    1.000 
Revascularization  0 (0.0%)  0 (0.0%)    1.000 
*List of abbreviations 
RIPC=Remote  ischemic  preconditioning;  CK=Creatinine  Kinase;  AKI=Acute  Kidney  Injury;  AF=atrial 
fibrillation; ICU=Intensive Care Unit; AUC=Area -under-the-curve. **Results shown as median (inter -
quartile range); *** P-value for Mann-Whitney-Wilcoxon test 
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6.7. Discussion  
 
In  the  most  recent  subgroup  analyses,  we  have  demonstrated  that 
simultaneous  multi-limb  IR  enhanced  cardioprotection  in  non-diabetic  patients 
undergoing unselected cardiac surgery as well as those having any cardiac surgery 
and receiving cardioplegia intra-operatively. Crucially we have also showed that our 
enhanced preconditioning stimulus decreased PMI and reduced the rate of new onset 
post-operative  AF  in  diabetic  patients  undergoing  CABG  surgery  although  similar 
subjects receiving cardioplegia were not significantly protected.  
Only a few studies investigating the effects of RIPC on PMI included diabetic 
patients: in literature we found 7 RCTs excluding subjects with DM (286, 291, 293, 
297-299, 302), 8 RCTs including both diabetic and non-diabetic patients (282, 285, 
294-296,  300,  303,  305)  and  5  RCTs  not  clearly  documenting  the  inclusion  or 
exclusion of diabetic patients (284, 301, 304, 306, 445) (Table 6.21). Importantly, even 
when diabetic subjects were enrolled, those taking glibenclamide were excluded due 
to its interference with RIPC-induced cardioprotection (549).  
Our  group  conducted  the  first  major  clinical  study  (291)  including  45  non-
diabetic  patients  undergoing  CABG  with  or  without  valve  surgery  with  cold 
cardioplegia: subjects randomised to standard RIPC sustained a significantly reduced 
PMI, similarly to our subgroup analysis comprising a larger cohort of 107 non-diabetic 
patients having unselected cardiac surgery with cardioplegia. 
Rahman et al (286) failed to demonstrate myocardial protection in non-diabetic 
patients undergoing CABG surgery with cardioplegia: similarly, when we analised data 
from  non-diabetic  patients  having  CABG  surgery  only  with  cardioplegia,  we  only 
obtained  a  non-significant  13%  reduction  of  72  hour  AUC,  although  in  this 
retrospective study our cohort size was remarkably reduced to 43 patients only.   259 
Table 6.21. Major clinical studies investigating the effects of RIPC in CABG surgery 
 
Group 
 
 
Number of patients and  
RIPC Stimulus 
 
Patient group and surgery 
setting 
 
 
Cardioprotection 
achieved 
 
Diabetic patients excluded 
 
Venugopal (291) 
(2009) 
 
 
45 
Upper-limb ischaemia  
(3 cycles of 5 min) 
Elective CABG±Valve Surgery  
 
Yes 
Thielmann (293) 
(2010) 
 
 
53 
Upper-limb ischaemia  
(3 cycles of 5 min) 
Elective CABG 
 
 
Yes 
 
Rahman  (286) 
(2010) 
 
 
162 
Upper-limb ischaemia  
(3 cycles of 5 min) 
Elective CABG  
 
No 
Li (302) 
2010 
81 
Lower limb ischemia (3 x 4 min) 
before (RIPC) or after (RIPerC) 
aortic cross-clamping 
 
Elective valve replacement 
 
Only in RIPerC group 
Lomirotov  (297) 
2012 
 
80 
Upper-limb ischemia  
(3 cycles of 5 min) 
 
Elective CABG 
 
No 
 
Kottenberg (298) 
2012 
72 
Upper-limb ischemia  
(3 cycles of 5 min) 
 
Elective CABG 
 
Only with RIPC given with 
isoflurane and not propofol 
 
Kim  (439) 
2012 
54 
Three-10 min cycles of leg 
ischemia prior to and after bypass  
 
Elective complex valve surgery  Not assessed 
Lucchinetti (299) 
2012 
 
55 
Lower limb ischaemia 
(4 cycles of 5 min) 
 
Elective CABG 
 
No  
 
Diabetic patients included 
 
Hausenloy  (282) 
(2007) 
 
 
57 
Upper-limb ischaemia 
(3 cycles of 5 min) 
 
Elective CABG 
 
Yes 
 
Wagner (295) 
2010 
101 
Upper limb ischaemia 
(3 cycles of 5 min) 
 
Elective CABG 
 
↓TnI at 8 hours only 
Tramadol group had↑ TnI at 
8, 16 and 24 hours. 
Choi (303) 
2011 
 
76 
Lower limb ischemia 
(3 x 10 min) 
Complex valve surgery 
 
Significant CK-MB reduction 
at 24 hours only 
 
 
Karuppasamy (294) 
2011 
54 
Upper-limb ischaemia  
(3 cycles of 5 min) 
 
Elective CABG surgery 
 
 
No  
Hong (285) 
2012 
70 
Lower-limb ischaemia 
(4 cycles of 5 min) 
 
Elective off-pump CABG 
 
Yes 
 
Young (296) 
2012 
 
96 
Upper-limb ischemia  
(3 x 5 min) 
 
High risk cardiac surgery 
 
No 
Thielmann (300) 
2013 
 
329 
Upper-limb ischaemia  
(3 cycles of 5 min) 
 
Elective CABG  
 
Yes   260 
 
Not clearly documented if diabetic patients included 
 
Li (301) 
2001 
 
 
 
40 
Aortic cross-clamping 
(two-3 minutes cycles of ischaemia 
and 2 minutes of reperfusion) 
 
MVR, AVR, DVR 
 
Improved pulmonary 
function and decreased 
inflammatory response 
Wu (306) 
2011 
 
40 
Upper-limb ischaemia  
(3 cycles of 5 min) with or without 
upper leg ischaemia (2x10 min 
cycles) 
 
MVR 
 
Reduced TnI release in 
combined upper arm and 
upper thigh IR group only 
Xie (304) 
2011 
 
73 
Upper-limb ischemia  
(3 cycles of 5 min) 
 
Elective valve replacement 
 
Yes 
Hong (284) 
2010 
 
130 
Upper-limb ischaemia 
(4 cycles of 5 min) 
 
Elective off-pump CABG  No 
Ali (292) 
2010 
 
100 
Upper-limb ischaemia  
(3 cycles of 5 min) 
 
Elective CABG  
 
Yes 
DVR=aortic  and  mitral  valve  replacement;  MVR=mitral  valve  replacement;  LIPC=limb  ischaemic 
preconditioning;  RIPC=remote  ischemic  preconditioning;  CABG=coronary  artery  bypass  graft; 
cTnI=cardiac  troponin  I;  cTnT=cardiac  troponin  T  CK=creatine  kinase;  AUC=area-under-the-curve; 
RIPost=remote  ischaemic  postconditioning;  CKD=chronic  kidney  disease;  DM=diabetes  mellitus; 
LVEF=left ventricular ejection fraction; CPB=cardiopulmonary bypass; BNP=brain natriuretic peptide; 
CRP=C-reactive protein; MV=mitral valve. 
 
 
 
 
 
In another study including 55 non-diabetic patients undergoing CABG surgery 
with cardioplegia, where a potent preconditioning stimulus of four-5 minutes cycles of 
lower limb IR (299), again no cardiac or neurological protection or clinical outcomes 
improvement  were  showed.  In  three  other  major  RCTs  excluding  diabetic  patients 
(293, 297, 298), discrepant results on cardioprotection outcomes  were obtained and 
only  the  study  from  Thielmann’s  group  (293)  showed  significant  PMI  reduction. 
However it is crucial to notice that in these studies, crystalloid cardioplegia was used, 
in contrast to blood cardioplegia utilised at the centre where we conducted our trial. 
In summary, proof-of-concept studies on diabetic or non-diabetic patients have 
reported discrepant results: whilst experimental studies have suggested the possibility   261 
of  inducing  cardioprotection  in  the  diabetic  heart  albeit  with  an  increased 
preconditioning  stimulus,  clinical  studies  have  so  far  not  entirely  confirmed  these 
findings,  although  no  trial  has  yet  been  conducted  with  the  inclusion  of  diabetic 
subjects only.  Intriguingly, in a retrospective analysis of patients undergoing CABG 
surgery (550), standard RIPC was associated with: 
  significant reduction of cTnI AUC by 41% in non-diabetic patients; 
  significant increase of 56% AUC in sulphonylurea-treated diabetics versus 
non-diabetics; 
  no significant change of PMI in: 
  all diabetics patients, regardless hypoglycaemic treatment administered; 
  non-sulphonylurea-treated diabetics (i.e. those treated with metformin or 
insulin); 
  non-sulphonylurea-treated diabetics compared to diabetics treated with 
other drugs; 
 
However, this was a retrospective analysis and certainly not powered for the 
designated endpoints and no control group of non-diabetics receiving sulphonylurea 
therapy  was  included,  although  of  course  for  ethical  reasons.  Moreover,  the  study 
could not clarify the reasons for the discrepant results between sulphonylurea-treated 
diabetics and non-diabetics, and in particular whether these could be secondary to 
molecular  effects  of  sulphonylurea  medications,  or  to  diabetes  in  itself  or  a 
combination of the two or even arterial blood glucose concentrations peri-operatively. 
Crucially, 40% of the diabetics in this study received the sulphonylurea glibenclamide, 
which  has  been  demsontrated  to  interefere  with  IPC  induced  cardioprotection  by 
blocking KATP channels in dogs (172, 551), pigs (552-554), and humans (555, 556). In   262 
our study, we excluded diabetic patients on glibenclamide for this reason,  and only 
gliclazide was used amongst sulphonylureas, which in contrast with the non-selective 
action of glibenclamide on pancreatic β-cells, vascular myocytes and cardiomyocytes, 
is  a  highly  pancreatic  selective  segretagogue  and  thereby  does  not  abolish  IPC 
effects.  
In addition, when we then went on to analyse any potential difference in PMI 
between  control  diabetics  and  control  non-diabetics,  we  found  no  statistically 
significant  difference  in  total  hsTnT  release  in  any  of  the  subgroup  analyses  we 
mentioned in the current chapter.  
 
 
 
 
Table 6.22. Comparison of peri-operative myocardial injury in control patients 
Patients  DM 
(mean (sd)) 
Non-DM 
(mean (sd)) 
Difference 
(95% CI) 
P value 
All diabetics (n=24)  
versus  
all non-diabetics (n=62) 
 
35.99 (21.86) 
 
36.43 (25.67) 
 
-0.44 (-12.24, 11.37) 
 
0.942 
Cardioplegia diabetics (n=18)  
versus  
Cardioplegia non-diabetics (n=52) 
 
34.88 (20.58) 
 
37.85 (27.43) 
 
-2.97 (-17.09, 11.16) 
 
0.676 
CABG diabetics (n=17)  
versus  
CABG non-diabetics (n=36) 
 
31.73 (18.63) 
 
30.29 (19.34) 
 
1.44 (-9.86, 12.73)  
 
0.800 
CABG-cardioplegia  diabetics 
(n=11)  
versus  
CABG-cardioplegia non-diabetics 
(n=26) 
 
27.59 (11.46) 
 
30.78 (21.81) 
 
-3.19 (-17.37, 10.99) 
 
0.650 
DM=diabetes mellitus; sd=standard deviation; CI=confidence interval; CABG=coronary artery bypass 
graft   263 
This  is  in  contrast  with  the  literature  on  animal  models,  showing  that  diabetic 
myocardium  is  more  resistant  to  IRI,  and  potentially  reflects  crucial  differences 
between animal and human models, including (457): 
  the single specific disease of animal models versus the presence of multiple co-
morbidities in the vast majority of patients with CAD potentially able to impact 
on RIPC-induced cardioprotection; 
  concomitant  multiple  drug  therapy  for  humans  which  can  again  potentially 
interfere with preconditioning in contrast with animal models; 
  the  frequent  presence  of  LV  hypertrophy/impairment  in  these  patients  with 
subsequent interaction with IRI; 
  the relatively advanced age of patients, which can potentially reduce the RIPC 
effects, versus young animal models used in the vast majority of experimental 
studies; 
  the use of type 1 DM models in the majority of preclinical studies, in contrast 
with human models, where 90% of DM cases are Type 2 DM. 
 
Crucially, a parallel unpublished study conducted at our Institute included diabetic 
and non-diabetic patients undergoing elective CABG surgery randomised to receive 
either  control  or  RIPC  comprising  three-5  min  cycles  of  upper  arm  IR  or  RIPC 
consisting of two-5 min cycles of simultaneous upper and lower limb.  Atrial trabeculae 
were isolated from the right atrial appendage and subjected to 90 minutes of simulated 
ischaemia and 120 minutes of simulated reperfusion, at the end of which the recovery 
of baseline contractile function was determined. Atrial trabeculae harvested from 13 
diabetic and 20 non-diabetic control patients were demonstrated to recover 24.5±2.4% 
and 29.3±1.3% of baseline contractile function, respectively. Treatment with standard   264 
RIPC  increased  the  recovery  of  baseline  contractile  function  in  both  non-diabetic 
(50.38±1.946%)  and  diabetic  patients  (41.55±1.946%),  however,  our  simultaneous 
multi-limb  preconditioning  stimulus  resulted  in  a  greater  recovery  of  baseline 
contractile  function  in  both  non-diabetic  (59.25±1.942%)  and  diabetic  patients 
(50.74±2.131%). As a positive control direct hypoxic preconditioning (HPC) of atrial 
trabeculae also improved the recovery of baseline contractile function (56.4±1.8% with 
HPC vs 27.5±1.7% in control; n=10 patients; p<0.0001). Therefore this study was the 
first  to  demonstrate that  in  vivo  RIPC can  protect  ex  vivo  atrial  trabeculae  against 
simulated IRI and confirmed that RIPC is able to produce a graded cardioprotective 
response.  
 
In  summary,  we  demonstrated  that  our  enhanced  preconditioning  stimulus 
significantly reduced total hsTnT release from 31.73±18.63 μg/L to 19.63±9.19 μg/L 
[12.09; CI 1.83, 22.35; p=0.022] and the incidence of new onset post-operative AF 
from 6 to 1 (p=0.023) in diabetics patients undergoing elective CABG surgery  with 
either cardioplegia or ICCF but not in those having cardioplegia only. We therefore 
showed  for  the  first  time  that  an  enhanced  RIPC  stimulus  is  potentially  able  to 
overcome the higher preconditioning threshold required in order to achieve significant 
cardioprotection.  In  addition,  we  also  demonstrated  that,  in  contrast  with  animal 
models,  human diabetic  myocardium  is not  more  resistant  to  IRI  than  non-diabetic 
hearts. However, again our findings derive from a relatively small cohort of patients 
and will need to be confirmed in a larger clinical trial: in this regards, our ERICCA will 
again provide the final conclusion as to whether an enhanced preconditioning stimulus 
will  improve  PMI  and  short  and  long-term  clinical  outcomes  in  these  higher  risk 
patients undergoing elective CABG surgery with or without valve surgery (290).    265 
CHAPTER 7 
 
 
 
7. Effects of RIPC on clinical outcomes in high-risk patients 
undergoing  CABG  surgery  with  or  without  valve  surgery 
(ERICCA Trial) 
 
 
7.1. Introduction and Rationale 
CABG  surgery  is  increasingly  becoming  the  treatment  strategy  of  choice  in 
patients with multi-vessel CAD, particularly involving LMS and/or proximal LAD, with 
an age greater than 65 years and with known DM (13, 14). The risk profile of patients 
undergoing CABG surgery continues to change due to factors such as (a) the aging 
population (the proportion of patients over 75 years old has increased by more than 
4.5-fold over the last decade with a 5-year mortality in this age group of 35%); (b) the 
increasing prevalence of diabetes (the proportion of diabetic patients has risen from 
15%  to  22%,  with  an  operative  mortality  of  2.6%)  resulting  in  an  increase  in  the 
number of higher-risk patients (defined as an additive EuroSCORE greater than or 
equal to 5) being operated on and a corresponding increase in overall operative risk to 
5-6% (33, 34). These higher-risk patients are at a greater risk of requiring inotropic 
support post-surgery and sustaining PMI, AKI (557) and stroke (1-3%) (558), resulting 
in  worse  clinical  outcomes.  Crucially,  PMI  has  been  associated  with  worse  clinical 
outcomes  following  surgery  (77-82).  Moreover,  the  incidence  of  AKI  post-cardiac 
surgery can be as high as 34% with up to 2% of patients requiring dialysis (364, 559,   266 
560),  which  increases  the  risk  of  death  7.9  times  (365).  Furthermore,  it  has  been 
reported that changes greater than 0.5 mg/dl (44 mmol/L) in creatinine after cardiac 
surgery also contribute to a significant increase in mortality at 30 days post-surgery 
(463). Clearly, new treatment strategies are required to protect the heart, the brain and 
the  kidney  during  higher-risk  CABG  with  or  without  valve  surgery,  in  order  to  that 
improve  clinical  short and  long term  clinical  outcomes  in  this  patient  group.  In  this 
regard, despite often discordant outcomes from the considerable number of relatively 
small proof-of-concept clinical studies so far published, RIPC has been demonstrated 
to be a simple, non-invasive, risk and cost-free intervention able to enhance the innate 
mechanism of cardioprotection and thereby to reduce myocardial damage in patients 
undergoing  cardiac  surgery  (282,  284,  285,  291,  293-299,  302-306,  445,  469). 
However, little data are available on the clinical significance of the impact of RIPC on 
PMI (Table  7.1): at the time of our current study initiation no RCT had determined 
whether  long-term  morbidity  and  mortality  are  improved  in  preconditioned  patients 
receiving  cardiac  surgery.  We  therefore  conducted  a  multi-centre,  double-blinded 
randomised-control clinical trial in order to establish the effects of RIPC on clinical 
outcomes  on  high-risk  patients  undergoing  CABG  surgery  with  or  without  valve 
surgery (ERICCA trial) (290).  
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Table 7.1. Summary of major clinical studies investigating clinical outcomes following discharge 
post-adult cardiac surgery 
 
Author 
 
Type of surgery  
 
 
Clinical Outcomes 
 
Mean EuroSCORE 
Li (301) 
2001 
 
MVR, AVR, DVR 
 
No difference in mortality rate at 30 
days post-surgery 
 
No mean EuroSCORE reported 
Hausenloy  (282) 
(2007) 
 
Elective CABG 
 
No clinical outcome  RIPC 3.2 (2.6)  
Control 3.3 (2.4) 
Venugopal (291) 
(2009) 
 
Elective CABG ± Valve 
Surgery  
 
No clinical outcome   RIPC 2.1 (1.9)  
Control 2.6 (2.1) 
Ali (292) 
2010 
 
Elective CABG  
 
No clinical outcome 
(abstract only) 
No mean EuroSCORE reported 
(abstract only) 
 
Thielmann (293) 
(2010) 
 
 
 
 Elective CABG 
 
No difference in MACCE at 30 days  
post-surgery 
 
Additive EuroSCORE 
RIPC 3.5 (2.0) 
Control 2.8 (2.2) 
Logistic EuroSCORE 
RIPC 3.0 (1.8) 
Control 2.4 (1.7) 
STS Score (%) 
RIPC 0.76 (0.49) 
Control 0.86 (0.73) 
 
Rahman  (286) 
(2010) 
 
 Elective CABG   No clinical outcome  RIPC 3 (IQR: 2, 4.5)  
Control 3 (IQR: 2, 5) 
Li (302) 
2010 
 
Elective valve replacement 
 
No clinical outcome  No mean EuroSCORE reported  
 
Karuppasamy (294) 
2011 
Elective CABG surgery 
 
 
No clinical outcome   RIPC 4.26 (2.03) 
Control 3.78 (2.15) 
Hong (284) 
2010 
 
Elective off-pump CABG  No clinical outcome  
(abstract only) 
No mean EuroSCORE reported  
(abstract only) 
Wagner (295) 
2010 
Elective CABG 
 
No clinical outcome  RIPC 5 (IQR: 1-6)  
Control 5 (IQR: 2-8)   
Tramadol 4 (IQR: 1-10)  
 
Choi (303) 
2011 
 
Complex valve surgery  
 
No clinical outcome  
 
RIPC 3.1 (1.4) 
Control 3.5 (2.4) 
 
Wu (306) 
2011 
 
MV surgery  No clinical outcome  
 
No mean EuroSCORE reported  
 
Xie (304) 
2011 
 
Elective valve replacement 
 
Improved NYHA status and LVEF at 
3 months post-surgery 
 
No mean EuroSCORE reported  
 
Young (296) 
2012 
 
High risk cardiac surgery  No clinical outcome  RIPC 7.1 (6.1)  
Control 6.6 (6.1) 
Lomirotov  (297) 
2012 
 
Elective CABG 
 
No difference in mortality rate at 30 
days post-surgery 
 
RIPC 2.2 (0.6)  
Control 2.5 (0.8) 
Kottenberg (298) 
2012 
Elective CABG 
 
No clinical outcome  No mean EuroSCORE reported  
 
Hong (285) 
2012 
 
Elective off-pump CABG 
 
No clinical outcome   Logistic EuroSCORE 
RIPC 2.1 (IQR: 1.5-3.1) 
Control 1.8 (1.3-3.5) 
 
Kim (305) 
2012 
 
Complex valve surgery  No clinical outcome  
 
No mean EuroSCORE reported  
Lucchinetti (299) 
2012 
 
Elective CABG 
 
Higher incidence in RIPC group for 
peri-operative composite end-point 
of new arrhythmias and MI but no 
difference at 6 months 
 
 
No mean EuroSCORE reported  
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Thielmann (300) 
2013 
 
Elective CABG  
 
Reduced all-cause mortality rate and 
MACCE at 1.5 years (mainly driven 
by reduced MI rate)  
 
Additive EuroSCORE 
RIPC 4.7 (1.9) 
Control 4.9 (2.0) 
Logistic EuroSCORE 
RIPC 4.1 (2.8) 
Control 4.6 (4.0) 
EuroSCORE II(%)  
RIPC 1.2 (0.5) 
Control 1.2 (0.5) 
 
RIPC=remote ischaemic preconditioning, MACCE=major cardiovascular  and cerebrovascular  events; 
CABG=coronary artery bypass graft; MVR=mitral  valve replacement; AVR=aortic valve replacement; 
DVR=double valve replacement; IQR=interquartile range; NYHA=New York health association 
 
 
7.2. Aims and Objectives 
7.2.1. Hypothesis 
We hypothesised that RIPC induced by brief arm IR improves clinical outcomes at one 
year  in  higher-risk  adult  patients  undergoing  CABG  with  or  without  valve  surgery 
compared to control (PICO=Population, Intervention, Comparator, Outcome). 
 
 
7.2.2. Overall Aim 
To  determine  whether  RIPC  improves  clinical  outcomes  at  one  year  in  high-risk 
patients undergoing CABG surgery with or without valve surgery. 
 
 
7.2.3. Objectives 
7.2.3.1. Primary research objective 
To  determine  whether  RIPC  improves  one  year  clinical  outcomes  in  patients 
undergoing CABG with or without valve surgery.  
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7.2.3.2. Secondary research objectives 
To determine whether, in patients undergoing CABG with or without valve surgery, 
RIPC: 
a.  improves 30-day clinical outcomes; 
b.  has an effect on all-cause death; 
c.  reduces PMI; 
d.  reduces AKI and preserves renal function;  
e.  improves patient morbidity, assessed by parameters such as: 
i.  ITU stay, 
ii.  inotrope score, 
iii.  six minute walk test, 
iv.  quality of life assessment; 
f.  improves  LVEF  measured  by  echocardiography  in  a  substudy  of  patients 
recruited via selected hospitals. 
 
 
 
7.3. Methods 
7.3.1. Overview 
We  conducted  a  multi-centre  double-blinded  randomised  control  clinical  trial  to 
investigate the effects of RIPC on clinical outcomes in high-risk patients undergoing 
CABG with or without valve surgery. A schematic overview of study design is given in 
Fig. 7.1. 
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Fig. 7.1. Study Synopsis 
 
CABG=coronary  artery  bypass  surgery;  PIS=patient  information  sheet;  SMWT=six  minute  walk  test; 
QOL=quality  of  life  questionnaire;  RIC=remote  ischaemic  conditioning;  AUC=area  under  the  curve; 
NGAL=neutrophil gelatinase associated lipocalin; ITU= intensive therapy unit; ECG=electrocardiogram; 
MACCE=major adverse cardiovascular and cerebrovascular events. 
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7.3.2. Ethical approval, informed consent and ethical considerations 
The study conformed to the spirit and the letter of the declaration of Helsinki, and in 
accordance  with  the  UCL  Good  Clinical  Practice  Guidelines.  Patients  gave  their 
informed consent to participate in the study and  could decide to withdraw from the 
study at any time without prejudice to their future care.  
Patients’  recruitment  and  consent  occurred  through  two  different  pathways,  the 
preadmission clinic, approximately 2 weeks prior to surgery, where eligible patients 
who had already received the patient information sheet (PIS) were given further full 
explanation of study details and potential implications, and the cardiac ward, where 
subjects awaiting surgery at the recruiting hospital were identified, given the PIS and 
further approached after 24 hours for consent, thereby after being given sufficient time 
to be able to give an informed consent. 
 
7.3.2.1.  Ethical  committee  review.  East  London  3  Research  Ethics  Committee 
reviewed and approved the trial (10/H0701/111). Copies of the approval letters were 
filed in the study files at each centre. Previous Ethical Approval was already in place to 
investigate  RIPC  in  the  setting  of  CABG  with  or  without  valve  surgery  (REC  Ref: 
06/20502/83). 
 
7.3.2.2. Data handling and record keeping. Electronic data will be returned to the 
London  School  of  Hygiene  and  Tropical  Medicine  (LSHTM)  and  kept  for  15  years 
following completion of the study. The use of the data from the study will be controlled 
by the chief investigator and the Clinical Trials Unit at the LSHTM. A signed hard-copy 
of the RIPC intervention sheet WAS kept at each centre and copied to the Clinical 
Trials Unit at the LSHTM.    272 
7.3.3. Study Design 
7.3.3.1. Primary research objective 
A multi-centre double-blinded randomised controlled trial to investigate whether RIPC 
improves clinical outcomes at one year in high-risk patients undergoing CABG with or 
without valve surgery. 
 
7.3.3.2. Number of centres  
The trial, co-ordinated by the Clinical Trials Unit, LSHTM (London), recruited patients 
were from the following 30 centres: 
  UCLH Heart Hospital  
  King’s College London Hospital 
  Papworth Hospital  
  Hammersmith Hospital 
  St Thomas’ Hospital 
  Essex Cardiothoracic Centre 
  Royal Sussex County Hospital 
  Royal Brompton Hospital 
  Harefield Hospital  
  Derriford Hospital 
  Manchester Royal Infirmary 
  Swansea Morriston Hospital 
  Edinburgh Royal Infirmary 
  St Barts’ Hospital 
  London Chest Hospital   
 
  St George’s Hospital 
  North Staffordshire University Hospital 
  University Hospital, Galway 
  Southampton General Hospital 
  Cardiff University Hospital 
  Golden Jubilee Hospital 
  Leeds General Infirmary 
  University Hospital, Coventry 
  Blackpool Victoria Hospital 
  Trent Cardiac Centre 
  Northern General Hospital 
  Castle Hill Hospital 
  Glenfield Hospital 
  Wythenshawe Hospital 
  Wolverhampton Hospital 
 
 
7.3.3.3. Patient Recruitment 
Adult patients were screened against inclusion and exclusion criteria and recruited if 
considered eligible to the study. 
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7.3.3.3.1. Inclusion criteria  
a.  Patients aged 18 years and above.  
b.  Patients undergoing CABG with or without valve surgery using blood cardioplegia.  
c.  Patients  with  an  additive  EuroSCORE  greater  than  or  equal  to  5.  This  was 
calculated  with  the  Microsoft  excel  EuroSCORE  calculator 
(http://www.euroscore.org/calculators) (47) and is an accepted criterion for defining 
higher-risk patients.  
 
7.3.3.3.2. Exclusion criteria  
a.  Cardiogenic shock or cardiac arrest on current admission (see chapter 3).  
b.  Pregnancy.  
c.  Significant PAD affecting the upper limbs. 
d.  Patients with significant hepatic dysfunction (INR>2) 
e.  Patients with significant pulmonary disease (FEV1<40% predicted).  
f.  Patients with known renal failure with an eGFR<30 mL/min/1.73 m2. 
g.  Patients on glibenclamide or nicorandil, as these medications may interfere with 
RIPC (171, 441) 
h.  Patients recruited into another study, which might have impacted on the ERICCA 
study.   
 
7.3.3.3.4. Randomisation 
The randomisation procedure, co-ordinated centrally by the LSHTM, was carried out 
as close as possible to the time of surgery, via a secure web site and stratified by 
centre using random permuted blocks. This was only accessed by the research nurse 
responsible  for  performing  either  the  RIPC  or  control  protocol,  who  was  the  only   274 
person in each centre aware of the treatment allocation for the patient and was not 
involved in the data collection other than those relating to the actual randomisation 
procedure.  
 
7.3.3.3.5. Treatment allocation and Method of blinding 
Treatment allocation was only known by one research nurse at each centre. Patients, 
cardiac surgeons, the research nurse collecting the data, and the assessor of clinical 
outcomes were blinded to the treatment allocation. A research nurse at each study site 
remained  blinded  to  the  allocation  of  patients  to  either  real  or  sham  RIPC.  The 
preconditioning procedure was performed by an investigator not involved in sample 
collection or data analysis.  
 
7.3.3.3.6. Withdrawal from study  
Patients could decide to withdraw from the study at any time without prejudice to their 
future care, although this was uncommon, because of the non-invasive nature of the 
intervention  and  the  follow-up,  which  was  integrated  within  routine  clinical  care 
wherever possible. We allowed in our sample size calculation for a drop-out rate of up 
to 5% (from the SYNTAX trial(561)) although it was expected to be lower than this.  
Patients were encouraged to allow data and samples collected before withdrawal to be 
used in the analyses. However, if consent to use data/samples was also withdrawn, 
then these were discarded. Patients withdrawing from the study were to be continued 
to be followed-up by their local team. There should be no need for further follow-up 
from the research team.  
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7.3.3.4. Intervention: RIPC and sham treatment protocols 
RIPC was applied after anaesthesia induction and consisted of inflation of a standard 
BP  cuff  applied  to  the  upper  arm  to  200mmHg  for  5  minutes,  then  deflated  for  5 
minutes,  a  cycle  which  was  repeated  4  times  in  total.  For  patients  with 
SBP>185mmHg, the cuff was inflated to at least 15mmHg above the patient’s SBP. 
The sham RIC protocol, applied after anaesthesia induction, was delivered using a 
standard BP cuff as follows: the air valve on the BP cuff was first opened such that the 
cuff was not inflated on squeezing the attached bulb. The bulb was then squeezed for 
a duration of 15 seconds to give the impression that the cuff was being inflated. After 5 
minutes  the  air  valve  was  closed  to  give  the  impression  that  the  cuff  was  being 
deflated. After 5 minutes, the air valve was opened again and the bulb squeezed as 
before. This  cycle  was  repeated 4  times  in  total.  These  interventions  were  not  to 
prolong the anaesthetic time or delay the onset of surgery.  
 
 
7.3.3.5. and 7.3.3.6. Anaesthetic procedure and Surgical Procedure 
These have already been discussed in chapter 3. 
 
 
 
7.3.3.7. Study Endpoints: rationale and assessment 
7.3.3.7.1. Study Primary Endpoint. 
 The  study  primary  endpoint  is  the  MACCE  rate  at  1  year  post-surgery, 
comprising  death,  MI,  revascularisation  and  death  (these  have  already  been 
defined in chapter 3.   276 
7.3.3.7.2. Study Secondary Endpoint. 
7.3.3.7.2.1. 30 day MACCE 
 
7.3.3.7.2.2. All cause death 
 
7.3.3.7.2.3. PMI 
This was assessed by measuring serum hsTnT pre-operatively and at 6, 12, 24, 48, 72 
hours post-surgery: several studies (77-82) have demonstrated that following cardiac 
surgery,  PMI,  indicated  by  cardiac  biomarkers  rise  in  the  post-operative  period,  is 
associated with worse short and long-term clinical outcomes. Assay details and AUC 
calculation  have  already  been  discussed  in  chapter  3.  Each  blood  sample  was 
labelled, centrifuged, divided into two samples, aliquoted, frozen (at -20ºC) and stored 
locally.  Every  quarterly  period  throughout  the  2-year  recruitment  period  batches  of 
samples were couriered from the recruitment centres to The Doctors’ Laboratories in 
London for analysis.  
 
7.3.3.7.2.4. AKI 
The rationale for the evaluation of AKI has already been elucidated in chapter 3.  
 
7.3.3.7.2.5. Creatinine  
Creatinine will be measured pre-operatively and daily for the first three post-operative 
days, at 6 weeks and one-year post-CABG with or without valve surgery.  
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7.3.3.7.2.6. Neutrophil Gelatinase Associated Lipocalin (NGAL) 
Plasma NGAL is a new early marker of AK, with levels rising rapidly following renal 
damage, and has been used to evaluate renal injury in the context of cardiac surgery 
(562, 563). NGAL was measured at 4 time-points: pre-operatively, 6, 12 and 24 hours 
post-coming  off  cardiac  bypass,  from  which  a  24  hours  AUC  was  calculated.  The 
NGAL  Rapid  ELISA  Kit  measures  human  NGAL  in  plasma/serum,  with  a  positive 
predictive  value  for  acute  renal  failure  is  over  90%  (562,  563).  Each  NGAL  blood 
sample was labelled, centrifuged, then plasma was divided into two samples, frozen 
(within 4 hours of collection) and stored locally at -20 ºC. Every quarter throughout the 
2 year recruitment period batches of samples were couriered to a single laboratory for 
analysis (Caltag Medsystems, Buckingham, UK).  
 
 
7.3.3.7.2.7. Inotrope requirement 
The  rationale  for  this  study  end-point  has  been  discussed  in  chapter  2.  Data  on 
inotrope  use  were  collected  daily from the medical drug  chart on  the  ICU and  the 
inotrope score will be calculated using the cited formula from Ko et al (443) at 0 (time 
when coming off bypass), 24, 48 and 72 hours after the surgery. We expect RIPC to 
impact on this outcome measure by reducing PMI and therefore preserving LV systolic 
function. 
 
7.3.3.7.2.8. and 7.3.3.7.2.9. Duration of ICU and hospital stay 
These have already been discussed in chapter 3. 
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7.2.3.10.2.10. The Six minute walk test (6MWT) 
The 6MWT was used to evaluate the functional status of patients undergoing CABG 
with or without valve surgery (564). Shortly after CABG with or without valve surgery, 
functional  capacity  is  significantly  reduced,  but  rapidly  improves  after  cardiac 
rehabilitation. This has been found to be independent of age, sex, co-morbidities and 
baseline functional capacity (564). The 6MWT was performed at baseline, 6 weeks, 
and one year. Patients were instructed to walk as far as possible along a straight, flat 
hospital corridor in 6 minutes. 
 
7.3.3.10.2.11. Quality of life 
A retrospective analysis on 1180 patients undergoing CABG surgery between 1994 
and 1996 showed that of 621 patients assessed for quality of life at 10 years, 85% had 
a quality of life within a 95% CI of the score found in the general population with similar 
age and that 14.7% of patients reported poor quality of life (565). Significant predictors 
of  poor  long-term  quality  of  life  were  current  smoking,  CCS  grade  III  or  IV,  redo-
operation,  female  sex,  DM,  PAD,  more  than  2-day  stay  on  ICU,  and  COPD. 
Interestingly  25%  of  patients  with  poor  outcome  of  Health-Related  Quality  of  Life 
(HRQOL)  questionnaire  had  grade  IV  angina.  The  HRQOL  questionnaire 
(www.euroqol.org) was used to assess patient quality of life post-CABG with or without 
valve surgery, at baseline, 6 weeks, 3, 6 and 9 months and one year. For details on 
HRQOL, see Appendix. 
 
7.3.3.10.2.12. ECHO Substudy 
LVEF  post-CABG  with  or  without  valve  surgery  is  a  strong  determinant  of  clinical 
outcome (1): a subgroup of 140 patients at a selection of centres had a transthoracic   279 
echocardiogram (TTE) performed at baseline to assess LVEF (by bi-planar Simpson’s 
technique and 3D techniques) either in the surgical pre-admission clinic or as an in-
patient prior to surgery and was to be repeated at one year. 
We intended to assess LV dimensions and LV volumes, LVEF, global peak systolic 
strain in radial and longitudinal axis, and mitral annular plane systolic excursion, RVEF 
by  fractional area  change  and  tricuspid  annular  plane  systolic  excursion  through a 
standardised protocol: 
1.  Acquisition  includes  3  short-axis  views  at  MV,  papillary  muscle  and  apical 
levels, and 4 apical views LV 4-chamber, RV 4-chamber, LV 2-chamber and LV 
3-chamber views.  
2.  When  3D  imaging  was  available,  2  full  volume  acquisitions  were  acquired 
during breath holding with 4 beats averaging.  
3.  Detection of severe valvular disease and other abnormalities were reported.  
Only recent echo machines from GE and Philips were used for the study. The Echo 
core laboratory at the Heart Hospital was in charge of analysis, interpretation, quality 
control, observer and centre variability, and echo database. 
 
7.3.3.2.13. Genetic and Biomarker analysis  
We  also  intend  to  perform  genetic  and  biomarker  analysis  in  order  to  evaluate 
expressions of genes and protein synthesis implicated in the mechanistic pathways of 
RIPC. At the time of writing of this thesis, specific targets of this analysis had not yet 
been determined, however we feel that the collection of such a considerable amount of 
data gives us the opportunity to have a very valuable resource available for further 
understanding mechanisms involved in RIPC.  
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7.3.3.8. Statistical considerations and sample size determination 
7.3.3.8.1. Primary clinical endpoints 
We originally planned to recruit 1610 patients through 30 surgical centres. In 
the SYNTAX study (14) the MACCE rate was 12.4% of patients at 12 months following 
CABG surgery. However, the patients recruited into the SYNTAX study were low-risk 
with a mean EuroSCORE of 3.8±2.7, whereas the patients we recruited in our study 
had a EuroSCORE greater than or equal to 5. In another study comprising higher-risk 
patients with LMS disease, the MACCE rate at one year was estimated to be 25% 
(566). Therefore, for our higher-risk CABG with or without valve surgery patients we 
estimated a MACCE rate of 20% at one year and in order to detect a 27% relative 
reduction in this primary endpoint in the RIPC-treated group (from 20.0% to 14.6%), 
with a power of 80% and a significance level of 5%, a sample size of 770 patients 
were required for each trial arm (1540 in total). A trial of this size would be able to 
detect an observed relative reduction of 20% (i.e. a risk ratio of 0.8) as statistically 
significant based on an event rate in the control arm of 20%. To allow for dropouts 
(4.5% in the SYNTAX study), we planned to recruit 1610 patients in total (805 patients 
each arm).  
Prior to the start of our study, we intended to recruit over a 24-month period as 
we expected an enrolment of approximately 3 high-risk patients per month at each of 
the  recruiting  centres.  At  least  80%  of  patients  undergoing  CABG  surgery  in  our 
recruiting centers had an additive EuroSCORE greater than or equal to 5. Each centre 
operates on about 5-6 high-risk surgical patients per week, meaning that we needed to 
recruit at least 25% of the eligible patients.  
Survival  analyses  techniques  will  be  used  for  MACCE  and  other  clinical 
endpoints.  Hazard  ratios  and  confidence  intervals  will  be  calculated  using  Cox   281 
proportional  hazards  modelling  and  Kaplan-Meier  curves  will  be  produced.  The 
assumptions underlying the Cox model will be assessed. In addition risk differences at 
one-year  together  with  95%  confidence  intervals  will  be  calculated.  Differences  in 
means (continuous variables) together with 95% confidence intervals will be calculated 
using  linear  regression  models  and  analysis  of  covariance  techniques  where 
appropriate.  Analysis  will  be  by  intention  to  treat  using  all  available  data.    The 
subgroups will be analysed using interaction tests. A Data Management Committee 
(DMC) will be convened to periodically review data. This will be the only group, along 
with the statistician producing the reports for the DMC, who will see interim analyses 
by treatment.  
 
 
7.3.3.8.2. Secondary clinical endpoints 
7.3.3.8.2.1. PMI  
Our group demonstrated that RIPC reduced PMI by 43% in patients undergoing CABG 
surgery from 36.1 μg/L.72hrs to 20.6 μg/L.72hrs (282). The mean difference was 15.5 
ng/ml  with  a  pooled  SD  of  17.8  μg/L.  To  demonstrate  such  a  difference  as  being 
statistically significant at the 5% level, with 90% power, 28 patients per group were 
required per group. 
 
7.3.3.8.2.2. Inotrope score  
Cheung et al (281) demonstrated that RIPC reduced the inotrope score 3 hours post-
operatively  by  29%  in  children  undergoing  corrective  cardiac  surgery  from 
11.4µg/kg/min to 8.1µg/kg/min. The mean difference was 3.3µg/kg/min with a SD of   282 
4.1µg/kg/min in each group. To demonstrate a similar difference as being statistically 
significant at the 5% level, with 90% power, 33 patients were required per group. 
 
7.3.3.8.2.3. The 6MWT 
Cardiac  rehabilitation  has  been  demonstrated  to  improve  the  6MWT  by  46%  in 
patients  following  CABG  surgery  from  281  metres  to  411  metres  (564).  We 
conservatively expected to demonstrate a difference of a third of this magnitude (i.e. 
15%). The mean difference would thus be 42 metres with a pooled SD of 99 metres. 
To demonstrate such a difference as being statistically significant at the 5% level, with 
90% power, 117 subjects were required per group. 
 
7.3.3.8.2.4. Quality of life 
The sample size of 770 patients per treatment group was sufficient to detect even 
small effects of RIPC on quality of life at the 12-month follow-up. With 770 patients per 
group, a 90% power could detect an effect size of 0.2 in the HRQOL as statistically 
significant  at  the  5%  level.  This  effect  size  is  similar  to  that  found  for  studies  of 
pacemaker implantation and is at the lower limit of a clinically worthwhile difference 
(567).  
 
7.3.3.8.235. Echo substudy 
In a previous study, RiPostC was reported to improve LVEF by 7% from 49% to 56% 
at one year in STEMI patients (568). In order to detect a smaller mean difference of 
5% with a common SD of 10.5%, our substudy required 70 patients in each group 
using 80% power and a 5% significance level.  
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7.3.3.9. Study duration and timetable 
The anticipated duration of the study was 48 months, distributed as follows: 
 1)  0-6 months. Study preparation to obtain: 
  Ethical  and  Research  &Department  approval  for  each  recruiting  centre  (0-2 
months). 
  Staff recruitment (advertising, interviews and training) (0-2 months).  
  Research protocol publication. Staff training at the 30 recruiting centres (4-6 
months). 
2)  6-30 months. Patient recruitment (1610 patients in 30 centres) over 24 months 
3)  7-32 months. Six week follow-up with: 
  Assessment of clinical outcomes. 
  6MWT 
  Blood test for creatinine 
  HRQOL questionnaire 
  ECG 
4)  9-39 months. 3, 6, 9 month HRQOL questionnaire  
5)  18-42 months. One year follow-up with: 
  Assessment of clinical outcomes.  
  SMWT 
  Blood test for creatinine 
  HRQOL questionnaire 
  ECG 
  Echocardiography (substudy) 
6) 42-48 months. Data analysis, with: 
  Closing the database, data cleaning and analysis of the data.   284 
  Time for production of the draft report.  
  Dissemination of findings and publication in a peer-reviewed journal. 
 
 
7.3.3.10. Criteria for Discontinuation 
This may depend on: 
  Individual subject 
  Patients were free to choose to withdraw from the trial at any time.  
  Operative complications that could directly influence graft revascularisation.  
  Unexpected safety issues on the advice of the DCM  
 
 
7.3.3.11. Data collection 
Recruited patients had data collected at the time of consent and in the peri-operative 
period till hospital discharge (see Appendix).  
 
7.3.3.11.1. Six weeks post-surgery 
Patients were reviewed in clinical outpatients’ clinic as per normal procedure. ECG 
and  6MWT  were  performed  and  blood  tests  were  taken  for  creatinine.  Patients 
completed HRQOL questionnaire and information on clinical outcomes was recorded. 
 
7.3.3.11.2 Three, Six and Nine months post-CABG with or without valve surgery 
Patients were contacted and the HRQOL questionnaire completed over the telephone 
or sent by post/e-mail to complete and return.  
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7.3.3.11.3. One-year post-surgery 
Patients are reviewed in research outpatient clinic by research nurse, as most surgical 
centres do not routinely follow-up post-surgery at one year. The general practitioner 
(GP)  and  hospital  medical  notes  will  be  reviewed  regarding  any  major  cardiac  or 
cerebral events. If the patient is unable to attend an outpatient clinic appointment the 
one-year follow up may be conducted over the telephone. In addition, the following 
information will be taken: 
  Weight  
  Heart rate 
  Blood Pressure  
  Recording of primary endpoints (see Appendix) 
  ECG 
  Blood test taken for creatinine 
  TTE to assess LVEF (substudy) 
  6MWT will be performed 
  HRQOL questionnaire.  
Analysis of data will be checked and information recorded. Patient will therefore be 
discharged from the clinical study at one year.  A summary of the study procedure 
schedule is given in Table 7.2. 
The trial shall be considered finished when the last patient recruited reaches the 1-
year follow up point. At that point notification of closure of the study will be sent to the 
Research Ethics Committee.  
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Table 7.2. Study procedures table  
   
Pre-
operative 
period 
 
 
Operatio
n 
 
Post-operative in hospital 
 
Outpatients 
  Scree
n 
PAC 
Or 
IP 
Day 0  Post-op 
Day 1 
Post-op 
Day 2 
Post-
op 
Day 3 
Discharge  6 
wks 
3 
mths 
6 
mths 
9 
mths 
12 
mths 
 
Clinical Assessments 
 
Informed 
consent 
 
 
X                     
Review of 
inclusion/ 
exclusion 
criteria 
 
 
X                     
History and 
examination 
 
 
X                     
Inotrope score 
 
    X  X  X  X             
ICU stay 
 
            X           
Hospital stay 
 
            X           
Six min walk 
test 
 
 
X            X        X 
Echo (substudy) 
 
  X                    X 
QOL 
questionnaire 
 
 
X            X  X  X  X  X 
 
Laboratory Assessments 
 
Creatinine 
 
    X  X  X  X    X        X 
hsTnT   
 
X 
Pre-op,  
6, 12 hr 
X 
24hr 
X 
48hr 
X 
72hr             
NGAL   
 
X 
Pre-op,  
6,12 hr 
X 
24hr                 
Urine volumes 
 
    X  X  X  X             
Proteomics 
 
 
  X 
Pre-
op 
X 
PostRIC                   
 
Clinical outcomes 
 
Death 
 
            X  X        X 
MI 
 
            X  X        X 
Revascularisatio
n 
 
         
  X  X        X 
Stroke 
 
            X  X        X 
PAC=pre-admission clinic; IP=in-patient; ICU=intensive care unit; QOL=quality of life; hsTnT=high sensitivity 
troponin-T; NGAL=neutrophil gelatinase lipocalin; MI=myocardial infarction 
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7.3.3.12. Assessment of Safety  
Crucially, our study is not a trial of an investigational medicinal product. Therefore, by 
definition all untoward occurrences are adverse events rather than adverse reactions. 
Safety assessments will be from time of randomisation to completion of follow up: an 
adverse event is any untoward medical occurrence affecting a patient, which does not 
necessarily  have  a  causal  relationship  with  the  RIPC  stimulus.  The  terms  “mild, 
moderate or severe” are used to describe the intensity of a specific event or reaction, 
which is not the same as “serious” (see below). An adverse event can therefore be any 
unfavourable  and  unintended  sign  (including  an  abnormal  laboratory  finding), 
symptom,  or  disease  temporally  associated  with  the  use  of  RIPC  whether  or  not 
considered related to the technique.  
 
7.3.3.12.1. Serious adverse event (SAE)  
A serious adverse event (SAE) is any untoward medical occurrence/effect that:  
1.  Results in death.  
2.  Is life-threatening.  
3.  Requires hospitalisation or prolongation of existing inpatient’s hospitalisation.  
4.  Results in persistent or significant disability or incapacity.  
“Life-threatening”  in  the  definition  of a  serious  adverse  event  refers to  an  event  in 
which the subject was at risk of death at the time of event; it does not refer to an event, 
which hypothetically might have caused death if it was more severe.  
 
7.3.3.12.2. Unexpected adverse event  
This is defined as an adverse event, the nature or severity of which is not consistent 
with an expected consequence of RIPC.    288 
7.3.3.12.3.  Expected  adverse  events  (recognised  to  be  caused  by  the  RIPC 
stimulus)  
The benign nature of the RIPC stimulus excluded there would be expected SAEs. Skin 
petechiae caused by cuff inflation were expected to be the only non-serious events in 
response to the RIPC stimulus and were be recorded on the Case Report Form (CRF).  
 
7.3.3.12.4. Expected SAEs related to usual clinical care  
These events are recognised complications of: 
1)  CABG with or without valve surgery. They were recorded on the CRF but did not 
need to be reported separately.  
  Death, PMI or MI. 
  Acute  renal  failure,  requiring  haemodialysis,  peritoneal  dialysis,  or 
haemofiltration. 
  AF. 
  Significant heart block requiring temporary or permanent cardiac pacing. 
  Bleeding requiring re-do surgery. 
2) Complications of surgery: 
  Bowel obstruction 
  Sepsis 
  Gastro-intestinal bleed or haematemesis 
  Chest infection 
  Respiratory failure 
  Respiratory tract infection 
  Pleural effusion 
  Urinary tract infection   289 
  Pulmonary embolism 
  Atrial flutter 
  Infection of donor site 
3) Complications due to administration of anaesthetic agents. 
4) Known adverse effects of other drugs used in routine clinical care. 
 
7.3.3.12.5. Unexpected adverse events  
Investigators will make their reports of all unexpected adverse events, whether serious 
or  not,  to  the  Clinical  Trials  Unit,  LSHTM.  SAEs  are  those  not  described  in  the 
previous  section  and  should  be  reported  with  an  assessment  of  causality  by  the 
Principal Investigator at each site. The Chief Investigator will be responsible for the 
prompt  notification  of  findings  that  could  adversely  affect  the  health  of  subjects  or 
impact on the conduct of the trial. Notification of confirmed unexpected SAEs will be to 
the Sponsor, the Research Ethics Committee and the DMC. All deaths will be reported 
to the sponsor irrespective of whether the death is related to cardiac surgery or is an 
unrelated event.  
Unexpected  non-serious  adverse  events  should  be  evaluated  by  the  Principal 
Investigatorr with an assessment of causality and intensity. The Clinical Trials Unit will 
keep  detailed  records  of  all  unexpected  adverse  events  reported.  Reports  will  be 
reviewed by the Chief Investigator to consider intensity, causality, and expectedness. 
As  appropriate  these  will  be  reported  to  the  sponsor,  the  DMC  and  the  Ethics 
Committee. The intensity will be classified as: 
  Mild: the subject is aware of the event or symptom, but this is easily tolerated.  
  Moderate:  the  subject  experiences  sufficient  discomfort  to  interfere  with  or 
reduce his or her usual level of activity.    290 
  Severe: the subject is unable to carry out usual activities and/or his/her life is at 
risk from the event.  
With regards to the relationship of causality, this will be: 
  Probable:  a  causal  relationship  is  clinically/biologically  highly  plausible  and 
there is a plausible time sequence between onset of the adverse event and 
administration of the intervention.  
  Possible: a causal relationship is clinically/biologically plausible and there is a 
plausible time sequence between onset of the adverse event and administration 
of the intervention.  
  Unlikely: a causal relationship is improbable and another documented cause of 
the adverse event is most plausible.  
  Unrelated:  a  causal  relationship  can  definitely  be  excluded  and  another 
documented cause of the adverse event is most plausible.  
 
7.3.3.13. Research Governance  
The nominated sponsor of our research study is UCL. 
Additionally a number of committees are in place in order to ensure the study validity: 
1.  Trial Steering Committee (TSC), meeting every 6 months and responsible for 
drafting the final report and submission for publication. 
2.  Program  Management  Group  (PMG),  meeting  weekly  during  the  planning 
stages of the study and less frequently during recruitment. 
3.  DMC, meeting at the start of the trial to establish a DMC charter then at 24, 36 
and 48 months to determine if there are any unforeseen effects of RIPC.  
4.  Endpoint  validation  committee  (EVC),  meeting  quarterly  to  validate  and 
adjudicate primary endpoints.   291 
7.4. Preliminary results 
Patients’  recruitment  started  in  April  2011  at  the  Heart  Hospital  and  then 
gradually progressed across the 30 participating centres in the UK: it was completed in 
March 2014 when the last patient was enrolled to the study for a total of 1612 subjects 
recruited.  An extension of the recruitment period was necessary in order to enrol the 
required number of patients as per sample size calculation. This also implies that the 
last outpatient follow-up will be due in March 2015 (Fig. 7.2).  
During these two years I have been involved in PMG and TSC meetings. I have 
been the clinical lead for the study at the Heart Hospital, the leading centre for the 
ERICCA trial. I have contributed to protocol changes and liaised with members from 
cardiothoracic and anaesthetic teams in order to ensure appropriate running of the 
study at all the participating centres.  
 
Fig. 7.2. The ERICCA Trial: study progress between April 2011 and March 2013 
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I  have  been  responsible  for  site  visit  initiations  across  the  UK  and  staff 
recruitment  and  coordinated  regular  meetings  with  biochemists  to  guarantee 
appropriate collection and storage of blood samples. I have been the reference point 
for  research  nurses  and  colleagues  when  question  arose  regarding  the  different 
aspects  of  the  study.  I  have  adjusted  the  Case  Report  Form  as  appropriate  and 
prepared  Standards  of  Procedures  on  hsTnT,  NGAL,  creatinine,  biomarkers  and 
6MWT (see Appendix). Crucially I have been the unblinded member of the team at the 
Heart hospital and I have written the relevant published peer-reviewed paper (290). I 
recruited  the  very  first  study  patients  at  the  Heart  Hospital:  our  clinical  trial  then 
progressed to recruit the expected number of patients with variable rates of enrolment 
across  the different  centres  (Figures.  7.3-7.4).  The  Adjudication  committee  is now 
meeting regularly: we intend to disseminate the study results in 2015. 
 
Fig. 7.3. Recruitment by centre 
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Fig. 7.4. Recruitment by month 
 
 
 
 
 
7.5. Discussion 
The  risk  profile  of  patients  undergoing  CABG  surgery  is  progressively 
increasing given the aging population, the growing prevalence of diabetes and other 
significant co-morbidities, and the more advanced complexity of cardiac surgery (34). 
This has resulted in an increase of operative risk of approximately 5-6% (33, 34) with a 
subsequent  augmented  potential  to  sustain  PMI,  AKI  (557),  stroke  (558)  and  to 
therefore  result  in  worse  short  and  long-term  clinical  outcomes.  RIPC  has  been 
demonstrated to  be a simple, non-invasive, risk-free intervention potentially able  to 
protect the myocardium and other organs from IRI (282, 284, 285, 291, 293-299, 302-
306,  445,  469)  (see  chapter  1).  In  our  ERICCA  trial  we  have  specifically  selected 
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higher-risk  patients  as  these  subjects  represent  the  group  which  more  significantly 
requires  optimisation  of  protective  strategies,  therefore  differently  from  previously 
published studies where no EuroSCORE was clearly documented or patients had a 
lower mean value in the vast majority of cases (Table 7.1). In line with the rationale of 
my  single-centre  study,  we  also  decided  to  increase  the  intensity  of  our 
preconditioning stimulus to four-5 minutes cycles of upper arm IR in order to maximise 
cardioprotection and to overcome potential resistance of the diabetic myocardium and 
interference  from  other  factors  including  volatile  anaesthetics.  Moreover,  the  same 
preconditioning  stimulus  had  successfully  been  applied  to  patients  presenting  with 
STEMI and undergoing PPCI (356).  
Crucially,  the  vast  majority  of  RCTs  investigating  the  effects  of  RIPC  are 
relatively small proof-of-concept studies and have often given discordant results for 
potential reasons, which we have comprehensively elucidated in chapter 3. At the time 
of  the  ERICCA  initiation,  a  significant  part  of  these  studies  endpoints  included 
surrogate endpoints such biochemical assessments of PMI through serial evaluation of 
serum levels of cardiac enzymes, yet very little data are available in literature with 
regards  to  the  potential  beneficial  effects  of  RIPC  on  short  and  long-term  clinical 
outcomes (Table 7.1). The very first study to describe the impact of RIPC on patients’ 
morbidity and mortality in the context of cardiac surgery reported no post-operative 
death  in  either  preconditioned  or  control  patients  30  days  after  elective  AVR,  MV 
surgery or double valve replacement (301). Similarly, no significant difference in major 
cardiac  and  cerebro-vascular  events  was  found  at  30  days  post-operatively  in  two 
small  studies  involving  patients  undergoing  elective  CABG  surgery  with  crystalloid 
cardioplegia  (293,  297).  Interestingly,  in  a  study  including  high-risk  patients  (296) 
(mean EuroSCORE of 7.1±6.1 in the RIPC group and 6.6±6.1 in the control group,   295 
p>0.05),  again  no  difference  in  mortality  rate  was  found  at  30  days  post-surgery. 
However, an improvement of NYHA functional status and mean LVEF at 3 months 
post-operatively  was  found  in  preconditioned  patients  undergoing  elective  valve 
replacement (304). Additionally, RIPC, given with four-5 minutes cycles of lower limb 
IR to patients undergoing CABG surgery under strict anaesthetic regime (299), was 
associated with a higher peri-operative composite end-point of new arrhythmias and 
new MI, yet no significant difference was found at 6 months follow-up. 
Crucially,  in  the  so-far  largest  proof-of-concept  clinical  trial  investigating  the 
effects of RIPC in the context of elective CABG surgery, unpublished at the time of the 
initiation of the ERICCA trial, Thielmann et al (469) reported a statistically significant 
improvement of all-cause mortality and MACCE rate in preconditioned patients at 1 
year  and  at  follow-up  completion  (1.54+/-1.22  years),  which  was  mainly  driven  by 
reduced  incidence  of  new  MI,  whereas  no  significant  difference  was  found  in  the 
occurrence of cardiac death, stroke and repeat revascularisation. Interestingly, of the 
329  patients  randomised  and  included  in  the  intention-to-treat  analysis,  71  were 
excluded of which 61 with known DM, and therefore the final in per-protocol analysis 
comprised a total of 258 subjects. However, the study was a single-centre trial and 
adequately powered for the primary endpoint of PMI but not for secondary end-points 
including  clinical  outcomes  and  crucially,  despite  still  lower,  the  rate  of  all-cause 
mortality became non-statistically significant when deaths from sepsis were excluded.  
In addition, a significant number of systematic reviews and meta-analyses in 
patients undergoing cardiac or vascular surgery or elective PCI have been conducted 
(289, 446-456): the overall conclusion confirmed the beneficial effects of RIPC on PMI 
reduction, however no statistically significant improvement of clinical outcomes was   296 
observed,  including  the  rate  of  death,  peri-operative  MI,  renal  failure,  stroke, 
mesenteric ischaemia, hospital or ICU stay.  
In our single centre RCT, we could not demonstrate that simultaneous multi-
limb preconditioning reduces the rate of death, MI, revascularisation and stroke at 6 
weeks post-cardiac surgery, a finding, which was also confirmed in the subsequent 
subgroup analyses: however, once again the study was not powered for this type of 
evaluation.  
Our ERICCA study is a multi-centre randomised control double-blinded clinical 
trial which we have demonstrated to be adequately powered for the primary endpoint 
as well as for each of the secondary end-points described: results from this study will 
therefore be able to determine whether RIPC can improve clinical outcomes at 1-year 
in  high-risk  patients  undergoing  CABG  with  or without  valve  surgery  and  have  the 
crucial potential to change clinical practice with the introduction of a non-invasive and 
risk-free intervention.  
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Chapter 8 
 
 
 
 
8.   Conclusions and future considerations 
 
8.1. Effects of multi-limb RIPC on cardioprotection 
With our single-centre single-blinded RCT we have demonstrated that an enhanced 
simultaneous multi-limb RIPC stimulus reduces total PMI in an unselected cohort of 
patients  undergoing  elective  cardiac  surgery,  as  demonstrated  by  a  statistically 
significant reduction of total hsTnT AUC (Table 8.1). This confirms our hypothesis that 
an enhanced preconditioning stimulus is able to confer cardioprotection in the context 
of cardiac surgery, where a number of factors, including patients’ age, concomitant co-
morbidities  and  pharmacotherapy,  clinical  setting,  type  of  surgery,  technique  of 
myocardial  preservation,  anaesthetic  agents  and  intraoperative  GTN,  are  able  to 
interfere with the protective mechanisms of RIPC. It also confirms our suggestion that 
the intensity of the preconditioning stimulus represents one of the key factors of RIPC-
induced cardioprotection and therefore a potential reason for the negative outcomes of 
recently  published  RCTs.  Our  trial  included  a  total  of  178  patients  and  to  our 
knowledge it was at the completion of recruitment the largest proof-of-concept study in 
this field. It was presented at the Conference of the British Cardiovascular Society 
(BCS) and at the Annual Congress of the Society of Cardiothoracic Surgery in 2013. In 
addition, my abstract with the relevant outcomes of the study obtained the BCS first 
prize  in  the  “Stable  IHD/Prevention/Hypertension  category”.  Results  from  our  RCT 
were published in the Heart Journal (569).    298 
Table 8.1. Effects of RIPC on PMI: study outcomes  
Type of surgery  Group  72-hours AUC 
(μg/L) (SD) 
Difference 
(95% CI) 
P value 
Unselected cohort  Control: n=89 
RIPC: n=89 
36.307(24.542) 
27.004 (16.523) 
-9.303 (-15.626, -2.979)  0.004 
All surgery with 
Cardioplegia 
Control n=73 
RIPC: n=75 
37.089 (25.730) 
27.942 (17.386) 
9.146 (1.861, 16.433)  0.014 
All surgery with ICCF 
 
Control n=16 
RIPC: n=14 
32.885 (18.771) 
20.692 (6.039) 
12.192 (0.066, 24.319)  0.049 
CABG±valve surgery  Control: n=64 
RIPC: n=66 
33.526 (20.164) 
24.772 (12.640) 
8.753 (2.808, 14.688)  0.004 
CABG±valve surgery with 
cardioplegia  
Control: n=48 
RIPC: n=52 
33.74 (20.81) 
25.64 (13.52) 
8.11 (1.01, 15.21)  0.026 
CABG surgery alone  Control: n=54  
RIPC: n=57 
30.753 (18.948) 
23.609 (12.004) 
7.14 (1.076, 13.21)  0.022 
CABG surgery with 
cardioplegia  
Control: n=38 
RIPC: n=43 
29.832 (19.206) 
24.355 (13.052) 
5.477 (-1.985, 12.938)  0.147 
Valve surgery alone 
 
Control: n=25 
RIPC: n=23 
43.925 (33.144) 
33.395 (23.719) 
10.529 (-6.868, 27.927)  0.229 
AVR alone  Control: n=15 
RIPC n=14) 
38.499 (37.661) 
27.947 (24.678) 
10.55 (-14.96, 36.06)  0.402 
All surgery with GTN  Control: n=65 
RIPC: n=21 
30.81 (17.56)  
26.69 (13.93) 
4.12 (-1.92, 10.17)  0.179 
All surgery without No-
GTN 
Control: n=53 
RIPC: n=35 
50.52 (34.20)  
27.86 (20.01) 
22.66 (8.03, 37.29)  0.003 
All surgery with DM  Control: n=24 
RIPC: n=28 
35.993 (21.859) 
25.927 (20.031) 
10.07 (-1.844, 21.00)  0.096 
All surgery with Non-DM  Control: n=65 
RIPC: n=61 
36.428 (25.673) 
27.479 (14.899) 
8.949 (1.423, 16.477)  0.020 
 All surgery + cardioplegia 
with DM  
Control: n=18 
RIPC: n=23 
34.88 (20.576) 
26.59 (21.23) 
7.51 (0.066, 21.029)  0.216 
All surgery + cardioplegia 
with no DM  
Control: n=55 
RIPC: n=52 
37.85 (27.43) 
28.55 (15.55) 
9.30 (0.58, 18.02)  0.037 
CABG surgery +DM  Control: n=17 
RIPC: n=19 
31.73 (18.63) 
19.63 (9.19) 
12.09 (1.83, 22.35)  0.022 
CABG surgery + NON-DM  Control: n=37 
RIPC: n=38 
30.29 (19.34) 
25.43 (12.79) 
4.86 (-2.84, 12.56)  0.212 
CABG surgery with 
cardioplegia + DM 
Control: n=11 
RIPC: n=27 
27.59 (11.46) 
19.37 (10.03) 
8.22 (-0.68, 17.11)  0.069 
CABG surgery with 
cardioplegia + NON-DM 
Control: n=14 
RIPC: n=29 
30.78 (21.81) 
26.76 (13.79) 
4.02 (-5.74, 13.78)  0.413 
AUC=area-under-the  curve;  SD=standard  deviation;  CI=confidence  interval;  RIPC=remote  ischaemic 
preconditioning;  ICCF=intermittent  cross-clamp  fibrillation;  CABG=coronary  artery  bypass  graft; 
AVR=aortic valve replacement; GTN=glyceryl trinitrate; DM=diabetes mellitus  
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Furthermore, we conducted a series of retrospective sub-group analyses, which 
are highly suggestive of further cardioprotective effects of RIPC in specific cohorts of 
patients:  in  particularly,  RIPC  was  associated  with  a  statistically  significant  PMI 
reduction in patients undergoing: 
  cardiac surgery irrespective of the technique of myocardial preservation used; 
  CABG with or without valve surgery; 
  CABG with or without valve surgery using cardioplegia; 
  CABG alone; 
  cardiac surgery when no GTN was used intra-operatively. 
 
This is the first study to demonstrate the cardioprotective effects of RIPC in the 
setting  of  ICCF,  as  only  one  study  previously  showed  PMI  reduction  with  IPC  in 
patients  undergoing  CABG  surgery  (468).  Furthermore,  we  found  no  significant 
difference between AUC of control patients receiving cardioplegia or ICCF, confirming 
previous studies showing that the two techniques are associated with comparable PMI 
magnitude. It is also the first clinical trial to show a significant impact of intravenous 
administration of nitrates in patients undergoing elective cardiac surgery. 
 
With  respect  to  DM,  we  also  found  that  RIPC  was  cardioprotective  in  diabetic 
subjects  undergoing  CABG  and  in  non-diabetic  patients  undergoing  any  cardiac 
surgery.  In  all  other  subgroups  RIPC  led  to  a  total  hsTnT  AUC  reduction,  which 
however did not reach statistical significance.  This confirms previous findings (440) 
that cardioprotection in the diabetic myocardium can be achieved with a more potent 
preconditioning  stimulus  able  to  overcome  the  higher  threshold  required  in  this   300 
condition. In contrast with previous literature, we found that the level of PMI sustained 
by our control diabetic patients was not different from that of non-diabetic controls.  
 
In a further subgroup analysis of control CABG patients, we showed that combined 
antegrade  and  retrograde  cardioplegia  conferred  more  significant  cardioprotection 
compared to antegrade cardioplegia alone and ICCF alone: this is to our knowledge 
the  first  analysis  combining  four  factors  such  as  the  aortic  cross-clamping  times, 
combined  antegrade/retrograde  versus  antegrade  cardioplegia  alone  versus  ICCF, 
hsTnT levels at 6 different time-points with total hsTnT-AUC, and exclusively CABG 
patients. The results of this study have been accepted for publication on the Journal of 
Cardiothoracic Society (see Appendix).  
 
 
8.2. Effects of multi-limb RIPC on secondary outcomes 
Our study comprised a number of secondary endpoints such incidence of post-
operative AKI and AF, inotrope requirement and length of ICU and hospital stay. RIPC 
significantly  reduced  the  incidence  of  AKI  by  71%  in  patients  undergoing  cardiac 
surgery  and  not  administered  GTN  intra-operatively.  Furthermore,  it  was  also 
associated with a significant decrease of the rate of new post-operative AF by 55% in 
unselected cohort of patients, 37% in patients undergoing CABG with or without valve 
surgery, 60% in those, within this group, receiving cardioplegia only, and in subjects 
having CABG alone, 83% in diabetics undergoing CABG only. 
Importantly, RIPC reduced the duration of ICU stay by 1 day in the unselected 
cohort of patients, in subjects undergoing CABG with or without valve surgery and in 
those within this group receiving cardioplegia only. The duration of hospital stay was   301 
also reduced by 1.5 days in preconditioned patients undergoing CABG with or without 
valve surgery with cardioplegia. 
  In addition, we also intended to evaluate whether the simultaneous inflation of 
two blood pressure cuffs, one around the upper arm, one around the thigh, in order to 
induce our enhanced preconditioning stimulus was associated with a more significant 
level  of  skeletal  muscle  injury  in  preconditioned  patients  compared  to  control.  We 
found no significantly difference in total AUC between the two intervention groups in 
either the  unselected cohort  of  any  of  the subgroups  we  then  went  on  to  analysis 
retrospectively.  We  therefore  demonstrated  that  the  enhanced  preconditioning 
stimulus proposed in our study can be safely applied without any significant increase 
of muscle injury. 
 
 
 
8.3. Limitations 
Our study presented a series of limitations, which are partly in common with the 
vast majority of clinical trials investigating the effects of RIPC in the context of cardiac 
surgery. Firstly, our patient recruitment took place at a single centre over almost a two 
year-period: therefore, despite the significant number of patients enrolled (n=178), the 
cohort size was still relatively small and consequently study outcomes will need to be 
taken  with  careful  consideration.  In  particular,  our  study  was  not  designed  -  and 
thereby not adequately powered - for any of the secondary endpoints: this implies that 
the positive outcomes in AF rate and ICU stay could have been due to chance and 
only a larger study will be able to confirm these findings. Conversely, AKI incidence 
remarkably leaned towards statistical significance (p=0.063) and again it is a possible 
that instead a larger study would also statistically prove the beneficial reno-protective   302 
effects of RIPC. In addition, we obtained extremely intriguing results from the series of 
retrospective  analyses  we  subsequently  conducted,  with  particular  regards  to 
outcomes in diabetic patients, in those who were not administered GTN or in control 
subjects  receiving  combined  antegrade/retrograde  cardioplegia:  however,  again  the 
study was not sufficiently powered for this.  
Secondly, our trial was single blinded and therefore only the member delivering 
the  intervention  was  aware  of  patient  baseline  characteristics  and  subsequently  of 
surgery details and results available: randomisation was operated via SNOSE system, 
which contributed to limiting any element of bias. Despite this, whilst the sham protocol 
involved leaving uninflated blood pressure cuffs on patient’s upper arm and thigh for 
15 minutes, it is possible that the anaesthetic and theatre team but not the operating 
surgeon, could have become aware of the nature of the intervention: however,  we 
strongly doubt that this could have changed patient management at any stage.  
Thirdly, our primary end-point was represented by total hsTnT-AUC over the 72 
post-operative  hours  as  an  indicator  of  PMI  sustained  by  these  subjects:  crucially, 
although  troponin  and  CK-MB  post-operative  concentrations  have  been  associated 
with short and long-term patient morbidity and mortality (see chapter 1), hsTnT-AUC 
remains a surrogate end-point. In our study, we could only establish MACCE rate at 
the six-week follow-up as this type of trial limited any further follow-up.  
A final drawback of our study is given by our selection criteria, which led to the 
exclusion of patients with severe renal, pulmonary or hepatic disease and of those with 
recent ACS proved by positive baseline cardiac biomarkers: this is however not a true 
representation of what happens in the “real world” where instead increasingly complex 
patients are being operated on.  
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8.4. On-going clinical trials and future considerations 
Our “Effects of Remote Ischaemic Preconditioning on Clinical outcomes in high-
risk patients undergoing CABG+/-valve surgery” (ERICCA trial) (290) addressed most 
of  the  above-mentioned  limitations:  in  this  large  multi-centre  double-blinded 
randomised control clinical trial, we recruited a total of 1612 patients across 30 tertiary 
centre in the UK: these were high risk subjects with an additive EuroSCORE of at least 
5 and underwent CABG with or without valve surgery with cardioplegia. In the first 
instance, the study is adequately powered for the specified  primary and secondary 
end-points,  which  will  make  the  outcomes  robust  and  objective  and  with  clear 
statistical  evidence.  In  particular,  our  primary  outcome  is  a  composite  of 
cardiovascular death, non-fatal MI, coronary revascularisation and stroke at one year, 
which will give a consistent evaluation of the effects of RIPC on patient morbidity and 
mortality. Also, the blinding strategy in ERICCA was robust and used an adjustable 
valve on the cuff rather than a sham arm, in order to give the impression that the cuff 
was being inflated even in control patients. Crucially we anticipated that the RIPC, 
given with four-5 minute cycles of upper arm IR, could reduce the event rate from 20% 
to 12%.  I prepared the article on the study design, which was published on the peer-
reviewed journal “Clinical research in cardiology” (290)(see Appendix).   
Another  large  multi-centre  trial  investigating  the  effects  of  RIPC  on  clinical 
outcomes  in  cardiac  surgery  is  the  “Remote  Ischaemic  Preconditioning  for  Heart 
Surgery  study”  (RIPHeart-Study)(570),  an  on-going  multi-centre  clinical  trial  in 
Germany. It aims to recruit 2070 high or low risk patients undergoing cardiac surgery 
with a standardised  cardiopulmonary bypass protocol and with only an intravenous 
anaesthetic regime in order to eliminate the potential preconditioning effect of volatile 
anaesthetics. The primary outcome is again a composite of all-cause mortality, non-  304 
fatal MI, new stroke, and/or acute renal failure, although only until hospital discharge 
(up to a maximum of 14 days after surgery).  
Moreover,  the  Renal  Protection  Against  Ischaemia  Reperfusion  in 
Transplantation  (REPAIR)  trial  is  another multi-centre  trial,  aimed  to  determine  the 
effect of RIPC on renal function after renal transplantation using eGFR at one year as 
the primary outcome: the study recruited a total of 406 patients and showed that limb 
RIPC  of  both  donors and  recipients  was  associated  with  a  preserved  transplanted 
kidney function at 6 months in recipients of live-donor related renal transplantation, 
therefore  showing  that    RIPC  is protective on  transplanted  renal grafts.  It also  will 
report on clinical outcomes at 2–5 years using registry follow up.  
Other on-going large RCTs investigating the effects of RIPC in setting different 
from cardio or renal protection have been already discussed in chapter 1. 
In  conclusion,  we  have  conducted  an  extremely  fascinating  and  intriguing 
journey though the different aspects of cardioprotection and RIPC in the context of 
experimental  and  clinical  studies.  These  have  demonstrated  that,  despite  many 
barriers  encountered  by  the  researchers,  with  particular  regard  to  the  mechanistic 
pathway and practical application of RIPC in the clinical context, RIPC is a novel, cost 
effective and widely available protective phenomenon. It has the potential to reduce 
IRI  in  major  cardiovascular  interventions  and  in  many  other  procedures:  biological 
mechanisms are still partly unknown and methodological issues exist, however RIPC 
research has advanced considerably over the recent decades and the future challenge 
will  be  to  clarify  the mechanistic pathways  and  demonstrate  substantial  benefits  in 
patient outcomes. 
 
   305 
REFERENCES 
 
1.  Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European 
system  for  cardiac  operative  risk  evaluation  (EuroSCORE).  Eur  J  Cardiothorac  Surg. 
1999;16(1):9-13. 
2.  Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart 
disease  and  stroke  statistics--2009  update:  a  report  from  the  American  Heart  Association 
Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21-181. 
3.  Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive 
summary: heart disease and stroke statistics--2010 update: a report from the American Heart 
Association. Circulation. 2010;121(7):948-54. 
4.  Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of 
disease  and  risk  factors,  2001:  systematic  analysis  of  population  health  data.  Lancet. 
2006;367(9524):1747-57. 
5.  Rodriguez  T,  Malvezzi  M,  Chatenoud  L,  Bosetti  C,  Levi  F,  Negri  E,  et  al.  Trends  in 
mortality  from  coronary  heart  and  cerebrovascular  diseases  in  the  Americas:  1970-2000. 
Heart. 2006;92(4):453-60. 
6.  Critchley J, Liu J, Zhao D, Wei W, Capewell S. Explaining the increase in coronary heart 
disease mortality in Beijing between 1984 and 1999. Circulation. 2004;110(10):1236-44. 
7.  Goyal A, Yusuf S. The burden of cardiovascular disease in the Indian subcontinent. 
Indian J Med Res. 2006;124(3):235-44. 
8.  Rogers WJ, Frederick PD, Stoehr E, Canto JG, Ornato JP, Gibson CM, et al. Trends in 
presenting characteristics and hospital mortality among patients with ST elevation and non-ST 
elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 
2006. American heart journal. 2008;156(6):1026-34. 
9.  Myerson M, Coady S, Taylor H, Rosamond WD, Goff DC, Jr., Investigators A. Declining 
severity of myocardial infarction from 1987 to 2002: the Atherosclerosis Risk in Communities 
(ARIC) Study. Circulation. 2009;119(4):503-14. 
10.  Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Heparin 
plus  a  glycoprotein  IIb/IIIa  inhibitor  versus  bivalirudin  monotherapy  and  paclitaxel-eluting 
stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year 
results from a multicentre, randomised controlled trial. Lancet. 2011;377(9784):2193-204. 
11.  Liu  JL,  Maniadakis  N,  Gray  A,  Rayner  M.  The  economic  burden  of  coronary  heart 
disease in the UK. Heart. 2002;88(6):597-603. 
12.  Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. Effect of coronary 
artery bypass graft surgery on survival: overview of 10-year results from randomised trials by 
the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344(8922):563-
70. 
13.  van Gaal WJ, Ponnuthurai FA, Selvanayagam J, Testa L, Porto I, Neubauer S, et al. The 
Syntax  score  predicts  peri-procedural  myocardial  necrosis  during  percutaneous  coronary 
intervention. International journal of cardiology. 2009;135(1):60-5. 
14.  Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Coronary 
artery bypass graft surgery versus percutaneous coronary intervention in patients with three-
vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical 
SYNTAX trial. Lancet. 2013;381(9867):629-38. 
15.  Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. Coronary artery bypass grafting vs 
percutaneous  coronary  intervention  and  long-term  mortality  and  morbidity  in  multivessel   306 
disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era. 
JAMA Intern Med. 2014;174(2):223-30. 
16.  Gibbon JH, Jr. Application of a mechanical heart and lung apparatus to cardiac surgery. 
Minn Med. 1954;37(3):171-85; passim. 
17.  Brown IW, Jr., Smith WW, Young WG, Jr., Sealy WC. Experimental and clinical studies 
of controlled hypothermia rapidly produced and corrected by a blood heat exchanger during 
extracorporeal circulation. J Thorac Surg. 1958;36(4):497-505. 
18.  Brown IW, Jr., Smith WW, Emmons WO. An efficient blood heat exchanger for use with 
extracorporeal circulation. Surgery. 1958;44(2):372-7. 
19.  Lucas SK, Gardner TJ, Elmer EB, Flaherty JT, Bulkley BH, Gott VL. Comparison of the 
effects  of  left  ventricular  distention  during  cardioplegic-induced  ischemic  arrest  and 
ventricular fibrillation. Circulation. 1980;62(2 Pt 2):I42-9. 
20.  Cordell  AR.  Milestones  in  the  development  of  cardioplegia.  Ann  Thorac  Surg. 
1995;60(3):793-6. 
21.  Bretschneider HJ. [Survival Time and Recuperative Time of the Heart in Normothermia 
and Hypothermia]. Verh Dtsch Ges Kreislaufforsch. 1964;30:11-34. 
22.  Gay WA, Jr., Ebert PA. Functional, metabolic, and morphologic effects of potassium-
induced cardioplegia. Surgery. 1973;74(2):284-90. 
23.  Roe BB, Hutchinson JC, Fishman NH, Ullyot DJ, Smith DL. Myocardial protection with 
cold, ischemic, potassium-induced cardioplegia. The Journal of thoracic and cardiovascular 
surgery. 1977;73(3):366-74. 
24.  Hearse  DJ,  Stewart  DA,  Braimbridge  MV.  Cellular  protection  during  myocardial 
ischemia: the development and characterization of a procedure for the induction of reversible 
ischemic arrest. Circulation. 1976;54(2):193-202. 
25.  Fremes  SE,  Weisel  RD,  Mickle  DA,  Ivanov  J,  Madonik  MM,  Seawright  SJ,  et  al. 
Myocardial metabolism and ventricular function following cold potassium cardioplegia. The 
Journal of thoracic and cardiovascular surgery. 1985;89(4):531-46. 
26.  Geissler HJ, Mehlhorn U. Cold crystalloid cardioplegia. Multimed Man Cardiothorac 
Surg. 2006;2006(109):mmcts 2004 001040. 
27.  Martin  J,  Benk  C.  Blood  cardioplegia.  Multimed  Man  Cardiothorac  Surg. 
2006;2006(1009):mmcts 2004 000745. 
28.  Buckberg GD. A proposed "solution" to the cardioplegic controversy. The Journal of 
thoracic and cardiovascular surgery. 1979;77(6):803-15. 
29.  Flack JE, 3rd, Cook JR, May SJ, Lemeshow S, Engelman RM, Rousou JA, et al. Does 
cardioplegia  type  affect  outcome  and  survival  in  patients  with  advanced  left  ventricular 
dysfunction? Results from the CABG Patch Trial. Circulation. 2000;102(19 Suppl 3):III84-9. 
30.  Karthik S, Grayson AD, Oo AY, Fabri BM. A survey of current myocardial protection 
practices during coronary artery bypass grafting. Ann R Coll Surg Engl. 2004;86(6):413-5. 
31.  Teoh LK, Grant R, Hulf JA, Pugsley WB, Yellon DM. A comparison between ischemic 
preconditioning,  intermittent  cross-clamp  fibrillation  and  cold  crystalloid  cardioplegia  for 
myocardial  protection  during  coronary  artery  bypass  graft  surgery.  Cardiovasc  Surg. 
2002;10(3):251-5. 
32.  Koppula AS, Jagannath BR, Balakrishnan KR, Gupta CM. Noncardioplegic myocardial 
protection for CABG deserves a second look. Ann Thorac Surg. 1997;63(3):914-5. 
33.  Ferguson TB, Jr., Hammill BG, Peterson ED, DeLong ER, Grover FL, Committee STSND. A 
decade of change--risk profiles and  outcomes for isolated coronary artery bypass grafting 
procedures, 1990-1999: a report from the STS National Database Committee and the Duke   307 
Clinical Research Institute. Society of Thoracic Surgeons. Ann Thorac Surg. 2002;73(2):480-9; 
discussion 9-90. 
34.  Biancari F, Kangasniemi OP, Aliasim Mahar M, Rasinaho E, Satomaa A, Tiozzo V, et al. 
Changing  risk  of  patients  undergoing  coronary  artery  bypass  surgery.  Interactive 
cardiovascular and thoracic surgery. 2009;8(1):40-4. 
35.  Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, et al. ACC/AHA 
2004 guideline update for coronary artery bypass graft surgery: a report of the American 
College  of  Cardiology/American  Heart  Association  Task  Force  on  Practice  Guidelines 
(Committee  to  Update  the  1999  Guidelines  for  Coronary  Artery  Bypass  Graft  Surgery). 
Circulation. 2004;110(14):e340-437. 
36.  Hannan  EL,  Racz  MJ,  Walford  G,  Jones  RH,  Ryan  TJ,  Bennett  E,  et  al.  Long-term 
outcomes  of  coronary-artery  bypass  grafting  versus  stent  implantation.  N  Engl  J  Med. 
2005;352(21):2174-83. 
37.  Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital 
volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128-37. 
38.  Peterson ED, Coombs LP, DeLong ER, Haan CK, Ferguson TB. Procedural volume as a 
marker of quality for CABG surgery. JAMA. 2004;291(2):195-201. 
39.  Cram P, Rosenthal GE, Vaughan-Sarrazin MS. Cardiac revascularization in specialty and 
general hospitals. N Engl J Med. 2005;352(14):1454-62. 
40.  Singh M, Gersh BJ, Li S, Rumsfeld JS, Spertus JA, O'Brien SM, et al. Mayo Clinic Risk 
Score  for  percutaneous  coronary  intervention  predicts  in-hospital  mortality  in  patients 
undergoing coronary artery bypass graft surgery. Circulation. 2008;117(3):356-62. 
41.  Ribeiro AL, Gagliardi SP, Nogueira JL, Silveira LM, Colosimo EA, Lopes do Nascimento 
CA.  Mortality  related  to  cardiac  surgery  in  Brazil,  2000-2003. The  Journal  of  thoracic  and 
cardiovascular surgery. 2006;131(4):907-9. 
42.  Wu C, Hannan EL, Ryan TJ, Bennett E, Culliford AT, Gold JP, et al. Is the impact of 
hospital and surgeon volumes on the in-hospital mortality rate for coronary artery bypass 
graft surgery limited to patients at high risk? Circulation. 2004;110(7):784-9. 
43.  Nallamothu BK, Saint S, Ramsey SD, Hofer TP, Vijan S, Eagle KA. The role of hospital 
volume  in  coronary  artery  bypass  grafting:  is  more  always  better?  J  Am  Coll  Cardiol. 
2001;38(7):1923-30. 
44.  Fortescue EB, Kahn K, Bates DW. Development and validation of a clinical prediction 
rule for major adverse outcomes in coronary bypass grafting. Am J Cardiol. 2001;88(11):1251-
8. 
45.  Yau  TM,  Fedak  PW,  Weisel  RD,  Teng  C,  Ivanov  J.  Predictors  of  operative  risk  for 
coronary  bypass  operations  in  patients  with  left  ventricular  dysfunction.  The  Journal  of 
thoracic and cardiovascular surgery. 1999;118(6):1006-13. 
46.  Baskett  R,  Buth  K,  Ghali  W,  Norris  C,  Maas  T,  Maitland  A,  et  al.  Outcomes  in 
octogenarians undergoing coronary artery bypass grafting. CMAJ. 2005;172(9):1183-6. 
47.  Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, et al. Risk 
factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational 
database of 19030 patients. Eur J Cardiothorac Surg. 1999;15(6):816-22; discussion 22-3. 
48.  Nashef SA, Roques F, Hammill BG, Peterson ED, Michel P, Grover FL, et al. Validation of 
European  System  for  Cardiac  Operative  Risk  Evaluation  (EuroSCORE)  in  North  American 
cardiac surgery. Eur J Cardiothorac Surg. 2002;22(1):101-5.   308 
49.  Hillis GS, Croal BL, Buchan KG, El-Shafei H, Gibson G, Jeffrey RR, et al. Renal function 
and  outcome  from  coronary  artery  bypass  grafting:  impact  on  mortality  after  a  2.3-year 
follow-up. Circulation. 2006;113(8):1056-62. 
50.  Zakeri R, Freemantle N, Barnett V, Lipkin GW, Bonser RS, Graham TR, et al. Relation 
between  mild  renal  dysfunction  and  outcomes  after  coronary  artery  bypass  grafting. 
Circulation. 2005;112(9 Suppl):I270-5. 
51.  Cooper WA, O'Brien SM, Thourani VH, Guyton RA, Bridges CR, Szczech LA, et al. Impact 
of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society 
of Thoracic Surgeons National Adult Cardiac Database. Circulation. 2006;113(8):1063-70. 
52.  Chaitman  BR,  Alderman  EL,  Sheffield  LT,  Tong T,  Fisher  L, Mock MB, et al.  Use  of 
survival analysis to determine the clinical significance of new Q waves after coronary bypass 
surgery. Circulation. 1983;67(2):302-9. 
53.  Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, et al. 
Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. 
N Engl J Med. 1986;314(1):1-6. 
54.  Cameron  A,  Davis  KB,  Green  G,  Schaff  HV.  Coronary  bypass  surgery  with  internal-
thoracic-artery  grafts--effects  on  survival  over  a  15-year  period.  N  Engl  J  Med. 
1996;334(4):216-9. 
55.  Lytle BW, Blackstone EH, Loop FD, Houghtaling PL, Arnold JH, Akhrass R, et al. Two 
internal thoracic artery grafts are better than one. The Journal of thoracic and cardiovascular 
surgery. 1999;117(5):855-72. 
56.  Ioannidis JP, Galanos O, Katritsis D, Connery CP, Drossos GE, Swistel DG, et al. Early 
mortality and morbidity of bilateral versus single internal thoracic artery revascularization: 
propensity and risk modeling. J Am Coll Cardiol. 2001;37(2):521-8. 
57.  Endo M, Nishida H, Tomizawa Y, Kasanuki H. Benefit of bilateral over single internal 
mammary  artery  grafts  for  multiple  coronary  artery  bypass  grafting.  Circulation. 
2001;104(18):2164-70. 
58.  O'Connor GT, Morton JR, Diehl MJ, Olmstead EM, Coffin LH, Levy DG, et al. Differences 
between men and women in hospital mortality associated with coronary artery bypass graft 
surgery.  The  Northern  New  England  Cardiovascular  Disease  Study  Group.  Circulation. 
1993;88(5 Pt 1):2104-10. 
59.  O'Connor NJ, Morton JR, Birkmeyer JD, Olmstead EM, O'Connor GT. Effect of coronary 
artery  diameter  in  patients  undergoing  coronary  bypass  surgery.  Northern  New  England 
Cardiovascular Disease Study Group. Circulation. 1996;93(4):652-5. 
60.  Vaccarino  V,  Abramson  JL,  Veledar  E,  Weintraub  WS.  Sex  differences  in  hospital 
mortality after coronary artery bypass surgery: evidence for a higher mortality in younger 
women. Circulation. 2002;105(10):1176-81. 
61.  Rodriguez F, Nguyen TC, Galanko JA, Morton J. Gastrointestinal complications after 
coronary artery bypass grafting: a national study of morbidity and mortality predictors. J Am 
Coll Surg. 2007;205(6):741-7. 
62.  Echahidi N, Pibarot P, Despres JP, Daigle JM, Mohty D, Voisine P, et al. Metabolic 
syndrome  increases  operative  mortality  in  patients  undergoing  coronary  artery  bypass 
grafting surgery. J Am Coll Cardiol. 2007;50(9):843-51. 
63.  Kulier A, Levin J, Moser R, Rumpold-Seitlinger G, Tudor IC, Snyder-Ramos SA, et al. 
Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass 
graft surgery. Circulation. 2007;116(5):471-9.   309 
64.  van Straten AH, Hamad MA, van Zundert AJ, Martens EJ, Schonberger JP, de Wolf AM. 
Preoperative hemoglobin level as a predictor of survival after coronary artery bypass grafting: 
a comparison with the matched general population. Circulation. 2009;120(2):118-25. 
65.  Zindrou D, Taylor KM, Bagger JP. Excess coronary artery bypass graft mortality among 
women with hypothyroidism. Ann Thorac Surg. 2002;74(6):2121-5. 
66.  Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, et al. Duration of red-cell 
storage and complications after cardiac surgery. N Engl J Med. 2008;358(12):1229-39. 
67.  Kirklin JW, Naftel CD, Blackstone EH, Pohost GM. Summary of a consensus concerning 
death and ischemic events after coronary artery bypass grafting. Circulation. 1989;79(6 Pt 
2):I81-91. 
68.  Shahian DM, O'Brien SM, Sheng S, Grover FL, Mayer JE, Jacobs JP, et al. Predictors of 
long-term survival after coronary artery bypass grafting surgery: results from the Society of 
Thoracic  Surgeons  Adult  Cardiac  Surgery  Database  (the  ASCERT  study).  Circulation. 
2012;125(12):1491-500. 
69.  Wu C, Camacho FT, Culliford AT, Gold JP, Wechsler AS, Higgins RS, et al. A comparison 
of long-term mortality for off-pump and on-pump coronary artery bypass graft surgery. Circ 
Cardiovasc Qual Outcomes. 2012;5(1):76-84. 
70.  Cameron AA, Green GE, Brogno DA, Thornton J. Internal thoracic artery grafts: 20-year 
clinical follow-up. J Am Coll Cardiol. 1995;25(1):188-92. 
71.  Myers  WO,  Blackstone EH,  Davis  K,  Foster  ED,  Kaiser  GC.  CASS  Registry  long  term 
surgical survival. Coronary Artery Surgery Study. J Am Coll Cardiol. 1999;33(2):488-98. 
72.  DeBakey  ME,  Glaeser  DH.  Patterns  of  atherosclerosis:  effect  of  risk  factors  on 
recurrence  and  survival-analysis  of  11,890  cases  with  more  than  25-year  follow-up.  Am  J 
Cardiol. 2000;85(9):1045-53. 
73.  Sprecher DL, Pearce GL. How deadly is the "deadly quartet"? A post-CABG evaluation. J 
Am Coll Cardiol. 2000;36(4):1159-65. 
74.  Weintraub WS, Clements SD, Jr., Crisco LV, Guyton RA, Craver JM, Jones EL, et al. 
Twenty-year survival after coronary artery surgery: an institutional perspective from Emory 
University. Circulation. 2003;107(9):1271-7. 
75.  Rosenhek  R,  Iung  B,  Tornos  P,  Antunes  MJ,  Prendergast  BD,  Otto  CM,  et  al.  ESC 
Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in 
patients with valvular heart disease. Eur Heart J. 2012;33(7):822-8, 8a, 8b. 
76.  Nashef SA, Roques F. Risk assessment, league tables, and report cards: where is true 
quality monitoring? Ann Thorac Surg. 2002;74(5):1748-9; author reply 9. 
77.  Kathiresan S, Servoss SJ, Newell JB, Trani D, MacGillivray TE, Lewandrowski K, et al. 
Cardiac troponin T elevation after coronary artery bypass grafting is associated with increased 
one-year mortality. Am J Cardiol. 2004;94(7):879-81. 
78.  Lehrke S, Steen H, Sievers HH, Peters H, Opitz A, Muller-Bardorff M, et al. Cardiac 
troponin T for prediction of short- and long-term morbidity and mortality after elective open 
heart surgery. Clinical chemistry. 2004;50(9):1560-7. 
79.  Mohammed AA, Agnihotri AK, van Kimmenade RR, Martinez-Rumayor A, Green SM, 
Quiroz R, et al. Prospective, comprehensive assessment of cardiac troponin T testing after 
coronary artery bypass graft surgery. Circulation. 2009;120(10):843-50. 
80.  Fellahi  JL,  Gue  X,  Richomme  X,  Monier  E,  Guillou  L,  Riou  B.  Short-  and  long-term 
prognostic  value  of  postoperative  cardiac troponin  I  concentration  in patients undergoing 
coronary artery bypass grafting. Anesthesiology. 2003;99(2):270-4.   310 
81.  Croal  BL,  Hillis  GS,  Gibson  PH,  Fazal MT,  El-Shafei  H,  Gibson  G,  et  al.  Relationship 
between postoperative cardiac troponin I levels and outcome of cardiac surgery. Circulation. 
2006;114(14):1468-75. 
82.  Muehlschlegel JD, Perry TE, Liu KY, Nascimben L, Fox AA, Collard CD, et al. Troponin is 
superior to electrocardiogram and creatinine kinase MB for predicting clinically significant 
myocardial  injury  after  coronary  artery  bypass  grafting.  European  heart  journal. 
2009;30(13):1574-83. 
83.  Wheatley  DJ.  Protecting  the  damaged  heart  during  coronary  surgery.  Heart. 
2003;89(4):367-8. 
84.  Khuri SF. Evidence, sources, and assessment of injury during and following cardiac 
surgery. Ann Thorac Surg. 2001;72(6):S2205-7; discussion S67-70. 
85.  Thatte HS, Khuri SF. The coronary artery bypass conduit: I. Intraoperative endothelial 
injury and its implication on graft patency. Ann Thorac Surg. 2001;72(6):S2245-52; discussion 
S67-70. 
86.  Raja  SG,  Dreyfus  GD.  Modulation  of  systemic  inflammatory  response  after  cardiac 
surgery. Asian Cardiovasc Thorac Ann. 2005;13(4):382-95. 
87.  Laffey  JG,  Boylan  JF,  Cheng  DC.  The  systemic  inflammatory  response  to  cardiac 
surgery: implications for the anesthesiologist. Anesthesiology. 2002;97(1):215-52. 
88.  Heusch  G,  Kleinbongard  P,  Bose  D,  Levkau  B,  Haude  M,  Schulz  R,  et  al.  Coronary 
microembolization:  from  bedside  to  bench  and  back  to  bedside.  Circulation. 
2009;120(18):1822-36. 
89.  Alhan HC, Karabulut H, Tosun R, Karakoc F, Okar I, Demiray E, et al. Intermittent aortic 
cross-clamping and cold crystalloid cardioplegia for low-risk coronary patients. Ann Thorac 
Surg. 1996;61(3):834-9. 
90.  Liu Z, Valencia O, Treasure T, Murday AJ. Cold blood cardioplegia or intermittent cross-
clamping in coronary artery bypass grafting? Ann Thorac Surg. 1998;66(2):462-5. 
91.  Anderson JR, Hossein-Nia M, Kallis P, Pye M, Holt DW, Murday AJ, et al. Comparison of 
two strategies for myocardial management during coronary artery operations. Ann Thorac 
Surg. 1994;58(3):768-72; discussion 72-3. 
92.  Taggart DP, Bhusari S, Hopper J, Kemp M, Magee P, Wright JE, et al. Intermittent 
ischaemic arrest and cardioplegia in coronary artery surgery: coming full circle? Br Heart J. 
1994;72(2):136-9. 
93.  Alex J, Ansari J, Guerrero R, Yogarathnam J, Cale AR, Griffin SC, et al. Comparison of the 
immediate  post-operative  outcome  of  two  different  myocardial  protection  strategies: 
antegrade-retrograde  cold  St  Thomas  blood  cardioplegia  versus  intermittent  cross-clamp 
fibrillation. Interactive cardiovascular and thoracic surgery. 2003;2(4):584-8. 
94.  Podgoreanu MV, White WD, Morris RW, Mathew JP, Stafford-Smith M, Welsby IJ, et al. 
Inflammatory  gene  polymorphisms  and  risk  of  postoperative  myocardial  infarction  after 
cardiac surgery. Circulation. 2006;114(1 Suppl):I275-81. 
95.  Vroom  MB,  van  Wezel  HB.  Myocardial  stunning,  hibernation,  and  ischemic 
preconditioning. Journal of cardiothoracic and vascular anesthesia. 1996;10(6):789-99. 
96.  Yellon  DM,  Hausenloy  DJ.  Myocardial  reperfusion  injury.  N  Engl  J  Med. 
2007;357(11):1121-35. 
97.  Thygesen K, Alpert JS, White HD, Joint ESCAAHAWHFTFftRoMI. Universal definition of 
myocardial infarction. J Am Coll Cardiol. 2007;50(22):2173-95.   311 
98.  Benoit  MO,  Paris  M,  Silleran  J,  Fiemeyer  A,  Moatti  N.  Cardiac  troponin  I:  its 
contribution to the diagnosis of perioperative myocardial infarction and various complications 
of cardiac surgery. Critical care medicine. 2001;29(10):1880-6. 
99.  Kovacevic  R,  Majkic-Singh  N,  Ignjatovic  S,  Otasevic  P,  Obrenovic  R,  Paris  M,  et  al. 
Troponin T levels in detection of perioperative myocardial infarction after coronary artery 
bypass surgery. Clinical laboratory. 2004;50(7-8):437-45. 
100.  Noora J, Ricci C, Hastings D, Hill S, Cybulsky I. Determination of troponin I release after 
CABG surgery. Journal of cardiac surgery. 2005;20(2):129-35. 
101.  Selvanayagam JB, Petersen SE, Francis JM, Robson MD, Kardos A, Neubauer S, et al. 
Effects  of  off-pump  versus  on-pump  coronary  surgery  on  reversible  and  irreversible 
myocardial injury: a randomized trial using cardiovascular magnetic resonance imaging and 
biochemical markers. Circulation. 2004;109(3):345-50. 
102.  Vassalos A, Lilley S, Young D, Peng E, MacArthur K, Pollock J, et al. Tissue Doppler 
imaging  following  paediatric  cardiac  surgery:  early  patterns  of  change  and  relationship to 
outcome. Interactive cardiovascular and thoracic surgery. 2009;9(2):173-7. 
103.  Dakik HA, Howell JF, Lawrie GM, Espada R, Weilbaecher DG, He ZX, et al. Assessment 
of  myocardial  viability  with  99mTc-sestamibi  tomography  before  coronary  bypass  graft 
surgery: correlation with histopathology and postoperative improvement in cardiac function. 
Circulation. 1997;96(9):2892-8. 
104.  Medrano  R,  Lowry  RW,  Young  JB,  Weilbaecher  DG,  Michael  LH,  Afridi  I,  et  al. 
Assessment  of  myocardial  viability  with  99mTc  sestamibi  in  patients  undergoing  cardiac 
transplantation. A scintigraphic/pathological study. Circulation. 1996;94(5):1010-7. 
105.  Klein C, Nekolla SG, Bengel FM, Momose M, Sammer A, Haas F, et al. Assessment of 
myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with 
positron emission tomography. Circulation. 2002;105(2):162-7. 
106.  Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, et al. Contrast-
enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion 
imaging  for  detection  of  subendocardial  myocardial  infarcts:  an  imaging  study.  Lancet. 
2003;361(9355):374-9. 
107.  Wackers FJ, Berger HJ, Johnstone DE, Goldman L, Reduto LA, Langou RA, et al. Multiple 
gated  cardiac  blood  pool  imaging  for  left  ventricular  ejection  fraction:  validation  of  the 
technique and assessment of variability. The American journal of cardiology. 1979;43(6):1159-
66. 
108.  Mahmarian  JJ,  Moye  L,  Verani  MS,  Eaton  T,  Francis  M,  Pratt  CM.  Criteria  for  the 
accurate interpretation of changes in left ventricular ejection fraction and cardiac volumes as 
assessed by rest and exercise gated radionuclide angiography. Journal of the American College 
of Cardiology. 1991;18(1):112-9. 
109.  Doenst T, Borger MA, Weisel RD, Yau TM, Maganti M, Rao V. Relation between aortic 
cross-clamp  time  and  mortality--not  as  straightforward  as  expected.  European  journal  of 
cardio-thoracic  surgery  :  official  journal  of  the  European  Association  for  Cardio-thoracic 
Surgery. 2008;33(4):660-5. 
110.  Trask RV, Billadello JJ. Tissue-specific distribution and developmental regulation of M 
and B creatine kinase mRNAs. Biochim Biophys Acta. 1990;1049(2):182-8. 
111.  Puleo PR, Guadagno PA, Roberts R, Perryman MB. Sensitive, rapid assay of subforms of 
creatine kinase MB in plasma. Clin Chem. 1989;35(7):1452-5. 
112.  Baker JO, Reinhold J, Redwood S, Marber MS. Troponins: redefining their limits. Heart. 
2011;97(6):447-52.   312 
113.  Katus HA, Schoeppenthau M, Tanzeem A, Bauer HG, Saggau W, Diederich KW, et al. 
Non-invasive  assessment  of  perioperative  myocardial  cell  damage  by  circulating  cardiac 
troponin T. Br Heart J. 1991;65(5):259-64. 
114.  Dehoux M, Provenchere S, Benessiano J, Lasocki S, Lecharny JB, Bronchard R, et al. 
Utility of cardiac troponin measurement after cardiac surgery. Clin Chim Acta. 2001;311(1):41-
4. 
115.  Fellahi JL, Hanouz JL, Gue X, Monier E, Guillou L, Riou B. Kinetic analysis of cardiac 
troponin  I  release  is  no  more  accurate  than  a  single  24-h  measurement  in  predicting  in-
hospital outcome after cardiac surgery. Eur J Anaesthesiol. 2008;25(6):490-7. 
116.  Paparella  D,  Scrascia  G,  Paramythiotis  A,  Guida  P,  Magari  V,  Malvindi  PG,  et  al. 
Preoperative cardiac troponin I to assess midterm risks of coronary bypass grafting operations 
in patients with recent myocardial infarction. Ann Thorac Surg. 2010;89(3):696-702. 
117.  van Geene Y, van Swieten HA, Noyez L. Cardiac troponin I levels after cardiac surgery 
as  predictor  for  in-hospital  mortality.  Interactive  cardiovascular  and  thoracic  surgery. 
2010;10(3):413-6. 
118.  Nesher N, Alghamdi AA, Singh SK, Sever JY, Christakis GT, Goldman BS, et al. Troponin 
after cardiac surgery: a predictor or a phenomenon? Ann Thorac Surg. 2008;85(4):1348-54. 
119.  Brener  SJ,  Lytle  BW,  Schneider  JP,  Ellis  SG,  Topol  EJ.  Association  between  CK-MB 
elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll 
Cardiol. 2002;40(11):1961-7. 
120.  Eigel P, van Ingen G, Wagenpfeil S. Predictive value of perioperative cardiac troponin I 
for adverse outcome in coronary artery bypass surgery. European journal of cardio-thoracic 
surgery  :  official  journal  of  the  European  Association  for  Cardio-thoracic  Surgery. 
2001;20(3):544-9. 
121.  Lasocki S, Provenchere S, Benessiano J, Vicaut E, Lecharny JB, Desmonts JM, et al. 
Cardiac troponin I is an independent predictor of in-hospital death after adult cardiac surgery. 
Anesthesiology. 2002;97(2):405-11. 
122.  Paparella  D,  Cappabianca  G,  Visicchio  G,  Galeone  A,  Marzovillo  A,  Gallo  N,  et  al. 
Cardiac  troponin  I  release  after  coronary  artery  bypass  grafting  operation:  effects  on 
operative and midterm survival. Ann Thorac Surg. 2005;80(5):1758-64. 
123.  Bottio T, Vida V, Padalino M, Gerosa G, Stellin G. Early and long-term prognostic value 
of Troponin-I after cardiac surgery in newborns and children. European journal of cardio-
thoracic  surgery :  official  journal  of  the  European  Association for  Cardio-thoracic  Surgery. 
2006;30(2):250-5. 
124.  Mildh  LH,  Pettila  V,  Sairanen  HI,  Rautiainen  PH.  Cardiac  troponin  T  levels  for  risk 
stratification in pediatric open heart surgery. The Annals of thoracic surgery. 2006;82(5):1643-
8. 
125.  Lurati Buse GA, Koller MT, Grapow M, Bruni CM, Kasper J, Seeberger MD, et al. 12-
month  outcome  after  cardiac  surgery:  prediction  by  troponin  T  in  combination  with  the 
European  system  for  cardiac  operative  risk  evaluation.  The  Annals  of  thoracic  surgery. 
2009;88(6):1806-12. 
126.  Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced 
by temporary occlusion of a coronary artery in the dog. Arch Pathol. 1960;70:68-78. 
127.  Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis 
during reperfusion of ischemic myocardium. Circulation. 1998;97(8):795-804.   313 
128.  Arai M, Lefer DJ, So T, DiPaula A, Aversano T, Becker LC. An anti-CD18 antibody limits 
infarct  size  and  preserves  left  ventricular  function  in  dogs  with  ischemia  and  48-hour 
reperfusion. J Am Coll Cardiol. 1996;27(5):1278-85. 
129.  Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc 
Res. 1998;38(2):291-300. 
130.  Hutter JF, Soboll S. Role of fatty acid metabolites in the development of myocardial 
ischemic damage. Int J Biochem. 1992;24(3):399-403. 
131.  Murphy  E,  Cross  HR,  Steenbergen  C.  Is  Na/Ca  exchange  during  ischemia  and 
reperfusion beneficial or detrimental? Ann N Y Acad Sci. 2002;976:421-30. 
132.  Buja LM, Entman ML. Modes of myocardial cell injury and cell death in ischemic heart 
disease. Circulation. 1998;98(14):1355-7. 
133.  Akar FG, Aon MA, Tomaselli GF, O'Rourke B. The mitochondrial origin of postischemic 
arrhythmias. J Clin Invest. 2005;115(12):3527-35. 
134.  Verma S, Fedak PW, Weisel RD, Butany J, Rao V, Maitland A, et al. Fundamentals of 
reperfusion injury for the clinical cardiologist. Circulation. 2002;105(20):2332-6. 
135.  Iliceto S, Galiuto L, Marchese A, Cavallari D, Colonna P, Biasco G, et al. Analysis of 
microvascular integrity, contractile reserve, and myocardial viability after acute myocardial 
infarction by dobutamine echocardiography and myocardial contrast echocardiography. Am J 
Cardiol. 1996;77(7):441-5. 
136.  Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. Apoptosis 
in human acute myocardial infarction. Circulation. 1997;95(2):320-3. 
137.  Bolli R, Becker L, Gross G, Mentzer R, Jr., Balshaw D, Lathrop DA, et al. Myocardial 
protection  at  a  crossroads:  the  need  for  translation  into  clinical  therapy.  Circ  Res. 
2004;95(2):125-34. 
138.  Bolli R, Jeroudi MO, Patel BS, DuBose CM, Lai EK, Roberts R, et al. Direct evidence that 
oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact 
dog. Proc Natl Acad Sci U S A. 1989;86(12):4695-9. 
139.  Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. 
Cardiovasc Res. 2006;70(2):181-90. 
140.  Ladilov YV, Siegmund B, Piper HM. Protection of reoxygenated cardiomyocytes against 
hypercontracture by inhibition of Na+/H+ exchange. Am J Physiol. 1995;268(4 Pt 2):H1531-9. 
141.  Meissner A, Morgan JP. Contractile dysfunction and abnormal Ca2+ modulation during 
postischemic reperfusion in rat heart. Am J Physiol. 1995;268(1 Pt 2):H100-11. 
142.  Ladilov  YV,  Siegmund  B,  Balser  C,  Piper  HM.  Simulated  ischemia  increases  the 
susceptibility of rat cardiomyocytes to hypercontracture. Circ Res. 1997;80(1):69-75. 
143.  Engler  RL,  Schmid-Schonbein  GW,  Pavelec  RS.  Leukocyte  capillary  plugging  in 
myocardial ischemia and reperfusion in the dog. Am J Pathol. 1983;111(1):98-111. 
144.  Panes  J,  Perry  M,  Granger  DN.  Leukocyte-endothelial  cell  adhesion:  avenues  for 
therapeutic intervention. Br J Pharmacol. 1999;126(3):537-50. 
145.  Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell 
injury in ischemic myocardium. Circulation. 1986;74(5):1124-36. 
146.  Jenkins  DP,  Steare  SE,  Yellon  DM.  Preconditioning  the  human  myocardium:  recent 
advances and aspirations for the development of a new means of cardioprotection in clinical 
practice.  Cardiovascular  drugs  and  therapy  /  sponsored  by  the  International  Society  of 
Cardiovascular Pharmacotherapy. 1995;9(6):739-47.   314 
147.  Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection 
against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit 
heart. Circulation. 1991;84(1):350-6. 
148.  Li  Y,  Kloner  RA.  The  cardioprotective  effects  of  ischemic  'preconditioning'  are  not 
mediated by adenosine receptors in rat hearts. Circulation. 1993;87(5):1642-8. 
149.  Sumeray  MS,  Yellon  DM.  Ischaemic  preconditioning  reduces  infarct  size  following 
global ischaemia in the murine myocardium. Basic research in cardiology. 1998;93(5):384-90. 
150.  Schott RJ, Rohmann S, Braun ER, Schaper W. Ischemic preconditioning reduces infarct 
size in swine myocardium. Circ Res. 1990;66(4):1133-42. 
151.  Kloner  RA,  Yellon  D.  Does  ischemic  preconditioning  occur  in  patients?  J  Am  Coll 
Cardiol. 1994;24(4):1133-42. 
152.  Lee HT, Emala CW. Protective effects of renal ischemic preconditioning and adenosine 
pretreatment:  role  of  A(1)  and  A(3)  receptors.  American  journal  of  physiology  Renal 
physiology. 2000;278(3):F380-7. 
153.  Kitagawa K, Matsumoto M, Kuwabara K, Tagaya M, Ohtsuki T, Hata R, et al. 'Ischemic 
tolerance' phenomenon detected in various brain regions. Brain research. 1991;561(2):203-
11. 
154.  Li G, Chen S, Lu E, Hu T. Protective effects of ischemic preconditioning on lung ischemia 
reperfusion  injury:  an  in-vivo  rabbit  study.  The  Thoracic  and  cardiovascular  surgeon. 
1999;47(1):38-41. 
155.  Lloris-Carsi  JM,  Cejalvo D,  Toledo-Pereyra  LH,  Calvo  MA,  Suzuki  S.  Preconditioning: 
effect  upon  lesion  modulation  in  warm  liver  ischemia.  Transplantation  proceedings. 
1993;25(6):3303-4. 
156.  Mounsey RA, Pang CY, Boyd JB, Forrest C. Augmentation of skeletal muscle survival in 
the  latissimus  dorsi  porcine  model  using  acute  ischemic  preconditioning.  The  Journal  of 
otolaryngology. 1992;21(5):315-20. 
157.  Li  X,  Lin  DL,  George  TF,  Sun  X.  Transient  nonlinear  optical  phenomena  in  exciton-
phonon systems. Phys Rev B Condens Matter. 1992;46(20):13035-41. 
158.  Murry CE, Richard VJ, Jennings RB, Reimer KA. Myocardial protection is lost before 
contractile  function  recovers  from  ischemic  preconditioning.  Am  J  Physiol.  1991;260(3  Pt 
2):H796-804. 
159.  Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 
hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. 
Circulation. 1993;88(3):1264-72. 
160.  Kuzuya  T,  Hoshida  S,  Yamashita  N,  Fuji  H,  Oe H,  Hori M, et  al. Delayed effects  of 
sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res. 1993;72(6):1293-9. 
161.  Baxter  GF,  Goma  FM,  Yellon  DM.  Characterisation  of  the  infarct-limiting  effect  of 
delayed  preconditioning:  timecourse  and  dose-dependency  studies  in  rabbit  myocardium. 
Basic research in cardiology. 1997;92(3):159-67. 
162.  Yellon DM, Baxter GF. A "second window of protection" or delayed preconditioning 
phenomenon: future horizons for myocardial protection? J Mol Cell Cardiol. 1995;27(4):1023-
34. 
163.  Mullane  K,  Bullough  D.  Harnessing  an  endogenous  cardioprotective  mechanism: 
cellular sources and sites of action of adenosine. J Mol Cell Cardiol. 1995;27(4):1041-54. 
164.  Vogt  AM,  Ando  H,  Arras  M,  Elsasser  A.  Lack  of  adenosine  causes  myocardial 
refractoriness. J Am Coll Cardiol. 1998;31(5):1134-41.   315 
165.  Dana A, Baxter GF, Walker JM, Yellon DM. Prolonging the delayed phase of myocardial 
protection:  repetitive  adenosine  A1  receptor  activation  maintains  rabbit  myocardium  in  a 
preconditioned state. J Am Coll Cardiol. 1998;31(5):1142-9. 
166.  Schultz JE, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic 
preconditioning  via  a  glibenclamide-sensitive  mechanism  in  the  rat  heart.  Circ  Res. 
1996;78(6):1100-4. 
167.  Bell  SP,  Sack  MN,  Patel  A,  Opie  LH,  Yellon  DM.  Delta  opioid  receptor  stimulation 
mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol. 2000;36(7):2296-
302. 
168.  Schultz JE, Rose E, Yao Z, Gross GJ. Evidence for involvement of opioid receptors in 
ischemic preconditioning in rat hearts. Am J Physiol. 1995;268(5 Pt 2):H2157-61. 
169.  Schultz JJ,  Hsu  AK,  Gross  GJ.  Ischemic  preconditioning is  mediated  by  a  peripheral 
opioid receptor mechanism in the intact rat heart. J Mol Cell Cardiol. 1997;29(5):1355-62. 
170.  McPherson BC, Yao Z. Morphine mimics preconditioning via free radical signals and 
mitochondrial K(ATP) channels in myocytes. Circulation. 2001;103(2):290-5. 
171.  Yao Z, Gross GJ. Acetylcholine mimics ischemic preconditioning via a glibenclamide-
sensitive mechanism in dogs. Am J Physiol. 1993;264(6 Pt 2):H2221-5. 
172.  Gross  GJ,  Auchampach  JA.  Blockade  of  ATP-sensitive  potassium  channels  prevents 
myocardial preconditioning in dogs. Circulation research. 1992;70(2):223-33. 
173.  Banerjee  A,  Locke-Winter  C,  Rogers  KB,  Mitchell  MB,  Brew  EC,  Cairns  CB,  et  al. 
Preconditioning against myocardial dysfunction after ischemia and reperfusion by an alpha 1-
adrenergic mechanism. Circ Res. 1993;73(4):656-70. 
174.  Liu Y, Tsuchida A, Cohen MV, Downey JM. Pretreatment with angiotensin II activates 
protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol. 
1995;27(3):883-92. 
175.  Goto  M,  Liu  Y,  Yang  XM,  Ardell  JL,  Cohen  MV,  Downey  JM.  Role  of  bradykinin  in 
protection of ischemic preconditioning in rabbit hearts. Circ Res. 1995;77(3):611-21. 
176.  Erikson JM, Velasco CE. Endothelin-1 and myocardial preconditioning. American heart 
journal. 1996;132(1 Pt 1):84-90. 
177.  Baines  CP,  Goto  M,  Downey  JM.  Oxygen  radicals  released  during  ischemic 
preconditioning contribute to cardioprotection in the rabbit myocardium. J Mol Cell Cardiol. 
1997;29(1):207-16. 
178.  Vanden Hoek TL, Becker LB, Shao Z, Li C, Schumacker PT. Reactive oxygen species 
released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes. J 
Biol Chem. 1998;273(29):18092-8. 
179.  Tritto I, D'Andrea D, Eramo N, Scognamiglio A, De Simone C, Violante A, et al. Oxygen 
radicals can induce preconditioning in rabbit hearts. Circ Res. 1997;80(5):743-8. 
180.  Forbes  RA,  Steenbergen  C,  Murphy  E.  Diazoxide-induced  cardioprotection  requires 
signaling through a redox-sensitive mechanism. Circ Res. 2001;88(8):802-9. 
181.  Crestanello JA, Lingle DM, Kamelgard J, Millili J, Whitman GJ. Ischemic preconditioning 
decreases  oxidative  stress  during  reperfusion:  a  chemiluminescence  study.  The  Journal  of 
surgical research. 1996;65(1):53-8. 
182.  Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for 
cardioprotection. Heart Fail Rev. 2007;12(3-4):217-34. 
183.  Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-
reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc 
Res. 2004;61(3):448-60.   316 
184.  Hausenloy DJ,  Lecour  S,  Yellon DM.  Reperfusion  injury  salvage  kinase and  survivor 
activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: 
two sides of the same coin. Antioxidants & redox signaling. 2011;14(5):893-907. 
185.  Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in 
apoptosis and necrosis. Annual review of physiology. 1998;60:619-42. 
186.  Hunter DR, Haworth RA. The Ca2+-induced membrane transition in mitochondria. I. 
The protective mechanisms. Archives of biochemistry and biophysics. 1979;195(2):453-9. 
187.  Hausenloy  DJ,  Yellon  DM.  Survival  kinases  in  ischemic  preconditioning  and 
postconditioning. Cardiovasc Res. 2006;70(2):240-53. 
188.  Crompton M, Costi A. Kinetic evidence for a heart mitochondrial pore activated by 
Ca2+,  inorganic  phosphate  and  oxidative  stress.  A  potential  mechanism  for  mitochondrial 
dysfunction  during  cellular  Ca2+  overload.  European  journal  of  biochemistry  /  FEBS. 
1988;178(2):489-501. 
189.  Halestrap AP, Kerr PM, Javadov S, Woodfield KY. Elucidating the molecular mechanism 
of the permeability transition pore and its role in reperfusion injury of the heart. Biochim 
Biophys Acta. 1998;1366(1-2):79-94. 
190.  Halestrap  AP.  Calcium,  mitochondria  and  reperfusion  injury:  a  pore  way  to  die. 
Biochem Soc Trans. 2006;34(Pt 2):232-7. 
191.  Bernardi  P.  The  mitochondrial  permeability  transition  pore:  a  mystery  solved? 
Frontiers in physiology. 2013;4:95. 
192.  Woodfield  K,  Ruck  A,  Brdiczka  D,  Halestrap  AP.  Direct  demonstration  of  a  specific 
interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role 
in the mitochondrial permeability transition. The Biochemical journal. 1998;336 ( Pt 2):287-90. 
193.  Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition 
pore  opening  at  reperfusion  protects  against  ischaemia-reperfusion  injury.  Cardiovascular 
research. 2003;60(3):617-25. 
194.  Shanmuganathan S, Hausenloy DJ, Duchen MR, Yellon DM. Mitochondrial permeability 
transition  pore  as  a  target  for  cardioprotection  in  the  human  heart.  American  journal  of 
physiology Heart and circulatory physiology. 2005;289(1):H237-42. 
195.  Miura T, Miki T, Yano T. Role of the gap junction in ischemic preconditioning in the 
heart. Am J Physiol Heart Circ Physiol. 2010;298(4):H1115-25. 
196.  Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of 
myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic 
preconditioning. Am J Physiol Heart Circ Physiol. 2003;285(2):H579-88. 
197.  Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. 
Cardiovasc Res. 2006;70(2):200-11. 
198.  Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified 
reperfusion"  protects  the  myocardium  by  activating  the  phosphatidylinositol  3-kinase-Akt 
pathway. Circ Res. 2004;95(3):230-2. 
199.  Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary 
occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J 
Am Coll Cardiol. 2004;44(5):1103-10. 
200.  Yang  XM,  Philipp  S,  Downey  JM,  Cohen  MV.  Postconditioning's  protection  is  not 
dependent on circulating blood factors or cells but involves adenosine receptors and requires 
PI3-kinase and guanylyl cyclase activation. Basic research in cardiology. 2005;100(1):57-63.   317 
201.  Przyklenk  K,  Bauer  B,  Ovize  M,  Kloner  RA,  Whittaker  P.  Regional  ischemic 
'preconditioning'  protects  remote  virgin  myocardium  from  subsequent  sustained  coronary 
occlusion. Circulation. 1993;87(3):893-9. 
202.  Nakano A, Heusch G, Cohen MV, Downey JM. Preconditioning one myocardial region 
does  not  neccessarily  precondition  the  whole  rabbit  heart.  Basic  research  in  cardiology. 
2002;97(1):35-9. 
203.  Przyklenk K, Darling CE, Dickson EW, Whittaker P. Cardioprotection 'outside the box'--
the  evolving  paradigm  of  remote  preconditioning.  Basic  research  in  cardiology. 
2003;98(3):149-57. 
204.  McClanahan TB NB, Wolke LJ, Martin BJ, Mertz TE, Gallagher KP. Brief renal occlusion 
and reperfusion reduces myocardial infarct size in rabbits. FASEB J. 1993;7(A118). 
205.  Gho  BC,  Schoemaker  RG,  van  den Doel MA,  Duncker  DJ,  Verdouw  PD.  Myocardial 
protection by brief ischemia in noncardiac tissue. Circulation. 1996;94(9):2193-200. 
206.  Pell TJ, Baxter GF, Yellon DM, Drew GM. Renal ischemia preconditions myocardium: 
role of adenosine receptors and ATP-sensitive potassium channels. Am J Physiol. 1998;275(5 
Pt 2):H1542-7. 
207.  Takaoka  A,  Nakae  I,  Mitsunami  K,  Yabe  T,  Morikawa  S,  Inubushi  T,  et  al.  Renal 
ischemia/reperfusion  remotely  improves  myocardial  energy  metabolism  during  myocardial 
ischemia via adenosine receptors in rabbits: effects of "remote preconditioning". J Am Coll 
Cardiol. 1999;33(2):556-64. 
208.  Diwan V, Jaggi AS, Singh M, Singh N, Singh D. Possible involvement of erythropoietin in 
remote  renal  preconditioning-induced  cardioprotection  in  rats.  J  Cardiovasc  Pharmacol. 
2008;51(2):126-30. 
209.  Kant R, Diwan V, Jaggi AS, Singh N, Singh D. Remote renal preconditioning-induced 
cardioprotection:  a  key  role  of  hypoxia  inducible  factor-prolyl  4-hydroxylases.  Mol  Cell 
Biochem. 2008;312(1-2):25-31. 
210.  Liem DA, te Lintel Hekkert M, Manintveld OC, Boomsma F, Verdouw PD, Duncker DJ. 
Myocardium tolerant to an adenosine-dependent ischemic preconditioning stimulus can still 
be protected by stimuli that employ alternative signaling pathways. Am J Physiol Heart Circ 
Physiol. 2005;288(3):H1165-72. 
211.  Patel HH, Moore J, Hsu AK, Gross GJ. Cardioprotection at a distance: mesenteric artery 
occlusion protects the myocardium via an opioid sensitive mechanism. J Mol Cell Cardiol. 
2002;34(10):1317-23. 
212.  Schoemaker RG, van Heijningen CL. Bradykinin mediates cardiac preconditioning at a 
distance.  American  journal  of  physiology  Heart  and  circulatory  physiology. 
2000;278(5):H1571-6. 
213.  Tang ZL, Dai W, Li YJ, Deng HW. Involvement of capsaicin-sensitive sensory nerves in 
early  and  delayed  cardioprotection  induced  by  a  brief  ischaemia  of  the  small  intestine. 
Naunyn Schmiedebergs Arch Pharmacol. 1999;359(3):243-7. 
214.  Wang YP, Maeta H, Mizoguchi K, Suzuki T, Yamashita Y, Oe M. Intestinal ischemia 
preconditions  myocardium:  role  of  protein  kinase  C  and  mitochondrial  K(ATP)  channel. 
Cardiovasc Res. 2002;55(3):576-82. 
215.  Wolfrum S, Schneider K, Heidbreder M, Nienstedt J, Dominiak P, Dendorfer A. Remote 
preconditioning protects the heart by activating myocardial PKCepsilon-isoform. Cardiovasc 
Res. 2002;55(3):583-9.   318 
216.  Xiao  L,  Lu  R,  Hu  CP,  Deng  HW,  Li  YJ.  Delayed  cardioprotection  by  intestinal 
preconditioning  is  mediated  by  calcitonin  gene-related  peptide.  Eur  J  Pharmacol. 
2001;427(2):131-5. 
217.  Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of 
myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of 
the gastrocnemius muscle in the rabbit. Circulation. 1997;96(5):1641-6. 
218.  Oxman T, Arad M, Klein R, Avazov N, Rabinowitz B. Limb ischemia preconditions the 
heart against reperfusion tachyarrhythmia. Am J Physiol. 1997;273(4 Pt 2):H1707-12. 
219.  Weinbrenner C, Nelles M, Herzog N, Sarvary L, Strasser RH. Remote preconditioning by 
infrarenal occlusion of the aorta protects the heart from infarction: a newly identified non-
neuronal but PKC-dependent pathway. Cardiovasc Res. 2002;55(3):590-601. 
220.  Weinbrenner  C,  Schulze  F,  Sarvary  L,  Strasser  RH.  Remote  preconditioning  by 
infrarenal aortic occlusion is operative via delta1-opioid receptors and free radicals in vivo in 
the rat heart. Cardiovasc Res. 2004;61(3):591-9. 
221.  Shahid M, Tauseef M, Sharma KK, Fahim M. Brief femoral artery ischaemia provides 
protection against myocardial ischaemia-reperfusion injury in rats: the possible mechanisms. 
Exp Physiol. 2008;93(8):954-68. 
222.  Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, 
et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation. 
2002;106(23):2881-3. 
223.  Li G, Labruto F, Sirsjo A, Chen F, Vaage J, Valen G. Myocardial protection by remote 
preconditioning: the role of nuclear factor kappa-B p105 and inducible nitric oxide synthase. 
Eur J Cardiothorac Surg. 2004;26(5):968-73. 
224.  Chen XG, Wu BY, Wang JK, Bai T. [Mechanism of the protective effects of noninvasive 
limbs preconditioning on myocardial ischemia-reperfusion injury]. Chinese medical journal. 
2005;118(20):1723-7. 
225.  Konstantinov IE, Li J, Cheung MM, Shimizu M, Stokoe J, Kharbanda RK, et al. Remote 
ischemic preconditioning of the recipient reduces myocardial ischemia-reperfusion injury of 
the  denervated  donor  heart  via  a  Katp  channel-dependent  mechanism.  Transplantation. 
2005;79(12):1691-5. 
226.  Kristiansen SB, Henning O, Kharbanda RK, Nielsen-Kudsk JE, Schmidt MR, Redington 
AN, et al. Remote preconditioning reduces ischemic injury in the explanted heart by a KATP 
channel-dependent mechanism. Am J Physiol Heart Circ Physiol. 2005;288(3):H1252-6. 
227.  Kharbanda RK, Li J, Konstantinov IE, Cheung MM, White PA, Frndova H, et al. Remote 
ischaemic preconditioning protects against cardiopulmonary bypass-induced tissue injury: a 
preclinical study. Heart. 2006;92(10):1506-11. 
228.  Shimizu  M,  Konstantinov  IE,  Kharbanda  RK,  Cheung  MH,  Redington  AN.  Effects  of 
intermittent lower limb ischaemia on coronary blood flow and coronary resistance in pigs. 
Acta Physiol (Oxf). 2007;190(2):103-9. 
229.  Shimizu M, Tropak M, Diaz RJ, Suto F, Surendra H, Kuzmin E, et al. Transient limb 
ischaemia  remotely  preconditions  through  a  humoral  mechanism  acting  directly  on  the 
myocardium: evidence suggesting cross-species protection. Clin Sci (Lond). 2009;117(5):191-
200. 
230.  Wang  L,  Oka  N,  Tropak  M,  Callahan  J,  Lee  J,  Wilson  G,  et  al.  Remote  ischemic 
preconditioning elaborates a transferable blood-borne effector that protects mitochondrial 
structure  and  function  and  preserves  myocardial  performance  after  neonatal  cardioplegic 
arrest. The Journal of thoracic and cardiovascular surgery. 2008;136(2):335-42.   319 
231.  de Zeeuw S, Lameris TW, Duncker DJ, Hasan D, Boomsma F, van den Meiracker AH, et 
al.  Cardioprotection  in  pigs  by  exogenous  norepinephrine  but  not  by  cerebral  ischemia-
induced  release  of  endogenous  norepinephrine.  Stroke;  a  journal  of  cerebral  circulation. 
2001;32(3):767-74. 
232.  Tokuno S, Hinokiyama K, Tokuno K, Lowbeer C, Hansson LO, Valen G. Spontaneous 
ischemic events in the brain and heart adapt the hearts of severely atherosclerotic mice to 
ischemia. Arterioscler Thromb Vasc Biol. 2002;22(6):995-1001. 
233.  Schulte G, Sommerschild H, Yang J, Tokuno S, Goiny M, Lovdahl C, et al. Adenosine A 
receptors are necessary for protection of the murine heart by remote, delayed adaptation to 
ischaemia. Acta Physiol Scand. 2004;182(2):133-43. 
234.  Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms 
and clinical application. Cardiovascular research. 2008;79(3):377-86. 
235.  Kharbanda  RK,  Nielsen  TT,  Redington  AN.  Translation  of  remote  ischaemic 
preconditioning into clinical practice. Lancet. 2009;374(9700):1557-65. 
236.  Costa  JF,  Fontes-Carvalho  R,  Leite-Moreira  AF.  Myocardial  remote  ischemic 
preconditioning:  from  pathophysiology  to  clinical  application.  Revista  portuguesa  de 
cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of 
cardiology : an official journal of the Portuguese Society of Cardiology. 2013;32(11):893-904. 
237.  Dickson EW, Blehar DJ, Carraway RE, Heard SO, Steinberg G, Przyklenk K. Naloxone 
blocks  transferred  preconditioning  in  isolated  rabbit  hearts.  J  Mol  Cell  Cardiol. 
2001;33(9):1751-6. 
238.  Addison PD, Neligan PC, Ashrafpour H, Khan A, Zhong A, Moses M, et al. Noninvasive 
remote ischemic preconditioning for global protection of skeletal muscle against infarction. 
Am J Physiol Heart Circ Physiol. 2003;285(4):H1435-43. 
239.  Zhang  SZ,  Wang  NF,  Xu  J,  Gao  Q,  Lin  GH,  Bruce  IC,  et  al.  Kappa-opioid  receptors 
mediate cardioprotection by remote preconditioning. Anesthesiology. 2006;105(3):550-6. 
240.  Chen YS, Chien CT, Ma MC, Tseng YZ, Lin FY, Wang SS, et al. Protection "outside the 
box" (skeletal remote preconditioning) in rat model is triggered by free radical pathway. The 
Journal of surgical research. 2005;126(1):92-101. 
241.  Dickson EW, Tubbs RJ, Porcaro WA, Lee WJ, Blehar DJ, Carraway RE, et al. Myocardial 
preconditioning factors evoke mesenteric ischemic tolerance via opioid receptors and K(ATP) 
channels. Am J Physiol Heart Circ Physiol. 2002;283(1):H22-8. 
242.  Hajrasouliha  AR,  Tavakoli  S,  Ghasemi  M,  Jabehdar-Maralani  P,  Sadeghipour  H, 
Ebrahimi F, et al. Endogenous cannabinoids contribute to remote ischemic preconditioning via 
cannabinoid CB2 receptors in the rat heart. Eur J Pharmacol. 2008;579(1-3):246-52. 
243.  Pacher  P,  Hasko  G.  Endocannabinoids  and  cannabinoid  receptors  in  ischaemia-
reperfusion injury and preconditioning. Br J Pharmacol. 2008;153(2):252-62. 
244.  Brzozowski T, Konturek PC, Konturek SJ, Pajdo R, Kwiecien S, Pawlik M, et al. Ischemic 
preconditioning  of  remote  organs  attenuates  gastric  ischemia-reperfusion  injury  through 
involvement of prostaglandins and sensory nerves. Eur J Pharmacol. 2004;499(1-2):201-13. 
245.  Wolfrum  S,  Nienstedt  J,  Heidbreder  M,  Schneider  K,  Dominiak  P,  Dendorfer  A. 
Calcitonin gene related peptide mediates cardioprotection by remote preconditioning. Regul 
Pept. 2005;127(1-3):217-24. 
246.  Ding YF, Zhang MM, He RR. Role of renal nerve in cardioprotection provided by renal 
ischemic preconditioning in anesthetized rabbits. Sheng Li Xue Bao. 2001;53(1):7-12.   320 
247.  Liem DA, van den Doel MA, de Zeeuw S, Verdouw PD, Duncker DJ. Role of adenosine in 
ischemic  preconditioning  in  rats  depends  critically  on  the  duration  of  the  stimulus  and 
involves both A(1) and A(3) receptors. Cardiovasc Res. 2001;51(4):701-8. 
248.  Dong  JH,  Liu  YX,  Ji  ES,  He  RR.  [Limb  ischemic  preconditioning  reduces  infarct  size 
following myocardial ischemia-reperfusion in rats]. Sheng Li Xue Bao. 2004;56(1):41-6. 
249.  Kristiansen SB, Lofgren B, Nielsen JM, Stottrup NB, Buhl ES, Nielsen-Kudsk JE, et al. 
Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on 
myocardial  infarct  size  and  metabolism  in  a  rat  model  of  type  2  diabetes.  Diabetologia. 
2011;54(2):451-8. 
250.  Dickson  EW,  Reinhardt  CP,  Renzi  FP,  Becker  RC,  Porcaro  WA,  Heard  SO.  Ischemic 
preconditioning  may  be  transferable  via  whole  blood  transfusion:  preliminary  evidence. 
Journal of thrombosis and thrombolysis. 1999;8(2):123-9. 
251.  Dickson EW, Lorbar M, Porcaro WA, Fenton RA, Reinhardt CP, Gysembergh A, et al. 
Rabbit  heart  can  be  "preconditioned"  via  transfer  of  coronary  effluent.  Am  J  Physiol. 
1999;277(6 Pt 2):H2451-7. 
252.  Serejo  FC,  Rodrigues  LF,  Jr.,  da  Silva  Tavares  KC,  de  Carvalho  AC,  Nascimento  JH. 
Cardioprotective properties of humoral factors released from rat hearts subject to ischemic 
preconditioning. J Cardiovasc Pharmacol. 2007;49(4):214-20. 
253.  Lang SC, Elsasser A, Scheler C, Vetter S, Tiefenbacher CP, Kubler W, et al. Myocardial 
preconditioning  and  remote  renal  preconditioning--identifying  a  protective  factor  using 
proteomic methods? Basic research in cardiology. 2006;101(2):149-58. 
254.  Davidson  SM,  Selvaraj  P,  He  D,  Boi-Doku  C,  Yellon  RL,  Vicencio  JM,  et  al.  Remote 
ischaemic preconditioning involves signalling through the SDF-1alpha/CXCR4 signalling axis. 
Basic research in cardiology. 2013;108(5):377. 
255.  Singh D, Chopra K. Evidence of the role of angiotensin AT(1) receptors in remote renal 
preconditioning of myocardium. Methods Find Exp Clin Pharmacol. 2004;26(2):117-22. 
256.  Loukogeorgakis  SP,  Panagiotidou  AT,  Broadhead  MW,  Donald  A,  Deanfield  JE, 
MacAllister RJ. Remote ischemic preconditioning provides early and late protection against 
endothelial ischemia-reperfusion injury in humans: role of the autonomic nervous system. 
Journal of the American College of Cardiology. 2005;46(3):450-6. 
257.  Mastitskaya S, Marina N, Gourine A, Gilbey MP, Spyer KM, Teschemacher AG, et al. 
Cardioprotection evoked by remote ischaemic preconditioning is critically dependent on the 
activity of vagal pre-ganglionic neurones. Cardiovascular research. 2012;95(4):487-94. 
258.  Leung  CH,  Wang  L,  Nielsen  JM,  Tropak  MB,  Fu  YY,  Kato  H,  et  al.  Remote 
cardioprotection by transfer of coronary effluent from ischemic preconditioned rabbit heart 
preserves  mitochondrial  integrity  and  function  via  adenosine  receptor  activation. 
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular 
Pharmacotherapy. 2014;28(1):7-17. 
259.  Jensen RV, Stottrup NB, Kristiansen SB, Botker HE. Release of a humoral circulating 
cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural 
pathways in diabetic patients. Basic research in cardiology. 2012;107(5):285. 
260.  Redington  KL,  Disenhouse  T,  Strantzas  SC,  Gladstone  R,  Wei  C,  Tropak  MB,  et  al. 
Remote  cardioprotection  by  direct  peripheral  nerve  stimulation  and  topical  capsaicin  is 
mediated by circulating humoral factors. Basic research in cardiology. 2012;107(2):241. 
261.  Peralta  C,  Fernandez  L,  Panes  J,  Prats N,  Sans  M,  Pique  JM,  et  al.  Preconditioning 
protects  against  systemic  disorders  associated  with  hepatic  ischemia-reperfusion  through   321 
blockade of tumor necrosis factor-induced P-selectin up-regulation in the rat. Hepatology. 
2001;33(1):100-13. 
262.  Olguner  C,  Koca  U,  Kar  A,  Karci  A,  Islekel  H,  Canyilmaz  M,  et  al.  Ischemic 
preconditioning attenuates the lipid peroxidation and remote lung injury in the rat model of 
unilateral lower limb ischemia reperfusion. Acta Anaesthesiol Scand. 2006;50(2):150-5. 
263.  Harkin  DW,  Barros  D'Sa  AA,  McCallion  K,  Hoper  M,  Campbell  FC.  Ischemic 
preconditioning before lower limb ischemia--reperfusion protects against acute lung injury. 
Journal of vascular surgery. 2002;35(6):1264-73. 
264.  Konstantinov IE, Arab S, Li J, Coles JG, Boscarino C, Mori A, et al. The remote ischemic 
preconditioning  stimulus  modifies  gene  expression  in  mouse  myocardium.  The  Journal  of 
thoracic and cardiovascular surgery. 2005;130(5):1326-32. 
265.  Konstantinov IE, Arab S, Kharbanda RK, Li J, Cheung MM, Cherepanov V, et al. The 
remote ischemic preconditioning stimulus modifies inflammatory gene expression in humans. 
Physiol Genomics. 2004;19(1):143-50. 
266.  Loukogeorgakis SP, Williams R, Panagiotidou AT, Kolvekar SK, Donald A, Cole TJ, et al. 
Transient  limb  ischemia  induces  remote  preconditioning  and  remote  postconditioning  in 
humans by a K(ATP)-channel dependent mechanism. Circulation. 2007;116(12):1386-95. 
267.  Kuntscher MV, Hartmann B, Germann G. Remote ischemic preconditioning of flaps: a 
review. Microsurgery. 2005;25(4):346-52. 
268.  Tong  H,  Chen  W,  Steenbergen  C,  Murphy  E.  Ischemic  preconditioning  activates 
phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res. 2000;87(4):309-15. 
269.  Mocanu  MM,  Bell  RM,  Yellon  DM.  PI3  kinase  and  not  p42/p44  appears  to  be 
implicated  in  the  protection  conferred  by  ischemic  preconditioning.  J  Mol  Cell  Cardiol. 
2002;34(6):661-8. 
270.  Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, et al. Mitochondrial 
PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial 
PKCepsilon-MAPK  interactions  and  differential  MAPK  activation  in  PKCepsilon-induced 
cardioprotection. Circ Res. 2002;90(4):390-7. 
271.  Eldar-Finkelman  H,  Seger  R,  Vandenheede  JR,  Krebs  EG.  Inactivation  of  glycogen 
synthase  kinase-3  by  epidermal  growth  factor  is  mediated  by  mitogen-activated  protein 
kinase/p90  ribosomal  protein  S6  kinase  signaling  pathway  in  NIH/3T3  cells.  J  Biol  Chem. 
1995;270(3):987-90. 
272.  Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, et al. Glycogen synthase 
kinase-3beta  mediates  convergence  of  protection  signaling  to  inhibit  the  mitochondrial 
permeability transition pore. J Clin Invest. 2004;113(11):1535-49. 
273.  Baines CP, Song CX, Zheng YT, Wang GW, Zhang J, Wang OL, et al. Protein kinase 
Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. 
Circ Res. 2003;92(8):873-80. 
274.  Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. 
Pharmacol Ther. 2007;116(2):173-91. 
275.  Heidbreder M, Naumann A, Tempel K, Dominiak P, Dendorfer A. Remote vs. ischaemic 
preconditioning:  the  differential  role  of  mitogen-activated  protein  kinase  pathways. 
Cardiovasc Res. 2008;78(1):108-15. 
276.  Claytor  RB,  Aranson  NJ,  Ignotz  RA,  Lalikos  JF,  Dunn  RM.  Remote  ischemic 
preconditioning modulates p38 MAP kinase in rat adipocutaneous flaps. J Reconstr Microsurg. 
2007;23(2):93-8.   322 
277.  Hausenloy  DJ,  Maddock  HL,  Baxter  GF,  Yellon  DM.  Inhibiting  mitochondrial 
permeability  transition  pore  opening:  a  new  paradigm  for  myocardial  preconditioning? 
Cardiovasc Res. 2002;55(3):534-43. 
278.  Cao  Y,  Zhang  SZ,  Xia  Q.  [Role  of  mitochondrial  permeability  transition  pore  in 
cardioprotection  by  remote  preconditioning].  Zhongguo  Ying  Yong  Sheng  Li  Xue  Za  Zhi. 
2009;25(4):516-20. 
279.  Gunaydin B, Cakici I, Soncul H, Kalaycioglu S, Cevik C, Sancak B, et al. Does remote 
organ ischaemia trigger cardiac preconditioning during coronary artery surgery? Pharmacol 
Res. 2000;41(4):493-6. 
280.  Candilio L, Hausenloy DJ, Yellon DM. Remote ischemic conditioning: a clinical trial's 
update. Journal of cardiovascular pharmacology and therapeutics. 2011;16(3-4):304-12. 
281.  Cheung  MM,  Kharbanda  RK,  Konstantinov  IE,  Shimizu  M,  Frndova  H,  Li  J,  et  al. 
Randomized controlled trial of the effects of remote ischemic preconditioning on children 
undergoing  cardiac  surgery:  first  clinical  application  in  humans.  Journal  of  the  American 
College of Cardiology. 2006;47(11):2277-82. 
282.  Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, et al. Effect 
of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary 
artery bypass graft surgery: a randomised controlled trial. Lancet. 2007;370(9587):575-9. 
283.  Sivaraman  V,  Yellon  DM.  Pharmacologic  therapy  that  simulates  conditioning  for 
cardiac ischemic/reperfusion injury. Journal of cardiovascular pharmacology and therapeutics. 
2014;19(1):83-96. 
284.  Hong  DM,  Mint  JJ,  Kim  JH,  Sohn  IS,  Lim  TW,  Lim  YJ,  et  al.  The  effect  of  remote 
ischaemic  preconditioning  on  myocardial  injury  in  patients  undergoing  off-pump  coronary 
artery bypass graft surgery. Anaesth Intensive Care. 2010;38(5):924-9. 
285.  Hong DM, Jeon Y, Lee CS, Kim HJ, Lee JM, Bahk JH, et al. Effects of remote ischemic 
preconditioning  with  postconditioning  in  patients  undergoing  off-pump  coronary  artery 
bypass surgery--randomized controlled trial. Circ J. 2012;76(4):884-90. 
286.  Rahman IA, Mascaro JG, Steeds RP, Frenneaux MP, Nightingale P, Gosling P, et al. 
Remote ischemic preconditioning in human coronary artery bypass surgery: from promise to 
disappointment? Circulation. 2010;122(11 Suppl):S53-9. 
287.  Kloner RA, Shook T, Antman EM, Cannon CP, Przyklenk K, Yoo K, et al. Prospective 
temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in 
TIMI-9B. Circulation. 1998;97(11):1042-5. 
288.  Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, et al. Previous angina 
alters  in-hospital  outcome  in  TIMI  4.  A  clinical  correlate  to  preconditioning?  Circulation. 
1995;91(1):37-45. 
289.  Pilcher JM, Young P, Weatherall M, Rahman I, Bonser RS, Beasley RW. A systematic 
review and meta-analysis of the cardioprotective effects of remote ischaemic preconditioning 
in open cardiac surgery. J R Soc Med. 2012;105(10):436-45. 
290.  Hausenloy DJ, Candilio L, Laing C, Kunst G, Pepper J, Kolvekar S, et al. Effect of remote 
ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass 
graft  surgery  (ERICCA):  rationale  and  study  design  of  a  multi-centre  randomized  double-
blinded controlled clinical trial. Clinical research in cardiology : official journal of the German 
Cardiac Society. 2012;101(5):339-48. 
291.  Venugopal V, Hausenloy DJ, Ludman A, Di Salvo C, Kolvekar S, Yap J, et al. Remote 
ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery 
with cold-blood cardioplegia: a randomised controlled trial. Heart. 2009;95(19):1567-71.   323 
292.  Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akthar AM, et al. Remote ischemic 
preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm 
repair: a randomized controlled trial. Circulation. 2007;116(11 Suppl):I98-105. 
293.  Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M, Peters J, et al. 
Remote  ischemic  preconditioning  reduces  myocardial  injury  after  coronary  artery  bypass 
surgery with crystalloid cardioplegic arrest. Basic research in cardiology. 2010;105(5):657-64. 
294.  Karuppasamy  P,  Chaubey  S,  Dew  T,  Musto  R,  Sherwood  R,  Desai  J,  et  al.  Remote 
intermittent ischemia before coronary artery bypass graft surgery: a strategy to reduce injury 
and inflammation? Basic research in cardiology. 2011;106(4):511-9. 
295.  Wagner R, Piler P, Bedanova H, Adamek P, Grodecka L, Freiberger T. Myocardial injury 
is decreased by late remote ischaemic preconditioning and aggravated by tramadol in patients 
undergoing  cardiac  surgery:  a  randomised  controlled  trial.  Interactive  cardiovascular  and 
thoracic surgery. 2010;11(6):758-62. 
296.  Young PJ, Dalley P, Garden A, Horrocks C, La Flamme A, Mahon B, et al. A pilot study 
investigating the effects of remote ischemic preconditioning in high-risk cardiac surgery using 
a randomised controlled double-blind protocol. Basic research in cardiology. 2012;107(3):256. 
297.  Lomivorotov  VV,  Shmyrev  VA,  Nepomnyaschih  VA,  Ponomarev  DN,  Knyazkova  LG, 
Lomivorotov  VN,  et  al.  Remote  ischaemic  preconditioning  does  not  protect  the  heart  in 
patients undergoing coronary artery bypass grafting. Interactive cardiovascular and thoracic 
surgery. 2012;15(1):18-22. 
298.  Kottenberg E, Thielmann M, Bergmann L, Heine T, Jakob H, Heusch G, et al. Protection 
by  remote  ischemic  preconditioning  during  coronary  artery  bypass  graft  surgery  with 
isoflurane but not propofol - a clinical trial. Acta Anaesthesiol Scand. 2012;56(1):30-8. 
299.  Lucchinetti E, Bestmann L, Feng J, Freidank H, Clanachan AS, Finegan BA, et al. Remote 
ischemic  preconditioning  applied  during  isoflurane  inhalation  provides  no  benefit  to  the 
myocardium of patients undergoing on-pump coronary artery bypass graft surgery: lack of 
synergy or evidence of antagonism in cardioprotection? Anesthesiology. 2012;116(2):296-310. 
300.  Thielmann  M,  Kottenberg  E,  Kleinbongard  P,  Wendt  D,  Gedik  N,  Pasa  S,  et  al. 
Cardioprotective  and  prognostic  effects  of  remote  ischaemic  preconditioning  in  patients 
undergoing  coronary  artery  bypass  surgery:  a  single-centre  randomised,  double-blind, 
controlled trial. Lancet. 2013;382(9892):597-604. 
301.  Li G, Chen S, Lu E, Luo W. Cardiac ischemic preconditioning improves lung preservation 
in valve replacement operations. Ann Thorac Surg. 2001;71(2):631-5. 
302.  Li L, Luo W, Huang L, Zhang W, Gao Y, Jiang H, et al. Remote perconditioning reduces 
myocardial injury in adult valve replacement: a randomized controlled trial. The Journal of 
surgical research. 2010;164(1):e21-6. 
303.  Choi YS, Shim JK, Kim JC, Kang KS, Seo YH, Ahn KR, et al. Effect of remote ischemic 
preconditioning  on  renal  dysfunction  after  complex  valvular  heart  surgery:  a  randomized 
controlled trial. The Journal of thoracic and cardiovascular surgery. 2011;142(1):148-54. 
304.  Xie  JJ,  Liao  XL,  Chen  WG,  Huang  DD,  Chang  FJ,  Chen  W,  et  al.  Remote  ischaemic 
preconditioning  reduces  myocardial  injury  in  patients  undergoing  heart  valve  surgery: 
randomised controlled trial. Heart. 2012;98(5):384-8. 
305.  Kim JC, Shim JK, Lee S, Yoo YC, Yang SY, Kwak YL. Effect of combined remote ischemic 
preconditioning and postconditioning on pulmonary function in valvular heart surgery. Chest. 
2012;142(2):467-75.   324 
306.  Wu  Q,  Gui  P,  Wu  J,  Ding  D,  Purusram  G,  Dong  N,  et  al.  Effect  of  limb  ischemic 
preconditioning on myocardial injury in patients undergoing mitral valve replacement surgery. 
-A randomized controlled trial. Circ J. 2011;75(8):1885-9. 
307.  Zhou W, Zeng D, Chen R, Liu J, Yang G, Liu P, et al. Limb ischemic preconditioning 
reduces  heart  and  lung  injury  after  an  open  heart  operation  in  infants.  Pediatr  Cardiol. 
2010;31(1):22-9. 
308.  Pavione  MA,  Carmona  F,  de  Castro  M,  Carlotti  AP.  Late  remote  ischemic 
preconditioning  in  children  undergoing  cardiopulmonary  bypass:  a  randomized  controlled 
trial. The Journal of thoracic and cardiovascular surgery. 2012;144(1):178-83. 
309.  Jones  BO,  Pepe  S,  Sheeran  FL,  Donath  S,  Hardy  P,  Shekerdemian  L,  et  al.  Remote 
ischemic  preconditioning  in  cyanosed  neonates  undergoing  cardiopulmonary  bypass:  a 
randomized  controlled  trial.  The  Journal  of  thoracic  and  cardiovascular  surgery. 
2013;146(6):1334-40. 
310.  McCrindle  BW,  Clarizia NA,  Khaikin  S,  Holtby  HM, Manlhiot  C,  Schwartz  SM,  et  al. 
Remote  ischemic  preconditioning  in  children  undergoing  cardiac  surgery  with 
cardiopulmonary  bypass:  a  single-center  double-blinded  randomized  trial.  Journal  of  the 
American Heart Association. 2014;3(4). 
311.  Diehl  JT,  Cali  RF,  Hertzer  NR,  Beven  EG.  Complications  of  abdominal  aortic 
reconstruction. An analysis of perioperative risk factors in 557 patients. Annals of surgery. 
1983;197(1):49-56. 
312.  Haggart PC, Adam DJ, Ludman PF, Ludman CA, Bradbury AW. Myocardial injury and 
systemic fibrinolysis in patients undergoing repair of ruptured abdominal aortic aneurysm: a 
preliminary report. Eur J Vasc Endovasc Surg. 2001;21(6):529-34. 
313.  Barbagallo  M,  Casati  A,  Spadini  E,  Bertolizio  G,  Kepgang  L,  Tecchio  T,  et  al.  Early 
increases  in  cardiac  troponin  levels  after  major  vascular  surgery  is  associated  with  an 
increased frequency of delayed cardiac complications. J Clin Anesth. 2006;18(4):280-5. 
314.  Le  Manach  Y,  Perel  A,  Coriat  P,  Godet  G,  Bertrand  M,  Riou  B.  Early  and  delayed 
myocardial infarction after abdominal aortic surgery. Anesthesiology. 2005;102(5):885-91. 
315.  McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, et al. Coronary-
artery  revascularization  before  elective  major  vascular  surgery.  N  Engl  J  Med. 
2004;351(27):2795-804. 
316.  Wald R, Waikar SS, Liangos O, Pereira BJ, Chertow GM, Jaber BL. Acute renal failure 
after endovascular vs open repair of abdominal aortic aneurysm. Journal of vascular surgery. 
2006;43(3):460-6; discussion 6. 
317.  Ellis SG, Hertzer NR, Young JR, Brener S. Angiographic correlates of cardiac death and 
myocardial  infarction  complicating  major  nonthoracic  vascular  surgery.  Am  J  Cardiol. 
1996;77(12):1126-8. 
318.  Brady  AR,  Fowkes  FG,  Greenhalgh  RM,  Powell  JT,  Ruckley  CV,  Thompson  SG.  Risk 
factors  for  postoperative  death  following  elective  surgical  repair  of  abdominal  aortic 
aneurysm: results from the UK Small Aneurysm Trial. On behalf of the UK Small Aneurysm 
Trial participants. Br J Surg. 2000;87(6):742-9. 
319.  Walsh SR, Boyle JR, Tang TY, Sadat U, Cooper DG, Lapsley M, et al. Remote ischemic 
preconditioning  for  renal  and  cardiac  protection  during  endovascular  aneurysm  repair:  a 
randomized controlled trial. J Endovasc Ther. 2009;16(6):680-9. 
320.  Walsh SR, Tang TY, Sadat U, Gaunt ME. Remote ischemic preconditioning in major 
vascular surgery. Journal of vascular surgery. 2009;49(1):240-3.   325 
321.  Walsh SR, Nouraei SA, Tang TY, Sadat U, Carpenter RH, Gaunt ME. Remote ischemic 
preconditioning for cerebral and cardiac protection during carotid endarterectomy: results 
from a pilot randomized clinical trial. Vasc Endovascular Surg. 2010;44(6):434-9. 
322.  Li C, Li YS, Xu M, Wen SH, Yao X, Wu Y, et al. Limb remote ischemic preconditioning for 
intestinal  and  pulmonary  protection  during  elective  open  infrarenal  abdominal  aortic 
aneurysm repair: a randomized controlled trial. Anesthesiology. 2013;118(4):842-52. 
323.  Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of 
creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 
2003;42(8):1406-11. 
324.  Porto I, Blackman DJ, Nicolson D, Niccoli G, Kahn FZ, Ormerod O, et al. What is the 
incidence of myocardial necrosis in elective patients discharged on the same day following 
percutaneous coronary intervention? Heart. 2004;90(12):1489-90. 
325.  Nageh T, Sherwood RA, Harris BM, Thomas MR. Prognostic role of cardiac troponin I 
after percutaneous coronary intervention in stable coronary disease. Heart. 2005;91(9):1181-
5. 
326.  Ramirez-Moreno  A,  Cardenal  R,  Pera  C,  Pagola  C,  Guzman  M,  Vazquez  E,  et  al. 
Predictors  and  prognostic  value  of  myocardial  injury  following  stent  implantation. 
International journal of cardiology. 2004;97(2):193-8. 
327.  Kizer JR, Muttrej MR, Matthai WH, McConnell J, Nardone H, Sonel AF, et al. Role of 
cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous 
coronary intervention. Eur Heart J. 2003;24(14):1314-22. 
328.  Ricciardi  MJ,  Davidson  CJ,  Gubernikoff  G,  Beohar  N,  Eckman  LJ,  Parker  MA,  et  al. 
Troponin I elevation and cardiac events after percutaneous coronary intervention. American 
heart journal. 2003;145(3):522-8. 
329.  Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, et al. 
Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am 
Coll Cardiol. 2002;39(11):1738-44. 
330.  Babu  GG,  Walker  JM,  Yellon  DM,  Hausenloy  DJ.  Peri-procedural  myocardial  injury 
during  percutaneous  coronary  intervention:  an  important  target  for  cardioprotection.  Eur 
Heart J. 2011;32(1):23-31. 
331.  Batchelor WB, Anstrom KJ, Muhlbaier LH, Grosswald R, Weintraub WS, O'Neill WW, et 
al.  Contemporary  outcome  trends  in  the  elderly  undergoing  percutaneous  coronary 
interventions: results in 7,472 octogenarians. National Cardiovascular Network Collaboration. 
J Am Coll Cardiol. 2000;36(3):723-30. 
332.  Kini A, Marmur JD, Kini S, Dangas G, Cocke TP, Wallenstein S, et al. Creatine kinase-MB 
elevation  after  coronary  intervention  correlates  with  diffuse  atherosclerosis,  and  low-to-
medium level elevation has a benign clinical course: implications for early discharge after 
coronary intervention. J Am Coll Cardiol. 1999;34(3):663-71. 
333.  Marso SP, Gimple LW, Philbrick JT, DiMarco JP. Effectiveness of percutaneous coronary 
interventions to prevent recurrent coronary events in patients on chronic hemodialysis. Am J 
Cardiol. 1998;82(3):378-80. 
334.  McKechnie RS, Smith D, Montoye C, Kline-Rogers E, O'Donnell MJ, DeFranco AC, et al. 
Prognostic  implication  of  anemia  on  in-hospital  outcomes  after  percutaneous  coronary 
intervention. Circulation. 2004;110(3):271-7. 
335.  Goldberg  A,  Gruberg  L,  Roguin  A,  Petcherski  S,  Rimer  D,  Markiewicz  W,  et  al. 
Preprocedural C-reactive protein levels predict myocardial necrosis after successful coronary 
stenting in patients with stable angina. American heart journal. 2006;151(6):1265-70.   326 
336.  Gurm HS, Bhatt DL, Gupta R, Ellis SG, Topol EJ, Lauer MS. Preprocedural white blood 
cell  count  and  death  after  percutaneous  coronary  intervention.  American  heart  journal. 
2003;146(4):692-8. 
337.  Hoole SP, Heck PM, Sharples L, Dutka DP, West NE. Coronary stent length predicts PCI-
induced cardiac myonecrosis. Coron Artery Dis. 2010;21(5):312-7. 
338.  Herrmann  J.  Peri-procedural  myocardial  injury:  2005  update.  Eur  Heart  J. 
2005;26(23):2493-519. 
339.  Iliodromitis  EK,  Kyrzopoulos  S,  Paraskevaidis  IA,  Kolocassides  KG,  Adamopoulos  S, 
Karavolias G, et al. Increased C reactive protein and cardiac enzyme levels after coronary stent 
implantation.  Is  there  protection  by  remote  ischaemic  preconditioning?  Heart. 
2006;92(12):1821-6. 
340.  Hoole  SP,  Heck  PM,  Sharples  L,  Khan  SN,  Duehmke  R,  Densem  CG,  et  al.  Cardiac 
Remote  Ischemic Preconditioning  in  Coronary Stenting  (CRISP  Stent)  Study:  a  prospective, 
randomized control trial. Circulation. 2009;119(6):820-7. 
341.  Hoole SP, Heck PM, White PA, Khan SN, O'Sullivan M, Clarke SC, et al. Remote ischemic 
preconditioning  stimulus  does not  reduce  microvascular  resistance  or improve  myocardial 
blood flow in patients undergoing elective percutaneous coronary  intervention. Angiology. 
2009;60(4):403-11. 
342.  Hoole SP, Khan SN, White PA, Heck PM, Kharbanda RK, Densem CG, et al. Remote 
ischaemic  pre-conditioning  does  not  attenuate  ischaemic  left  ventricular  dysfunction  in 
humans. Eur J Heart Fail. 2009;11(5):497-505. 
343.  Davies WR, Brown AJ, Watson W, McCormick LM, West NE, Dutka DP, et al. Remote 
ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary 
intervention: the CRISP stent trial long-term follow-up. Circ Cardiovasc Interv. 2013;6(3):246-
51. 
344.  Luo SJ, Zhou YJ, Shi DM, Ge HL, Wang JL, Liu RF. Remote ischemic preconditioning 
reduces myocardial injury in patients undergoing coronary stent implantation. The Canadian 
journal of cardiology. 2013;29(9):1084-9. 
345.  Zografos TA, Katritsis GD, Tsiafoutis I, Bourboulis N, Katsivas A, Katritsis DG. Effect of 
one-cycle remote ischemic preconditioning to reduce myocardial injury during percutaneous 
coronary intervention. The American journal of cardiology. 2014;113(12):2013-7. 
346.  Xu  X,  Zhou  Y,  Luo  S,  Zhang  W,  Zhao  Y,  Yu  M,  et  al.  Effect  of  remote  ischemic 
preconditioning in the elderly patients with coronary artery disease with diabetes mellitus 
undergoing elective drug-eluting stent implantation. Angiology. 2014;65(8):660-6. 
347.  Liu Z, Wang YL, Hua Q, Chu YY, Ji XM. Late remote ischemic preconditioning provides 
benefit to patients undergoing elective percutaneous coronary intervention. Cell biochemistry 
and biophysics. 2014;70(1):437-42. 
348.  Ahmed RM, Mohamed el HA, Ashraf M, Maithili S, Nabil F, Rami R, et al. Effect of 
remote ischemic preconditioning on serum troponin T level following elective percutaneous 
coronary intervention. Catheterization and cardiovascular interventions : official journal of the 
Society for Cardiac Angiography & Interventions. 2013;82(5):E647-53. 
349.  Prasad  A,  Gossl  M,  Hoyt  J,  Lennon  RJ,  Polk  L,  Simari  R,  et  al.  Remote  ischemic 
preconditioning  immediately  before  percutaneous  coronary  intervention  does  not  impact 
myocardial  necrosis,  inflammatory  response,  and  circulating  endothelial  progenitor  cell 
counts: a single center randomized sham controlled trial. Catheterization and cardiovascular 
interventions  :  official  journal  of  the  Society  for  Cardiac  Angiography  &  Interventions. 
2013;81(6):930-6.   327 
350.  D'Ascenzo F, Moretti C, Omede P, Cerrato E, Cavallero E, Er F, et al. Cardiac remote 
ischaemic  preconditioning  reduces  periprocedural  myocardial  infarction  for  patients 
undergoing percutaneous coronary interventions: a meta-analysis of randomised clinical trials. 
EuroIntervention  :  journal  of  EuroPCR  in  collaboration  with  the  Working  Group  on 
Interventional Cardiology of the European Society of Cardiology. 2014;9(12):1463-71. 
351.  Moretti  C,  Cavallero  E,  D'Ascenzo  F,  Cerrato  E,  Zoccai  GB,  Omede  P,  et  al.  The 
EUROpean  and  Chinese  cardiac  and  renal  Remote  Ischemic  Preconditioning  Study  (EURO-
CRIPS): study design and methods. Journal of cardiovascular medicine. 2014. 
352.  Bell RM, Rear R, Cunningham J, Dawnay A, Yellon DM. Effect of remote ischaemic 
conditioning  on  contrast-induced  nephropathy  in  patients  undergoing  elective  coronary 
angiography (ERICCIN): rationale and study design of a randomised single-centre, double-blind 
placebo-controlled trial. Clinical research in cardiology : official journal of the German Cardiac 
Society. 2014;103(3):203-9. 
353.  Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic 
therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 
2003;361(9351):13-20. 
354.  McManus DD, Chinali M, Saczynski JS, Gore JM, Yarzebski J, Spencer FA, et al. 30-year 
trends in heart failure in patients hospitalized with acute myocardial infarction. The American 
journal of cardiology. 2011;107(3):353-9. 
355.  Rentoukas  I,  Giannopoulos  G,  Kaoukis  A,  Kossyvakis  C,  Raisakis  K,  Driva  M,  et  al. 
Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary 
intervention: enhancement by opioid action. JACC Cardiovasc Interv. 2010;3(1):49-55. 
356.  Botker  HE,  Kharbanda  R,  Schmidt  MR,  Bottcher  M,  Kaltoft  AK,  Terkelsen  CJ,  et  al. 
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, 
and effect on myocardial salvage in patients with acute myocardial infarction: a randomised 
trial. Lancet. 2010;375(9716):727-34. 
357.  Er  F,  Nia  AM,  Dopp  H,  Hellmich  M,  Dahlem  KM,  Caglayan  E,  et  al.  Ischemic 
preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot 
RenPro Trial (Renal Protection Trial). Circulation. 2012;126(3):296-303. 
358.  Ghaemian  A,  Nouraei  SM,  Abdollahian  F,  Naghshvar  F,  Giussani  DA,  Nouraei  SA. 
Remote ischemic preconditioning in percutaneous coronary revascularization: a double-blind 
randomized controlled clinical trial. Asian cardiovascular & thoracic annals. 2012;20(5):548-
54. 
359.  Crimi G, Pica S, Raineri C, Bramucci E, De Ferrari GM, Klersy C, et al. Remote ischemic 
post-conditioning of the lower limb during primary percutaneous coronary intervention safely 
reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial. 
JACC Cardiovascular interventions. 2013;6(10):1055-63. 
360.  Sloth  AD,  Schmidt  MR,  Munk  K,  Kharbanda  RK,  Redington  AN,  Schmidt  M,  et  al. 
Improved  long-term  clinical  outcomes  in  patients  with  ST-elevation  myocardial  infarction 
undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary 
intervention. European heart journal. 2014;35(3):168-75. 
361.  White SK, Frohlich GM, Sado DM, Maestrini V, Fontana M, Treibel TA, et al. Remote 
Ischemic  Conditioning  Reduces  Myocardial  Infarct  Size  and  Edema  in  Patients  With  ST-
Segment Elevation Myocardial Infarction. JACC Cardiovascular interventions. 2014. 
362.  Prunier F, Angoulvant D, Saint Etienne C, Vermes E, Gilard M, Piot C, et al. The RIPOST-
MI  study,  assessing  remote  ischemic  perconditioning  alone  or  in  combination  with  local   328 
ischemic postconditioning in ST-segment elevation myocardial infarction. Basic research in 
cardiology. 2014;109(2):400. 
363.  Manchurov  V,  Ryazankina  N,  Khmara  T,  Skrypnik  D,  Reztsov  R,  Vasilieva  E,  et  al. 
Remote ischemic preconditioning and endothelial function in patients with acute myocardial 
infarction and primary PCI. The American journal of medicine. 2014;127(7):670-3. 
364.  Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am 
Soc Nephrol. 2006;1(1):19-32. 
365.  Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association 
between  acute  renal  failure  and  mortality  following  cardiac  surgery.  Am  J  Med. 
1998;104(4):343-8. 
366.  Kagawa H, Morita K, Nagahori R, Shinohara G, Kinouchi K, Hashimoto K. Prevention of 
ischemia/reperfusion-induced  pulmonary  dysfunction  after  cardiopulmonary  bypass  with 
terminal  leukocyte-depleted  lung  reperfusion.  The  Journal  of  thoracic  and  cardiovascular 
surgery. 2010;139(1):174-80. 
367.  Suzuki  T.  Additional  lung-protective  perfusion  techniques  during  cardiopulmonary 
bypass. Annals of thoracic and cardiovascular surgery : official journal of the Association of 
Thoracic and Cardiovascular Surgeons of Asia. 2010;16(3):150-5. 
368.  Kirklin  JK,  Blackstone  EH,  Kirklin  JW,  McKay  R,  Pacifico  AD,  Bargeron  LM,  Jr. 
Intracardiac  surgery  in  infants  under  age  3  months:  incremental  risk  factors  for  hospital 
mortality. The American journal of cardiology. 1981;48(3):500-6. 
369.  Kirklin  JK,  Westaby  S,  Blackstone  EH,  Kirklin  JW,  Chenoweth  DE,  Pacifico  AD. 
Complement and the damaging effects of cardiopulmonary bypass. The Journal of thoracic 
and cardiovascular surgery. 1983;86(6):845-57. 
370.  Rady  MY,  Ryan  T,  Starr  NJ.  Early  onset  of  acute  pulmonary  dysfunction  after 
cardiovascular  surgery:  risk  factors  and  clinical  outcome.  Critical  care  medicine. 
1997;25(11):1831-9. 
371.  Greenstein AJ, Chassin MR, Wang J, Rockman CB, Riles TS, Tuhrim S, et al. Association 
between minor and major surgical complications after carotid endarterectomy: results of the 
New  York  Carotid  Artery  Surgery  study.  Journal  of  vascular  surgery.  2007;46(6):1138-44; 
discussion 45-6. 
372.  Dellagrammaticas D, Lewis S, Colam B, Rothwell PM, Warlow CP, Gough MJ, et al. 
Carotid endarterectomy in the UK: acceptable risks but unacceptable delays. Clinical medicine. 
2007;7(6):589-92. 
373.  Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, et al. Impact of 
steatosis on perioperative outcome following hepatic resection. Journal of gastrointestinal 
surgery : official journal of the Society for Surgery of the Alimentary Tract. 2003;7(8):1034-44. 
374.  Chok KS, Ng KK, Poon RT, Lo CM, Fan ST. Impact of postoperative complications on 
long-term outcome of curative resection for hepatocellular carcinoma. The British journal of 
surgery. 2009;96(1):81-7. 
375.  Belghiti J, Noun R, Malafosse R, Jagot P, Sauvanet A, Pierangeli F, et al. Continuous 
versus  intermittent  portal  triad  clamping for  liver  resection:  a  controlled  study.  Annals  of 
surgery. 1999;229(3):369-75. 
376.  Chouker A, Schachtner T, Schauer R, Dugas M, Lohe F, Martignoni A, et al. Effects of 
Pringle  manoeuvre  and  ischaemic  preconditioning  on  haemodynamic  stability  in  patients 
undergoing  elective  hepatectomy:  a  randomized  trial.  British  journal  of  anaesthesia. 
2004;93(2):204-11.   329 
377.  Clavien  PA,  Yadav  S,  Sindram  D,  Bentley  RC.  Protective  effects  of  ischemic 
preconditioning for liver resection performed under inflow occlusion in humans. Annals of 
surgery. 2000;232(2):155-62. 
378.  Lorenzo AR, Lin CH, Lin CH, Lin YT, Nguyen A, Hsu CC, et al. Selection of the recipient 
vein in microvascular flap reconstruction of the lower extremity: analysis of 362 free-tissue 
transfers. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2011;64(5):649-55. 
379.  Nahabedian MY, Momen B, Manson PN. Factors associated with anastomotic failure 
after  microvascular  reconstruction  of  the  breast.  Plastic  and  reconstructive  surgery. 
2004;114(1):74-82. 
380.  Moran SL, Serletti JM. Outcome comparison between free and pedicled TRAM flap 
breast  reconstruction  in  the  obese  patient.  Plastic  and  reconstructive  surgery. 
2001;108(7):1954-60; discussion 61-2. 
381.  Hoffmann TF, Leiderer R, Harris AG, Messmer K. Ischemia and reperfusion in pancreas. 
Microscopy research and technique. 1997;37(5-6):557-71. 
382.  Sun Z, Wang X, Deng X, Lasson A, Wallen R, Hallberg E, et al. The influence of intestinal 
ischemia and reperfusion on bidirectional intestinal barrier permeability, cellular membrane 
integrity, proteinase inhibitors, and cell death in rats. Shock. 1998;10(3):203-12. 
383.  Newton H, Aubard Y, Rutherford A, Sharma V, Gosden R. Low temperature storage and 
grafting of human ovarian tissue. Human reproduction. 1996;11(7):1487-91. 
384.  Aubard Y,  Piver P,  Cogni  Y,  Fermeaux V, Poulin  N, Driancourt  MA.  Orthotopic  and 
heterotopic  autografts  of  frozen-thawed  ovarian  cortex  in  sheep.  Human  reproduction. 
1999;14(8):2149-54. 
385.  Baird DT, Webb R, Campbell BK, Harkness LM, Gosden RG. Long-term ovarian function 
in sheep after ovariectomy and transplantation of autografts stored at -196 C. Endocrinology. 
1999;140(1):462-71. 
386.  Oktay  K,  Newton  H,  Gosden  RG.  Transplantation  of  cryopreserved  human  ovarian 
tissue results in follicle growth initiation in SCID mice. Fertility and sterility. 2000;73(3):599-
603. 
387.  Liu  J,  Van  der Elst  J, Van  den  Broecke  R,  Dhont M.  Early  massive  follicle  loss  and 
apoptosis  in  heterotopically  grafted  newborn  mouse  ovaries.  Human  reproduction. 
2002;17(3):605-11. 
388.  Candilio L, Malik A, Hausenloy DJ. Protection of organs other than the heart by remote 
ischemic conditioning. Journal of cardiovascular medicine. 2013;14(3):193-205. 
389.  Ates E, Genc E, Erkasap N, Erkasap S, Akman S, Firat P, et al. Renal protection by brief 
liver ischemia in rats. Transplantation. 2002;74(9):1247-51. 
390.  Song T, Peng YF, Guo SY, Liu YH, Liul LY. Brief small intestinal ischemia lessens renal 
ischemia-reperfusion injury in rats. Comparative medicine. 2007;57(2):200-5. 
391.  Lazaris AM, Maheras AN, Vasdekis SN, Karkaletsis KG, Charalambopoulos A, Kakisis JD, 
et  al.  Protective  effect  of  remote  ischemic  preconditioning  in  renal  ischemia/reperfusion 
injury,  in  a  model  of  thoracoabdominal  aorta  approach.  The  Journal  of  surgical  research. 
2009;154(2):267-73. 
392.  Kadkhodaee M, Seifi B, Najafi A, Sedaghat Z. First report of the protective effects of 
remote  per-  and  postconditioning  on  ischemia/reperfusion-induced  renal  injury. 
Transplantation. 2011;92(10):e55. 
393.  Wever KE, Warle MC, Wagener FA, van der Hoorn JW, Masereeuw R, van der Vliet JA, 
et al. Remote ischaemic preconditioning by brief hind limb ischaemia protects against renal   330 
ischaemia-reperfusion  injury:  the  role  of  adenosine.  Nephrol  Dial  Transplant. 
2011;26(10):3108-17. 
394.  Wever KE, Menting T, Masereeuw R, van der Vliet JA, Rongen GA, Warle MC. Local and 
remote  ischemic  postconditionings  have  synergistic  protective  effects  on  renal  ischemia-
reperfusion injury. Transplantation. 2012;94(1):e1-2. 
395.  Xia Z, Herijgers P, Nishida T, Ozaki S, Wouters P, Flameng W. Remote preconditioning 
lessens the deterioration of pulmonary function after repeated coronary artery occlusion and 
reperfusion  in  sheep.  Canadian  journal  of  anaesthesia  =  Journal  canadien  d'anesthesie. 
2003;50(5):481-8. 
396.  Waldow T, Alexiou K, Witt W, Albrecht S, Wagner F, Knaut M, et al. Protection against 
acute  porcine  lung  ischemia/reperfusion  injury  by  systemic  preconditioning  via  hind  limb 
ischemia.  Transplant  international  :  official  journal  of  the  European  Society  for  Organ 
Transplantation. 2005;18(2):198-205. 
397.  Leung  CH,  Caldarone  CA,  Wang  F,  Venkateswaran  S,  Ailenberg  M,  Vadasz  B,  et  al. 
Remote  Ischemic  Conditioning  Prevents  Lung  and  Liver  Injury  After  Hemorrhagic 
Shock/Resuscitation: Potential Role of a Humoral Plasma Factor. Annals of surgery. 2014. 
398.  Wang Z, Ji Y, Wang S, Wang R, Li Z, Kang A, et al. Protective Effect of Intestinal Ischemic 
Preconditioning on Ischemia Reperfusion-Caused Lung Injury in Rats. Inflammation. 2014. 
399.  Lai  IR,  Chang  KJ,  Chen  CF,  Tsai  HW.  Transient  limb  ischemia  induces  remote 
preconditioning in liver among rats: the protective role of heme oxygenase-1. Transplantation. 
2006;81(9):1311-7. 
400.  Kanoria S, Jalan R, Davies NA, Seifalian AM, Williams R, Davidson BR. Remote ischaemic 
preconditioning  of  the  hind  limb  reduces  experimental  liver  warm  ischaemia-reperfusion 
injury. The British journal of surgery. 2006;93(6):762-8. 
401.  Gustafsson  BI,  Friman  S,  Wallin  M,  Heiman  J,  Delbro  DS.  Effect  of  remote 
preconditioning on mild or severe ischemia-reperfusion injury to rat liver. Transplantation 
proceedings. 2006;38(8):2708-9. 
402.  Tapuria N, Junnarkar SP, Dutt N, Abu-Amara M, Fuller B, Seifalian AM, et al. Effect of 
remote ischemic preconditioning on hepatic microcirculation and function in a rat model of 
hepatic  ischemia  reperfusion  injury.  HPB  :  the official journal of the  International  Hepato 
Pancreato Biliary Association. 2009;11(2):108-17. 
403.  Wang  F,  Birch  SE,  He  R,  Tawadros  P,  Szaszi  K,  Kapus  A,  et  al.  Remote  ischemic 
preconditioning by hindlimb occlusion prevents liver ischemic/reperfusion injury: the role of 
High Mobility Group-Box 1. Annals of surgery. 2010;251(2):292-9. 
404.  Abu-Amara M, Yang SY, Quaglia A, Rowley P, de Mel A, Tapuria N, et al. Nitric oxide is 
an  essential  mediator  of  the  protective  effects  of  remote  ischaemic  preconditioning  in  a 
mouse model of liver ischaemia/reperfusion injury. Clinical science. 2011;121(6):257-66. 
405.  Abu-Amara  M,  Yang  SY,  Quaglia  A,  Rowley  P,  Fuller  B,  Seifalian  A,  et  al.  Role  of 
endothelial nitric oxide synthase in remote ischemic preconditioning of the mouse liver. Liver 
transplantation  :  official  publication  of  the  American  Association  for  the  Study  of  Liver 
Diseases and the International Liver Transplantation Society. 2011;17(5):610-9. 
406.  Kanoria S, Glantzounis G, Quaglia A, Dinesh S, Fusai G, Davidson BR, et al. Remote 
preconditioning improves hepatic oxygenation after ischaemia reperfusion injury. Transplant 
international  :  official  journal  of  the  European  Society  for  Organ  Transplantation. 
2012;25(7):783-91. 
407.  Abu-Amara M, Yang SY, Quaglia A, Rowley P, Tapuria N, Fuller B, et al. The hepatic 
soluble guanylyl cyclase-cyclic guanosine monophosphate pathway mediates the protection of   331 
remote ischemic preconditioning on the microcirculation in liver ischemia-reperfusion injury. 
Transplantation. 2012;93(9):880-6. 
408.  Wang  M,  Shen  J,  Feng  B,  Gui  L,  Chen  Q,  Zhang  B,  et  al.  Remote  ischemic 
preconditioning promotes early liver cell proliferation in a rat model of small-for-size liver 
transplantation. The Journal of surgical research. 2012. 
409.  Uysal AI, Ocmen E, Akan M, Ozkardesler S, Ergur BU, Guneli E, et al. The effects of 
remote ischemic preconditioning and N-acetylcysteine with remote ischemic preconditioning 
in  rat  hepatic  ischemia  reperfusion  injury  model.  BioMed  research  international. 
2014;2014:892704. 
410.  Wang  Y,  Shen  J,  Xiong  X,  Xu  Y,  Zhang  H,  Huang  C,  et  al.  Remote  ischemic 
preconditioning  protects  against  liver  ischemia-reperfusion  injury  via  heme  oxygenase-1-
induced autophagy. PloS one. 2014;9(6):e98834. 
411.  Shin  HJ,  Won  NH,  Lee  HW.  Remote  ischemic  preconditioning  prevents 
lipopolysaccharide-induced  liver  injury through inhibition of  NF-kappaB  activation  in  mice. 
Journal of anesthesia. 2014. 
412.  Kageyama S, Hata K, Tanaka H, Hirao H, Kubota T, Okamura Y, et al. Intestinal Ischemic 
preconditioning  ameliorates  hepatic  ischemia  reperfusion  injury  in  rats:  Role  of  heme 
oxygenase-1 in the second-window of protection. Liver transplantation : official publication of 
the  American  Association  for  the  Study  of  Liver  Diseases  and  the  International  Liver 
Transplantation Society. 2014. 
413.  Dave  KR,  Saul  I,  Prado  R,  Busto  R,  Perez-Pinzon  MA.  Remote  organ  ischemic 
preconditioning  protect  brain  from  ischemic  damage  following  asphyxial  cardiac  arrest. 
Neuroscience letters. 2006;404(1-2):170-5. 
414.  Gurcun  U,  Discigil  B,  Boga  M,  Ozkisacik  E,  Badak  MI,  Yenisey  C,  et  al.  Is  remote 
preconditioning  as  effective  as  direct  ischemic  preconditioning  in  preventing  spinal  cord 
ischemic injury? The Journal of surgical research. 2006;135(2):385-93. 
415.  Zhao H, Xiong LZ, Dong HL, Chen SY, Lu ZH, Sun YY, et al. [Protective effect of remote 
ischemic preconditioning against focal cerebral ischemia/reperfusion injury in rats]. Zhongguo 
Wei Zhong Bing Ji Jiu Yi Xue. 2007;19(6):340-2. 
416.  Rehni  AK,  Shri  R,  Singh  M.  Remote  ischaemic  preconditioning  and  prevention  of 
cerebral injury. Indian journal of experimental biology. 2007;45(3):247-52. 
417.  Ren C, Gao X, Steinberg GK, Zhao H. Limb remote-preconditioning protects against 
focal  ischemia  in  rats  and  contradicts  the  dogma  of  therapeutic  time  windows  for 
preconditioning. Neuroscience. 2008;151(4):1099-103. 
418.  Saxena P, Bala A, Campbell K, Meloni B, d'Udekem Y, Konstantinov IE. Does remote 
ischemic preconditioning prevent delayed hippocampal neuronal death following transient 
global cerebral ischemia in rats? Perfusion. 2009;24(3):207-11. 
419.  Yannopoulos  FS,  Makela  T,  Niemela  E,  Tuominen  H,  Lepola  P,  Alestalo  K,  et  al. 
Improved  cerebral  recovery  from  hypothermic  circulatory  arrest  after  remote  ischemic 
preconditioning. Ann Thorac Surg. 2010;90(1):182-8. 
420.  Xu T, Gong Z, Zhu WZ, Wang JF, Li B, Chen F, et al. Remote ischemic preconditioning 
protects neurocognitive function of rats following cerebral hypoperfusion. Med Sci Monit. 
2011;17(11):BR299-304. 
421.  Malhotra  S,  Naggar  I,  Stewart  M,  Rosenbaum  DM.  Neurogenic  pathway  mediated 
remote preconditioning protects the brain from transient focal ischemic injury. Brain research. 
2011;1386:184-90.   332 
422.  Jensen HA, Loukogeorgakis S, Yannopoulos F, Rimpilainen E, Petzold A, Tuominen H, et 
al.  Remote  ischemic  preconditioning  protects  the  brain  against  injury  after  hypothermic 
circulatory arrest. Circulation. 2011;123(7):714-21. 
423.  Zhou  Y,  Fathali  N,  Lekic  T,  Ostrowski  RP,  Chen  C,  Martin  RD,  et  al.  Remote  limb 
ischemic postconditioning protects against neonatal hypoxic-ischemic brain injury in rat pups 
by the opioid receptor/Akt pathway. Stroke; a journal of cerebral circulation. 2011;42(2):439-
44. 
424.  Hahn CD, Manlhiot C, Schmidt MR, Nielsen TT, Redington AN. Remote ischemic per-
conditioning:  a  novel  therapy  for  acute  stroke?  Stroke;  a  journal  of  cerebral  circulation. 
2011;42(10):2960-2. 
425.  Sun J, Tong L, Luan Q, Deng J, Li Y, Li Z, et al. Protective effect of delayed remote limb 
ischemic  postconditioning:  role  of  mitochondrial  K(ATP)  channels  in  a  rat  model  of  focal 
cerebral ischemic reperfusion injury. Journal of cerebral blood flow and metabolism : official 
journal of the International Society of Cerebral Blood Flow and Metabolism. 2012;32(5):851-9. 
426.  Geng  X,  Ren  C,  Wang  T,  Fu  P,  Luo  Y,  Liu  X,  et  al.  Effect  of  remote  ischemic 
postconditioning on an intracerebral hemorrhage stroke model in rats. Neurological research. 
2012;34(2):143-8. 
427.  Wei  D,  Ren  C,  Chen  X,  Zhao  H.  The  chronic  protective  effects  of  limb  remote 
preconditioning  and  the  underlying  mechanisms  involved  in  inflammatory  factors  in  rat 
stroke. PloS one. 2012;7(2):e30892. 
428.  Hu S, Dong H, Zhang H, Wang S, Hou L, Chen S, et al. Noninvasive limb remote ischemic 
preconditioning contributes neuroprotective effects via activation of adenosine A1 receptor 
and redox status after transient focal cerebral ischemia in rats. Brain Res. 2012;1459:81-90. 
429.  Yannopoulos F, Makela T, Arvola O, Haapanen H, Anttila V, Kiviluoma K, et al. Remote 
ischemic  precondition  preserves  cerebral  oxygen  tension  during  hypothermic  circulatory 
arrest. Scandinavian cardiovascular journal : SCJ. 2012;46(4):245-50. 
430.  Hu X, Lu Y, Zhang Y, Li Y, Jiang L. Remote ischemic preconditioning improves spatial 
learning  and  memory  ability  after  focal  cerebral  ischemia-reperfusion  in  rats.  Perfusion. 
2013;28(6):546-51. 
431.  Yannopoulos FS, Arvola O, Haapanen H, Herajarvi J, Miinalainen I, Jensen H, et al. Leg 
ischaemia before circulatory arrest alters brain leucocyte count and respiratory chain redox 
state. Interactive cardiovascular and thoracic surgery. 2014;18(3):272-7. 
432.  Hu X, Yang Z, Yang M, Qian J, Cahoon J, Xu J, et al. Remote ischemic preconditioning 
mitigates myocardial and neurological dysfunction via K(ATP) channel activation in a rat model 
of hemorrhagic shock. Shock. 2014;42(3):228-33. 
433.  Walsh SR, Sadat U, Boyle JR, Tang TY, Lapsley M, Norden AG, et al. Remote ischemic 
preconditioning  for  renal  protection  during  elective  open  infrarenal  abdominal  aortic 
aneurysm  repair:  randomized  controlled  trial.  Vascular  and  endovascular  surgery. 
2010;44(5):334-40. 
434.  Venugopal V, Laing CM, Ludman A, Yellon DM, Hausenloy D. Effect of remote ischemic 
preconditioning on acute kidney injury in nondiabetic patients undergoing coronary artery 
bypass graft surgery: a secondary analysis of 2 small randomized trials. American journal of 
kidney diseases : the official journal of the National Kidney Foundation. 2010;56(6):1043-9. 
435.  Zimmerman RF, Ezeanuna PU, Kane JC, Cleland CD, Kempananjappa TJ, Lucas FL, et al. 
Ischemic preconditioning at a remote site prevents acute kidney injury in patients following 
cardiac surgery. Kidney international. 2011;80(8):861-7.   333 
436.  Pedersen KR, Ravn HB, Povlsen JV, Schmidt MR, Erlandsen EJ, Hjortdal VE. Failure of 
remote ischemic preconditioning to reduce the risk of postoperative acute kidney injury in 
children undergoing operation for complex congenital heart disease: a randomized single-
center study. The Journal of thoracic and cardiovascular surgery. 2012;143(3):576-83. 
437.  Whittaker P, Przyklenk K. Remote-conditioning ischemia provides a potential approach 
to  mitigate  contrast  medium-induced  reduction  in  kidney  function:  a  retrospective 
observational cohort study. Cardiology. 2011;119(3):145-50. 
438.  Lin LN, Wang LR, Wang WT, Jin LL, Zhao XY, Zheng LP, et al. Ischemic preconditioning 
attenuates  pulmonary  dysfunction  after  unilateral  thigh  tourniquet-induced  ischemia-
reperfusion. Anesthesia and analgesia. 2010;111(2):539-43. 
439.  Kim JC, Shim JK, Lee S, Yoo YC, Yang SY, Kwak YL. Effect of Combined Remote Ischemic 
Preconditioning and Postconditioning on Pulmonary Function in Valvular Heart Surgery. Chest. 
2012. 
440.  Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic 
heart: the importance of Akt phosphorylation. Diabetes. 2005;54(8):2360-4. 
441.  Ogawa K, Ikewaki K, Taniguchi I, Takatsuka H, Mori C, Sasaki H, et al. Mitiglinide, a 
novel  oral  hypoglycemic  agent,  preserves  the  cardioprotective  effect  of  ischemic 
preconditioning in isolated perfused rat hearts. Int Heart J. 2007;48(3):337-45. 
442.  Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative 
w.  Acute  renal  failure  -  definition,  outcome  measures,  animal  models,  fluid  therapy  and 
information technology needs: the Second International Consensus Conference of the Acute 
Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204-12. 
443.  Ko  WJ,  Lin  CY,  Chen  RJ,  Wang  SS,  Lin  FY,  Chen  YS.  Extracorporeal  membrane 
oxygenation  support  for  adult  postcardiotomy  cardiogenic  shock.  Ann  Thorac  Surg. 
2002;73(2):538-45. 
444.  Crystal E, Garfinkle MS, Connolly SS, Ginger TT, Sleik K, Yusuf SS. Interventions for 
preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane 
Database Syst Rev. 2004(4):CD003611. 
445.  Ali  N,  Rizwi  F,  Iqbal  A,  Rashid  A.  Induced  remote  ischemic  pre-conditioning  on 
ischemia-reperfusion injury in patients undergoing coronary artery bypass. J Coll Physicians 
Surg Pak. 2010;20(7):427-31. 
446.  Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. 
Lancet. 2013;381(9861):166-75. 
447.  Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T. Review and meta-analysis of 
randomized  controlled  clinical  trials  of  remote  ischemic  preconditioning  in  cardiovascular 
surgery. The American journal of cardiology. 2008;102(11):1487-8. 
448.  Takagi H, Umemoto T. Remote ischemic preconditioning for cardiovascular surgery: an 
updated  meta-analysis  of  randomized  trials.  Vascular  and  endovascular  surgery. 
2011;45(6):511-3. 
449.  Yetgin T, Manintveld OC, Boersma E, Kappetein AP, van Geuns RJ, Zijlstra F, et al. 
Remote  ischemic  conditioning  in  percutaneous  coronary  intervention  and  coronary  artery 
bypass  grafting.  Circulation  journal  :  official  journal  of  the  Japanese  Circulation  Society. 
2012;76(10):2392-404. 
450.  Alreja G, Bugano D, Lotfi A. Effect of remote ischemic preconditioning on myocardial 
and  renal  injury:  meta-analysis  of  randomized  controlled  trials.  J  Invasive  Cardiol. 
2012;24(2):42-8.   334 
451.  Zhou  C,  Liu  Y,  Yao  Y,  Zhou  S,  Fang  N,  Wang  W,  et  al.  beta-blockers  and  volatile 
anesthetics  may  attenuate  cardioprotection  by  remote  preconditioning  in  adult  cardiac 
surgery:  a  meta-analysis  of  15  randomized  trials.  Journal  of  cardiothoracic  and  vascular 
anesthesia. 2013;27(2):305-11. 
452.  Brevoord D, Kranke P, Kuijpers M, Weber N, Hollmann M, Preckel B. Remote ischemic 
conditioning to protect against ischemia-reperfusion injury: a systematic review and meta-
analysis. PloS one. 2012;7(7):e42179. 
453.  D'Ascenzo F, Cavallero E, Moretti C, Omede P, Sciuto F, Rahman IA, et al. Remote 
ischaemic  preconditioning  in  coronary  artery  bypass  surgery:  a  meta-analysis.  Heart. 
2012;98(17):1267-71. 
454.  Yang L, Wang G, Du Y, Ji B, Zheng Z. Remote ischemic preconditioning reduces cardiac 
troponin I release in cardiac surgery: a meta-analysis. Journal of cardiothoracic and vascular 
anesthesia. 2014;28(3):682-9. 
455.  Haji Mohd Yasin NA, Herbison P, Saxena P, Praporski S, Konstantinov IE. The role of 
remote ischemic preconditioning in organ protection after cardiac surgery: a meta-analysis. 
The Journal of surgical research. 2014;186(1):207-16. 
456.  Remote Preconditioning Trialists G, Healy DA, Khan WA, Wong CS, Moloney MC, Grace 
PA,  et  al.  Remote  preconditioning  and  major  clinical  complications  following  adult 
cardiovascular  surgery:  Systematic  review  and  meta-analysis.  International  journal  of 
cardiology. 2014;176(1):20-31. 
457.  Ferdinandy  P,  Schulz  R,  Baxter  GF.  Interaction  of  cardiovascular  risk  factors  with 
myocardial  ischemia/reperfusion  injury,  preconditioning,  and  postconditioning. 
Pharmacological reviews. 2007;59(4):418-58. 
458.  Ebrahim Z, Yellon DM, Baxter GF. Ischemic preconditioning is lost in aging hypertensive 
rat  heart:  independent  effects  of  aging  and  longstanding  hypertension.  Experimental 
gerontology. 2007;42(8):807-14. 
459.  Lucchinetti  E,  Hofer  C,  Bestmann  L,  Hersberger  M,  Feng  J,  Zhu  M,  et  al.  Gene 
regulatory control of myocardial energy metabolism predicts postoperative cardiac function in 
patients  undergoing  off-pump  coronary  artery  bypass  graft  surgery:  inhalational  versus 
intravenous anesthetics. Anesthesiology. 2007;106(3):444-57. 
460.  Symons JA, Myles PS. Myocardial protection with volatile anaesthetic agents during 
coronary artery bypass surgery: a meta-analysis. Br J Anaesth. 2006;97(2):127-36. 
461.  Yu  CH,  Beattie  WS.  The  effects  of  volatile  anesthetics  on  cardiac  ischemic 
complications  and  mortality  in  CABG:  a  meta-analysis.  Canadian  journal  of  anaesthesia  = 
Journal canadien d'anesthesie. 2006;53(9):906-18. 
462.  So SI. Coronary artery bypass surgery versus percutaneous coronary intervention with 
stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery 
trial): a randomised controlled trial. Lancet. 2002;360(9338):965-70. 
463.  Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, et al. 
Minimal  changes  of  serum  creatinine  predict  prognosis  in  patients  after  cardiothoracic 
surgery: a prospective cohort study. Journal of the American Society of Nephrology : JASN. 
2004;15(6):1597-605. 
464.  Brevoord D, Hollmann MW, De Hert SG, van Dongen EH, Heijnen BG, de Bruin A, et al. 
Effect of remote ischemic conditioning on atrial fibrillation and outcome after coronary artery 
bypass grafting (RICO-trial). BMC Anesthesiol. 2011;11:11. 
465.  Schlattner U, Tokarska-Schlattner M, Wallimann T. Mitochondrial creatine kinase in 
human health and disease. Biochim Biophys Acta. 2006;1762(2):164-80.   335 
466.  Mack MJ, Duhaylongsod FG. Through the open door! Where has the ride taken us? The 
Journal of thoracic and cardiovascular surgery. 2002;124(4):655-9. 
467.  Izzat MB, West RR, Bryan AJ, Angelini GD. Coronary artery bypass surgery: current 
practice in the United Kingdom. Br Heart J. 1994;71(4):382-5. 
468.  Jenkins  DP,  Pugsley  WB,  Alkhulaifi  AM,  Kemp  M,  Hooper  J,  Yellon  DM.  Ischaemic 
preconditioning reduces troponin T release in patients undergoing coronary artery bypass 
surgery. Heart. 1997;77(4):314-8. 
469.  Thielmann M, Wendt D, Tsagakis K, Price V, Dohle DS, Pasa S, et al. Remote ischemic 
preconditioning: the surgeon's perspective. J Cardiovasc Med (Hagerstown). 2013;14(3):187-
92. 
470.  Zeng J, He W, Qu Z, Tang Y, Zhou Q, Zhang B. Cold blood versus crystalloid cardioplegia 
for myocardial protection in adult cardiac surgery: a meta-analysis of randomized controlled 
studies. Journal of cardiothoracic and vascular anesthesia. 2014;28(3):674-81. 
471.  Jakobsen CJ, Berg H, Hindsholm KB, Faddy N, Sloth E. The influence of propofol versus 
sevoflurane  anesthesia  on  outcome  in  10,535  cardiac  surgical  procedures.  Journal  of 
cardiothoracic and vascular anesthesia. 2007;21(5):664-71. 
472.  Landoni G, Biondi-Zoccai GG, Zangrillo A, Bignami E, D'Avolio S, Marchetti C, et al. 
Desflurane and sevoflurane in cardiac surgery: a meta-analysis of randomized clinical trials. 
Journal of cardiothoracic and vascular anesthesia. 2007;21(4):502-11. 
473.  Onorati  F,  De  Feo  M,  Mastroroberto  P,  Cristodoro  L,  Pezzo  F,  Renzulli  A,  et  al. 
Determinants and prognosis of myocardial damage after coronary artery bypass grafting. The 
Annals of thoracic surgery. 2005;79(3):837-45. 
474.  Greaves SC, Rutherford JD, Aranki SF, Cohn LH, Couper GS, Adams DH, et al. Current 
incidence and determinants of perioperative myocardial infarction in coronary artery surgery. 
American heart journal. 1996;132(3):572-8. 
475.  Becker  H,  Vinten-Johansen  J,  Buckberg  GD,  Follette  DM,  Robertson  JM.  Critical 
importance of ensuring cardioplegic delivery with coronary stenoses. The Journal of thoracic 
and cardiovascular surgery. 1981;81(4):507-15. 
476.  Ehrenberg J, Intonti M, Owall A, Brodin LA, Ivert T, Lindblom D. Retrograde crystalloid 
cardioplegia preserves left ventricular systolic function better than antegrade cardioplegia in 
patients with occluded coronary arteries. Journal of cardiothoracic and vascular anesthesia. 
2000;14(4):383-7. 
477.  Fiore AC, Naunheim KS, McBride LR, Pennington DG, Kaiser GC, Castanis J, et al. Aortic 
valve  replacement.  Aortic  root  versus  coronary  sinus  perfusion  with  blood  cardioplegic 
solution. The Journal of thoracic and cardiovascular surgery. 1992;104(1):130-7; discussion 7-
8. 
478.  Aldea  GS,  Hou  D,  Fonger  JD,  Shemin  RJ.  Inhomogeneous  and  complementary 
antegrade and retrograde delivery of cardioplegic solution in the absence of coronary artery 
obstruction. The Journal of thoracic and cardiovascular surgery. 1994;107(2):499-504. 
479.  Bhayana  JN,  Kalmbach  T,  Booth  FV,  Mentzer  RM,  Jr.,  Schimert  G.  Combined 
antegrade/retrograde cardioplegia for myocardial protection: a clinical trial. The Journal of 
thoracic and cardiovascular surgery. 1989;98(5 Pt 2):956-60. 
480.  Sun  SC,  Diaco  M,  Laurence  RD,  DiSesa  VJ,  Cohn  LH.  The  dynamics  of  antegrade 
cardioplegia  with  simultaneous  coronary  sinus  occlusion.  Effects  on  aortic  root  infusion 
pressure,  coronary  sinus  pressure,  and  myocardial  cooling.  The  Journal  of  thoracic  and 
cardiovascular surgery. 1991;101(3):517-25.   336 
481.  Menasche P, Kural S, Fauchet M, Lavergne A, Commin P, Bercot M, et al. Retrograde 
coronary sinus perfusion: a safe alternative for ensuring cardioplegic delivery in aortic valve 
surgery. The Annals of thoracic surgery. 1982;34(6):647-58. 
482.  Hilton CJ, Teubl W, Acker M, Levinson HJ, Millard RW, Riddle R, et al. Inadequate 
cardioplegic protection with  obstructed  coronary  arteries.  The  Annals of  thoracic  surgery. 
1979;28(4):323-34. 
483.  Emery RW, Arom KV. Results with retrograde delivery of cardioplegia for myocardial 
protection during cardiac surgery. The Journal of cardiovascular surgery. 1993;34(2):123-7. 
484.  Cernaianu  AC,  Flum  DR,  Maurer  M,  Cilley  JH,  Jr.,  Grosso  MA,  Browstein  L,  et  al. 
Comparison of antegrade with antegrade/retrograde cold blood cardioplegia for myocardial 
revascularization. Texas Heart Institute journal / from the Texas Heart Institute of St Luke's 
Episcopal Hospital, Texas Children's Hospital. 1996;23(1):9-14. 
485.  Bates  RJ,  Toscano  M,  Balderman  SC,  Anagnostopoulos  CE.  The  cardiac  veins  and 
retrograde coronary venous perfusion. The Annals of thoracic surgery. 1977;23:83-90. 
486.  Blanco G, Adam A, Fernandez A. A direct experimental approach to the aortic valve. II. 
Acute retroperfusion of the coronary sinus. The Journal of thoracic surgery. 1956;32(2):171-7. 
487.  Salerno TA, Houck JP, Barrozo CA, Panos A, Christakis GT, Abel JG, et al. Retrograde 
continuous warm blood cardioplegia: a new concept in myocardial protection. The Annals of 
thoracic surgery. 1991;51(2):245-7. 
488.  Drinkwater  DC,  Laks  H,  Buckberg  GD.  A  new  simplified  method  of  optimizing 
cardioplegic delivery without right heart isolation. Antegrade/retrograde blood cardioplegia. 
The Journal of thoracic and cardiovascular surgery. 1990;100(1):56-63; discussion -4. 
489.  Ito  H,  Saito  S,  Miyahara  K,  Takemura  H,  Mizutani  S,  Toyama  M,  et  al.  Retrograde 
Cardioplegia  Revisited:  Open  Technique  for  Long  Aortic  Cross  Clamping.  Heart,  lung  & 
circulation. 2013. 
490.  Radmehr  H,  Soleimani A,  Tatari  H,  Salehi  M. Does  combined  antegrade-retrograde 
cardioplegia  have  any  superiority  over  antegrade  cardioplegia?  Heart,  lung  &  circulation. 
2008;17(6):475-7. 
491.  Weisel  RD,  Hoy  FB,  Baird  RJ,  Ivanov  J,  Hilton  JD,  Burns  RJ,  et  al.  Comparison  of 
alternative  cardioplegic  techniques.  The  Journal  of  thoracic  and  cardiovascular  surgery. 
1983;86(1):97-107. 
492.  Yau TM, Ikonomidis JS, Weisel RD, Mickle DA, Hayashida N, Ivanov J, et al. Which 
techniques  of  cardioplegia  prevent  ischemia?  The  Annals  of  thoracic  surgery. 
1993;56(5):1020-8. 
493.  Pratt FH. "the Circulation through the Veins of Thebesius.". Journal Boston Society of 
Medical Sciences. 1897;1(15):29-34. 
494.  Eckstein  RQ,  Hornberger  JC,  Sano  T.  Acute  effects  of  elevation  of  coronary  sinus 
pressure. Circulation. 1953;7(3):422-36. 
495.  Gundry  SR,  Kirsh  MM.  A  comparison  of  retrograde  cardioplegia  versus  antegrade 
cardioplegia in the presence of coronary artery obstruction. The Annals of thoracic surgery. 
1984;38(2):124-7. 
496.  Kshettry  VR,  Salerno  CT,  Lakhanpal  S,  Kroshus  TJ.  Coronary  sinus  injury  during 
retrograde cardioplegia: a report of three cases. Journal of cardiac surgery. 1996;11(5):359-
62. 
497.  Guiraudon GM, Campbell CS, McLellan DG, Kostuk WJ, Purves PD, MacDonald JL, et al. 
Retrograde coronary sinus versus aortic root perfusion with cold cardioplegia: randomized 
study of levels of cardiac enzymes in 40 patients. Circulation. 1986;74(5 Pt 2):III105-15.   337 
498.  Fiore AC, Naunheim KS, Kaiser GC, Willman VL, McBride LR, Pennington DG, et al. 
Coronary sinus versus aortic root perfusion with blood cardioplegia in elective myocardial 
revascularization. The Annals of thoracic surgery. 1989;47(5):684-8. 
499.  Kautzner J. Thebesian valve: the guard dog of the coronary sinus? Europace : European 
pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac 
pacing,  arrhythmias,  and  cardiac  cellular  electrophysiology  of  the  European  Society  of 
Cardiology. 2009;11(9):1136-7. 
500.  Kuroda M, Takahashi T, Mita N, Kagaya S, Miyoshi S, Saito S. Difficult cannulation of 
the coronary sinus due to a large Thebesian valve. Anesthesia and analgesia. 2013;116(3):563-
6. 
501.  Echeverri  D,  Cabrales  J,  Jimenez  A.  Myocardial  venous  drainage:  from  anatomy  to 
clinical use. The Journal of invasive cardiology. 2013;25(2):98-105. 
502.  Menasche P, Subayi JB, Piwnica A. Retrograde coronary sinus cardioplegia for aortic 
valve  operations:  a  clinical  report  on  500  patients.  The  Annals  of  thoracic  surgery. 
1990;49(4):556-63; discussion 63-4. 
503.  Bar-El Y, Adler Z, Kophit A, Kertzman V, Sawaed S, Ross A, et al. Myocardial protection 
in operations requiring more than 2 h of aortic cross-clamping. European journal of cardio-
thoracic  surgery : official  journal  of  the  European  Association for  Cardio-thoracic  Surgery. 
1999;15(3):271-5. 
504.  Balderman  SC,  Bhayana  JN,  Binette  P,  Chan  A,  Gage  AA,  Alder  RH.  Perioperative 
preservation of myocardial ultrastructure and high-energy phosphates in man. The Journal of 
thoracic and cardiovascular surgery. 1981;82(6):860-9. 
505.  Chambers  DJ,  Darracott-Cankovic  S,  Braimbridge  MV.  Clinical  and  quantitative 
birefringence  assessment  of  100  patients  with  aortic  clamping  periods  in  excess  of  120 
minutes  after  hypothermic  cardioplegic  arrest.  The  Thoracic  and  cardiovascular  surgeon. 
1983;31(5):266-72. 
506.  Kaukoranta PK, Lepojarvi MV, Kiviluoma KT, Ylitalo KV, Peuhkurinen KJ. Myocardial 
protection during antegrade versus retrograde cardioplegia. The Annals of thoracic surgery. 
1998;66(3):755-61. 
507.  Fan Y, Zhang AM, Xiao YB, Weng YG, Hetzer R. Warm versus cold cardioplegia for heart 
surgery: a meta-analysis. European journal of cardio-thoracic surgery : official journal of the 
European Association for Cardio-thoracic Surgery. 2010;37(4):912-9. 
508.  Tan TE, Ahmed S, Paterson HS. Intermittent tepid blood cardioplegia improves clinical 
outcome. Asian cardiovascular & thoracic annals. 2003;11(2):116-21. 
509.  Sogo N, Campanella C, Webb DJ, Megson IL. S-nitrosothiols cause prolonged, nitric 
oxide-mediated  relaxation  in  human  saphenous  vein  and  internal  mammary  artery: 
therapeutic potential in bypass surgery. British journal of pharmacology. 2000;131(6):1236-
44. 
510.  Heusch  G,  Post  H,  Michel  MC,  Kelm  M,  Schulz  R.  Endogenous  nitric  oxide  and 
myocardial adaptation to ischemia. Circ Res. 2000;87(2):146-52. 
511.  Bolli R, Manchikalapudi S, Tang XL, Takano H, Qiu Y, Guo Y, et al. The protective effect 
of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric 
oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late 
phase of ischemic preconditioning. Circ Res. 1997;81(6):1094-107. 
512.  Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia/reperfusion injury. 
Cardiovasc Res. 2004;61(3):402-13.   338 
513.  Bolli  R,  Bhatti  ZA,  Tang  XL,  Qiu  Y,  Zhang  Q,  Guo  Y,  et  al.  Evidence  that  late 
preconditioning  against  myocardial  stunning  in  conscious  rabbits  is  triggered  by  the 
generation of nitric oxide. Circ Res. 1997;81(1):42-52. 
514.  Bolli R, Dawn B, Tang XL, Qiu Y, Ping P, Xuan YT, et al. The nitric oxide hypothesis of 
late preconditioning. Basic research in cardiology. 1998;93(5):325-38. 
515.  Hill  M,  Takano  H,  Tang  XL,  Kodani  E,  Shirk  G,  Bolli  R.  Nitroglycerin  induces  late 
preconditioning  against myocardial  infarction  in  conscious  rabbits despite development  of 
nitrate tolerance. Circulation. 2001;104(6):694-9. 
516.  Bolli  R,  Li  QH,  Tang  XL,  Guo  Y,  Xuan  YT,  Rokosh  G,  et  al.  The  late  phase  of 
preconditioning and its natural clinical application--gene therapy. Heart Fail Rev. 2007;12(3-
4):189-99. 
517.  West MB, Rokosh G, Obal D, Velayutham M, Xuan YT, Hill BG, et al. Cardiac myocyte-
specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion 
injury by preventing mitochondrial permeability transition. Circulation. 2008;118(19):1970-8. 
518.  Penna C, Cappello S, Mancardi D, Raimondo S, Rastaldo R, Gattullo D, et al. Post-
conditioning reduces infarct size in the isolated rat heart: role of coronary flow and pressure 
and the nitric oxide/cGMP pathway. Basic research in cardiology. 2006;101(2):168-79. 
519.  Steensrud T, Li J, Dai X, Manlhiot C, Kharbanda RK, Tropak M, et al. Pretreatment with 
the nitric oxide donor SNAP or nerve transection blocks humoral preconditioning by remote 
limb ischemia or intra-arterial adenosine. Am J Physiol Heart Circ Physiol. 2010;299(5):H1598-
603. 
520.  Forys  J,  Peruga  J,  Plewka  M,  Lipiec  P,  Jasinska  A,  Krzeminska-Pakula  M,  et  al. 
Nitroglycerin infusion after percutaneous coronary intervention does not influence short- and 
long-term  outcome--a  prospective  NAPI  (Nitroglycerin  Administration  after  Percutaneous 
Intervention) study. Kardiol Pol. 2007;65(7):789-803; discussion 4-5. 
521.  Kleinbongard P, Thielmann M, Jakob H, Peters J, Heusch G, Kottenberg E. Nitroglycerin 
does  not  interfere  with  protection  by  remote  ischemic  preconditioning  in  patients  with 
surgical  coronary  revascularization  under  isoflurane  anesthesia.  Cardiovascular  drugs  and 
therapy  /  sponsored  by  the  International  Society  of  Cardiovascular  Pharmacotherapy. 
2013;27(4):359-61. 
522.  Simmons RK, Unwin N, Griffin SJ. International Diabetes Federation: An update of the 
evidence  concerning  the  prevention  of  type  2  diabetes.  Diabetes  research  and  clinical 
practice. 2010;87(2):143-9. 
523.  Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for 
the year 2000 and projections for 2030. Diabetes care. 2004;27(5):1047-53. 
524.  Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current 
trends. Oman medical journal. 2012;27(4):269-73. 
525.  Effect  of  intensive  blood-glucose  control  with  metformin  on  complications  in 
overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) 
Group. Lancet. 1998;352(9131):854-65. 
526.  Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart 
disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior 
myocardial infarction. The New England journal of medicine. 1998;339(4):229-34. 
527.  Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, et al. Outcome of 
patients  with  diabetes mellitus  and  acute  myocardial  infarction  treated  with  thrombolytic 
agents.  The  Thrombolysis  and  Angioplasty  in  Myocardial  Infarction  (TAMI)  Study  Group. 
Journal of the American College of Cardiology. 1993;21(4):920-5.   339 
528.  Abbud ZA, Shindler DM, Wilson AC, Kostis JB. Effect of diabetes mellitus on short- and 
long-term mortality  rates  of  patients  with  acute  myocardial  infarction:  a  statewide  study. 
Myocardial  Infarction  Data  Acquisition  System  Study  Group.  American  heart  journal. 
1995;130(1):51-8. 
529.  Behar  S,  Boyko  V,  Reicher-Reiss  H,  Goldbourt  U.  Ten-year  survival  after  acute 
myocardial infarction: comparison of patients with and without diabetes. SPRINT Study Group. 
Secondary  Prevention  Reinfarction  Israeli  Nifedipine  Trial.  American  heart  journal. 
1997;133(3):290-6. 
530.  West NE, Ruygrok PN, Disco CM, Webster MW, Lindeboom WK, O'Neill WW, et al. 
Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. 
Circulation. 2004;109(7):867-73. 
531.  Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, et al. Diabetes 
mellitus and the clinical and angiographic outcome after coronary stent placement. Journal of 
the American College of Cardiology. 1998;32(7):1866-73. 
532.  Cohen  Y,  Raz  I,  Merin  G,  Mozes  B.  Comparison  of  factors  associated  with  30-day 
mortality  after  coronary  artery  bypass  grafting  in  patients  with  versus  without  diabetes 
mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium. The American journal of 
cardiology. 1998;81(1):7-11. 
533.  Thourani VH, Weintraub WS, Stein B, Gebhart SS, Craver JM, Jones EL, et al. Influence 
of diabetes mellitus on early and late outcome after coronary artery bypass grafting. The 
Annals of thoracic surgery. 1999;67(4):1045-52. 
534.  Tosaki A, Pali T, Droy-Lefaix MT. Effects of Ginkgo biloba extract and preconditioning 
on the diabetic rat myocardium. Diabetologia. 1996;39(11):1255-62. 
535.  Ravingerova T, Pyne NJ, Parratt JR. Ischaemic preconditioning in the rat heart: the role 
of G-proteins and adrenergic stimulation. Molecular and cellular biochemistry. 1995;147(1-
2):123-8. 
536.  Di  Filippo  C,  Marfella  R,  Cuzzocrea  S,  Piegari  E,  Petronella  P,  Giugliano  D,  et  al. 
Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with 
low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes. 2005;54(3):803-10. 
537.  Marfella R, Di Filippo C, Esposito K, Nappo F, Piegari E, Cuzzocrea S, et al. Absence of 
inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in 
streptozotocin-induced hyperglycemic mice. Diabetes. 2004;53(2):454-62. 
538.  Forrat  R,  Sebbag  L,  Wiernsperger  N,  Guidollet  J,  Renaud  S,  de  Lorgeril  M.  Acute 
myocardial  infarction  in  dogs  with  experimental  diabetes.  Cardiovascular  research. 
1993;27(11):1908-12. 
539.  Bakth S, Arena J, Lee W, Torres R, Haider B, Patel BC, et al. Arrhythmia susceptibility 
and myocardial composition in diabetes. Influence of physical conditioning. The Journal of 
clinical investigation. 1986;77(2):382-95. 
540.  Liu Y, Thornton JD, Cohen MV, Downey JM, Schaffer SW. Streptozotocin-induced non-
insulin-dependent diabetes protects the heart from infarction. Circulation. 1993;88(3):1273-8. 
541.  Hadour G, Ferrera R, Sebbag L, Forrat R, Delaye J, de Lorgeril M. Improved myocardial 
tolerance to ischaemia in the diabetic rabbit. Journal of molecular and cellular cardiology. 
1998;30(9):1869-75. 
542.  Galagudza  MM,  Nekrasova  MK,  Syrenskii  AV,  Nifontov  EM.  Resistance  of  the 
myocardium  to  ischemia  and  the  efficacy  of  ischemic  preconditioning  in  experimental 
diabetes mellitus. Neuroscience and behavioral physiology. 2007;37(5):489-93.   340 
543.  Tani M, Neely JR. Hearts from diabetic rats are more resistant to in vitro ischemia: 
possible role of altered Ca2+ metabolism. Circulation research. 1988;62(5):931-40. 
544.  Ghosh  S,  Standen  NB,  Galinianes  M.  Failure  to  precondition  pathological  human 
myocardium. Journal of the American College of Cardiology. 2001;37(3):711-8. 
545.  Kristiansen SB, Lofgren B, Stottrup NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT, et al. 
Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 
2 diabetes. Diabetologia. 2004;47(10):1716-21. 
546.  Butler  M,  McKay  RA,  Popoff  IJ,  Gaarde  WA,  Witchell  D,  Murray  SF,  et  al.  Specific 
inhibition  of  PTEN  expression  reverses  hyperglycemia  in  diabetic  mice.  Diabetes. 
2002;51(4):1028-34. 
547.  Sivaraman  V,  Hausenloy  DJ,  Wynne  AM,  Yellon  DM.  Preconditioning  the  diabetic 
human myocardium. Journal of cellular and molecular medicine. 2010;14(6B):1740-6. 
548.  Hassouna  A,  Loubani  M,  Matata  BM,  Fowler  A,  Standen  NB,  Galinanes  M. 
Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human 
myocardium. Cardiovascular research. 2006;69(2):450-8. 
549.  Mocanu  MM,  Maddock  HL,  Baxter  GF,  Lawrence  CL,  Standen  NB,  Yellon  DM. 
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either 
ischemic preconditioning or diazoxide. Circulation. 2001;103(25):3111-6. 
550.  Kottenberg  E,  Thielmann  M,  Kleinbongard  P,  Frey  UH,  Heine  T,  Jakob  H,  et  al. 
Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-
treated diabetics undergoing coronary revascularisation. Acta anaesthesiologica Scandinavica. 
2014;58(4):453-62. 
551.  Kersten JR, Lowe D, Hettrick DA, Pagel PS, Gross GJ, Warltier DC. Glyburide, a KATP 
channel  antagonist,  attenuates  the  cardioprotective  effects  of  isoflurane  in  stunned 
myocardium. Anesthesia and analgesia. 1996;83(1):27-33. 
552.  Schulz R, Post H, Sakka S, Wallbridge DR, Heusch G. Intraischemic preconditioning. 
Increased tolerance to sustained low-flow ischemia by a brief episode of no-flow ischemia 
without intermittent reperfusion. Circulation research. 1995;76(6):942-50. 
553.  Schulz R, Rose J, Heusch G. Involvement of activation of ATP-dependent potassium 
channels  in  ischemic  preconditioning  in  swine.  The  American  journal  of  physiology. 
1994;267(4 Pt 2):H1341-52. 
554.  Schulz  R,  Gres  P,  Heusch  G.  Activation  of  ATP-dependent  potassium  channels  is  a 
trigger  but  not  a  mediator  of  ischaemic  preconditioning  in  pigs.  British  journal  of 
pharmacology. 2003;139(1):65-72. 
555.  Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, et al. Sulfonylureas 
and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride 
and glibenclamide. European heart journal. 1999;20(6):439-46. 
556.  Cleveland  JC,  Jr.,  Meldrum  DR,  Cain  BS,  Banerjee  A,  Harken  AH.  Oral  sulfonylurea 
hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes 
revisited. Circulation. 1997;96(1):29-32. 
557.  Karkouti K, Wijeysundera DN, Yau TM, Callum JL, Cheng DC, Crowther M, et al. Acute 
kidney  injury  after  cardiac  surgery:  focus  on  modifiable  risk  factors.  Circulation. 
2009;119(4):495-502. 
558.  Whitaker DC, Stygall J, Newman SP. Neuroprotection during cardiac surgery: strategies 
to reduce cognitive decline. Perfusion. 2002;17 Suppl:69-75. 
559.  Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. 
Renal  dysfunction  after  myocardial  revascularization:  risk  factors,  adverse  outcomes,  and   341 
hospital  resource  utilization.  The  Multicenter  Study  of  Perioperative  Ischemia  Research 
Group. Annals of internal medicine. 1998;128(3):194-203. 
560.  Suen WS, Mok CK, Chiu SW, Cheung KL, Lee WT, Cheung D, et al. Risk factors for 
development  of  acute  renal  failure  (ARF)  requiring  dialysis  in  patients  undergoing  cardiac 
surgery. Angiology. 1998;49(10):789-800. 
561.  Serruys  PW,  Morice  MC,  Kappetein  AP,  Colombo  A,  Holmes  DR,  Mack  MJ,  et  al. 
Percutaneous  coronary  intervention  versus  coronary-artery  bypass  grafting  for  severe 
coronary artery disease. N Engl J Med. 2009;360(10):961-72. 
562.  Haase  M,  Bellomo  R,  Devarajan  P,  Ma  Q,  Bennett  MR,  Mockel  M,  et  al.  Novel 
biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann 
Thorac Surg. 2009;88(1):124-30. 
563.  Bennett  M,  Dent  CL,  Ma  Q,  Dastrala  S,  Grenier  F,  Workman  R,  et  al.  Urine  NGAL 
predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am 
Soc Nephrol. 2008;3(3):665-73. 
564.  Fiorina C, Vizzardi E, Lorusso R, Maggio M, De Cicco G, Nodari S, et al. The 6-min 
walking test early after cardiac surgery. Reference values and the effects of rehabilitation 
programme. Eur J Cardiothorac Surg. 2007;32(5):724-9. 
565.  Dunning J, Waller JR, Smith B, Pitts S, Kendall SW, Khan K. Coronary artery bypass 
grafting is associated with excellent long-term survival and quality of life: a prospective cohort 
study. Ann Thorac Surg. 2008;85(6):1988-93. 
566.  Lee MS, Kapoor N, Jamal F, Czer L, Aragon J, Forrester J, et al. Comparison of coronary 
artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for 
unprotected left main coronary artery disease. J Am Coll Cardiol. 2006;47(4):864-70. 
567.  van Eck JW, van Hemel NM, van den Bos A, Taks W, Grobbee DE, Moons KG. Predictors 
of  improved  quality  of  life  1  year  after  pacemaker  implantation.  American  heart  journal. 
2008;156(3):491-7. 
568.  Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, et al. Long-term benefit 
of postconditioning. Circulation. 2008;117(8):1037-44. 
569.  Candilio L, Malik A, Ariti C, Barnard M, Di Salvo C, Lawrence D, et al. Effect of remote 
ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: 
a randomised controlled clinical trial. Heart. 2014. 
570.  Meybohm P, Zacharowski K, Cremer J, Roesner J, Kletzin F, Schaelte G, et al. Remote 
ischaemic preconditioning for heart surgery. The study design for a multi-center randomized 
double-blinded  controlled  clinical  trial--the  RIPHeart-Study.  European  heart  journal. 
2012;33(12):1423-6. 
  
APPENDIX 
 ORIGINAL ARTICLE
Effect of remote ischaemic preconditioning on
clinical outcomes in patients undergoing cardiac
bypass surgery: a randomised controlled clinical trial
Luciano Candilio,
1 Abdul Malik,
1 Cono Ariti,
2 Matthew Barnard,
3 Carmelo Di Salvo,
3
David Lawrence,
3 Martin Hayward,
3 John Yap,
3 Neil Roberts,
3 Amir Sheikh,
3
Shyam Kolvekar,
3 Derek J Hausenloy,
1 Derek M Yellon
1
1The Hatter Cardiovascular
Institute, University College
London, London, UK
2The Nufﬁeld Trust, London, UK
3The Heart Hospital, University
College London Hospital,
London, UK
Correspondence to
Dr Derek J Hausenloy, The
Hatter Cardiovascular Institute,
University College London,
67 Chenies Mews,
London WC1E 6HX, UK;
d.hausenloy@ucl.ac.uk
DJH and DMY are joint senior
authors.
Received 9 May 2014
Revised 22 August 2014
Accepted 28 August 2014
To cite: Candilio L,
Malik A, Ariti C, et al. Heart
Published Online First:
[please include Day Month
Year] doi:10.1136/heartjnl-
2014-306178
ABSTRACT
Objectives Remote ischaemic preconditioning (RIPC),
using brief cycles of limb ischaemia/reperfusion, is a
non-invasive, low-cost intervention that may reduce
perioperative myocardial injury (PMI) in patients
undergoing cardiac surgery. We investigated whether
RIPC can also improve short-term clinical outcomes.
Methods One hundred and eighty patients undergoing
elective coronary artery bypass graft (CABG) surgery and/
or valve surgery were randomised to receive either RIPC
(2–5 min cycles of simultaneous upper arm and thigh
cuff inﬂation/deﬂation; N=90) or control (uninﬂated cuffs
placed on the upper arm and thigh; N=90). The study
primary end point was PMI, measured by 72 h area
under the curve (AUC) serum high-sensitive troponin-T
(hsTnT); secondary end point included short-term clinical
outcomes.
Results RIPC reduced PMI magnitude by 26%
(−9.303 difference (CI −15.618 to −2.987) 72 h
hsTnT-AUC; p=0.003) compared with control. There was
also evidence that RIPC reduced the incidence of
postoperative atrial ﬁbrillation by 54% (11% RIPC vs
24% control; p=0.031) and decreased the incidence of
acute kidney injury by 48% (10.0% RIPC vs 21.0%
control; p=0.063), and intensive care unit stay by 1 day
(2.0 days RIPC (CI 1.0 to 4.0) vs 3.0 days control (CI 2.0
to 4.5); p=0.043). In a post hoc analysis, we found that
control patients administered intravenous glyceryl
trinitrate (GTN) intraoperatively sustained 39% less PMI
compared with those not receiving GTN, and RIPC did
not appear to reduce PMI in patients given GTN.
Conclusions RIPC reduced the extent of PMI in
patients undergoing CABG and/or valve surgery. RIPC
may also have beneﬁcial effects on short-term clinical
outcomes, although this will need to be conﬁrmed in
future studies.
Trial registration number ClinicalTrials.gov ID:
NCT00397163.
INTRODUCTION
Coronary artery bypass graft (CABG) surgery is the
revascularisation strategy of choice for patients
with multivessel coronary artery disease.
Higher-risk patients are being operated on for a
number of different reasons, including the aging
population, the presence of comorbidities such as
diabetes, obesity and hypertension, and the increas-
ing incidence of concomitant valve surgery. These
higher-risk patients are more susceptible to peri-
operative myocardial injury (PMI) and experience
worse short-term and long-term clinical outcomes.
1
Therefore, novel therapeutic interventions are
required to protect the heart during CABG surgery
in these higher-risk patients in order to improve
patient morbidity and mortality.
In this regard, remote ischaemic preconditioning
(RIPC), in which the application of one or more
brief cycles of non-lethal ischaemia and reperfusion
to an organ or tissue protects the heart against a
lethal episode of acute ischaemia-reperfusion injury
(IRI),
23has emerged as a non-invasive, low-cost
therapeutic intervention for potentially reducing
the extent of PMI (as measured by serum cardiac
enzymes) in patients undergoing CABG and/or
valve surgery.
4–16 The majority of these clinical
studies have reported beneﬁcial effects using a
standard single-limb RIPC protocol comprising
three or four 5 min cycles of inﬂation and deﬂation
of a cuff placed on either the upper arm or thigh to
induce transient ischaemia. However, several recent
studies have failed to demonstrate any reduction in
PMI using this standard single-limb RIPC stimulus,
suggesting that under certain conditions this RIPC
stimulus may be ineffective.
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Whether increasing the intensity of the RIPC
stimulus by simultaneously applying the RIPC
protocol to the upper arm and thigh is more effect-
ive in patients undergoing CABG and/or valve
surgery is unknown and is investigated in this study.
Furthermore, whether RIPC can improve short-
term clinical outcomes in this patient group is
unknown and is explored here.
METHODS
Study design
This double-blinded randomised controlled clinical
trial received local University College London
Hospitals (UCLH) Ethics Committee approval and
was conducted at the UCLH Heart Hospital
(London, UK), in accordance with UCLH guide-
lines. Written informed consent was obtained from
all patients recruited into the study. Randomisation
was carried out using a computer-generated list of
randomised numbers, and allocation concealment
obtained using Sequentially Numbered Opaque
Sealed Envelopes.
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control protocols were performed by an unblinded investigator
not involved in data collection or analysis. The investigator col-
lecting and analysing the data, patients, cardiac surgeons and
anaesthetists, operating theatre staff and staff on intensive care
unit (ICU) and cardiac wards were all blinded to treatment
allocation.
Inclusion and exclusion criteria
We recruited adult patients (>18 years of age) undergoing
on-pump CABG and/or valve surgery at the UCLH Heart
Hospital between December 2010 and July 2012. Patient exclu-
sion criteria were cardiogenic shock or cardiac arrest in the
current hospital admission; positive baseline serum hsTnT; preg-
nancy; signiﬁcant peripheral arterial disease affecting upper and/
or lower limbs; signiﬁcant hepatic (INR>2.0), pulmonary
(forced expiratory volume-1<40% predicted) or renal disease
(estimated glomerular ﬁltration rate <30 mL/min/1.73 m
2); and
concomitant therapy with glibenclamide or nicorandil, as these
medications may interfere with RIPC.
Intervention
RIPC and control protocols were initiated after anaesthesia
induction and completed prior to sternotomy. RIPC was deliv-
ered with one standard blood pressure cuff placed on the upper
arm and another standard blood pressure cuff placed on the
upper thigh. The cuffs were then simultaneously inﬂated to
200 mm Hg and left inﬂated for 5 min, then deﬂated to
0 mm Hg and left uninﬂated for 5 min. This cycle was repeated
twice so that the total duration of the RIPC protocol was
20 min. If the systolic blood pressure was >185 mm Hg, the
cuffs were inﬂated to 15 mm Hg above that level. For the
control protocol, the two cuffs were placed on the upper arm
and the upper thigh and left uninﬂated for 20 min.
Surgical procedure
Patients received premedication with oral temazepam 10–20 mg
1 h prior to surgery. Anaesthesia induction was achieved with
different combinations of midazolam, etomidate, propofol, fen-
tanyl and antinicotinic agents (rocuronium, vecuronium or pan-
curonium). The trachea was intubated and mechanical
ventilation commenced with oxygen with or without air.
Anaesthesia maintenance was achieved with volatile agents (iso-
ﬂurane or sevoﬂurane) and propofol infusion with or without
fentanyl. Arterial blood pressure, central venous pressure, leads
I and III of the ECG and nasopharyngeal temperature were
recorded continuously. An intravenous glyceryl trinitrate (GTN)
infusion, initiated prior to sternotomy and continued until
patient transfer to ICU, was administered at the discretion of
the anaesthetist at a dose of 25–85 μg/kg/min (titrated to blood
pressure). Standard non-pulsatile cardiopulmonary bypass (CPB)
was employed using a membrane oxygenator and cardiotomy
suction: following this, all coronary grafts were constructed
during CPB using either intermittent cross-clamp ﬁbrillation or
Figure 1 Study proﬁle. RIPC, remote
ischaemic preconditioning; eGFR,
estimated glomerular ﬁltration rate;
PAD, peripheral arterial disease; FEV,
forced expiratory volume.
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valve replacement/repair, CPB was discontinued and protamine
was used to achieve heparin reversal.
Study primary end point
The study primary end point was PMI, assessed by measuring
the total 72-hour area under the curve (AUC) hsTnT. Blood
samples for hsTnT were taken preoperatively and at 6, 12, 24,
48 and 72 h postsurgery: hsTnTwas measured quantitatively by
a one-step enzyme immunoassay based on electrochemilumines-
cence technology (Elecsys 2010, Roche, Switzerland). This assay
can allow detection of concentrations <1.0 ng/L. These assays
measure the upper range limit with a coefﬁcient of variation
<10%. The threshold level of ≥14 ng/L indicates signiﬁcant
myocardial necrosis.
Study secondary end points
These included the following:
1. Acute kidney injury (AKI) score:
18 Serum creatinine and
urine output were measured preoperatively and 24, 48 and
72 h postsurgery. AKI was classiﬁed with the following
grades:
▸ Grade 1: serum creatinine rise of >26.4 mmol/L or
150%–200% of baseline and/or urine output
<0.5 mL/kg/h for >6 contiguous hours.
▸ Grade 2: serum creatinine rise of 200%–300% of base-
line and/or urine output <0.5 mL/kg/h for >12 con-
tiguous hours.
▸ Grade 3: serum creatinine rise of >300% of baseline or
serum creatinine >354 mmol/L with an acute rise of at
least 44 mmol/L and/or urine output <0.3 mL/kg/h for
>24 h or anuria for 12 h.
2. Inotrope requirement,
19 measured every 24 h over the 72 h
postoperative period as dosages (mg/kg/min) of
ðDopamine þ Dobutamine þ Dopeximine) þð ð Adrenaline
þ Noradrenaline þ IsoprotenerolÞ 100Þþ½ ð Enoximone
þ MilrinoneÞ 15 :
3. Length of ICU and hospital stay, calculated as the total dur-
ation in days of length of stay on ICU and in hospital.
4. Incidence of postoperative atrial ﬁbrillation (AF): This was
the incidence of new-onset AF in the ﬁrst 72 h after surgery
Table 1 Patient baseline characteristics
Patients Control (n=89) RIPC (n=89)
Age (years) 66±10 65±10
Gender
Male 67 (75%) 72 (81%)
Female 22 (25%) 17 (19%)
Ethnicity
Caucasian 74 (83%) 71 (80%)
Asian 10 (11%) 12 (13%)
Afro-Caribbean 4 (5%) 6 (7%)
Chinese 1 (1%) 0 (0%)
BMI 28.4±5.5 28.8±7.1
SBP (mm Hg) 130.0±18.0 129.0±15.7
DBP (mm Hg) 70.7±9.0 70.8±9.4
HR (bpm) 69.2±11.7 66.3±9.8
Smoking history
Smoker 12 (14%) 11 (12%)
Ex-smoker 52 (58%) 48 (54%)
Non-smoker 25 (28%) 30 (34%)
Family history of IHD 57 (64%) 64 (72%)
NYHA class
0 8 (9%) 8 (9%)
I 22 (26%) 31 (36%)
II 38 (44%) 39 (46%)
III 17 (20%) 7 (8%)
IV 1 (1%) 0 (0%)
CCS class
0 30 (35%) 25 (29%)
I 17 (20%) 19 (22%)
II 30 (35%) 30 (35%)
III 7 (8%) 9 (11%)
IV 2 (2%) 2 (2%)
LVEF
>50% 70 (79%) 67 (75%)
30%–50% 17 (19%) 16 (18%)
<30% 2 (2%) 6 (7%)
Comorbidities
Diabetes mellitus 24 (27%) 28 (32%)
Hypertension 70 (79%) 65 (73%)
Hypercholesterolaemia 64 (72%) 68 (76%)
Atrial fibrillation 16 (18%) 10 (11%)
Previous MI 23 (26%) 28 (32%)
Previous PCI 11 (12%) 11 (12%)
Previous CVA/TIA 9 (10%) 5 (6%)
Previous cardiac surgery 2 (2%) 4 (5%)
Other comorbidities 35 (40%) 32 (36%)
Peripheral arterial disease 6 (7%) 1 (1%)
Drug history
Aspirin 66 (76%) 72 (84%)
Clopidogrel/prasugrel 27 (31%) 24 (28%)
Warfarin 9 (10%) 6 (7%)
Beta-blocker 55 (63%) 57 (66%)
Calcium channel blocker 32 (37%) 22 (26%)
Statin 72 (83%) 72 (84%)
ACE-I/ARB 61 (70%) 57 (66%)
Long-acting nitrates 14 (16%) 12 (14%)
Continued
Table 1 Continued
Patients Control (n=89) RIPC (n=89)
Antidiabetics
Insulin 7 (8%) 8 (9%)
Biguanide 16 (18%) 19 (22%)
Sulfonylurea 11 (13%) 7 (8%)
Diuretics 27 (31%) 31 (36%)
Data are mean±SD.
The following characteristics have missing values: BMI (control 2, RIPC 2), SBP
(control 2, RIPC 2), DBP (control 2, RIPC 2), HR (control 2, RIPC 2), NYHA (control 3,
RIPC 4), CSS (control 3, RIPC 4), other comorbidities (control 1, RIPC 1), aspirin
(control 2, RIPC 3), clopidogrel/prasugrel (control 2, RIPC 3), warfarin (control 2, RIPC
3), beta-blocker (control 2, RIPC 3), calcium channel blocker (control 2, RIPC 3), statin
(control 2, RIPC 3), ACE-I/ARB (control 2, RIPC 3), long-acting nitrates (control 2, RIPC
3), insulin (control 2, RIPC 3), biguanide (control 2, RIPC 3), sulfonylurea (control 2,
RIPC 3), diuretics (control 2, RIPC 3).
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
BMI, body mass index; CCS, Canadian Cardiovascular Society; CVA, cerebrovascular
accident; DBP, diastolic blood pressure; HR, heart rate; IHD, ischaemic heart disease;
INR, international normalised ratio; LVEF, left ventricular ejection fraction;
MI, myocardial infarction; NYHA, New York Health Association; PCI, percutaneous
coronary intervention; RIPC, remote ischaemic preconditioning; SBP, systolic blood
pressure; TIA, transient ischaemic attack.
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blinded staff nurse on a daily basis and immediately after the
detection of AF on the telemetry, and then analysed by a
blinded investigator) and requiring intervention with pharma-
cological treatment and/or direct current cardioversion.
5. Major adverse cardiovascular events at 6 weeks: This was the
rate of death, non-fatal myocardial infarction, coronary artery
revascularisation and stroke at 6 weeks postoperatively.
Study safety end points
The main study safety end point was skeletal muscle injury from
the RIPC protocol (measured by total creatine kinase (CK)-AUC
over the ﬁrst 72 postoperative hours) and any adverse events
relating to the RIPC protocol.
Statistical analysis and sample size estimation
Data are presented as mean (SD) or median (IQR). Comparison
between treatment groups was made using unpaired Student t
test for approximately normally distributed variables or
Wilcoxon–Mann–Whitney test for non-normal data. For out-
comes collected at different time points, a repeated measures
linear regression model was used to estimate the difference at
each time point and 95% CIs. Categorical data were analysed
using Fisher’s exact test. The post hoc analysis of associations
between RIPC and GTN was performed using an interaction
test in a linear regression model. We hypothesised that RIPC
would reduce hsTnT-AUC by a standardised difference of 0.6.
At 90% power and signiﬁcance at the two-sided 5% level, this
required a sample size of 60 subjects, which we increased by
33% to accommodate withdrawal or missing data points. A
sample size of at least 80 patients per intervention group was
determined based on the following assumptions: (a) the largest
published study to date on RIPC in PMI,
6 (b) a power of at least
90%, (c) an SD of 0.2 mg/L and (d) type I error rate of 5%.
Analysis was by intention to treat. No adjustment for multipli-
city has been applied for secondary outcomes or post hoc ana-
lyses. Data were analysed using Stata V .12.1.
RESULTS
We assessed 340 patients for eligibility (see ﬁgure 1), of whom
180 patients were enrolled into the study and randomised to
receive either RIPC (N=90) or control (N=90): a total of 178
patients were included for ﬁnal analysis. No signiﬁcant differ-
ence was found between the two treatment groups with respect
to baseline patient characteristics (table 1). With regards to the
details of surgery, the only evidence of a difference between the
two groups was the percentage of patients receiving intravenous
GTN, which was higher in the control group (65 vs 53 patients;
table 2).
In all patients, the RIPC protocol was completed within an
interval period not longer than 45 min prior to sternotomy.
There were no untoward consequences or side effects with the
RIPC protocol.
RIPC reduced the extent of PMI
The primary end point of total 72 h AUC hsTnT was reduced
by 25.6% in patients randomised to receive RIPC compared
with control (−9.30 μg/L, 95% CI −15.618 to −2.987,
p=0.004; ﬁgure 2, table 3). Moreover, baseline preoperative
hsTnT levels were <0.02 μg/L and were not signiﬁcantly differ-
ent between RIPC and control groups (−0.003 μg/L, 95% CI
−0.009 to 0.003), p=0.308; ﬁgure 2, table 3). In patients ran-
domised to RIPC, the mean hsTnT was signiﬁcantly reduced
at 6, 12, 24, 48 and 72 h postsurgery compared with control
(ﬁgure 2, table 3).
RIPC protected kidney function during surgery
The incidence of AKI was decreased in RIPC-treated patients,
with 10 new cases of postoperative AKI in the preconditioned
Table 2 Details of surgical procedure
Patients Control (n=89) RIPC (n=89)
Indication for surgery
Angina 44 (49%) 40 (45%)
Myocardial infarction 12 (14%) 19 (21%)
Valve disease 23 (26%) 23 (26%)
Angina and valve disease 7 (8%) 4 (5%)
Myocardial infarction and valve disease 1 (1%) 2 (2%)
Infective endocarditis 2 (2%) 1 (1%)
EuroSCORE 3.72±2.03 3.70±2.59
Additive perioperative risk
Low (EuroSCORE 0–2) 26 (29%) 29 (33%)
Medium (EuroSCORE 3–5) 47 (53%) 38 (43%)
High (EuroSCORE >5) 16 (18%) 22 (25%)
Bypass time (min) 96.7±32.6 89.6±31.0
Cross-clamp time (min) 64.8±26.4 61.5±26.9
Cardioprotection
Blood cardioplegia 73 (82%) 75 (84%)
Cross-clamp fibrillation 16 (18%) 14 (16%)
Operation
CABG alone 54 (61%) 57 (64%)
AVR alone 15 (17%) 14 (16%)
CABG+AVR 10 (11%) 9 (10%)
MVR or MV repair 9 (10%) 8 (9%)
AVR+MVR 1 (1%) 1 (1%)
Number of grafts
One 4 (6%) 5 (8%)
Two 19 (30%) 15 (23%)
Three 29 (45%) 35 (53%)
Four 12 (19%) 11 (17%)
Anaesthetic agents
Induction
Antinicotinic agents
Rocuronium 68 (81.0%) 76 (89%)
Pancuronium 14 (17%) 6 (7%)
Vecuronium 2 (2%) 3 (4%)
Midazolam 45 (54%) 33 (39%)
Etomidate 8 (9%) 7 (8%)
Fentanyl 86 (100%) 85 (100%)
Propofol 76 (88%) 77 (91%)
Maintenance
Propofol 86 (100%) 85 (100%)
Volatile anaesthetics
Isoflurane 80 (93%) 81 (95%)
Sevoflurane 6 (7%) 4 (5%)
Intraoperative GTN 65 (76%) 53 (60%)
Values are mean±SEM.
The following procedure variables had missing values: bypass time (control 2,
RIPC 1), cross-clamp time (control 4, RIPC 1), antinicotinic agents (control 5, RIPC 4),
midazolam (control 5, RIPC 4), etomidate (control 3, RIPC 4), fentanyl (control 3,
RIPC 4), propofol on induction (control 3, RIPC 4), propofol during maintenance
(control 3, RIPC 4), volatile anaesthetics (control 3, RIPC 4), intraoperative GTN
(control 3, RIPC 1).
AVR, aortic valve replacement; CABG, coronary artery bypass graft; EuroSCORE,
European System for Cardiac Operative Risk Evaluation; GTN, glyceryl trinitrate; MV,
mitral valve; MVR, mitral valve replacement; RIPC, remote ischaemic preconditioning.
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is, 10.0% versus 21.0% of new cases, which corresponded to a
relative reduction of AKI 48% (p=0.063: table 3).
RIPC reduced the incidence of AF and shortened ICU stay
RIPC reduced the incidence of new onset of postoperative AF
in the ﬁrst 72 h postsurgery by 54% (10 RIPC vs 22 control;
p=0.03) and decreased the length of ICU stay (RIPC 2.0 days
(IQR 1.0 to 4.0) vs control 3.0 days (IQR 2.0 to 4.5); p=0.04)
(table 3).
Other end points
Total CK release was not statistically different between control
and RIPC patients (32 543±27 087 mg/L control vs 36 312
±19 496 μg/L RIPC; 3769.6 difference (CI −4647.0 to
12186.2); p=0.38), demonstrating that the multilimb RIPC
stimulus was not associated with a signiﬁcant skeletal muscle
injury (table 3). There was no difference in total inotrope
Table 3 Summary of study end points
Endpoint
Control
(n=89)
(mean (SD))
RIPC
(n=89)
(mean (SD))
Difference*
(95% CI) p Value*
hsTnT (μg/L)
Preoperatively 0.018 (0.019) 0.015 (0.020) −0.003 (−0.099 to 0.093)
6 h postoperatively 0.802 (0.498) 0.614 (0.381) −0.188 (−0.285 to −0.092)
12 h postoperatively 0.709 (0.438) 0.556 (0.376) −0.153 (−0.250 to −0.057)
24 h postoperatively 0.529 (0.341) 0.408 (0.268) −0.124 (−0.221–0.027)
48 h postoperatively 0.440 (0.408) 0.307 (0.202) −0.137 (−0.234 to −0.041)
72 h postoperatively 0.407 (0.349) 0.277 (0.219) −0.136 (−0.233 to −0.038)
Total 72 h AUC 36.307 (24.542) 27.004 (16.523) −9.303 (−15.626 to −2.979) 0.004
CK (μg/L)
Total AUC 32 542.8 (19 495.5) 36 312.3 (27 087.2) 3769.6 (–4647.0 to 12186.2) 0.377
AKI score (N)
0 70 (79%) 80 (90%)
1 11 (12%) 6 (7%)
2 5 (6%) 2 (2%)
3 3 (3%) 1 (1%)
Total number of AKI cases 19 (21%) 9 (10%) 0.063
Inotrope score (mg/kg/h)
Postbypass 6.8 (13.5) 6.8 (15.3) 0.0 (−4.8 to 4.8)
24 h postoperatively 11.6 (20.9) 9.4 (16.6) −2.2 (−7.0 to 2.6)
48 h postoperatively 8.4 (19.1) 5.5 (14.1) −2.9 (−7.7 to 2.0)
72 h postoperatively 5.6 (16.8) 1.7 (8.3) −3.9 (−8.7 to 1.0)
Total 32.7 (58.8) 22.7 (42.3) −10.0 (−25.6 to 5.6) 0.206
New onset AF (N) 22 (25%) 10 (11%) 0.031
Length of ICU stay (days) 3.0 (2.0–4.5)† 2 .0 (1.0–4.0)† 0.043‡
Length of hospital stay (days) 8.5 (7.0–12.0)† 8.0 (6.0–10.0)† 0.094‡
Clinical outcomes at 6 weeks (N)
Death 5 (7%) 0 (0%) 0.057
Myocardial infarction 1 (1%) 0 (0%) 0.401
Stroke 0 (0%) 1 (1%) 0.451
Revascularisation 0 (0%) 0 (0%) 1.000
The following secondary end points had missing values: hsTnT 24 h postoperatively (RIPC 1), hsTnT 48 h postoperatively (control 1, RIPC 2), hsTnT 72 h postoperatively (control 3, RIPC
4), total 72 h AUC (control 3, RIPC 4), total AUC CK (control 29, RIPC 24), inotrope score postbypass (control 5, RIPC 4), inotrope score 24 h postoperatively (control 6, RIPC 4),
inotrope score 48 h postoperatively (control 7, RIPC 4), inotrope score 72 h postoperatively (control 7, RIPC 4), total inotrope score (control 7, RIPC 4), length of ICU stay (control 1),
length of hospital stay (control 1), death (control 15, RIPC 20), myocardial infarction (control 15, RIPC 20), stroke (control 15, RIPC 19), revascularisation (control 15, RIPC 20).
*Differences, 95% CIs of the differences and p value are calculated from repeated measures regression model.
†Results shown as median (IQR).
‡p Value for Mann–Whitney–Wilcoxon test.
AF, atrial fibrillation; AKI, acute kidney injury; AUC, area under the curve; CK, creatine kinase; IABP, intra-aortic balloon Pump; ICU, intensive care unit; RIPC, remote ischaemic
preconditioning; hsTnT, high-sensitive troponin-T.
Figure 2 Serum hsTnT levels. Values are mean±SEM. hsTnT,
high-sensitivity troponin-T; RIPC, remote ischaemic preconditioning.
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patients randomised to RIPC compared with control (table 3).
Post hoc subgroup analysis
We performed a post hoc subgroup analysis to examine the
effect of administering an intravenous GTN infusion during
surgery on the magnitude of PMI. Interestingly, we found that
the total 72 h AUC hsTnTwas reduced by 39% in those control
patients who had been administered intraoperative intravenous
GTN compared with those control patients who had not (GTN
30.8±17.6 μg/L vs no GTN 50.5±34.2 μg/L (−19.7 difference
(CI −29.7 to −9.8); p<0.001; ﬁgure 3A; table 4), suggesting
that intraoperative intravenous GTN itself can reduce PMI.
We also investigated whether administering an intravenous
GTN infusion during surgery affected the cardioprotective efﬁ-
cacy of RIPC. RIPC did not reduce the magnitude of PMI in
those patients who had been administered intraoperative intraven-
ous GTN compared with those RIPC patients who had not
(RIPC+GTN 26.7±13.9 μg/L vs RIPC+no GTN 27.9
±20.10 μg/L (−1.2 difference (CI −9.9 to −7.6); p=0.793, ﬁgure
3B; table 4), suggesting that the beneﬁcial effect of RIPC on PMI
was absent in the presence of intraoperative intravenous GTN.
DISCUSSION
In an unselected prospective cohort of 180 adult patients under-
going elective CABG and/or valve surgery, we have demon-
strated that a shortened RIPC protocol can reduce the amount
of PMI by 26%. In addition, there is a possibility that RIPC
may also improve short-term clinical outcomes with a 54%
reduction in the incidence of postoperative AF, a 48% decrease
in the incidence of AKI and a shortening of ICU stay by 1 day.
However, the effect of RIPC on these outcome measures will
have to be repeated in future studies.
A number of small clinical trials have investigated the effect
of a standard single-limb RIPC protocol on the magnitude of
PMI in patients undergoing cardiac surgery, the majority of
which have demonstrated beneﬁcial effects on PMI magni-
tude.
457This has also been conﬁrmed by a number of recent
meta-analyses.
20 One clinical study has even suggested reduced
mortality in preconditioned patients.
21 However, several recent
studies have failed to demonstrate beneﬁcial effects of RIPC in
this patient group.
61 01 7One potential explanation for these
differences may relate to the RIPC stimulus itself, which may not
be sufﬁcient to elicit cardioprotection under certain conditions:
the majority of clinical studies have used a standard single-limb
RIPC protocol comprising either three or four 5 min cycles of
inﬂation/deﬂation of a cuff placed on either the upper arm or
thigh. In our study, we used a more intense RIPC protocol com-
prising two 5 min cycles of simultaneous upper arm and thigh
cuff inﬂation and deﬂation, which can be delivered far more
rapidly, requiring only 20 min, compared with 40 min using the
standard single-limb four-cycle RIPC protocol. This allowed the
multilimb RIPC protocol to be delivered after the induction of
anaesthesia and well before sternotomy. Another potential
explanation could be the timing of delivery of the RIPC stimulus:
two of the negative studies that failed to report any beneﬁcial
effects with RIPC administered the protocol after sternotomy had
taken place,
61 0whereas in the vast majority of clinical studies the
RIPC stimulus is initiated and completed prior to sternotomy.
A further possible reason for failing to observe RIPC cardio-
protection in patients undergoing cardiac surgery may be due to
concomitant therapy, including intravenous GTN: in a post hoc
subgroup analysis of data, we investigated the effect of intrao-
perative intravenous GTN on PMI, in relation to the cardiopro-
tective effect of RIPC. Interestingly, we found that control
patients given intravenous GTN during surgery sustained 39%
less PMI than control patients who did not receive intravenous
GTN. Furthermore, in preconditioned patients administered
intravenous GTN during surgery, RIPC had no beneﬁcial effect
on PMI, whereas in preconditioned patients not given intraven-
ous GTN, RIPC signiﬁcantly reduced the amount of PMI. It is
well established in the published literature that nitric oxide
donors such as GTN are highly effective mediators of cardio-
protection in both the preclinical and the clinical settings.
22 23
These ﬁndings suggest that RIPC may not be able to elicit cardi-
oprotection in the presence of intravenous GTN, as the myocar-
dium may have already been protected by the GTN itself. In
contrast to our ﬁndings, a recently published retrospective ana-
lysis by Kleinbongard et al
21 has suggested that intravenous
GTN had no effect on RIPC cardioprotection in patients under-
going CABG surgery. Therefore, it will be important to investi-
gate whether GTN is cardioprotective and whether RIPC
cardioprotection is attenuated when it is present in a suitably
powered prospective randomised controlled clinical trial.
In our study, the incidence of postoperative AF was reduced
by 55% in RIPC-treated patients: new-onset AF occurs in 30%–
50% of patients following cardiac surgery
24 and is associated
Figure 3 (A) Serum high-sensitivity troponin-T release in a subgroup
of patients receiving intravenous GTN intraoperatively. Values are mean
±SEM. (B) Serum high-sensitivity troponin-T release in a subgroup of
patients not receiving intravenous GTN intraoperatively. Values are
mean±SEM. hsTnT, GTN, glyceryl trinitrate; high-sensitivity troponin-T;
RIPC, remote ischaemic preconditioning.
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tricular failure, prolonged hospitalisation, reduced quality of life
and poor exercise capacity.
24 The aetiology of postoperative AF
is multifactorial, with acute myocardial IRI being one contribu-
tory factor.
24 Therefore, RIPC may have decreased the inci-
dence of postoperative AF by protecting the myocardium
against acute IRI. However, Rahman et al
6 failed to demonstrate
any effect of RIPC on AF incidence following cardiac surgery.
An ongoing large multicentre RICO trial is currently investigat-
ing the effects of RIPC on the incidence of postoperative AF in
patients with CABG (ClinicalTrials.gov: NCT01107184).
25
AKI can affect up to 30% of patients postcardiac surgery,
necessitating dialysis in 1%–2% of cases and ultimately leading
to an eightfold increase in death rate.
26 A number of clinical
studies have investigated the effect of RIPC on postoperative
renal function in patients undergoing cardiac surgery, where
once again IRI plays a signiﬁcant pathogenic role.
26 However,
the results have been controversial:
61 01 12 72 8our study is the
largest to report a potential renoprotective effect with RIPC in
patients undergoing cardiac surgery and found both an
improved postoperative urine output and a reduced AKI inci-
dence of 48% in preconditioned patients, although this did not
reach statistical signiﬁcance.
Finally, our study is the ﬁrst to report beneﬁcial effects of
RIPC on the length of ICU stay following cardiac surgery: we
found that RIPC shortened the duration of ICU stay by 1 day, a
ﬁnding that may well be related to reduced PMI magnitude and
decreased postoperative AF and AKI incidence.
One important limitation of our study was the blinding of the
RIPC protocol in the anaesthetic room, which, because of the
nature of the intervention, was difﬁcult to achieve in an optimal
manner. However, it is important to note that all data were
collected by a research investigator blinded to the treatment
allocation. Another limitation of our study was not adjusting for
multiple comparisons and therefore, we restricted the number
of comparisons we performed to the minimum in order to
reduce the risk of a type I error. However, despite doing this,
the effect of RIPC on clinical outcomes should be treated as
‘hypothesis generating’ and there is a possibility that the results
may have arisen by chance, and therefore the clinical outcome
data will need to be conﬁrmed in future studies.
In summary, we have demonstrated that RIPC applied by sim-
ultaneous multilimb IRI can reduce the magnitude of PMI and
Table 4 Effect of intravenous glyceryl trinitrate (GTN) on plasma hsTnT levels in control and RIPC patients
hsTnT level (μg/L)
Control
(mean(SD))
RIC
(mean(SD)) Difference (95% CI) p Value
Preoperatively
GTN given 0.015 (0.015) 0.018 (0.023) 0.002 (−0.113 to 0.118)
GTN not given 0.027 (0.027) 0.011 (0.015) −0.016 (−0.188 to 0.156)
6 h postoperatively
GTN given 0.750 (0.487) 0.635 (0.319) −0.114 (−0.229 to 0.001)
GTN not given 0.904 (0.468) 0.591 (0.464) −0.313 (−0.484 to −0.141)
12 h postoperatively
GTN given 0.627 (0.395) 0.578 (0.371) −0.050 (−0.165 to 0.065)
GTN not given 0.905 (0.447) 0.533 (0.389) −0.372 (−0.544 to −0.200
24 h postoperatively
GTN given 0.454 (0.265) 0.401 (0.239) −0.054 (−0.169 to 0.061)
GTN not given 0.745 (0.446) 0.425 (0.313) −0.324 (−0.497 to −0.152)
48 h postoperatively
GTN given 0.357 (0.214) 0.296 (0.168) −0.065 (−0.181 to 0.050)
GTN not given 0.701 (0.678) 0.327 (0.249) −0.379 (−0.551 to −0.207)
72 h postoperatively
GTN given 0.350 (0.300) 0.250 (0.165) −0.110 (−0.227 to −0.007)
GTN not given 0.552 (0.435) 0.321 (0.281) −0.235 (−0.408 to −0.063)
72 h total AUC
GTN given 30.811 (17.561) 26.687 (13.934) −4.124 (−11.169 to 3.367) 0.006
GTN not given 50.515 (34.204) 27.858 (20.012) −22.658 (−33.597 to −11.719)
Differences, 95% CIs of the differences and p value for test of interaction between RIC and GTN given are calculated from a repeated measures regression model.
The following secondary end points had missing values: hsTnT 24 h postoperatively—GTN not given (RIPC 1), hsTnT 48 h postoperatively—GTN given (control 1, RIPC 1), hsTnT 48 h
postoperatively—GTN not given (RIPC 1), hsTnT 72 h postoperatively—GTN given (control 3, RIPC 3), hsTnT 72 h postoperatively—GTN not given (RIPC 1), 72 h total AUC—GTN given
(control 3, RIPC 3), 72 h total AUC—GTN not given (RIPC 1).
AUC, area under the curve; hsTnT, high-sensitivity troponin-T; RIC, remote ischaemic conditioning; RIPC, remote ischaemic preconditioning.
Key messages
What is known on this subject?
Remote ischaemic preconditioning (RIPC) may reduce
perioperative myocardial injury in patients undergoing coronary
artery bypass graft (CABG) surgery. Whether it can improve
clinical outcomes in this patient group is unknown and is
investigated in our study.
What might this study add?
We ﬁnd that RIPC may improve short-term clinical outcomes as
evidenced by reduced incidences of postoperative atrial
ﬁbrillation, acute kidney injury and a shortened ICU stay.
How might this impact on clinical practice?
RIPC may improve morbidity and mortality in patients
undergoing CABG surgery and it, therefore, has the potential to
change clinical practice.
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unselected cohort of adult patients undergoing elective CABG
and/or valve surgery. However, the effect of RIPC on short-term
clinical outcomes will have to be conﬁrmed in future studies.
Large multicentre randomised controlled clinical trials are cur-
rently being undertaken to evaluate the potential effects of
RIPC on long-term clinical outcomes in patients undergoing
CABG with or without valve surgery (ERICCA trial,
29
ClinicalTrial.gov identiﬁer: NCT01247545 and RIPHeart
trial,
30 ClinicalTrials.gov identiﬁer: NCT01067703).
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Abstract  
Background. Retrograde perfusion into coronary sinus during coronary artery bypass 
graft (CABG) surgery reduces the need for cardioplegic interruptions and ensures the 
distribution  of  cardioplegia  to  stenosed  vessel  territories,  therefore  enhancing  the 
delivery  of  cardioplegia  to  the  subendocardium.  Peri-operative  myocardial  injury 
(PMI),  as  measured  by  the  rise  of  serum  level  of  cardiac  biomarkers,  has  been 
associated with short and long-term clinical outcomes. We conducted a retrospective 
analysis  to  investigate  whether  the  combination  of  antegrade  and  retrograde 
techniques  of  cardioplegia  delivery  is  associated  with  a  reduced  PMI  than  that 
observed with the traditional methods of myocardial preservation.  
Methods.  Fifty-four  consecutive  patients  underwent  CABG  surgery  using  either 
antegrade cold blood cardioplegia (group 1, n=28) or cross-clamp fibrillation (group 
2, n=16) or antegrade retrograde warm blood cardioplegia (group 3, n=10). The study 
primary end-point was PMI, evaluated with total area under the curve (AUC) of high-
sensitivity Troponin-T (hsTnT), measured pre-operatively and at 6, 12, 24, 48 and 72 
hours post-surgery. Secondary endpoints were acute kidney injury (AKI) and inotrope 
scores,  length  of  intensive  care  unit  (ICU)  and  hospital  stay,  new  onset  atrial 
fibrillation  (AF)  and  clinical  outcomes  at  6  weeks  (death,  non-fatal  myocardial 
infarction, coronary artery revascularization, stroke).  
Comparison between exposure groups was made  by including the exposure variable 
as  a  categorical  variable  in  a  linear  regression  model  for  approximately  normally 
distributed endpoint variables. For skewed endpoint variables the median T-test was 
used.  For  continuous  endpoint  variables  measured  over  time  a  repeated  measures 
linear regression model was fitted to measure the association between the exposure 
variable and endpoint. Categorical data were analysed using Fisher’s exact test. No   - 4 - 
adjustement for multiplicity has been made. Data were analysed using Stata version 
12.1. 
Results. There was evidence that mean total AUC of hsTnT was different among the 
three  groups (P=0.050). In particular mean total AUC of hsTnT was significantly 
lower in group 3 compared to both group 1 (-16.55; 95% CI: -30.08, -3.01; P=0.018) 
with slightly weaker evidence of a lower mean hsTnT in group 3 when compared to 
group  2  (-15.13,;  95%  CI  -29.87,  -0.39;  P=0.044).    There  was  no  evidence  of  a 
difference  when  comparing  group  2  to  group  1  (-1.42,;  95%  CI:  -12.95,  10.12, 
P=0.806). 
Conclusions.  Our  retrospective  analayis  suggests  that,  compared  to  traditional 
methods of myocardial preservation, antegrade retrograde cardioplegia may reduce 
PMI in patients undergoing first time CABG surgery. 
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Background  
The prompt delivery of cardioplegic solution to all regions of the heart during cardiac 
surgery  is  essential  for  successful  myocardial  protection
[1].  PMI,  detected  through 
serial measurements of specific serum biomarkers including troponin  I (TnI) or T 
(TnT) or creatine kinase (CK)-MB, is associated with worse clinical outcomes
[2-7]. 
Antegrade  delivery  of  cardioplegic  solution  to  myocardial  cells  is  adequate  when 
supplied by unobstructed coronary arteries but may not be equally effective in the 
presence of occluded or stenosed arteries as in the case of coronary artery disease 
(CAD), which may lead to maldistribution of cardioplegic solution
[8].  This might 
induce  PMI  and  poor  recovery  of  left  ventricular  function  (LV)  following 
revascularization
[9].  Limitations  associated  with  antegrade  delivery  may  be 
circumvented by the administration of cardioplegic solution in a retrograde fashion 
through the coronary sinus which relies on the principle that coronary venous systems 
free of disease and valves can serve as a conduit for the delivery of cardioplegic 
solution in a homogenous manner
[10).  With this technique, the cardioplegic solution is 
distributed to the cardiac microstructure through a transmural network of veins that is 
independent  to  flow-limiting  lesions
[11].    Nevertheless,  retrograde  cardioplegia 
presents important potential limitations, which could in part explain the reason why 
its use remains still relatively limited: 
1)  the anterior cardiac veins supplying the right ventricle (RV) are not directly 
connected to the coronary sinus and this may lead to a suboptimal distribution 
of the cardioplegic solution  to the RV
[12,13]; 
2)  accurate cannulation of the coronary sinus is crucial as failure in this might 
lead to the distribution of the cardioplegic solution to the right atrium and not 
to the venous system;   - 6 - 
3)  the perfusion pressure requires very close monitoring, as too low a pressure 
suggests  misplacement  of  the  cannula,  and  too  high  a  pressure  can  cause 
rupture  of  the  coronary  sinus
[14,15].  These  potential  issues  can  generally  be 
avoided by care and precision by the surgeon; 
4)  the delay in arresting the heart due to slow retrograde perfusion if retrograde 
cardioplegia  is  used  alone  (lower  flow  rates  and  pressures  used  to  prevent 
coronary sinus damage and myocardial oedema)
[16,17].   
Therefore, the combination of both methods of antegrade and retrograde cardioplegia 
is thought to overcome limitations inherent to both techniques
[18]. However, although 
both antegrade perfusion and retrograde coronary sinus perfusion have been studied 
experimentally  and  used clinically  in  patients  undergoing  CABG  surgery,  there  is 
little  information  comparing  PMI  magnitude  between  different  methods  of 
cardioprotection  during  revascularization.    In  this  regards,  we  conducted  a 
retrospective subgroup analysis to determine whether the combination of antegrade 
and retrograde cardioplegia is associated with improved myocardial preservation in 
patients undergoing CABG surgery. 
 
 
Methods 
Study design 
We  conducted  a  retrospective  analysis  of  patients  undergoing  first  time  CABG 
surgery recruited between December 2010 and July 2012 as a subgroup of control 
patients in a large parallel single-blinded randomised controlled clinical trial carried 
out at the Heart Hospital, University College London Hospital (London, UK), and 
investigating the effects of remote ischaemic preconditioning (RIPC)
[4,5] in patients   - 7 - 
undergoing  cardiac  surgery.  The  surgery  was  carried  out  in  accordance  with  the 
University College London Hospital NHS Trust guidelines and received local Ethics 
Committee  approval.  We  obtained  written  informed  consent  from  all  patients 
recruited into the study. 
 
 
Inclusion and Exclusion Criteria 
Patients included in the current analysis were recruited within a single centre study 
investigating the effects of RIPC
[19,20] in patients undergoing CABG surgery at the 
Heart  Hospital  (UCLH  London,  UK):  only  patients  receiving  the  control  protocol 
were included. 
Patient exclusion criteria comprised:  
a)  cardiogenic shock or cardiac arrest preceding surgery; 
b)  positive baseline serum hsTnT; 
c)  pregnancy; 
d)  significant peripheral arterial disease (PAD) affecting upper and/or lower limbs; 
e)  significant hepatic dysfunction (International Normalised Ratio>2.0); 
f)  significant pulmonary disease (Forced Expiratory Volume-1<40% predicted); 
g)  renal failure with an estimated glomerular filtration rate <30 mL/min/1.73 m
2; 
h)  concomitant therapy with glibenclamide or nicorandil, as these medications have 
been demonstrated to potentially interfere with RIPC. 
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Surgical procedure 
Temazepam 10-20 mg was given one hour prior to surgery. Anaesthesia induction 
was obtained under cardiac monitoring with combinations of midazolam, etomidate, 
propofol,  fentanyl  and  anti-nicotinic  agents  (rocuronium,  vecuronium  or 
pancuronium).  Endotracheal  intubation  was  achieved  and  mechanical  ventilation 
commenced with oxygen with or without air. For anaesthesia maintenance volatile 
anaesthetic  agents  and  propofol  infusion  with  or  without  fentanyl  were  used. 
Continuous  monitoring  of  arterial  blood  pressure,  central  venous  pressure, 
nasopharyngeal temperature was carried out. 
Standard non-pulsatile cardiopulmonary bypass (CPB) was initiated with the use of 
membrane oxygenator and cardiotomy suction, followed by the construction of all 
coronary artery bypass grafts, using either blood cardioplegia or intermittent cross-
clamp fibrillation. 
    Group 1 had 1 litre of cold blood cardioplegia given once the cross clamp was 
placed  and  maintenance  cold  blood  cardioplegia  was  given  down  the  grafts  in 
occluded arteries and also into the aortic root every 20-30 minutes. 
    Group  2  had  coronary  artery  surgery  with  the  cross  clamp  fibrillation 
technique and therefore no cardioplegic solution was given.  
    Group 3 had warm blood cardioplegia delivered with antegrade and retrograde 
techniques and was performed by one cardiothoracic surgeon, with an initial 800ml 
dose of antegrade cardioplegia followed by 400ml of retrograde cardioplegia. After 
this,  maintenance  was  achieved  with  100ml  of  retrograde  cardioplegia  after  each 
anastamosis. A hot shot of warm blood without potassium was given after the internal 
mammary  artery  (IMA) anastamosis and prior to removal of the cross clamp. All   - 9 - 
anastomoses were constructed with the single clamp technique. Systemic temperature 
in group 3 was 35°C. 
Following anastomosis of the grafts, CPB was discontinued and protamine was used 
to achieve heparin reversal.   
 
 
Objectives 
To determine whether the addition of retrograde cardioplegia to standard antegrade 
cardioplegia can reduce PMI and subsequently improve short-term clinical outcomes 
in patients undergoing first time CABG surgery compared to patients receiving either 
standard antegrade cardioplegia alone or cross-clamp fibrillation. 
 
 
Study Endpoints  
The primary study end-point was PMI, measured by total 72 hour AUC of hsTnT. 
Blood samples for hsTnT were taken pre-operatively and at 6, 12, 24, 48 and 72 hours 
post-surgery; hsTnT was measured quantitatively by a one-step enzyme immunoassay 
based on electrochemiluminescence technology (Elecsys 2010, Roche, Switzerland). 
The  lower  detection  limit  of  this  assay  is  1ng/L  with  a  threshold  of  ≥14  ng/L 
indicating significant myocardial necrosis.  
Secondary end-points included:  
1. AKI score, classified as grade 1, 2  or 3 based on a combination of laboratory 
(serum  creatinine  levels)  and  clinical  (urine  output)  parameters
[21].  Serum 
creatinine was measured pre-operatively and 24, 48 and 72 hours post-surgery.   - 10 - 
2. Inotrope requirement during the first 3 post-operative days, measured using the 
formula modified from a study by Ko et al.
[22]:  
Inotrope score= Dosages (µg/kg/min) of: 
  [Dopamine + Dobutamine + Dopeximine] +   
[(Adrenaline+ Noradrenaline + Isoprotenerol) x 100] + [(Enoximone + 
Milrinone) x 15]; 
3.Length of ICU and hospital stay; 
4. New onset of AF in the three post-operative days; 
5. Clinical outcomes at 6 weeks (death, non-fatal myocardial infarction, coronary 
artery revascularization, stroke). 
 
 
Statistical analysis 
Continouos data are presented as mean (standard deviation (SD)) or median (IQR). 
Categorical  data  are  shown  as  number  (percent).  The  exposure  variable  was  a 
categorical variable with three groups corresponding to each of the cardioprotection 
categories.  Comparison  between  exposure  groups  was  made  by  including  the 
exposure  variable  as  a  categorical  variable  in  a  linear  regression  model  for 
approximately  normally  distributed  endpoint  variables.  For  very  skewed  endpoint 
variables  the  median  T-test  was  used.  Where  continuous  endpoint  variables  were 
measured over time a repeated measures linear regression model was fitted to measure 
the association between exposure variable and endpoint. The assumptions of the linear 
regression models  were performed by  analysis  of residuals. Categorical data were 
analysed using Fisher’s exact test. No adjustment for multiplicity has been made. Data 
were analysed using Stata version 12.1.   - 11 - 
Results  
Included patients were recruited into an original RIPC trial enrolling a total of 180 
subjects  of  which  90  patients  were  randomised  to  control:  36  patients  were 
subsequently  excluded  (1  patient  died  intra-operatively  and  the  remaining  35 
underwent CABG and valve surgery or valve surgery alone). Therefore we ultimately 
analysed data for 54 patients undergoing CABG surgery alone: 28 received antegrade 
cold blood cardioplegia (group 1), 16 patients received cross-clamp fibrillation (group 
2) and 10 antegrade retrograde warm blood cardioplegia (group 3). 
Group  3  had  a  lower  rate  of  positive  family  history  of  CAD  and  previous 
percutaneous coronary intervention (p=0.047) whereas group 3 had a higher incidence 
of cerebro-vascular accidents prior to CABG surgery (p=0.025, Table 1): no other 
significant  difference  was  found  among  the  three  groups  with  respect  to  baseline 
patient  baseline  characteristics  (Table  1).  Expectedly,  cross-clamp  time  was 
significantly lower in group 2 (p<0.001), however all the remaining parameters of 
surgery were similar amongst the 3 groups (Table 1). 
 
Primary endpoint 
Overall there was evidence that the mean total 72 hr AUC hsTnT was different among 
the three groups (P=0.050). Examining the subgroup differences showed evidence of  
lower mean hsTnT in group 3 compared to group 1 (-16.55; 95% CI: -30.08, -3.01; 
P=0.018) with slightly weaker evidence of a lower mean hsTnT in group 3 when 
compared  to  group  2  (-15.13,;  95%  CI  -29.87,  -0.39;  P=0.044).    There  was  no 
evidence of a difference when comparing group 2 to group 1 (-1.42,; 95% CI: -12.95, 
10.12, P=0.806) (Figure 1, Table 2). 
   - 12 - 
Secondary endpoints 
Baseline pre-operative hsTnT levels were <0.02 µg/L and not significantly different 
between the 3 groups (Figure 2, Table 2). Overall there was evidence that the mean 
hsTnT differed at 6 hours (P<0.001) and 12 hours (P<0.001). At 6 hours there was 
evidence that mean hsTnT was lower in group 3 than groups 1 (-0.56; 95% CI: -0.78, 
-0.34). Similarly at 12 hours there was some evidence that mean hsTnT was lower in 
group 3 than group 1 (-0.43, 95% CI: -0.65, -0.21) (Figure 2, Table 2).  
There  was  no  evidence  of  a  significant  difference  among  the  three  groups  with 
regards to each of the secondary endpoints (Table 3). 
 
 
Discussion  
Myocardial preservation during cardiac surgery is certainly one of the most debated 
topics in this field. One method of achieving myocardial protection is by using  a 
cardioplegic solution administered into the heart to achieve a temporary arrest of the 
myocardium whilst the surgeon performs the operation in a bloodless field.  
    In the UK a variety of myocardial protection strategies are used, including 
cold  blood  antegrade  cardioplegia  with  topical  cooling,  warm  blood  antegrade 
cardioplegia, warm blood antegrade and retrograde cardioplegia, cold blood antegrade 
and retrograde cardioplegia and cross clamp fibrillation. 
    In current practice the route of delivery is at the surgeon’s discretion and as 
such there is no consensus on using a specific route to supply the cardioplegia into the 
myocardium.  
    The most common technique used by the majority of cardiac surgeons is the 
antegrade route, in which cardioplegia is delivered into the aortic root and spreads via   - 13 - 
the  coronary  arteries  supplying  the  myocardium.  Although  significant  clinical 
evidence favours the safety of this method, severe stenoses of coronary arteries in 
patients  undergoing  CABG  may  prevent  the  uniform  distribution  of  cardioplegic 
solution  through  the  myocardium
[23]  and,  importantly,  sub-optimal  or  inadequate 
distribution to parts of the myocardium increases the risk for PMI.  
    A  proposed  solution  to  overcome  this  limitation  is  the  retrograde  route  of 
delivery,  in  which  cardioplegia  is  administered  through  the  coronary  sinus  and 
through the extensive venous network of the myocardium.  Following the pioneering 
idea of Pratts
[24] who suggested that an ischemic myocardium could be revived back 
into its healthy form by supplying oxygenated blood through the veins, retrograde 
cardioplegia was applied for the first time by  Blanco et al
[25] in 1956 and further 
developed in a significant number of centres: one of the seminal works on retrograde 
cardioplegia  was  conducted  by  Menasche  et  al.
[26] who  demonstrated  that,  during 
aortic  valve  replacement  (AVR)  surgery,  post-operative  haemodynamic  stability, 
cardiac outputs and right and left ventricular stroke indices were similar in patients 
receiving retrograde cardioplegia compared to those receiving antegrade cardioplegia. 
The same authors also conducted a retrospective observational study on a relatively 
large group of patients undergoing isolated AVR or CABG surgery with or without 
concomitant valve surgery using retrograde cardioplegia alone
[27] and, although there 
was no antegrade cardioplegia group for direct comparison, they reported that the 
overall trend in mortality rates was either similar or less than what other studies had 
shown.   
    With the knowledge that the anterior cardiac veins supplying the RV are not 
directly  connected  to  the  coronary  sinus  and  thus  may  lead  to  a  suboptimal 
distribution of the cardioplegic solution to the RV
[12,13] Kaukoranta et al.
[28] conducted   - 14 - 
a small study on patients undergoing CABG surgery and receiving either antegrade or 
retrograde cardioplegia and reported that, despite more significant ischaemic changes 
within the RV in the retrograde cardioplegia group, no post-operative complication 
related to the retrograde route was observed.  
    It is therefore clear from the literature that multifactorial clinical endpoints 
have been used to determine a difference between myocardial protection strategies: 
moreover  the  population  size  in  these  studies  was  often  too  small  to  come  to  a 
meaningful conclusion on the benefit of a particular protection strategy. Importantly, 
many  of  the  studies  on  retrograde  cardioplegia  used  retrograde  cardioplegia  alone 
when compared to antegrade cardioplegia and only very few studies have compared 
the  combination  of  antegrade  and  retrograde  techniques  against  antegrade 
cardioplegia alone: this is one more reason to interpret current literature with caution.  
    In the only other study similar to our retrospective analysis, Radmehr and his 
colleagues
[13]  compared  the  combined  antegrade  and  retrograde  versus  antegrade 
cardioplegia alone in patients undergoing CABG surgery and found that the use of 
combined  antegrade  and  retrograde  cardioplegia  was  associated  with  a  16.5% 
statistically significant decrease in inotropic requirement.  
    Our retrospective study suggests that myocardial protection can be improved 
by combined antegrade and retrograde technique and, in contrast to literature already 
available, our patient cohort is divided into three groups (the combined technique of 
antegrade and retrograde cardioplegia, antegrade cardioplegia alone and cross-clamp 
fibrillation).  We  only  included  patients  undergoing  CABG  surgery  and  excluded 
subjects  undergoing  either  valve  surgery  alone  or  CABG  combined  with  valve 
surgery.  This  enabled  us  to  assess  the  drawbacks  of  the  antegrade  technique  via 
blocked coronaries and therefore the potential benefit of retrograde cardioplegia.    - 15 - 
    In  addition  to  this,  with  an  increase  in  the  cross-clamp  time  the  general 
understanding  is  that  the  myocardium  is  more  prone  to  becoming  ischaemic  and 
damaged:  our  study  suggests  that  despite  longer  cross-clamping  times  in  the 
combined  group,  the  total  PMI  was  consistently  lower  in  these  patients  when 
compared  to  the  other  two  groups.  This  correlates  with  a  retrospective  study 
conducted by Bar-El et al.
[29] on patients undergoing CABG surgery with or without 
valve  repair  or  replacement  and  receiving  antegrade  followed  by  retrograde 
cardioplegia, demonstrating that the expected mortality was lower in patients with 
longer  aortic  cross-clamping  times  compared  to  those  with  shorter  aortic  cross-
clamping  times,  and  therefore  indicating  that  retrograde  cardioplegia  can  enhance 
myocardial protection despite the longer cross-clamp times. We therefore suggest that 
the absolute value of the cross-clamp time may potentially be less important than the 
type of myocardial protection used: this could be crucial in complex patients with 
poor  LV  function  or  anticipated  long  cross-clamp  times,  for  whom  the  best 
myocardial protection available would be warranted. 
    Another  important  difference  between  groups  1  and  3  is  the  temperature 
employed during the cardioplegic techniques utilizing cold blood and warm blood 
cardioplegia  respectively:  the  optimal  temperature  of  cardioplegia  during  cardiac 
surgery is another crucial aspect of myocardial protection besides the actual technique 
used and it could be argued that the lower troponin rise in group 3 may be partially 
explained  by  the  temperature  difference.  Cold  cardioplegia  is  able  to  attenuate 
myocardial oxygen demand and the risk of ischaemic damage but conversely may 
lead to the inhibition of myocardial enzymes leading to a stunning of the metabolic 
and  functional  recovery  following  surgery.    However  warm  blood  cardioplegia  is 
thought to counteract this potential deleterious effect. In a meta-analysis
[30] involving   - 16 - 
8814  patients  randomised  to  either  warm  cardioplegia  or  cold  cardioplegia 
predominantly in the setting of CABG surgery, there was no significant difference in 
all-cause mortality or incidence of myocardial infarction, intra-aortic balloon pump 
usage, stroke, low output syndromes and post-operative AF between the two patients 
groups and postoperative cardiac index was significantly improved in the warm blood 
cardioplegia group.  Similarly, Tan et al.
[31] compared cold to tepid cardioplegia and 
found  no  difference  in  mortality,  peri-operative  myocardial  infarction,  stroke  or 
inotrope requirement.  
Our retrospective study has several limitations. The cohort population was small and 
in particular the group consisting of the combined use of retrograde cardioplegia and 
antegrade  cardioplegia  contained  only  10  patients,  who  were  operated  on  by  one 
consultant, which may result in some potential bias. Typically in a study of this type 
strong prognostic and confounding variables would be adjusted for in the analysis. In 
this case the small sample size precluded detailed adjustment and we acknowledge 
some  residual  confounding  bias  may  remain.  Finally,  we  have  not  adjusted  for 
multiplicity in our analysis and there is a possibility that the results may have arisen 
by chance, and therefore the clinical outcome data will need to be confirmed in future 
studies. 
       
    In conclusion our retrospective clinical analysis suggests that the combined 
use of retrograde cardioplegia and antegrade cardioplegia during first time CABG 
surgery can be beneficial in reducing PMI. Also, importantly, to our knowledge there 
is no study which combines the following four factors together into one analysis on 
PMI: aortic cross-clamping times, combined antegrade retrograde versus antegrade 
alone  versus  no  cardioplegia,  hsTnT  levels  at  6  different  time-points  with  AUC-  - 17 - 
hsTnT, and exclusively CABG patients. We do not suggest surgeons to change their 
practice for routine CABG surgery, as we have not yet demonstrated that the change 
in  measured  troponin  levels  may  have  a  significant  impact  on  clinical  outcomes. 
However, we feel that this evidence should be available, so surgeons can choose to 
add retrograde cardioplegia for more complex cases in an evidence based fashion, 
knowing  that  the  addition  of  retrograde  cardioplegia  may  have  the  potential  to 
enhance  myocardial  protection.  Our  retrospective  study  also  suggests  that  larger 
studies  are  required  in  order  to  further  evaluate  our  findings  and  to  investigate 
whether  the  reduction  of  PMI  in  patients  undergoing  CABG  would  result  in 
improvement of clinical outcomes. 
     
 
Conclusions  
 
Our study suggests that, compared to traditional methods of myocardial preservation, 
the combined use of retrograde and antegrade cardioplegia may have the potential to 
reduce PMI in patients undergoing first-time CABG surgery. Whether this can lead to 
an improvement of clinical outcomes is yet unknown and therefore larger studies are 
required in order to further evaluate this potential impact. 
 
 
 
 
   - 18 - 
List of Abbreviations 
CABG= coronary artery bypass graft 
PMI= peri-operative myocardial injury 
AUC= area under the curve  
hsTnT= high-sensitivity Troponin-T  
AKI= acute kidney injury  
ICU= intensive care unit  
AF= atrial fibrillation  
SD= standard deviation  
CK= creatine kinase 
CAD= coronary artery disease 
RV= right ventricle  
RIPC= remote ischaemic preconditioning  
PAD= peripheral arterial disease  
CPB= cardiopulmonary bypass  
 
Competing interests 
 
There are no finanicial and non-financial competing interests. 
Authors' contributions 
LC and AM carried out the study, acquired, analysed and interpreted data. 
LC, AM. SAK, NR made substantial contributions in drafting the manuscript and/or 
revising it critically for important intellectual content.  
CA performed the statistical analysis   - 19 - 
NR, MB, CDS, DRL, MPH, JAP, AMS, SKK provided patients for the study 
DJH, NR read and approved final manuscript  
All authors read and approved the final manuscript 
 
 
Acknowledgements  
Maria Xenou for identification of patients for recruitment. 
All staff at the Heart Hospital, London. 
 
 
 
 
 
  
 
 
Figures legends 
 
Figure 1. Mean hsTnT pre-operatively and at 6, 12, 24, 48 and 72 hours post-surgery 
in the three study groups. 
 
Figure 2. AUC of hsTnT over the 72 hours post-surgery in the three study groups. 
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Abstract
Background Novel cardioprotective strategies are required
to improve clinical outcomes in high risk patients under-
going coronary artery bypass graft (CABG) ± valve sur-
gery. Remote ischemic preconditioning (RIC), in which
brief episodes of non-lethal ischemia and reperfusion are
applied to the arm or leg, has been demonstrated to reduce
perioperative myocardial injury following CABG ± valve
surgery. Whether RIC can improve clinical outcomes in
this setting is unknown and is investigated in the effect of
remote ischemic preconditioning on clinical outcomes
(ERICCA) trial in patients undergoing CABG surgery.
(ClinicalTrials.gov Identiﬁer: NCT01247545).
Methods The ERICCA trial is a multicentre randomized
double-blinded controlled clinical trial which will recruit
1,610 high-risk patients (Additive Euroscore C 5) under-
going CABG ± valve surgery using blood cardioplegia via
27 tertiary centres over 2 years. The primary combined
endpoint will be cardiovascular death, non-fatal myocardial
infarction, coronary revascularization and stroke at 1 year.
Secondary endpoints will include peri-operative myocar-
dial and acute kidney injury, intensive care unit and hos-
pital stay, inotrope score, left ventricular ejection fraction,
changes of quality of life and exercise tolerance. Patients
will be randomized to receive after induction of anesthesia
either RIC (4 cycles of 5 min inﬂation to 200 mmHg and
5 min deﬂation of a blood pressure cuff placed on the
upper arm) or sham RIC (4 cycles of simulated inﬂations
and deﬂations of the blood pressure cuff).
Implications The ﬁndings from the ERICCA trial have the
potential to demonstrate that RIC, a simple, non-invasive
and virtually cost-free intervention, can improve clinical
outcomes in higher-risk patients undergoing CABG ±
valve surgery.
Keywords Remote preconditioning  Ischaemia 
Reperfusion  Clinical trial  CABG surgery
Background
Coronary heart disease (CHD) is the leading cause of death
and disability worldwide and accounts for 3.8 million of
men and 3.4 million of women deaths every year. CABG
surgery remains the procedure of choice for coronary artery
revascularization in patients with multi-vessel coronary
artery disease. Currently, high-risk CHD patients are being
operated on due to the aging population, the increasing
prevalence of co-morbidities such as diabetes, hyperten-
sion, valve disease and the presence of more complex
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DOI 10.1007/s00392-011-0397-xdisease [1]. Surgery in these patients is associated with an
elevated overall operative risk of 5–6% compared to 1% in
lower-risk patients [2], as well as an increased risk of peri-
procedural myocardial injury (as measured by serum CK-
MB, Troponin T or I) [3], acute kidney injury (AKI) [4]
and stroke [5], the presence of which are associated with
worse clinical outcomes [6–16]. Myocardial injury during
CABG surgery may be attributed to different mechanisms,
including most importantly acute myocardial ischemia–
reperfusion injury (IRI), but also inﬂammatory response to
the extraneous substances in the cardiopulmonary bypass
circuit, left ventricular over-distension, coronary athero-
embolism [17], increased cardiac workload during the
intraoperative period, and direct myocardial injury due to
retraction and handling of the heart [18].
According to the technique used, myocardial IRI can be
the result of intermittent cross-clamping, intermittent or
continuous administration of cardioplegic solution, cross-
clamp ﬁbrillation or a combination of these methods and
may manifest as myocardial stunning [19], the so called
no-reﬂow phenomenon [20], reperfusion arrhythmias [21]
and lethal reperfusion injury [22], the latter of which would
be of most concern. A variety of factors are believed to
contribute to lethal myocardial IRI and include oxidative
stress [23], pH changes [24] calcium overload [22], the
acute inﬂammatory response [25] and important metabolic
changes [26], many of which impact on the opening of the
mitochondrial permeability transition pore (mPTP), a crit-
ical determinant of cell death in the setting of acute
IRI [27].
Whilst cardioprotective strategies have been overall
extremely encouraging in experimental studies, the trans-
lation from bench to bedside has not always resulted in
positive outcomes and this could be due to the obvious
differencesbetweenthespeciesinvolved,thesizeandageof
animals used and the absence of co-morbidities and con-
comitant treatments in the experimental models [28, 29].
Both pharmacological and non-pharmacological inter-
ventions have been investigated to enhance the innate
process of cardioprotection and therefore to limit or
prevent acute myocardial IRI. Amongst the non-pharma-
cological strategies, ischemic preconditioning (IPC), per-
conditioning (IPerC) and postconditioning (IPost) have
been extensively investigated in both the laboratory and
clinical settings. In IPC, the heart is subject to brief epi-
sodes of non-lethal ischemia and reperfusion prior to the
sustained episode of lethal ischemia and reperfusion; in
IPerC and IPost the protective stimulus is applied after the
onset of myocardial ischemia or at the time of myocardial
reperfusion, respectively [30]. However, both IPerC and
IPost require an invasive intervention applied directly to
the myocardium in order to achieve cardioprotection and
may therefore be impractical or even harmful, particularly
in the setting of an acute myocardial infarction (AMI). In
this perspective, the phenomenon of remote ischemic
conditioning (RIC) appears extremely encouraging: it
describes the phenomenon in which brief episodes of non-
lethal ischemia and reperfusion to an organ (i.e. kidney,
liver or small intestine) or tissue (i.e. skeletal muscle),
protect the heart against a sustained episode of lethal IRI
[31, 32]. Therefore, RIC does not imply a direct inter-
vention on the heart to achieve cardioprotection.
The concept of RIC was ﬁrst introduced in 1993 by
Przyklenk et al. [31], who demonstrated that IPC protects
canine myocardium both in the territory exposed to brief
coronary occlusion and in a vascular bed distant or remote
or ‘‘virgin’’. Following this, pioneering studies by Mac-
Allister et al. [33] demonstrated that RIC could be
reproduced by non-invasively applying brief episodes of
ischemia and reperfusion to the forearm using a standard
blood pressure cuff. Since then, a number of proof-of-
concept clinical studies have demonstrated that RIC com-
prising brief episodes of non-lethal ischemia and reperfu-
sion to the arm or leg, non-invasively applied by inﬂating a
blood pressure to supra-systolic pressures placed on the
arm or leg, can protect the heart during CABG surgery
from peri-operative myocardial injury as evidenced by
reduced serum troponin T [34–37]. A similar RIC stimulus
has been reported to be protective in a number of different
clinical settings including elective surgical repair of
abdominal aortic aneurysm (AAA) [38, 39], elective cer-
vical decompression surgery [40]; elective PCI [41] and
in ST-segment elevation myocardial infarction patients
undergoing primary percutaneous intervention (PCI) [42].
Currently, whether this non-invasive virtually cost-free
intervention can improve clinical outcomes in higher-risk
patients undergoing CABG ± valve surgery is unknown and
is the objective of the proposed effect of remote ischemic
preconditioning on clinical outcomes (ERICCA) trial in
patients undergoing coronary artery bypass graft (CABG)
surgery. (ClinicalTrials.gov Identiﬁer: NCT01247545).
Methods
Study objectives
The primary objective of this study is to determine whether
RIC improves 1 year clinical outcomes (cardiovascular
death, non-fatal myocardial infarction, revascularization
and stroke) in higher-risk adult patients undergoing
CABG ± valve surgery. The secondary research objectives
are to determine whether RIC improves the above clinical
outcomes at 30 days post-surgery; has an effect on all-
cause death; reduces peri-operative myocardial injury and
preserves LV systolic function; reduces AKI; improves
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123patient morbidity [intensive care unit (ICU) stay and hos-
pital stay], lessens inotrope requirements and improves
exercise tolerance and quality of life.
Study design
The study has received Ethical Committee approval. The
ERICCA trial is a controlled randomized multi-centre
double blind trial. It investigates the effect of RIC on
1 year clinical outcomes in 1,610 high-risk (Euroscore
C 5) patients undergoing CABG ± valve surgery recruited
via 27 tertiary cardiac centres in the UK.
Study population
Patient inclusion criteria are as follows: the patient is
C18 years old, scheduled for CABG ± valve surgery with
blood cardioplegia, and has an additive Euroscore equal or
above 5 (Fig. 1). Patient exclusion criteria include the
following: history of cardiogenic shock or cardiac arrest
during the current admission; pregnancy; signiﬁcant
peripheral arterial disease affecting the upper limbs; sig-
niﬁcant hepatic impairment (Bilirubin [20 mmol/L, INR
[2.0); signiﬁcant pulmonary disease (FEV1 \40% pre-
dicted); renal failure with a GFR \30 mL/min/1.73 m
2;
concomitant treatment with glibenclamide or nicorandil (as
these medications may interfere with the cardioprotection
elicited by RIC). All patients will freely give their
informed consent to participate in the study and may decide
to withdraw from the study at any time. The study will
conform to the spirit and the letter of the declaration of
Helsinki, and in accordance with the UCL Good Clinical
Practice Guidelines.
Intervention
The intervention being assessed is RIC, which will be
performed after the induction of anesthesia but prior to
surgery and will occur within 1 hour of the institution of
cardiac bypass. Those patients randomized to receive RIC
will have a standard blood pressure cuff placed on the
upper arm, inﬂated to 200 mmHg for 5 min and then
deﬂated for 5 min, a cycle which will be performed four
times in total. For patients with systolic blood pressures
[185 mmHg, the cuff will be inﬂated to at least 15 mmHg
above the patient’s systolic blood pressure. The sham RIC
protocol is described as follows: the air valve on the blood
pressure cuff is ﬁrst opened such that the cuff is not inﬂated
on squeezing the attached bulb. The bulb will then be
squeezed for a duration of 15 s to give the impression that
the cuff is being inﬂated. After 5 min, the air valve will be
closed to give the impression that the cuff is being deﬂated.
After 5 min, the air valve will be opened again and the bulb
squeezed as before: the above cycle will be repeated four
times in total. This is to ensure the rigorous blindness of the
anesthetic and surgical teams as well as non-medical the-
atre staff. These interventions will be undertaken after the
induction of anesthesia and will not prolong the anesthetic
time or delay the onset of surgery.
We have decided to use four cycles of 5 min of cuff
inﬂation and deﬂation as we wish to maximize the RIC
stimulus to overcome potential resistance of diabetic heart
and the presence of other factors interfering with cardio-
protection such as volatile anesthetics including isoﬂurane.
Moreover, the application of four cycles of 5 min inﬂation/
deﬂation was reported to be beneﬁcial in patients with
STEMI undergoing primary PCI [42].
Randomization and allocation
On the morning of surgery, patients will be randomized to
one of two groups, either RIC or control. Randomization
will be coordinated centrally by the Clinical Trials Unit
based at the London School of Hygiene and Tropical
Medicine via a secure web-site and will be stratiﬁed by
center using random permuted blocks. This will only be
accessed by the research nurse responsible for performing
either the RIC or sham RIC protocol. The same research
nurse will be the only person in each centre aware of the
treatment allocation for the patient and he/she will not be
involved with the data collection other than those relating to
the actual randomization procedure. Treatment allocations
will only be known by one research nurse at each centre.
The patient, cardiac surgeons and anesthetists, the research
nurses collecting the data, and the assessor of clinical out-
comes will all be blinded to the treatment allocation.
Study endpoints
Primary clinical endpoint
Major adverse cardiac events (cardiovascular death, non-
fatal myocardial infarction, repeat revascularization) and
cerebrovascular events (stroke) calculated at 12 months
post-surgery.
Cardiovascular death will be deﬁned as death due to a
known cardiovascular cause or where the cause of death is
unknown, i.e. where no other cause of death has been
identiﬁed from the medical history or an autopsy.
Repeat revascularization will be deﬁned as any PCI or
repeat-CABG ± valve surgery within the ﬁrst year post-
surgery.
Myocardial infarction will include both peri-operative
myocardial infarction and myocardial infarction following
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123cardiac surgery. Peri-operative myocardial infarction (type
5 myocardial infarction) [43] will be indicated by bio-
marker (high-sensitive Troponin T) values more than ﬁve
times the 99th percentile of the normal reference range
during the ﬁrst 72 h following CABG ± valve surgery,
when associated with the appearance of new pathological
Q-waves or new left bundle branch block (LBBB), or an-
giographically documented new graft or native coronary
artery occlusion, or imaging evidence of new loss of viable
myocardium. Post-surgical myocardial infarction will be
deﬁned by: (1) a rise and/or fall of Troponin T compared to
baseline with at least one value above the 99th percentile of
the upper reference limit together with evidence of myo-
cardial ischemia with at least one of the following: symp-
toms of ischemia, ECG changes indicative of new ischemia
(new ST-T changes of new LBBB), development of Q
waves in the ECG, imaging evidence of new loss of viable
myocardium or new regional wall motion abnormality; (2)
PATIENTS UNDERGOING CABG WITH OR WITHOUT VALVE SURGERY 
(EUROSCORE GREATER THAN OR EQUAL TO 5)
Patient recruited 
while outpatient
PIS sent 2 weeks prior to 
pre-admission clinic
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Echo substudy
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RANDOMISATION
1:1 Control:RIC
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CARDIAC SURGERY
72hr area under curve (AUC) Trop T, 24hr NGAL, serum creatinine, 
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Q
Fig. 1 Study ﬂow chart
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123sudden unexpected cardiac death involving cardiac arrest
often with symptoms suggestive of myocardial ischemia
and accompanied by presumably new ST-elevation or new
LBBB and/or fresh thrombus on coronary angiography
and/or at autopsy, but death occurring before blood sam-
ples could be obtained or at time before the appearance of
cardiac troponin T in the blood.
Stroke will be deﬁned as a focal, central neurological
deﬁcit lasting [72 h which results in irreversible brain
damage or body impairment.
Secondary clinical end-points
Clinical outcome at 30 days, including CV death, non-fatal
myocardial infarction, revascularization and stroke.
All-cause death
Peri-operative high-sensitive Troponin-T
This will be assessed by measuring serum high-sensitive
Troponin-T pre-operatively and at 6, 12, 24, 48, 72 h post
coming off cardiac bypass. Following elective CABG ±
valve surgery, several studies have demonstrated that peri-
operative myocardial injury, indicated by the release of the
cardiac enzymes CK-MB, Troponin-T and Troponin-I is
associated with worse clinical outcomes following surgery
[6–16].
Length of ICU/hospital stay and inotrope score
The length of ICU and hospital stay and the inotrope score
are factors which can be inﬂuenced by the outcome of
surgery and which have an important impact on health-care
resources. The inotrope score provides an objective mea-
surement of the requirement of inotropes in the immediate
post-operative period. Data on inotrope requirement will be
collected daily from the medical drug chart on the ICU. This
will be adapted from a study by Ko et al. [44] and will be
calculated at 0 (time when coming off bypass), 24, 48 and
72 h after the surgery using the formula below. The ino-
trope score for the particular time point is calculated as
follows: at time 0, the inotrope score will be calculated from
the dose of the individual inotropes used at the time of
coming off bypass. For 24-, 48- and 72-h time-points, the
inotrope score will be calculated from the maximum dose of
the individual inotropes used in the previous 24-h period.
Inotrope score =
1. Dopamine ? Dobutamine ?
2. ? [(Adrenaline ? Noradrenaline ?
Isoproterenol ? Isoproterenol) 9 100]
3. ? [Enoximone (or Milrinone) 9 15]
All dosages will be in lg/kg/min.
The dosage of Levosimendan will be documented when
given.
Remote ischemic preconditioning may impact on these
outcome measures by reducing myocardial ischemic injury
and preserving left ventricular (LV) systolic function.
Peri-operative AKI
This will be measured by (1) the AKI Score, calculated
over the 3-day peri-operative period (Table 1) with serum
creatinine measured daily for 3 days (and at 6 weeks and
1-year post-surgery) and urine volumes monitored daily;
(2) Neutrophil gelatinase-associated lipocalin (NGAL), a
new early marker for AKI, with levels rising rapidly after
renal injury [45, 46], measured pre-operatively, 6, 12 and
24 h (post-coming off cardiac bypass).
The six minute walk test (6MWT)
This will be performed at baseline, 6 weeks (in the out-
patient clinic follow-up appointment), and at 1-year (in the
research outpatient clinic follow-up appointment) post-
CABG ± valve surgery. Patients will be instructed to walk
as far as possible along a straight, ﬂat hospital corridor in
6 min. The 6MWT will be used to evaluate the effect of
RIC on the functional status of patients undergoing
CABG ± valve surgery [47]. Shortly after CABG ± valve
surgery, functional capacity is signiﬁcantly reduced, but
it rapidly improves after cardiac rehabilitation. This
improvement has been found to be independent of age, sex,
co-morbidities and baseline functional capacity [47].
Quality of life
The EuroQol EQ-5D Health-Related Quality of Life
(HRQOL) questionnaire (http://www.euroqol.org) will be
used to assess patients’ quality of life post-CABG ± valve
surgery [48], at baseline, at 6 weeks (in the surgical out-
patient clinic follow-up appointment), at 3 months
(by post/e-mail), at 6 months (by post/e-mail), at 9 months
Table 1 The acute kidney injury score
AKI
grade
Creatinine criteria Urine output
criteria
1 A rise of[26.4 lmol/L or 150–200%
of baseline
\0.5 ml/kg/h for
[6h
2 A rise of 200–300% of baseline \0.5 ml kg/h for
[12 h
3 An increase of[300%; or serum
creatinine[354 lmol/L with an
acute rise of at least of 44 lmol/L
\0.3 ml/kg/h for
[24 h or anuria
for 12 h
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123(by post/e-mail) and at 1-year post surgery (in the research
outpatient clinic follow-up appointment). Non-responders
will be telephoned.
Left ventricular ejection fraction
A subgroup of 140 patients at two recruitment centres
will have a transthoracic echocardiogram performed by bi-
planar Simpson’s technique and 3D echo techniques, in
order to assess left ventricular ejection fraction (LVEF)
at baseline and at 1-year post surgery (in the research
outpatient clinic follow-up appointment).
Statistical considerations
A detailed statistical analysis plan will be produced prior to
unblinding of any data.
Sample size calculation
Therewillbetwoarmstothetrial: RICandcontrol.Weplan
to recruit 1,610 patients through 27 tertiary centres. In the
SYNTAX study the MACCE (death, myocardial infarction,
revascularization and stroke) rate was 12.4% of patients at
12 months following CABG surgery [49]. However, the
patients recruited into the SYNTAX study were generally
lower-risk than those to be recruited in ERICCA with a
mean EuroSCORE of 3.8, whereas the patients we intend to
recruit in our study are higher-risk with EuroSCORE C 5.
In another study comprising higher-risk patient deﬁned
by them all having left main stem coronary lesions, the
MACCE rate (which included some additional neurological
criteria) at 1 year was estimated to be 25% [50]. Therefore,
forour higher-risk CABG ± valve surgery patients we have
estimated an MACCE rate of 20% at 1 year, which means
that to detect a 27% relative reduction in this primary end-
point in the RIC-treated group (from 20.0 to 14.6%), with a
power of 80% and a signiﬁcance level of 5%, a sample size
of 770 patients will be required for each trial arm (1,540 in
total). This was chosen to represent a clinically signiﬁcant
effect, which is less than the reductions in myocardial injury
observed in the previously mentioned proof-of-concept
clinical studies (i.e. 40–50% reductions in serum cardiac
enzymes).Toallowforupto5%dropouts,weplantorecruit
1,610 patients in total (805 patients each arm).
With regards to the ECHO subgroup analysis involving
140 patients in two of the centres, in a previous study [51]
IPost was reported to improve LVEF by 7% (absolute
increase) from 49 to 56% at 1 year in ST-elevation myo-
cardial infarction patients. In order to detect a smaller mean
difference of 5% with a common SD of 10.5%, the sub-
study requires 70 patients in each group (140 in total) using
80% power and a 5% signiﬁcance level.
Statistical analysis
The primary analysis will be a comparison of the 1-year
MACCE rate between the RIC and control arms of the trial.
Survival analyses techniques will be used for MACCE and
other clinical endpoints. Hazard ratios and conﬁdence
intervals will be calculated using Cox proportional hazards
modeling and Kaplan–Meier curves produced. The
assumptions underlying the Cox model will be assessed. In
addition, risk differences at 1 year together with 95%
conﬁdence intervals will be calculated. Differences in
means (continuous variables) together with 95% conﬁ-
dence intervals will be calculated using linear regression
models and analysis of covariance techniques where
appropriate. Analysis will be by intention to treat on using
all available data. We plan to undertake a limited number
of subgroup analyses: these will include age, baseline
EuroSCORE, LVEF, diabetic status, aortic cross-clamp
time, cardiac bypass time and method of cardioplegia
(anterograde vs. retrograde blood cardioplegia). All sub-
jects randomized to the study will be analyzed on an
intention to treat basis. Data will be validated and the data
analysis will take appropriate account of missing values.
Study monitoring
A Trial Steering Committee (TSC) will be responsible for
drafting the ﬁnal report and submission for publication and
will meet every 6 months. A Trial Management Group
(TMG) will meet weekly during the planning stages of the
study and less frequently when the study is actually
recruiting. An independent clinical events committee will
be convened comprising an independent cardiologist, car-
diac surgeon and neurologist. A Data Monitoring and
Ethics Committee (DMEC) will meet at the start of the trial
to establish a DMEC charter, soon after recruitment has
started and then at least annually to determine if there are
any unforeseen effects of RIC. This will be the only group,
along with the statistician producing the reports for the
DMEC, who will see interim analyses by treatment.
Discussion
In the ERICCA trial, we will investigate whether RIC, a
non-invasive virtually cost free cardioprotective strategy
can improve clinical outcomes at 1 year in higher-risk
patients undergoing CABG ± valve surgery. The risk
proﬁle of patients undergoing CABG surgery continues to
change with factors such as (a) the aging population (the
proportion of patients over 75 years old has increased by
more than 4.5-fold over the last decade with the 5-year
mortality in this age group being 35%); (b) the increasing
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123prevalence of diabetes (the proportion of diabetic patients
has risen from 15 to 22%, with the operative mortality in
this patient group being 2.6%) resulting in an increase in
the number of higher-risk patients (deﬁned as an additive
EuroSCORE C 5) being operated upon and a correspond-
ing increase in overall operative risk to 5–6% [1, 2]. These
higher-risk patients are at a greater risk of peri-operative
complications, which are associated with a worse clinical
outcome, such as peri-procedural myocardial injury [3],
inotropic support post-surgery, signiﬁcant AKI (up to 34%
of patients) [4] and stroke (1–3%) [5]. Peri-operative
myocardial injury, as measured by serum CK-MB, Tro-
ponin-T or Troponin-I during surgery has been associated
with worse clinical outcomes post-surgery [6–16].
The discovery that the RIC stimulus could be reproduced
by applying brief episodes of ischemia and reperfusion to
the upper or lower limb [52, 53] has facilitated its recent
translation from animal studies into the clinical arena.
MacAllister et al. [30, 54] were the ﬁrst to demonstrate the
concept of RIC in human volunteers by inﬂating a blood
pressure cuff around the upper arm to 200 mmHg for 5 min
and deﬂating the cuff for 5 min (to induce ischemia and
reperfusion, respectively), a cycle which was repeated two
more times, with subsequent attenuation of ischemia-
induced endothelial dysfunction in the contralateral arm.
Cheung et al. [36] applied RIC in children undergoing
cardiac surgery using four-5 min cycles of lower limb
ischemia and reperfusion, with reduction of myocardial
injury, airway resistance and inotrope score. We then
demonstrated [34, 35] that three-5 min cycles of upper limb
ischemia and reperfusion reduced myocardial injury in
adult patients undergoing elective CABG ± valve surgery.
More recently, RIC using lower limb ischemia/reperfu-
sion has also been reported to induce cardiac, renal and
neurological protection in elective surgery for AAA [38,
39] and cervical decompression [40]. Hoole et al. [41] have
reported that RIC using brief ischemia and reperfusion of
the arm reduced the peri-procedural myocardial injury
associated with elective PCI for stable CHD. Botker et al.
[42] have recently demonstrated that RIC using four-5
minute cuff inﬂations/deﬂations administered in ambulance
reduced myocardial infarct size in ST-elevation myocardial
infarction patients undergoing primary PCI. In patients
undergoing valve surgery alone, RIC comprising three
4-min cycles of cuff inﬂation and deﬂation on the lower
limb applied at the time of aortic bypass was found to
reduce peri-operative myocardial injury although RIC with
the same stimulus applied prior to surgery was reported to
be ineffective [55]. In patients undergoing off-pump
CABG surgery, RIC only resulted in a non-signiﬁcant 26%
reduction in peri-operative myocardial injury as measured
by cTnI [56].
Interestingly, not all the studies investigating the effects
of RIC in CHD have been positive: Iliodromitis et al. [57]
showed more myocardial injury in low-risk patients
undergoing elective PCI receiving RIC, although a non-
standard RIC protocol was applied, comprising bilateral
arm cuff inﬂation and deﬂation, and the study may have
been underpowered. Moreover, the largest clinical study of
RIC in CABG surgery to be published (162 patients ran-
domized to RIC or control) [58] failed to demonstrate any
beneﬁts with RIC (three-5-min cycles of inﬂation and
deﬂation of a blood pressure cuff placed on the upper arm)
in terms of peri-operative myocardial injury (cTnT
release), ECG changes, cardiac index, inotrope require-
ments, renal impairment and lung injury. The reason for
this negative study is not clear but may be attributable to
patient selection (patients with unstable angina were
included- these patients may have been inadvertently pre-
conditioned), the RIC stimulus (which was applied in a
‘blinded’ fashion with the position of the cuff on the arm
hidden from view) or concomitant medication (the pres-
ence of inhalational anesthetics and intravenous glycerine
trinitrate may have interfered with the cardioprotective
effect of RIC). In a recently published small study com-
prising 54 patients undergoing elective CABG under a
strict anesthetic regime (the volatile anesthetic isoﬂurane
was given for maintenance of anesthesia until institution of
cardio-pulmonary bypass and the intravenous anesthetic
propofol was used for induction and following cardio-
pulmonary bypass initiation until the end of surgery),
Karuppasamy et al. [59] again demonstrated no signiﬁcant
difference in myocardial injury and inﬂammatory response
between RIC and placebo subjects59, although it is possi-
ble that the same anesthetics choice and/or their timing
might have interfered with RIC [60].
Importantly, in our proposed ERICCA trial, we also
intend to include patients undergoing valve surgery in
addition to CABG surgery in order to determine whether
this higher-risk surgical group may beneﬁt in terms of
improved clinical outcomes with RIC. Furthermore, in the
previously cited proof-of-concept clinical trials [34, 35]
valve surgery patients were included and were demon-
strated to beneﬁt from RIC and recent studies speciﬁcally
investigating ischemic postconditioning have reported
beneﬁt in patients undergoing aortic valve surgery [55].
In summary, the ERICCA trial is a large multicentre
randomized double blinded clinical trial, which will
investigate whether RIC can improve clinical outcomes at
1 year in higher-risk patients undergoing CABG ± valve
surgery. The ﬁndings from this trial have the potential to
change clinic practice with the introduction of a non-
invasive virtually cost-free cardioprotective strategy for
improving clinical outcomes in patients with IHD.
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CASE REPORT FORM (CRF) 
 
 
 
Patient Initials:           
           
Date of Birth: 
 
Hospital Number: 
           
   
The Efficacy and Mechanism Evaluation programme (www.eme.ac.uk) is funded by the MRC  
and managed by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC),  
based at the University of Southampton. 
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RANDOMISATION FORM (Eligibility) 
 
 
 
 
 
 
 
* Definition of cardiogenic shock: 
Systolic blood pressure <90 mmHg for 30 minutes before inotrope/vasopressor administration  
Or 
Vasopressors or IABP are required to maintain systolic blood pressure >90 mm Hg 
 
 
Inclusion criteria: 
 
(Tick)                                                                                                         Yes     No 
1.  Is  the  patient  undergoing  CABG±valve  surgery  using  blood 
cardioplegia? 
   
2.  Is the patient 18 years of age or over?     
3.  Is the patient’s additive EuroSCORE greater than or equal to 5?     
Answers to questions 1 - 3 must be “YES” to qualify for the study 
Exclusion criteria: 
(Tick)                                                                                                               Yes     No 
1.  Is there a history of cardiac arrest (on current admission)     
2.  Is the patient in cardiogenic shock? *     
3.  Is the patient pregnant?     
4.  Does  the  patient  have  significant  peripheral  arterial  disease 
affecting the upper limbs? 
   
5.  Does  the  patient  have  significant  hepatic  dysfunction 
(Prothrombin>2.0 ratio)? 
   
6.  Does the patient have significant pulmonary disease (FEV1<40% 
predicted)?     
7.  Does the patient have renal failure with a GFR<30 mL/min/1.73 m
2?     
8.  Is the patient on glibenclamide or nicorandil?     
9.  Is the patient involved in another study which may impact on the 
ERICCA study? 
   
All answers to questions 1 – 9 must be “NO” to qualify for the study 
 
Patient Initials:          Date of Birth: 
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RANDOMISATION FORM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date informed consent document signed: 
 
 
Additive EuroSCORE:  
 
           
 
 
           
 
ERICCA Study Number:                      
           
Randomisation date:                                  
 
Time of randomisation:         
 
 
           
       
 
Patient Initials:          Date of Birth: 
           
      : 
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BASELINE DATA   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date baseline data collected: 
 
Indications for surgery:  Number of diseased vessels  1  2  3 
 
        Valve disease      YES           NO 
   
Sex:                 Male            Female   
 
   
Weight:                   kg 
 
 
Height:                    cm  Body Mass Index will be calculated automatically on the eCRF      
   
           
Ethnicity: Caucasian          Asian          Afro-Caribbean           Other       (Specify below) 
 
                                                    ___________________   
Systolic Blood Pressure:                     mmHg       
 
 
Diastolic Blood Pressure:            mmHg 
 
 
Heart rate:         bpm 
 
 
Smoking history:  Current    Ex    Never 
 
 
Shortness of breath in previous month:  YES    NO 
 
If yes, NYHA class (see below):  I    II    III    IV 
 
 
Class  Symptoms 
I  No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing 
stairs etc. 
II  Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. 
III 
Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short 
distances (20–100 m). 
Comfortable only at rest. 
IV  Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. 
 
     
     
     
     
     
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
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BASELINE DATA (Continued)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Angina symptoms in previous month:    YES    NO 
 
If yes, CCS class (see below):    I    II    III    IV 
 
CCS Functional Classification of Angina 
Class  Activity Evoking Angina  Limits to Physical Activity 
I  Prolonged exertion  None 
II  Walking > 2 blocks or > 1 flight of stairs  Slight 
III  Walking < 2 blocks or < 1 flight of stairs  Marked 
IV  Minimal or at rest  Severe 
 
Left ventricle ejection fraction:   Please enter value or description or not known 
 
Value available:     YES    NO    If YES, value       %   
 
If NO, description:   Poor      Moderate             Good/Normal           Not known   
 
   
Family history of IHD*:   YES    NO 
 
* Defined as IHD in primary female relative (mother/sister) <65 years old or primary male relative (father/brother) 
<60 years old 
 
 
Six minute walk test 
 
Undertaken:  Yes        No         If No, give reason:__________________________________   
 
If Yes, total distance walked:           metres 
 
Was the test stopped before 6 minutes:  Yes        No     
 
If Yes, at what time:         mm:ss    
                           
If Yes, give reason:__________________________________ 
 
Quality of Life questionnaire (EQ-5D) 
 
Completed:  Yes    No       
 
If YES, you will be prompted to enter the EQ-5D data onto the eCRF 
 
 
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
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BASELINE DATA (Medical history) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history:       
  Yes  No  Year of Diagnosis 
(Enter 0000 if unknown) 
1.  Diabetes Mellitus       
2.  Hypercholesterolaemia       
3.  Hypertension       
4.  Previous myocardial infarction       
5.  Previous PCI       
6.  Previous CABG       
7.  Previous stroke       
8.  Atrial fibrillation       
9.  Peripheral arterial  disease       
10.  Other 
If Yes specify:__________________________       
       
       
       
       
       
       
       
       
       
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
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BASELINE DATA (Cardiac medication at time of surgery)   
 
 
 
 
 
 
Cardiac medication at time of surgery:     
 
  Yes 
No, 
stopped 
prior to 
surgery 
No 
1.  Aspirin     
 
2.  β-blocker     
 
3.  Calcium channel blocker     
 
4.  Nitrates 
If YES specify:______________________________     
 
5.  Cholesterol-lowering drug  
If YES specify:______________________________ 
   
 
6.  ACE inhibitor/AT2 receptor antagonist     
 
7.  Insulin     
 
8.  Sulphonylurea     
 
9.  Metformin     
 
10.  Clopidogrel / prasugrel     
 
11.  Warfarin     
 
12.  Diuretics     
 
13.  Other 
If YES specify:______________________________     
 
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
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BASELINE DATA (Blood sample collection) 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood sample collection on the day of surgery (pre surgery):   
 
 
For more information please refer to the ERICCA trial blood SOP  Collected 
BIOMARKERS                                     Date taken   
Pre RIC/Sham – EDTA tube   
Pre RIC/Sham – SST tube   
Post RIC/Sham – EDTA tube   
Post RIC/Sham – SST tube   
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
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STUDY INTERVENTION (On day of cardiac surgery) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
Date:         
 
Intervention:                           RIC            Sham    Not done     
 
   
Systolic Blood Pressure:                    mmHg 
 
Cuff Site:               Left Arm               Right Arm                Both   
 
                      
(time 24 hr) 
Cuff Inflation   1:        Inflation Pressure:     mmHg 
 
Cuff Deflation  1:  
 
Cuff Inflation   2:        Inflation Pressure:     mmHg 
 
Cuff Deflation  2: 
 
Cuff Inflation   3:        Inflation Pressure:     mmHg 
 
Cuff Deflation  3: 
 
Cuff Inflation   4:        Inflation Pressure:     mmHg 
 
Cuff Deflation  4: 
 
 
           
        
        
        
        
        
        
Has the intervention been completed as intended?  YES      NO           
If “NO” please specify: ______________________________________ 
(“NO” should be selected if the duration of any of the cuff inflations is less than 5 minutes) 
 
Expected adverse events:     Skin petechiae      YES   NO 
                   
Unexpected adverse events: YES    NO       
 
If YES, please complete relevant SAE or NSAE Form (See ERICCA Trial protocol for information) 
 
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
           
 
 
           
 
Form completed by:                                                                     Date:        
 
Signature:                                                                    
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SURGERY DETAILS   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surgery details: Date and Time, 
Consultant       
 
   
 
1.  Pre-op ECG_________________ 
   
 
2.  Post-op ECG_________________       
3.  Anaesthetic 
induction_________________     
 
4.  Anaesthetic 
maintenance_________________       
5.  Type of cardioplegia ant/retro/other       
6.  Bypass time (min)_________________       
7.  Cross-clamp (min)_________________ 
   
 
8.  Number of grafts 1, 2, 3, 4 
Type______________   
 
 
9.  Valve replaced Aortic, mitral, other 
     
10.  Complications____________________ 
     
Was CABG performed: Yes      No         
 
If No give reason:___________________________________________________________  
 
If Yes: Date of surgery:        Time of starting bypass:        (24 hr) 
               
Consultant: _________________________________________ 
 
Pre-op ECG:   Yes           No    If Yes, date:         Time:                      (24 hr) 
 
Post-op ECG: Yes           No         If Yes, date:              Time:                      (24 hr) 
 
Has the patient had an angiogram in the last 5 days:     Yes          No 
 
Were any of the following used for anaesthetic induction or maintenance:    
               Yes    No        Yes    No        Yes    No 
Fentanyl       Propofol        Rocuronium 
Midazolam       Pancuronium      Bevicuronium 
Isoflurane       Vecuronium       Alphentanyl 
Morphine       Glycopyrrolate      Sevoflurane 
Etomidate       Paracurium 
         
Please list any other anaesthetic drugs used:__________________________________   
 
Was levosimendan used:        Yes           No 
Were IV nitrates given during surgery:  Yes           No 
 
Type of cardioplegia:    Anterograde          Retrograde           
        Other                     (specify):________________________ 
Bypass time:                                  hh:mm (elaspsed time)   
Cross-clamp time:             hh:mm (elaspsed time)   
 
Time for coming off-bypass:      (24 hr)     
 
Number of grafts:   
 
Valve replaced: YES        NO     
 
If YES:     Aortic     Mitral   Other        (specify):________________________ 
 
Complications: YES        NO   
 
If YES specify: 
 
            
                    
        
                    
                    
       
       
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
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BLOOD SAMPLE COLLECTION (Creatinine) 
 
 
 
 
 
 
 
 
 
 
* Post-op times are recorded from the time of coming off bypass 
  Pre-op samples should be taken on the day of surgery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood sample collection (Creatinine): 
 
 
  Timepoint *  Date  Collected 
Sent to 
local 
laboratory 
Creatinine   Pre-op 
     
Creatinine   24 hours 
post-op 
     
Creatinine   48 hours 
post-op 
 
   
Creatinine   72 hours 
post-op 
     
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
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BLOOD SAMPLE COLLECTION (NGAL and Troponin-T) 
 
 
 
 
 
 
 
 
 
* Post-op times are recorded from the time of coming off bypass 
  Pre-op samples should be taken on the day of surgery 
Blood sample collection (NGAL): 
 
Please note samples should be taken within +/- 1 hour of the specified time 
 
 
Timepoint * 
 
 
Date  Collected 
NGAL  Pre-op     
NGAL  6 hours post-op     
NGAL  12 hours post-op     
NGAL  24 hours post-op     
Blood sample collection (Troponin-T): 
 
Please note samples should be taken within +/- 1 hour of the specified time 
 
 
Timepoint * 
 
 
Date  Collected 
Troponin-T  Pre-op     
Troponin-T  6 hours post-op     
Troponin-T  12 hours post-op     
Troponin-T  24 hours post-op     
Troponin-T  48 hours post-op     
Troponin-T  72 hours post-op     
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
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BLOOD SAMPLE COLLECTION (Creatinine values) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      * Post-op times are recorded from the time of coming off bypass 
         Pre-op samples should be taken on the day of surgery 
   
        
Creatinine values: 
Timepoint * 
 
Date 
 
Value (µmol/L) 
Pre-op 
 
 
24 hours 
   
48 hours 
   
72 hours 
   
These creatinine values should be collected from electronic biochemistry result records 
 
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
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POST-OP PERIOD (Urine output) 
 
 
 
 
 
 
 
* Post-op times are recorded from the time of coming off bypass 
*NK = Not known 
*NA – Not applicable  
Urine volumes:  These values should be collected daily from patient fluid balance charts 
 
Timepoint *                  Date  Volume (ml) 
0 - 24 hours 
 
Urine output known?  
 
 
 
 
 
YES                                 ml 
 
NK*     
 
NA* 
Was urine output <0.5ml/kg/hr for >6 hrs    Yes         No  NK* 
Was urine output <0.5ml/kg/hr for >12 hrs  Yes         No  NK* 
Was urine output <0.3ml/kg/hr for all 24 hrs    Yes         No  NK* 
24 - 48 hours 
 
Urine output known?  
 
 
 
 
YES                                 ml 
 
NK*     
 
NA* 
Was urine output <0.5ml/kg/hr for >6 hrs    Yes         No  NK* 
Was urine output <0.5ml/kg/hr for >12 hrs  Yes         No  NK* 
Was urine output <0.3ml/kg/hr for all 24 hrs    Yes         No  NK* 
48 - 72 hours 
 
Urine output known?  
 
 
 
 
 
YES                                 ml 
 
NK*     
 
NA* 
Was urine output <0.5ml/kg/hr for >6 hrs    Yes         No   NK* 
Was urine output <0.5ml/kg/hr for >12 hrs  Yes         No   NK* 
Was urine output <0.3ml/kg/hr for all 24 hrs    Yes         No   NK* 
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
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POST-OP PERIOD (Inotrope scores) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These INOTROPE values should be collected daily from patient drug chart whilst patient is on ITU. The 
inotrope score for the particular timepoint is calculated as follows: at time 0, the inotrope score will be 
calculated from the dose of the individual inotropes used at the time of coming off bypass. For 24, 48 and 
72  hour time-points, the  inotrope  score  will be  calculated  from the maximum  dose  of  the  individual 
inotropes used in the previous 24 hour period.  The score will be calculated automatically after entering 
the individual doses onto the eCRF. If any of the drugs are not given please enter 0 to the calculation. 
 
Post-op times are recorded from the time of coming off bypass and 0 hours is defined as the time of 
coming off bypass. 
 
     
 
 
 
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
           
 
 
           
Intra-aortic balloon pump (as non pharmacological inotropic support):    Yes  No 
 
If Yes, for how long:           hours 
TIMEPOINT: 0 HOURS 
Date 
 
Dopamine                  µg/kg/min 
Dobutamine                  µg/kg/min 
Adrenaline                  µg/kg/min  
Noradrenaline                µg/kg/min  
Isoproterenol                 µg/kg/min 
Enoximone /                   µg/kg/min 
Milrinone             
 
     
 
 
 
           
.             
.             
.             
.             
.             
.             
TIMEPOINT: 48 HOURS 
Date 
 
Dopamine                  µg/kg/min 
Dobutamine                  µg/kg/min 
Adrenaline                  µg/kg/min  
Noradrenaline                µg/kg/min  
Isoproterenol                 µg/kg/min 
Enoximone /                   µg/kg/min 
Milrinone             
 
     
 
 
 
           
.             
.             
.             
.             
.             
.             
TIMEPOINT: 72 HOURS 
Date 
 
Dopamine                  µg/kg/min 
Dobutamine                  µg/kg/min 
Adrenaline                  µg/kg/min  
Noradrenaline                µg/kg/min  
Isoproterenol                 µg/kg/min 
Enoximone /                   µg/kg/min 
Milrinone             
 
     
 
 
 
           
.             
.             
.             
.             
.             
.             
TIMEPOINT: 24 HOURS 
Date 
 
Dopamine                  µg/kg/min 
Dobutamine                  µg/kg/min 
Adrenaline                  µg/kg/min  
Noradrenaline                µg/kg/min  
Isoproterenol                 µg/kg/min 
Enoximone /                   µg/kg/min 
Milrinone             
 
     
 
 
 
           
.             
.             
.             
.             
.             
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CLINICAL DATA UP TO DISCHARGE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL DATA UP TO DISCHARGE (Continued) 
 
 
ERICCA Study Number: 
 
Initials:                     Date of Birth: 
           
 
 
           
 
Date of discharge:          
 
If patient dies before discharge please leave this date blank but complete the rest of the form 
 
Death:                  Yes        No          (If “YES” please complete page 26)   
 
MI:            Yes        No          (If “YES” please complete page 27)   
 
Revascularisation:   Yes        No          (If “YES” please complete page 29) 
 
Stroke:          Yes        No          (If “YES” please complete page 30) 
 
Peri-operative myocardial injury:  Yes     No 
 
Atrial fibrillation:        Yes     No     
 
Acute renal failure:      Yes     No 
 
If Yes, specify:     Haemodialysis             Peritoneal dialysis       Haemofiltration 
 
            No dialysis or haemofiltration 
 
Significant heart block requiring temporary or     Yes    No 
permanent cardiac pacing:  
 
Bleeding requiring repeat surgery or drainage:  Yes     No 
 
Length of ITU stay:                    days      Length of hospital stay:                 days  
 
Acute Kidney Injury (AKI) Grade:     1       2    3       N/A        
(Please tick N/A if patient does not develop AKI)      
       
Resource diary given to patient:  Yes     No 
If no give reason: 
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Cardiac medication at discharge:   
 
  Yes  No 
1.  Aspirin     
2.  β-blocker     
3.  Calcium channel blocker     
4.  Nitrates 
If YES specify:______________________________ 
   
5.  Cholesterol-lowering drug  
If YES specify:______________________________ 
   
6.  ACE inhibitor/AT2 receptor antagonist     
7.  Insulin     
8.  Sulphonylurea     
9.  Metformin     
10.  Clopidogrel / prasugrel     
11.  Warfarin     
12.  Diuretics     
13.  Other 
If YES specify:______________________________ 
   
 
ERICCA Study Number: 
 
Initials:                     Date of Birth: 
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FOLLOW-UP - CLINICAL DATA (6 weeks following surgery) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SINCE DISCHARGE   (or date of surgery if still inpatient)   Follow-up date:  
 
Death:                  Yes        No          (If “YES” please complete page 26)   
 
MI:                    Yes        No          (If “YES” please complete page 27)   
 
Revascularisation:           Yes        No          (If “YES” please complete page 29)   
 
Stroke:                  Yes        No          (If “YES” please complete page 30)   
 
Hospital admission:  Yes        No          Number of admissions:         
(If “YES” please complete the form on page 25 for each admission) 
 
ECG performed:  Yes   No     If Yes, date:          Time:                       (24 hr) 
 
Blood sample collection  
Creatinine collected: Yes   No          If yes, value:       µmol/L 
 
Six minute walk test 
 
Undertaken:  Yes        No         If No, give reason:__________________________________   
 
If Yes, total distance walked:           metres 
 
Was the test stopped before 6 minutes:  Yes        No    If Yes, at what time? __________ 
 
If Yes, give reason:__________________________________ 
 
 
Quality of Life questionnaire (EQ-5D) 
 
Completed:  Yes    No        If YES, you will be prompted to enter the EQ-5D data onto the eCRF 
 
 
Resource diary 
 
Has the resource diary been reviewed:        Yes    No 
 
If no give reason: 
           
       
       
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
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FOLLOW-UP – Cardiac medication  
(6 weeks following surgery) 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiac medication at 6 week follow-up:   
 
  Yes  No 
1.  Aspirin     
2.  β-blocker     
3.  Calcium channel blocker     
4.  Nitrates 
If YES specify:______________________________ 
   
5.  Cholesterol-lowering drug  
If YES specify:______________________________ 
   
6.  ACE inhibitor/AT2 receptor antagonist     
7.  Insulin     
8.  Sulphonylurea     
9.  Metformin     
10.  Clopidogrel / prasugrel     
11.  Warfarin     
12.  Diuretics     
13.  Other 
If YES specify:______________________________     
 
ERICCA Study Number: 
 
Initials:                     Date of Birth: 
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FOLLOW-UP (3 months following surgery) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
           
 
 
           
 
Quality of Life questionnaire (EQ-5D) 
 
Completed:  Yes    No           Date completed or received: 
 
 
If YES, you will be prompted to enter the EQ-5D data onto the eCRF 
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FOLLOW-UP (6 months following surgery) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
           
 
 
           
 
Quality of Life questionnaire (EQ-5D) 
 
Completed:  Yes    No            Date completed or received: 
 
If YES, you will be prompted to enter the EQ-5D data onto the eCRF 
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FOLLOW-UP (9 months following surgery) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
           
 
 
           
 
Quality of Life questionnaire (EQ-5D) 
 
Completed:  Yes    No            Date completed or received: 
 
If YES, you will be prompted to enter the EQ-5D data onto the eCRF 
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FOLLOW-UP (12 months following surgery) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
           
 
 
           
SINCE LAST FOLLOW-UP      Follow-up date:                                                 
 
Death:                  Yes        No          (If “YES” please complete page 26)   
 
MI:                    Yes        No          (If “YES” please complete page 27)   
 
Revascularisation:           Yes        No          (If “YES” please complete page 29)   
 
Stroke:                  Yes        No          (If “YES” please complete page 30)   
 
Hospital admission:  Yes        No          Number of admissions:         
(If “YES” please complete the form on page 25 for each admission) 
Weight:                  kg     
       
Systolic Blood Pressure:                   mmHg     Diastolic Blood Pressure:     mmHg 
 
Heart rate:                bpm      
 
ECG performed:  Yes    No        If Yes, date:          Time:                     (24 hr)  
 
Blood sample collection  
Creatinine collected:  Yes    No          If yes, value:          µmol/L 
 
Six minute walk test 
Undertaken:  Yes        No         If No, give reason:__________________________________   
 
If Yes, total distance walked:           metres 
 
Was the test stopped before 6 minutes:  Yes        No    If Yes, at what time? __________ 
 
If Yes, give reason:__________________________________ 
 
Quality of Life questionnaire (EQ-5D) 
Completed:  Yes    No         If YES, you will be prompted to enter the EQ-5D data onto the eCRF 
 
Resource diary 
Has the resource diary been reviewed:    Yes    No 
If no give reason: 
_________________________________________________________________ 
HEART HOSPITAL ECHO SUB STUDY ONLY 
Left ventricle ejection fraction:   Please enter value or description or not known 
Value available:     YES    NO    If YES, value       %   
If NO, description:   Poor      Moderate             Good/Normal           Not known 
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FOLLOW-UP – Cardiac medication  
(12 months following surgery) 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiac medication at 12 month follow-up:   
 
  Yes  No 
1.  Aspirin     
2.  β-blocker     
3.  Calcium channel blocker     
4.  Nitrates 
If YES specify:______________________________ 
   
5.  Cholesterol-lowering drug  
If YES specify:______________________________ 
   
6.  ACE inhibitor/AT2 receptor antagonist     
7.  Insulin     
8.  Sulphonylurea     
9.  Metformin     
10.  Clopidogrel / prasugrel     
11.  Warfarin     
12.  Diuretics     
13.  Other 
If YES specify:______________________________ 
   
 
ERICCA Study Number: 
 
Initials:                     Date of Birth: 
           
 
 
           ERICCA CRF Version 20.0 19
th August 2011                    NCT01247545  Page 25 of 30 
 
 
FOLLOW-UP – HOSPITAL ADMISSION HISTORY 
(Up to 12 months following surgery) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This form should be completed for EVERY ADMISSION in the first 12 MONTHS following 
surgery. Data should be collected from CLINICAL RECORDS 
Please complete RELEVANT FORM if indicated 
(See ERICCA Trial protocol for information) 
 
 
Reason for admission codes: 
01: Myocardial infarction   
02: Revascularisation   
03: Stroke   
04: Other CV (specify) ______________________________ 
05: Other non-CV (specify) ______________________________ 
 
           
 
Admission date:                               Discharge date:  
 
Primary reason for admission:      (See below for admission codes) 
   
 
Death:       Yes     No       (If “YES”, please complete page 26) 
   
                       
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
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CAUSE OF DEATH DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These data should be collected from CLINICAL RECORDS 
Please complete RELEVANT FORM if indicated 
(See ERICCA Trial protocol for information) 
 
Autopsy Information (if available):           
 
 
Description of cause of death (from death certificate or relevant medical notes):   
       
 
 
 
 
 
 
 
 
Was the primary cause of death: 
 
Cardiovascular death     
 
Non cardiovascular death     
 
Unknown *   
 
(* in the absence of an identifiable cause of death)        
 
 
 
 
 
 
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
           
 
 
           
 
Date of death:                                 
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MI DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These data should be collected from CLINICAL RECORDS 
Please complete RELEVANT FORM if indicated 
(See ERICCA Trial protocol for information) 
 
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
           
 
 
           
 
Date of MI:                                
 
Hospital:____________________________________ 
 
MI timepoint:    Peri-operative      Post-surgical 
      
 
NSTEMI or STEMI:   NSTEMI     STEMI 
 
Treatment received: 
 
 
 
Other relevant information: 
       
 
 
 
 
 
 
PLEASE PROVIDE SUPPORTING DOCUMENTATION  
(clearly marked with ERICCA study number and date of birth) 
Please send supporting documents (ECG, blood tests for Troponin T or I or CKMB, copy of hospital admission or 
GP record) to the Clinical Trials Unit at the LSHTM. 
 
Please see over for definitions 
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MI DATA (Continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Myocardial infarction definition 
Myocardial  infarction  will  include  both  peri-operative  myocardial  infarction  and  post-surgical 
myocardial infarction. 
 
 
Peri-operative myocardial infarction is defined as follows: 
“A rise in Troponin T or I to more than five times the 99th percentile of the normal reference 
range  during  the  first  72  hours  following  CABG  with  or  without  valve  surgery,  when 
associated  with  the  appearance  of  new  pathological  Q-waves  or  new  LBBB,  or 
angiographically  documented  new  graft  or  native  coronary  artery  occlusion,  or  imaging 
evidence of new loss of viable myocardium”.  
 
 
Post-surgical myocardial infarction is defined as follows: 
1.  A rise and/or fall of Troponin T or I with at least one value above the 99
th percentile of 
the upper reference limit (URL) together with evidence of myocardial ischaemia with at 
least one of the following: 
  Symptoms of ischaemia 
  ECG changes indicative of new ischaemia (new ST-T changes of new LBBB) 
  Development of Q waves in the ECG 
  Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality. 
 
2.  Sudden  unexpected  cardiac  death  involving  cardiac  arrest  often  with  symptoms 
suggestive  of  myocardial  ischaemia  and  accompanied  by  presumably  new  ST 
elevation  or  new  LBBB  and/or fresh  thrombus  on  coronary  angiography  and/or  at 
autopsy,  but  death  occurring  before  blood  samples  could  be  obtained  or  at  time 
before the appearance of cardiac troponin T or I in the blood. 
       
 
STEMI (ST-elevation MI) 
New ST elevation at the J-point in two contiguous leads with the cut-off points: 
≥0.2 mV in men or ≥0.15 mV in women in leads V2-V3 and/or ≥0.1 mV in other leads. 
 
 
NSTEMI (non-ST-elevation MI)  
All MIs that are not STEMI are defined as NSTEMI. 
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REVASCULARISATION DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These data should be collected from CLINICAL RECORDS 
Please complete RELEVANT FORM if indicated 
(See ERICCA Trial protocol for information) 
 
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
           
 
 
           
 
Date of revascularisation:                            
 
 
Hospital:________________________________ 
 
 
Procedure:    CABG      PCI   
 
 
Was the procedure completed as intended:  Yes    No 
 
 
 
Other relevant information: 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Revascularisation definition 
Repeat revascularisation will be defined as any repeat PCI or CABG with or without valve 
within the first year post-surgery. 
 
 
 
 
           ERICCA CRF Version 20.0 19
th August 2011                    NCT01247545  Page 30 of 30 
 
 
STROKE DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These data should be collected from CLINICAL RECORDS 
Please complete RELEVANT FORM if indicated 
(See ERICCA Trial protocol for information) 
 
 
ERICCA Study Number: 
 
Patient Initials:                   Date of Birth: 
           
 
 
           
 
Date of stroke:                                 
 
 
Hospital:_________________________________ 
 
 
Clinical features:___________________________________________________ 
 
 
CT scan confirmed diagnosis:    YES    NO 
 
 
Haemorrhage or infarct:_______________________ 
 
 
Other relevant information: 
 
 
 
 
 
 
 
 
PLEASE PROVIDE SUPPORTING DOCUMENTATION 
(clearly marked with ERICCA study number and date of birth) 
Please send supporting documents (Copy of medical admission or GP record or result of CT head scan) to the 
Clinical Trials Unit at the LSHTM.  
 
Stroke definition 
Stroke will be defined as a focal, central neurological deficit lasting >72 hours which results in 
irreversible brain damage or body impairment. 
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